<SEC-DOCUMENT>0001125345-17-000041.txt : 20170228
<SEC-HEADER>0001125345-17-000041.hdr.sgml : 20170228
<ACCEPTANCE-DATETIME>20170228160549
ACCESSION NUMBER:		0001125345-17-000041
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		81
CONFORMED PERIOD OF REPORT:	20161231
FILED AS OF DATE:		20170228
DATE AS OF CHANGE:		20170228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		17647602

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mgnx-123116x10k.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s6F3AE24BA58CA9100600E278A34F27A7"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C.&#160;&#160;20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 10-K</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Mark One)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61px;"></td><td style="width:621px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#9746;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OR</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61px;"></td><td style="width:621px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#9744;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commission File Number 001-36112</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;font-weight:bold;">MACROGENICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Exact name of registrant)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:4%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delaware&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">06-1591613</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(State of organization)&#160;&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(I.R.S. Employer Identification Number)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9704 Medical Center Drive, Rockville, Maryland 20850</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Address of principal executive offices and zip code)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(301)&#160;&#160;251-5172</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Registrant's telephone number)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:4%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Title of Each Class</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name of Each Exchange on Which Registered</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, par value $0.01 per share</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The NASDAQ Stock Market LLC</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities registered pursuant to Section 12(g) of the Act: None</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Yes&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#9745; </font><font style="font-family:inherit;font-size:10pt;">&#32;No&#160;&#160;&#160;&#9744;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Yes&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;">&#9744;</font><font style="font-family:inherit;font-size:10pt;">&#160;No&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#9745;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Yes&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#9745;</font><font style="font-family:inherit;font-size:10pt;">&#32;No&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;">&#9744;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Yes&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#9745;</font><font style="font-family:inherit;font-size:10pt;">&#32;No&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;">&#9744;</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein and will not be contained, to the best of the registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. </font><font style="font-family:Wingdings 2;font-size:10pt;">&#163; </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.&#160;&#160;See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:25%;"></td><td style="width:25%;"></td><td style="width:25%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large accelerated filer </font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#9745;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated filer&#160;&#160;&#9744;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-accelerated filer&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;">&#9744;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller reporting company&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;">&#9744;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Yes&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;">&#9744;</font><font style="font-family:Wingdings 2;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">No&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#9745;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate market value of the registrant's common stock, par value $0.01 per share, held by non-affiliates of the registrant on June&#160;30, 2016, the last business day of the registrant's most recently completed second fiscal quarter, was approximately $936 million based on the closing price of the registrant's common stock on the NASDAQ Global Select Market on that date.&#160;&#160;Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, direct or indirect, to direct or cause the direction of management or policies of the registrant, or that such person is controlled by or under common control with the registrant.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The number of shares of the registrant's common stock outstanding on </font><font style="font-family:inherit;font-size:10pt;">February&#160;24, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">34,974,985</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Portions of MacroGenics, Inc.'s definitive proxy statement for the </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;annual meeting of stockholders are incorporated by reference into Part III of this Annual Report.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s3E59EFBCF4F4784FFCE5E278A3AC7026"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MACROGENICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ANNUAL REPORT ON FORM 10-K</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:12%;"></td><td style="width:88%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB2142E94A5BFE15DE27FE278A643EB0A"><font style="font-family:inherit;font-size:10pt;">Business</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 1A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8BF87854CDF1686ABD17E278A674B3CC"><font style="font-family:inherit;font-size:10pt;">Risk Factors</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 1B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB035ADF398BBE670F6EFE278A698FAB1"><font style="font-family:inherit;font-size:10pt;">Unresolved Staff Comments</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s60563F697BEBC39E13A6E278A6ADBF49"><font style="font-family:inherit;font-size:10pt;">Properties</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s64DABA41ED910180558FE278A6BD76FA"><font style="font-family:inherit;font-size:10pt;">Legal Proceedings</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1B89214D8B3577ED3236E278A6E33488"><font style="font-family:inherit;font-size:10pt;">Mine Safety Disclosures</font></a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 5</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD51F6A6B087F2599D62BE278A73583A0"><font style="font-family:inherit;font-size:10pt;">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA6540334485E4E06F182E278A786C25F"><font style="font-family:inherit;font-size:10pt;">Selected Financial Data</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0304F33B25A6951BD12FE278A7BD06CD"><font style="font-family:inherit;font-size:10pt;">Management's Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 7A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA135436217E4A8EE0520E278A9914777"><font style="font-family:inherit;font-size:10pt;">Quantitative and Qualitative Disclosures about Market Risk</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s76B9804F088260BC1E5FE278A9BBA532"><font style="font-family:inherit;font-size:10pt;">Financial Statements and Supplementary Data</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5E847A02FB1B95DE0EDBE278A9F04D9C"><font style="font-family:inherit;font-size:10pt;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 9A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1CF732DDBBB6DA7EE99BE278AA2552B2"><font style="font-family:inherit;font-size:10pt;">Controls and Procedures</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 9B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2D10789F5BC02846BBF3E278AA579887"><font style="font-family:inherit;font-size:10pt;">Other Information</font></a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s314FFC179F13145F1D50E278AA9439F2"><font style="font-family:inherit;font-size:10pt;">Directors, Executive Officers and Corporate Governance</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA192C1A3D83B0084A502E278AAAFB25E"><font style="font-family:inherit;font-size:10pt;">Executive Compensation</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7D15E79FFEEF0ADF82B6E278AAE73C31"><font style="font-family:inherit;font-size:10pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 13</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2A6101A1CB1EC8D8408BE278AB06A53A"><font style="font-family:inherit;font-size:10pt;">Certain Relationships and Related Transactions, and Director Independence</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 14</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEDE12330B9D83CC6073DE278AB4331B3"><font style="font-family:inherit;font-size:10pt;">Principal Accountant Fees and Services</font></a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART IV</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s079A77224C91B785485DE278AB83E60D"><font style="font-family:inherit;font-size:10pt;">Exhibits and Financial Statement Schedules</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3c2ec9c45b604b258dfb64c4a8d65252"><font style="font-family:inherit;font-size:10pt;">Form 10-K Summary</font></a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sE24F6859A87A4FCDF308E278ABA52EA4"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s35F7D51ECCC3458CBCE6E278A5D3D533"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This report includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". Forward-looking statements can often be identified by the use of terminology such as "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among others (including those set forth under "Risk Factors"), could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our plans to develop and commercialize our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the outcomes of our ongoing and planned clinical trials and the timing of those outcomes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to enter into new collaborations or to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to recover the investment in our manufacturing capabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the rate and degree of market acceptance and clinical utility of our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our commercialization, marketing and manufacturing capabilities and strategy;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">significant competition in our industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs of litigation and the failure to successfully defend lawsuits and other claims against us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">economic, political and other risks associated with our international operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to receive research funding and achieve anticipated milestones under our collaborations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to protect and enforce patents and other intellectual property;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">loss or retirement of key members of management;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure to successfully execute our growth strategy, including any delays in our planned future growth; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our failure to maintain effective internal controls.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consequently, forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance or achievements. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s697794168C1377D0A277E278A6206A97"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</font></div><div><a name="sB2142E94A5BFE15DE27FE278A643EB0A"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1.</font><font style="font-family:inherit;font-size:5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BUSINESS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Except as otherwise indicated herein or as the context otherwise requires, references in this annual report on Form 10-K to "MacroGenics," the "company," "we," "us" and "our" refer to MacroGenics, Inc. and its consolidated subsidiaries.</font><font style="font-family:inherit;font-size:10pt;color:#1f497d;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">MacroGenics, the MacroGenics logo, DART, TRIDENT and the phrase "Breakthrough Biologics, Life-Changing Medicines" are our trademarks or registered trademarks. The other trademarks, trade names and service marks appearing in this report are the property of their respective owners.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer as well as various autoimmune disorders and infectious diseases. We currently have a pipeline of product candidates in human clinical testing that have been created primarily using our proprietary technology platforms. We believe our programs have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our most advanced clinical product candidate is margetuximab, a monoclonal antibody directed against human epidermal growth factor receptor 2, or HER2, that has been enhanced using our proprietary "Fc Optimization" platform described in greater detail below. The HER2 protein is expressed by certain breast, gastroesophageal and other cancers. We have an ongoing Phase 3 clinical trial, which we call SOPHIA, to study margetuximab in patients with HER2 positive metastatic breast cancer that has progressed despite treatment with other HER2-directed therapeutic agents. We anticipate that a successful outcome from the SOPHIA study will allow us to seek approval of the product from the U.S. Food and Drug Administration, or FDA. We are also conducting a Phase 1b/2 clinical trial by treating patients with HER2-positive gastric or gastroesophageal junction cancer with margetuximab in combination with an anti-PD-1 monoclonal antibody, an immune checkpoint inhibitor molecule that plays a critical role in modulation of the immune system's response to cancer.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. B7-H3 is widely expressed by a number of different tumor types and may play a key role in regulating the immune response to various types of cancer. There are no currently approved therapeutic agents directed against B7-H3. We have two clinical product candidates directed against B7-H3, enoblituzumab and MGD009, and we also have ongoing research efforts underway to advance MGC018, an antibody-drug conjugate, or ADC, directed against B7-H3. Our most advanced candidate in this franchise, enoblituzumab, is a monoclonal antibody that has also been enhanced using our Fc Optimization platform. Enoblituzumab is being evaluated clinically in multiple studies &#8211; as monotherapy, in combination with an anti-PD-1 antibody and in combination with an anti-CTLA-4 antibody, another immune checkpoint inhibitor &#8211; in each case, across multiple tumor types.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD009 is one of six clinical-stage molecules developed using our proprietary platform technology for making DART</font><font style="font-family:Arial;font-size:10pt;">&#174; </font><font style="font-family:inherit;font-size:10pt;">molecules, which is described in greater detail below. Unlike standard monoclonal antibodies, DART molecules are bispecific, which means they can be directed against two different biological targets, and therefore lend themselves to a variety of different applications. MGD009, for example, is directed to both B7-H3 expressed on tumor cells as well as CD3, a protein expressed by normal T cells, which are specialized white blood cells in the human immune system. In preclinical models, MGD009 has re-directed T cells to reduce or eliminate B7-H3 expressing tumors. We are currently conducting a Phase 1 clinical trial with MGD009 in patients with B7-H3 positive tumors.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Four additional DART molecules, MGD006 (or flotetuzumab), MGD007, MGD011 (or duvortuxizumab) and PF-06671008, are also currently in Phase 1 clinical testing and each uses the same approach of targeting CD3 and a specific tumor antigen known to be expressed on certain cancers. Flotetuzumab is being tested in patients with relapsed and refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and MGD007 is being tested in patients with colorectal cancer. Our collaborator, Les Laboratoires Servier and Institut de Recherches Servier, or, collectively, Servier, has development and commercialization rights outside North America, Japan, Korea and India for flotetuzumab and has an option to gain similar rights with regards to MGD007. The clinical program for duvortuxizumab is being advanced by our collaborator, Janssen Biotech, Inc., or Janssen, and is being studied in a variety of B-cell hematological malignancies. PF-06671008 is being advanced by our collaborator Pfizer, Inc. and is being studied in certain undisclosed solid tumors. These five DART molecules that redirect T cells against cancer targets are manufactured using a conventional antibody platform without the complexity of having to genetically modify T cells from individual patients, as would be required by approaches such as chimeric antigen receptor (CAR) T cells.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our sixth clinical-stage DART molecule, MGD010, has a different mechanism of action than the other DART molecules currently in development. MGD010 targets two proteins expressed by B cells, which are specialized white blood </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">cells that play a role in modulating the human immune system's inflammatory response. We believe that MGD010 may be able to reduce the harmful inflammatory effects seen in a variety of autoimmune and inflammatory disorders by modulating the function of human B cells while avoiding their depletion. We have completed a Phase 1a clinical study in healthy volunteers and observed acceptable safety and pharmacodynamic activity consistent with the expected mechanism of action of MGD010.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, we also initiated Phase 1 clinical testing of MGA012, a monoclonal antibody directed against an immune system protein known as PD-1. Antibodies targeting PD-1, a checkpoint molecule, have shown efficacy against various tumors by releasing the "brakes" on the immune system which is often seen when tumors evade detection by the immune system. We anticipate that a successful anti-PD-1 monoclonal antibody in our pipeline would allow us to conduct combination studies with our other potential cancer therapeutics. In addition to MGA012, we use the anti-PD-1 specificity as we continue to design additional bispecific and trispecific molecules that engage this target together with other immune regulatory molecules.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We continue to invest in our clinical-stage programs, advance additional preclinical product candidates, primarily using our proprietary technology platforms, and expand the potential of our platforms using our antibody and protein engineering expertise. We develop new therapeutic product candidates internally using our proprietary platforms and also in collaboration with other biopharmaceutical companies, when such relationships are advantageous for strategic or financial reasons. These arrangements have allowed us to expand and accelerate the breadth of our product candidates and also have generated a significant portion of the funding we have received to date. We also have our own manufacturing facility, primarily for generation of earlier-stage clinical trial material, and have been investing in expanding our manufacturing capacity to meet later-stage clinical and future potential commercial requirements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We estimate that in 2016, 2015 and 2014, we spent approximately </font><font style="font-family:inherit;font-size:10pt;">$122.1 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$98.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$70.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;on research and development activities, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Strategy</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Primary Objectives</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our goal is to be a fully integrated biotechnology company leading in the discovery, development and commercialization of breakthrough biologics for the treatment of patients with cancer, as well as various autoimmune disorders and infectious diseases.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Key elements of our strategy are as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Therapeutic focus, science driven.</font><font style="font-family:inherit;font-size:10pt;">&#160; We create therapeutic biological products primarily to treat various types of cancers, including both solid tumors and hematological malignancies.&#160; Our proprietary DART and Fc Optimization technology platforms are particularly useful for targeting and harnessing specific elements of the human immune system, allowing us to design molecules that (1) directly target cancer cells and enhance the ability of the immune system to destroy those cells, (2) re-direct effector cells to attack tumors or (3) affect mechanisms that regulate the immune response to cancer, either by stimulating pathways that enhance this response or by blocking pathways that inhibit this response, including checkpoint molecules.&#160; This field of scientific discovery, broadly known as immuno-oncology, has been developing rapidly in the last few years, and most therapeutic products to date are largely focused on affecting individual biological pathways.&#160; We believe that cancers are sufficiently complex that effective treatments must simultaneously affect more than one pathway.&#160; We believe that we are well-positioned, particularly through the adaptability of our DART platform, to be able to create and develop therapeutic molecules designed to simultaneously target more than one pathway.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:78px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This same flexibility in our platforms allows us to create therapeutic molecules that may be useful for other unmet medical needs beyond cancer, such as for autoimmune disorders and infectious diseases.&#160; Our core strategic focus is on development of cancer therapeutics, but we may also opportunistically pursue such possibilities when they arise.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fully integrated with a deep pipeline.</font><font style="font-family:inherit;font-size:10pt;">&#160; Our objective is to be a fully-integrated biotechnology company, and we intend to continue to grow and establish all necessary functions from early-stage research through commercialization in at least the United States.&#160; At our current stage of development as a company, we have established early-stage discovery, process development, clinical development and clinical-stage manufacturing functions, and we intend to build commercial manufacturing as well as U.S.-based sales and marketing infrastructure as our development pipeline matures.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:78px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a broad portfolio of product candidates and we are not dependent upon the success of any one of them for the overall success of the company.&#160; We continue to augment our pipeline through the discovery and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:78px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">development of new product candidates, primarily through utilization of our internal scientific expertise and strategically seeking external collaborations that can augment our own skills.&#160; From 2014 to 2016, we advanced six programs into clinical development.&#160; Our goal is to continue to advance one or more programs into clinical development per year to ensure a robust pipeline and to replace product candidates that fail to progress.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leveraging collaborations.</font><font style="font-family:inherit;font-size:10pt;">&#32;Throughout our company's history, we have entered into collaborations with other biopharmaceutical companies and intend to continue to do so.&#160; We enter into collaborations when there is a strategic advantage to us to do so and when we believe the financial terms of the collaboration are favorable for meeting our short-term and long-term strategic objectives.&#160; We are not dependent upon any one of these collaborations, but in many cases we have rights to receive sales royalties and other significant financial payments if the partnered product candidates achieve certain development and sales milestones.&#160; Some of the collaborations also preserve our right to participate in future commercialization, for example by securing co-promotion or profit-sharing rights under certain circumstances.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investments in talent and culture.&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;One of our most valuable assets is the quality of our employee base. We invest significant effort in selecting and retaining high caliber, talented individuals who reflect our values.&#160; As we continue to grow, we continue to seek and develop employees who are strongly committed to delivering life-changing medicines for unmet medical needs through a collaborative work environment.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Core Therapeutic Areas We Target</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cancer</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancer is a broad group of diseases in which cells divide and grow in an uncontrolled fashion, forming malignancies that can invade other parts of the body. In normal tissues, the rates of new cell growth and cell death are tightly regulated and kept in balance. In cancerous tissues, this balance is disrupted as a result of mutations, causing unregulated cell growth that leads to tumor formation and growth. While tumors can grow slowly or rapidly, the dividing cells will nevertheless accumulate and the normal organization of the tissue will become disrupted. Cancers subsequently can spread throughout the body by processes known as invasion and metastasis. Once cancer spreads to sites beyond the primary tumor, it generally becomes more difficult to treat and may be incurable. Cancer cells that arise in the lymphatic system and bone marrow are referred to as hematological malignancies. Cancer cells that arise in other tissues or organs are referred to as solid tumors. Cancer can arise in virtually any part of the body, with the most common types arising in the prostate gland, breast, lung, colon and skin.&#160; We believe that our platforms position us very well strategically to actively develop approaches for the treatment of both solid tumors and hematologic malignancies.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancer is the second leading cause of death in the United States, exceeded only by heart disease.  An increasing number of people are also living longer with cancer. The American Cancer Society has estimated that by January 2026, the population of cancer survivors in the United States will increase to almost 20.3 million people. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Autoimmune Disorders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Autoimmune disorders, including rheumatoid arthritis, Crohn's disease, systemic lupus erythematosus and multiple sclerosis, collectively affect more than 20&#160;million people in the United States. Autoimmune disorders involve self-reactivity and destruction by T cells, B cells and antibodies due to a lack of self-tolerance. Anti-inflammatory therapies, such as tumor necrosis factor inhibitors, have been able to improve diseases like rheumatoid arthritis.&#160; However, in addition to T cells, more evidence indicates that B cells play an important role in many common autoimmune and allergic disorders by initiating and amplifying the pathological disease processes. Current B cell targeted therapies either cause depletion of B cells, thus limiting their applicability due to the potential for infections (e.g., rituximab), or exhibit a delayed onset of action and limited efficacy across patient populations (e.g., belimumab).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Infectious Diseases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are a wide variety of infectious diseases, and the epidemiology for each varies significantly with the type of pathogen and patients who are affected. However, in order to avoid being recognized as foreign by the human immune system, many infectious agents have found ways to evade detection. In this way, they may behave similarly, at a biological level, to certain types of cancer. Accordingly, our expertise in designing protein-based therapeutics that are designed to activate the human immune system to eliminate foreign substances may have applicability to various types of infectious diseases, and we explore those possibilities opportunistically.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Product Candidates</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below depicts the current status of product candidates that are in or near human clinical development and for which we retain all or some commercial rights:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;"><img src="form10k2016pipeline.jpg" alt="form10k2016pipeline.jpg" style="height:359px;width:684px;"></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Oncology</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Margetuximab</font><font style="font-family:inherit;font-size:10pt;">&#32;is a monoclonal antibody that targets HER2-expressing tumors, including certain types of breast and gastroesophageal cancers. HER2 is critical for the growth of many types of tumors. Using our Fc Optimization platform, we have engineered the constant region, or Fc region, of margetuximab to increase its ability to kill tumor cells through an Fc-dependent mechanism, including antibody dependent cell-mediated cytotoxicity, or ADCC. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-left:78px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Phase 1 data for margetuximab, in addition to demonstrating margeutximab was well-tolerated at the dose levels studied, demonstrated that anti-tumor activity had been observed at a range of doses tested, including the lowest dose level of margetuximab, even in patients who were heavily pre-treated (frequently with other anti-HER2 agents). We are currently studying margetuximab in a Phase 3 clinical trial, which we call SOPHIA, in patients with metastatic breast cancer expressing HER2 at the 3+ level by immunohistochemistry (IHC) or 2+ level by IHC with gene amplification whose tumors have progressed despite therapy with other HER2-directed therapeutic agents.&#160; We are also conducting an exploratory Phase 1b/2 clinical trial combining margetuximab with an anti-PD-1 antibody in patients with HER2-positive gastric or gastroesophageal junction cancer.  Finally, we have completed an exploratory Phase 2a clinical trial in patients with lower levels of HER2 expression (1+ or 2+ level by IHC with no gene amplification), a distinct patient population that is not traditionally treated with anti-HER2 antibodies. We did not observe sufficient clinical activity to justify further study in this patient population.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Enoblituzumab </font><font style="font-family:inherit;font-size:10pt;">is a monoclonal antibody that targets B7-H3. We engineered enoblituzumab to utilize the same Fc Optimization enhancements that we incorporated in margetuximab to target B7-H3 that is over-expressed on differentiated tumor cells, cancer stem cells and supporting tumor vasculature and underlying tissues. We are currently evaluating enoblituzumab in an ongoing Phase 1 clinical trial as monotherapy in multiple solid tumor types as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Flotetuzumab (previously known as MGD006)</font><font style="font-family:inherit;font-size:10pt;">&#32;is a DART molecule that targets both CD123 and CD3. CD123, the Interleukin-3 receptor alpha chain, is expressed on leukemia and leukemic stem cells, but only at very low levels or not at all on normal hematopoietic stem cells. T cells, which express CD3, can destroy tumor cells. In preclinical studies, we have demonstrated the ability of flotetuzumab to recruit, activate, and expand T cell populations to eliminate leukemia cells. We are currently enrolling patients in the United States and Europe in a Phase 1 clinical trial of flotetuzumab in patients with AML or MDS. Under the terms of our collaboration with </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:78px;padding-bottom:12px;"><font style="font-family:inherit;font-size:10pt;">Servier, Servier has the exclusive right to develop and commercialize flotetuzumab in all countries outside North America, Japan, Korea and India, and MacroGenics retains exclusive rights in those countries.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">MGD007</font><font style="font-family:inherit;font-size:10pt;">&#32;is a DART molecule that targets both the glycoprotein A33 (gpA33) and CD3, and has an Fc domain, which is designed to provide extended pharmacokinetic properties and convenient intermittent dosing. gpA33 is expressed on gastrointestinal tumors, including more than 95% of human colon cancers. We have demonstrated that this molecule is able to mediate T&#160;cell killing of gpA33-expressing cancer cells and cancer stem cells in preclinical experiments. We are currently enrolling patients with colorectal cancer in a Phase 1 clinical trial of MGD007. Under the terms of our collaboration with Servier, Servier has an option to obtain exclusive rights to develop and commercialize MGD007 in all countries outside North America, Japan, Korea and India.&#160; If the option is exercised, MacroGenics would still retain exclusive rights in those countries.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Duvortuxizumab</font><font style="font-family:inherit;font-size:10pt;">&#32;is a DART molecule that targets both CD19 and CD3 and is being developed for the treatment of B-cell hematological malignancies. CD19, a lymphocyte-specific marker expressed from early B-lymphocyte development through mature memory B cells, is highly represented in B cell malignancies. This makes it attractive for targeted interventions. Duvortuxizumab is designed to redirect T cells, via their CD3 component, to eliminate CD19-expressing cells found in many hematological malignancies.&#160; Duvortuxizumab has been engineered to address half-life challenges posed by other programs targeting CD19 and CD3. Like MGD007, this product candidate has an Fc domain, which allows for extended pharmacokinetic properties and convenient dosing at a once-a-week or longer interval.&#160;Under our collaboration and license agreement, Janssen is leading the development of this product candidate, subject to our options to co-promote the product in the United States and Canada and to invest in later-stage development in exchange for a United States and Canada profit-share. Janssen has an ongoing Phase 1 study of duvortuxizumab in a variety of B-cell hematological malignancies.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">MGD009</font><font style="font-family:inherit;font-size:10pt;">&#32;is the second molecule in our B7-H3 franchise. This DART molecule recognizes B7-H3 and CD3, and has an Fc domain, which is designed to provide extended pharmacokinetic properties. We have demonstrated that this molecule is able to mediate T&#160;cell killing of cancer cells in preclinical experiments. We are currently enrolling patients in a Phase 1 clinical trial of MGD009 in patients across a variety of different solid tumors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">MGA012</font><font style="font-family:inherit;font-size:10pt;">&#32;is a monoclonal antibody targeting PD-1. Antibodies targeting PD-1 have shown efficacy against various tumors by releasing the "brakes" on the immune system that are often seen when tumors evade detection by the immune system. We anticipate that MGA012 may be used in combination studies with our other therapeutics. We are currently enrolling patients in a Phase 1 clinical trial of MGA012 in patients across a variety of different solid tumors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">MGD013</font><font style="font-family:inherit;font-size:10pt;">&#32;is a DART molecule that is intended to enable the co-blockade with a single recombinant agent of two immune checkpoint molecules, PD-1 and LAG-3, which may be co-expressed on T cells. We anticipate that MGD013 could be used for the treatment of a wide range of cancers, including both solid tumors and hematological malignancies. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">MGC018</font><font style="font-family:inherit;font-size:10pt;">&#32;is a B7-H3 antibody-drug conjugate (ADC) for which we are conducting Investigational New Drug Application (IND)-enabling activities. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">MGC018 is based on a MacroGenics proprietary B7-H3 antibody and a duocarmycin-based, linker-drug technology licensed from Synthon Biopharmaceuticals B.V.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Autoimmune Disorders</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">MGD010</font><font style="font-family:inherit;font-size:10pt;">&#32;is a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells. In preclinical studies, this DART molecule modulated the function of human B cells without B cell depletion. In normal conditions, B cells utilize CD32B as one of the key checkpoints or negative regulators to ensure that tolerance to self is maintained and autoimmune disease does not occur. MGD010 is designed to further exploit this mechanism by triggering this inhibitory "immune checkpoint" loop. We believe this molecule preferentially blocks those B cells that are activated to produce the pathogenic antibodies that promote the autoimmune process. We have completed a Phase 1a clinical study in healthy volunteers and observed acceptable safety and pharmacodynamic activity consistent with the expected mechanism of action of MGD010.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Teplizumab</font><font style="font-family:inherit;font-size:10pt;">&#32;is an anti-CD3 monoclonal antibody being developed for the treatment of type 1 diabetes. Teplizumab has been engineered to alter the function of the T cells that mediate the destruction of the insulin-producing beta cells of the islets of the pancreas. Teplizumab potentially represents an advance in the treatment of type 1 diabetes by addressing the underlying disorder, rather than treating the symptoms through insulin replacement therapy. Teplizumab is being evaluated in a Phase 2 clinical trial for potential application to patients </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:78px;padding-bottom:12px;"><font style="font-family:inherit;font-size:10pt;">at risk of developing Type 1 diabetes. We have elected to collaborate with NIDDK/TrialNet to execute this clinical trial. In addition, we continue to seek strategic collaborations for the advancement of this program that could include joint funding, spinning the program out into a new company, divesting the program or pursuing other transaction structures that we feel would be aligned with our strategic objectives and provide financial consideration commensurate with our expectations of value for the program.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Infectious Diseases</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">MGD014</font><font style="font-family:inherit;font-size:10pt;">&#32;is a DART molecule that targets the envelope protein of human immunodeficiency virus, or HIV-infected cells (Env) and CD3-expressing T cells. We are developing MGD014 under contract number HHSN272201500032C awarded to us in September 2015 by the National Institute of Allergy and Infectious Diseases, or NIAID, part of the National Institutes of Health. MGD014 is our first DART molecule targeting an infectious agent that is planned for clinical testing. The work under this contract will build on preclinical studies demonstrating that DART molecules targeting the Env and T cells, via their CD3 component, are able to redirect the immune system's T cells to kill HIV-infected cells. DART molecules could be used independently or become a key part of a "shock-and-kill" strategy in conjunction with HIV latency-reversing agents currently under development.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Platforms and Technology Expertise</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We apply our understanding of disease biology, immune-mediated mechanisms and next generation antibody technologies to design specifically targeted antibody-based product candidates based on our DART and Fc Optimization platforms.&#160; Through these platforms and utilization of our proprietary cancer stem-like cell, or CSLC, technology, we have designed antibody-based product candidates that have the potential to improve on standard treatments by having one or more of the following attributes: (1)&#160;multiple specificities; (2)&#160;increased abilities to interact with the body's immune system to fight tumors; (3)&#160;capacity to bind more avidly to antigen targets: (4)&#160;increased potency; (5)&#160;reduced immunogenicity or (6)&#160;the ability to target cancer cells that are resistant to standard treatments. Moreover, these technology platforms are complementary and can be combined.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">DART and TRIDENT</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;Platforms: Our Proprietary Approach to Engineer Multi-Specific Antibodies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use our DART platform to create derivatives of antibodies with the ability to bind to two distinct targets instead of a single one found in traditional monoclonal antibodies. DART product candidates are therefore bispecific. An example of a bispecific molecule is illustrated below:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;"><img src="form10k2016image1.jpg" alt="form10k2016image1.jpg" style="height:208px;width:466px;"></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because cancer cells have developed ways to escape the immune system, we have created DART molecules, which are alternative antibody-like structures with more potent immune properties than the parent antibody molecules from which they are derived. The two variable regions of an antibody are mono-specific and are able to target only a single type structural component of an antigen. For many years, researchers have sought to create recombinant molecules that are capable of targeting two antigens or epitopes (i.e., specific part of an antigen bound by the antibody) within the same molecule. The challenges in creating such molecules have been the instability of the resulting bispecific molecules and their inherently short half-lives, as well as the inefficiencies in manufacturing these compounds. We believe our DART platform has overcome these engineering challenges by incorporating proprietary covalent di-sulfide linkages and particular amino acid sequences that efficiently pair the chains of the DART molecule. This is designed to provide a structure with enhanced manufacturability, long-</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">term structural stability and the ability to tailor the half-lives of the DART molecules to their clinical needs. This engineered antibody-like protein has a compact and stable structure and enables the targeting of two different antigens with a single recombinant molecule.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The DART platform has been specifically engineered to accommodate virtually any variable region sequence with predictable expression, folding and antigen recognition. We believe our multi-specific platforms may provide a significant advantage over current biological interventions in cancer, autoimmune disorders and infectious disease by enabling a range of modalities, including those described below.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have also advanced beyond our DART platform to establish a TRIDENT platform, which reflects the continuing evolution of our multi-specific antibody-based targeting expertise. Built on the DART module, the trivalent TRIDENT platform incorporates in an Ig-like format an additional domain capable of engaging an independent antigen. With the inclusion of a third targeting arm, TRIDENT molecules enable a broader range of mechanisms of action than bispecific targeting, allowing, for instance, the engagement of multiple antigens on a single or on different cells or enabling enhanced target selectivity by modulating the avidity of one of two antigens.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:79%;"></td><td style="width:21%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Redirected T cell activation and killing</font><font style="font-family:inherit;font-size:10pt;">. In this version of the DART molecule, we are enabling the cancer-fighting properties of the immune effector cells, such as T lymphocytes to: (1)&#160;recognize and bind to structures expressed on a cancer cell (e.g., B7-H3, the first specificity in the example on the right), (2)&#160;enable the recruitment of all types of cytotoxic, or cell killing, T cells, irrespective of their ability to recognize cancer cells (e.g., CD3, a common component of the T cell antigen receptor, is the second specificity in the example on the right) and (3)&#160;trigger T cell activation, expansion, and cell killing mechanisms to destroy a cancer cell. The outcome is that any of the body's T cells, in theory, could be recruited to destroy a cancer cell and thus, are not limited to the small numbers of specific T cells that might have been generated in response to cancer to kill tumor cells. Furthermore, since any T cell could be recruited for this killing process, only small amounts of a DART molecule are required to trigger this potent immune response. Additionally, the compact structure of the DART protein makes it well suited for maintaining cell-to-cell contact, which we believe contributes to the high level of target cell killing. Similarly, DART molecules targeting CD3 and a viral antigen can be used to recruit T cells to eliminate cells infected by a virus, such as HIV-infected cells.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="form10k2016image2.jpg" alt="form10k2016image2.jpg" style="height:246px;width:124px;"></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Modulation of receptor signaling</font><font style="font-family:inherit;font-size:10pt;">. In another configuration of the DART molecule, we have taken advantage of the two different specificities engineered in a DART structure to bind to particular cells involved in autoimmune processes, such as autoimmune B cells, and to usurp the immune checkpoint signaling pathways programmed within the cells to impede the pathogenic autoimmune responses. Our MGD010 product candidate targets both CD32B, a co-inhibitory molecule, and CD79B, part of the B cell antigen receptor complex, two proteins expressed on the immune system's B cells. Using a single DART molecule, we attempt to promote the interaction of these two receptors, a step required to interrupt the B cell activation and immune response that single antibodies directed against CD32B, CD79B or both cannot accomplish independently.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="form10k2016image3.jpg" alt="form10k2016image3.jpg" style="height:178px;width:130px;"></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:5pt;">&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Simultaneous targeting of multiple co-inhibitory receptors or checkpoints, such as those involved in inhibiting T cell responses and B cell responses.</font><font style="font-family:inherit;font-size:10pt;">&#160;The immune system generally prevents the development of autoimmune phenomena by regulating activated immune cells that have responded to non-self or foreign antigens. This negative feedback loop is triggered by the interactions of co-inhibitory receptors, or checkpoint molecules, expressed on the immune cells with ligands expressed by other cells, such as antigen-presenting cells. This phenomenon is exploited by cancer, whereby tumor cells express checkpoint ligands that block the development of an immune response against the tumor. Antibodies that block the interaction of checkpoint molecules with their ligands have been shown to significantly improve the clinical outcomes of patients with certain advanced cancers. Because of the diversity of immune checkpoint pathways, blockade of a single axis, while clinically significant, as shown in the case of the blockade of the PD-1/PD-L1 axis with pembrolizumab or nivolumab, will not benefit all patients. In fact, combinations of checkpoint inhibitors, such as nivolumab and ipilimumab, a CTLA-4 blocker, have resulted in significantly enhanced benefit compared to ipilimumab or nivolumab alone. We believe that DART molecules targeting two immunoregulatory pathways, such as two checkpoints in a single molecule, could afford the clinical benefit of the combination together with the potential for synergistic activity, as well as significant advantages in manufacturing, simplified clinical development, and enhanced patient convenience.</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="form10k2016image4.jpg" alt="form10k2016image4.jpg" style="height:204px;width:117px;"></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Enhanced effector cell selectivity. </font><font style="font-family:inherit;font-size:10pt;">T lymphocytes with lytic effector function belong preferentially to the CD8 lineage, while CD4-positive T cells preferentially provide immune regulatory function, such as the secretion of cytokines or the differentiation into regulatory T cells. Greater selectivity in the recruitment of effector T cells is an example of the range of applications of our TRIDENT technology. By encoding a CD8 recognition arm in addition to the CD3- and tumor antigen-specific arms, our TRIDENT technology allow the preferential engagement of CD8-positive T lymphocytes and redirects them against tumor cells. This strategy allows for retention of lytic effector function, while limiting the CD4 cell engagement and associated effects, such as inflammatory cytokine release.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="form10k2016image5.jpg" alt="form10k2016image5.jpg" style="height:190px;width:109px;"></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the ability to tailor a DART molecule's valency, we have the capacity to modify the strength by which the binding sites attach to their targets and the molecule's half-life in the blood circulation after delivery to a patient. Furthermore, when an Fc domain is coupled with a DART molecule, additional changes can be included that can modulate the DART molecule's engagement with different immune cells.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have developed proof-of-concept preclinical data and are developing specific product candidates using this technology, including flotetuzumab, MGD007, MGD009, MGD010 and duvortuxizumab, among others. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fc Optimization Platform: Our Proprietary Approach to Enhance Immune-Mediated Cancer Cell Killing</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To enhance the body's immune ability, we developed our Fc Optimization platform which introduces certain mutations into the Fc region of an antibody and is able to modulate antibody interaction with immune effector cells. Such interaction enhances the body's immune ability to mediate the killing of cancer cells through ADCC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ADCC</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><img src="form10k2016image6.jpg" alt="form10k2016image6.jpg" style="height:185px;width:216px;"></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Fc region mediates the function of IgG antibodies by binding to different activating and inhibitory receptors, referred to as Fc&#947;Rs, on immune effector cells found within the innate immune system. By engineering Fc regions to bind with an increased affinity to the activating Fc&#947;Rs and with a reduced affinity to the inhibitory Fc&#947;Rs, we have been able to impart a more effective immune response and improve effector functions, such as ADCC. This is another example in which small changes in antibody structure can confer improvements on normal immune processes.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have established a proprietary platform to engineer, screen, identify and test antibodies' Fc regions with customizable activity. In particular, we have licenses to use transgenic mice that express human Fc&#947;Rs. These mice can be used for in vivo testing of antibodies that incorporate Fc domain variants, including those antibodies intended for cancer therapy.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, we have successfully incorporated our Fc variants in two of our clinical-stage antibody product candidates, margetuximab and enoblituzumab. We have preclinical data demonstrating that these Fc variants have substantially improved the activity of these antibodies.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cancer Stem-like Cell Technology: Our Proprietary Approach to Discover Cancer Targets</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our CSLC technology provides new approaches to discover and identify cancer targets that are not susceptible to current cancer therapies. We have generated over 2,700 monoclonal antibodies that we have screened by IHC for lower-binding to normal, non-malignant tissues. Cancer stem cells represent important potential targets in oncology drug development because they are theorized to be the basis for tumor re-growth, metastasis and resistance to much standard chemotherapy.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Collaborations</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our current strategic collaborations, we have received significant non-dilutive funding to date and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products.&#160; Each of our collaborations has a unique set of terms and conditions, but in general, they fall into two categories:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">MacroGenics-Created Programs</font><font style="font-family:inherit;font-size:10pt;">.&#160; We have a number of collaborations relating to product candidates that we have created from our internal research efforts. These include Janssen for duvortuxizumab and MGD015; Servier for flotetuzumab and MGD007; and Green Cross Corp., or Green Cross, for margetuximab.&#160; In the case of these product candidates, we entered into collaborations because we believed that our collaborator could further enable </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:54px;padding-bottom:12px;"><font style="font-family:inherit;font-size:10pt;">development of the program or provide additional capabilities and funding to supplement MacroGenics' investment, or both.&#160; We obtained financial terms that we believed were beneficial to us and retained commercial rights for multiple major markets or options to other commercial rights.&#160; For example, under the Janssen agreements, we have the option to co-promote products in the United States as well as an option to share in profits in the United States and Canada if we invest in late-stage development.&#160; Under the Servier agreement, we retain full commercialization and development rights in the United States, Canada, Mexico, Japan, South Korea and India, and regain worldwide rights if Servier opts not to continue co-developing MGD007. Under the Green Cross agreement, we retain full commercialization rights worldwide except for South Korea.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Joint Research Programs.</font><font style="font-family:inherit;font-size:10pt;">&#160; We have several programs under which collaborators have sought to utilize some aspect of our protein engineering platforms with new product concepts that are jointly directed, sometimes employing a collaborator's own proprietary technology.&#160; These collaborations give us the ability to expand the breadth of our potential products, develop greater scientific expertise and obtain additional funding for research.&#160; Pfizer, Inc. and Boehringer Ingelheim GmbH, or Boehringer, are currently advancing projects in their own pipelines based on these types of programs.&#160; With these collaborators, we have more limited development or commercial rights related to the product candidates that may emerge from joint research programs, although we will receive royalties from these programs as well as other consideration upon the occurrence of specified development and sales milestones.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We strive to protect the proprietary technologies that we believe are important to our business, including seeking and maintaining patents intended to protect, for example, the composition of matter of our product candidates, their methods of use, the technology platforms used to generate them, related technologies and/or other aspects of the inventions that are important to our business. We also rely on trade secrets, confidentiality and invention assignment agreements and careful monitoring of our proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business.&#160; In addition, there is cost and risk to our business in defending and enforcing our patents, maintaining our licenses to use intellectual property owned by third parties and preserving the confidentiality of our trade secrets and operating without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary positions. We currently use multiple industry-standard patent monitoring systems to monitor new United States Patent and Trademark Office, or USPTO, filings for any applications by third parties that may infringe on our patents.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The patent positions of biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted by the courts after issuance. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, narrowed, circumvented or invalidated by third parties.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A third party may hold patents or other intellectual property rights that are important to or necessary for the development of our product candidates or use of our technology platforms. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially. For example, certain patents held by third parties cover Fc engineering methods and mutations in Fc regions to enhance the binding of Fc regions to Fc receptors on immune cells. Although we believe that these patents are not infringed and invalid, should a court find that they cover margetuximab or enoblituzumab and we are unable to invalidate them, or if licenses for them are not available on commercially reasonable terms, our business could be harmed, perhaps materially.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because patent applications in the United States and certain other jurisdictions can be maintained in secrecy for 18 months or potentially even longer, and because publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending patent applications. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention. In the ordinary course of business we participate in post-grant challenge proceedings, such as oppositions, that challenge the patentability of third party patents. Such proceedings could result in substantial cost, even if the eventual outcome is favorable to us.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pipeline Patent Protection</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we held 82 patents in the United States with 51 patent applications pending and 281 patents in other countries of the world with 262 patent applications pending. In addition to patents and patent applications generally providing protection for various aspects of our Fc Optimization, DART, TRIDENT and Cancer Stem-Like Cell platforms, we have patent and patent applications for the composition of matter of each of our clinical pipeline product candidates and, in some cases, we also have other patents and patent application related to various aspects of the technology underlying these product candidates or their methods of use.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patent terms may be adjusted or extended, as described in greater detail below, in certain circumstances. However, assuming no adjustments or extensions, the primary composition of matter patent for each of our clinical pipeline product candidates is expected to expire in the following timeframes:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:66%;"></td><td style="width:34%;"></td></tr><tr><td style="vertical-align:top;background-color:#d9d9d9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Candidate</font></div></td><td style="vertical-align:top;background-color:#d9d9d9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expiration Date</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">margetuximab</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2029</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">enoblituzumab</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2031</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">flotetuzumab</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2034*</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD007</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2034*</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD009</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2036*</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD010</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2034*</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">duvortuxizumab</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2035*</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGA012</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2036*</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">* pending</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patent Term Extension and Reference Product Exclusivity</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Hatch-Waxman Act permits a patent term extension for FDA-approved drugs, including biological products, of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our pharmaceutical product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We intend to seek patent term extensions to any of our issued patents in any jurisdiction where these are available, however there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Affordability Reconciliation Act, collectively the ACA, created a regulatory scheme authorizing the FDA to approve biosimilars via an abbreviated licensure pathway. In many cases, this allows biosimilars to be brought to market without conducting the full suite of clinical trials typically required of originators. Under the ACA, a manufacturer may submit an application for licensure of a biologic product that is "biosimilar to" or "interchangeable with" a previously approved biological product or "reference product." The "biosimilar" application must include specific information demonstrating biosimilarity based on data derived from: (1) analytical studies, (2) animal studies, and&#160;(3) a clinical study or studies that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed, except that FDA may waive some of these requirements for a given application. Under this new statutory scheme, an application for a biosimilar product may not be submitted to the FDA until four years after the date of first licensure. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was first licensed. The law does not change the duration of patents granted on biological products. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full Biologics License Application, or BLA, for such product containing the sponsor's own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. There have been recent proposals to repeal or modify the ACA and it is uncertain how any of those proposals, if approved, would affect these provisions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Trade Secrets</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also rely on trade secret protection for our confidential and proprietary information. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual's relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In many cases our confidentiality and other agreements with consultants, outside scientific collaborators, sponsored researchers and other advisors require them to assign or grant us licenses to inventions they invent as a result the work or services they render under such agreements or grant us an option to negotiate a license to use such inventions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">In-Licensed Intellectual Property</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into patent and know-how license agreements that grant us the rights to use certain technologies related to biological manufacturing for our clinical product candidates. We anticipate using these technologies for future product candidates. These licensors have businesses dedicated to licensing this type of technology and we anticipate that licenses to use these technologies for our future products will be available. The licenses typically include yearly maintenance payments and sales royalties, and may also include upfront payments or milestone payments.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Manufacturing</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently manufacture our drug substance for our clinical trials at our manufacturing facility located in Rockville, Maryland. For our antibody product candidates, we have supplemented our drug substance manufacturing capacity through an arrangement with CMC Biologics, Inc., or CMC, a contract manufacturing organization, and plan to commercially produce margetuximab at CMC assuming the success of the Phase 3 SOPHIA clinical trial on the expected timeline. We have also initiated the build-out of a manufacturing suite at our headquarters building in Rockville, Maryland, which has been designed to increase our internal capacity to manufacture more drug substance lots, at larger scale and in full compliance with current Good Manufacturing Practices (cGMP) to be able to sell commercial product. In addition, we currently rely on and will continue to rely on contract fill-finish service providers, primarily Ajinomoto Althea, Inc. and Baxter Healthcare Corporation, to fulfill our fill-finish needs for our current and future product candidates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Most of the principal materials we use in our manufacturing operations are available from more than one source. However, we obtain certain raw materials principally from only one source. In the event one of these suppliers was unable to provide the materials or product, we generally seek to maintain sufficient inventory to supply the market until an alternative source of supply can be implemented. However, in the event of an extended failure of a supplier, it is possible that we could experience an interruption in supply until we established new sources or, in some cases, implemented alternative processes.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Production processes for biological therapeutic products are complex, highly regulated, and vary widely from product to product. Shifting or adding manufacturing capacity can be a very lengthy process requiring significant capital expenditures, process modifications, and regulatory approvals. Accordingly, if we were to experience extended plant shutdowns at one of our own facilities, extended failure of a contract supplier or contract manufacturing organization, or extraordinary unplanned increases in demand, we could experience an interruption in supply of certain products or product shortages until production could be resumed or expanded.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commercialization</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We cannot market or promote a new product until a marketing application has been approved by the FDA. We currently have no approved products in the United States. We have not yet established a&#160;sales, marketing or product distribution infrastructure.&#160;We believe that it will be possible for us to access the United States oncology market through a specialty sales force.&#160;Subject to receiving marketing authorization in the United States, we expect to commence commercialization via&#160;our then-in-place&#160;sales and marketing organizations. We believe that these organizations will be able to serve the oncology community in treating the patient populations for which our oncology product candidates are being developed. Outside the United States, we expect to enter into arrangements with third-party commercial partners for any of our product candidates that obtain marketing approval.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Competition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are a large number of companies developing or marketing treatments for cancer and autoimmune disorders, including many major pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work by using next-generation antibody technology platforms to address specific cancer targets. In particular, margetuximab is directed against HER2 and several companies have cancer therapeutics directed </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">against HER2 marketed or in development, such as F. Hoffmann-La Roche Ltd., or Roche, particularly through its affiliate, Genentech, Inc., as well as Puma Biotechnology, Inc. and Cascadian Therapeutics. Market competition may limit the utilization of margetuximab as a therapeutic, even if market approval and adequate reimbursement is obtained, and competition among development-stage programs for patients enrolling in clinical trials for HER2-directed therapies may delay expected timelines for our clinical trials.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the immuno-oncology field is competitive, with treatments currently approved and on the market or in development for various tumor types and patient populations from a variety of different companies such as Merck &amp; Co., Inc., or Merck, The Bristol Myers Squibb Company, or BMS, and Roche, all of which have significantly greater resources than we do. Many of our pipeline programs, if successful, will likely face significant competition both by therapeutics that are already being marketed as well as those that will be approved for marketing before our programs. Of particular note, we are developing MGA012, a monoclonal antibody against PD-1, as well as other therapeutics that could potentially be used in combination with an anti-PD-1 antibody or utilize a portion of MGA012 as part of a multi-specific molecule. Merck, BMS and Roche all have approved products that target either the PD-1 receptor or its ligand, PD-L1, and there are several other companies that have anti-PD-1 or anti-PD-L1 antibodies in clinical development, all of which would compete with ours.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finally, several companies are also developing therapeutics that work by targeting multiple specificities using a single recombinant molecule. Amgen Inc. has obtained marketing approval for one product that works by targeting antigens both on immune effector cell populations and those expressed on certain cancer cells, and has other product candidates in development that use this mechanism. In addition, other companies are developing new treatments for cancer and autoimmune diseases that utilize multi-specific approaches, including Roche, Genmab A/S, Merus B.V., Abbvie Inc., Affimed Therapeutics AG Corporation, Eli Lilly and Company and Xencor, Inc.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining top qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The key competitive factors affecting the success of all of our therapeutic product candidates, if approved, are likely to be their efficacy, safety, dosing convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, the level of generic or biosimilar competition and the availability of reimbursement from government and other third-party payors.&#160; In addition, the standard of medical care provided to cancer patients continues to evolve as more scientific and medical information becomes available.&#160; These changes in medical care relate to pharmaceutical products, but are also affected by other factors, and such changes can positively or negatively affect the prospects of our product candidates as well as those of our competitors.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop, or the standards of care for cancer patients change while our clinical trials are ongoing. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third party payors seeking to encourage the use of biosimilar products. Biosimilar products are expected to become available over the coming years. For example, certain products that are trastuzumab biosimilars may be approved in the U.S. prior to margetuximab, if approved.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The most common methods of treating patients with cancer are surgery, radiation and drug therapy. There are a variety of available drug therapies marketed for cancer. Many of these approved drugs are well established therapies and are widely accepted by physicians, patients and third party payors. In many cases, these drugs are administered in combination to enhance efficacy. While our product candidates may compete with many existing drug and other therapies, to the extent an approved drug is ultimately used in combination with or as an adjunct to these therapies, our product candidates will not be competitive with the approved drug.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Government Regulation and Product Approval</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import and export of pharmaceutical products such as those we are developing. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The processes for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">FDA Regulation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of our current product candidates are subject to regulation in the United States by the FDA as biological products, or biologics. The FDA subjects biologics to extensive pre- and post-market regulation. The Public Health Service Act, the Federal Food, Drug, and Cosmetic Act and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of biologics. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending BLAs, withdrawal of approvals, clinical holds, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, or criminal penalties.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preclinical Studies</font><font style="font-family:inherit;font-size:10pt;">. Drug development in our industry is complex, challenging and risky; failure rates are high. Product development cycles are long - approximately 10 to 15 years from discovery to market. A potential new biological product must undergo many years of preclinical and clinical testing to establish it is pure, potent and safe.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preclinical studies include laboratory evaluation of product chemistry, formulation and toxicity, pharmacology, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements including FDA's good laboratory practice, or GLP, regulations and the U.S. Department of Agriculture's regulations implementing the Animal Welfare Act. After laboratory analysis and preclinical testing in animals, we file an IND with FDA to begin human testing. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature, and a proposed clinical trial protocol, among other things, to the FDA as part of an IND application. Certain preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold or agrees on an alternate approach with us. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Clinical Development</font><font style="font-family:inherit;font-size:10pt;">. Clinical trials involve the administration of the investigational new drug to human subjects (healthy volunteers or patients) under the supervision of a qualified investigator. Clinical trials must be conducted: (i) in compliance with all applicable federal regulations and guidance, including those pertaining to good clinical practice, or GCP, standards that are meant to protect the rights, safety, and welfare of human subjects and to define the roles of clinical trial sponsors, investigators, and monitors; as well as (ii) under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing of a new drug in the United States (whether in patients or healthy volunteers) must be included in the IND submission, and FDA must be notified of subsequent protocol amendments. In addition, the protocol must be reviewed and approved by an institutional review board, or IRB, and all study subjects must provide informed consent prior to participating in the study. Typically, each institution participating in the clinical trial will require review of the protocol before any clinical trial commences at that institution. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their ClinicalTrials.gov website. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and there are additional, more frequent reporting requirements for suspected unexpected serious adverse events.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A study sponsor might choose to discontinue a clinical trial or a clinical development program for a variety of reasons. The FDA may impose a temporary or permanent clinical hold, or other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial subjects. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB's requirements, or may impose other conditions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trials to support BLAs for marketing approval are typically conducted in three pre-approval phases, but the phases may overlap or be combined, particularly in testing for oncology indications. In Phase 1, testing is conducted in a small group of subjects who may be patients with the target disease or condition or healthy volunteers, to evaluate its safety, determine a safe dosage range, and identify side effects. In Phase 2, the drug is given to a larger group&#160;of subjects with the target condition to further evaluate its safety and gather preliminary evidence of efficacy. Phase 3 studies typically last multiple years for oncology indications. In Phase 3, the drug is given to a large group of subjects with the target disease or condition (several hundred to several thousand), often at multiple geographical sites, to confirm its effectiveness, monitor side effects, and collect data to support drug approval. In some cases, FDA may require post-market studies, known as Phase 4 studies, to be </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">conducted as a condition of approval in order to gather additional information on the drug's effect in various populations and any side effects associated with long-term use. Depending on the risks posed by the drugs, other post-market requirements may be imposed. Only a small percentage of investigational drugs complete all three phases and obtain marketing approval.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Approval</font><font style="font-family:inherit;font-size:10pt;">. After completion of the required clinical testing, a BLA can be prepared and submitted to the FDA. FDA approval of the BLA is required before marketing of the product may begin in the United States. The BLA must include the results of preclinical, clinical and other testing and a compilation of data relating to the product's chemistry, manufacture and controls. The cost of preparing and submitting a BLA is substantial. Under federal law, the submission of most BLAs is additionally subject to a substantial application user fee, and annual product and establishment user fees also apply. These fees are typically increased annually.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA has 60&#160;days from its receipt of a BLA to determine whether the application will be accepted for filing based on the FDA's threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins a substantive review, and the review period under the Prescription Drug User Fee Act begins. The standard for reviewing a BLA is whether the product is safe, pure and potent, which has been interpreted to include that the product is safe and effective and has a favorable benefit-risk profile. FDA's current performance goals call for FDA to complete review of 90 percent of standard (non-priority) BLAs within 10 months of receipt and within six months for priority BLAs, which is 12 months and eight months, respectively, if the 60-day review of the initial application is included in the timeline.  In addition, the FDA has developed approaches intended to make certain qualifying products available to patients rapidly - Priority Review, Breakthrough Therapy, Accelerated Approval, and Fast Track.   While the timelines for approval under these pathways may be shorter, there are requirements and conditions associated with each pathway, and there can be no assurance that any of our investigational products will be able to meet the conditions or requirements necessary to receive any such designation or be able to receive the review or approval benefits associated with such designations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes outside clinicians and other experts, for review, evaluation and a recommendation as to whether sufficient data exist in the application to support product approval. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will typically inspect the facility or the facilities at which the drug is manufactured. FDA will not approve the product unless compliance with cGMPs is satisfactory.&#160; FDA also reviews the proposed labeling submitted with the BLA and typically requires changes in the labeling text.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After the FDA evaluates the BLA and the manufacturing and testing facilities, it issues either an approval letter or a complete response letter. Complete response letters generally outline the deficiencies in the submission and delineate the additional testing or information needed in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA's satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing 90 percent of resubmissions within two or six months from receipt depending on the type of information included.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An approval letter authorizes commercial marketing of the drug for the approved indication or indications and the other conditions of use set out in the approved prescribing information.&#160; Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a condition of BLA approval, the FDA may require substantial post-approval testing and surveillance to monitor the drug's safety or efficacy and may impose other conditions, including labeling restrictions that can materially affect the potential market and profitability of the product. As a condition of approval, or after approval, the FDA also may require submission of a risk evaluation and mitigation strategy, or REMS, to mitigate any identified or suspected serious risks. The REMS may include medication guides, physician communication plans, assessment plans, and elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other U.S. Post-Marketing Regulatory Requirements</font><font style="font-family:inherit;font-size:10pt;">. Once a BLA is approved, a product will be subject to certain post-approval requirements, including those relating to advertising, promotion, adverse event reporting, recordkeeping, and cGMPs, as well as registration, listing, and inspection. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FDA regulates the content and format of prescription drug labeling, advertising, and promotion, including direct-to-consumer advertising and promotional Internet communications. FDA also establishes parameters for permissible non-promotional communications between industry and the medical community, including industry-supported scientific and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">educational activities. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion for uses not consistent with the approved labeling, and a company that is found to have improperly promoted off-label uses or otherwise not to have met applicable promotion rules may be subject to significant liability under both the FDCA and other statutes, including the False Claims Act. See "Other Healthcare Laws and Compliance Requirements" below for more information.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All aspects of pharmaceutical manufacture must conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA during which the FDA inspects manufacturing facilities to assess compliance with cGMPs. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMPs.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Products may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, labeling, product formulation or manufacturing processes or facilities, require submission and FDA approval of a new BLA or BLA supplement, in some cases before the change may be implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it does in reviewing BLAs.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturers are subject to requirements for adverse event reporting and submission of periodic reports following FDA approval of a BLA. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, or failure of Phase 4 studies to meet their specified endpoints, may result in revisions to the approved labeling to add new safety information, the need to conduct additional post-market studies or clinical trials to assess new safety risks,&#160; imposition of distribution or other restrictions under a REMS program, or recall of the product and withdrawal of the BLA.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Noncompliance with postmarket requirements can result in one or more of the following consequences:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font><font style="font-family:inherit;font-size:5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font><font style="font-family:inherit;font-size:5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Warning letters;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font><font style="font-family:inherit;font-size:5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Holds on post-approval clinical trials;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font><font style="font-family:inherit;font-size:5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of product license approvals;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font><font style="font-family:inherit;font-size:5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Product seizure or detention, or refusal to permit the import or export of products; or</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font><font style="font-family:inherit;font-size:5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Injunctions or the imposition of civil or criminal penalties.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Approval of Biosimilars</font><font style="font-family:inherit;font-size:10pt;">. The ACA authorized the FDA to approve biosimilars via a separate, abbreviated pathway. In many cases, this allows biosimilars to be brought to market without conducting the full suite of clinical trials typically required of originators. The law establishes a period of 12 years of data exclusivity for reference products in order to preserve incentives for future innovation and outlines statutory criteria for science-based biosimilar approval standards that take into account patient safety considerations. Under this framework, data exclusivity protects the data in the innovator's regulatory application by prohibiting others, for a period of 12 years, from granting FDA approval based in part on reliance on or reference to the innovator's data in their application to the FDA. The law does not change the duration of patents granted on biological products.  There have been recent proposals to repeal or modify the ACA and it is uncertain how any of those proposals, if approved, would affect the provisions governing biosimilars.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Healthcare Laws and Compliance Requirements</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the United States, our activities are potentially subject to regulation by federal, state, and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, and state and local governments.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For example, certain financial interactions with healthcare professionals may be subject to the anti-kickback and fraud and abuse provisions of the Social Security Act and the False Claims Act, and in addition our activities may be affected by the privacy regulations issued under the Health Insurance Portability and Accountability Act, as amended, and similar state laws.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">International Regulation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to regulations in the United States, a variety of foreign regulations govern clinical trials, commercial sales, distribution of product candidates and other areas outlined above. These regulations can vary between jurisdictions and can be more onerous than regulations in the United States.&#160; Penalties for violating such regulations also exist in these jurisdictions. The approval process varies from country to country and the time to approval may be longer or shorter than that required for FDA approval.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pharmaceutical Coverage, Pricing, and Reimbursement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the United States and other countries, sales of any future products for which we receive regulatory approval for commercial sale will depend in part on the availability of adequate reimbursement from third-party payors, including government health administrative authorities, managed care providers, private health insurers, and other organizations. Third-party payors are increasingly examining the medical necessity and cost effectiveness of medical products and services in addition to safety and efficacy and, accordingly, significant uncertainty exists as to the reimbursement status of newly approved therapeutics. Third-party reimbursement adequate to enable us to realize an appropriate return on our investment in research and product development may not be available for our products.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Drug prices have become a subject of increased focus in recent years. Although there are currently no direct government price controls over private sector purchases in the U.S., federal law requires pharmaceutical manufacturers to pay prescribed rebates on certain Medicaid-reimbursed drugs to enable them to be eligible for reimbursement under certain public healthcare programs such as Medicaid and Medicare Part B. Various states have adopted further mechanisms that seek to control drug prices, including by disfavoring certain higher priced drugs or by seeking supplemental rebates from manufacturers. Managed care has also become a potent force in the market place that increases downward pressure on the prices of pharmaceutical products.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Public and private healthcare payers control costs and influence drug pricing through a variety of mechanisms, including through negotiating discounts with the manufacturers and through the use of tiered formularies and other mechanisms that provide preferential access to certain drugs over others within a therapeutic class. Payers also set other criteria to govern the uses of a drug that will be deemed medically appropriate and therefore reimbursed or otherwise covered.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Facilities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our headquarters building, located in Rockville, Maryland, currently houses laboratory and office space and we are also building a suite for manufacturing at commercial quantities and scale. This space is occupied under a lease that expires in 2022 and may be extended for up to two additional seven-year terms. We also have a smaller-scale manufacturing facility, also in Rockville. The lease for a portion of that facility expires on March 31, 2018 and may be extended for a five-year term, and the lease for the remainder of that facility expires on December 31, 2019 and may be extended for up to two additional five-year terms. Finally, we have additional laboratory and office space in Rockville under two leases that each expire on January 31, 2020, and each of those leases may be extended for a five-year term. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also lease office and laboratory space in South San Francisco under a lease that expires on February 28, 2018.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employees</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of February 24, 2017, we had 318 full-time employees, 268 of whom were primarily engaged in research and development activities and 63 of whom had an M.D. or Ph.D. degree.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time we may be involved in various disputes and litigation matters that arise in the ordinary course of business. We are not currently a party to any material legal proceedings.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Available Information</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our website address is www.macrogenics.com. We post links to our website to the following filings as soon as reasonably practicable after they are electronically filed with or furnished to the Securities and Exchange Commission, or the SEC: Annual Reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, and any amendments to those reports filed or furnished pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. All such filings are available through our website free of charge. Our filings may also be read and copied at the SEC's Public Reference Room at 100 F Street, NE, Washington, DC 20549. Information on the operation of the Public Reference Room may be obtained by calling the SEC at 1-800-SEC-0330. The SEC also maintains an internet site at www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">18</font></div></div><hr style="page-break-after:always"><div><a name="s8BF87854CDF1686ABD17E278A674B3CC"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1A.</font><font style="font-family:inherit;font-size:5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RISK FACTORS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our business and results of operations are subject to numerous risks, uncertainties and other factors that you should be aware of, some of which are described below.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Any of the risks, uncertainties and other factors described below could have a materially adverse effect on our business, financial condition or results of operations and could cause the trading price of our common stock to decline substantially.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Business and the Development and Commercialization of Our Product Candidates.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">All of our product candidates are in preclinical or clinical development. Clinical drug development is expensive, time consuming and uncertain and we may ultimately not be able to obtain regulatory approvals for the commercialization of some or all of our product candidates.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug products are subject to extensive regulation by the U.S. Food and Drug Administration, or FDA, and non-U.S. regulatory authorities, which regulations differ from country to country. We are not permitted to market our product candidates in the United States or in other countries until we receive approval of a Biologics License Application, or BLA, from the FDA or marketing approval from applicable regulatory authorities outside the United States. Our product candidates are in various stages of development and are subject to the risks of failure inherent in drug development. We have not submitted an application for or received marketing approval for any of our product candidates. We have limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA. Obtaining approval of a BLA can be a lengthy, expensive and uncertain process. In addition, failure to comply with FDA and non-U.S. regulatory requirements may, either before or after product approval, if any, subject our company to administrative or judicially imposed sanctions, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">restrictions on the products, manufacturers, manufacturing facilities or manufacturing process;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">warning letters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">civil and criminal penalties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">injunctions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">suspension or withdrawal of regulatory approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product seizures, detentions or import bans;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">voluntary or mandatory product recalls and publicity requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">total or partial suspension of production;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">imposition of restrictions on operations, including costly new manufacturing requirements; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">refusal to approve pending BLAs or supplements to approved BLAs or analogous marketing approvals outside the United States.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA and foreign regulatory authorities also have substantial discretion in the drug approval process. The number of preclinical studies and clinical trials that will be required for regulatory approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular drug candidate. Regulatory agencies can delay, limit or deny approval of a product candidate for many reasons, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a product candidate may not be deemed safe or effective;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the results may not confirm the positive results from earlier preclinical studies or clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory agencies may not find the data from preclinical studies and clinical trials sufficient;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory agencies might not approve or might require changes to our manufacturing processes or facilities; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory agencies may change their approval policies or adopt new regulations.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price. Furthermore, any regulatory approval to market a product may be subject to limitations on the indicated uses for which we may market the product. These limitations may limit the size of the market for the product.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If clinical trials for our product candidates are prolonged, delayed or stopped, we may be unable to obtain regulatory approval and commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any product revenue.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are currently enrolling patients in clinical trials for margetuximab, enoblituzumab, MGD006 (or flotetuzumab), MGD007, MGD009 and MGA012 and anticipate initiating or continuing clinical trials for these product candidates and others in 2017. In addition, our collaborators are currently enrolling patients in clinical trials for MGD011 (or duvortuxizumab), PF-06671008 and teplizumab.&#160; The commencement of new clinical trials could be substantially delayed or prevented by several factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">further discussions with the FDA or other regulatory agencies regarding the scope or design of our clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the limited number of, and competition for, suitable sites to conduct our clinical trials, many of which may already be engaged in other clinical trial programs, including some that may be for the same indication as our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any delay or failure to obtain regulatory approval or agreement to commence a clinical trial in any of the countries where enrollment is planned;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inability to obtain sufficient funds required for a clinical trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">clinical holds on, or other regulatory objections to, a new or ongoing clinical trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delay or failure to manufacture sufficient supplies of the product candidate for our clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delay or failure to reach agreement on acceptable clinical trial agreement terms or clinical trial protocols with prospective sites or clinical research organizations, CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different sites or CROs; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delay or failure to obtain institutional review board, or IRB, approval to conduct a clinical trial at a prospective site.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The completion of our clinical trials could also be substantially delayed or prevented by several factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">slower than expected rates of patient recruitment and enrollment;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure of patients to complete the clinical trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unforeseen safety issues, including severe or unexpected drug-related adverse effects experienced by patients, including possible deaths;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">lack of efficacy during clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">termination of our clinical trials by one or more clinical trial sites;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inability or unwillingness of patients or clinical investigators to follow our clinical trial protocols;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inability to monitor patients adequately during or after treatment by us and/or our CROs; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the need to repeat or terminate clinical trials as a result of inconclusive or negative results or unforeseen complications in testing.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in regulatory requirements and guidance may also occur and we may need to significantly amend clinical trial protocols to reflect these changes with appropriate regulatory authorities. Amendments may require us to renegotiate terms with CROs or resubmit clinical trial protocols to IRBs for re-examination, which may impact the costs, timing or successful completion of a clinical trial. Our clinical trials may be suspended or terminated at any time by the FDA, other regulatory authorities, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or us, due to a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unforeseen safety issues or any determination that a clinical trial presents unacceptable health risks;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">lack of adequate funding to continue the clinical trial due to unforeseen costs or other business decisions; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">upon a breach or pursuant to the terms of any agreement with, or for any other reason by, current or future collaborators that have responsibility for the clinical development of any of our product candidates.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any failure or significant delay in completing clinical trials for our product candidates would adversely affect our ability to obtain regulatory approval and our commercial prospects and ability to generate product revenue will be diminished.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The results of previous clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any of our current and future collaborators may decide, or regulators may require us, to conduct additional clinical or preclinical testing. Success in early clinical trials does not mean that future larger registration clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and non-U.S. regulatory authorities despite having progressed through initial clinical trials. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further, our product candidates may not be approved even if they achieve their primary endpoints in Phase 3 clinical trials or registration trials. The FDA or other non-U.S. regulatory authorities may disagree with our trial design and our interpretation of data from preclinical studies and clinical trials. In addition, any of these regulatory authorities may change requirements for the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a pivotal Phase 3 clinical trial. In addition, any of these regulatory authorities may also approve a product candidate for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials. The FDA or other non-U.S. regulatory authorities may not approve the labeling claims that we believe would be necessary or desirable for the successful commercialization of our product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We use new technologies in the development of our product candidates and the FDA and other regulatory authorities have not approved products that utilize these technologies.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our products in development are based on new technologies, such as Fc Optimization, DART molecules and TRIDENT molecules. Given the novelty of our technologies, we intend to work closely with FDA and other regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates. The validation process takes time and resources, may require independent third-party analyses, and may not be accepted by the FDA and other regulatory authorities. For some of our product candidates that are based on these technology platforms, the regulatory approval path and requirements may not be clear or evolve as more data becomes available for this product candidates, which could add significant delay and expense. Delays or failure to obtain regulatory approval of any of the product candidates that we develop would adversely affect our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be successful in our efforts to use and expand our technology platforms to build a pipeline of product candidates. We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A key element of our strategy is to use and expand our technology platforms to build a pipeline of product candidates and progress these product candidates through clinical development for the treatment of a variety of different types of diseases. Although our research and development efforts to date have resulted in a pipeline of product candidates directed at&#160;various cancers, as well as autoimmune disorders and infectious diseases, we may not be able to develop product candidates that are safe and effective. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we do not continue to successfully develop and begin to commercialize product candidates, we will face difficulty in obtaining product revenues in future periods, which could result in significant harm to our financial position and adversely affect our stock price.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize our products outside of the United States, which would limit our ability to realize their full market potential.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and may require additional preclinical studies or clinical trials or additional administrative review periods, which could result in significant </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays, difficulties and costs for us. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of our products will be harmed.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our product candidates may have undesirable side effects which may delay or prevent marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although all of our product candidates have undergone or will undergo safety testing, not all adverse effects of drugs can be predicted or anticipated. Unforeseen side effects from any of our product candidates could arise either during clinical development or, if approved by regulatory authorities, after the approved product has been marketed. All of our product candidates are still in clinical or preclinical development. While our clinical trials for our initial product candidates to date have demonstrated a favorable safety profile, the results from future trials may not support this conclusion. The results of future clinical or preclinical trials may show that our product candidates cause undesirable or unacceptable side effects, which could interrupt, delay or halt clinical trials, and result in delay of, or failure to obtain, marketing approval from the FDA and other regulatory authorities, or result in marketing approval from the FDA and other regulatory authorities with restrictive label warnings or potential product liability claims.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any of our product candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects caused by such products:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory authorities may require us to take our approved product off the market;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be required to change the way the product is administered, impose other risk-management measures, conduct additional clinical trials or change the labeling of the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be subject to limitations on how we may promote the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sales of the product may decrease significantly;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be subject to litigation or product liability claims; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our reputation may suffer.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any of these events could prevent us, our collaborators or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our products.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Even if approved, if any of our product candidates do not achieve broad market acceptance among physicians, patients, the medical community, and third-party payors our revenue generated from their sales will be limited.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The commercial success of our product candidates will depend upon their acceptance among physicians, patients and the medical community. The degree of market acceptance of our product candidates will depend on a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">limitations or warnings contained in the approved labeling for a product candidate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in the standard of care for the targeted indications for any of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">limitations in the approved clinical indications for our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">demonstrated clinical safety and efficacy compared to other products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">lack of significant adverse side effects;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sales, marketing and distribution support;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">availability and extent of reimbursement from managed care plans and other third-party payors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">timing of market introduction and perceived effectiveness of competitive products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the degree of cost-effectiveness of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">availability of alternative therapies at similar or lower cost, including generic and over-the-counter products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the extent to which the product candidate is approved for inclusion on formularies of hospitals and managed care organizations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy for particular diseases;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adverse publicity about our product candidates or favorable publicity about competitive products;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">convenience and ease of administration of our products; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">potential product liability claims.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any of our product candidates are approved, but do not achieve an adequate level of acceptance by physicians, patients and the medical community, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The manufacture of our product candidates is complex, and we may encounter difficulties in production.&#160; If we encounter any such difficulties, our ability to supply our product candidates for clinical trials or, if approved, for commercial sale could be delayed or halted entirely.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The process of manufacturing our product candidates is extremely susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, contamination and inconsistency in yields, variability in product characteristics, and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Any adverse developments affecting manufacturing operations for our product candidates, if any are approved, may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our manufacturing facilities are subject to significant government regulations and approvals, which are often costly and could result in adverse consequences to our business if we fail to comply with the regulations or maintain the approvals.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We must comply with the FDA's current Good Manufacturing Practice, or cGMP, requirements, as set out in statute, regulations and guidance. We may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm compliance with applicable regulatory requirements. See "Other U.S. Post-Marketing Regulatory Requirements" above for additional information. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our product candidates as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, including leading to significant delays in the availability of drug product for our clinical trials or the termination or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Significant noncompliance could also result in the imposition of sanctions, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation. If we are not able to maintain regulatory compliance, we may not be permitted to market our product candidates and/or may be subject to product recalls, seizures, injunctions, or criminal prosecution.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We currently have no marketing, sales or distribution infrastructure. If we are unable to develop sales, marketing and distribution capabilities on our own or through collaborations, we will not be successful in commercializing our product candidates.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently have no marketing, sales and distribution infrastructure and we have limited sales and marketing experience within our organization. If any of our product candidates are approved, we intend to establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize our product candidates in the United States and, potentially, to outsource this function to a third party outside of the United States. Both of these options would be expensive and time consuming. These costs may be incurred in advance of any approval of our product candidates. In addition, we may not be able to engage a sales force in the United States that is sufficient in size or has adequate expertise in the medical markets that we intend to target. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of our products.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to certain of our existing and future product candidates, we have entered into collaboration or other licensing arrangements with third party collaborators that have direct sales forces and established distribution systems. To the extent that we enter into additional collaboration agreements, our product revenue may be lower than if we directly marketed or sold any approved products. In addition, any revenue we receive will depend in whole or in part upon the efforts of these third party collaborators, which may not be successful and are generally not within our control. If we are unable to enter into additional arrangements on acceptable terms or at all, we may not be able to successfully commercialize certain approved </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">products. If we are not successful in commercializing approved products, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We face significant competition and if our competitors develop and market products that are more effective, safer or less expensive than our product candidates, our commercial opportunities will be negatively impacted.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The life sciences industry is highly competitive and subject to rapid and significant technological change. We are currently developing therapeutics that will compete with other drugs and therapies that currently exist or are being developed. Products we may develop in the future are also likely to face competition from other drugs and therapies, some of which we may not currently be aware. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or FDA approval or discovering, developing and commercializing products in our field before we do.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Specifically, there are a large number of companies developing or marketing treatments for cancer and autoimmune disorders, including many major pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work by using next-generation antibody technology platforms to address specific cancer targets. In addition, several companies are developing therapeutics that work by targeting multiple specificities using a single recombinant molecule. See "Competition" above for additional information.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third party payors seeking to encourage the use of biosimilar products. Biosimilar products are expected to become available over the coming years. For example, certain HER2 biosimilar products are approved in certain countries and others may be approved prior to margetuximab. Even if our product candidates achieve marketing approval, they may be priced at a significant premium over competitive biosimilar products if any have been approved by then.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance. If there is not sufficient reimbursement for our products, it is less likely that our products will be widely used.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even if our product candidates are approved for sale by the appropriate regulatory authorities, market acceptance and sales of these products will depend on reimbursement policies and may be affected by future healthcare reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will reimburse and establish payment levels and, in some cases, utilization&#160;management strategies, such as tiered formularies and prior authorization. We cannot be certain that reimbursement will be available for any products that we develop or that the reimbursement level will be adequate to allow us to operate profitably. Also, we cannot be certain that reimbursement policies will not reduce the demand for, or the price paid for, our products. If reimbursement is not available or is available on a limited basis, or if the reimbursement amount is inadequate, we may not be able to successfully commercialize any of our approved products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Actual or anticipated changes to the laws and regulations governing the health care system may have a negative impact on cost and access to health insurance coverage and reimbursement of healthcare items and services. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The United States and several foreign jurisdictions are considering, or have already enacted, a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell any of our future approved products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access to healthcare. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives, including the Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Affordability Reconciliation Act, collectively the ACA, which became law in 2010. While it is difficult to assess the impact of the ACA in isolation, either in general or on our business specifically, it is widely thought that the ACA increases downward pressure on pharmaceutical reimbursement, which could negatively affect market acceptance of, and the price we may charge for, any products we develop that receive regulatory approval. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is further difficult to assess the impact  the new presidential administration in the United States will have on pricing and market acceptance of our products in the future.  The change in presidential administration has injected significant uncertainty into the status of the systems and policies implemented by the ACA and the health insurance marketplace.  Further, it is uncertain whether some or all of the ACA may undergo significant legislative or executive branch reform, up to and including total repeal without replacement or reformation.   During the campaign, the President and Congressional leaders expressed a desire, in addition to repeal of the ACA, to exert downward pressure on pharmaceutical reimbursement via changes in government reimbursement policies or other mechanisms.  Government and other regulatory oversight and future regulatory and government interference with the health care system may adversely impact our business and results of operations. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to experience pricing pressures in connection with the sale of any products that we develop, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative proposals.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If any product liability lawsuits are successfully brought against us or any of our collaborators, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We face an inherent risk of product liability lawsuits related to the testing of our product candidates in seriously ill patients, and will face an even greater risk if product candidates are approved by regulatory authorities and introduced commercially. Product liability claims may be brought against us or our collaborators by participants enrolled in our clinical trials, patients, health care providers or others using, administering or selling any of our future approved products. If we cannot successfully defend ourselves against any such claims, we may incur substantial liabilities. Regardless of their merit or eventual outcome, liability claims may result in:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">decreased demand for our future approved products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">injury to our reputation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">withdrawal of clinical trial participants;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">termination of clinical trial sites or entire trial programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased regulatory scrutiny;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">significant litigation costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">substantial monetary awards to or costly settlement with patients or other claimants;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product recalls or a change in the indications for which they may be used;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">loss of revenue;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">diversion of management and scientific resources from our business operations; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the inability to commercialize our product candidates.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any of our product candidates are approved for commercial sale, we will be highly dependent upon consumer perceptions of us and the safety and quality of our products. We could be adversely affected if we are subject to negative publicity. We could also be adversely affected if any of our products or any similar products distributed by other companies prove to be, or are asserted to be, harmful to patients. Because of our dependence upon consumer perceptions, any adverse publicity associated with illness or other adverse effects resulting from patients' use or misuse of our products or any similar products distributed by other companies could have a material adverse impact on our financial condition or results of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently hold $20 million in product liability insurance coverage in the aggregate, with a per incident limit of $20 million, which may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage when we begin the commercialization of our product candidates. Insurance coverage is becoming increasingly expensive. As a result, we may be unable to maintain or obtain sufficient insurance at a reasonable cost to protect us against losses that could have a material adverse effect on our business. A successful product liability claim or series of claims brought against us, particularly if judgments exceed any insurance coverage we may have, could decrease our cash resources and adversely affect our business, financial condition and results of operation.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The contract with the National Institute of Allergy and Infectious Diseases (NIAID)&#160;makes us a government contractor. Laws and regulations affecting government contracts&#160;may&#160;make it more costly and difficult for us to successfully conduct our business.&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We must comply with numerous laws and regulations relating to the procurement, formation, administration and performance of government contracts.&#160;Failure to comply with these laws could result in significant civil and criminal penalties. &#160;Among the most significant government contracting regulations that&#160;may&#160;affect&#160;our&#160;business&#160;are:&#160;&#160;the Federal Acquisition Regulation, or FAR, and&#160;NIH-NIAID-specific regulations supplemental to the FAR, which comprehensively regulate the procurement, formation, administration and performance of government contracts;&#160;&#160;business ethics and public integrity obligations, which govern conflicts of interest and the hiring of former government employees, restrict the granting of gratuities and funding of lobbying activities and incorporate other requirements such as the Anti-Kickback Act, the Procurement Integrity Act,&#160;and&#160;the False Claims Act;&#160;&#160;export and import control laws and regulations; and&#160;laws, regulations and executive orders restricting the use and dissemination of&#160;sensitive&#160;information&#160;we may receive pursuant to our performance of the government contract. &#160;&#160;U.S. government agencies routinely audit and investigate government contractors for compliance with applicable laws and standards. If we are audited, such audit could result in disallowance of expected cost reimbursement, or if such audit were to uncover improper or illegal activities, we could be subject to civil and criminal penalties, administrative sanctions, including suspension or debarment from government contracting and significant reputational harm.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Financial Position and Need for Additional Capital</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We have no products approved for commercial sale, and to date we have not generated any revenue or profit from product sales. We may never achieve or sustain profitability.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a clinical-stage biopharmaceutical company. We have incurred significant losses since our inception. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, our accumulated deficit was approximately </font><font style="font-family:inherit;font-size:10pt;">$292.7 million</font><font style="font-family:inherit;font-size:10pt;">. We expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates, prepare for and begin to commercialize any approved products, and add infrastructure and personnel to support our product development efforts and operations as a public company. The net losses and negative cash flows incurred to date, together with expected future losses, have had, and likely will continue to have, an adverse effect on our stockholders' deficit and working capital. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. For example, our expenses could increase if we are required by the FDA to perform trials in addition to those that we currently expect to perform, or if there are any delays in completing our currently planned clinical trials or in the development of any of our product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To become and remain profitable, we must succeed in developing and commercializing products with significant market potential. This will require us to be successful in a range of challenging activities for which we are only in the preliminary stages, including developing product candidates, obtaining regulatory approval for them, and manufacturing, marketing and selling those products for which we may obtain regulatory approval. We may never succeed in these activities and may never generate revenue from product sales that is significant enough to achieve profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to become or remain profitable would depress our market value and could impair our ability to raise capital, expand our business, develop other product candidates, or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, scale back, or cease our product development programs or operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are advancing our product candidates through clinical development. Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. In order to obtain such regulatory approval, we will be required to conduct clinical trials for each indication for each of our product candidates. We will continue to require additional funding beyond what was raised in our public offerings and through our collaborations and license agreements to complete the development and commercialization of our product candidates and to continue to advance the development of our other product candidates, and such funding may not be available on acceptable terms or at all. Although it is difficult to predict our funding requirements, based upon our current operating plan, we anticipate that our cash, cash equivalents and marketable securities as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, combined with the proceeds from collaboration payments we anticipate receiving, will enable us to fund our operations through late 2018, assuming all of our programs and collaborations advance as currently contemplated. Because successful development of our product candidates is uncertain, we are unable to estimate the actual funds we will require to complete research and development and to commercialize our product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our future funding requirements will depend on many factors, including but not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the number and characteristics of other product candidates and indications that we pursue;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the scope, progress, timing, cost and results of research, preclinical development, and clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs, timing and outcome of seeking and obtaining FDA and non-U.S. regulatory approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs associated with manufacturing our product candidates and establishing sales, marketing, and distribution capabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to maintain, expand, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make in connection with the licensing, filing, defense and enforcement of any patents or other intellectual property rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our need and ability to hire additional management, scientific, and medical personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the effect of competing products that may limit market penetration of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our need to implement additional internal systems and infrastructure, including financial and reporting systems; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the economic and other terms, timing of and success of our existing collaborations, and any collaboration, licensing, or other arrangements into which we may enter in the future, including the timing of receipt of any milestone or royalty payments under these agreements.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Until we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never do, we expect to finance future cash needs primarily through a combination of public or private equity offerings, debt financings, strategic collaborations, and grant funding. If sufficient funds on acceptable terms are not available when needed, or at all, we could be forced to significantly reduce operating expenses and delay, scale back or eliminate one or more of our development programs or our business operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish substantial rights.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available at all, may involve agreements that include covenants limiting or restricting our ability to take specific actions such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, product candidates, or future revenue streams, or grant licenses on terms that are not favorable to us. We cannot assure you that we will be able to obtain additional funding if and when necessary. If we are unable to obtain adequate financing on a timely basis, we could be required to delay, scale back or eliminate one or more of our development programs or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our ability to use our net operating loss carryforwards and other tax attributes may be limited.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to utilize our federal net operating losses, or NOLs, and federal tax credits is currently limited, and may be limited further, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended. The limitations apply if an ownership change, as defined by Section&#160;382, occurs. Generally, an ownership change occurs when certain shareholders increase their aggregate ownership by more than 50 percentage points over their lowest ownership percentage in a testing period, which is typically three years or since the last ownership change. We are already subject to Section&#160;382 limitations due </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to acquisitions we made in 2002 and 2008.&#160; As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we had federal and state NOL carryforwards of </font><font style="font-family:inherit;font-size:10pt;">$215.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and research and development tax credit carryforwards of </font><font style="font-family:inherit;font-size:10pt;">$32.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;available. Future changes in stock ownership may also trigger an ownership change and, consequently, another Section&#160;382 limitation. Any limitation may result in expiration of a portion of the net operating loss or tax credit carryforwards before utilization which would reduce our gross deferred income tax assets and corresponding valuation allowance. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards and tax credit carryforwards to reduce United States federal income tax may be subject to limitations, which could potentially result in increased future cash tax liability to us.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Dependence on Third Parties</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our existing therapeutic collaborations are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have limited capabilities for drug development and do not yet have any capability for sales, marketing or distribution. We have entered into collaborations with other companies that we believe can provide such capabilities, including our collaboration and license agreements with Janssen Biotech, Inc., or Janssen, Les Laboratoires Servier and Institut de Recherches Servier, or collectively Servier, Boehringer Ingelheim GmbH, or Boehringer, Pfizer, Inc., or Pfizer, and Green Cross Corp., or Green Cross. These collaborations also have provided us with important funding for our development programs and technology platforms and we expect to receive additional funding under these collaborations in the future. Our existing therapeutic collaborations, and any future collaborations we enter into, may pose a number of risks, including the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborators may not perform their obligations as expected;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators' strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. For example, each of our collaboration and license agreements may be terminated for convenience upon the completion of a specified notice period.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If our therapeutic collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our technology platforms and product candidates could be delayed and we may need additional resources to develop product candidates and our technology platforms. All of the risks relating to product development, regulatory approval and commercialization described in this report also apply to the activities of our program collaborators.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For some of our product candidates, we may in the future determine to collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator's resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator's evaluation of a number of factors. These factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our technology platforms and our business may be materially and adversely affected.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. Aside from our agreement with Green Cross, subject to certain specified exceptions, each of our existing therapeutic collaborations contains a restriction on our engaging in activities that are the subject of the collaboration with third parties for specified periods of time.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Independent clinical investigators and CROs that we engage to conduct our clinical trials may not devote sufficient time or attention to our clinical trials or be able to repeat their past success.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to continue to depend on independent clinical investigators and CROs to conduct our clinical trials. CROs may also assist us in the collection and analysis of data. There is a limited number of third-party service providers that specialize or have the expertise required to achieve our business objectives. Identifying, qualifying and managing performance of third-party service providers can be difficult, time consuming and cause delays in our development programs. These investigators and CROs will not be our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. Further, the FDA requires that we comply with standards, commonly referred to as current Good Clinical Practice, or GCP, for conducting, recording and reporting clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial subjects are protected. Failure of clinical investigators or CROs to meet their obligations to us or comply with GCP procedures could adversely affect the clinical development of our product candidates and harm our business.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Failure of our third-party contractors to successfully develop and commercialize companion diagnostics for use with our product candidates could harm our ability to commercialize our product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We plan to develop companion diagnostics for our product candidates where appropriate. We expect that, at least in some cases, the FDA and similar regulatory authorities outside the United States may require the development and regulatory approval of a companion diagnostic as a condition to approving our product candidates. We do not have experience or capabilities in developing or commercializing diagnostics and plan to rely in large part on third parties to perform these functions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In most cases, we will likely outsource the development, production and commercialization of companion diagnostics to third parties. By outsourcing these companion diagnostics to third parties, we become dependent on the efforts of our third party contractors to successfully develop and commercialize these companion diagnostics. Our contractors:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">may not perform their obligations as expected;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">may encounter production difficulties that could constrain the supply of the companion diagnostic;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">may have difficulties gaining acceptance of the use of the companion diagnostic in the clinical community;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">may not commit sufficient resources to the marketing and distribution of such product; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">may terminate their relationship with us.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any companion diagnostic for use with one of our product candidates fails to gain market acceptance, our ability to derive revenues from sales of such product candidate could be harmed. If our third party contractors fail to commercialize such companion diagnostic, we may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with such product candidate or do so on commercially reasonable terms, which could adversely affect and delay the development or commercialization of such product candidate.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We expect to contract with third parties for the manufacture of our product candidates for clinical testing in the future and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently have a manufacturing facility located in Rockville, Maryland. We manufacture drug substance at this facility that we use for research and development purposes and for clinical trials of our product candidates. We believe we currently have capacity to produce some but not all of the material required for our clinical trials. Our current facility will be insufficient to support our needs for our Phase 3 clinical trials for our antibody product candidates and for commercial quantities of such candidates. We do not have experience in manufacturing products at commercial scale. We are in the process of expanding our manufacturing capacity, but that expansion will be time-consuming, costly and will not be ready in time for the anticipated commercial launch of margetuximab, assuming the success of the Phase 3 SOPHIA clinical trial.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into agreements with contract manufacturing organizations to supplement our clinical supply and internal capacity as we advance our product candidate pipeline. We expect to use third parties for the manufacture of certain of our product candidates for clinical testing, as well as for commercial manufacture of some of our product candidates that receive marketing approval and that are not manufactured by one of our third party collaborators. We plan eventually to enter into long-term supply agreements with several manufacturers for commercial supplies. We may be unable to reach agreement with any of these contract manufacturers, or to identify and reach arrangements on satisfactory terms with other contract manufacturers, to manufacture any of our product candidates. Additionally, the facilities used by any contract manufacturer to manufacture any of our product candidates must be the subject of a satisfactory inspection before the FDA and other regulatory authorities approve a BLA or marketing authorization for the product candidate manufactured at that facility. We will depend on these third-party manufacturing partners for compliance with the FDA's requirements for the manufacture of our finished products. If our manufacturers cannot successfully manufacture material that conforms to our specifications and the FDA and other regulatory authorities' cGMP requirements, our product candidates will not be approved or, if already approved, may be subject to recalls.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured the product candidates ourselves, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the possibility of a breach of the manufacturing agreements by the third parties because of factors beyond our control;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the possibility of termination or nonrenewal of the agreements by the third parties before we are able to arrange for a qualified replacement third-party manufacturer; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the possibility that we may not be able to secure a manufacturer or manufacturing capacity in a timely manner and on satisfactory terms in order to meet our manufacturing needs.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any of these factors could cause the delay of approval or commercialization of our product candidates, cause us to incur higher costs or prevent us from commercializing our product candidates successfully. Furthermore, if any of our product candidates are approved and contract manufacturers fail to deliver the required commercial quantities of finished product on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent volumes and quality and on a timely basis, we would likely be unable to meet demand for our products and could lose potential revenue. It may take several years to establish an alternative source of supply for our product candidates and to have any such new source approved by the FDA or any other relevant regulatory authorities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are in the process of building a manufacturing suite that could support future commercial production of our product candidates, if and when any are commercialized. We have no experience in large-scale or commercial manufacturing, and there can be no assurance that we will be able to build our manufacturing facility or, if built, we will be able to manufacture commercial products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are in the process of expanding our manufacturing capacity to support future commercial production and have entered into a contract to build a suite with additional capacity at our current headquarters for this purpose.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although some of our employees have experience in the manufacturing of pharmaceutical products from prior employment at other companies, we as a company have no prior experience in large-scale or commercial manufacturing. Designing and building a manufacturing facility will be time-consuming and expensive, and we may experience delays or cost overruns. In addition, government approvals would be required for us to operate a commercial manufacturing facility and can be time-consuming to obtain. As a manufacturer of pharmaceutical products, we also would be required to demonstrate and maintain compliance with cGMPs which include requirements related to production processes, quality control and assurance and recordkeeping. Furthermore, establishing commercial manufacturing operations may require a reallocation of other resources, particularly the time and attention of our senior management. Any failure or delay in the development of our commercial manufacturing capabilities could adversely impact the commercialization of our product candidates.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Intellectual Property</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our commercial success depends significantly on our ability to operate without infringing the valid patents and other proprietary rights of third parties.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our success will depend in part on our ability to operate without infringing the proprietary rights of third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our future approved products or impair our competitive position. For example, certain patents held by third parties cover Fc engineering methods and mutations in Fc regions to enhance the binding of Fc regions to Fc receptors on immune cells. Although we believe that these patents are not infringed and invalid, if a court should find that they cover margetuximab or enoblituzumab and we are unable to invalidate their patents, or if licenses for them are not available on commercially reasonable terms, our business could be harmed, perhaps materially.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents that we may ultimately be found to infringe could be issued to third parties. Third parties may have or obtain valid and enforceable patents or proprietary rights that could block us from developing product candidates using our technology. Our failure to obtain a license to any technology that we require may materially harm our business, financial condition and results of operations. Moreover, our failure to maintain a license to any technology that we require may also materially harm our business, financial condition, and results of operations. Furthermore, we would be exposed to a threat of litigation.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the pharmaceutical industry, significant litigation and other proceedings regarding patents, patent applications, trademarks and other intellectual property rights have become commonplace. The types of situations in which we may become a party to such litigation or proceedings include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we or our collaborators may initiate litigation or other proceedings against third parties seeking to invalidate the patents held by those third parties or to obtain a judgment that our products or processes do not infringe those third parties' patents;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if our competitors file patent applications that claim technology also claimed by us or our licensors, we or our licensors may be required to participate in interference or opposition proceedings to determine the priority of invention, which could jeopardize our patent rights and potentially provide a third party with a dominant patent position;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if third parties initiate litigation claiming that our processes or products infringe their patent or other intellectual property rights, we and our collaborators will need to defend against such proceedings; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if a license to necessary technology is terminated, the licensor may initiate litigation claiming that our processes or products infringe or misappropriate their patent or other intellectual property rights and/or that we breached our obligations under the license agreement, and we and our collaborators would need to defend against such proceedings.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These lawsuits would be costly and could affect our results of operations and divert the attention of our management and scientific personnel. There is a risk that a court would decide that we or our collaborators are infringing the third party's patents and would order us or our collaborators to stop the activities covered by the patents. In that event, we or our collaborators may not have a viable alternative to the technology protected by the patent and may need to halt work on the affected product candidate or cease commercialization of an approved product. In addition, there is a risk that a court will order us or our collaborators to pay the other party damages. An adverse outcome in any litigation or other proceeding could subject us to significant liabilities to third parties and require us to cease using the technology that is at issue or to license the technology from third parties. We may not be able to obtain any required licenses on commercially acceptable terms or at all. Any of these outcomes could have a material adverse effect on our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform or predictable. If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management's time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The cost of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the cost of such litigation and proceedings more effectively than we can because of their substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Patent litigation and other proceedings may also absorb significant management time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to obtain and enforce patent protection for our product candidates and related technology, our business could be materially harmed.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued patents may be challenged, narrowed, invalidated or circumvented. In addition, court decisions may introduce uncertainty in the enforceability or scope of patents owned by biotechnology companies. The legal systems of certain countries do not favor the aggressive enforcement of patents, and the laws of foreign countries may not allow us to protect our inventions with patents to the same extent as the laws of the United States. Because patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, or in some cases not at all, and because publications of discoveries in scientific literature lag behind actual discoveries, we cannot be certain that we were the first to make the inventions claimed in our issued patents or pending patent applications, or that we were the first to file for protection of the inventions set forth in our patents or patent applications. As a result, we may not be able to obtain or maintain protection for certain inventions. Therefore, the enforceability and scope of our patents in the United States and in foreign countries cannot be predicted with certainty and, as a result, any patents that we own or license may not provide sufficient protection against competitors. We may not be able to obtain or maintain patent protection from our pending patent applications, from those we may file in the future, or from those we may license from third parties. Moreover, even if we are able to obtain patent protection, such patent protection may be of insufficient scope to achieve our business objectives.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our strategy depends on our ability to identify and seek patent protection for our discoveries. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. Despite our efforts to protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary. The issuance of a patent does not ensure that it is valid or enforceable, so even if we obtain patents, they may not be valid or enforceable against third parties. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own patented product and practicing our own patented technology. Third parties may also seek to market biosimilar versions of any approved products. Alternatively, third parties may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or agency with jurisdiction may find our patents invalid and/or unenforceable. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The patent position of pharmaceutical or biotechnology companies, including ours, is generally uncertain and involves complex legal and factual considerations. The standards which the United States Patent and Trademark Office, or USPTO, and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. The laws of some foreign countries do not protect proprietary information to the same extent as the laws of the United States, and many companies have encountered significant problems and costs in protecting their proprietary information in these foreign countries. Outside the United States, patent protection must be sought in individual jurisdictions, further adding to the cost and uncertainty of obtaining adequate patent protection outside of the United States. Accordingly, we cannot predict whether additional patents protecting our technology will issue in the United States or in foreign jurisdictions, or whether any patents that do issue will have claims of adequate scope to provide competitive advantage. Moreover, we cannot predict whether third parties will be able to successfully obtain claims or the breadth of such claims. The allowance of broader claims may increase the incidence and cost of patent interference proceedings, opposition proceedings, and/or reexamination proceedings, the risk of infringement litigation, and the vulnerability of the claims to challenge. On the other hand, the allowance of narrower claims does not eliminate the potential for adversarial proceedings, and may fail to provide a competitive advantage. Our issued patents may not contain claims sufficiently broad to protect us against third parties with similar technologies or products, or provide us with any competitive advantage.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even after they have been issued, our patents and any patents which we license may be challenged, narrowed, invalidated or circumvented. If our patents are invalidated or otherwise limited or will expire prior to the commercialization of our product candidates, other companies may be better able to develop products that compete with ours, which could adversely affect our competitive business position, business prospects and financial condition.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following are examples of litigation and other adversarial proceedings or disputes that we could become a party to involving our patents or patents licensed to us:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we or our collaborators may initiate litigation or other proceedings against third parties to enforce our patent rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">third parties may initiate litigation or other proceedings seeking to invalidate patents owned by or licensed to us or to obtain a declaratory judgment that their product or technology does not infringe our patents or patents licensed to us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">third parties may initiate opposition,  reexamination or inter partes review proceedings challenging the validity or scope of our patent rights, requiring us or our collaborators and/or licensors to participate in such proceedings to defend the validity and scope of our patents;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">there may be a challenge or dispute regarding inventorship or ownership of patents currently identified as being owned by or licensed to us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the U.S. Patent&#160;and Trademark Office may initiate an interference between patents or patent applications owned by or licensed to us and those of our competitors, requiring us or our collaborators and/or licensors to participate in an interference proceeding to determine the priority of invention, which could jeopardize our patent rights; or</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">third parties may seek approval to market biosimilar versions of our future approved products prior to expiration of relevant patents owned by or licensed to us, requiring us to defend our patents, including by filing lawsuits alleging patent infringement.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These lawsuits and proceedings would be costly and could affect our results of operations and divert the attention of our managerial and scientific personnel. There is a risk that a court or administrative body would decide that our patents are invalid or not infringed by a third party's activities, or that the scope of certain issued claims must be further limited. An adverse outcome in a litigation or proceeding involving our own patents could limit our ability to assert our patents against these or other competitors, affect our ability to receive royalties or other licensing consideration from our licensees, and may curtail or preclude our ability to exclude third parties from making, using and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition.</font></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">others may be able to develop a platform that is similar to, or better than, ours in a way that is not covered by the claims of our patents;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">others may be able to make compounds that are similar to our product candidates but that are not covered by the claims of our patents;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we might not have been the first to make the inventions covered by patents or pending patent applications;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we might not have been the first to file patent applications for these inventions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any patents that we obtain may not provide us with any competitive advantages or may ultimately be found invalid or unenforceable; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may not develop additional proprietary technologies that are patentable.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to comply with our obligations under our intellectual property licenses with third parties, we could lose license rights that are important to our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are currently party to various intellectual property license agreements. These license agreements impose, and we expect that future license agreements may impose, various diligence, milestone payment, royalty, insurance and other obligations on us. For example, we have entered into patent and know-how license agreements that grant us the right to use certain technologies related to biological manufacturing to manufacture our clinical product candidates. These licenses typically include an obligation to pay yearly maintenance payments and royalties on sales, and may also include upfront and milestone payments. If we fail to comply with our obligations under the licenses, the licensors may have the right to terminate their respective license agreements, in which event we might not be able to market any product that is covered by the agreements. Termination of the license agreements or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms, which could adversely affect our competitive business position and harm our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely affected.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, and other proprietary information. To maintain the confidentiality of trade secrets and proprietary information, we enter into confidentiality agreements with our employees, consultants, collaborators and others upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual's relationship with us be kept confidential and not disclosed to third parties. Our agreements with employees and our personnel policies also provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. Thus, despite such agreement, such inventions may become assigned to third parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. To the extent that an individual who is not obligated to assign rights in intellectual property to us is rightfully an inventor of intellectual property, we may need to obtain an assignment or a license to that intellectual property from that individual, or a third party or from that individual's assignee. Such assignment or license may not be available on commercially reasonable terms or at all.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adequate remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. The disclosure of our trade secrets would impair our competitive position and may materially harm our business, financial condition and results of operations. Costly and time consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade secret protection could adversely affect our competitive business position. In addition, others may independently discover or develop our trade secrets and proprietary information, and the existence of our own trade secrets affords no protection against such independent discovery.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously or concurrently employed at research institutions and/or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that patents and applications we have filed to protect inventions of these employees, even those related to one or more of our product candidates, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside counsel to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business. In addition, we are responsible for the payment of patent fees for patent rights that we have licensed from other parties. If any licensor of these patents does not itself elect to make these payments, and we fail to do so, we may be liable to the licensor for any costs and consequences of any resulting loss of patent rights.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Legal Compliance Matters</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our research and development involves, and may in the future involve, the use of potentially hazardous materials and chemicals. Our operations may produce hazardous waste products. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by local, state and federal laws and regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations and fire and building codes, including those governing laboratory procedures, exposure to blood-borne pathogens, use and storage of flammable agents and the handling of biohazardous materials. Although we maintain workers' compensation insurance as prescribed by the States of Maryland and California to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. Additional federal, state and local laws and regulations affecting our operations may be adopted in the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we market products in a manner that violates healthcare fraud and abuse laws, or if we violate government price reporting laws, we may be subject to civil or criminal penalties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal healthcare laws commonly referred to as "fraud and abuse" laws have been applied in recent years to restrict certain marketing practices in the pharmaceutical industry. These laws include false claims and anti-kickback statutes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, or causing to be made, a false statement to get a claim paid. The federal healthcare program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are several statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. In addition, under the Sunshine Act provisions of the ACA, pharmaceutical manufacturers are subject to federal reporting and disclosure requirements with regard to payments or other transfers of value made to physicians and teaching hospitals. Most states also have statutes or regulations similar to the federal anti-kickback law and federal false claims laws, which may apply to items such as pharmaceutical products and services reimbursed by private insurers. Some state laws also prohibit certain gifts to healthcare providers, require pharmaceutical companies to report payments to healthcare professionals, and/or require companies to adopt compliance programs or codes of conduct. Administrative, civil and criminal sanctions may be imposed under these federal and state laws.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Over the past few years, a number of pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of promotional and marketing activities, such as: providing free trips, free goods, sham consulting fees and grants and other monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in off-label promotion; and submitting inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates. At such time, if ever, as we market any of our future approved products and these products are paid for by governmental programs, it is possible that some of our business activities could also be subject to challenge under one or more of these "fraud and abuse" laws.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, results of operations and financial condition.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act, or FCPA, and other anti-corruption laws that apply in countries where we do business. The FCPA and these other laws generally prohibit us and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We and our commercial partners operate in a number of jurisdictions that pose a risk of potential FCPA violations, and we participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA or other anti-corruption laws. There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws. If we violate provisions of the FCPA or other anti-corruption laws or are subject to an investigation or audit pursuant to these laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures and legal expenses, which could have an adverse impact on our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA or other agencies, to comply with federal and state health care fraud and abuse laws and regulations, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Relating to Employee Matters and Managing Growth</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are highly dependent on the research and development, clinical and business development expertise of Scott Koenig, M.D., Ph.D., our President and Chief Executive Officer, as well as the other members of our senior management, scientific and clinical team. Although we have entered into employment agreements with certain of our executive officers, each of them may terminate their employment with us at any time. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. In addition, we will need to expand and effectively manage our managerial, operational, financial, development and other resources in order to successfully pursue our research, development and commercialization efforts for our existing and future product candidates. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We will need to grow our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of February 24, 2017, we had 318 full-time employees. As our development and commercialization plans and strategies develop, we expect to expand our employee base for managerial, operational, sales, marketing, financial and other resources. Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, motivate and integrate additional employees. Also, our management may need to divert a disproportionate amount of their attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations which may result in weaknesses in our infrastructure, give rise to operational errors, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of existing and additional product candidates. If our management is unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our product candidates and compete effectively with others in our industry will depend, in part, on our ability to effectively manage any future growth.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Relating to Our Common Stock</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our stock price may be volatile and fluctuate substantially, which may subject us to securities class action litigation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our stock price is likely to be volatile.&#160; The stock market has experienced significant volatility, particularly with respect to pharmaceutical, biotechnology, and other life sciences company stocks. The volatility of pharmaceutical, biotechnology, and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the past, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit and divert the time and attention of our management, which could seriously harm our business.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Provisions of our charter, bylaws, third-party agreements and Delaware law may make an acquisition of us or a change in our management more difficult.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain provisions of our restated certificate of incorporation and amended and restated bylaws that became effective upon the completion of our IPO could discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. Stockholders who wish to participate in these transactions may not have the opportunity to do so. Furthermore, since our board of directors is responsible for appointing the members of our management team, these provisions could prevent or frustrate attempts by our stockholders to replace or remove our management by making it more difficult for stockholders to replace members of our board of directors. These provisions:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">allow the authorized number of directors to be changed only by resolution of our board of directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">establish a classified board of directors, providing that not all members of the board of directors be elected at one time;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">authorize our board of directors to issue without stockholder approval blank check preferred stock that, if issued, could operate as a "poison pill" to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that is not approved by our board of directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit stockholder action by written consent;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">establish advance notice requirements for stockholder nominations to our board of directors or for stockholder proposals that can be acted on at stockholder meetings;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">limit who may call stockholder meetings; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">require the approval of the holders of 75% of the outstanding shares of our capital stock entitled to vote in order to amend certain provisions of our restated certificate of incorporation and restated bylaws.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furthermore, in the ordinary course of our business, from time to time we discuss and enter into collaborations, licenses and other transactions with various third parties, including other pharmaceutical companies and biotechnology companies. When we deem it appropriate, our agreements with such third parties may include standstill provisions. These standstill provisions, several of which may be in force from time-to-time, typically prohibit such parties from acquiring our securities for a period of time, which may discourage such parties from acquiring MacroGenics even if doing so would be beneficial to our stockholders.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which may, unless certain criteria are met, prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a prescribed period of time. This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Future issuances of our common stock or rights to purchase common stock pursuant to our equity incentive plans could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we had options to purchase </font><font style="font-family:inherit;font-size:10pt;">3,838,060</font><font style="font-family:inherit;font-size:10pt;">&#32;shares outstanding under our equity compensation plans. We are also authorized to grant equity awards, including stock options, to our employees, directors and consultants, covering up to 2,644,706 shares of our common stock, pursuant to our equity compensation plans. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sB035ADF398BBE670F6EFE278A698FAB1"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNRESOLVED STAFF COMMENTS</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div><a name="s60563F697BEBC39E13A6E278A6ADBF49"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PROPERTIES</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We lease approximately 200,000 square feet of manufacturing, office and laboratory space in Rockville, Maryland under five leases that have terms that expire between 2018 and 2022 unless renewed.&#160; We also lease office and laboratory space in South San Francisco, California under a lease that expires in 2018.&#160; We believe that our properties are generally in good condition, well maintained, suitable and adequate to carry on our business.&#160;&#160;We believe our capital resources are sufficient to lease any additional facilities required to meet our expected growth needs.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">38</font></div></div><hr style="page-break-after:always"><div><a name="s64DABA41ED910180558FE278A6BD76FA"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LEGAL PROCEEDINGS</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the ordinary course of business, we are involved in various legal proceedings, including, among others, patent oppositions, patent revocations, patent infringement litigation and other matters incidental to our business.&#160;&#160;We are not currently a party to any material legal proceedings.</font></div><div><a name="s1B89214D8B3577ED3236E278A6E33488"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MINE SAFETY DISCLOSURES</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">39</font></div></div><hr style="page-break-after:always"><div><a name="s2929977F187C20552E3DE278A723DEF4"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</font></div><div><a name="sD51F6A6B087F2599D62BE278A73583A0"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MARKET FOR REGISTRANT'S COMMON EQUITY,&#160;RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Market Information</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common stock has been listed on the NASDAQ Global Select Market under the symbol "MGNX" since October 10, 2013.&#160;&#160;Prior to that date, there was no public trading market for our common stock.&#160;&#160;Shares sold in our initial public offering, or IPO, on October 9, 2013 were priced at $16.00 per share.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">February&#160;24, 2017</font><font style="font-family:inherit;font-size:10pt;">, the closing price for our common stock as reported on the NASDAQ Global Select Market was $19.60. The following table sets forth the high and low intra-day sale prices per share of our common stock as reported on the NASDAQ Global Select Market for the periods indicated.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:77%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">High</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Low</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30.66</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.84</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33.30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fourth Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38.37</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.68</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fourth Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.67</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shareholders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">February&#160;24, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">34,974,985</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock outstanding held by approximately 89 holders of record, which include shares held by a broker, bank or other nominee.&#160;&#160;We have never declared or paid any cash dividends.&#160;&#160;We do not anticipate declaring or paying cash dividends for the foreseeable future.&#160;&#160;Instead, we will retain our earnings, if any, for the future operation and expansion of our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Performance Graph</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following graph compares the performance of our common stock to the performance of the NASDAQ Composite Index (U.S.) and the NASDAQ Biotechnology Index since October 10, 2013 (the first date that shares of our common stock were publicly traded).&#160;&#160;The comparison assumes a $100 investment on October 10, 2013 in our common stock, the stocks comprising the NASDAQ Composite Index, and the stocks comprising the NASDAQ Biotechnology Index, and assumes reinvestment of the full amount of all dividends, if any.&#160;&#160;Historical stockholder return is not necessarily indicative of the performance to be expected for any future periods.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;"><img src="mgnx-123116_chartx18988.jpg" alt="mgnx-123116_chartx18988.jpg" style="height:366px;width:673px;"></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The performance graph shall not be deemed to be incorporated by reference by means of any general statement incorporating by reference this Form 10-K into any filing under the Securities Act of 1933, as amended or the Exchange Act, except to the extent that we specifically incorporate such information by reference, and shall not otherwise be deemed filed under such acts.</font></div><div><a name="sA6540334485E4E06F182E278A786C25F"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SELECTED FINANCIAL DATA</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated statement of operations and comprehensive income (loss) data for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and the consolidated balance sheet data as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;presented below have been derived from our audited consolidated financial statements and footnotes included elsewhere in this Annual Report on Form 10-K.&#160;&#160;The consolidated statement of operations and comprehensive income (loss) data for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2012</font><font style="font-family:inherit;font-size:10pt;">&#32;and the consolidated balance sheet data as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2012</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;have been derived from our audited consolidated financial statements which are not included herein.&#160;&#160;Historical results are not necessarily indicative of future results.&#160;&#160;The following data should be read in conjunction with Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statement of Operations and Comprehensive Income (Loss):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,880</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,854</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,797</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,035</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,826</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost and expenses:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,091</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,271</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,186</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,582</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,433</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,831</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,765</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,926</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,087</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,188</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,922</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121,036</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,112</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,669</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,621</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60,042</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,514</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(627</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,528</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss):</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized loss on investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(77</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,605</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,145</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,313</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(261</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,362</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted&#160;&#160;net income (loss) per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted weighted average number of common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,685,274</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,801,645</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,384,990</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,847,697</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,083,276</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Balance Sheet Data:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">284,982</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">339,049</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,591</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,481</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,743</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311,263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">359,269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173,886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,306</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,497</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,720</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,403</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,080</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders' equity (deficit)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">268,751</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">313,337</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121,286</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,914</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,237</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">42</font></div></div><hr style="page-break-after:always"><div><a name="s0304F33B25A6951BD12FE278A7BD06CD"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The following discussion of our financial condition and results of operations should be read together with our selected consolidated financial data and the consolidated financial statements and related notes included elsewhere herein. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth under the section entitled "Risk Factors", "Forward-Looking Statements" and elsewhere herein, our actual results may differ materially from those anticipated in these forward-looking statements.</font></div><div><a name="s9368E60703254471F820E278A7E78875"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics for the treatment of cancer as well as various autoimmune disorders and infectious diseases. We currently have a pipeline of product candidates in human clinical testing, primarily against different types of cancers, which have been created using our proprietary technology platforms. We believe our programs have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We commenced active operations in 2000, and have since devoted substantially all of our resources to staffing our company, developing our technology platforms, identifying potential product candidates, undertaking preclinical studies, conducting clinical trials, developing collaborations, business planning and raising capital. We have not generated any revenues from the sale of any products to date. We have financed our operations primarily through the public and private offerings of our securities, collaborations with other biopharmaceutical companies, and government grants and contracts.&#160; Although it is difficult to predict our funding requirements, based upon our current operating plan, we anticipate that our cash, cash equivalents and marketable securities as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, combined with collaboration payments we anticipate receiving, will enable us to fund our operations through late 2018 based on our current business plan.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$292.7 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;We expect that over the next several years this deficit will increase as we increase our expenditures in research and development in connection with our ongoing activities with several clinical trials.&#160;</font></div><div><a name="s7FCDCB28246B09F6E4F6E278A82BADE6"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Strategic Collaborations</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones, or royalties and other payments upon the commercial sale of products. Currently, our most significant strategic collaborations include the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Janssen</font><font style="font-family:inherit;font-size:10pt;">. In December 2014, we entered into a collaboration and license agreement with Janssen for the development and commercialization of duvortuxizumab, a product candidate that incorporates our proprietary DART technology to simultaneously target CD19 and CD3 for the potential treatment of B-cell hematological malignancies.&#160;&#160;We contemporaneously entered into an agreement with JJDC, an affiliate of Janssen, under which JJDC agreed to purchase 1,923,077 new shares of our common stock for proceeds of $75.0 million.&#160;&#160;Upon closing, we received a $50.0 million upfront payment from Janssen as well as the $75.0 million investment in our common stock.&#160;&#160;Janssen is leading the development of this product candidate, subject to our options to co-promote the product in the United States and Canada and to invest in later-stage development in exchange for a United States and Canada profit-share.&#160; Janssen initiated a human clinical trial in 2015 for a variety of B-cell hematological malignancies, including diffuse-large B cell lymphoma, follicular lymphoma, mantle-cell lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia.&#160; The initiation of this trial triggered a $10.0 million milestone payment to us.&#160; Assuming successful development and commercialization, we could receive up to an additional $565.0 million in clinical, regulatory and commercialization milestone payments. If commercialized, we would be eligible to receive low double-digit royalties on any global net sales.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2016, we entered into a separate collaboration and license agreement with Janssen for the development and commercialization of MGD015, a product candidate that incorporates our proprietary DART technology to simultaneously target CD3 and an undisclosed tumor target for the potential treatment of various hematological malignancies and solid tumors. The transaction closed in June 2016, and we received the $75.0 million upfront payment from Janssen in July 2016.&#160;&#160;Under the collaboration and license agreement, we granted an exclusive license to Janssen to develop and commercialize MGD015. Janssen will complete the IND-enabling activities and will be fully responsible for the future clinical development and commercialization of MGD015.&#160;&#160; Assuming successful development and commercialization, the agreement entitles us to receive up to $665.0 million in </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">development, regulatory and sales milestone payments. If commercialized, we would be eligible to receive low double-digit royalties on any global net sales and have the option to co-promote the molecule with Janssen in the United States.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Servier. </font><font style="font-family:inherit;font-size:10pt;">In September 2012, we entered into an agreement with Servier to develop and commercialize three DART molecules in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. We received a $20.0 million upfront option fee. In addition, we became eligible to receive up to approximately $1.0 billion in additional license fees and clinical, development, regulatory and sales milestone payments for each product Servier successfully develops, obtains regulatory approval for, and commercializes. Additionally, assuming exercise of its options, Servier may share Phase 2 and Phase 3 development costs and would be obligated to pay us low double-digit to mid-teen royalties on product sales in its territories. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2014, Servier exercised its option to develop and commercialize flotetuzumab, for which we received a $15.0 million license option fee.&#160;&#160;We also received two $5.0 million milestone payments from Servier in 2014 in connection with the IND applications for flotetuzumab and MGD007 clearing the 30-day review period by the U.S. Food and Drug Administration (FDA). As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, Servier still retains an option to obtain a license for MGD007, but has notified us that they have terminated their rights to license the third DART molecule.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Boehringer: </font><font style="font-family:inherit;font-size:10pt;">In October 2010, we entered into an agreement with Boehringer to discover, develop, and commercialize multiple DART molecules for which we granted an exclusive, worldwide, royalty-bearing license. These DART molecules were evaluated during a five year period that ended in October 2015. We continue to have the potential to earn additional development, regulatory and sales milestone payments that can reach up to approximately $205.0 million for each of the two ongoing programs under development. Boehringer would be required to pay us mid-single digit royalties on product sales.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;color:#0000ff;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pfizer</font><font style="font-family:inherit;font-size:10pt;">: In October 2010, we entered into an agreement with Pfizer to discover, develop and commercialize multiple DART molecules for which we granted an exclusive, worldwide, royalty-bearing license. We continue to be eligible to receive development and sales milestone payments that can reach up to approximately $200.0 million for the ongoing program under development, PF-06671008, which is being evaluated by Pfizer in a Phase 1 trial. Pfizer would also be required to pay us mid-single digit to low-teen royalties on product sales.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For additional programs outside of our core oncology focus, we have sought to complement our internal expertise and capabilities with strategic collaborators that may help us advance those programs. For example, we created MGD014, a DART molecule targeting CD3 and the HIV envelope protein, to potentially eliminate latent reservoirs of HIV in patients who are taking anti-retroviral therapy. We receive funding under this program from the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, and collaborate in the execution of this program with the University of North Carolina, Chapel Hill and Duke University, among others.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finally, teplizumab is an immunomodulatory anti-CD3 monoclonal antibody that is being evaluated in a Phase 2 study for potential application to patients at risk of developing Type 1 diabetes. We have elected to collaborate with NIDDK/TrialNet to execute this clinical trial. In addition, we continue to seek strategic collaborations for the advancement of this program that could include joint funding, spinning the program out into a new company, divesting the program or pursuing other transaction structures that we feel would be aligned with our strategic objectives and provide financial consideration commensurate with our expectations of value for the program.</font></div><div><a name="sF3675832FB391CAFBE6CE278A86497F4"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Operations Overview</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenues</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our revenue consists primarily of collaboration revenue, including amounts recognized relating to upfront nonrefundable payments for licenses or options to obtain future licenses, research and development funding and milestone payments earned under our collaboration and license agreement with our strategic collaborators. In addition, we have earned revenues through several grants and/or contracts with the U.S. government and other research institutions on behalf of the U.S. government, primarily with respect to research and development activities related to infectious disease product candidates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expense</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses consist of expenses incurred in performing research and development activities. These expenses include conducting preclinical experiments and studies, clinical trials, manufacturing efforts and regulatory </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">filings for all product candidates, and other indirect expenses in support of our research and development activities. We capture research and development expense on a program-by-program basis for our product candidates that are in clinical development and recognize these expenses as they are incurred. The following are items we include in research and development expenses:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee-related expenses such as salaries and benefits;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee-related overhead expenses such as facilities and other allocated items;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense to employees and consultants engaged in research and development activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation of laboratory equipment, computers and leasehold improvements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fees paid to consultants, subcontractors, clinical research organizations (CROs) and other third party vendors for work performed under our preclinical and clinical trials including but not limited to investigator grants, laboratory work and analysis, database management, statistical analysis, and other items;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts paid to vendors and suppliers for laboratory supplies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Costs related to manufacturing clinical trial materials, including vialing, packaging and testing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">License fees and other third party vendor payments related to in-licensed product candidates and technology; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Costs related to compliance with regulatory requirements.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is difficult to determine with certainty the duration and completion costs of our current or future preclinical programs and clinical trials of our product candidates, or if, when or to what extent we will generate revenues from the commercialization and sale of any of our product candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our product candidates. The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including the uncertainties of future clinical trials and preclinical studies, uncertainties in clinical trial enrollment rate and significant and changing government regulation. In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate's commercial potential.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative Expense</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses consist of salaries and related benefit costs for employees in our executive, finance, legal and intellectual property, business development, human resources and other support functions, travel expenses and other legal and professional fees.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Income (Expense)</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense) consists of interest income earned on our cash, cash equivalents and marketable securities, offset by other expenses.</font></div><div><a name="s4B94855ED3E38DD310F7E278A8947DC2"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management's discussion and analysis of financial conditions and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the balance sheets and the reported amount of the revenue and expenses recorded during the reporting period. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. We review and evaluate these estimates on an on-going basis. These assumptions and estimates form the basis for making judgments about the carrying values of assets and liabilities and amounts that have been recorded as revenues and expenses. Actual results and experiences may differ from these estimates. The results of any material revisions would be reflected in the consolidated financial statements prospectively from the date of the change in estimate.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While a summary of significant accounting policies is described fully in Note 2 in our consolidated financial statements, we believe that the following accounting policies are the most critical to assist you in fully understanding and evaluating our financial results and any affect the estimates and judgments we used in preparing our consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We enter into collaboration and license agreements with collaborators for the development of monoclonal antibody-based therapeutics to treat cancer and other complex diseases. The terms of these agreements contain multiple deliverables which may include (i) licenses, or options to obtain licenses, to our technological platforms, such as our Fc engineering and DART technologies, (ii) rights to future technological improvements, (iii) research and development activities to be performed on behalf of the collaborator or as part of the collaboration, and (iv) the manufacture of preclinical or clinical materials for the collaborator. Payments to us under these agreements may include nonrefundable license fees, option fees, exercise fees, payments for research and development activities, payments for the manufacture of preclinical or clinical materials, license maintenance payments, payments based upon the achievement of certain milestones and royalties on product sales. Other benefits to us from these agreements include the right to sell products resulting from the collaborative efforts of the parties in specific geographic territories. We follow the provisions of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 605-25, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition&#8211;Multiple-Element Arrangements,</font><font style="font-family:inherit;font-size:10pt;">&#32;and ASC Topic 605-28, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition&#8211;Milestone Method</font><font style="font-family:inherit;font-size:10pt;">, in accounting for these agreements. In order to account for these agreements, we must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we had two types of agreements: 1) exclusive development and commercialization licenses to use our technology and/or certain other intellectual property to develop compounds against specified targets, which we refer to as exclusive licenses; and 2) option/research agreements to secure on established terms development and commercialization licenses to therapeutic product candidates to collaborator-selected targets developed by us during an option period, which we refer to as right-to-develop agreements.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Exclusive Licenses</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The deliverables under an exclusive license agreement generally include the exclusive license to our technology with respect to a specified antigen target, and may also include deliverables related to rights to future technological improvements, research and preclinical development activities to be performed on behalf of the collaborator. In some cases we may have an option to participate in the co-development of product candidates that result from such agreements.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Generally, exclusive license agreements contain nonrefundable terms for payments and, depending on the terms of the agreement, provide that we will (i) at the collaborator's request, provide research and preclinical development services at negotiated prices which are generally consistent with what other third parties would charge, (ii) earn payments upon the achievement of certain milestones, (iii) earn royalty payments, and (iv) in some cases grant us an option to participate in the development and commercialization of products that result from such agreements. Royalty rates may vary over the royalty term depending on our intellectual property rights and whether we exercise any co-development and co-commercialization rights.&#160;We do not directly control when any collaborator will achieve milestones or become liable for royalty payments.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In determining the separate units of accounting, management evaluates whether the exclusive license has stand-alone value from the undelivered elements to the collaborator based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research and development capabilities of the collaborator and the availability of technology platform and product research expertise in the general marketplace. In addition, we consider whether or not (i) the collaborator could use the license for its intended purpose without the receipt of the remaining deliverables, (ii) the value of the license was dependent on the undelivered items and (iii) the collaborator or other vendors could provide the undelivered items.&#160;&#160;If we conclude that the license has stand-alone value and therefore will be accounted for as a separate unit of accounting, we then determine the estimated selling prices of the license and all other units of accounting based on market conditions, similar arrangements entered into by third parties, and entity-specific factors such as the terms of our previous collaboration agreements, recent preclinical and clinical testing results of therapeutic product candidates that use our technology platforms, our pricing practices and pricing objectives, the likelihood that technological improvements will be made, the likelihood that technological improvements made will be used by our collaborators and the nature of the research services to be performed on behalf of our collaborators and market rates for similar services. The upfront payment is recognized upon delivery of the license if facts and circumstances dictate that the license has stand-alone value from the undelivered elements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront payments on exclusive licenses are deferred if facts and circumstances dictate that the license does not have stand-alone value, and revenue is then recognized throughout the period of performance. We reassess the period of performance over which we recognize deferred upfront license fees and make adjustments as appropriate. In the event a collaborator elects to discontinue development of a specific product candidate under a single target license, but retains its right to use our </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">technology to develop an alternative product candidate to the same target or a target substitute, we would cease amortization of any remaining portion of the upfront fee until there is substantial preclinical activity on another product candidate and its remaining period of substantial involvement can be estimated. In the event that a single target license were to be terminated, we would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination or through the remaining substantial involvement in the wind down of the agreement.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue related to research and preclinical development services that represent separate units of accounting as they are performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection is reasonably assured. We recognize revenue related to the rights to future technological improvements over the estimated term of the applicable license.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We typically perform research activities and preclinical development services, including generating and engineering product candidates, on behalf of our licensees during the early evaluation and preclinical testing stages of drug development under our exclusive licenses. We record amounts received for research materials produced or services performed as revenue from collaborative agreements.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our license agreements have milestone payments which for reporting purposes are aggregated into three categories: (i) development milestones, (ii) regulatory milestones, and (iii) sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the FDA or other countries' regulatory authorities or on receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of each agreement that includes milestone payments, we evaluate whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a) the consideration is commensurate with either (1) our performance to achieve the milestone, or (2) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from our performance to achieve the milestone, (b) the consideration relates solely to past performance and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. We evaluate factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-refundable development and regulatory milestones that are expected to be achieved as a result of our efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because we did not contribute effort to their achievement are generally recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligations, assuming all other revenue recognition criteria are met.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Right-to-Develop Agreements</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our right-to-develop agreements provide collaborators with an exclusive option to obtain licenses to develop and commercialize in specified geographic territories product candidates developed by us under agreed upon research and preclinical development programs. The product candidates resulting from each program are all directed to a specific target selected by the collaborator. Under these agreements, fees may be due to us (i) at the inception of the arrangement (referred to as "upfront" fees or payments), (ii) upon the selection of a target for a program, (iii) upon the exercise of an option to acquire a development and commercialization license, referred to as exercise fee, for a program, or (iv) some combination of all of these fees.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accounting for right-to-develop agreements is dependent on the nature of the options granted to the collaborator. Options are considered substantive if, at the inception of a right-to-develop agreement, we are at risk as to whether the collaborator will choose to exercise the options to secure development and commercialization licenses. Factors that are considered in evaluating whether options are substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the total upfront consideration, and the additional financial commitments imposed on the collaborator as a result of exercising the options.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For right-to-develop agreements where the options to secure development and commercialization licenses to a product program are considered substantive, we do not consider the development and commercialization licenses to be a deliverable at </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the inception of the agreement, and therefore defer any upfront payments received and recognize this revenue over the period during which the collaborator could elect to exercise options for development and commercialization licenses. These periods are specific to each collaboration agreement. If a collaborator selects a target for a product program, any substantive option fee is deferred and recognized over the life of the option. If a collaborator exercises an option and acquires a development and commercialization license to a product program, we attribute the exercise fee to the development and commercialization license.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon exercise of an option to acquire a development and commercialization license, we would also attribute any remaining deferred option fee, in addition to the consideration received for the license upon exercise of the option, to the development and commercialization license. We then apply the multiple-element revenue recognition criteria to the development and commercialization license and other deliverables, if any, to determine the appropriate revenue recognition method. This method is consistent with our accounting policy for upfront payments on exclusive licenses (discussed above). In the event a right-to-develop agreement were to be terminated, we would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For right-to-develop agreements where the options to secure development and commercialization licenses to product programs are not considered substantive, we consider the development and commercialization licenses to be a deliverable at the inception of the agreement and apply the multiple-element revenue recognition criteria to determine the appropriate revenue recognition. All of our right-to-develop agreements have been determined to contain substantive options. We do not directly control when any collaborator will exercise its options for development and commercialization licenses.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expense and related Accrued Expenses</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the process of preparing our consolidated financial statements, we may be required to estimate accrued expenses. In order to obtain reasonable estimates, we review open contracts and purchase orders. In addition, we communicate with applicable personnel in order to identify services that have been performed, but for which we have not yet been invoiced. In most cases, our vendors provide us with monthly invoices in arrears for services performed. We confirm our estimates with these vendors and make adjustments as needed. The following are examples of our accrued expenses:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fees paid to CROs for services performed on clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fees paid to investigator sites for performance on clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fees paid for professional services; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development expenses incurred by our collaborators which we share. &#160;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of expenses related to clinical trials performed by our CROs are dependent on the successful enrollment of patients. These expenses can vary from site to site and contract to contract. We base our estimated accruals on the time period over which the services are to be performed and the level of effort to be expended in each period based on the estimated enrollment of patients in each trial. We also receive estimates from our collaborators when we are sharing development expenses.  We use these estimates to record an increase or decrease in research and development expense, depending on how much we have each spent during the period.  We will adjust accordingly should the estimates vary from the actual expenses. However, we do not anticipate that our actual expenses will differ materially from our estimates.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160; </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Our policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recorded net deferred tax assets of </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, which have been fully offset by a valuation allowance due to uncertainties surrounding our ability to realize these tax benefits. The deferred tax assets are primarily comprised of federal and state tax net operating loss (NOL) carryforwards and research and development tax credit carryforwards. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we had federal and state NOL carryforwards of </font><font style="font-family:inherit;font-size:10pt;">$215.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and research and development tax credit carryforwards of </font><font style="font-family:inherit;font-size:10pt;">$32.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;available. The federal NOL carryforwards will begin to expire at various </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">dates starting in </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;">. We are already subject to Section 382 limitations due to acquisitions we made in 2002 and 2008. Future changes in stock ownership may also trigger an ownership change and, consequently, another Section 382 limitation. Any limitation may result in expiration of a portion of the net operating loss or tax credit carryforwards before utilization which would reduce our gross deferred income tax assets and corresponding valuation allowance. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards and tax credit carryforwards to reduce United States federal income tax may be subject to limitations, which could potentially result in increased future cash tax liability to us.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize stock-based compensation expense in accordance with the provisions of ASC Topic 718, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#8212;Stock Compensation</font><font style="font-family:inherit;font-size:10pt;">. The fair value of stock-based payments is estimated, on the date of grant, using a Black-Scholes model. The resulting fair value is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the option. The use of a Black-Scholes model requires us to apply judgment and make assumptions and estimates that include the following:&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:6pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value of Common Stock</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Before our entry into the public market on October 10, 2013, our Board of Directors determined the fair value of the common stock. The Board of Directors made determinations of fair value based, in part, upon contemporaneous valuations to determine fair value. The contemporaneous valuations were performed in accordance with applicable methodologies, approaches and assumptions of the technical practice-aid issued by the American Institute of Certified Public Accountants Practice Aid entitled </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:6pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Volatility</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. As we do not yet have sufficient history of our own volatility, we have identified several public entities of similar size, complexity and stage of development and estimate volatility based on the volatility of these companies.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:6pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Dividend Yield</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; We have never declared or paid dividends and have no plans to do so in the foreseeable future.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:6pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risk-Free Interest Rate</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:6pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Term</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of ten years and we have estimated the expected life of the option term to be 6.25 years. We use a simplified method to calculate the average expected term.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:6pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Forfeiture Rate</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested. We estimate the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Note 2, Summary of Significant Accounting Policies, to the consolidated financial statements for information under the caption "Recently Issued Accounting Standards."</font></div><div><a name="s224B4226A59DB947C3C4E278A8C3EC8D"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations for the Years Ended </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following represents a comparison of our research and development revenue for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase/(Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(dollars in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from collaborative agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from government agreements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.8</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">253</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">91.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">100.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(9.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)%</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The decrease in collaboration revenue of $12.8 million for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;is primarily due to the decrease in revenue recognition related to the Boehringer and Takeda Pharmaceutical Company Limited (Takeda) agreements. Revenue under the Boehringer agreement decreased because the development period, and therefore the related revenue recognition period, was completed in September 2015. Revenue under the Takeda MGD010 agreement decreased primarily due to a $3.0 million milestone being recognized during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">.  These decreases were partially offset by the $75.0 million in revenue recognized during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;under the Janssen MGD015 agreement compared to $72.3 million recognized during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;under the Janssen duvortuxizumab agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from government agreements increased for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;due to revenue from the NIAID contract which began in September 2015.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expense</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following represents a comparison of our research and development expense for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase/(Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(dollars in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Margetuximab</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Enoblituzumab</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Flotetuzumab (a)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD007</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD009</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD010</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGA012</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD013</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Immune checkpoint programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NA</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other preclinical and clinical programs, collectively</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.7</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.2</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total research and development expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">122.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">98.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">23.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">24</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) - Expenses are shown net of reimbursements from collaborator.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;our research and development expense increased by $23.8 million compared to </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">. This increase was primarily due to increased activity in our preclinical immune checkpoint programs, including MGD013, the initiation of two Phase 1 clinical trials combining enoblituzumab with other compounds, the initiation of a Phase 1 clinical trial of MGA012 and the addition of the NIAID MGD014 contract (which is included in Other preclinical and clinical studies, collectively above).  These increases were partially offset by decreased manufacturing costs for margetuximab. &#160;   </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative Expense</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following represents a comparison of our general and administrative expense for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.6484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase/(Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(dollars in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expense increased for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;by $7.0 million compared to </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;primarily due to increased staff, recruiting costs, stock-based compensation expense and patent expense.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Income</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The increase in other income for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;is primarily due to an increase in interest income earned on marketable securities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations for the Years Ended December 31, 2015 and 2014</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following represents a comparison of our revenue for the years ended December 31, 2015 and 2014:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase/(Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(dollars in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from collaborative agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from government agreements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">100.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">47.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">53.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">111</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The increase in collaboration revenue of $52.1 million for the year ended December 31, 2015 compared to 2014 is primarily due to the $72.3 million in revenue recognized under the Janssen agreement, partially offset by decreases in revenue recognition related to the Servier DART, Gilead, Boehringer, and Green Cross agreements.&#160; Revenue under the Servier DART agreement&#160;included two milestones payments totaling $10.0 million in 2014, whereas no such milestones were recognized in 2015. We received reimbursement under the Gilead agreement during part of 2014, but not in 2015 as the research and development period ended in 2014. Revenue under the Boehringer agreement decreased in 2015 because the development period, and therefore the related revenue recognition period, was completed in September 2015, and revenue from the Green Cross agreement decreased from 2014 to 2015 due to additional revenue recorded in 2014 related to a material modification to the agreement.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from government agreements increased for the year ended December 31, 2015 compared to 2014 primarily due to revenue from the NIAID contract and increased activity on the Dengue virus grant.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expense</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following represents a comparison of our research and development expense for the years ended December 31, 2015 and 2014:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase/(Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(dollars in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Margetuximab</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Enoblituzumab</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Flotetuzumab</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD007</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD009</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD010</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Duvortuxizumab</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preclinical immune checkpoint programs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">592</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other preclinical and clinical programs, collectively</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.3</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total research and development expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">98.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">70.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">28.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">40</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December 31, 2015 our research and development expense increased by $28.1 million compared to 2014. This increase was primarily due to the initiation of SOPHIA, a margetuximab Phase 3 study, and a Phase 1b/2 study of margetuximab in combination with pembrolizumab, increased activity in our preclinical immune checkpoint programs, including MGD013, and the initiation of a Phase 1a study of MGD010.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative Expense</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following represents a comparison of our general and administrative expense for the years ended December 31, 2015 and 2014:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:90.0390625%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase/(Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(dollars in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expense increased for the year ended December 31, 2015 by $6.9 million compared to 2014 primarily due to an increase in labor-related costs, including stock-based compensation expense and information technology-related expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Income</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The increase in other income for the year ended December 31, 2015 compared to 2014 is primarily due to interest income earned on investments.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sD824017830DD4911F6C4E278A8F77974"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have historically financed our operations primarily through public and private offerings of equity, upfront fees, milestone payments and license option fees from collaborators and reimbursement through government grants and contracts.&#160;&#160;&#160; As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">$285.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash, cash equivalents and marketable securities. In addition to our existing cash, cash equivalents and marketable securities, we are eligible to receive additional reimbursement from our collaborators, including under various government grants or contracts, for certain research and development services rendered, additional milestone and opt-in payments and grant revenue. However, our ability to receive these milestone payments is dependent upon our ability to successfully complete specified research and development activities and is therefore uncertain at this time.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Funding Requirements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have not generated any revenue from product sales to date and do not expect to do so until such time as we obtain regulatory approval of and commercialize one or more of our product candidates. As we are currently in the clinical trial stage of development, it will be some time before we expect to achieve this and it is uncertain that we ever will. We expect that we will continue to increase our operating expenses in connection with ongoing as well as additional clinical trials and preclinical development of product candidates in our pipeline. We expect to continue our collaboration arrangements and will look for additional collaboration opportunities. We also expect to continue our efforts to pursue additional grants and contracts from the U.S. government in order to further our research and development. Although it is difficult to predict our funding requirements, based upon our current operating plan, we anticipate that our existing cash, cash equivalents and marketable securities as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, as well as other collaboration payments we anticipate receiving, will enable us to fund our operations through late 2018, assuming all of our programs and collaborations advance as currently contemplated.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table represents a summary of our cash flows for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(dollars in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net cash provided by (used in):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(70.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(152.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204.3</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77.4</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net increase (decrease) in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(112.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">38.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">41.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Activities</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities reflects, among other things, the amounts used to run our clinical trials and preclinical activities. The difference between net cash used in operating activities during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;was primarily due an increase in the number of ongoing clinical trials, increased enrollment in clinical trials and an increase in the number of employees.&#160; The difference between net cash used in operating activities during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;was primarily due to revenue under the Janssen agreement in 2015 partially offset by more spending on margetuximab and MGD010 clinical trials and our preclinical immune checkpoint programs.&#160; &#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investing Activities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in investing activities during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;is primarily due to investing our cash in marketable securities and making leasehold improvements to our facilities.&#160; Net cash used in investing activities during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;is primarily due to the acquisition of additional lab equipment needed to further our research and development activities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financing Activities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;includes cash from stock option exercises.  Net cash provided by financing activities for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;includes net proceeds from the JJDC investment, the follow-on equity offering, and cash from stock option exercises.&#160; Net cash provided by financing activities for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;includes net proceeds from the follow-on equity offering and cash from stock option exercises.&#160;&#160;</font></div><div><a name="s09D9A79AF040D69822CDE278A92EF3DC"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Obligations and Contingent Liabilities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table represents future minimum operating lease payments under non-cancelable operating leases as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Less than 1 year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">1 to 3 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">3 to 5 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">More than 5 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Operating Leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our current obligations and contingent liabilities are limited to the operating leases at our facilities in Rockville, Maryland and South San Francisco, California.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2008, we acquired Raven Biotechnologies (Raven). The Raven purchase agreement provides for certain contingent payments that are based on the achievement of development and commercialization activities for product candidates derived from the acquired Raven technology. We are required to make a onetime payment of $5.0 million to the former Raven stockholders upon the initiation of patient dosing in the first Phase 2 clinical trial of any product derived from the Raven cancer stem cell program. No payment shall be made if the Phase 2 trial start date has not occurred on or before July 15, 2018. Other consideration includes a percentage of revenue (excluding consideration for research and development, equity and certain cost reimbursements) we may recognize for each license of a product candidate derived from the Raven cancer stem cell program. The revenue percentage in each case is based upon the execution date of the subject license. No consideration is owed for licenses executed after July 16, 2018. There is additional contingent consideration of one time payments of $8.0 million and $12.0 million, which depend upon the achievement of a specified level of sales of a product derived from the Raven cancer stem cell program. At our sole discretion, each payment can be made in cash, common stock or a combination thereof.&#160; No additional amounts related to the Raven purchase agreement were recorded during the three years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The contractual obligations table does not include any potential future payments we may be required to make under the purchase agreement with Raven. Due to the uncertainty of the achievement and timing of the events requiring payment under that agreement, the amounts to be paid by us are not fixed or determinable at this time.&#160;</font></div><div><a name="s13D7D3E0D063C2CD9241E278A95F1239"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not have any off-balance sheet arrangements, as defined under the rules and regulations of the Securities and Exchange Commission.</font></div><div><a name="sA135436217E4A8EE0520E278A9914777"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 7A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our primary objective when considering our investment activities is to preserve capital in order to fund our operations.&#160;We also seek to maximize income from our investments without assuming significant risk.&#160;&#160;Our current investment </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">policy is to invest principally in deposits and securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations, corporate debt obligations and money market instruments.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we had cash, cash equivalents and marketable securities of </font><font style="font-family:inherit;font-size:10pt;">$285.0 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;Our primary exposure to market risk is related to changes in interest rates.&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#252525;">Due to the short-term maturities of our cash equivalents and marketable securities and the low risk profile of our marketable securities, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents and marketable securities. We have the ability to hold our marketable securities until maturity, and we therefore do not expect a change in market interest rates to affect our operating results or cash flows to any significant degree.</font></div><div><a name="s76B9804F088260BC1E5FE278A9BBA532"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this item is set forth on pages F-1 - F-28.</font></div><div><a name="s5E847A02FB1B95DE0EDBE278A9F04D9C"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CHANGES AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FINANCIAL DISCLOSURE</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><a name="s1CF732DDBBB6DA7EE99BE278AA2552B2"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 9A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONTROLS AND PROCEDURES</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management, including our principal executive and principal financial officers, has evaluated the effectiveness of our disclosure controls and procedures as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in this annual report on Form 10-K has been appropriately recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, to allow timely decisions regarding required disclosure.&#160;&#160;Based on that evaluation, our principal executive and principal financial officers have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Internal Control</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management, including our principal executive and principal financial officers, has evaluated any changes in our internal control over financial reporting that occurred during the quarterly period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, and has concluded that there was no change that occurred during the quarterly period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Management Report on Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting.&#160;&#160;Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by, or under the supervision of, the Company's principal executive and principal financial officers and effected by the Company's board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pertain to the management of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have a material effect on the financial statements.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.&#160;&#160;Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.&#160;&#160;All internal control systems, no matter how well designed, have inherent limitations.&#160;&#160;Therefore, even those </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's management assessed the effectiveness of the Company's internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;In making this assessment, the Company's management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (COSO) in Internal Control-Integrated Framework.&#160; Based on our assessment, management believes that, as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company's internal control over financial reporting is effective based on those criteria.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effectiveness of our internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;has been audited by Ernst &amp; Young, LLP, an independent registered public accounting firm, as stated in their report which is included herein.</font></div><div><a name="s2D10789F5BC02846BBF3E278AA579887"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 9B.</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;font-size:10pt;text-indent:-96px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OTHER INFORMATION</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">55</font></div></div><hr style="page-break-after:always"><div><a name="s85a4664a5db544478450b7ac0ebfe3ae"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Report of Ernst&#160;&amp; Young LLP,</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Independent Registered Public Accounting Firm,</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Regarding Internal Control Over Financial Reporting</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Board of Directors and Shareholders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MacroGenics, Inc.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have audited MacroGenics, Inc.'s internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). MacroGenics, Inc.'s management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in Item 9A, Management Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the company's internal control over financial reporting based on our audit.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our opinion, MacroGenics, Inc. maintained, in all material respects, effective internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, based on the COSO criteria.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of MacroGenics, Inc. as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, and the related consolidated statements of operations and comprehensive loss, stockholders' equity and cash flows for each of the three years in the period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;of MacroGenics, Inc. and our report dated </font><font style="font-family:inherit;font-size:10pt;">February&#160;28, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;expressed an unqualified opinion thereon.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ernst &amp; Young LLP</font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Baltimore, Maryland</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February&#160;28, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">56</font></div></div><hr style="page-break-after:always"><div><a name="sFB203B4925BFF972B160E278AA72703E"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</font></div><div><a name="s314FFC179F13145F1D50E278AA9439F2"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We incorporate herein by reference the relevant information concerning directors, executive officers and corporate governance to be included in our definitive proxy statement for the </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;annual meeting of stockholders (the "</font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;Proxy Statement").</font></div><div><a name="sA192C1A3D83B0084A502E278AAAFB25E"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXECUTIVE COMPENSATION</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We incorporate herein by reference the relevant information concerning executive compensation to be included in the </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;Proxy Statement.</font></div><div><a name="s7D15E79FFEEF0ADF82B6E278AAE73C31"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We incorporate herein by reference the relevant information concerning security ownership of certain beneficial owners and management to be included in the </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;Proxy Statement.</font></div><div><a name="s2A6101A1CB1EC8D8408BE278AB06A53A"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We incorporate herein by reference the relevant information concerning certain other relationships and related transactions to be included in the </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;Proxy Statement.</font></div><div><a name="sEDE12330B9D83CC6073DE278AB4331B3"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRINCIPAL ACCOUNTANT FEES AND SERVICES</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We incorporate herein by reference the relevant information concerning principal accountant fees and services to be included in the </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;Proxy Statement.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">57</font></div></div><hr style="page-break-after:always"><div><a name="sB359A078C6E961B6FA8BE278AB569F8A"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART IV</font></div><div><a name="s079A77224C91B785485DE278AB83E60D"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 15.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) The following documents are filed as part of this Annual Report on Form 10-K:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated Financial Statements:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:74%;"></td><td style="width:26%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm on the Audited Consolidated Financial Statements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-2</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-3</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-4</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Stockholders' Equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-5</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Cash Flows</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-6</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes to Consolidated Financial Statements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-7</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial Statement Schedules:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibits</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The exhibits filed as part of this Annual Report on Form 10-K are set forth on the Exhibit Index immediately following our consolidated financial statements. The Exhibit Index is incorporated herein by reference.</font></div><div><a name="s3c2ec9c45b604b258dfb64c4a8d65252"></a></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">58</font></div></div><hr style="page-break-after:always"><div><a name="sE24F6859A87A4FCDF308E278ABA52EA4"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:center;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:8%;"></td><td style="width:43%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MacroGenics, Inc.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Scott Koenig</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scott Koenig, M.D., Ph.D.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">President and CEO and Director</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Act of 1934, as amended, this Report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:31%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Signature</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Title</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Scott Koenig</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and CEO and Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scott Koenig, M.D., Ph.D.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ James Karrels</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President, Chief Financial</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">James Karrels</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officer and Secretary (Principal Financial Officer)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Lynn Cilinski</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President, Controller and Treasurer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lynn Cilinski</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Accounting Officer)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Paulo Costa</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Paulo Costa</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Karen Ferrante, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Karen Ferrante, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Matthew Fust</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew Fust</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Kenneth Galbraith</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kenneth Galbraith</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Edward Hurwitz</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Edward Hurwitz</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Scott Jackson</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2017</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scott Jackson</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ David Stump, M.D.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David Stump, M.D.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">59</font></div></div><hr style="page-break-after:always"><div><a name="s4144B47533A9A52B68B5E278ABC41749"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:90%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Page</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8294DAA18133ADD3176DE278ABE22DB6"><font style="font-family:inherit;font-size:10pt;">Report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm, on the Audited Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8294DAA18133ADD3176DE278ABE22DB6">F - 2</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3631768CADC7E7ED3EBFE2787DB04A75"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets at December 31, 2016 and December 31, 2015</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3631768CADC7E7ED3EBFE2787DB04A75">F - 3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s709FB47ABD13BA29047CE2787D536EA1"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2016, 2015 and 2014</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s709FB47ABD13BA29047CE2787D536EA1">F - 4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB0683E3DD171371A7EE2E2787D0230A4"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Stockholders' Equity for the years ended December 31, 2016, 2015 and 2014</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB0683E3DD171371A7EE2E2787D0230A4">F - 5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB6D72133909FD24D7ABFE2787E30FC0F"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Cash Flows for the years ended December 31, 2016, 2015 and 2014</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB6D72133909FD24D7ABFE2787E30FC0F">F - 6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB427F67C192C4B66CC13E278AD59D325"><font style="font-family:inherit;font-size:10pt;">Notes to Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB427F67C192C4B66CC13E278AD59D325">F - 7</a></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 1</font></div></div><hr style="page-break-after:always"><div><a name="s8294DAA18133ADD3176DE278ABE22DB6"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Report of Ernst&#160;&amp; Young LLP,</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Independent Registered Public Accounting Firm,</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">on the Audited Consolidated Financial Statements</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Board of Directors and Shareholders</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MacroGenics, Inc.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have audited the accompanying consolidated balance sheets of MacroGenics, Inc. as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, and the related consolidated statements of operations and comprehensive loss, stockholders' equity and cash flows for each of the three years in the period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements.&#160; An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of MacroGenics, Inc. at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, and the consolidated results of its operations and its cash flows for each of the three years in the period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, in conformity with U.S. generally accepted accounting principles.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), MacroGenics Inc.'s internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated </font><font style="font-family:inherit;font-size:10pt;">February&#160;28, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;expressed an unqualified opinion thereon.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ernst &amp; Young LLP</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Baltimore, Maryland</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 2</font></div></div><hr style="page-break-after:always"><div><a name="s3631768CADC7E7ED3EBFE2787DB04A75"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MACROGENICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196,172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,898</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,877</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,764</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,483</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,806</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">704</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">305</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">283,947</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">342,384</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,961</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,841</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities, non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,986</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,369</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,044</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311,263</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">359,269</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities and stockholders' equity</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,134</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,708</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,866</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,319</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">914</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease exit liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,593</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">727</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,302</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,202</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, net of current portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,045</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent, net of current portion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,867</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,406</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease exit liability, net of current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">298</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,693</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,512</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,932</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders' equity:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, $0.01 par value &#8211; 125,000,000 shares authorized, 34,870,607 and 34,345,754 shares outstanding at December 31, 2016 and 2015, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">349</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">561,198</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547,185</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(292,714</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(234,186</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders' equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">268,751</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">313,337</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities and stockholders' equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311,263</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">359,269</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 3</font></div></div><hr style="page-break-after:always"><div><a name="s709FB47ABD13BA29047CE2787D536EA1"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MACROGENICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from collaborative agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,582</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,368</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,264</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from government agreements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,298</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,486</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">533</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,880</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,854</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,797</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Costs and expenses:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,271</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,186</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,831</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,765</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,926</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,922</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121,036</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,112</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60,042</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,514</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,528</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,140</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,313</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive loss:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized loss on investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(77</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,605</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,145</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,313</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.69</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.63</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.40</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted weighted average number of common shares</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,685,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,801,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,384,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 4</font></div></div><hr style="page-break-after:always"><div><a name="sB0683E3DD171371A7EE2E2787D0230A4"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MACROGENICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except share amounts)</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.59537572254335%;border-collapse:collapse;text-align:left;"><tr><td colspan="30"></td></tr><tr><td style="width:25%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Treasury Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Paid-In</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Comprehensive Income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stockholders'</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Equity</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,177,597</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,381</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">254,453</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(175,733</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,914</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,244</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,244</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of common stock, net of offering costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,250,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,694</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,716</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock plan related activity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">568,041</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">738</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">725</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Retirement of treasury stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,381</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,313</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,313</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,995,638</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">280</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">865</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335,071</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(214,046</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121,286</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,847</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,847</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of common stock, net of offering costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,976,827</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203,407</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203,467</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock plan related activity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">373,289</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">908</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Retirement of treasury stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,790</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized loss on investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,140</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,140</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,345,754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(234,186</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">313,337</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,165</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,165</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock plan related activity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">524,853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,862</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,887</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Retirement of treasury stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,862</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized loss on investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,528</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,528</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,870,607</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">561,198</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(292,714</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(82</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">268,751</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 5</font></div></div><hr style="page-break-after:always"><div><a name="sB6D72133909FD24D7ABFE2787E30FC0F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MACROGENICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,528</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,140</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,313</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net loss to net cash used in operating activities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,608</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,863</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,822</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,165</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,847</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,244</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,711</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(931</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,677</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,405</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,239</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(285</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,179</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,232</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,659</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,545</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,346</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease exit liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,822</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,439</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,191</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,223</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,317</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(727</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(878</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,242</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,679</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,661</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(347,762</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(142,910</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from sales and maturities of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">288,894</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,381</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,197</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,572</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(70,249</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(152,107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,572</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from issuance of common stock, net of offering costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203,467</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,716</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from stock option exercises</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,893</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">911</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase of treasury stock</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,854</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204,349</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,441</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net change in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(112,074</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,581</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,110</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196,172</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,591</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,481</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,098</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196,172</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,591</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 6</font></div></div><hr style="page-break-after:always"><div><a name="sB427F67C192C4B66CC13E278AD59D325"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MACROGENICS, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div><a name="sB705F8E326B2D4A64D01E2787D5E1CC0"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1. Organization and Nature of Operations</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MacroGenics, Inc. (the Company) was incorporated in Delaware on August 14, 2000. The Company is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. These product candidates, which the Company has identified through its understanding of disease biology and immune-mediated mechanisms, may address disease-specific challenges which are not currently being met by existing therapies.</font></div><div><a name="sE3C72F9EBD8980647C0AE2787C54B493"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2. Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation and Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited.&#160; All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;segment, which is developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, stock-based compensation, income taxes, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Marketable Securities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income (expense).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. The Company considers factors including: the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not that it will be required to sell a security prior to recovery of its fair value.&#160; An impairment loss is recognized at the time the Company determines that a decline in the fair value below its cost basis is other-than-temporary. There were </font><font style="font-family:inherit;font-size:10pt;color:#252525;">no</font><font style="font-family:inherit;font-size:10pt;color:#252525;">&#32;unrealized losses at </font><font style="font-family:inherit;font-size:10pt;color:#252525;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;color:#252525;">&#32;or </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;color:#252525;">&#32;that the Company determined to be other-than-temporary.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;allowance was recorded as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;or </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, as the Company has a history of collecting on all outstanding accounts.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#252525;">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements and Disclosures</font><font style="font-family:inherit;font-size:10pt;">&#32;(ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 &#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 &#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 &#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.34146341463415%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurement at December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices in</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Active Markets for</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Identical Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Observable Inputs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inputs</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,781</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,781</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S Treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government-sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,759</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,759</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,300</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,300</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets measured at fair value </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">251,666</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,781</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204,885</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Total assets measured at fair value at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;includes approximately </font><font style="font-family:inherit;font-size:10pt;">$50.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;reported in cash and cash equivalents on the balance sheet.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.24390243902438%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:39%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurement at December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices in</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Active Markets for</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Identical Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Observable Inputs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inputs</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,353</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,353</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S Treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government-sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,202</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,202</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,928</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,928</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets measured at fair value </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250,831</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,353</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188,478</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Total assets measured at fair value at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;includes approximately </font><font style="font-family:inherit;font-size:10pt;">$108.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;reported in cash and cash equivalents on the balance sheet.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of Level 2 securities is determined from </font><font style="font-family:inherit;font-size:10pt;color:#252525;">market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data.  There were no transfers between Level 1 and Level 2 investments during the periods presented.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </font><font style="font-family:inherit;font-size:10pt;color:#252525;">We maintain our cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, we have not experienced any losses on related accounts to date.&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#252525;">Our investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</font><font style="font-family:inherit;font-size:10pt;">&#32;The counterparties are various corporations, financial institutions and government agencies of high credit standing.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's revenue relates to agreements with various collaborators and&#160;contracts and research grants received from U.S. government agencies.&#160;The following table includes those collaborators that represent more than 10% of total revenue earned in the periods indicated:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:62%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen Biotech, Inc. (Janssen)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Les Laboratoires Servier and Institut de Reserches Servier (collectively, Servier) </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Boehringer Ingelheim GmbH (Boehringer)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Takeda Pharmaceutical Company Limited (Takeda)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gilead Sciences, Inc. (Gilead)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes those collaborators that represent more than 10% of accounts receivable at the date indicated:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:75%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Servier</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Takeda</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Eli Lilly</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">* Balance is less than 10%</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred. Depreciation is computed using the straight-line method over the following estimated useful lives:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory and office equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shorter of lease term or useful life</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property, Plant and Equipment</font><font style="font-family:inherit;font-size:10pt;">. ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company determined that there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;impaired assets and had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;assets held-for-sale.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company's policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenues</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company enters into collaboration and license agreements with collaborators for the development of monoclonal antibody-based therapeutics to treat cancer and other complex diseases. The terms of these agreements contain multiple deliverables which may include (i) licenses, or options to obtain licenses, to the Company's technological platforms, such as its Fc Optimization and Dual-Affinity Re-Targeting (DART) technologies, (ii) rights to future technological improvements, (iii) research and development activities to be performed on behalf of the collaborator or as part of the collaboration, and (iv) the manufacture of preclinical or clinical materials for the collaborator. Payments to the Company under these agreements may include nonrefundable license fees, option fees, exercise fees, payments for research and development activities, payments for the manufacture of preclinical or clinical materials, license maintenance payments, payments based upon the achievement of certain milestones and royalties on product sales. Other benefits to the Company of these agreements include the right to sell products resulting from the collaborative efforts of the parties in specific geographic territories. The Company follows the provisions of FASB ASC Topic 605-25, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition &#8211; Multiple-Element Arrangements</font><font style="font-family:inherit;font-size:10pt;">, and FASB ASC Topic 605-28, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition&#8211;Milestone Method</font><font style="font-family:inherit;font-size:10pt;">, in accounting for these agreements. In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the periods presented, the Company had the following two types of agreements: 1) exclusive development and commercialization licenses to use the Company's technology and/or certain other intellectual property to develop compounds against specified targets (referred to herein as exclusive licenses); and 2) option/research agreements to secure on established terms, development and commercialization licenses to therapeutic product candidates to collaborator-selected targets developed by the Company during an option period (referred to herein as right-to-develop agreements).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are no performance, cancellation, termination or refund provisions in any of the arrangements that contain material financial consequences to the Company.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exclusive Licenses</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The deliverables under an exclusive license agreement generally include the exclusive license to the Company's DART technology with respect to a specified antigen target, and may also include deliverables related to rights to future technological improvements, research and preclinical development activities to be performed on behalf of the collaborator. In some cases the Company may have an option to participate in the co-development of product candidates that result from such agreements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Generally, exclusive license agreements contain nonrefundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i) at the collaborator's request, provide research and preclinical development services at negotiated prices which are generally consistent with what other third parties would charge, (ii) earn payments upon the achievement of certain milestones, (iii) earn royalty payments, and (iv) in some cases grant the Company an option to participate in the development and commercialization of products that result from such agreements. Royalty rates may vary over the royalty term depending on the Company's intellectual property rights and whether the Company exercises any co-development and co-commercialization rights.The Company does not directly control when any collaborator will achieve milestones or become liable for royalty payments.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When entering into a new collaboration arrangement or materially modifying an existing arrangement, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator.&#160;&#160;The selling prices of deliverables under an arrangement may be derived using third-party evidence (TPE), or a best estimate of selling price (BESP), if vendor specific objective evidence (VSOE) is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the license agreement was sold on a standalone basis. Establishing BESP involves management's judgment and considers multiple factors, including market conditions, company-specific factors, and factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i) the delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the Company's control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of accounting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In determining the separate units of accounting, the Company evaluates whether the exclusive license has standalone value to the collaborator based on consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research and development capabilities of the collaborator and the availability of relevant research expertise in the marketplace. In addition, the Company considers whether or not (i) the collaborator could use the license for its intended purpose without the receipt of the remaining deliverables, (ii) the value of the license was dependent on the undelivered items and (iii) the collaborator or other vendors could provide the undelivered items. If the Company concludes that the license has stand-alone value and therefore will be accounted for as a separate unit of accounting, the Company then determines the estimated selling prices of the license and all other units of accounting based on market conditions, similar arrangements entered into by third parties, and entity-specific factors such as the terms of the Company's previous collaboration agreements, recent preclinical and clinical testing results of therapeutic product candidates that use the Company's technology platforms, the Company's pricing practices and pricing objectives, the likelihood that technological improvements will be made, the likelihood that technological improvements made will be used by the Company's collaborators and the nature of the research services to be performed on behalf of its collaborators and market rates for similar services. Total arrangement consideration is then allocated to each of the units of accounting using the relative-selling-price method.&#160;&#160;If facts and circumstances dictate that the exclusive license does not have stand-alone value, then the related payments are deferred and revenue is recognized throughout the period of performance.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management reassesses the period of performance over which the Company recognizes deferred upfront license fees and makes adjustments as appropriate in the period in which a change in the estimated period of performance is identified. In the event a collaborator elects to discontinue development of a specific product candidate under a single target license, but retains its right to use the Company's technology to develop an alternative product candidate to the same target or a target substitute, the Company would cease amortization of any remaining portion of the upfront fee until there is substantial preclinical activity on another product candidate and its remaining period of substantial involvement can be estimated. In the event that a single target license were to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination or through the remaining substantial involvement in the wind down of the agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront payments on exclusive licenses may be recognized upon delivery of the license if facts and circumstances dictate that the license has stand-alone value from the undelivered elements, which generally include rights to future technological improvements, research services and the manufacture of preclinical and clinical materials.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue related to research and preclinical development services that represent separate units of accounting as they are performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection is reasonably assured. The Company recognizes revenue related to the rights to future technological improvements over the estimated term of the applicable license.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company typically performs research activities and preclinical development services, including generating and engineering product candidates, on behalf of its licensees during the early evaluation and preclinical testing stages of drug development under its exclusive licenses. The Company records amounts received for research materials produced or services performed as revenue from collaborative agreements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's license agreements have milestone payments which for reporting purposes are aggregated into three categories: (i) development milestones, (ii) regulatory milestones, and (iii) sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the U.S. Food and Drug Administration (FDA) or other countries' regulatory authorities or on receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of each agreement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (i) the consideration is commensurate with either (a) the entity's performance to achieve the milestone, or (b) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity's performance to achieve the milestone, (ii) the consideration relates solely to past performance and (iii) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-refundable development and regulatory milestones that are expected to be achieved as a result of the Company's efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute effort to their achievement are generally recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligations, assuming all other revenue recognition criteria are met.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Right-to-Develop Agreements</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's right-to-develop agreements provide collaborators with an exclusive option to obtain licenses to develop and commercialize in specified geographic territories product candidates developed by the Company under agreed upon research and preclinical development product programs. The product candidates resulting from each program are all directed to a specific target selected by the collaborator. Under these agreements, fees may be due to the Company (i) at the inception of the arrangement (referred to as "upfront" fees or payments), (ii) the selection of a target for a program, (iii) upon the exercise of an option to acquire a development and commercialization license (referred to as exercise fees or payments earned) for a program, or (iv) some combination of all of these fees.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accounting for right-to-develop agreements is dependent on the nature of the options granted to the collaborator. Options are considered substantive if, at the inception of a right-to-develop agreement, the Company is at risk as to whether the collaborator will choose to exercise the options to secure development and commercialization licenses. Factors that are </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">considered in evaluating whether options are substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the total upfront consideration, and the additional financial commitments imposed on the collaborator as a result of exercising the options.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For right-to-develop agreements where the options to secure development and commercialization licenses to a product program are considered substantive, the Company does not consider the development and commercialization licenses to be a deliverable at the inception of the agreement, and therefore defers any upfront payments received and recognizes this revenue over the period during which the collaborator could elect to exercise options for development and commercialization licenses. These periods are specific to each collaboration agreement. If a collaborator selects a target for a product program, any substantive option fee is deferred and recognized over the life of the option. For right-to-develop agreements that include multiple deliverables, the Company determines the selling prices of deliverables under the arrangement using TPE or a BESP, if VSOE is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the right-to-develop agreement was sold on a standalone basis. Establishing BESP involves management's judgment and considers multiple factors, including market conditions and company-specific factors, including those factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the right-to-develop agreement. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i) the delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the Company's control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of accounting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a collaborator exercises an option and acquires a development and commercialization license to a product program, the Company attributes the exercise fee to the development and commercialization license. The Company determines the selling price of the option license, upon exercise, through management's best estimate using the process for an exclusive license as described above.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon exercise of an option to acquire a development and commercialization license, the Company would also attribute any remaining deferred option fee, in addition to the consideration received for the license upon exercise of the option, to the development and commercialization license.&#160;&#160;The Company then applies the multiple-element revenue recognition criteria to the development and commercialization license and other deliverables, if any, to determine the appropriate revenue recognition method. This model is consistent with the Company's accounting policy for upfront payments on exclusive licenses (discussed above).&#160;&#160;In the event a right-to-develop agreement were to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination. The Company's right-to-develop agreements have been determined to contain substantive options.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For right-to-develop agreements where the options to secure development and commercialization licenses to product programs are not considered substantive, the Company considers the development and commercialization licenses to be a deliverable at the inception of the agreement and applies the multiple-element revenue recognition criteria to determine the appropriate revenue recognition. The Company does not directly control when any collaborator will exercise its options for development and commercialization licenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Costs</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities.&#160; Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive Loss</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale securities.</font><font style="font-family:inherit;font-size:10pt;">&#32;Comprehensive loss equals net loss for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;as there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;unrealized gains or losses in that period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based payments are accounted for in accordance with the provisions of ASC 718, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation &#8211; Stock Compensation</font><font style="font-family:inherit;font-size:10pt;">. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per common share is computed as follows (in thousands except share and per share data):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.97560975609755%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss used for calculation of basic and diluted EPS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,528</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,140</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,313</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, basic</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,685,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,801,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,384,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options and restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,685,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,801,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,384,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.69</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.63</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.40</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following common stock equivalents were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:65%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,394,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,955,398</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,094,904</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Standards</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers </font><font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;">(Topic 606)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;">(ASU 2014-09).  ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract.  ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017 and interim periods therein, with early adoption permitted for interim and annual reporting periods beginning after December 15, 2016.  ASU 2014-09 may be adopted either retrospectively or on a modified retrospective basis&#160;whereby ASU 2014-09 would be applied to new contracts and existing contracts with remaining performance obligations&#160;as of the effective date, with a cumulative catch-up adjustment recorded to beginning retained&#160;earnings at the effective date for existing contracts with remaining performance obligations.  </font><font style="font-family:inherit;font-size:10pt;color:#252525;">In 2016, the FASB issued ASU 2016-08, </font><font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;">Revenue from Contracts with Customers: Principal versus Agent Considerations</font><font style="font-family:inherit;font-size:10pt;color:#252525;">, ASU 2016-10,&#160; </font><font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;">Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing</font><font style="font-family:inherit;font-size:10pt;color:#252525;">, and ASU 2016-12, </font><font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;">Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients</font><font style="font-family:inherit;font-size:10pt;color:#252525;">&#32;&#160;to provide supplemental adoption guidance and clarification to ASU 2014-09.  The effective date for these new standards is the same as the effective date and transition requirements for ASU 2014-09.  </font><font style="font-family:inherit;font-size:10pt;">Management has begun an initial review of each of the Company's collaboration and license agreements and is performing an assessment of the potential effects of the standard on the Company's consolidated financial statements, accounting policies, and internal controls over financial reporting. The Company anticipates that the adoption of the new revenue recognition standard will have primarily two impacts on its contract revenues generated by its collaborative research and license agreements: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i) Changes in the model for distinct licenses of functional intellectual property which may result in a timing difference of revenue recognition.&#160;&#160;Whereas revenue from these arrangements was previously recognized over a period of time pursuant to revenue recognition guidance that was in place for the arrangements at the time such arrangements commenced, revenue from these arrangements may now be recognized at point in time under the new guidance. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii) Assessments of milestone payments, which are linked to events that are in the Company&#8217;s control, will result in variable consideration that may be recognized at an earlier point in time under the new guidance, when it is probable that the milestone will be achieved without a significant future reversal of cumulative revenue expected. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has not yet completed its final review of the impact of this guidance. The Company has also not concluded on the implementation approach to be used.&#160;&#160;Management plans to adopt the new standard effective January 1, 2018. The Company continues to monitor additional changes, modifications, clarifications or interpretations being undertaken by the FASB, which may impact the implementation approach management decides to use. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">In August 2014, the FASB issued ASU 2014-15, </font><font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;">Presentation of Financial Statements - Going Concern, </font><font style="font-family:inherit;font-size:10pt;color:#252525;">which requires management of an entity to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued or available to be issued.  ASU 2014-15 is effective for annual periods ending after December&#160;15, 2016, and interim periods within </font><font style="font-family:inherit;font-size:10pt;">annual periods beginning after December 15, 2016</font><font style="font-family:inherit;font-size:10pt;color:#252525;">. The Company&#8217;s adoption of this new standard for the year ended December&#160;31, 2016 had no impact on the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes, Balance Sheet Classification of Deferred Taxes</font><font style="font-family:inherit;font-size:10pt;">&#32;(ASU 2015-17).&#160; ASU 2015-17 requires entities to present deferred tax assets and deferred tax liabilities as noncurrent on a classified balance sheet. ASU 2015-17 is effective for annual and interim reporting periods after December 15, 2016 and companies are permitted to apply ASU 2015-17 either prospectively or retrospectively. Early adoption of ASU 2015-17 is permitted. The Company adopted ASU 2015-17 on a prospective basis in the first quarter of 2016.&#160; The prior reporting period was not retrospectively adjusted. The adoption of this guidance had no impact on the Company's results of operations or cash flows.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#32;(ASU 2016-02) that provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors.&#160; ASU 2016-02 requires a lessee to recognize assets and liabilities on the balance sheet for operating leases and changes many key definitions, including the definition of a lease. ASU 2016-02 includes a short-term lease exception for leases with a term of 12 months or less, in which a lessee can make an accounting policy election not to recognize lease assets and lease liabilities. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous guidance. ASU 2016-02 is effective for fiscal years beginning after December&#160;15, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018, and interim periods within those fiscal years, with earlier application permitted. The Company is currently evaluating the effect of the standard on its consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March&#160;2016, the FASB issued ASU 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Improvements</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">to Employee Share-Based Payment Accounting </font><font style="font-family:inherit;font-size:10pt;">(ASU 2016-09). This amendment addresses several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within that year. Early adoption is permitted. The Company is evaluating the impact&#160;of the standard on its consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.</font></div><div><a name="sD42E6BBDC26B4B9D23FAE2787CB9D61C"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;font-weight:bold;">3. Marketable Securities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">Available-for-sale marketable securities as of </font><font style="font-family:inherit;font-size:10pt;color:#252525;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;color:#252525;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#252525;">2015</font><font style="font-family:inherit;font-size:10pt;color:#252525;">&#32;were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government-sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,764</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,759</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,376</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(127</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,300</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(138</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,884</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,354</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,349</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government-sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,055</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,047</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,473</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,481</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,882</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,877</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">The contractual maturities of the available-for-sale marketable securities as of </font><font style="font-family:inherit;font-size:10pt;color:#252525;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;color:#252525;">&#32;were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mature in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,985</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mature between one and five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,981</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,986</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,884</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the Company's available-for-sale securities held at December 31, 2015 had maturity dates of less than one year.  All available-for-sale securities in an unrealized loss position as of </font><font style="font-family:inherit;font-size:10pt;color:#252525;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;were in a loss position for less than twelve months.&#160; There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;unrealized losses at </font><font style="font-family:inherit;font-size:10pt;color:#252525;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;or </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;that the Company determined to be other-than-temporary.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">&#160;&#160;&#160;&#160;</font></div><div><a name="sCCB8821A5C0233FDF40FE2787CC32839"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4. Property and Equipment</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment consists of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,352</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,801</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and office equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">919</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,208</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,306</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,807</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,936</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,784</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,031</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,823</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,190</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,961</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,841</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment balance at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;includes approximately </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in assets that were purchased in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;but were not paid for by year end.&#160; Depreciation expense for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$6.8 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div><a name="sD69A96667F6F66EDEE77E2787CA311AF"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5. Stockholders' Equity</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;The Company's amended and restated certificate of incorporation authorizes </font><font style="font-family:inherit;font-size:10pt;">125,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock, and </font><font style="font-family:inherit;font-size:10pt;">5,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of undesignated preferred stock, both with a par value of </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.&#160;&#160;There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of undesignated preferred stock issued or outstanding as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;or </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2014, the Company completed an equity offering, in which the Company sold </font><font style="font-family:inherit;font-size:10pt;">1,800,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of its common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$36.50</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.&#160;&#160;Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional </font><font style="font-family:inherit;font-size:10pt;">450,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company's common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$36.50</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.&#160;&#160;The Company received proceeds of </font><font style="font-family:inherit;font-size:10pt;">$76.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from this offering, net of underwriting discounts and commissions and other offering expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2015, the Company's stock purchase agreement and investor agreement, each with Johnson &amp; Johnson Innovation &#8211; JJDC, Inc. (JJDC) became effective (See Note 9 for additional information).&#160; Under these agreements, JJDC purchased </font><font style="font-family:inherit;font-size:10pt;">1,923,077</font><font style="font-family:inherit;font-size:10pt;">&#32;new shares of the Company's common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$39.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, representing proceeds of </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the Company completed an equity offering, in which the Company sold </font><font style="font-family:inherit;font-size:10pt;">3,525,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of its common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$37.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.&#160; Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional </font><font style="font-family:inherit;font-size:10pt;">528,750</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company's common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$37.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.&#160; The Company received net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$141.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from this offering, net of underwriting discounts and commissions and other estimated offering expenses.</font></div><div><a name="s4A9B23765F27D92FED48E2787C5FF035"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6. Stock-based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. The 2003 Plan originally allowed for the grant of awards in respect of an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,051,644</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company's common stock. Between 2006 and 2012, the maximum number of shares of common stock authorized to be issued by the Company under the 2003 Plan was increased to </font><font style="font-family:inherit;font-size:10pt;">4,336,730</font><font style="font-family:inherit;font-size:10pt;">. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan. Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Plan, up to a specified number of shares.&#160; As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, under the 2003 Plan, there were options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,193,941</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock outstanding at a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.81</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2013, the Company implemented the 2013 Stock Incentive Plan (2013 Plan).&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards. The aggregate number of shares of common stock initially available for issuance pursuant to awards under the 2013 Plan was </font><font style="font-family:inherit;font-size:10pt;">1,960,168</font><font style="font-family:inherit;font-size:10pt;">&#32;shares.&#160;&#160;The </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">number of shares of common stock reserved for issuance will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) </font><font style="font-family:inherit;font-size:10pt;">1,960,168</font><font style="font-family:inherit;font-size:10pt;">&#32;shares, (b) </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Board of Directors. During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to </font><font style="font-family:inherit;font-size:10pt;">5,375,064</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, under the 2013 Plan, there were options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,644,119</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock outstanding at a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$26.66</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following stock-based compensation amounts were recognized for the periods indicated (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,778</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,623</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,562</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,387</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,224</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,682</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,165</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,847</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,244</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employee Stock Options</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:62%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64% - 69%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73% - 75%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2% - 2.4%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.6% - 2.1%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.8% - 2.3%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25 years</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expected Dividend Yield</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expected Volatility</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period.&#160;&#160;As the Company does not yet have sufficient history of its own volatility, the Company has identified several public entities of similar size, complexity and stage of development and estimates volatility based on the volatility of these companies.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk-Free Interest Rate</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expected Term</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;">. The Company uses a simplified method to calculate the average expected term.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the assumptions above, the Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.&#160;&#160;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option and restricted stock unit (RSU) activity for </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:49%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate Intrinsic Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,146,064</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">399,949</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised or RSUs vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(526,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited or expired</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(181,238</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.53</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,838,060</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,862</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,292,923</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.71</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,458</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,651,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,496</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;the Company issued </font><font style="font-family:inherit;font-size:10pt;">526,715</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">374,214</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">568,906</font><font style="font-family:inherit;font-size:10pt;">&#32;net shares of common stock, respectively, in conjunction with stock option exercises and RSU lapses.&#160;&#160;The Company received cash proceeds from the exercise of stock options of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted-average grant-date fair value of options granted during </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$15.17</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$20.90</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$17.41</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, respectively. The total intrinsic value of options exercised during </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;was approximately </font><font style="font-family:inherit;font-size:10pt;">$10.8 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$10.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$14.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;The total fair value of stock options which vested during </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$11.6 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$7.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the total unrecognized compensation expense related to non-vested stock options and RSUs, net of related forfeiture estimates, was </font><font style="font-family:inherit;font-size:10pt;">$22.2 million</font><font style="font-family:inherit;font-size:10pt;">, which the Company expects to recognize over a weighted-average period of approximately </font><font style="font-family:inherit;font-size:10pt;">2.5 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><a name="s01B06869FB392DAF98B1E2787C739EC1"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.&#160;&#160;Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;there was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;provision for income taxes due to taxable losses generated, fully offset by a valuation allowance.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal U.S. net operating loss carryforward</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,377</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,949</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State net operating loss carryforward</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,907</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development credit, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,829</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,278</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Orphan drug credit, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,855</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,497</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,947</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,632</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,926</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,597</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,085</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,532</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross deferred income tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130,250</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,126</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(128,844</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(104,399</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred income tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,406</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">727</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenditures</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,406</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(727</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross deferred income tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,406</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(727</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred income tax asset/(liability)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i) future reversals of existing taxable temporary differences; (ii) future taxable income exclusive of reversing temporary difference and carryforwards; (iii) taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv) tax planning strategies. The Company's net deferred income tax asset is not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. The net increase in the valuation allowance in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;is due to the fact the Company generated research and development and orphan drug credits and NOL carryforwards which increased the net deferred tax asset.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company has U.S. federal and state NOL carryforwards of approximately </font><font style="font-family:inherit;font-size:10pt;">$215.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;that will expire in various years beginning in </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;">&#32;through </font><font style="font-family:inherit;font-size:10pt;">2036</font><font style="font-family:inherit;font-size:10pt;">. In addition, the Company has U.S. federal tax credits of </font><font style="font-family:inherit;font-size:10pt;">$32.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;which will expire in various years beginning in </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;">&#32;through </font><font style="font-family:inherit;font-size:10pt;">2036</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The use of the Company's U.S. federal NOL and tax credit carryforwards in future years are restricted due to changes in the Company's ownership and tax attributes acquired through the Company's acquisitions. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$13.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of the Company's US Federal NOLs are limited for use over the years </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; </font><font style="font-family:inherit;font-size:10pt;">2029</font><font style="font-family:inherit;font-size:10pt;">&#32;in which a range of such amounts could be utilized on an annual basis of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">. The remaining </font><font style="font-family:inherit;font-size:10pt;">$201.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of NOLs is not limited and can be offset against future taxable income.&#160;&#160;Additionally, approximately </font><font style="font-family:inherit;font-size:10pt;">$18.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of NOLs will be recognized as a benefit through additional-paid-in-capital when realized.&#160;&#160;Further, despite the NOL and credit carryforwards, the Company may have a future tax liability due to an alternative minimum tax or state tax requirements in which net operating losses do not exist.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States federal tax at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,489</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,049</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,410</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State taxes (net of federal benefit)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">661</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred state blended rate adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(493</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,034</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research credit, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,551</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,296</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,228</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transaction cost deduction</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transaction cost deduction - prior year adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(564</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Orphan drug credit, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(571</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(139</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other permanent items</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(382</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,997</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">756</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,444</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,103</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,920</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense/(benefit)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,708</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases/(decreases) for current year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">308</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">357</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases/(decreases) for prior year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(268</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,465</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,425</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,047</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, of the total gross unrecognized tax benefits, approximately </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;would favorably impact the Company's effective income tax rate, respectively. Although, due to the Company's determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance would be recorded, therefore, zero net impact would result within the Company's effective income tax rate. The Company's uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute carryforward amounts.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, the Company has </font><font style="font-family:inherit;font-size:10pt;">not</font><font style="font-family:inherit;font-size:10pt;">&#32;recognized any interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within the next twelve months.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's U.S. Federal and state income tax returns from </font><font style="font-family:inherit;font-size:10pt;">2001</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#252525;">forward remain open to examination due to the carryover of unused net operating losses and tax credits.</font></div><div><a name="sBFA90418334E36E8931AE2787CD271D7"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.&#160;&#160;Lease Exit Liability</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2008, the Company acquired Raven Biotechnologies, Inc. (Raven), a private South San Francisco-based company focused on the development of monoclonal antibody therapeutics for treating cancer. The Company undertook restructuring activities related to the acquisition of Raven. In connection with these restructuring activities, as part of the cost of acquisition, the Company established a restructuring liability attributed to an existing operating lease.&#160; During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into an agreement to sublease a portion of the space subject to this operating lease.&#160; The Company will receive approximately </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in sublease payments over its term, which ends at the same time as the original lease in February 2018.&#160; No sublease income was contemplated when the restructuring liability was recorded in 2008; therefore, the Company adjusted the liability to reflect the future sublease income during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and recorded an offset to research and development expenses of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the same period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the lease exit liability are as follows (in thousands): </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:88%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrual balance at December&#160;31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal payments and other adjustments </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,293</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrual balance at December&#160;31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,713</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal payments and other adjustments (net of sublease receipts)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,822</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrual balance at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,891</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During 2015, the Company corrected an immaterial error attributed to the estimated lease term that resulted in a reduction of research and development expense of </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future principal payments to be made under the lease agreement as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, net of the sublease amounts, are as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:88%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,593</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">298</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,891</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s00DD8424CDEFE2B922DAE2787C38401A"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9. Collaboration and Other Agreements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Janssen</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">December 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a collaboration and license agreement with Janssen for the development and commercialization of MGD011 (also known as JNJ-64052781 or duvortuxizumab), a product candidate that incorporates the Company's proprietary DART technology to simultaneously target CD19 and CD3 for the potential treatment of B-cell hematological malignancies (MGD011 Agreement). The Company contemporaneously entered into an agreement with JJDC under which JJDC agreed to purchase </font><font style="font-family:inherit;font-size:10pt;">1,923,077</font><font style="font-family:inherit;font-size:10pt;">&#32;new shares of the Company's common stock for proceeds of </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Upon closing the transaction in January 2015, the Company received a </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payment from Janssen as well as the </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;investment in the Company's common stock.&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the MGD011 Agreement, the Company granted an exclusive license to Janssen to develop and commercialize duvortuxizumab. Following the Company's submission of the Investigational New Drug (IND) application, Janssen became fully responsible for the development and commercialization of duvortuxizumab.&#160;&#160; Assuming successful development and commercialization, the agreement entitles the Company to receive up to </font><font style="font-family:inherit;font-size:10pt;">$205.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in development milestone payments, </font><font style="font-family:inherit;font-size:10pt;">$220.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in regulatory milestone payments and </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in sales milestone payments. The Company determined that each potential future clinical and regulatory milestone is substantive.&#160; Although the sales milestones are not considered substantive, they will be recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time.&#160; The Company may elect to fund a portion of late-stage clinical development in exchange for a profit share with Janssen in the U.S. and Canada. If commercialized, the Company would be eligible to receive low double-digit royalties on any global net sales and has the option to co-promote the molecule with Janssen in the United States.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the MGD011 Agreement with Janssen and determined that it is a revenue arrangement with multiple deliverables, or performance obligations.&#160; The Company's substantive performance obligations under the collaboration and license agreement include the delivery of an exclusive license and research and development services during the preclinical research period (through the filing of the IND for duvortuxizumab). &#160; The Company evaluated the MGD011 Agreement and determined that the license and preclinical research and development activities each represented separate deliverables and were accounted for as separate units of accounting.&#160; The Company concluded that the license had standalone value to Janssen and was separable from the research and development services because the license was sublicensable, there were no restrictions as to Janssen's use of the license and Janssen or other third parties have significant research capabilities in this field.&#160; Thus, the total arrangement consideration for these two deliverables was allocated using the relative best estimate of selling price method to each deliverable.&#160; The best estimate of selling price for the exclusive license was determined using a discounted cash flow model that includes Level 3 fair value measurements. The best estimate of selling price for the research and development services was determined using third party evidence of other similar research and development arrangements, which are Level 2 fair value measurements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the stock purchase agreement and the collaboration and license agreement as one arrangement and determined that the stock purchase price of </font><font style="font-family:inherit;font-size:10pt;">$39.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share exceeded the fair value of the common stock by </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$12.3 million</font><font style="font-family:inherit;font-size:10pt;">. This excess was recognized in the same manner as the upfront payment allocated to the license and preclinical research and development activities.&#160; Of the total arrangement consideration of </font><font style="font-family:inherit;font-size:10pt;">$125.0 million</font><font style="font-family:inherit;font-size:10pt;">, the Company allocated </font><font style="font-family:inherit;font-size:10pt;">$62.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to equity (representing the fair value of common stock purchased), </font><font style="font-family:inherit;font-size:10pt;">$62.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to the license and preclinical research and development activities, and a de minimis amount to the ongoing research and development activities.&#160; The Company submitted the IND application and therefore met its performance obligation during the year ended December&#160;31, 2015.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, Janssen dosed the first patient in an open-label Phase 1 study of duvortuxizumab which triggered a </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;milestone to the Company.&#160; During the years ended December&#160;31, 2016 and 2015, the Company recognized revenue of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$72.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, under the MGD011 agreement. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2016, the Company entered into a separate collaboration and license agreement with Janssen, a related party through ownership of the Company's common stock, for the development and commercialization of MGD015, a product candidate that incorporates the Company's proprietary DART technology to simultaneously target CD3 and an undisclosed tumor target for the potential treatment of various hematological malignancies and solid tumors (MGD015 Agreement). The transaction closed in June 2016, and the Company received the </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payment from Janssen in July 2016.&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the MGD015 Agreement, the Company granted an exclusive license to Janssen to develop and commercialize MGD015. Janssen will complete the IND-enabling activities and will be fully responsible for the future clinical development and commercialization of MGD015.&#160;&#160; Assuming successful development and commercialization, the agreement entitles the Company to receive up to </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in development milestone payments, </font><font style="font-family:inherit;font-size:10pt;">$265.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in regulatory milestone payments and </font><font style="font-family:inherit;font-size:10pt;">$300.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in sales milestone payments. The Company determined that each potential future clinical and regulatory milestone is substantive.&#160; Although the sales milestones are not considered substantive, they will be recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time.&#160; The Company may elect to fund a portion of late-stage clinical development in exchange for a profit share with Janssen in the U.S. and Canada. If commercialized, the Company would be eligible to receive low double-digit royalties on any global net sales and has the option to co-promote the molecule with Janssen in the United States.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the MGD015 Agreement with Janssen and determined that it is a revenue arrangement with multiple deliverables, or performance obligations.&#160; The Company's substantive performance obligations under the MGD015 Agreement include the delivery of an exclusive license and research and development services during the preclinical research period. &#160; The Company evaluated the MGD015 Agreement with Janssen and determined that the license and preclinical research and development activities each represented separate deliverables and were accounted for as two separate units of accounting.&#160; The Company concluded that the license had standalone value to Janssen and was separable from the research and development services because the license was sublicensable, there were no restrictions as to Janssen's use of the license and Janssen or other third parties have significant research capabilities in this field.&#160; Thus, the total arrangement consideration for these two deliverables was allocated using the best estimate of relative selling price method to each deliverable.&#160; The best estimate of selling price for the exclusive license was determined using information from the previous collaboration and license agreement with Janssen as well as other third party collaboration and license agreements, which are Level 2 fair value measurements. The best estimate of selling price for the research and development services was determined using other similar research and development arrangements, which are also Level 2 fair value measurements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized revenue of </font><font style="font-family:inherit;font-size:10pt;">$75.8 million</font><font style="font-family:inherit;font-size:10pt;">, including the </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront fee for the exclusive license under the MGD015 Agreement.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Takeda</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">May 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a license and option agreement with Takeda for the development and commercialization of MGD010, a product candidate that incorporates the Company's proprietary DART technology to simultaneously engage CD32B and CD79B, which are two B-cell surface proteins.&#160;&#160;MGD010 is being developed for the treatment of autoimmune disorders.&#160; Upon execution of the agreement, Takeda made a non-refundable payment of </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to the Company.&#160;&#160;Takeda had an option to obtain an exclusive worldwide license for MGD010 following the completion of a pre-defined Phase 1a study.&#160; Following the announcement of its therapeutic area re-prioritization, Takeda gave formal notification in September 2016 that it did not intend to exercise this option.&#160; As a result of Takeda not exercising the option, the Company regained worldwide development and commercialization rights to MGD010. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of the license and option agreement with Takeda, the Company evaluated it and determined that it was a revenue arrangement with multiple deliverables, or performance obligations. The Company's substantive performance obligations under the license and option agreement included exclusivity, research and development services through the Phase 1a study and delivery of a future license for an initial research compound.&#160;&#160;The Company concluded that the MGD010 option </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">was substantive and that the license fee payable upon exercise of the option was not a deliverable at the inception of the arrangement as there was considerable uncertainty that the option would be exercised. The Company determined that each potential future clinical and regulatory milestone was substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time.&#160;&#160;&#160;The Company determined that these performance obligations represent a single unit of accounting, because the exclusivity clause does not have stand-alone value to Takeda without the Company's technical expertise and development through the pre-defined Phase 1a study.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After identifying the deliverables included within the arrangement, the Company determined its best estimate of selling price.&#160;&#160;The Company allocated </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to the exclusivity clause to its technology and the research and development services and </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to the exclusive license for the initial research compound.&#160;&#160;The Company's determination of best estimate of selling price for the research and development services relied upon other similar transactions.&#160;&#160;The Company relied upon the income approach (e.g., discounted future cash flows) to determine the value of the license of the to-be-delivered compound along with other similar license transactions with differing indications but similar stage of development. The portion of the up-front fee allocated to the MGD010 option was being recognized over an initial </font><font style="font-family:inherit;font-size:10pt;">24</font><font style="font-family:inherit;font-size:10pt;">-month period, which represented the expected period of development through the completion of a pre-defined Phase 1a study.&#160;&#160;During the first quarter of 2016, the Company determined that the development period would be extended by eight months, and prospectively adjusted the MGD010 option fee recognition period.&#160; The portion of the up-front fee allocated to the license for the initial research compound was deferred until the research collaboration and license option agreement was executed and the license delivered in September 2014.&#160; Upon the notification that Takeda would not exercise the option to obtain an exclusive worldwide license for MGD010 during the three months ended September 30, 2016, the Company's performance obligation to Takeda ceased, and the remaining deferred revenue under the MGD010 agreement was recognized in full.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized revenue of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$8.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;under the MGD010 agreement during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160; Revenue recognized during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;included a </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;milestone payment received upon initiation of a Phase 1a trial of MGD010.&#160;&#160;&#160;At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;revenue was deferred under this agreement.&#160; At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenue was deferred under this agreement, all of which was current.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">September 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company and Takeda executed a research collaboration and license option agreement, which formalized the license for the initial research compound contemplated in the May 2014 arrangement. Under the terms of the agreement, Takeda may nominate up to three additional compounds on or before September 25, 2017, which will be subject to separate research and development plans.&#160;&#160;The Company determined that it could recognize the entire license fee allocated to this agreement as (1) the executed contract constituted persuasive evidence of an arrangement, (2) the delivery of the license occurred and the Company had no current or future performance obligations, (3) the total consideration for the license was fixed and known at the time of its execution and there were not any extended payment terms or rights of return, and (4) the cash was received. &#160;The Company is also entitled to receive reimbursements for research and development services provided to Takeda with respect to the initial research compound under a separate research plan.&#160; The Company recognized revenue of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;under this agreement during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160; Revenue during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;includes the </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;license fee.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;text-indent:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Takeda terminated its option to license the first program under this research collaboration agreement in 2015 and retains an option for three others.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Servier</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">September 2012</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a right-to-develop collaboration agreement with Servier and granted it options to obtain three separate exclusive licenses to develop and commercialize DART molecules, consisting of those designated by the Company as MGD006 (or flotetuzumab) (also known as S80880) and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India.  During 2014, Servier exercised its exclusive option to develop and commercialize flotetuzumab, and during 2016 Servier notified the Company that it did not intend to exercise the option for the third DART molecule.  Servier retains the option to obtain a license for MGD007.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon execution of the agreement, Servier made a nonrefundable payment of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to the Company. In addition, the Company will be eligible to receive up to </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in license fees, </font><font style="font-family:inherit;font-size:10pt;">$63.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in clinical milestone payments, </font><font style="font-family:inherit;font-size:10pt;">$188.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in regulatory milestone payments and </font><font style="font-family:inherit;font-size:10pt;">$420.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in sales milestone payments if Servier exercises the remaining available options and successfully develops, obtains regulatory approval for, and commercializes a product under each license. In addition to these milestones, the Company and Servier will share Phase 2 and Phase 3 development costs. The Company has determined that each potential future clinical and regulatory milestone is substantive. Although sales milestones </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. Under this agreement, Servier would be obligated to pay the Company from low double-digit to mid-teen royalties on net product sales in its territories.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the research collaboration agreement with Servier and determined that it is a revenue arrangement with multiple deliverables, or performance obligations. The Company concluded that each option is substantive and that the license fees for each option are not deliverables at the inception of the arrangement and were not issued with a substantial discount. The Company's substantive performance obligations under this research collaboration include an exclusivity clause to its technology, technical, scientific and intellectual property support to the research plan and participation on an executive committee and a research and development committee. The Company determined that the performance obligations with respect to the preclinical development represent a single unit of accounting, since the license does not have stand-alone value to Servier without the Company's technical expertise and committee participation. As such, the initial upfront license payment was deferred and initially recognized ratably over a </font><font style="font-family:inherit;font-size:10pt;">29</font><font style="font-family:inherit;font-size:10pt;">-month period, which represented the expected development period. During 2014, the Company and Servier further refined the research plan related to the three DART molecules and as such, the development period was extended.&#160;&#160;Based on this revised development period, the Company prospectively adjusted its period of recognition of the upfront payment to a </font><font style="font-family:inherit;font-size:10pt;">75</font><font style="font-family:inherit;font-size:10pt;">-month period. The impact of this change in accounting estimate reduced revenue that would have been recognized in 2014 by </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of Servier exercising its option in 2014, the Company received a </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;payment from Servier for its license to develop and commercialize flotetuzumab in its territories.&#160;&#160;Upon exercise of the option, the Company evaluated its performance obligations with respect to the license for flotetuzumab. The Company's substantive performance obligations under this research collaboration include an exclusive license to its technology, technical, scientific and intellectual property support to the research plan and participation on an executive committee and a research and development committee. The Company determined that the performance obligations with respect to the clinical development represent a single unit of accounting, since the license does not have stand-alone value to Servier without the Company's technical expertise and committee participation. As such, the </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;license fee was deferred and is being recognized ratably over a period of </font><font style="font-family:inherit;font-size:10pt;">82 months</font><font style="font-family:inherit;font-size:10pt;">, which represents the expected development period for flotetuzumab.&#160;&#160;In accordance with the agreement, the Company and Servier will share costs incurred to develop flotetuzumab.&#160;&#160;Reimbursement of research and development expenses received in connection with this collaborative cost-sharing agreement is recorded as a reduction to research and development expense.&#160;&#160;During the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;the Company recorded approximately </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as an offset to research and development costs under this collaboration arrangement, respectively.&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;the Company recognized revenue of </font><font style="font-family:inherit;font-size:10pt;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$16.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, under this agreement.&#160;&#160;Revenue during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;includes </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;milestone payments from Servier upon the achievement of clinical milestones related to the IND applications for flotetuzumab and MGD007 clearing the </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">-day review period by the U.S. FDA.&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;milestones were recognized under this agreement during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;or </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$11.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenue was deferred under this agreement, </font><font style="font-family:inherit;font-size:10pt;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of which was current and </font><font style="font-family:inherit;font-size:10pt;">$7.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of which was non-current. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$14.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenue was deferred under this agreement, </font><font style="font-family:inherit;font-size:10pt;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of which was current and </font><font style="font-family:inherit;font-size:10pt;">$11.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of which was non-current.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Boehringer</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">October 2010</font><font style="font-family:inherit;font-size:10pt;">&#32;the Company entered into a collaboration and license agreement with Boehringer to discover, develop and commercialize multiple DART molecules that were to be evaluated during a five-year period that ended in </font><font style="font-family:inherit;font-size:10pt;">October 2015</font><font style="font-family:inherit;font-size:10pt;">. Under the terms of the agreement, the Company granted Boehringer an exclusive, worldwide, royalty-bearing, license under its intellectual property to research, develop, and market DART molecules generated under the agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon execution of the agreement, the Company received an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;">. The Company subsequently received </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;annual maintenance payments. These maintenance payments were being recognized over the estimated period of development. The Company has the potential to earn additional milestone payments of approximately </font><font style="font-family:inherit;font-size:10pt;">$34.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to preclinical and clinical development, </font><font style="font-family:inherit;font-size:10pt;">$88.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to regulatory milestones and </font><font style="font-family:inherit;font-size:10pt;">$82.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to sales milestones for each of the two ongoing programs under this agreement. The Company determined that each potential future preclinical, clinical and regulatory milestone is substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. Boehringer would be required to pay the Company mid-single digit royalties on product sales.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the deliverables under the Boehringer agreement include the license, the research and development services to be performed by the Company, and the co-promotion/manufacturing services. The Company concluded that the co-promotional activities were optional and were subject to further negotiation upon reaching regulatory approval. As such, the co-promotional period is not included in the expected obligation period to perform services.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company concluded that the undelivered element of research and development services had fair value. The Company concluded that the license did not have value on a standalone basis (e.g. absent the provision of the research and development services) and therefore did not represent a separate unit of accounting. The Company concluded that because the drug candidate had not yet been developed, the license was of no value to Boehringer without the ensuing research and development activities using the DART technology, which is proprietary to the Company. Likewise, Boehringer could not sell the license to another party (without the Company agreeing to provide the research and development activities for the other party). Therefore, the upfront license fee and research and development services were treated as a combined unit of accounting and recognized over the expected obligation period associated with the research and development services through October 2015, which represented the estimated period of development.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company and Boehringer also agreed to establish a joint research committee to facilitate the governance and oversight of the parties' activities under the agreements. Management considered whether participation on the joint committee may be a deliverable and determined that it was not a deliverable. However, had management considered participation on the joint committee as a deliverable, it would not have had a material impact on the accounting for the arrangement as the period of participation in this committee matched the obligation period for the research and development services.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;revenue under this agreement during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.  The Company recognized revenue of approximately </font><font style="font-family:inherit;font-size:10pt;">$12.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$13.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, under this agreement. Revenue recognized during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;included milestone payments of </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, for the achievement of clinical milestones.  </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;revenue was deferred under this agreement at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;or </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Green Cross</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">June 2010</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a collaboration agreement with Green Cross Corp. (Green Cross) for the development of the Company's anti-HER2 antibody margetuximab. This arrangement grants Green Cross an exclusive license to conduct specified Phase 1 and Phase 2 clinical trials and commercialize margetuximab in South Korea. In March 2014, the Company and Green Cross entered into an amendment to the original agreement, causing the terms of the original agreement to be materially modified.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon execution of the amendment, the Company became eligible to receive reimbursement for costs incurred for Phase 2 and Phase 3 clinical trials up to </font><font style="font-family:inherit;font-size:10pt;">$5.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as well as clinical development and commercial milestone payments of up to </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">. The Company determined that each potential clinical development and commercial milestone is substantive. The Company is also entitled to receive royalties on net sales of margetuximab in South Korea. The Company and Green Cross have formed a joint steering committee to coordinate and oversee activities on which the companies collaborate under the agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the collaboration agreement with Green Cross and determined that it is a revenue arrangement with multiple deliverables or performance obligations. As a result of the material modification to the arrangement in March 2014, the Company reassessed the entire arrangement in accordance with the guidance provided by ASC 605-25, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Multiple Element Arrangements (Revenue Recognition)</font><font style="font-family:inherit;font-size:10pt;">&#32;as the original agreement was accounted for prior to adopting ASU 2009-13</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;">&#32;The Company's substantive performance obligations under this agreement include an exclusive license to its technologies, research and development services, and participation in a joint steering committee. The Company concluded that the license and the reimbursements for research and development services do not have value on a standalone basis and therefore do not represent separate units of accounting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The initial </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payment received by the Company upon execution of the original agreement is non-refundable; as such, there is no right of return for the license. Therefore, the upfront license fee and participation on the joint steering committee were treated as a combined unit of accounting and will be recognized over the term of the agreement through </font><font style="font-family:inherit;font-size:10pt;">June 2020</font><font style="font-family:inherit;font-size:10pt;">. Further, due to the fact the research and development services are not deemed to have stand-alone value, revenue for those services will be recognized over the entire term of the agreement (through June 2020). As a result of reassessing the arrangement in accordance with ASC 605-25, the Company was required to record an adjustment on the date of the material modification to reflect the revenue that would have resulted had the entity applied the requirements of ASC 605-25 from the inception of the agreement.&#160;&#160;As a result, the Company recorded an additional </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenue during 2014.  The Company has received a total of </font><font style="font-family:inherit;font-size:10pt;">$5.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;for reimbursement of research and development services, which is also being recognized over the remaining term of the agreement.  </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized revenues of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;under this agreement during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;milestones were achieved under this agreement during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenue was deferred under this agreement, </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of which was current and </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of which was non-current.&#160; At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenue was deferred under this agreement, </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of which was current and </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of which was non-current.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">NIAID Contract</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;15, 2015</font><font style="font-family:inherit;font-size:10pt;">,&#160;to perform product development and to advance up to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;DART molecules, including MGD014. Under this contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. This contract includes a base period of </font><font style="font-family:inherit;font-size:10pt;">$7.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to support development of MGD014 through IND application submission with the FDA, as well as up to </font><font style="font-family:inherit;font-size:10pt;">$17.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to </font><font style="font-family:inherit;font-size:10pt;">$24.5 million</font><font style="font-family:inherit;font-size:10pt;">. The total potential period of performance under the award is from September 15, 2015 through </font><font style="font-family:inherit;font-size:10pt;">September&#160;14, 2022</font><font style="font-family:inherit;font-size:10pt;">. The Company recognized </font><font style="font-family:inherit;font-size:10pt;">$5.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in revenue under this contract during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div><a name="s204F4C27D8E4D06CE1D9E2787D6C93F9"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10. Commitments and Contingencies</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company leases manufacturing, office and laboratory space in Rockville, Maryland under </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;leases that have terms that expire between </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2022</font><font style="font-family:inherit;font-size:10pt;">&#32;unless renewed.&#160;&#160;&#160;This includes a </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;">-year lease executed in </font><font style="font-family:inherit;font-size:10pt;">July 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;for additional space that the Company intends to use as mixed-use office, laboratory and manufacturing space.&#160;&#160; Under the terms of the lease, which commenced on </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company received an assignment fee from the former tenant and a tenant improvement allowance from the landlord totaling </font><font style="font-family:inherit;font-size:10pt;">$5.1 million</font><font style="font-family:inherit;font-size:10pt;">, which has been recorded as deferred rent and will be recognized over the lease term.&#160;&#160; The Company also leases office and laboratory space in South San Francisco under a lease that expires on </font><font style="font-family:inherit;font-size:10pt;">February&#160;28, 2018</font><font style="font-family:inherit;font-size:10pt;">.  During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a sublease agreement for a portion of the South San Francisco space (see Note 8). Future payments to be received by the Company under this sublease total approximately </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the leases contain rent escalation clauses and certain leases contain rent abatements.&#160;&#160;For financial reporting purposes, rent expense is charged to operations on a straight-line basis over the term of the lease.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company had recorded a deferred rent liability of </font><font style="font-family:inherit;font-size:10pt;">$6.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$7.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Rent expense for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future minimum lease payments under noncancelable operating leases as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:88%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,210</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,142</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,636</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,679</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company does not believe it is currently subject to any material matters where there is at least a reasonable possibility that a material loss may be incurred.</font></div><div><a name="s30183021A6287F55FD5AE2787D4D74FC"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11. Employee Benefit Plan</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section 401(k) of the IRC. Under this Plan, all employees at least </font><font style="font-family:inherit;font-size:10pt;">21</font><font style="font-family:inherit;font-size:10pt;">&#32;years of age are eligible to participate in the Plan, starting on the first day of each month. Employees may contribute up to </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;">&#32;of their salary, subject to government maximums.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees are </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;">&#32;vested in their contributions to the Plan. The Company's contribution to the Plan, as determined by the Board of Directors, is discretionary. The Company's contributions to the Plan totaled </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div><a name="s953B06D927EE439D124DE2787C5D2412"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12.&#160;&#160;Quarterly Financial Information (unaudited)</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1st Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2nd Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3rd Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4th Quarter</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in thousands, except per share data)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,846</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,673</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,255</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,106</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,464</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.88</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.97</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.97</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,279</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,716</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,681</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,178</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,129</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,376</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,442</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,451</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.53</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.71</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.46</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.83</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 28</font></div></div><hr style="page-break-after:always"><div><a name="s61D502D0EEBD5F9CB3E4E278B0FCF1F4"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:4%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restated Certificate of Incorporation of the Company and Certificate of Correction to the Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibits 3.1 and 3.3, respectively, to the Company's Current Report on Form 8-K filed on October 18, 2013)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amended and Restated By-Laws of the Company (incorporated by reference to Exhibit 3.4 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Specimen Stock Certificate (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 9, 2013)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investor Agreement by and between Johnson and Johnson Innovation-JJDC, Inc. and the Company, dated December 19, 2014 (incorporated by reference to Exhibit 4.3 to the Company's Annual Report on Form 10-K filed on March 3, 2015)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.14 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.2&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Option for a License Agreement by and between the Company and Les Laboratoires Servier and Institut de Recherches Servier, dated September 19, 2012 (incorporated by reference to Exhibit 10.20 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 4, 2013)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.3&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration and License Agreement by and between Janssen Biotech, Inc. and the Company, dated December 19, 2014 (incorporated by reference to Exhibit 10.25 to the Company's Annual Report on Form 10-K filed on March 3, 2015)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.4+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Company 2003 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September 4, 2013)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.5+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Incentive Stock Option Agreement under 2003 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September 4, 2013)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.6+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Company 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.7+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Incentive Stock Option Agreement under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.8+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Nonstatutory Stock Option Agreement under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.9+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Restricted Stock Units Grant Notice under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on May 6, 2015)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.10+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016 Employee Stock Purchase Plan (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-8 (File No. 333-214386) filed by the Company on November 2, 2016)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.11+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employment Agreement between the Company and Scott Koenig, M.D., Ph.D. (incorporated by reference to Exhibit 10.14 to the Company's Annual Report on Form 10-K filed by the Company on February 29, 2016)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.12+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employment Agreement between the Company and James Karrels (incorporated by reference to Exhibit 10.15 to the Company's Annual Report on Form 10-K filed by the Company on February 29, 2016)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.13+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employment Agreement between the Company and Jon Wigginton, M.D. (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on May 4, 2016)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.14+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted Stock Units Grant Notice and Agreement between the Company and Jon Wigginton, M.D. (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on May 4, 2016)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.15+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employment Agreement between the Company and Ezio Bonvini, M.D. (incorporated by reference to Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q filed on May 4, 2016)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.16+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employment Agreement between the Company and Eric Risser</font></div></td></tr></table></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:4%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consent of Ernst &amp; Young, LLP, Independent Registered Public Accounting Firm</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rule 13a-14(a) Certification of Principal Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rule 13a-14(a) Certification of Principal Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 1350 Certification of Principal Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 1350 Certification of Principal Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.INS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Instance Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Schema Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.CAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Calculation Linkbase Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Definition Linkbase Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.LAB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Labels Linkbase Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Presentation Linkbase Document</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8224;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment granted by the SEC.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">+</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicates management contract or compensatory plan.</font></div></td></tr></table><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>2
<FILENAME>exhibit1016.htm
<DESCRIPTION>EXHIBIT 10.16
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s3D0F3E714CA76777EECD70FB34F920D6"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 10.16</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EMPLOYMENT AGREEMENT</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Employment Agreement (the </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Agreement&#8221;</font><font style="font-family:inherit;font-size:11pt;">) is entered into as of March 8, 2016 (the </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Effective Date&#8221;</font><font style="font-family:inherit;font-size:11pt;">), by and between MacroGenics, Inc., a Delaware corporation, including its successors and assigns (the </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Employer&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;or </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Company&#8221;</font><font style="font-family:inherit;font-size:11pt;">), and Eric Risser (</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Executive&#8221;</font><font style="font-family:inherit;font-size:11pt;">).  </font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In consideration of the promises and the respective undertakings of Employer and Executive set forth below, Employer and Executive hereby agree as follows:</font></div><div style="line-height:138%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Employment</font><font style="font-family:inherit;font-size:11pt;">.  Employer hereby employs Executive, and Executive hereby accepts such employment and agrees to perform services for Employer, for the period and on the other terms and subject to the conditions set forth in this Agreement.  </font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Employment at Will</font><font style="font-family:inherit;font-size:11pt;">.  Executive is employed &#8220;at-will&#8221; which means that Executive&#8217;s employment is not for any defined term and may be terminated by either Executive or the Company at any time, with or without cause, for any or no reason, subject to the notice provisions in Section 5.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Position and Duties</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3.01.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Service with Employer</font><font style="font-family:inherit;font-size:11pt;">.  Employer hereby employs Executive in an executive capacity with the title of Senior Vice President, Business Development and Portfolio Management (</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Title&#8221;</font><font style="font-family:inherit;font-size:11pt;">), and Executive hereby accepts such employment and undertakes and agrees to serve in such capacity.  Subject to the overall policy directives of the Board of Directors (the </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Board&#8221;</font><font style="font-family:inherit;font-size:11pt;">) and applicable law, in Executive&#8217;s capacity as Title, Executive shall have such powers, perform such duties and fulfill such responsibilities as are typically associated with such position in other similarly situated companies.  </font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3.02.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Performance of Duties</font><font style="font-family:inherit;font-size:11pt;">.  Executive agrees to: (i) devote substantially all of Executive&#8217;s business time, attention and efforts to the business and affairs of Employer while employed; and (ii) adhere to all Employer&#8217;s written employment policies and procedures as shall be in force from time to time.  Executive shall perform Executive&#8217;s duties primarily at the Company&#8217;s headquarters in Rockville, Maryland, but is expected to travel as Company business necessitates.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3.03.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Outside Activities</font><font style="font-family:inherit;font-size:11pt;">.  During the term of Executive&#8217;s employment with the Company pursuant to this Agreement, Executive shall not, except as set forth below: (i) accept other employment; (ii) render or perform services for compensation to any Person (as hereinafter defined) other than Employer; (iii) serve as an officer or on the board of directors (or similar governing body) of any entity other than Employer, whether or not for compensation; or (iv)&#160;engage in any other business or professional activity that will require any effort on the part of Executive that, in the sole discretion of Employer, could reasonably be expected to materially detract from the ability of Executive to perform Executive&#8217;s duties to Employer pursuant to this Agreement; </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:11pt;">, </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:11pt;">, Executive may engage in the activities (x) set forth in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Schedule 1</font><font style="font-family:inherit;font-size:11pt;">&#32;hereto (as may be amended from time to time by mutual written agreement of the parties) so long as in doing so Executive is not in any way competing with the Company and such outside activities do not materially detract from Executive&#8217;s performance of his duties hereunder or (y) described in clause (iii) or (iv) above if prior to engaging in such activity described in clause (iii) or (iv), Executive has disclosed such activity to the Board and received written approval to engage in such </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">activity from the Board.  Executive may engage in personal investments without disclosure to or written approval from the Board provided Executive is not required or expected to serve as a board member, advisor or consultant and Executive shall, at any time, own beneficially less than 5% of the outstanding securities of any issuer and such personal investment shall not otherwise interfere with Executive&#8217;s performance of duties hereunder and/or the provisions of Executive&#8217;s written agreements with Employer.  Although Executive may be engaged in outside activities pursuant to this section, nothing herein is intended to limit or waive Executive&#8217;s fiduciary duties.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3.04.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Executive Representations</font><font style="font-family:inherit;font-size:11pt;">.  Executive represents that Executive is not subject to any restrictive covenant, confidentiality agreement, or any other agreement that would prevent Executive from accepting employment with Employer, and based on the information provided to Employer by Executive, Employer accepts such representation.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Compensation</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.01.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Base Salary</font><font style="font-family:inherit;font-size:11pt;">.  Employer shall pay to Executive an annual base salary for all services to be rendered by Executive under this Agreement of $345,100 (the </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Base Salary&#8221;</font><font style="font-family:inherit;font-size:11pt;">), which Base Salary shall be paid in accordance with Employer&#8217;s normal payroll schedule, procedures and policies (which schedule, procedures and policies may be modified from time to time) and subject to applicable deductions as required by law.  Employer shall review Executive&#8217;s salary on an annual basis and may, in its discretion, consider and declare from time to time increases in the Base Salary that it pays Executive.  Any and all increases in Executive&#8217;s salary pursuant to this section shall cause the level of Base Salary to be increased by the amount of each such increase for purposes of this Agreement.  The increased level of Base Salary as provided in this section shall become the level of Base Salary for the remainder of the term of this Agreement unless there is a further increase in Base Salary as provided herein. </font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.02.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Annual Bonus</font><font style="font-family:inherit;font-size:11pt;">.  Executive shall also be eligible to receive, in addition to the Base Salary, an annual bonus having a target amount equal to 35% of Executive&#8217;s Base Salary (</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Target Bonus&#8221;</font><font style="font-family:inherit;font-size:11pt;">), with the actual amount being determined by the Compensation Committee of the Board in its discretion taking into account the Company&#8217;s performance and Executive&#8217;s individual performance.  In order to receive a Target Bonus, Executive must be employed by Employer on the date the bonus is paid.  </font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.03.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Participation in Benefit Plans</font><font style="font-family:inherit;font-size:11pt;">.  Executive shall be entitled to participate in all employee benefit plans or programs offered to other senior executives from time to time (to the extent that Executive meets the requirements for each such plan or program), including participation in any health insurance plan, disability insurance plan, dental plan, eye care plan, 401(k) plan, life insurance plan, or other similar plans (all such benefits, the </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Benefit Plans&#8221;</font><font style="font-family:inherit;font-size:11pt;">).  </font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.04.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Expenses</font><font style="font-family:inherit;font-size:11pt;">.  Employer shall reimburse Executive for all ordinary and necessary business expenses reasonably incurred by Executive in the performance of Executive&#8217;s duties under this Agreement, subject to the presentment and approval of appropriate itemized expense statements, receipts, vouchers or other supporting documentation in accordance with Employer&#8217;s normal policies for expense verification in effect from time to time.  </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.05.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Vacation</font><font style="font-family:inherit;font-size:11pt;">.  Executive shall be entitled to twenty (20) vacation days per calendar year, accruing in accordance with the Company&#8217;s vacation policy.  Executive may carry over up to a maximum of 200 hours of annual leave (including sick pay) at any time, and any unused vacation time beyond that will be forfeited.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.06.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Total Compensation</font><font style="font-family:inherit;font-size:11pt;">.  Other than as may be approved by the Board, Executive shall not receive any other compensation or benefits from the Company other than as provided in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Sections 4.01</font><font style="font-family:inherit;font-size:11pt;">&#32;through </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">4.06</font><font style="font-family:inherit;font-size:11pt;">&#32;hereof.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Payments Upon Termination</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5.01.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Voluntary Resignation without Good Reason</font><font style="font-family:inherit;font-size:11pt;">.  Executive may terminate Executive&#8217;s employment by providing Employer with 30 days&#8217; advance written notice, which notice period may be waived by the Company in its discretion and will be deemed to be waived in the case of the Executive&#8217;s effective resignation due to death or Disability (as defined below).  If Executive terminates Executive&#8217;s employment (other than for Good Reason (as defined below) or by reason of death or Disability (as defined below)) (i) Employer shall pay to Executive the Accrued Obligations (as defined below), (ii) Executive&#8217;s participation in the Benefit Plans shall terminate as of the Termination Date, and (iii) Employer shall have no other obligations to Executive under this Agreement, other than those provided in this </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 5.01</font><font style="font-family:inherit;font-size:11pt;">.   </font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">For purposes of this Agreement, </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Accrued Obligations&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;means: (i) Executive&#8217;s earned and unpaid Base Salary through the Termination Date; (ii)&#160;reimbursement for any reimbursable business expenses incurred by Executive through the Termination Date in accordance with </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 4.05</font><font style="font-family:inherit;font-size:11pt;">; and (iii)&#160;Executive&#8217;s accrued but unused vacation time as of the Termination Date.  The Accrued Obligations payable hereunder shall be paid no later than sixty (60) days following Executive&#8217;s Termination Date. </font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">For purposes of this Agreement, </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Termination Date&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;means: the effective date of Executive&#8217;s &#8220;separation from service&#8221; as defined in Section 409A of the Internal Revenue Code, or any applicable successor provision in effect at the Termination Date (the &#8220;Code&#8221;).</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5.02.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Termination by Employer For Cause</font><font style="font-family:inherit;font-size:11pt;">.  If Executive is terminated for Cause: (i) Employer shall pay to Executive the Accrued Obligations, (ii) Executive&#8217;s participation in the Benefit Plans shall terminate as of the Termination Date, and (iii) Employer shall have no further obligations to Executive under this Agreement, other than those provided in this </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 5.02</font><font style="font-family:inherit;font-size:11pt;">.  For purposes of this Agreement, </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Cause</font><font style="font-family:inherit;font-size:11pt;">&#8221; means: (a) Executive&#8217;s failure to substantially perform Executive&#8217;s duties with the Company (if Executive has not cured such failure to substantially perform, if curable, within thirty (30) days after Executive&#8217;s receipt of written notice thereof from the Board that specifies the conduct constituting Cause under this clause (a)); (b) Executive&#8217;s willful misconduct, or gross negligence in the performance of Executive&#8217;s duties hereunder; (c)&#160;the conviction of Executive, or the entering by Executive of a guilty plea or plea of no contest with respect to, any crime that constitutes a felony or involves fraud, dishonesty or moral turpitude; (d) Executive&#8217;s commission of an act of fraud, </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">embezzlement or misappropriation against the Company; (e)&#160;Executive&#8217;s material breach of the fiduciary duty owed by Executive to Company; (f) Executive&#8217;s engaging in any improper conduct that has or is likely to have an adverse economic or reputational impact on the Company; or (g)&#160;Executive&#8217;s material breach of this Agreement (if Executive has not cured such breach, if curable, within thirty (30) days after Executive&#8217;s receipt of written notice thereof from the Board that specifies the conduct constituting Cause under this clause (g)).  </font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5.03.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Termination by Employer Without Cause or by Executive for Good Reason</font><font style="font-family:inherit;font-size:11pt;">.  If Executive is terminated by Employer without Cause or by Executive for Good Reason: (i) Employer shall pay to Executive the Accrued Obligations, (ii) Executive shall be entitled to receive the Severance Benefits (as defined below in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 5.05</font><font style="font-family:inherit;font-size:11pt;">&#32;and subject to the conditions described therein and in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 5.06</font><font style="font-family:inherit;font-size:11pt;">,  (iii) Employer shall pay to Executive any earned, but unpaid, bonus obligation relating to the prior fiscal year payable at the same time as bonuses are paid to the senior management team (but not later than March 15 of the subsequent fiscal year) and (iv) Employer shall have no further obligations to Executive under this Agreement, other than those provided in this </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 5.03</font><font style="font-family:inherit;font-size:11pt;">. For purposes of this Agreement, </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Good Reason&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;means the occurrence of any of the following events (without Executive&#8217;s consent):  </font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">a material adverse change in Executive&#8217;s functions, duties, or responsibilities as Title with the Company, which change would cause Executive&#8217;s position to become one of materially lesser responsibility, importance, or scope;</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">a material change in the geographic location at which Executive must perform services to the Company of 50 miles or more from the Company&#8217;s headquarters in Rockville, Maryland (unless Executive is permitted to telecommute rather than work at the Company&#8217;s new headquarters); or</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">a material breach of this Agreement by the Company.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Notwithstanding the foregoing, no such event shall constitute &#8220;Good Reason&#8221; unless (A) Executive shall have given written notice of such event to the Company within six (6) months after the initial occurrence thereof, (B) the Company shall have failed to cure the condition constituting Good Reason within thirty (30) days following the delivery of such notice (or such longer cure period as may be agreed upon by the parties), and (C) Executive terminates employment within thirty (30) days after expiration of such cure period.  </font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5.04.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Termination by Employer due to Executive&#8217;s Death or Disability</font><font style="font-family:inherit;font-size:11pt;">.  If Executive&#8217;s employment is terminated by reason of death or Disability (as defined below): (i) Employer shall pay to Executive the Accrued Obligations, (ii) Employer shall pay to Executive any earned, but unpaid, bonus obligation relating to the prior fiscal year payable at the same time as bonuses are paid to the senior management team (but not later than March 15 of the subsequent fiscal year), (iii) Executive&#8217;s participation in the Benefit Plans shall terminate as of the Termination Date (except to the extent Executive is eligible for continued death or disability benefits under the applicable Employer plan), and (iv) Employer shall have no further obligations to Executive under this Agreement, other than those provided in this </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section&#160;5.04</font><font style="font-family:inherit;font-size:11pt;">.  For the purposes of clarity, nothing in this Section 5.04 is to be construed </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">as limiting Executive&#8217;s right to recover insurance proceeds under the Company&#8217;s life or disability insurance benefit plans that would otherwise be applicable to Executive&#8217;s death or Disability. For purposes of this Agreement, </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Disability&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;means (a) Executive being determined to be totally disabled as defined by guidelines of the then-existing Company disability insurance plan in which Executive is participating, or (b) a determination by the Social Security Administration that the Executive is &#8220;totally disabled&#8221; or (c) Executive&#8217;s inability to engage in comparable professional activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than twelve months.  </font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5.05.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Severance Benefits</font><font style="font-family:inherit;font-size:11pt;">:  </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Severance Benefits&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;means: </font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The payment to Executive of the Severance Amount in substantially equal installments over one year (with the first payment commencing on the first payroll date that occurs at least 28 days following the Termination Date), in accordance with Employer&#8217;s normal payroll practices (</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Severance Period&#8221;</font><font style="font-family:inherit;font-size:11pt;">).  If the Executive&#8217;s termination is in connection with or in the twelve (12) months following a Change of Control, then Severance Amount means (i) one year of Executive&#8217;s then-current Base Salary plus (ii) the Target Bonus multiplied by the Executive&#8217;s then-current Base Salary. If the Executive&#8217;s termination precedes a Change of Control, then Severance Amount means (x) one year of Executive&#8217;s then-current Base Salary plus (y) the Target Bonus multiplied by the Executive&#8217;s then-current Base Salary, prorated for the number of days that have elapsed between January 1 of the calendar year of termination and the Termination Date.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The continuation of Executive&#8217;s participation in the Company&#8217;s medical, dental, and vision benefit plans at the same premium cost to Executive as charged to Executive immediately prior to the Termination Date for a period of twelve (12) months immediately following the Termination Date, or if earlier, until Executive obtains other employment which provides the same type of benefit; </font><font style="font-family:inherit;font-size:11pt;font-style:italic;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:11pt;">, </font><font style="font-family:inherit;font-size:11pt;font-style:italic;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:11pt;">, that (a) it is understood and agreed that such continued medical, dental and vision benefits may at the election of the Company be provided by Executive electing the continuation of such coverage pursuant to COBRA with the Company reimbursing Executive for COBRA premiums to the extent required so that Executive&#8217;s premium cost for the coverage in effect for Executive prior to the Termination Date is substantially the same as immediately prior to the Termination Date, and (b) if the Company determines, in its reasonable judgment, that providing medical, dental, and/or vision benefits in accordance with the preceding provisions of this </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 5.05(b)</font><font style="font-family:inherit;font-size:11pt;">&#32;would result in a violation of applicable law, the imposition of any penalties under applicable law, or adverse tax consequences for participants covered by the Company&#8217;s medical, dental, and/or vision plans, the Company may terminate such coverage (or reimbursement) with respect to Executive and instead pay to Executive taxable cash payments at the same time and in the same amounts as the Company would have paid as premiums (or as COBRA premium reimbursements) to provide such coverage.&#160;</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">If the Termination Date occurs upon or within one year after the occurrence of a Change in Control, each stock option granted by the Company to Executive that </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">is outstanding as of the Termination Date and is not fully vested as of the date of the Termination Date shall, as of the date Executive provides the Company with the Irrevocable Release provided for in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 5.06</font><font style="font-family:inherit;font-size:11pt;">&#32;(but only if the Irrevocable Release is provided within the period provided for by </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 5.06</font><font style="font-family:inherit;font-size:11pt;">), become vested with respect to 100% of the shares with respect to which the stock option is not vested as of the Termination Date; provided, however that in no event shall any such option vest to the extent the option has expired prior to the date Executive provides the Company with the Irrevocable Release.  For the avoidance of doubt, in the event that any of Executive&#8217;s unvested stock options are to be terminated in connection with a Change of Control, Executive shall nonetheless be entitled to the accelerated vesting of 100% of the unvested stock options described in and subject to the conditions of this clause (c). </font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">For purposes of this Agreement, </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Change of Control&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;means, and shall be deemed to have occurred, if:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:192px;"><font style="font-family:inherit;font-size:11pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">any Person, excluding&#160;(i) employee benefit plans of the Company or any of its Affiliates, is or becomes the &#8220;beneficial owner&#8221; (as defined in Rules 13d-3 and 13d-5 under the Exchange Act, which Rules shall apply for purposes of this clause (a) whether or not the Company is subject to the Exchange Act), directly or indirectly, of Company securities representing more than fifty percent (50%) of the combined voting power of the Company&#8217;s then outstanding securities (</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Voting Power&#8221;</font><font style="font-family:inherit;font-size:11pt;">); </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:192px;"><font style="font-family:inherit;font-size:11pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">the Company consummates a merger, consolidation, share exchange, division or other reorganization or transaction of the Company (a </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Fundamental Transaction&#8221;</font><font style="font-family:inherit;font-size:11pt;">) with any other corporation, other than a Fundamental Transaction that results in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) at least fifty percent (50%) of the combined Voting Power immediately after such Fundamental Transaction of (i) the Company&#8217;s outstanding securities, (ii)&#160;the surviving entity&#8217;s outstanding securities, or (iii)&#160;in the case of a division, the outstanding securities of each entity resulting from the division;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:192px;"><font style="font-family:inherit;font-size:11pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">the stockholders of the Company approve a plan of complete liquidation or winding&#8209;up of the Company or the consummation of the sale or disposition (in one transaction or a series of transactions) of all or substantially all of the Company&#8217;s assets; or</font></div></td></tr></table><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:192px;"><font style="font-family:inherit;font-size:11pt;">d.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">during any period of 24 consecutive months, individuals who at the beginning of such period constituted the Board (including for this purpose any new director whose election or nomination for election by the Company&#8217;s stockholders was approved by a vote of at least two-thirds (2/3) of the directors then still in office who were directors at the beginning of such period or whose appointment, election or nomination was previously so approved or recommended) cease for any reason to constitute at least a majority of the Board.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The foregoing payment of Severance Benefits are expressly conditioned on receipt by the Company of an Irrevocable Release (as defined below) and the expiration of any statutory revocation period without any such revocation. To the extent such an Irrevocable Release has not been received by the Company, the time periods for payment of the Severance Benefits may be tolled by the Company until receipt of such an Irrevocable Release and expiration of such revocation period, at which point the Company may make a one-time catch-up payment for the applicable time period and then resume the regular periodic payment of Severance Benefits as provided in this Section 5.05.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5.06&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Required Delivery of Irrevocable Release; Compliance with Section 6 Obligations</font><font style="font-family:inherit;font-size:11pt;">.  Notwithstanding the provisions of </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 5.05</font><font style="font-family:inherit;font-size:11pt;">, as a condition to entitlement to the Severance Benefits, Executive must provide to the Company an Irrevocable Release not later than the twenty-first (21</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">st</sup></font><font style="font-family:inherit;font-size:11pt;">) day after the Date of Termination (or longer, to the extent there is an applicable statutory period pursuant to which Executive may consider and/or revoke such release and such period has lapsed without any such revocation).  In the event Executive fails to provide an Irrevocable Release to the Company within such period, the Company will immediately cease to pay or provide any further Severance Benefits and no accelerated vesting of stock options pursuant to </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 5.05(c)</font><font style="font-family:inherit;font-size:11pt;">&#32;shall occur.   </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Irrevocable Release&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;means a confidential separation agreement and release of claims, in the form attached </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:11pt;">&#32;(as may be modified to reflect any change in laws or regulations that would pertain to such an agreement and release at the time of separation) that has been executed by Executive, delivered to the Company, and become irrevocable by Executive.  In addition, in the event that Executive breaches the obligations under </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 6</font><font style="font-family:inherit;font-size:11pt;">&#32;of this Agreement at any time during the Severance Period, Executive will cease to be entitled to any further Severance Benefits.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Promises and Covenants Regarding Confidential Information and Goodwill; Inventions and Assignment; Restrictive Covenants</font><font style="font-family:inherit;font-size:11pt;">.  </font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6.01.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Confidential Information and Goodwill</font><font style="font-family:inherit;font-size:11pt;">.  In consideration of Executive&#8217;s promises and covenants contained in this Agreement, including Executive&#8217;s promise and covenant not to disclose Confidential Information, Employer will provide Executive with Confidential Information.  In further consideration of Executive&#8217;s promises and covenants contained in this Agreement, including Executive&#8217;s promise and covenant to utilize the Goodwill exclusively for the benefit of Employer, </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Employer will allow Executive to receive Confidential Information concerning the Company&#8217;s customers, labs, vendors and employees and, to the extent required to fulfill Executive&#8217;s duties, the Company will permit Executive to represent the Company on its behalf with such persons.  To the extent that Executive&#8217;s duties involve sales or customer relations, the Company will permit Executive to utilize the Goodwill in Executive&#8217;s sales efforts and will provide sales support to Executive similar to that which it provides to its sales representatives.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6.02.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Duties</font><font style="font-family:inherit;font-size:11pt;">.  While employed by Company, Executive shall perform the duties required of Executive hereunder and shall devote Executive&#8217;s best efforts and, subject to the matters set forth on </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Schedule 1</font><font style="font-family:inherit;font-size:11pt;">&#32;(as amended from time to time by mutual written agreement of the parties), exclusive business time, energy and skill to performing such duties; not make any disparaging remarks regarding Company to any person with whom Company has business relations, including any employee or vendor of Company; use the Goodwill solely for the benefit of Company; and not interfere in such Goodwill, either during or following Executive&#8217;s employment with Company.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6.03.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Delivery of Company Property</font><font style="font-family:inherit;font-size:11pt;">.  Executive recognizes that all documents, magnetic media and other tangible items which contain Confidential Information are the property of Company exclusively.  Upon request by Company or termination of Executive&#8217;s employment with Company, Executive shall promptly return to Company all Confidential Information and Company Property within Executive&#8217;s possession and control, and shall refrain from taking any Confidential Information or Company Property or allowing any Confidential Information or Company Property to be taken from Company; and immediately return to Company all information pertaining to Company or Company Property in Executive&#8217;s possession.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6.04.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Promise and Covenant Not to Disclose</font><font style="font-family:inherit;font-size:11pt;">.  The parties acknowledge that Company is the sole and exclusive owner of Confidential Information, and that Company has legitimate business interests in protecting Confidential Information.  The parties further acknowledge that Company has invested, and continues to invest, considerable amounts of time and money in obtaining, developing, and preserving the confidentiality of Confidential Information and that, by reason of the trust relationship arising between Executive and Company, Executive owes Company a fiduciary duty to preserve and protect Confidential Information from all unauthorized disclosure and unauthorized use.  Executive shall not, directly or indirectly, disclose Confidential Information to any third party (except to Executive&#8217;s attorneys, the Company&#8217;s personnel, other persons designated in writing by the Company, or except as otherwise provided by law) or use Confidential Information for any purpose other than for the direct benefit of Company while in Company&#8217;s employ and thereafter.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6.05.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Inventions and Assignment</font><font style="font-family:inherit;font-size:11pt;">.  Executive agrees that he will promptly disclose to the Company any and all Company Inventions and that Executive hereby irrevocably assigns to the Company all ownership rights in and to any and all Company Inventions.&#160;  During Executive&#8217;s employment or at any time thereafter, upon request of the Company, Executive will sign, execute and deliver any and all documents or instruments, including, without limitation, patent applications, declarations, invention assignments and copyright assignments, and will take reasonable action which the Company shall request to perfect in the Company trademark, copyright or patent rights with respect to Company Inventions, or to otherwise protect the Company&#8217;s trade secrets and proprietary interests.  The </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">term </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Inventions</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;means discoveries; developments; trade secrets; processes; formulas; data; lists; software programs; graphics; artwork; logos, and all other works of authorship, ideas, concepts, know-how, designs, and techniques, whether or not any of the foregoing is or are patentable, copyrightable, or registrable under any intellectual property laws or industrial property laws in the United States.  The term </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Company Inventions</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;means all Inventions that (a) relate to the business or proposed business of the Company or any of its predecessors or that are discovered, developed, created, conceived, reduced to practice, made, learned or written by Executive, either alone or jointly with others, in the course of Executive&#8217;s  employment; (b) utilize, incorporate or otherwise relate to Confidential Information; or (c) are discovered, developed, created, conceived, reduced to practice, made, or written by him using property or equipment of the Company or any of its predecessors.  Executive agrees to promptly and fully communicate in writing to the Company (to such department or officer of the Company and in accordance with such procedures as the Company may direct from time to time) any and all Company Inventions.  Executive acknowledges and agrees that any work of authorship by Executive or others comprising Company Inventions shall be deemed to be a &#8220;work made for hire,&#8221; as that term is defined in the United States Copyright Act (17 U.S.C.  &#167; 101 (2000)).  To the extent that any such work of authorship may not be deemed to be a work made for hire, Executive hereby irrevocably assigns any ownership rights Executive may have in and to such work to the Company.  This Agreement does not apply to any Inventions Executive made or to which Executive contributed before Executive&#8217;s employment with the Company.  </font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6.06.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Other Promises and Covenants</font><font style="font-family:inherit;font-size:11pt;">. </font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">During Executive&#8217;s employment with Company and for a period of 12 months following termination of employment for any reason (the </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Non-Competition Period&#8221;</font><font style="font-family:inherit;font-size:11pt;">), Executive shall not either directly or indirectly, on Executive&#8217;s own or another&#8217;s behalf, engage in or assist others in any of the following activities (except on behalf of Company):</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">(whether as principal, agent, partner or otherwise) engage in, own, manage, operate, control, finance, invest in, participate in, or otherwise carry on, or be employed by, associated with, or in any manner connected with, lend such Executive&#8217;s name to, lend Executive&#8217;s credit to, or render services or advice to a Competing Business anywhere in the Geographic Area; </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">provided</font><font style="font-family:inherit;font-size:11pt;">, </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">however</font><font style="font-family:inherit;font-size:11pt;">, that Executive may be employed by a Competing Business if (A) the role and responsibilities to be taken by Executive can clearly be segregated from any responsibility relating to the competing Company Business and (B) such Competing Business provides the Company with written confirmation acknowledging Executive&#8217;s obligations under this Agreement with such Competing Business&#8217;s agreement that it will ensure that Executive&#8217;s role and responsibilities will be segregated in such manner; </font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">provide or develop any products, technology or services that are the same or Substantially Similar to the products, technology and services provided or developed by the Company or any of its Affiliates; </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">induce or attempt to induce any customer, agent, supplier, licensee, or business relation of the Company or any of its Affiliates to cease doing business with the Company or any of its Affiliates, or in any way interfere with the relationship between any customer, supplier, licensee, or business relation of the Company or any of its Affiliates; or</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">on behalf of a Competing Business, solicit or attempt to solicit the business or patronage of any Person who is a customer or agent of the Company or any of its Affiliates, whether or not Executive had personal contact with such Person.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">For clarity, this Section 6.06(a) does not prohibit Executive from working at a non-Competing Business in the Geographic Area.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">During Executive&#8217;s employment with Company and for a period of 12 months following termination of employment for any reason  (the &#8220;Non-Solicitation Period&#8221;), Executive shall not either directly or indirectly, on Executive&#8217;s own or another&#8217;s behalf, engage in or assist others in any of the following activities:</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">solicit, encourage, or take any other action which is intended to induce any employee, independent contractor or agent of the Company or any of its Affiliates to terminate Executive&#8217;s employment or other business relationship with the Company or such Affiliate;</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">in any way interfere in any manner with the employment or other business relationship between the Company and/or any of its Affiliates, on the one hand, and any employee, independent contractor or agent of the Company or such Affiliate, on the other hand; or</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">employ, or otherwise engage as an employee, independent contractor or otherwise, any individual who was an employee or was otherwise affiliated with the Company or any of its Affiliates from the period beginning one year prior to Executive&#8217;s last day of employment and continuing through the expiration of the Non-Solicitation Period.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:11pt;">, </font><font style="font-family:inherit;font-size:11pt;font-style:italic;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:11pt;">, that nothing set forth in this </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 6</font><font style="font-family:inherit;font-size:11pt;">&#32;shall prohibit Executive from owning, as a passive investment, not in excess of five percent (5%) in the aggregate of any class of capital stock of any corporation if such stock is publicly traded and listed on any national or regional stock exchange or reported on the Nasdaq Stock Market.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6.07.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Definitions</font><font style="font-family:inherit;font-size:11pt;">.  For purposes hereof: </font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;Affiliate&#8221;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;">means, with respect to any Entity, any Entity that, directly or indirectly through one or more intermediaries, controls, is controlled by or under common control with, such Entity.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;Agreement&#8221;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;">means this Employment Agreement.  </font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;Company Business&#8221; </font><font style="font-family:inherit;font-size:11pt;">means the research, development, testing and/or marketing/sales of pharmaceutical products or processes that are, rely on, target or rely upon (i) monoclonal antibodies directed against HER2 or B7-H3 that are in active clinical development (meaning that an IND has been filed and accepted by the FDA or EMA with respect to that product candidate and the Company is developing the protocol, enrolling sites or patients or analyzing patients with respect to a human clinical trial for such product candidate), (ii) any bi-specific or multi-specific antibody-based protein targeting any of the Company&#8217;s product candidates that are in active clinical development (as described in (i))), or (iii) any target or specific combination of targets that is the subject of pre-clinical research and for which the Company intends to file an IND for a product candidate with such specificity or specificities in the 12 months following Termination.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;Company Property&#8221;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;">means all physical materials, documents, information, keys, computer software and hardware, including laptop computers and mobile or handheld scheduling computers, manuals, data bases, product samples, tapes, magnetic media, technical notes and any other equipment or items which Company provides for or to Executive or which otherwise belongs to the Company, and those documents and items which Executive may develop or help develop while in Company&#8217;s employ, whether or not developed during regular working hours or on Company&#8217;s premises.  The term </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#8220;Company Property&#8221; </font><font style="font-family:inherit;font-size:11pt;">shall include the original of such materials, any copies thereof, any notes derived from such materials, and any derivative work of such materials.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;Competing Business&#8221;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">means any other Entity engaged in the Company Business, other than the Company and its Affiliates. For clarity, &#8220;Competing Business&#8221; does not include the Food &amp; Drug Administration, any of the National Institutes of Health or other government or regulatory agencies, and non-profit Entities are applicable only to the extent they are engaged in the research and/or development of biopharmaceutical products.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;Confidential Information&#8221;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;">means the trade secrets and other information of Company, including but not limited to (i) the customer lists, customer contact information, customer purchase information, pricing information, strategic and marketing plans, compilations of customer information, names of employees, contracts with third parties, training, financial and marketing books, sales projections, internal employer databases, reports, manuals and information including information related to Company, its Affiliates or its customers, including those documents and items which any employee may develop or help develop while in the employ of the Company or any of its Affiliates, whether or not developed during regular working hours or on the premises of the Company or such Affiliate; (ii)  the identity, skills, personnel file information, performance appraisals and compensation of job applicants, employees, contractors, and consultants; (iii) specialized training; (iv) source code, scripts, user screens, reports or any other information pertaining to the internal information technology or </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">network of the Company and/or its Affiliates, including the proprietary database system commonly referred to as the Office System; and (v) information related to inventions owned by the Company or any of its Affiliates or licensed from third parties; and unless the context requires otherwise, the term &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Confidential Information</font><font style="font-family:inherit;font-size:11pt;">&#8221; includes the original of such materials, any copies thereof, any notes derived from such materials, and any derivative work of such materials.  The term &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Confidential Information</font><font style="font-family:inherit;font-size:11pt;">&#8221; does not include (1)&#160;information that was or becomes generally available publicly other than through disclosure by Executive, or (2) is required to be disclosed to any governmental agency or self-regulatory body or is otherwise required to be disclosed by law.  Unless the context requires otherwise, the term </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#8220;Confidential Information&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;shall include the original of such materials, any copies thereof, any notes derived from such materials, and any derivative work of such materials.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;Entity</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;means and includes any person, partnership, association, corporation, limited liability company, trust, unincorporated organization or any other business entity or enterprise.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(h)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;Geographic Area&#8221;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;">mean those states in the United States in which the Company or any of its subsidiaries conducts business and has a physical location, or in which its products are being sold or marketed at the time of the termination of Executive&#8217;s employment.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;Goodwill&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;means the value of the relationships between the Company and its agents, customers, vendors, labs, and employees.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(j)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;Substantially Similar&#8221;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;">means substantially competitive to the products or services being developed, manufactured or sold by the Company during and/or at the end of Executive&#8217;s employment, or are marketed to substantially the same type of user or customer as that to which the products and services of the Company are marketed or proposed to be marketed. </font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6.08.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Acknowledgements Regarding Other Promises and Covenants</font><font style="font-family:inherit;font-size:11pt;">.  With regard to the promises and covenants set forth herein, Executive acknowledges and agrees that:</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">the restrictions are ancillary to an otherwise enforceable agreement including the provisions of this Agreement regarding the disclosure, ownership and use of the Confidential Information and Goodwill of Company;</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">the limitations as to time, geographical area, and scope of activity to be restricted are reasonable and acceptable to Executive, and do not impose any greater restraint than is reasonably necessary to protect the Goodwill and other legitimate business interests of Company;</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">the performance by Executive, and the enforcement by Company, of such promises and covenants will cause no undue hardship on Executive;</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Executive will play a key business role for the Company in which he will have access to the Company&#8217;s Confidential Information and Goodwill;</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">the time periods covered by the promises and covenants will not include any period(s) of violation of, or any period(s) of time required for litigation brought by Company to enforce any such promise or covenant, it being understood that the extension of time provided in this paragraph may not exceed two (2) years. </font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6.09.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">[Reserved.]</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6.10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Independent Elements</font><font style="font-family:inherit;font-size:11pt;">.  The parties acknowledge that the promises and covenants contained in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 6</font><font style="font-family:inherit;font-size:11pt;">&#32;above are essential independent elements of this Agreement and that, but for Executive agreeing to comply with them, Company would not employ Executive.  Accordingly, the existence or assertion of any claim by Executive against Company, whether based on this Agreement or otherwise, shall not operate as a defense to Company&#8217;s enforcement of the promises and covenants in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 6</font><font style="font-family:inherit;font-size:11pt;">.  An alleged or actual breach of the Agreement by Company will not be a defense to enforcement of any such promise or covenant, or other obligations of Executive to Company.  The promises and covenants in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 6</font><font style="font-family:inherit;font-size:11pt;">&#32;will remain in full force and effect whether Executive is terminated by Company or voluntarily resigns.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6.11.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Remedies for Breach of Agreement</font><font style="font-family:inherit;font-size:11pt;">.  Executive acknowledges that Executive&#8217;s breach of any promise or covenant contained in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 6</font><font style="font-family:inherit;font-size:11pt;">&#32;will result in irreparable injury to Company and that Company&#8217;s remedies at law for such a breach will be inadequate. Accordingly, Executive agrees and consents that Company, in addition to all other remedies available at law and in equity, shall be entitled to both preliminary and permanent injunctions to prevent and/or halt a breach or threatened breach by Executive of any such promise or covenant, and Executive waives the requirement of the posting of any bond in connection with such injunctive relief.  Executive further acknowledges and agrees that the promises and covenants contained in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 6</font><font style="font-family:inherit;font-size:11pt;">&#32;are enforceable, reasonable, and valid.  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6.12&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Directors and Officers Insurance</font><font style="font-family:inherit;font-size:11pt;">.  During Executive&#8217;s period of employment with the Company (and for any applicable &#8220;tail-period&#8221; thereafter), Executive shall be covered under a director and officer&#8217;s liability insurance policy that provides insurance coverage for Executive on substantially the same terms and conditions as the other senior executives of the Company.  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Miscellaneous</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.01.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Governing Law; Arbitration</font><font style="font-family:inherit;font-size:11pt;">&#32;</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">This Agreement is made under and shall be governed by and construed in accordance with the laws of Maryland, without regard to its conflicts of law principles.  </font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">With respect to claims by the Company against Executive related to Executive&#8217;s threatened or actual breach of </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 6</font><font style="font-family:inherit;font-size:11pt;">&#32;of this Agreement, each Party hereby irrevocably agrees that all actions or proceedings concerning such disputes may be brought by the Company in (a) the United States District Court for the District of Maryland; or (b)&#160;in any court of the State of Maryland sitting in Montgomery County, provided that the United States District Court lacks subject matter jurisdiction over such action or proceeding.  Executive consents to jurisdiction of and venue in the courts in the State of Maryland set forth in this Section, and </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">hereby waives to the maximum extent permitted by applicable law any objection which Executive may have based on improper venue or </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">forum non conveniens</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:105px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Except to the extent provided for in subsection (b) above,  the Company and Executive agree that any claim, dispute or controversy arising under or in connection with this Agreement, or otherwise in connection with Executive&#8217;s employment by the Company or termination of his employment (including, without limitation, any such claim, dispute or controversy arising under any federal, state or local statute, regulation or ordinance or any of the Company&#8217;s employee benefit plans, policies or programs) shall be resolved solely and exclusively by binding, confidential, arbitration.  The arbitration shall be held in Rockville, MD (or at such other location as shall be mutually agreed by the parties).  The arbitration shall be conducted in accordance with the Commercial Rules of the American Arbitration Association (the </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;AAA&#8221;</font><font style="font-family:inherit;font-size:11pt;">) in effect at the time of the arbitration, including the Expedited Procedures.  All fees and expenses of the arbitration, including a transcript if either requests, shall be borne equally by the parties.  Each party is responsible for the fees and expenses of its own attorneys, experts, witnesses, and preparation and presentation of proofs and post-hearing briefs (unless the party prevails on a claim for which attorney&#8217;s fees are recoverable under law).  In rendering a decision, the arbitrator shall apply all legal principles and standards that would govern if the dispute were being heard in court.  This includes the availability of all remedies that the parties could obtain in court.  In addition, all statutes of limitation and defenses that would be applicable in court, will apply to the arbitration proceeding.  The decision of the arbitrator shall be set forth in writing, and be binding and conclusive on all parties.  Any action to enforce or vacate the arbitrator&#8217;s award shall be governed by the Federal Arbitration Act, if applicable, and otherwise by applicable state law.  If either the Company or Executive improperly pursues any claim, dispute or controversy against the other in a proceeding other than the arbitration provided for herein, the responding party shall be entitled to dismissal or injunctive relief regarding such action and recovery of all costs, losses and attorney&#8217;s fees related to such action. If Company and Executive cannot mutually agree on selection of an arbitrator, the AAA rules then in effect regarding arbitrator selection will be used to select an arbitrator.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.02.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:11pt;">.  This Agreement and the documents referenced herein (including applicable stock option agreements and the equity plans to which they relate) contain the entire agreement of the parties relating to the employment of Executive by Employer and the ancillary matters discussed herein and supersedes all prior agreements, negotiations and understandings with respect to such matters, including, without limitation, any term sheet between the parties hereto with respect to such matters, and the parties hereto have made no agreements, representations or warranties relating to such employment or ancillary matters which are not set forth herein. </font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.03.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Withholding Taxes</font><font style="font-family:inherit;font-size:11pt;">.  Employer may withhold from any compensation and Benefits payable under this Agreement all federal, state, city or other taxes as shall be required pursuant to any law or governmental regulation or ruling. </font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.04.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Golden Parachute Limit</font><font style="font-family:inherit;font-size:11pt;">.&#160; Notwithstanding any other provision of this Agreement, in the event that any portion of the Severance Benefits or any other payment or benefit </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">received or to be received by Executive (whether pursuant to the terms of this Agreement or any other plan, arrangement or agreement) (collectively, the </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Total Benefits&#8221;</font><font style="font-family:inherit;font-size:11pt;">) would be subject to the excise tax imposed under Section 4999 of the Code (the </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Excise Tax&#8221;</font><font style="font-family:inherit;font-size:11pt;">), the Total Benefits shall be reduced to the extent necessary so that no portion of the Total Benefits is subject to the Excise Tax; provided, however, that no such reduction in the Total Benefits shall be made if by not making such reduction, Executive&#8217;s Retained Amount (as hereinafter defined) would be more than ten percent (10%) greater than Executive&#8217;s Retained Amount if the Total Benefits are so reduced.&#160; All determinations required to be made under this </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section&#160;7.04</font><font style="font-family:inherit;font-size:11pt;">&#32;shall be made by tax counsel selected by the Company and reasonably acceptable to Executive (</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Tax Counsel&#8221;</font><font style="font-family:inherit;font-size:11pt;">), which determinations shall be conclusive and binding on Executive and the Company absent manifest error.&#160; All fees and expenses of Tax Counsel shall be borne solely by the Company.&#160; Prior to any reduction in Executive&#8217;s Total Benefits pursuant to this </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 7.04</font><font style="font-family:inherit;font-size:11pt;">, Tax Counsel shall provide Executive and the Company with a report setting forth its calculations and containing related supporting information.&#160; In the event any such reduction is required, the Total Benefits shall be reduced in the following order: (i) the Severance Amount (in reverse order of payment), (iii) any other portion of the Total Benefits that are not subject to Section 409A of the Code (other than Total Benefits resulting from any accelerated vesting of equity awards), (iv) other Total Benefits that are subject to Section 409A of the Code in reverse order of payment, and (v) Total Benefits that are not subject to Section 409A and arise from any accelerated vesting of any equity awards.&#160; </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Retained Amount&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;shall mean the present value (as determined in accordance with sections 280G(b)(2)(A)(ii) and 280G(d)(4) of the Code) of the Total Benefits net of all federal, state and local taxes imposed on Executive with respect thereto. </font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.05.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Compliance With Section 409A</font><font style="font-family:inherit;font-size:11pt;">.  This Agreement is intended to comply with the requirements of Section 409A of the Code (including the exceptions thereto), to the extent applicable, and shall be interpreted accordingly.&#160; If any provision contained in this Agreement conflicts with the requirements of Section&#160;409A of the Code (or the exemptions intended to apply under this Agreement), this Agreement shall be deemed to be reformed to comply with the requirements of Section&#160;409A of the Code (or applicable exemptions thereto).&#160; Notwithstanding anything to the contrary herein, for purposes of determining Executive&#8217;s entitlement to the Severance Benefits under </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 5</font><font style="font-family:inherit;font-size:11pt;">&#32;hereof, (a)&#160;Executive&#8217;s employment shall not be deemed to have terminated unless and until Executive incurs a &#8220;separation from service&#8221; as defined in Section 409A of the Code, and (b) the effective date of any termination or resignation of employment (or any similar term) shall be the effective date of Executive&#8217;s separation from service.&#160; Reimbursement of any expenses provided for in this Agreement shall be made in accordance with the Company&#8217;s policies (as applicable) with respect thereto as in effect from time to time (but in no event later than the end of calendar year following the year such expenses were incurred) and in no event shall (i) the amount of expenses eligible for reimbursement hereunder during a taxable year affect the expenses eligible for reimbursement in any other taxable year or (ii) the right to reimbursement be subject to liquidation or exchange for another benefit.&#160; Notwithstanding anything to the contrary herein, if a payment or benefit under this Agreement is due to a &#8220;separation from service&#8221; for purposes of the rules under Treas. Reg. &#167; 1.409A-3(i)(2) (payments to specified employees upon a separation from service) and Executive is determined to be a &#8220;specified employee&#8221; (as determined under Treas. Reg. &#167; 1.409A-1(i)), such payment shall, to the extent necessary to comply with the requirements of Section 409A of the Code, be made on the later of (x) the date specified by the foregoing provisions of this Agreement or (y) the date </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">that is six (6) months after the date of Executive&#8217;s separation from service (or, if earlier, the date of Executive&#8217;s death).&#160; Any installment payments that are delayed pursuant to the provisions of this section shall be accumulated and paid in a lump sum on the first day of the seventh month following Executive&#8217;s separation from service (or, if earlier, upon Executive&#8217;s death) and the remaining installment payments shall begin on such date in accordance with the schedule provided in this Agreement.&#160;&#160; To the extent permitted by Section 409A, each payment hereunder shall be deemed to be a separate payment for purposes of Section 409A of the Code. Notwithstanding the foregoing, to the extent this Agreement (or any provision of this Agreement) is determined not to be compliant with Section 409A of the Code, the Company shall not be liable for any resulting taxes to be paid by Executive.  </font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.06.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Amendments</font><font style="font-family:inherit;font-size:11pt;">.  No amendment or modification of the terms of this Agreement shall be valid unless made in writing and signed by both Executive and Employer.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.07.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Severability; Reformation</font><font style="font-family:inherit;font-size:11pt;">.  Whenever possible, each provision of this Agreement shall be interpreted in such a manner as to be effective and valid under applicable Law but if any provision of this Agreement is held to be invalid, illegal or unenforceable under any applicable Law or rule, the validity, legality and enforceability of the other provisions of this Agreement will not be affected or impaired thereby.  If any provision of this Agreement is found invalid, illegal or unenforceable because it is too broad in scope, too lengthy in duration or violates any Law or regulation, it shall be reformed by limiting its scope, limiting its duration or construing it to avoid such violation (as the case may be) while giving the greatest effect to the intent of the parties as is legally permissible.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.08.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">No Waiver</font><font style="font-family:inherit;font-size:11pt;">.  No waiver of any provision of this Agreement shall in any event be effective unless the same shall be in writing and signed by the party against whom such waiver is sought to be enforced, and any such waiver shall be effective only in the specific instance and for the specific purpose for which given.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.09.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Assignment; No Third Party Beneficiary</font><font style="font-family:inherit;font-size:11pt;">.  This Agreement is a personal service contract, and shall not be assignable by Executive.  This Agreement shall be assignable by Employer to any affiliate of Employer without the written consent of the Executive. This Agreement shall be assignable by Employer to any successor to the business of Employer, without the written consent of Executive; provided, however, that the assignee or transferee is the successor to all or substantially all of the business assets of Employer and such assignee or transferee expressly assumes all the obligations, duties, and liabilities of Employer set forth in this Agreement.  Any purported assignment of this Agreement in violation of this </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 7.09</font><font style="font-family:inherit;font-size:11pt;">&#32;shall be null and void.  This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns, and no other Person shall have any right, benefit or obligation hereunder.  </font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Counterparts; Facsimile Signatures</font><font style="font-family:inherit;font-size:11pt;">.  This Agreement may be executed in separate counterparts, each of which will be an original and all of which taken together shall constitute one and the same agreement, and any party hereto may execute this Agreement by signing any such counterpart.  A facsimile signature by any party on a counterpart of this Agreement shall be binding and effective for all purposes.  Such party shall subsequently deliver to the other party an original, executed </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">copy of this Agreement; provided, however, that a failure of such party to deliver an original, executed copy shall not invalidate Executive&#8217;s  or its signature.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.11.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:11pt;">.  All notices and other communications relating to this Agreement will be in writing and will be deemed to have been given when personally delivered, three (3) days following mailing by certified or registered mail, return receipt requested, and one (1) Business Day following delivery to a reliable overnight courier or immediately following transmission by electronic facsimile.  All notices to Employer shall be addressed and delivered to:</font></div><div style="line-height:138%;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">MacroGenics, Inc.</font></div><div style="line-height:138%;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">9640 Medical Center Drive <br>Rockville, MD 20850</font></div><div style="line-height:138%;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attn:  General Counsel</font></div><div style="line-height:138%;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">or to such other address and facsimile number as designated by Employer in a written notice to Executive.  All notices to Executive shall be addressed and delivered to:</font></div><div style="line-height:138%;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Eric Risser</font></div><div style="line-height:138%;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">XXXXXXXXXXXXXXXXXXX</font></div><div style="line-height:138%;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">XXXXXXXXXXXXXXXXXXX</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">or to such other address and facsimile number as Executive has designated in a written notice to Employer.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.12.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Interpretation</font><font style="font-family:inherit;font-size:11pt;">. The headings contained in this Agreement are for reference purposes only and shall not in any way affect the meaning or interpretation of this Agreement.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.13.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Cumulative Remedies</font><font style="font-family:inherit;font-size:11pt;">.  The rights and remedies of the parties hereunder are cumulative and not exclusive of any rights or remedies any party hereto may otherwise have.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.14.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Expenses Relating to this Agreement</font><font style="font-family:inherit;font-size:11pt;">.  Each party shall pay its or Executive&#8217;s own expenses incident to the negotiation, preparation and execution of this Agreement.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, Executive and Employer have executed this Employment Agreement as of the date set forth in the first paragraph.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">&#8220;EMPLOYER&#8221;</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:240px;text-indent:18px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">MacroGenics, Inc.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:240px;text-indent:18px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:240px;text-indent:18px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:240px;text-indent:18px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Scott Koenig&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:&#160;&#160;&#160;&#160;Scott Koenig</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:&#160;&#160;&#160;&#160;President and CEO</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:240px;text-indent:18px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">&#8220;EXECUTIVE&#8221;</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Eric Risser&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Eric Risser</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SCHEDULE 1</font></div><div style="line-height:138%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">OUTSIDE ACTIVITIES</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EXHIBIT A</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Pursuant to the Employment Agreement by and between Eric Risser (</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Executive&#8221;</font><font style="font-family:inherit;font-size:11pt;">) and MacroGenics, Inc. (the </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Company&#8221;</font><font style="font-family:inherit;font-size:11pt;">), in order for Executive to receive the Severance Amount therein, Executive is required to enter into this Separation Agreement and General Release (this </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Release&#8221;</font><font style="font-family:inherit;font-size:11pt;">).</font></div><div style="line-height:138%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In consideration of the foregoing, of the mutual promises herein contained, of other good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged by the Parties, it is agreed as follows:</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">As of the Termination Date, and at all times forward, Executive will not hold himself out to any person or entity as being an employee, officer, representative, or agent of the Company.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">In exchange for the considerations provided for in this Agreement including the receipt of the Severance Amount, Executive hereby completely, irrevocably, and unconditionally releases and forever discharges the Company, and any of its affiliated companies, and each and all of their officers, agents, directors, supervisors, employees, representatives, and their successors and assigns, and all persons acting by, through, under, for, or in concert with them, or any of them, in any and all of their capacities (hereinafter individually or collectively, the </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Released Parties&#8221;</font><font style="font-family:inherit;font-size:11pt;">), from any and all charges, complaints, claims, and liabilities of any kind or nature whatsoever, known or unknown, suspected or unsuspected (hereinafter referred to as &#8220;claim&#8221; or &#8220;claims&#8221;) which Executive at any time heretofore had or claimed to have or which Executive may have or claim to have regarding events that have occurred as of the Effective Date of this Agreement, including, without limitation, those based on:  any employee welfare benefit or pension plan governed by the Employee Retirement Income Security Act as amended (hereinafter </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;ERISA&#8221;</font><font style="font-family:inherit;font-size:11pt;">) (provided that this release does not extend to any vested retirement benefits of Executive under Company&#8217;s 401(k) Safe Harbor Plan); the Civil Rights Act of 1964, as amended (race, color, religion, sex and national origin discrimination and harassment); the Civil Rights Act of 1966 (42 U.S.C. &#167;&#160;1981) (discrimination); the Age Discrimination in Employment Act of 1967 (hereinafter </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;ADEA&#8221;</font><font style="font-family:inherit;font-size:11pt;">), as amended; the Older Workers Benefit Protection Act, as amended; the Americans With Disabilities Act (hereinafter </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;ADA&#8221;</font><font style="font-family:inherit;font-size:11pt;">), as amended; &#167;&#160;503 of the Rehabilitation Act of 1973; the Fair Labor Standards Act, as amended (wage and hour matters); the Family and Medical Leave Act, as amended, (family leave matters), Article 49B of the Maryland Code (discrimination), any other federal, state, or local laws or regulations regarding employment discrimination or harassment, wages, insurance, leave, privacy or any other matter; any negligent or intentional tort; any contract, policy or practice (implied, oral, or written); or any other theory of recovery under federal, state, or local law, and whether for compensatory or punitive damages, or other equitable relief, including, but not limited to, any and all claims which Executive may now have or may have had, arising from or in any way whatsoever connected with Executive&#8217;s employment or contacts, with Company or any other of the Released Parties.  </font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:192px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Executive acknowledges, understands and agrees that Executive has been paid in full for all hours that Executive has worked for the </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:192px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Company and that Executive has been paid any and all compensation or bonuses which have been earned by Executive through the date of execution of this Agreement other than payments required by </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 5</font><font style="font-family:inherit;font-size:11pt;">&#32;of the Employment Agreement.  Executive acknowledges, understands and agrees that Executive has not been denied any leave requested under the FMLA or applicable state leave laws and that, to the extent applicable, Executive has been returned to Executive&#8217;s job, or an equivalent position, following any FMLA or state leave taken pursuant to the FMLA or state laws.  Executive acknowledges, understands and agrees that Executive has reported to the Employer&#8217;s management personnel any work related injury or illness that occurred up to and including Executive&#8217;s last day of employment.  Executive acknowledges, understands, and agrees that Executive has no knowledge of any actions or inactions by any of the Released Parties or by Executive not previously disclosed to the Company that Executive believes could possibly constitute a basis for a claimed violation of any federal, state, or local law, any common law or any rule promulgated by an administrative body. </font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">To the extent permitted by law, Executive agrees that he will not cause or encourage any future legal proceedings to be maintained or instituted against any of the Released Parties.  To the extent permitted by law, Executive agrees that he will not accept any remedy or recovery arising from any charge filed or proceedings or investigation conducted by the EEOC or by any state or local human rights or employment rights enforcement agency relating to any of the matters released in this Agreement. Nothing in this Section 3 is intended to preclude, limit or inhibit Executive&#8217;s ability or willingness to cooperate with any government agency in any investigation of the Released Parties.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Older Workers Benefit Protection Act /ADEA Waiver</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.01.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Executive acknowledges that Company has advised him in writing to consult with an attorney of his choice before signing this Agreement, and Executive has been given the opportunity to consult with an attorney of his choice before signing this Agreement.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.02.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Executive acknowledges that he has been given the opportunity to review and consider this Agreement for a full twenty-one days before signing it, and that, if he has signed this Agreement in less than that time, he has done so voluntarily in order to obtain sooner the benefits of this Agreement.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.03.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Executive further acknowledges that he may revoke this Agreement within seven (7) days after signing it, provided that this Agreement will not become effective until such seven (7) day period has expired.  To be effective, any such revocation must be in writing and delivered to Company&#8217;s principal place of business by the close of business on the seventh (7th) day after signing the Agreement and must expressly state Executive&#8217;s intention to revoke this Agreement.  Provided that </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Executive does not timely revoke this Agreement, the eighth (8th) day following Executive&#8217;s execution hereof shall be deemed the &#8220;Effective Date&#8221; of this Agreement.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.04.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Parties also agree that the release provided by Executive in this Agreement does not include a release for claims under the ADEA arising after the date Executive signs this Agreement.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Executive shall promptly turn over to the Company any and all documents, files, computer records, or other materials belonging to, or containing confidential or proprietary information obtained from, the Company that are in Executive&#8217;s possession, custody, or control, including any such materials that may be at Executive&#8217;s home.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Executive acknowledges his obligation to comply with any confidentiality or non-disclosure agreement Executive has executed including as set forth in the Employment Agreement.  </font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Parties agree that they will keep absolutely confidential, and not make any future disclosures to anyone except that the Parties may disclose this Agreement:</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.01.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">to enforce this Agreement; and/or</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.02.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">to an attorney; and/or</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.03.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">&#32;tax advisor or attorney in connection with a tax matter; and/or</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.04.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">to the United States Internal Revenue Service, or state or local tax authority upon its request for tax purposes; and/or</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.05.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">as required by court order or otherwise required by law or in response to valid legal process; provided that the Parties may make disclosure to attorneys, accountants, tax advisors, and family members only if such persons agree to keep the information confidential; and provided further that before providing information pursuant to a court order or other legal requirement, the Party providing such information shall promptly notify the other Party, and to the extent possible will comply with the court order or other legal requirement in ways that preserve confidentiality; and</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.06.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">to prospective employers consistent with </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 6.09</font><font style="font-family:inherit;font-size:11pt;">&#32;of the Employment Agreement.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Executive agrees that Executive will not publicly make or publish any adverse, disparaging, untrue, or misleading statement or comment about the Company or any of its officers, directors, employees, or agents.  The Company agrees to instruct its directors, officers, and senior management not to publicly make or publish any adverse, disparaging, untrue, or misleading statement or comment about Executive.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Executive agrees to answer questions that the Company may have from time to time regarding matters that Executive worked on and to cooperate with the Company, upon request, to assist in the investigation, prosecution or defense of any claim, grievance, investigation, or audit by or against the </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Company. The time requirement for these activities will be nominal, will not be disruptive to the ability of the Executive to perform his own ongoing personal or professional responsibilities and will not require travel unless agreed upon by the Executive. The Company agrees to reimburse Executive for any reasonable and necessary out-of-pocket expenses he incurs as a result of such cooperation and to compensate him a reasonable hourly rate in the event such cooperation exceeds an aggregate of 20 hours (provided that the first 20 hours of cooperation has been performed to the reasonable satisfaction of the Company).</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">This Agreement shall not in any way be construed as an admission by the Company of any acts of unlawful conduct, wrongdoing or discrimination against Executive, and the Company specifically disclaims any liability to Executive on the part of itself, its employees, or its agents.  This Agreement shall not in any way be construed as an admission by Executive of any acts of unlawful conduct, wrongdoing or discrimination against the Company, and Executive specifically disclaims any liability to Company on the part of himself or his agents.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">This Agreement shall be binding upon Executive and upon Executive&#8217;s heirs, administrators, representatives, executors, successors, and assigns, and shall inure to the benefit of the Company, and its representatives, executors, successors, and assigns.  This Agreement shall be binding upon the Company and upon the Company&#8217;s assigns and shall inure to the benefit of Executive and his heirs, administrators, representatives, executors, successors, and assigns.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">This Agreement, including its Exhibits, and any applicable stock option agreements and the equity plans to which they relate, set forth the entire agreement between the Company and Executive and, except as expressly provided for in this Agreement, fully supersedes any and all prior agreements or understandings between the Company and Executive pertaining to the subject matter hereof, except that Executive&#8217;s obligations in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 6</font><font style="font-family:inherit;font-size:11pt;">&#32;of the Employment Agreement between Executive and the Company shall remain in full force and effect.  In reaching this Agreement, neither the Company nor Executive has relied upon any representation or promise except those set forth herein.  If any provision, or portion of a provision, of this Agreement is held to be invalid or unenforceable for any reason, the remainder of the Agreement shall remain in full force and effect, as if such provision, or portion of such provision, had never been contained herein.  The unenforceability or invalidity of a provision of the Agreement in one jurisdiction shall not invalidate or render that provision unenforceable in any other jurisdiction.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">13.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">This Agreement cannot be amended, modified, or supplemented in any respect except by written agreement entered into and signed by the Parties.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">14.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">This Agreement shall be governed by the laws of the State of Maryland without giving effect to conflict of laws principles, and Executive consents to exclusive personal jurisdiction in the state and federal courts of the State of Maryland for any proceeding arising out of or relating to this Agreement.  The language of all parts of the Agreement shall in all cases be construed as a whole, according to its fair meaning, and not strictly for or against any of the Parties.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Executive acknowledges that he has read each and every section of this Agreement and that he understands his rights and obligations under this Agreement.  Executive acknowledges that the Company has advised him in writing to consult with an attorney of his choice before signing this Agreement, and that Executive has been given the opportunity to consult with an attorney of his choice before signing this Agreement.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">16.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">This Agreement may be signed in counterparts, each of which shall be considered an original for all purposes, and all of which taken together shall constitute one and the same written agreement.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the Company, has caused this Agreement to be executed by its duly authorized officer, and Executive has executed this Agreement, on the date(s) set forth below.</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Executive</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">_______________________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Eric Risser&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;/Date</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">MacroGenics, Inc.</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:-192px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:-192px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:____________________________________</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;/Date</font></div><div style="line-height:120%;text-align:left;padding-left:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:&#160;&#160;&#160;&#160;</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>exhibit231.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sE40A4B8DF073F658A276E278863CF8EF"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT 23.1</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We consent to the incorporation by reference in the following Registration Statements:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-8 No. 333-192277) pertaining to the 2000 Stock Option Incentive Plan, the 2003 Equity Incentive Plan, and 2013 Equity Incentive Plan of MacroGenics, Inc.; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statements (Form S-8 No. 333-202470 and Form S-8 No. 333-209812) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-8 No. 333-214386) pertaining to the 2016 Employee Stock Purchase Plan of MacroGenics, Inc.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statements (Form S-3 No. 333-200092 and Form S-3 ASR No. 333-214385) of MacroGenics, Inc.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of our reports dated </font><font style="font-family:inherit;font-size:10pt;">February&#160;28, 2017</font><font style="font-family:inherit;font-size:10pt;">, with respect to the consolidated financial statements of MacroGenics, Inc. and the effectiveness of internal control over financial reporting of MacroGenics, Inc.&#160;included in this Annual Report (Form 10-K) of MacroGenics, Inc. for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:24px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ernst&#160;&amp; Young LLP</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Baltimore, Maryland</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February&#160;28, 2017</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exhibit311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD2280F0C0AEB76A9F0D3E27890E1D3D9"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT 31.1</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Scott Koenig, certify that:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Annual Report on Form 10-K for the period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;of MacroGenics, Inc.;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><div style="line-height:120%;padding-left:168px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:168px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:168px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:168px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:168px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:3%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Scott&#160;Koenig</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scott Koenig, M.D., Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated:&#160;</font><font style="font-family:inherit;font-size:10pt;">February&#160;28, 2017</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exhibit312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1DF978274EF2285120E9E27891869F7B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT 31.2</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, James Karrels, certify that:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Annual Report on Form 10-K for the period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;of MacroGenics, Inc.;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:3%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ James Karrels</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">James Karrels</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President and Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated:&#160;</font><font style="font-family:inherit;font-size:10pt;">February&#160;28, 2017</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exhibit321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s5804D464967E17E83E2FE278966E041A"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT 32.1</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002)</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Scott Koenig, President and Chief Executive Officer (principal executive officer) of MacroGenics, Inc. (the &#8220;Registrant&#8221;), certify, to the best of my knowledge, based upon a review of the Annual Report on Form 10-K for the period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;of the Registrant (the &#8220;Report&#8221;), that:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:26px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:2px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a) or 15(d)&#160;of the Securities Exchange Act of 1934, as amended; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:26px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:2px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Scott Koenig&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name: Scott Koenig, M.D., Ph.D.</font></div><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:  </font><font style="font-family:inherit;font-size:10pt;text-transform:default;">February&#160;28, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>exhibit322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s14D1BF1E0449483C9F6CE27896E74087"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT 32.2</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002)</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, James Karrels, Senior Vice President and Chief Financial Officer (principal financial officer) of MacroGenics, Inc. (the &#8220;Registrant&#8221;), certify, to the best of my knowledge, based upon a review of the Annual Report on Form 10-K for the period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;of the Registrant (the &#8220;Report&#8221;), that:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:26px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:2px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a) or 15(d)&#160;of the Securities Exchange Act of 1934, as amended; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:26px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:2px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ James Karrels&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name: James Karrels</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">February&#160;28, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>mgnx-20161231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:e183c586424a4456aebe139e03978b76,x:d1a78855ca1242659fc040404844190c-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2015-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgnx="http://macrogenics.com/20161231" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:us-roles="http://fasb.org/us-roles/2015-01-31" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="mgnx-20161231.xsd" xlink:type="simple" />
	<xbrli:context id="FD2016Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb24">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-24</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_BoehringerIngelheimMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_JanssenBiotechIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_ServierMGA271Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:ServierMGA271Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_TakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:TakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_JanssenBiotechIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_GileadSciencesIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:GileadSciencesIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_BoehringerIngelheimMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mgnx_LaboratoryAndOfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:LaboratoryAndOfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_JanssenBiotechIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_EliLillyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:EliLillyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_TakedaPharmaceuticalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:TakedaPharmaceuticalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_JanssenBiotechIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_USGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:USGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_ServierMGA271Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:ServierMGA271Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_ServierMGA271Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:ServierMGA271Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_USGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:USGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mgnx_FurnitureAndOfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mgnx_FurnitureAndOfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul1-Jul31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q1Feb28">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1SD_us-gaap_CounterpartyNameAxis_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JohnsonAndJohnsonDevelopmentCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgnx_UndesignatedPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q1Feb1-Feb28">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-02-01</xbrli:startDate>
			<xbrli:endDate>2014-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q3Jul31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1Jan31_us-gaap_CounterpartyNameAxis_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JohnsonAndJohnsonDevelopmentCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_mgnx_UndesignatedPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q4Oct31_us-gaap_PlanNameAxis_mgnx_StockIncentivePlan2013Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2003Q1Feb28_us-gaap_PlanNameAxis_mgnx_EquityIncentivePlan2003Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:EquityIncentivePlan2003Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2003-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PlanNameAxis_mgnx_EquityIncentivePlan2003Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:EquityIncentivePlan2003Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4SD_us-gaap_PlanNameAxis_mgnx_EquityIncentivePlan2003Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:EquityIncentivePlan2003Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2006-01-01</xbrli:startDate>
			<xbrli:endDate>2012-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PlanNameAxis_mgnx_StockIncentivePlan2013Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PlanNameAxis_mgnx_StockIncentivePlan2013Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BusinessAcquisitionAxis_mgnx_RavenBiotechnologiesIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mgnx:RavenBiotechnologiesIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May31_us-gaap_BusinessAcquisitionAxis_mgnx_RavenBiotechnologiesIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mgnx:RavenBiotechnologiesIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1SD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD011AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q3Sep30_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD015AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD015AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD011AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q3Sep1-Sep30_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-09-01</xbrli:startDate>
			<xbrli:endDate>2012-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q2May1-May31_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:TakedaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ResearchCollaborationAndLicenseOptionAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-05-01</xbrli:startDate>
			<xbrli:endDate>2014-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:TakedaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ResearchCollaborationAndLicenseOptionAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2010Q3Oct31_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2010-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD015AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD015AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:TakedaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:TakedaMGD010AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD011AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1Jan31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD011AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q2May1-May31_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:TakedaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:TakedaMGD010AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-05-01</xbrli:startDate>
			<xbrli:endDate>2014-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2010Q4Oct1-Oct31_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2010-10-01</xbrli:startDate>
			<xbrli:endDate>2010-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Sep15-Sep15_us-gaap_CounterpartyNameAxis_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-09-15</xbrli:startDate>
			<xbrli:endDate>2015-09-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:TakedaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:TakedaMGD010AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Sep15-Sep15_us-gaap_CounterpartyNameAxis_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-09-15</xbrli:startDate>
			<xbrli:endDate>2015-09-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1Jan31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD011AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2010Q2Jun1-Jun30_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2010-06-01</xbrli:startDate>
			<xbrli:endDate>2010-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Jul01-Jul31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD015AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD015AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:TakedaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:TakedaMGD010AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2010Q2Jun30_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2010-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:TakedaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ResearchCollaborationAndLicenseOptionAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Dec01-Dec31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD011AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-12-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:TakedaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:TakedaMGD010AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:TakedaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:TakedaMGD010AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q3Jul31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD011AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_mgnx_MixedUseOfficeLaboratoryAndManufacturingSpaceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">mgnx:MixedUseOfficeLaboratoryAndManufacturingSpaceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-01-01</xbrli:startDate>
			<xbrli:endDate>2012-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="U011">
		<xbrli:measure>mgnx:Segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="U010">
		<xbrli:measure>mgnx:Lease</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="U007">
		<xbrli:measure>mgnx:Milestone</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="U004">
		<xbrli:measure>mgnx:Molecule</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="U008">
		<xbrli:measure>mgnx:Payment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2016Q4YTD" id="Fact-13AA992B3C3A8B9A77BCE2787B83A2F0">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2016Q4YTD" id="Fact-4FC3217E021962EF85D0E2787B6615CE">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2016Q4YTD" id="Fact-F42FFB7E91FCBD3B9530E2787B99132C">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2016Q4YTD" id="Fact-CB96906C8A4C9CF76DAAE2787AEB30D6">2016</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2016Q4YTD" id="Fact-A13D92A838A16F077CB9E2787B0858C0">2016-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2016Q4YTD" id="Fact-BC63212B86C4013D426AE2787AF90A31">10-K</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2016Q4YTD" id="Fact-95ECA37C8B560287F4EDE2787B7FD3C4">0001125345</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2017Q1Feb24" decimals="INF" id="Fact-033EC7F3E6293D9B9723E2787B941DBC" unitRef="shares">34974985</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2016Q4YTD" id="Fact-EDBB629B9EE9B10845B8E2787B100138">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityFilerCategory contextRef="FD2016Q4YTD" id="Fact-2EF961EA8C428C7822A8E2787AE407FD">Large Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityPublicFloat contextRef="FI2016Q2" decimals="-6" id="Fact-0D0A6B3A44225C3963E6E2787B0B86BE" unitRef="usd">936000000</dei:EntityPublicFloat>
	<dei:EntityRegistrantName contextRef="FD2016Q4YTD" id="Fact-9C9F019DEB0F73FD316AE2787B00AEC0">MACROGENICS INC</dei:EntityRegistrantName>
	<dei:EntityVoluntaryFilers contextRef="FD2016Q4YTD" id="Fact-AA755713ACB3955C4BA8E2787B0C04C3">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="FD2016Q4YTD" id="Fact-DEC18E9AEF3C03CA5CCFE2787AFECEE2">Yes</dei:EntityWellKnownSeasonedIssuer>
	<mgnx:AdditionalDevelopmentFundingOptionsUnderAgreement contextRef="D2015Q3Sep15-Sep15_us-gaap_CounterpartyNameAxis_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-B7A0ED25F84614781545E2787B962B46" unitRef="usd">17000000.0</mgnx:AdditionalDevelopmentFundingOptionsUnderAgreement>
	<mgnx:AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement contextRef="I2010Q2Jun30_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-BA4E0092B93C5B792E65E2787B79B886" unitRef="usd">2500000.0</mgnx:AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement>
	<mgnx:AdditionalPotentialClinicalMilestonePaymentsUnderAgreement contextRef="I2010Q3Oct31_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember" decimals="-5" id="Fact-B4B56D055993C1D66E08E2787B155A27" unitRef="usd">34000000</mgnx:AdditionalPotentialClinicalMilestonePaymentsUnderAgreement>
	<mgnx:AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement contextRef="I2010Q3Oct31_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember" decimals="-5" id="Fact-E77E9717C6A657B10854E2787B80FE45" unitRef="usd">88500000</mgnx:AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement>
	<mgnx:AdditionalPotentialSalesMilestonePaymentsUnderAgreement contextRef="I2010Q3Oct31_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember" decimals="-5" id="Fact-EE2825CCA541C9F8D07CE2787B68F604" unitRef="usd">82500000</mgnx:AdditionalPotentialSalesMilestonePaymentsUnderAgreement>
	<mgnx:AdjustmentToRevenueUnderAccountingStandardsCodification contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="-5" id="Fact-792AB25B314CAAFA19A9E2787B97DB83" unitRef="usd">1300000</mgnx:AdjustmentToRevenueUnderAccountingStandardsCodification>
	<mgnx:AggregatePotentialFutureCostReimbursement contextRef="I2010Q2Jun30_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-BE139635619FA5B232B8E2787B6B469F" unitRef="usd">5500000.0</mgnx:AggregatePotentialFutureCostReimbursement>
	<mgnx:AmountAllocatedToEquity contextRef="D2015Q1SD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="-5" id="Fact-98B5F17DD606430ABCB6E2787B1CE8DE" unitRef="usd">62700000</mgnx:AmountAllocatedToEquity>
	<mgnx:AmountAllocatedToLicenseAndRD contextRef="D2015Q1SD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="-5" id="Fact-A2868F5EC54F86DC15EFE2787B20D636" unitRef="usd">62300000</mgnx:AmountAllocatedToLicenseAndRD>
	<mgnx:AmountOfImmaterialErrorCorrection contextRef="FD2016Q4YTD" decimals="-5" id="Fact-23DB721CC1E43BBF37ACE2787C0136F1" unitRef="usd">1900000</mgnx:AmountOfImmaterialErrorCorrection>
	<mgnx:ChangeInAccountingEstimateCurrentYearImpact contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-2F1BE5A032357E865E8FE2787B09D064" unitRef="usd">3700000</mgnx:ChangeInAccountingEstimateCurrentYearImpact>
	<mgnx:ClinicalMilestoneEarnedDuringPeriod contextRef="I2015Q3Jul31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="-5" id="Fact-348C4553EF8DEE9D5067E2787B871C18" unitRef="usd">10000000</mgnx:ClinicalMilestoneEarnedDuringPeriod>
	<mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-58B967778FA6A621FA68647BDBC024BB" unitRef="usd">1000000</mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts>
	<mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-A3147BC0591A37C808D4E2787B00DFA4" unitRef="usd">500000</mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts>
	<mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-A0E4DBDE34D23CD7FA79E2787B1B5224" unitRef="usd">2600000</mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts>
	<mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance contextRef="FI2016Q4_us-gaap_PlanNameAxis_mgnx_StockIncentivePlan2013Member" decimals="INF" id="Fact-E11AFF47FDAADDBB2506E2787AE3F56A" unitRef="shares">1960168</mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance>
	<mgnx:DefinedContributionPlanEmployeesContributionVestedPercentage contextRef="FD2016Q4YTD" decimals="INF" id="Fact-6E134E0D7127C4D0465DE2787B8E6BF4" unitRef="number">1</mgnx:DefinedContributionPlanEmployeesContributionVestedPercentage>
	<mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount contextRef="FD2014Q4YTD" decimals="-3" id="Fact-14DF6AACEE611EF2D4EFE2787B8680DB" unitRef="usd">0</mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount>
	<mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount contextRef="FD2015Q4YTD" decimals="-3" id="Fact-71144D90904B425E5DF5E2787C039849" unitRef="usd">661000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount>
	<mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount contextRef="FD2016Q4YTD" decimals="-3" id="Fact-33BE9A0040096859D36CE2787B727408" unitRef="usd">173000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount>
	<mgnx:EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount contextRef="FD2014Q4YTD" decimals="-3" id="Fact-F8A5FD5E3A461FDF7131E2787B6722EB" unitRef="usd">-3034000</mgnx:EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount>
	<mgnx:EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount contextRef="FD2015Q4YTD" decimals="-3" id="Fact-454736ABE91B91F9C892E2787B96117A" unitRef="usd">493000</mgnx:EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount>
	<mgnx:EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2873C30E54B71344355CE2787B9385CE" unitRef="usd">32000</mgnx:EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount>
	<mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan contextRef="FD2012Q4YTD" id="Fact-A63675FA498B950F015EE2787BA16F64">P21Y</mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan>
	<mgnx:FundedValueOfBasePeriod contextRef="D2015Q3Sep15-Sep15_us-gaap_CounterpartyNameAxis_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="-5" id="Fact-E08F17226033AADB328BE2787B7442F3" unitRef="usd">7500000</mgnx:FundedValueOfBasePeriod>
	<mgnx:IncomeTaxRateReconciliationDeductionPriorYearAdjustment contextRef="FD2014Q4YTD" decimals="-3" id="Fact-EE455EC55C10B23E47BCE2787B852C19" unitRef="usd">564000</mgnx:IncomeTaxRateReconciliationDeductionPriorYearAdjustment>
	<mgnx:IncomeTaxRateReconciliationDeductionPriorYearAdjustment contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C4A878211F366B144498E2787BB4B8FD" unitRef="usd">0</mgnx:IncomeTaxRateReconciliationDeductionPriorYearAdjustment>
	<mgnx:IncomeTaxRateReconciliationDeductionPriorYearAdjustment contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6601C0F7F9D199C82A5CE2787BB7B1D8" unitRef="usd">0</mgnx:IncomeTaxRateReconciliationDeductionPriorYearAdjustment>
	<mgnx:IncreaseDecreaseInDeferredRent contextRef="FD2014Q4YTD" decimals="-3" id="Fact-A96CADB1FE53EADC46EFE2787AF56925" unitRef="usd">-234000</mgnx:IncreaseDecreaseInDeferredRent>
	<mgnx:IncreaseDecreaseInDeferredRent contextRef="FD2015Q4YTD" decimals="-3" id="Fact-8897C451486EAC408EE5E2787AD44944" unitRef="usd">4650000</mgnx:IncreaseDecreaseInDeferredRent>
	<mgnx:IncreaseDecreaseInDeferredRent contextRef="FD2016Q4YTD" decimals="-3" id="Fact-A143890AD35610EC5D5DE2787BED4E4C" unitRef="usd">-1134000</mgnx:IncreaseDecreaseInDeferredRent>
	<mgnx:NonRefundableUpfrontFees contextRef="D2010Q2Jun1-Jun30_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="-5" id="Fact-F149345114DBA43CF92FE2787B1E569F" unitRef="usd">1000000</mgnx:NonRefundableUpfrontFees>
	<mgnx:NonRefundableUpfrontFees contextRef="D2010Q4Oct1-Oct31_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember" decimals="-5" id="Fact-AC467377F0C8A824573BE2787B120A9C" unitRef="usd">15000000</mgnx:NonRefundableUpfrontFees>
	<mgnx:NonRefundableUpfrontFees contextRef="D2012Q3Sep1-Sep30_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-9F3182CBE636A6808B2BE2787B876DC3" unitRef="usd">20000000</mgnx:NonRefundableUpfrontFees>
	<mgnx:NonRefundableUpfrontFees contextRef="D2014Q2May1-May31_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember" decimals="-5" id="Fact-6C0E388D0A08185DEF8DE2787B134CCD" unitRef="usd">15000000</mgnx:NonRefundableUpfrontFees>
	<mgnx:NonRefundableUpfrontFees contextRef="D2016Q3Jul01-Jul31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD015AgreementMember" decimals="-5" id="Fact-24F9DE637F26ED9E543A6D37DB45690B" unitRef="usd">75000000</mgnx:NonRefundableUpfrontFees>
	<mgnx:NonRefundableUpfrontFees contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="-5" id="Fact-B4875F4C927EA3AA2C5FE2787B901896" unitRef="usd">50000000</mgnx:NonRefundableUpfrontFees>
	<mgnx:NonRefundableUpfrontFees contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD015AgreementMember" decimals="-5" id="Fact-D8A14AD8BD20D7E0AC3971C59D3F65CC" unitRef="usd">75000000</mgnx:NonRefundableUpfrontFees>
	<mgnx:NumberOfAnnualMaintenancePaymentReceived contextRef="D2010Q4Oct1-Oct31_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember" decimals="INF" id="Fact-66A2458FA179F1D50510E2787BB3C6A8" unitRef="U008">3</mgnx:NumberOfAnnualMaintenancePaymentReceived>
	<mgnx:NumberOfLease contextRef="FD2016Q4YTD" decimals="INF" id="Fact-1FC6E1454041895E1295E2787B66CA50" unitRef="U010">5</mgnx:NumberOfLease>
	<mgnx:NumberOfMilestonesAchieved contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="INF" id="Fact-FA42865158217C322EE0E2787B1E6049" unitRef="U007">2</mgnx:NumberOfMilestonesAchieved>
	<mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement contextRef="D2015Q3Sep15-Sep15_us-gaap_CounterpartyNameAxis_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="INF" id="Fact-660616F47760F82994ABE2787B95087E" unitRef="U004">2</mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement>
	<mgnx:OperatingLossCarryforwardsAnnualLimitationAmount contextRef="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="-5" id="Fact-0114C1D0979164E62139E2787B3C9657" unitRef="usd">1400000</mgnx:OperatingLossCarryforwardsAnnualLimitationAmount>
	<mgnx:OperatingLossCarryforwardsAnnualLimitationAmount contextRef="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="-5" id="Fact-2B0967599B58F9DAFD5EE2787B3A4A72" unitRef="usd">200000</mgnx:OperatingLossCarryforwardsAnnualLimitationAmount>
	<mgnx:OperatingLossCarryforwardsLimitationsOnUseAmount contextRef="FD2016Q4YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-5" id="Fact-7CF359EC55FE5ECD19AFE2787B26C3BB" unitRef="usd">13500000</mgnx:OperatingLossCarryforwardsLimitationsOnUseAmount>
	<mgnx:OperatingLossCarryforwardsNotSubjectToLimitation contextRef="FI2016Q4" decimals="-5" id="Fact-C1D6652CF1145E48104CE2787B2845AD" unitRef="usd">201900000</mgnx:OperatingLossCarryforwardsNotSubjectToLimitation>
	<mgnx:OptionExerciseFee contextRef="FI2014Q4_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-2D80CE11F96526317E36E2787B84D401" unitRef="usd">15000000</mgnx:OptionExerciseFee>
	<mgnx:OptionExerciseFeeRecognitionPeriod contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" id="Fact-C70A654774ACA51FAEC3E2787ADE7AF3">P82M</mgnx:OptionExerciseFeeRecognitionPeriod>
	<mgnx:OriginalPeriodOfDevelopment contextRef="D2012Q3Sep1-Sep30_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" id="Fact-567A64D394D8D2036A9CE2787BA1B840">P29M</mgnx:OriginalPeriodOfDevelopment>
	<mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_mgnx_StockIncentivePlan2013Member" decimals="3" id="Fact-3DC506CAA1DC075B372FE2787AE0CD74" unitRef="number">0.040</mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan>
	<mgnx:PotentialClinicalMilestonePaymentsUnderAgreement contextRef="I2012Q3Sep30_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="INF" id="Fact-48C54DFB15D6E34C7AEEE2787B84101E" unitRef="usd">63000000</mgnx:PotentialClinicalMilestonePaymentsUnderAgreement>
	<mgnx:PotentialClinicalMilestonePaymentsUnderAgreement contextRef="I2015Q1Jan31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="INF" id="Fact-C14CACE6E072B7A788BDE2787B93E2B7" unitRef="usd">205000000.0</mgnx:PotentialClinicalMilestonePaymentsUnderAgreement>
	<mgnx:PotentialClinicalMilestonePaymentsUnderAgreement contextRef="I2016Q2May31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD015AgreementMember" decimals="INF" id="Fact-83B1D0048DF8511BB4006D406C1545D2" unitRef="usd">100000000.0</mgnx:PotentialClinicalMilestonePaymentsUnderAgreement>
	<mgnx:PotentialLicenseFee contextRef="I2012Q3Sep30_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="INF" id="Fact-43385695BD4B037DD24DE2787B576B33" unitRef="usd">40000000</mgnx:PotentialLicenseFee>
	<mgnx:PotentialRegulatoryMilestonePaymentsUnderAgreement contextRef="I2012Q3Sep30_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="INF" id="Fact-FD52717C0A5E48DBF142E2787AC88112" unitRef="usd">188000000</mgnx:PotentialRegulatoryMilestonePaymentsUnderAgreement>
	<mgnx:PotentialRegulatoryMilestonePaymentsUnderAgreement contextRef="I2015Q1Jan31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="INF" id="Fact-2041FA2141738F4A434EE2787B87B8B0" unitRef="usd">220000000.0</mgnx:PotentialRegulatoryMilestonePaymentsUnderAgreement>
	<mgnx:PotentialRegulatoryMilestonePaymentsUnderAgreement contextRef="I2016Q2May31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD015AgreementMember" decimals="-5" id="Fact-2F91F5FC815ED9F579186D4306F5C9C5" unitRef="usd">265000000</mgnx:PotentialRegulatoryMilestonePaymentsUnderAgreement>
	<mgnx:PotentialSalesMilestonePaymentsUnderAgreement contextRef="I2012Q3Sep30_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="INF" id="Fact-52BD4AED656A53EFF3B0E2787B11D86E" unitRef="usd">420000000</mgnx:PotentialSalesMilestonePaymentsUnderAgreement>
	<mgnx:PotentialSalesMilestonePaymentsUnderAgreement contextRef="I2015Q1Jan31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="INF" id="Fact-181E26795DB989C751FDE2787AFEA721" unitRef="usd">150000000.0</mgnx:PotentialSalesMilestonePaymentsUnderAgreement>
	<mgnx:PotentialSalesMilestonePaymentsUnderAgreement contextRef="I2016Q2May31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD015AgreementMember" decimals="-5" id="Fact-D872F9FAD3C3F50EF6E16D4379A2B711" unitRef="usd">300000000</mgnx:PotentialSalesMilestonePaymentsUnderAgreement>
	<mgnx:PremiumReceivedOnStockPurchase contextRef="D2015Q1SD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="-5" id="Fact-60E7DCA3CE7F31576640E2787BA5B63F" unitRef="usd">12300000</mgnx:PremiumReceivedOnStockPurchase>
	<mgnx:ProceedsFromResearchAndDevelopmentServices contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="-5" id="Fact-5E93ABF8ADF62801B26F7160D2DB4A54" unitRef="usd">5500000</mgnx:ProceedsFromResearchAndDevelopmentServices>
	<mgnx:PropertyPlantAndEquipmentNonCashAdditions contextRef="FI2016Q4" decimals="-5" id="Fact-A720F5E321232A79572FE2787B76E94D" unitRef="usd">300000</mgnx:PropertyPlantAndEquipmentNonCashAdditions>
	<mgnx:ReductionInResearchAndDevelopmentExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-C7B9A47B125FF101FD5C6E649285551D" unitRef="usd">1300000</mgnx:ReductionInResearchAndDevelopmentExpense>
	<mgnx:ReviewPeriodByRegulatoryAuthority contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" id="Fact-36E9878064520F479073E2787B105414">P30D</mgnx:ReviewPeriodByRegulatoryAuthority>
	<mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease contextRef="D2016Q4SD_us-gaap_PlanNameAxis_mgnx_EquityIncentivePlan2003Member" decimals="INF" id="Fact-4F3161A13925BA1C9A82E2787AE09EED" unitRef="shares">4336730</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease>
	<mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_mgnx_StockIncentivePlan2013Member" decimals="INF" id="Fact-B489466654E6FFC49B1EE2787AD4FEFA" unitRef="shares">5375064</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease>
	<mgnx:StockIssuedDuringPeriodSharesStockPlanActivity contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-06B9FFF7165566B0902AE2787BB17CB8" unitRef="shares">568041</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodSharesStockPlanActivity contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-F1F048991B2EF9AAF29263E88C4E96BF" unitRef="shares">865</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodSharesStockPlanActivity contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-3B36232012A686A20D72E2787B01B0E7" unitRef="shares">373289</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodSharesStockPlanActivity contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-C4F3E5E55A0E78D8C7E5E2787C0B896B" unitRef="shares">925</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodSharesStockPlanActivity contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-D2639D1BA3E55E1101FCE2787AF4FFAE" unitRef="shares">524853</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodSharesStockPlanActivity contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-333EC7EAD75A802EA822814665108079" unitRef="shares">1862</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption contextRef="D2014Q1Feb1-Feb28" decimals="INF" id="Fact-C520250FCE530F68ECC1E2787B3CD6FC" unitRef="shares">450000</mgnx:StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption>
	<mgnx:StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption contextRef="D2015Q3Jul1-Jul31" decimals="INF" id="Fact-5FD3773EE4A878CBACDAE2787BEE8E6B" unitRef="shares">528750</mgnx:StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption>
	<mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="FD2014Q4YTD" decimals="-3" id="Fact-02F2AD66350EA5E7E673E2787BD0E181" unitRef="usd">725000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-17DDB0B5C129063DC00EE2787AC975AA" unitRef="usd">738000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-E4CC33C130894E0B4CD6E2787BF43346" unitRef="usd">6000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-7E25801ECDEBFA1F31D0E2787BB1B7B8" unitRef="usd">-19000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="FD2015Q4YTD" decimals="-3" id="Fact-D52D6B20746A41A3AAD9E2787BC4D6AF" unitRef="usd">882000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-3C159C51FEC6E257F6BDE2787B6938F6" unitRef="usd">908000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-20152B152E7B63B4B4CAE2787AD93B50" unitRef="usd">3000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-5A30A208C33F92FF3BF5E2787BDC595C" unitRef="usd">-29000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6502A17D494BA9893F47E2787B5D1557" unitRef="usd">1854000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-B3AFCD1719457C6560E1E2787B0705B7" unitRef="usd">1887000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-5C88473B7E479BF8A9A0E2787B457493" unitRef="usd">6000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-71F54DB08C18EC1C97E7E2787BA2C935" unitRef="usd">-39000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
	<mgnx:TotalConsideration contextRef="D2015Q1SD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="-5" id="Fact-EA047A8D1BCAC95F0954E2787B174304" unitRef="usd">125000000</mgnx:TotalConsideration>
	<mgnx:TotalPotentialValueUnderAgreement contextRef="D2015Q3Sep15-Sep15_us-gaap_CounterpartyNameAxis_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-3EACB75C67733C4C31E1E2787BB06712" unitRef="usd">24500000.0</mgnx:TotalPotentialValueUnderAgreement>
	<mgnx:UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward contextRef="FI2016Q4" decimals="-5" id="Fact-171A5FA41C3984B0C79EE2787B376874" unitRef="usd">18600000</mgnx:UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward>
	<mgnx:UpfrontFeeAllocatedToAgreement contextRef="D2014Q2May1-May31_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember" decimals="-5" id="Fact-F03DD211709B8C12CD1DE2787B775A7C" unitRef="usd">5000000</mgnx:UpfrontFeeAllocatedToAgreement>
	<mgnx:UpfrontFeeAllocatedToAgreement contextRef="D2014Q2May1-May31_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember" decimals="-5" id="Fact-5E4887CD3374F51FB5A8E2787BBDA425" unitRef="usd">10000000</mgnx:UpfrontFeeAllocatedToAgreement>
	<mgnx:UpfrontPaymentRecognitionPeriod contextRef="D2012Q3Sep1-Sep30_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" id="Fact-2E0727D728E003FD68D0E2787BA12460">P75M</mgnx:UpfrontPaymentRecognitionPeriod>
	<mgnx:UpfrontPaymentRecognitionPeriod contextRef="D2014Q2May1-May31_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember" id="Fact-B6CEBA992B5A311AB1C9E2787B876F61">P24M</mgnx:UpfrontPaymentRecognitionPeriod>
	<us-gaap:AccountsPayableCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-BABC9127559004F5F659E2787BC02F3D" unitRef="usd">2967000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-BCD6D75EEFEE0D450170E2787B352CB9" unitRef="usd">3995000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-72D3C867B78DE4819E99E2787AE78521" unitRef="usd">1224000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-BA6365DD60A60DC30081E2787AEB209E" unitRef="usd">2764000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-F6663B4859FB1088B1EFE2787ADB0923" unitRef="usd">11708000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-32AA3727AAB8BBEEDC02E2787BCCC6E4" unitRef="usd">16134000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2015Q4" decimals="-3" id="Fact-48DBA894B9F65E999946E2787BB454A1" unitRef="usd">20190000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2016Q4" decimals="-3" id="Fact-0CBCBE07B7CB9C0BC837E2787B6B6C86" unitRef="usd">25823000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FI2015Q4" decimals="-3" id="Fact-E83AF13A9288EF53E695E2787B083FEE" unitRef="usd">-5000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FI2016Q4" decimals="-3" id="Fact-83ABD00D773B7C8D7D34E2787AF1FB28" unitRef="usd">-82000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2015Q4" decimals="-3" id="Fact-71A98C9F9FC480B50E4DE2787B5C29E6" unitRef="usd">547185000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2016Q4" decimals="-3" id="Fact-A5869A4D423F36957C84E2787AF6AF5B" unitRef="usd">561198000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2014Q4YTD" decimals="-3" id="Fact-5B3011C4EADE470520CFE2787B051793" unitRef="usd">3244000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-B8BEF8E32794202DB119E2787B01E460" unitRef="usd">3244000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-ACDFC22BFA233489028AE2787B34CEC8" unitRef="usd">7847000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-AEC56C9A2EB3D420628DE2787BEEE713" unitRef="usd">7847000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-904B4E64862B18FBC50AE2787BC6BDBA" unitRef="usd">12165000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-96E211A1A87AABC9043FE2787BEFB6A5" unitRef="usd">12165000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD" decimals="-3" id="Fact-63B683DC78EAA535AE7CE2787BFF8881" unitRef="usd">3244000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-6D72300231128350EBF7E2787BC39B64" unitRef="usd">1682000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-7449B71BE09422B98AA6E2787B0C5EEE" unitRef="usd">1562000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-E1FBEE003C16E523EA0DE2787C017C36" unitRef="usd">7847000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-85210C5F95A45FB71EFAE2787B6BBC86" unitRef="usd">4224000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-B67709C5D4D544831D8EE2787B99D228" unitRef="usd">3623000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-12329CE9971FF739ACD6E2787AE17C39" unitRef="usd">12165000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-4E0BBE32D8555AC39A9EE2787BEC7EC8" unitRef="usd">6387000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-93E64647460D0C3744FFE2787B04CA38" unitRef="usd">5778000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="FI2015Q4" decimals="INF" id="Fact-EC75733AA152F849BA7A6761BD66A9D4" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
	<us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="FI2016Q4" decimals="INF" id="Fact-A97E617BEF0D9948A6C1E2787B00DF35" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2014Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember" decimals="0" id="Fact-2A9AE27D96573881B75BE2787B920A55" unitRef="shares">2094904</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember" decimals="0" id="Fact-4332E950CBC5A49894BBE2787B9140E3" unitRef="shares">1955398</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember" decimals="0" id="Fact-AA5E5F53AA65B0C2F201E2787B9539A5" unitRef="shares">1394608</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2015Q4" decimals="-3" id="Fact-2CB1B1E868B92FAF9870E2787B2732D4" unitRef="usd">359269000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2016Q4" decimals="-3" id="Fact-B94D379935F40AB039BAE2787AEE04E9" unitRef="usd">311263000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-2B0FF2063799A7506CEFE2787B03CFB9" unitRef="usd">342384000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-5955F706216C2B17CD75E2787AEC81EF" unitRef="usd">283947000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4" decimals="-3" id="Fact-0CB61724FA775B34A019E2787BD13EC9" unitRef="usd">250831000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-2987200C7FD142AB69F5E2787BDE5DDC" unitRef="usd">62353000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-E182AE3B6025ABFF203CE2787BDB3014" unitRef="usd">188478000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-1A29EAC5954855F68B41E2787BD25430" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4" decimals="-3" id="Fact-AF7206ACDE2BAB7E941EE2787BC02C29" unitRef="usd">251666000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-3B96020D001BBE4E1BFFE2787BB10992" unitRef="usd">46781000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-5AEE1F5B9F6FD20C8065E2787BB33A40" unitRef="usd">204885000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-1A8834BF26A36CC0B1AAE2787BB15928" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup contextRef="FI2015Q4" decimals="INF" id="Fact-992952631BFE165D8A08674C49BA6B82" unitRef="usd">0</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup>
	<us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup contextRef="FI2016Q4" decimals="INF" id="Fact-2553DB3D00CB44E2B146E2787AFBB8BB" unitRef="usd">0</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4" decimals="-3" id="Fact-FF0C913E6E67AC7E4D636424A7263656" unitRef="usd">44000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-DBDFE34DA2F7DE4DB0BC64249BFF2E3D" unitRef="usd">42000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-23B12AC60916BB946D0B642490B474B2" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-1BF01E9552767D13A8FC642485A93315" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4" decimals="-3" id="Fact-2092C08CA95727D080DEE2787BB21FAC" unitRef="usd">56000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-B53F0EE61A365D9B57D1E2787B167720" unitRef="usd">51000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-D1FF09C57A5FB415BD90E2787BA0C833" unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-47EE978C89CC4D9E73C4E2787B7FDEC5" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4" decimals="-3" id="Fact-C28C6A4BCBB0B61CD0256424A8C92E8F" unitRef="usd">49000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-439DC91704A6C04698E264249F599B4E" unitRef="usd">34000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-7F8E113A489276897E8E6424936A8F9C" unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-9D7F797D4EB0873AB278642488DEBB95" unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4" decimals="-3" id="Fact-93038AAE54AABB05C96FE2787BB32AB1" unitRef="usd">138000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-17B329979CDC88B00E03E2787B0D3883" unitRef="usd">127000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-AC295FA0DFAE4D704456E2787BF0FF3F" unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-9336D464B0F2550B589EE2787BE235FA" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2015Q4" decimals="-3" id="Fact-38878D6D9D7612D3DA066424A597DBEB" unitRef="usd">142882000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-AEAB3E2234B65478ABE76424997CF634" unitRef="usd">111473000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-CD883AA1230693EB9F7564248E13C603" unitRef="usd">22055000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-84DEA36D75A374FA042864248225DD66" unitRef="usd">9354000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2016Q4" decimals="-3" id="Fact-EBA7334BE0A3936AD91FE2787BA4C41F" unitRef="usd">200966000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-4765F2F751A6F4D905ACE2787B26FB8D" unitRef="usd">166376000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-8086B793AEFE1D68BF32E2787BD596EC" unitRef="usd">29764000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-7876AD76A2CDC7AF3824E2787B97F155" unitRef="usd">4826000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-D3D27CDAF5ACFE761849E2787BD42698" unitRef="usd">137928000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-DCBA81F3199D58B87CB1E2787BD1BD24" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-7F7684450FC802EBB80AE2787BDDD0EE" unitRef="usd">137928000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-18674717E70429BE55DFE2787BD4A7AB" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-C791E7063FF3F6411645BD0919A4CB7D" unitRef="usd">41202000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-369CAF9087F750684FCDBD9153CA97DD" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-D27211B2F2E605993697BD93CC4629CB" unitRef="usd">41202000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-CC0E090571F5407CEC21BD945060E0C5" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-2A0654132216C0AC0EA2BD0896F63690" unitRef="usd">9348000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-DDBCD092182ED3B72C94BD910C177B45" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-5614BE415D6AF5E65CF5BD9397D21428" unitRef="usd">9348000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-700C98933F030A52630DBD94179B860F" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-48150D1AD78F45794562E2787BB527C1" unitRef="usd">166300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-348FA7FF4A24CAD51CE2E2787BB020DF" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-4E5C485DCAC5AE458CD9E2787BA57279" unitRef="usd">166300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-19F452C3463F43FA1C43E2787BB2AEE8" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-8FECBD2F8510B3357A55E2787BA4E70E" unitRef="usd">29759000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-56B2BB65E9D3BB27CFD4E2787BC252F0" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-B6C5A530EA8D734CFDA5E2787BA92E42" unitRef="usd">29759000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-093829F743AF9E8914FCE2787BA54E52" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-88AE541133C89968B21FE2787BBF48DF" unitRef="usd">8826000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-5E34D7499CF0C5724D7DE2787BA79FAB" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-942ABFC46D1931963605E2787BB6C6C0" unitRef="usd">8826000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-79040EC89CDFC98E8F82E2787BA7C5A0" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-AD1D066ED3FEF0034E46E2787BCCD12E" unitRef="usd">142877000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-EF94340E32D2F043AB70E2787AF346CC" unitRef="usd">192898000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="FI2016Q4" decimals="-3" id="Fact-FB6B0B2B25B1D2F7EF2864277FF3F45D" unitRef="usd">7981000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2016Q4" decimals="-3" id="Fact-A8E7900F226515927AA464284991CB1B" unitRef="usd">7986000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="FI2016Q4" decimals="-3" id="Fact-59268D4B604FF0AED5866427086BE848" unitRef="usd">192985000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2016Q4" decimals="-3" id="Fact-936C61DCD00D47089FDE6427DF72BBB3" unitRef="usd">192898000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2015Q4" decimals="-3" id="Fact-538BB709ACEB5948487A6424AA8AE42B" unitRef="usd">142877000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-4EC93E2F7F29293F693F6424A28E7BD2" unitRef="usd">111481000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-6CF1832F8BDFE5825790642496ACF6E9" unitRef="usd">22047000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-D4AFEFDDC29A90C7D4A664248B926426" unitRef="usd">9349000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2016Q4" decimals="-3" id="Fact-4BEA38A3F9E8F2F0C35BE2787BA89424" unitRef="usd">200884000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-6A7FC0405642247B8404E2787BA90F91" unitRef="usd">166300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-FB8C358ACE14AFEAC608E2787C002881" unitRef="usd">29759000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-9F1C5BEFB8C74E20BDE5E2787BB63B61" unitRef="usd">4825000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-FE4EF04D0B4B90F0364F6266CB6E827F" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesNoncurrent>
	<us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-69DDDD6D3092A7722750626699E6D142" unitRef="usd">7986000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2013Q4" decimals="-3" id="Fact-7B2DCA4FDF3D73BEC2B9E2787B7899FC" unitRef="usd">116481000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-3" id="Fact-C3C1BCFAD11FC921A5B2E2787B3F0421" unitRef="usd">157591000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-3" id="Fact-26A32831B791A08D177CE2787B082A65" unitRef="usd">196172000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-3" id="Fact-6BB90934AF75064A4F40E2787B05453C" unitRef="usd">84098000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4" decimals="-5" id="Fact-1E3CEA270736843424F5BDF728306809" unitRef="usd">108000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-F7820C52666D4BF715BCE2787BDC5104" unitRef="usd">62353000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-64C663A054C07059952EE2787BD45E86" unitRef="usd">62353000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-ECAFCB6939B040BBC0C5E2787BDFB80F" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-5A24CA0A8A4AC12A309AE2787BD2EF9D" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4" decimals="-5" id="Fact-57804D26831DAA985BABE2787AFEB6D6" unitRef="usd">50800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-36CE5EF3C21150B07050E2787BA9AADB" unitRef="usd">46781000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-171AA3273FC924DE5A99E2787BA9ADE9" unitRef="usd">46781000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-CFD6D2B210CAB793C7B3E2787BC1F41F" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-218710D750C4B412C6C8E2787BAFA8F8" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2014Q4YTD" decimals="-3" id="Fact-688307CCC1C29588CCADE2787BB160EB" unitRef="usd">41110000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2015Q4YTD" decimals="-3" id="Fact-9A2C883F733BB02822A5E2787B85D431" unitRef="usd">38581000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2016Q4YTD" decimals="-3" id="Fact-B37F883D3286CB8F06A7E2787BB7C193" unitRef="usd">-112074000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2015Q4" decimals="INF" id="Fact-4B15383B14A7698A65BBE2787B35C5E8" unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-C978B3B4BA422E0E8B61E2787B1EEC36" unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2015Q4" decimals="INF" id="Fact-6C2EDFB8355145F24626E2787BA32F70" unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-27B23B0837C94B51CE31E2787B4696C0" unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2015Q4" decimals="INF" id="Fact-552F767DFC5CA16A3181E2787BC11739" unitRef="shares">34345754</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-E42AD2D826CB2E7E2850E2787B28A144" unitRef="shares">34870607</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2015Q4" decimals="-3" id="Fact-706BC705A3CE82A69A15E2787B579D18" unitRef="usd">343000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2016Q4" decimals="-3" id="Fact-00CF20569756C6984F4AE2787B0027F5" unitRef="usd">349000</us-gaap:CommonStockValue>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_BoehringerIngelheimMember" decimals="2" id="Fact-551E6F07AB1BEFA60921E2787B352E87" unitRef="number">0.29</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_GileadSciencesIncMember" decimals="2" id="Fact-3F049CDC3D99B09DE1D4E2787B2A54DF" unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_ServierMGA271Member" decimals="2" id="Fact-750C68FE89709C13D34BE2787B27225B" unitRef="number">0.36</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_TakedaMember" decimals="2" id="Fact-7169D1C1471CA113BE936C621F4A2D71" unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_EliLillyMember" decimals="2" id="Fact-D2F52E883551EEEE310963B870C83DA8" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_JanssenBiotechIncMember" decimals="2" id="Fact-7809641153F8A9F8F39163B870CE26DA" unitRef="number">0.39</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_ServierMGA271Member" decimals="2" id="Fact-53127F000C2CE1AD2E0F63B870CC3B15" unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_TakedaPharmaceuticalMember" decimals="2" id="Fact-C7DD2946B0B2DD35C71763B870C55219" unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_USGovernmentMember" decimals="2" id="Fact-27484C5D6888421D942B63B870C07475" unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_BoehringerIngelheimMember" decimals="2" id="Fact-C80E05C0F70B6C99DD9CE2787B29A221" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_JanssenBiotechIncMember" decimals="2" id="Fact-A51ED6FD1412859628466C5BAD14B0AE" unitRef="number">0.72</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_JanssenBiotechIncMember" decimals="2" id="Fact-D04B87DC4C0FBDC33945E2787B22FD85" unitRef="number">0.40</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_ServierMGA271Member" decimals="2" id="Fact-439779E5F9D1A746E43AE2787B49443F" unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_USGovernmentMember" decimals="2" id="Fact-6F40F32BF02C14CEDC34E2787B56FB4A" unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_JanssenBiotechIncMember" decimals="2" id="Fact-F51BD356D8B2D2CCEA68E2787B36A198" unitRef="number">0.85</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:CostsAndExpenses contextRef="FD2014Q4YTD" decimals="-3" id="Fact-3C62888374973E59302EE2787B1979B6" unitRef="usd">86112000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2015Q4YTD" decimals="-3" id="Fact-3707BA4E04614AE7DDF8E2787B1B4923" unitRef="usd">121036000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2F03D2668DE07B212EF9E2787B1F2554" unitRef="usd">151922000</us-gaap:CostsAndExpenses>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="INF" id="Fact-B7E62F17358C080FF8BE677B4445155E" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="INF" id="Fact-DB9033F84B46DDD24F89677B2B182597" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="INF" id="Fact-247B44C022E1F90C3F06E2787B257F9A" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxLiabilities contextRef="FI2015Q4" decimals="-3" id="Fact-DEA42250E5F3E63F6233E2787C0BCAF5" unitRef="usd">727000</us-gaap:DeferredIncomeTaxLiabilities>
	<us-gaap:DeferredIncomeTaxLiabilities contextRef="FI2016Q4" decimals="-3" id="Fact-088202749D5E46EF24CAE2787BF5047C" unitRef="usd">1406000</us-gaap:DeferredIncomeTaxLiabilities>
	<us-gaap:DeferredRentCredit contextRef="FI2015Q4" decimals="-5" id="Fact-AF58D7C97900CEEA3823E2787BC1DD0D" unitRef="usd">7300000</us-gaap:DeferredRentCredit>
	<us-gaap:DeferredRentCredit contextRef="FI2016Q4" decimals="-5" id="Fact-68FCF38CC287A01EE6B7E2787BC5E25D" unitRef="usd">6200000</us-gaap:DeferredRentCredit>
	<us-gaap:DeferredRentCreditCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-76EEE07A6DFFCC1CB3A6626C4D8DF589" unitRef="usd">914000</us-gaap:DeferredRentCreditCurrent>
	<us-gaap:DeferredRentCreditCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-ABE2845F2EE0FC46F9CC626C15AEE489" unitRef="usd">1319000</us-gaap:DeferredRentCreditCurrent>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-168A5E1AB237B4BCDDE9E2787AF692F1" unitRef="usd">6406000</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-5D891102B42B1919DCC3E2787BFFC04A" unitRef="usd">4867000</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DeferredRevenue contextRef="FI2015Q4_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember" decimals="INF" id="Fact-B92C9CAECC68DFE6F03371A81913F4CF" unitRef="usd">0</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2015Q4_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="-5" id="Fact-B1BEEFE6253939BC78386EDFCC33F6C1" unitRef="usd">2000000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2015Q4_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-C9D1E7335D0F5B896A13E2787BC481FD" unitRef="usd">14400000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2015Q4_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember" decimals="-5" id="Fact-20545E4E0491ABD2A70F7224CE6DD093" unitRef="usd">2100000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2016Q4_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember" decimals="INF" id="Fact-1B6E31E831BCB86C5DAFE2787B947496" unitRef="usd">0</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2016Q4_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="-5" id="Fact-24B2ED6E3BE04CDCBDC0E2787B192E0B" unitRef="usd">3200000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2016Q4_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-5392F36068AF70E097BFE2787BB6C0F1" unitRef="usd">11100000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2016Q4_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember" decimals="INF" id="Fact-D2695AE4B8DD87899522E2787B95A6D5" unitRef="usd">0</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-3A6AD84D17215C6284D5E2787BC3F701" unitRef="usd">5866000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2015Q4_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="-5" id="Fact-E7B8AD8A9DC940D265886EE00BF0B3C0" unitRef="usd">400000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2015Q4_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-4F8FCBD00378CF90CDCDE2787B13CEB4" unitRef="usd">3300000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2015Q4_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember" decimals="-5" id="Fact-9FC3869D5CD607DEE484E2787BEF7C14" unitRef="usd">2100000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-946674D5579C8CB9D25BE2787BBEE8C2" unitRef="usd">4261000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2016Q4_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="-5" id="Fact-92A54A0648F03A550EC3E2787AFE33EE" unitRef="usd">900000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2016Q4_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-4BF2A6805A5E70902CF9E2787B1DE3CB" unitRef="usd">3300000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-6CDE5C0F78FCB363D54FE2787B4E7451" unitRef="usd">12631000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2015Q4_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="-5" id="Fact-A0DCC122C40C72B309FF6EE043AFB8E3" unitRef="usd">1600000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2015Q4_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-3E92A5E6289ABC2504F1E2787B85C2E5" unitRef="usd">11100000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-7262E8BDC4CF48BE9441E2787BD1AC6A" unitRef="usd">10045000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2016Q4_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="-5" id="Fact-52DB82F38B00213EF274E2787B3F1323" unitRef="usd">2300000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2016Q4_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-4A5D1B871781C4185E12E2787B740B58" unitRef="usd">7800000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredTaxAssetsDeferredIncome contextRef="FI2015Q4" decimals="-3" id="Fact-E93868AA946C0A8DA2D6E2787BF39E8D" unitRef="usd">6632000</us-gaap:DeferredTaxAssetsDeferredIncome>
	<us-gaap:DeferredTaxAssetsDeferredIncome contextRef="FI2016Q4" decimals="-3" id="Fact-807CD6D431E3EC49A0A8E2787BFC014D" unitRef="usd">5098000</us-gaap:DeferredTaxAssetsDeferredIncome>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2015Q4" decimals="-3" id="Fact-CB3B3CE6F20144892A83E2787AC381C4" unitRef="usd">105126000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2016Q4" decimals="-3" id="Fact-968845A45EAFCB793B3CE2787B6A2254" unitRef="usd">130250000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="FI2015Q4" decimals="-3" id="Fact-DBE6847FF0CF3B0A9F3AE2787C0388F8" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
	<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="FI2016Q4" decimals="-3" id="Fact-5DF438BBD91242392A6DE2787BFDAD7D" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2015Q4" decimals="-3" id="Fact-0445C10343022F1CC949E2787C013725" unitRef="usd">727000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2016Q4" decimals="-3" id="Fact-1054545E12FC6C184B0FE2787BF42213" unitRef="usd">1406000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="FI2015Q4" decimals="-3" id="Fact-69541E275AC52ADB928BE2787C0AF9F0" unitRef="usd">57949000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="FI2016Q4" decimals="-3" id="Fact-7D737352FA9B296F6895E2787B694988" unitRef="usd">75377000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="FI2015Q4" decimals="-3" id="Fact-A2290906A9FCA023FCBDE2787C03FB5C" unitRef="usd">3907000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="FI2016Q4" decimals="-3" id="Fact-77B205416BFAD74664F9E2787BFD5881" unitRef="usd">6583000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" decimals="-5" id="Fact-0578D49EDAB39C896180E2787B26B4DF" unitRef="usd">215400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2015Q4" decimals="-3" id="Fact-A45D8BEF5C8F52EB2B30E2787B7212A6" unitRef="usd">2532000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2016Q4" decimals="-3" id="Fact-B9D727D37802B38D5AB3E2787B6761F0" unitRef="usd">5085000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="FI2015Q4" decimals="-3" id="Fact-7EAF4832C0A8A9312E79E2787BFE5960" unitRef="usd">1597000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
	<us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="FI2016Q4" decimals="-3" id="Fact-4BE1128BACD3DDAA2A78E2787BFB0B1E" unitRef="usd">2926000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther contextRef="FI2015Q4" decimals="-3" id="Fact-5AB2B8015A7EDC0C5EDDE2787BFF0567" unitRef="usd">19284000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther contextRef="FI2016Q4" decimals="-3" id="Fact-10D86385CF4B26812AD5E2787BFEB2F9" unitRef="usd">19855000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="FI2015Q4" decimals="-3" id="Fact-2347AC7245204A7103D3E2787B656228" unitRef="usd">10278000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="FI2016Q4" decimals="-3" id="Fact-C9AE14A6432D92A6952FE2787BFA0692" unitRef="usd">12829000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="FI2015Q4" decimals="-3" id="Fact-65C63929E237E3C978CCE2787BFC5445" unitRef="usd">2947000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="FI2016Q4" decimals="-3" id="Fact-2DCE6D0B924AD00821A5E2787B6B107D" unitRef="usd">2497000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2015Q4" decimals="-3" id="Fact-DFFD554ECB4F9090DA56E2787C04EFD4" unitRef="usd">104399000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2016Q4" decimals="-3" id="Fact-7F1EC0B87B180C144692E2787B6AEC6E" unitRef="usd">128844000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="FI2015Q4" decimals="-3" id="Fact-7F9DA6A115AA7231F3B8E2787BFAD2C4" unitRef="usd">727000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
	<us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="FI2016Q4" decimals="-3" id="Fact-E25C9A3229A579452361E2787B727909" unitRef="usd">1406000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
	<us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="FD2014Q4YTD" decimals="-5" id="Fact-B8957314C9B608454A29E2787BA0E203" unitRef="usd">300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
	<us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="FD2015Q4YTD" decimals="-5" id="Fact-7A9F62921155526420D4E2787B9720F7" unitRef="usd">400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
	<us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="FD2016Q4YTD" decimals="-5" id="Fact-539C181443B8A0534A5CE2787B97017D" unitRef="usd">1000000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
	<us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent contextRef="FD2012Q4YTD" decimals="INF" id="Fact-B508586157A84418C691E2787B845D64" unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
	<us-gaap:Depreciation contextRef="FD2014Q4YTD" decimals="-5" id="Fact-E3529348A045902EA830E2787B73CAD1" unitRef="usd">1800000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2015Q4YTD" decimals="-5" id="Fact-EB7DF03D3641D1B6543AE2787B757ED4" unitRef="usd">3200000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2016Q4YTD" decimals="-5" id="Fact-15E670BE6B791927C139E2787B730ABD" unitRef="usd">6800000</us-gaap:Depreciation>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2014Q4YTD" decimals="-3" id="Fact-B7892E037E344913B730E2787B06A665" unitRef="usd">1822000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2015Q4YTD" decimals="-3" id="Fact-61FE8F7B2ACFB56D9BA9E2787BDC3919" unitRef="usd">2863000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2016Q4YTD" decimals="-3" id="Fact-1F0413C7753846340F03E2787BF02983" unitRef="usd">7608000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q1QTD" decimals="2" id="Fact-60ADDA6763CDAE7915C5E2787B3CC11E" unitRef="usdPerShare">1.53</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q2QTD" decimals="2" id="Fact-A8814FF4AC291AC187A4E2787B485EE8" unitRef="usdPerShare">-0.71</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q3QTD" decimals="2" id="Fact-690B112DD160FC801867E2787B213CAE" unitRef="usdPerShare">-0.46</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q4QTD" decimals="2" id="Fact-7421EBEA2D6F6D0EF1D5E2787B237410" unitRef="usdPerShare">-0.83</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q1QTD" decimals="2" id="Fact-6EEA61B2CB3CA9918E8DE2787C04F6A2" unitRef="usdPerShare">-0.88</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q2QTD" decimals="2" id="Fact-F177EDA05922C2CF5C93E2787B2595C2" unitRef="usdPerShare">1.17</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q3QTD" decimals="2" id="Fact-DD5C41CB5BAE3BFA9452E2787B259618" unitRef="usdPerShare">-0.97</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q4QTD" decimals="2" id="Fact-7B91BD8829AC2FB30FEDE2787C00A511" unitRef="usdPerShare">-1.00</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2014Q4YTD" decimals="2" id="Fact-412301C161494F8BF4C4669CD5AA2826" unitRef="usdPerShare">-1.40</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2015Q4YTD" decimals="2" id="Fact-7C10582E849A2F9510B8669CD30662AC" unitRef="usdPerShare">-0.63</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q4YTD" decimals="2" id="Fact-DC562C757E2F876C5DBD669CFE29B837" unitRef="usdPerShare">-1.69</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2015Q1QTD" decimals="2" id="Fact-C993F7F40DF12CE6791B6485D8445551" unitRef="usdPerShare">1.42</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2015Q2QTD" decimals="2" id="Fact-55590E597119F56312416485D9D7C41A" unitRef="usdPerShare">-0.71</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2015Q3QTD" decimals="2" id="Fact-F25F5A8A86A4CE960BAA6485DB785657" unitRef="usdPerShare">-0.46</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2015Q4QTD" decimals="2" id="Fact-38EB8AAF85772905FDAC6485DD1142E4" unitRef="usdPerShare">-0.83</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q1QTD" decimals="2" id="Fact-C3250C30E84BD8E22E0CE2787B2457F4" unitRef="usdPerShare">-0.88</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q2QTD" decimals="2" id="Fact-EEBA1F13F18FF3822186E2787B855D48" unitRef="usdPerShare">1.12</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q3QTD" decimals="2" id="Fact-35E02F8AC042C3145437E2787B46D4E4" unitRef="usdPerShare">-0.97</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q4QTD" decimals="2" id="Fact-B8BD4D2605642D89F3D3E2787B213D12" unitRef="usdPerShare">-1.00</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2016Q4" decimals="-5" id="Fact-E46FA0F3EE6843BB7E5AE2787AD22A14" unitRef="usd">22200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2016Q4YTD" id="Fact-46BA31CC2896D5C5CD49E2787B08AE8F">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2014Q4YTD" decimals="-3" id="Fact-62B8CF7886FA435D8045E2787BD1F0C2" unitRef="usd">15926000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-E510AB0ABD6159798C91E2787BCF4C70" unitRef="usd">22765000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-1DB285DEAFCC76CFF40FE2787BD1700B" unitRef="usd">29831000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset contextRef="FI2015Q4" decimals="INF" id="Fact-E791FD376D35B161E1BA674BF417B177" unitRef="usd">0</us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset>
	<us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset contextRef="FI2016Q4" decimals="INF" id="Fact-2FABBD3D78A02833C702E2787B06D421" unitRef="usd">0</us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2014Q4YTD" decimals="2" id="Fact-08A550DFCEDA74CCF155E2787B224DA3" unitRef="usdPerShare">-1.40</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2015Q4YTD" decimals="2" id="Fact-212A5FF00EF9FE2FED91E2787BFD0B93" unitRef="usdPerShare">-0.63</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2016Q4YTD" decimals="2" id="Fact-BA5DFD2518485E72570BE2787B21029D" unitRef="usdPerShare">-1.69</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-3" id="Fact-250FF1CCAD2263938F0AE2787BA14EAB" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-EBADB687FF13473E13F4E2787C002D49" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-EA12ED7119E185F464FDE2787BB332AE" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2014Q4YTD" decimals="-3" id="Fact-695E96A652B3D05B31A6E2787BAAE44D" unitRef="usd">14920000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2015Q4YTD" decimals="-3" id="Fact-6769755AB91B318402D4E2787BFF3836" unitRef="usd">10103000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2016Q4YTD" decimals="-3" id="Fact-1B0712865FE1CC775BDAE2787BFE52EA" unitRef="usd">24444000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationDeductions contextRef="FD2014Q4YTD" decimals="-3" id="Fact-566564150C2F7E6F1EE9E2787B8309D8" unitRef="usd">379000</us-gaap:IncomeTaxReconciliationDeductions>
	<us-gaap:IncomeTaxReconciliationDeductions contextRef="FD2015Q4YTD" decimals="-3" id="Fact-1FD9663A4B9A5A8D0D68E2787C0A2879" unitRef="usd">0</us-gaap:IncomeTaxReconciliationDeductions>
	<us-gaap:IncomeTaxReconciliationDeductions contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D658E701215B0996CFC2E2787BA4F321" unitRef="usd">0</us-gaap:IncomeTaxReconciliationDeductions>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2014Q4YTD" decimals="-3" id="Fact-E27685EC1E77610539C0E2787BB4B07E" unitRef="usd">-13410000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2015Q4YTD" decimals="-3" id="Fact-B247CEC6CD7FA96BA333E2787B9ACFC5" unitRef="usd">-7049000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2016Q4YTD" decimals="-3" id="Fact-10FC4C5A22D4AC8CC947E2787C02D46A" unitRef="usd">-20489000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="FD2014Q4YTD" decimals="-3" id="Fact-E277B7CA632A5D737CA0E2787BA062EE" unitRef="usd">756000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="FD2015Q4YTD" decimals="-3" id="Fact-639694DED43068F6EE4DE2787B782574" unitRef="usd">1102000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="FD2016Q4YTD" decimals="-3" id="Fact-93BF532B3CE726060310E2787B806BA0" unitRef="usd">1997000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="FD2014Q4YTD" decimals="-3" id="Fact-6586E3ABD492E3B7E1C4E2787BA8F807" unitRef="usd">-382000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
	<us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="FD2015Q4YTD" decimals="-3" id="Fact-25E9539F3AF7FAFF057FE2787B6B80E8" unitRef="usd">-25000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
	<us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="FD2016Q4YTD" decimals="-3" id="Fact-F50C60EF112FAD8E6EC3E2787B745359" unitRef="usd">145000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="FD2014Q4YTD" decimals="-3" id="Fact-C8584F66CFB2C0808F3BE2787BB42D4B" unitRef="usd">-1608000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="FD2015Q4YTD" decimals="-3" id="Fact-CA1DF6147EA376FDC6C7E2787B94F4D6" unitRef="usd">-897000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="FD2016Q4YTD" decimals="-3" id="Fact-A1A01E7FE61D850BED30E2787BAA25AA" unitRef="usd">-3116000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationTaxCreditsOther contextRef="FD2014Q4YTD" decimals="-3" id="Fact-704F930247F62390F6CBE2787B6AB635" unitRef="usd">139000</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
	<us-gaap:IncomeTaxReconciliationTaxCreditsOther contextRef="FD2015Q4YTD" decimals="-3" id="Fact-9C3967EC647FC4C6CDACE2787B69E7C8" unitRef="usd">106000</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
	<us-gaap:IncomeTaxReconciliationTaxCreditsOther contextRef="FD2016Q4YTD" decimals="-3" id="Fact-7E3CEB4D0CAB7C6B775CE2787B6AD4ED" unitRef="usd">571000</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
	<us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="FD2014Q4YTD" decimals="-3" id="Fact-7CF588631ED75EC9A64AE2787B81D3C5" unitRef="usd">2228000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
	<us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="FD2015Q4YTD" decimals="-3" id="Fact-73A7DE982828977C2BE1E2787B73FAB8" unitRef="usd">3296000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
	<us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="FD2016Q4YTD" decimals="-3" id="Fact-67D7E366CA5B8FD00EADE2787BA33668" unitRef="usd">2551000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2014Q4YTD" decimals="-3" id="Fact-069F3901E05FF45E92F2E2787B753F73" unitRef="usd">-1500000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F50739E9E92114AF3A14E2787BB0324A" unitRef="usd">-163000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D9B854E098AE2F1B7635E2787C035323" unitRef="usd">2232000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2014Q4YTD" decimals="-3" id="Fact-C07CD8854A8E79E2C6A8E2787BA4F4C9" unitRef="usd">931000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A6CF23693EBF0DF52E59E2787AF5CDBC" unitRef="usd">-1711000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2016Q4YTD" decimals="-3" id="Fact-8D522B25CECFFAE08BA6E2787B678516" unitRef="usd">1540000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-93E7CCF4D6CCFC2CB509E2787BB408D8" unitRef="usd">4346000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-D1A90669C851598C9DE8E2787AEE69CF" unitRef="usd">3545000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6F237766599D5615F7F2E2787AFF308F" unitRef="usd">4659000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2014Q4YTD" decimals="-3" id="Fact-6B34C57B1FFAB2823883E2787B908251" unitRef="usd">3317000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-3670AAC69418A1AB1F3AE2787B499301" unitRef="usd">-12223000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-1C1554B80F10E9B45ECFE2787B3DE0AF" unitRef="usd">-4191000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-1C6DEBCAD7D8B872C9CFE2787B3E5B10" unitRef="usd">1242000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
	<us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-91ADFE06027E0BE66271E2787B05005C" unitRef="usd">-878000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
	<us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-7E566879F65281C6676DE2787AE39902" unitRef="usd">-727000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2014Q4YTD" decimals="-3" id="Fact-9BFC43F1F115357C7552E2787BDD40A8" unitRef="usd">1179000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2015Q4YTD" decimals="-3" id="Fact-21BDEC7E609CD47E984DE2787B72C5C0" unitRef="usd">285000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2016Q4YTD" decimals="-3" id="Fact-7CA7041E890DF0DD5C2CE2787AE35370" unitRef="usd">-276000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="FD2014Q4YTD" decimals="-3" id="Fact-291C306154C11839F5D3E2787B814E8D" unitRef="usd">3239000</us-gaap:IncreaseDecreaseInPrepaidExpense>
	<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-613FA8B112CAA0AC787BE2787BE53BC2" unitRef="usd">-2405000</us-gaap:IncreaseDecreaseInPrepaidExpense>
	<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-3D911CB05D576BDB6FC9E2787B4EFFCF" unitRef="usd">1677000</us-gaap:IncreaseDecreaseInPrepaidExpense>
	<us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-7A4CCEE20CAECF5C1F3DE2787B64C90F" unitRef="usd">-105000</us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities>
	<us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C8494FF6AF5ACFB07BF9E2787BFDB2AF" unitRef="usd">-300000</us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities>
	<us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-317948214CA459D08622E2787B5DF6C7" unitRef="usd">0</us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities>
	<us-gaap:IncreaseDecreaseInRestructuringReserve contextRef="FD2014Q4YTD" decimals="-3" id="Fact-DFD33317904A3A5A1536E2787B3643AF" unitRef="usd">-1439000</us-gaap:IncreaseDecreaseInRestructuringReserve>
	<us-gaap:IncreaseDecreaseInRestructuringReserve contextRef="FD2015Q4YTD" decimals="-3" id="Fact-9D18E0D52366D684CAADE2787B1661BD" unitRef="usd">-3293000</us-gaap:IncreaseDecreaseInRestructuringReserve>
	<us-gaap:IncreaseDecreaseInRestructuringReserve contextRef="FD2016Q4YTD" decimals="-3" id="Fact-C6D4338FFA9CB8AF508EE2787B376C0F" unitRef="usd">-2822000</us-gaap:IncreaseDecreaseInRestructuringReserve>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2014Q4YTD" decimals="0" id="Fact-44657E5C66B85625703DE2787AF362AE" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2015Q4YTD" decimals="0" id="Fact-B134BD2FCA7D3F5D62B5E2787AF255C0" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q4YTD" decimals="0" id="Fact-EEA9820A10E8DC016716E2787AED8293" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="FD2016Q4YTD_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_mgnx_MixedUseOfficeLaboratoryAndManufacturingSpaceMember" id="Fact-185202E207B9795A8498E2787B66B21B">P7Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
	<us-gaap:Liabilities contextRef="FI2015Q4" decimals="-3" id="Fact-58DE5CA2135AC4D5BDFCE2787B5A2219" unitRef="usd">45932000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2016Q4" decimals="-3" id="Fact-565D9B00CEB774FCD32EE2787AE6ACE9" unitRef="usd">42512000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2015Q4" decimals="-3" id="Fact-95CCEF948A67B02B2031E2787B0F8E01" unitRef="usd">359269000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-9A515C22A6B562DA34F0E2787AEB6601" unitRef="usd">311263000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-A67580793DC12086755CE2787AEC2DAE" unitRef="usd">24202000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-5D97FB8A17B8B0771E29E2787AE5EFEA" unitRef="usd">27302000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2014Q4YTD" decimals="-3" id="Fact-7F46F3B49A91593F59CCE2787B17AE7A" unitRef="usd">47264000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-B0351AEA7D92CFC3699CE2787B390543" unitRef="usd">99368000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-0A97C9EAB024FC01CB2DE2787BEE91A6" unitRef="usd">86582000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember" decimals="-5" id="Fact-B74EAED636B99AABD09AE2787B0E1111" unitRef="usd">13700000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="-5" id="Fact-0A3D0FC6282D126C0AB3E2787AE1950F" unitRef="usd">1700000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-3C1F487C6B161D5EF5E2E2787B3AECA8" unitRef="usd">16700000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember" decimals="-5" id="Fact-A506A0BFB97B1931934A6D489E51876A" unitRef="usd">5000000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember" decimals="-5" id="Fact-2915F69342730350712F647A55442470" unitRef="usd">3000000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember" decimals="-5" id="Fact-815D6B0171147F8EFA84E2787BB837EC" unitRef="usd">12500000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="-5" id="Fact-13E269EAA87D00862409E2787B4F18CB" unitRef="usd">500000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="-5" id="Fact-ECB95A06E53E48BB0F2A6E906593828D" unitRef="usd">72300000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="-5" id="Fact-03B187CA1E8A1343C1F36EE0847F498B" unitRef="usd">200000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-8BA5CE3409ECBFC1B3B9E2787B1B4D18" unitRef="usd">3500000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember" decimals="-5" id="Fact-576C71D3FAA979FD99E5E2787B98F389" unitRef="usd">1300000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember" decimals="-5" id="Fact-F207A5A77A77A3158911E2787B078A60" unitRef="usd">8000000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember" decimals="INF" id="Fact-76A60B9B9F014C35CDAEE2787B99483B" unitRef="usd">0</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="-5" id="Fact-217A47EB1C94C99D76B8E2787B01B75F" unitRef="usd">800000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="-5" id="Fact-AEA30B6B2A4A2E0A8551E2787B774C96" unitRef="usd">2000000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD015AgreementMember" decimals="-5" id="Fact-CE2078CB91C24E1CBCFD6E93F7BB8B36" unitRef="usd">75800000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="-5" id="Fact-2BB004C2544047C775CAE2787B19245C" unitRef="usd">5100000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-2FBEA4FB566ACFAFD9ADE2787BA6C002" unitRef="usd">3300000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember" decimals="-5" id="Fact-90204B64A4537A791BF8E2787B0BCA1A" unitRef="usd">2100000</us-gaap:LicensesRevenue>
	<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="FD2014Q4YTD" decimals="-3" id="Fact-F315482ACC2D3E638CEFE2787B785717" unitRef="usd">77441000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="FD2015Q4YTD" decimals="-3" id="Fact-E9F24388DF103D460088E2787C030EDE" unitRef="usd">204349000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="FD2016Q4YTD" decimals="-3" id="Fact-BCFDB5498D18E3B6B623E2787BCECF8A" unitRef="usd">1854000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="FD2014Q4YTD" decimals="-3" id="Fact-1FF8E0731CB09DF54B04E2787B236360" unitRef="usd">-3572000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="FD2015Q4YTD" decimals="-3" id="Fact-16B9B7F340160F74FE87E2787ADA1C6E" unitRef="usd">-152107000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="FD2016Q4YTD" decimals="-3" id="Fact-4FA36DF3421AE227AB6CE2787B6B9476" unitRef="usd">-70249000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2014Q4YTD" decimals="-3" id="Fact-27A1DDFF6EE07C3CE28DE2787B16385F" unitRef="usd">-32759000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2015Q4YTD" decimals="-3" id="Fact-BD2A0E3EC15C75FB4FA6E2787B1E173F" unitRef="usd">-13661000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6D24E8722C8355B1B7CEE2787B11B01F" unitRef="usd">-43679000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4YTD" decimals="-3" id="Fact-5056DCC21FD4EAE40D71E2787BCDDB89" unitRef="usd">-38313000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-56D54F90F8E4D493AF0DE2787B0DC28F" unitRef="usd">-38313000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q1QTD" decimals="-3" id="Fact-477A0F90B782333E22E0E2787B361D1F" unitRef="usd">45129000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q2QTD" decimals="-3" id="Fact-23744C2EA7F68F55ECAFE2787B22DBF1" unitRef="usd">-21376000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q3QTD" decimals="-3" id="Fact-8302A4B973649641CC91E2787B1F41BC" unitRef="usd">-15442000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4QTD" decimals="-3" id="Fact-C070A7FD0D74BF587E8DE2787B651F65" unitRef="usd">-28451000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-11E5F5FB87CA8CA5E3FBE2787BDE3CD4" unitRef="usd">-20140000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-9C2BC1A71F74B42B1490E2787BD535C4" unitRef="usd">-20140000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q1QTD" decimals="-3" id="Fact-5C1326B540E441B3DE54E2787B1A7E6E" unitRef="usd">-30363000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q2QTD" decimals="-3" id="Fact-A5446712E4E45C1ECD3FE2787B00166E" unitRef="usd">40464000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q3QTD" decimals="-3" id="Fact-CEAFA79BA9B3AB3197DCE2787B3E4BB4" unitRef="usd">-33846000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4QTD" decimals="-3" id="Fact-C0769259AC621F586A0DE2787B03EDBB" unitRef="usd">-34783000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD" decimals="-3" id="Fact-05A98CA4109987EE3B91E2787B1FDEB7" unitRef="usd">-58528000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-A57FBEC6F20EE7A816ECE2787B108D26" unitRef="usd">-58528000</us-gaap:NetIncomeLoss>
	<us-gaap:NumberOfOperatingSegments contextRef="FD2016Q4YTD" decimals="INF" id="Fact-99311A0E3E4631FB5FDEE2787B0403BF" unitRef="U011">1</us-gaap:NumberOfOperatingSegments>
	<us-gaap:OperatingIncomeLoss contextRef="FD2014Q4YTD" decimals="-3" id="Fact-1630E465AB654CA97E3FE2787BE239BC" unitRef="usd">-38315000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-CB644C080282A1481A19E2787C0A5631" unitRef="usd">-20182000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q4YTD" decimals="-3" id="Fact-9CCEE2F424348049885EE2787BE3E269" unitRef="usd">-60042000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2016Q4" decimals="-3" id="Fact-4AFEAB626278F616A2B0E2787B816016" unitRef="usd">21679000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2016Q4_us-gaap_BusinessAcquisitionAxis_mgnx_RavenBiotechnologiesIncMember" decimals="-3" id="Fact-A559A56C507922868D58E2787B645AD3" unitRef="usd">1891000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-4AA79614B8ED91690B84E2787B7803FA" unitRef="usd">6314000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="FI2016Q4_us-gaap_BusinessAcquisitionAxis_mgnx_RavenBiotechnologiesIncMember" decimals="-3" id="Fact-0FAAF86A42D01AAAEFCAE2787B63F2F8" unitRef="usd">1593000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals contextRef="FI2016Q4" decimals="-5" id="Fact-4A196517F4C3975F570D6E8A10919CAA" unitRef="usd">900000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals contextRef="I2016Q2May31_us-gaap_BusinessAcquisitionAxis_mgnx_RavenBiotechnologiesIncMember" decimals="-5" id="Fact-71A1C11B78E0733143F66E61E73E5C96" unitRef="usd">1300000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="FI2016Q4" decimals="-3" id="Fact-C9223F825F6A814C9971E2787B9A4960" unitRef="usd">2574000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2016Q4" decimals="-3" id="Fact-BA43E4E8E678122DAD09E2787B6ABC76" unitRef="usd">2142000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2016Q4" decimals="-3" id="Fact-A9D18CCAACD8386AFF4FE2787B8F7A8C" unitRef="usd">3803000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2016Q4" decimals="-3" id="Fact-E3B9FD2DCEAD84585411E2787B1F07E4" unitRef="usd">4210000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2016Q4_us-gaap_BusinessAcquisitionAxis_mgnx_RavenBiotechnologiesIncMember" decimals="-3" id="Fact-60CBA1D462E77C3DC22DE2787B5B4960" unitRef="usd">298000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="FI2016Q4" decimals="-3" id="Fact-B155D4236C486D201F6DE2787BB4EF7D" unitRef="usd">2636000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2014Q4YTD" decimals="-5" id="Fact-A400648994E04C3C2B63E2787B686B2E" unitRef="usd">2000000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2015Q4YTD" decimals="-5" id="Fact-34352F017CED82CC5AE6E2787B599EEB" unitRef="usd">900000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2016Q4YTD" decimals="-5" id="Fact-430DDC5F4E0CA53A5F97E2787B5572BA" unitRef="usd">3000000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OtherAssets contextRef="FI2015Q4" decimals="-3" id="Fact-EA71B6576A8505FA49DDE2787AFA3A52" unitRef="usd">305000</us-gaap:OtherAssets>
	<us-gaap:OtherAssets contextRef="FI2016Q4" decimals="-3" id="Fact-00B596B27876BB63DAB1E2787B28671E" unitRef="usd">704000</us-gaap:OtherAssets>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-1A3BD1611F91690C2A7FE2787B591022" unitRef="usd">2044000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-4B775BE8AB6CD7A35A03E2787B477A6D" unitRef="usd">1369000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2014Q4YTD" decimals="-3" id="Fact-B35EA6FE49BC48DF0C27E2787BE13034" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A82F81290C296F19A09CE2787BEF82EC" unitRef="usd">-5000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2016Q4YTD" decimals="-3" id="Fact-5FBB4ED46F45C6F99D2EE2787C045162" unitRef="usd">-77000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2014Q4YTD" decimals="-3" id="Fact-29851DC1F252B10D5267E2787BCFBF57" unitRef="usd">-38313000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2015Q4YTD" decimals="-3" id="Fact-2F0D7F592292272C4886E2787B1B9356" unitRef="usd">-20145000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2016Q4YTD" decimals="-3" id="Fact-9FEC3140F3498D8143F8E2787B1DF5D7" unitRef="usd">-58605000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-BA861EBFDC8BC482D563E2787B0A4975" unitRef="usd">727000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-23EB2A9C7BD1309E0258E2787BD0798C" unitRef="usd">0</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2014Q4YTD" decimals="-3" id="Fact-19C68BCBBCB6799C9DF8E2787C026088" unitRef="usd">2000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-EEC4928B4C2DE7874366E2787BCF5A90" unitRef="usd">42000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2F7C854A380F7EEF021CE2787B14FF72" unitRef="usd">1514000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities contextRef="FD2015Q4YTD" decimals="INF" id="Fact-9EF0277117D235FE544067448FBD7245" unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
	<us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities contextRef="FD2016Q4YTD" decimals="INF" id="Fact-F3045C7C471E28D44BA1BDCC1F6C467D" unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
	<us-gaap:PaymentsForProceedsFromTenantAllowance contextRef="FD2016Q4YTD" decimals="-5" id="Fact-73F49CEF26323A6575FDE2787B649EBB" unitRef="usd">-5100000</us-gaap:PaymentsForProceedsFromTenantAllowance>
	<us-gaap:PaymentsForRestructuring contextRef="FD2015Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-3" id="Fact-1D8B7CDA15FF096EB679E2787BEAD96D" unitRef="usd">3293000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsForRestructuring contextRef="FD2016Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-3" id="Fact-526325495D3736BA1AFEE2787BE1BBF0" unitRef="usd">2822000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2014Q4YTD" decimals="-3" id="Fact-4ECDAFE08E87DE697593E2787BE4AC8A" unitRef="usd">19000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2015Q4YTD" decimals="-3" id="Fact-7B62B5C88EE65E514B2EE2787B4D0D5B" unitRef="usd">29000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2016Q4YTD" decimals="-3" id="Fact-17D391213D38F5677B4EE2787BC58873" unitRef="usd">39000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="FD2014Q4YTD" decimals="-3" id="Fact-0C76B6235EBD02B55213E2787BED5A08" unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="FD2015Q4YTD" decimals="-3" id="Fact-5787A13D4C6C5F362259E2787B1DE1E4" unitRef="usd">142910000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="FD2016Q4YTD" decimals="-3" id="Fact-9217FA9BF30A3BC1A4EAE2787B4FF2D7" unitRef="usd">347762000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2014Q4YTD" decimals="-3" id="Fact-E98B5E18CDE98376B7CDE2787B59A336" unitRef="usd">3572000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2015Q4YTD" decimals="-3" id="Fact-638D57D46469BCF21D2FE2787B586804" unitRef="usd">9197000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6B682CD0FA2EEC7D32BCE2787BE31477" unitRef="usd">11381000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgnx_UndesignatedPreferredStockMember" decimals="INF" id="Fact-F81A5AF4EA92000ABEA2E2787BD2EBDA" unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgnx_UndesignatedPreferredStockMember" decimals="INF" id="Fact-0C476A7E536524BEE85AE2787B4EB013" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_mgnx_UndesignatedPreferredStockMember" decimals="INF" id="Fact-A2251CB5227F2C54E286E2787BA64790" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgnx_UndesignatedPreferredStockMember" decimals="INF" id="Fact-E66B9E393707F50766F1E2787B4F48B2" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_mgnx_UndesignatedPreferredStockMember" decimals="INF" id="Fact-E13F1502F1F4107A7BCFE2787BB32135" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgnx_UndesignatedPreferredStockMember" decimals="INF" id="Fact-FE178B10D18D02679530E2787BB29AAB" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PrepaidExpenseCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-5310089FE7F2E94EABA4E2787B060A52" unitRef="usd">1806000</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:PrepaidExpenseCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-2BE186ED826D08BCC830E2787AC6C290" unitRef="usd">3483000</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2014Q4YTD" decimals="-3" id="Fact-E5B4853D89AA327E51ABE2787B5AD628" unitRef="usd">76716000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2015Q4YTD" decimals="-3" id="Fact-7B67D48D5F87FA94585CE2787B7352B2" unitRef="usd">203467000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2016Q4YTD" decimals="-3" id="Fact-FF63048A78AF64346E2AE2787BFD4556" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="D2014Q1Feb1-Feb28" decimals="-5" id="Fact-90771CC94402960886BAE2787BE099F1" unitRef="usd">76700000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="D2015Q3Jul1-Jul31" decimals="-5" id="Fact-5C0CFA3AAA6417E8C975E2787BCFF769" unitRef="usd">141000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-54BEBE40FD959F340E1E63F8D67E1903" unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-CC3573A143868B658C3563F8C8279537" unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-888C101A14CD911A214C63F87AB3233B" unitRef="usd">288894000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2014Q4YTD" decimals="-3" id="Fact-BF0DADBE1D791ECBC022E2787AF799A1" unitRef="usd">744000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2014Q4YTD" decimals="-5" id="Fact-DA4442BFCDF0C19C1BE8E2787AE4799B" unitRef="usd">700000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2015Q4YTD" decimals="-3" id="Fact-E3B8175CA4E78C500D3EE2787B649A9B" unitRef="usd">911000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2015Q4YTD" decimals="-5" id="Fact-CF327E6D460CF5DE62C8E2787AD6F569" unitRef="usd">900000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2016Q4YTD" decimals="-5" id="Fact-4911BF7B0AE632AB7A5AE2787AF478FB" unitRef="usd">1900000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2016Q4YTD" decimals="-3" id="Fact-C7FC7B533C4A1F6DD390E2787BA8D5C1" unitRef="usd">1893000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" id="Fact-ED53BDBF9AE85C456EB2E2787ADA84B6">Shorter of lease term or useful life</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4" decimals="-3" id="Fact-338A04868C49D766A03AE2787BB272C4" unitRef="usd">35031000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mgnx_FurnitureAndOfficeEquipmentMember" decimals="-3" id="Fact-E26DF981BCA1344EE8A8E2787B733226" unitRef="usd">919000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" decimals="-3" id="Fact-CADAAA807B24690BA3C0E2787B4A6232" unitRef="usd">3069000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" decimals="-3" id="Fact-0FB2C7141688EDE3E578E2787B682A2E" unitRef="usd">17306000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-3E5A1161003E3D46A1F7E2787BDF6731" unitRef="usd">11936000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" decimals="-3" id="Fact-753F3387AA9C10387234E2787AC926CB" unitRef="usd">1801000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4" decimals="-3" id="Fact-5AFCD28550C79D8C03FBE2787B999D4C" unitRef="usd">43784000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mgnx_FurnitureAndOfficeEquipmentMember" decimals="-3" id="Fact-295518CB2A10FA795293E2787BF3762F" unitRef="usd">897000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" decimals="-3" id="Fact-ED227C00F5CDB388B987E2787BCEB314" unitRef="usd">2520000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" decimals="-3" id="Fact-297694039AEE6443D1B5E2787C01D892" unitRef="usd">20208000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-6ED74147E581B53C9859E2787B791DC1" unitRef="usd">17807000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" decimals="-3" id="Fact-B33E5B42E1789274060AE2787B656271" unitRef="usd">2352000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2015Q4" decimals="-3" id="Fact-8EEEEAD651A8917E352AE2787BC226C7" unitRef="usd">14841000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2016Q4" decimals="-3" id="Fact-FD872E942A38D4BC5620E2787B593A14" unitRef="usd">17961000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mgnx_LaboratoryAndOfficeEquipmentMember" id="Fact-9CCEF8F7BA63F12F9635E2787ADD775F">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" id="Fact-ADAB4D381B41E4659D3BE2787ADC2A33">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" id="Fact-736760FF682BC3803189E2787ADD6487">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" id="Fact-A99B0EBA4A96B8B09BF2E2787ADDD16F">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2014Q4YTD" decimals="-3" id="Fact-667239FF90D1313F26F5E2787BF220D8" unitRef="usd">70186000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-1EEDCB6506966BB78D88E2787BDF99C2" unitRef="usd">98271000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-49A674C8262F0AF27940E2787C021801" unitRef="usd">122091000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RestructuringReserve contextRef="FI2014Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-3" id="Fact-34197C0B5DE44EA3B6E6E2787BE2843E" unitRef="usd">8006000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2015Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-3" id="Fact-F03DFCC3D471AB0A893AE2787BE46592" unitRef="usd">4713000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-3" id="Fact-084FE0AC95A3CAA606CFE2787BEB39B3" unitRef="usd">1891000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserveCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-A338BC4FF7129A193BD6E2787AEE40C2" unitRef="usd">2020000</us-gaap:RestructuringReserveCurrent>
	<us-gaap:RestructuringReserveCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-D123D999272F564D2452E2787AD04976" unitRef="usd">1593000</us-gaap:RestructuringReserveCurrent>
	<us-gaap:RestructuringReserveNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-971375266BF8820351C6E2787BCFDAC9" unitRef="usd">2693000</us-gaap:RestructuringReserveNoncurrent>
	<us-gaap:RestructuringReserveNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-7D1929819BC47987A4D5E2787BC50F8A" unitRef="usd">298000</us-gaap:RestructuringReserveNoncurrent>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2015Q4" decimals="-3" id="Fact-EAEA3AE3F9C81272F410E2787BC58050" unitRef="usd">-234186000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2016Q4" decimals="-3" id="Fact-D0FF06DF709FEEA9EC4AE2787B0EF266" unitRef="usd">-292714000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RevenueFromGrants contextRef="FD2014Q4YTD" decimals="-3" id="Fact-43A931BC73D26BE3C8A2E2787BDF04FD" unitRef="usd">533000</us-gaap:RevenueFromGrants>
	<us-gaap:RevenueFromGrants contextRef="FD2015Q4YTD" decimals="-3" id="Fact-492162AD8B09A43506ECE2787BEBB91A" unitRef="usd">1486000</us-gaap:RevenueFromGrants>
	<us-gaap:RevenueFromGrants contextRef="FD2016Q4YTD" decimals="-3" id="Fact-57E27E36B27506FE8FE0E2787BFB94DF" unitRef="usd">5298000</us-gaap:RevenueFromGrants>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember" decimals="-5" id="Fact-A20CD1395601140EB7F5E2787B76F630" unitRef="usd">2000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="INF" id="Fact-71CCBC67BF23548F89AEE2787B59E3DE" unitRef="usd">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-31C63040D3C35BCD5F956ED56EFAD417" unitRef="usd">5000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember" decimals="-5" id="Fact-8A4B1AC22920D252D9C7E2787B141D54" unitRef="usd">5000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="INF" id="Fact-398FFFEB2927D48B4CA2E2787BFE279C" unitRef="usd">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="INF" id="Fact-214B62A9A6F3040DA079E2787B4AA19A" unitRef="usd">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember" decimals="-5" id="Fact-C5C00FD0F454A95AD72AE2787B181C85" unitRef="usd">3000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="INF" id="Fact-7A5F6DDF327E9CF369F4E2787B04D5D0" unitRef="usd">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-6" id="Fact-BBF937712EDEEFD4FCA5E2787B1127B6" unitRef="usd">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:Revenues contextRef="FD2014Q4YTD" decimals="-3" id="Fact-AB7F832E8BEC5DE807D6E2787BFAF6F0" unitRef="usd">47797000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q1QTD" decimals="-3" id="Fact-69AAEEA83CAFD42BE3FAE2787B21CC0D" unitRef="usd">71279000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q2QTD" decimals="-3" id="Fact-CEB1FFB46B889DE7B139E2787B2264A6" unitRef="usd">6716000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q3QTD" decimals="-3" id="Fact-3FA956E88DC9C08BAEB7E2787B3D7886" unitRef="usd">14681000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q4QTD" decimals="-3" id="Fact-E88411BBF15E90F9D71BE2787B1DD41F" unitRef="usd">8178000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q4YTD" decimals="-3" id="Fact-EFC0A7952A8108198F35E2787BE4D1FC" unitRef="usd">100854000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q1QTD" decimals="-3" id="Fact-40746A736F98013185B6E2787B4883B0" unitRef="usd">2846000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q2QTD" decimals="-3" id="Fact-883EFF0E3E92415A4D3BE2787BC1FD2F" unitRef="usd">80673000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q3QTD" decimals="-3" id="Fact-799ADA788180430B403FE2787B1E1FDE" unitRef="usd">3255000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4QTD" decimals="-3" id="Fact-D5333B693CAA8B5FA9A5E2787B15675E" unitRef="usd">5106000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD" decimals="-3" id="Fact-A5D3E2F3B3BFA3B94C8BE2787BCEB68C" unitRef="usd">91880000</us-gaap:Revenues>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2014Q4Dec01-Dec31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="-5" id="Fact-4ABC34A3E7DB2C29F740E2787B1AF830" unitRef="usd">75000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2015Q1SD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="-5" id="Fact-7C7AFBA78C2EA8C3E249E2787B782864" unitRef="usd">75000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2015Q1SD_us-gaap_CounterpartyNameAxis_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember" decimals="-5" id="Fact-08183590905A513C2F0DE2787BC69CF9" unitRef="usd">75000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2014Q4Dec01-Dec31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="INF" id="Fact-845E8EA2773FDD3669BCE2787B99CAB2" unitRef="shares">1923077</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2015Q1SD_us-gaap_CounterpartyNameAxis_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember" decimals="INF" id="Fact-88FEA70432475D255684E2787BCEC91B" unitRef="shares">1923077</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2015Q1Jan31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="INF" id="Fact-876868FF627A1A2BEE72E2787AF67885" unitRef="usdPerShare">39.00</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2015Q1Jan31_us-gaap_CounterpartyNameAxis_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember" decimals="INF" id="Fact-D842E0398EE9C69B1C73E2787B5E1549" unitRef="usdPerShare">39</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:ShareBasedCompensation contextRef="FD2014Q4YTD" decimals="-3" id="Fact-BA85A479C06C3871EF26E2787BA516C8" unitRef="usd">3244000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q4YTD" decimals="-3" id="Fact-BFD268AD0F886E6D0CF0E2787B09EF9F" unitRef="usd">7847000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q4YTD" decimals="-3" id="Fact-5101063F6E938AA62287E2787B158638" unitRef="usd">12165000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2014Q4YTD" decimals="INF" id="Fact-836CF6D80DAF8974F9FFE2787B759180" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2015Q4YTD" decimals="INF" id="Fact-930D45D58F438FE2EF81E2787B698FB9" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2016Q4YTD" decimals="INF" id="Fact-4EE423FA92BDCBC3C3B7E2787B72D356" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2014Q4YTD" decimals="2" id="Fact-9A93F3D3AFE3974A95456C419CBE10B0" unitRef="number">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-7462646728F2468F6927676C7B800291" unitRef="number">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-FB7F4D9A83D70366E175676C79A4E48F" unitRef="number">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-0F901B2267F39FD92215E2787BF0D52B" unitRef="number">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-7AE0BECDF7A55068E56CE2787BBE3DF6" unitRef="number">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2014Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="3" id="Fact-F966806AF3E26D3286C1E2787BD3F406" unitRef="number">0.023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2014Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="3" id="Fact-BE36EB7704F759D1CFA8E2787BA426EF" unitRef="number">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="3" id="Fact-4EE6918E9B40E2BB5388E2787BD59610" unitRef="number">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="3" id="Fact-D65694D29F4117E3572FE2787BB6B89C" unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="3" id="Fact-70EA204108BA4F7C80A7E2787BE24EBD" unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="3" id="Fact-E60222A2ACEBB9652331E2787BA37E8F" unitRef="number">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2003Q1Feb28_us-gaap_PlanNameAxis_mgnx_EquityIncentivePlan2003Member" decimals="INF" id="Fact-81B9AC012E00C7AE2798E2787AF0962A" unitRef="shares">2051644</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2013Q4Oct31_us-gaap_PlanNameAxis_mgnx_StockIncentivePlan2013Member" decimals="INF" id="Fact-E207929469E3770AC7D8E2787AD0E980" unitRef="shares">1960168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2016Q4" decimals="INF" id="Fact-26C57536B1F27340E9CFE2787AC9940E" unitRef="shares">2292923</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2016Q4" decimals="2" id="Fact-7D850CDF69ADEE3CF3C3E2787B75F755" unitRef="usdPerShare">13.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2014Q4YTD" decimals="-5" id="Fact-46E938CE055F8FA5DC57E2787AF19730" unitRef="usd">14500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2015Q4YTD" decimals="-5" id="Fact-B764D236081C9E671D6DE2787ADE3AE8" unitRef="usd">10900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2016Q4YTD" decimals="-5" id="Fact-D0F88A968D853EA589A5E2787AE08304" unitRef="usd">10800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2016Q4YTD" decimals="INF" id="Fact-A809B64692C2FE5D2ADEE2787B65229F" unitRef="shares">181238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="FD2016Q4YTD" decimals="INF" id="Fact-7B44CA2771D262B792F0E2787B717906" unitRef="shares">399949</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2014Q4YTD" decimals="2" id="Fact-F56BCBAE0B6AABCB70F9E2787AF5F98E" unitRef="usdPerShare">17.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD" decimals="2" id="Fact-2EF436A9671FA1F2B239E2787AD4210C" unitRef="usdPerShare">20.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD" decimals="2" id="Fact-75C8D0AC5759BF3B7E91E2787AF4E3F9" unitRef="usdPerShare">15.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2016Q4" decimals="-3" id="Fact-983BC998DE9198FA9B6BE2787AC60403" unitRef="usd">24862000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2015Q4" decimals="INF" id="Fact-E8CBBACD2F4E0CFC8AA9E2787ACFD408" unitRef="shares">4146064</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2016Q4" decimals="INF" id="Fact-447E8610460082C87326E2787AD342D2" unitRef="shares">3838060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2016Q4_us-gaap_PlanNameAxis_mgnx_EquityIncentivePlan2003Member" decimals="INF" id="Fact-36374AB65C61FB335492E2787AFDF572" unitRef="shares">1193941</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2016Q4_us-gaap_PlanNameAxis_mgnx_StockIncentivePlan2013Member" decimals="INF" id="Fact-C563CD93F4CA07FACFEDE2787AD8CC64" unitRef="shares">2644119</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4" decimals="2" id="Fact-4BF47756C6C4FEE51B93E2787AD4D036" unitRef="usdPerShare">16.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4" decimals="2" id="Fact-468F7E68FA1D3C28D5FBE2787B7314A5" unitRef="usdPerShare">18.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4_us-gaap_PlanNameAxis_mgnx_EquityIncentivePlan2003Member" decimals="2" id="Fact-73F29022B0AF1DE5751CE2787AD8D7DA" unitRef="usdPerShare">1.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4_us-gaap_PlanNameAxis_mgnx_StockIncentivePlan2013Member" decimals="2" id="Fact-E1E51DC2AF47DDF1E895E2787B0E4D39" unitRef="usdPerShare">26.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="FI2016Q4" decimals="-3" id="Fact-E48BCE4A62FFBFE7B716E2787B8232CF" unitRef="usd">24496000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="FI2016Q4" decimals="INF" id="Fact-BB118F013C3A25A06E05E2787ACECAC3" unitRef="shares">3651523</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4" decimals="2" id="Fact-55582707733C83493ACCE2787B785308" unitRef="usdPerShare">18.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD" decimals="2" id="Fact-13A5D6B1B0617580690CE2787B674E52" unitRef="usdPerShare">3.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD" decimals="2" id="Fact-ECECA1E17460BCDE9FF4E2787AD8AC3E" unitRef="usdPerShare">26.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD" decimals="2" id="Fact-61BA7D407CBFC31BB7EEE2787B66ACA9" unitRef="usdPerShare">23.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharePrice contextRef="I2014Q1Feb28" decimals="INF" id="Fact-DD99BAAD82F1CFD99438E2787BEFC183" unitRef="usdPerShare">36.50</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2015Q3Jul31" decimals="INF" id="Fact-F39EAD0109FB5485C4F6E2787B2016D0" unitRef="usdPerShare">37.00</us-gaap:SharePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-342C18042626F3AE274EE2787ADAA9A3">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2014Q4YTD" id="Fact-0A9C76E57489551CD477E2787B69DE06">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2015Q4YTD" id="Fact-AF28C7A233E945920053E2787B7224CE">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q4YTD" id="Fact-A8B19D527A1F2EBCC64BE2787B6CAB65">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2016Q4" decimals="-3" id="Fact-6866969D5F9099467C46E2787B75A6B7" unitRef="usd">22458000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2016Q4YTD" id="Fact-D23EC73B3E864D17A31FE2787B809E28">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2015Q4YTD" id="Fact-A6840D3038D611423221E2787B77A5E8">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2016Q4YTD" id="Fact-61380C36D5EF2613EF47E2787AC5B074">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="FD2016Q4YTD" id="Fact-EFD6C6FD0C1B25A8B9BDE2787B6AF3FF">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2014Q4YTD" decimals="-5" id="Fact-B25F1328EACEFBEEF03EE2787AD1BA6B" unitRef="usd">3000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2015Q4YTD" decimals="-5" id="Fact-6E7D37183F679D825ACEE2787B055DB8" unitRef="usd">7300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2016Q4YTD" decimals="-5" id="Fact-A4EBF23109B236EB3E9AE2787AF5F981" unitRef="usd">11600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharesIssued contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-913306D53751EF277D40E2787AE8BDF0" unitRef="shares">25177597</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-D671A8FF4DB6EA461FB1E2787ADE4B2F" unitRef="shares">14381</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-BB895D540ADD3AFF3F13E2787B5DFBD1" unitRef="shares">27995638</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-9A39BA64BD4A280B08B2E2787B4DC7E1" unitRef="shares">865</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-B602D165A319A404C843E2787BC1972F" unitRef="shares">34345754</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-A393193DBE4D27C66B6663E5CC6D48E7" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-B97C736432A82AA53229E2787B38326C" unitRef="shares">34870607</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-F1349F5A197E80BF370DE2787B4DA809" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2014Q1Feb1-Feb28" decimals="INF" id="Fact-A1E98D123E175894412CE2787BDB158D" unitRef="shares">1800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2015Q3Jul1-Jul31" decimals="INF" id="Fact-876886F8FAD4350ECE6FE2787BC0635E" unitRef="shares">3525000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-A482AD6316A7D428E42DE2787B089E54" unitRef="shares">2250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-2F11161318D0423190A1E2787AEB8325" unitRef="shares">5976827</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2014Q4YTD" decimals="INF" id="Fact-35AC05841B00628103D9E2787ADFD998" unitRef="shares">568906</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q4YTD" decimals="INF" id="Fact-63AB21473A55460191C4E2787AD78F4B" unitRef="shares">374214</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2016Q4YTD" decimals="INF" id="Fact-758076CB5F63B7FDF2DCE2787B7F6687" unitRef="shares">526715</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2014Q4YTD" decimals="-3" id="Fact-A0FDD2FD3ECCDAEB5FE9E2787ACD70C7" unitRef="usd">76716000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-81F8BB0CB3E4DF919471E2787B0F40F6" unitRef="usd">76694000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-30923D5F3DC738E7BF3BE2787BBF847B" unitRef="usd">22000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2015Q4YTD" decimals="-3" id="Fact-D3A5B863D492314B203AE2787BBED00E" unitRef="usd">203467000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-6949E4CAC244B50E7562E2787BC77F58" unitRef="usd">203407000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-21D572AEE78A64BC993BE2787B26D1E8" unitRef="usd">60000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockholdersEquity contextRef="FI2013Q4" decimals="-3" id="Fact-98B120CCEDD99191EB73E2787AEFC6DC" unitRef="usd">78914000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-8B1CB2AC40A20938742D63E60A18182B" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-60227749C7945ECDB94EE2787BD4B216" unitRef="usd">254453000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-A1F59A717B4231A46DB9E2787AEBCD4C" unitRef="usd">252000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-A80F612B5131CE839A66E2787AC4A889" unitRef="usd">-175733000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-408CF625FFC8135FC665E2787ADEA441" unitRef="usd">-58000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4" decimals="-3" id="Fact-A84F0673CBC54ACFD93EE2787AD55646" unitRef="usd">121286000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-427D0ABA51FF4062033963E6A310A947" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-7EB76104C000A3531CE4E2787B0B5EBE" unitRef="usd">335071000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-7CB66F4BBF85A26B619AE2787AE2DFE0" unitRef="usd">280000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-DC688017FFEEC6D5FC9CE2787AE55487" unitRef="usd">-214046000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-36A927AA218F452FCBACE2787B4CBF07" unitRef="usd">-19000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4" decimals="-3" id="Fact-B6EEC6C8850ED78AC943E2787B063036" unitRef="usd">313337000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-14043098E3BA69A7AC85E2787B2868AD" unitRef="usd">-5000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-CC3BB18D8BE44BB491BFE2787BFDAC52" unitRef="usd">547185000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-7AEDE82AC42CB0880AC3E2787ADC3623" unitRef="usd">343000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-12001F7A2E6ABAA52D78E2787B442EAA" unitRef="usd">-234186000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-B035539CC8E113C4357B63E5CDCDA2B7" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-F48FDDE79962E542185FE2787AF840E6" unitRef="usd">268751000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-91B809E1352DD300463BE2787BE31C84" unitRef="usd">-82000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-762A91335E0891DF0439E2787AEAFEF2" unitRef="usd">561198000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-393AE1BDEB0D65D4CA8FE2787B131D1A" unitRef="usd">349000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-BE735E05305EE8E0B8F8E2787AFD6FE0" unitRef="usd">-292714000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-430031EBDF6D642AC8D7E2787B227982" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-5" id="Fact-060989D531454B0C0709E2787B29CF06" unitRef="usd">32500000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TreasuryStockRetiredParValueMethodAmount contextRef="FD2014Q4YTD" decimals="-3" id="Fact-6748FE8BE3C5F6661E73E2787BF2A50F" unitRef="usd">0</us-gaap:TreasuryStockRetiredParValueMethodAmount>
	<us-gaap:TreasuryStockRetiredParValueMethodAmount contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-51307FF84FD181E41BCFE2787B656C2B" unitRef="usd">58000</us-gaap:TreasuryStockRetiredParValueMethodAmount>
	<us-gaap:TreasuryStockRetiredParValueMethodAmount contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-61A74D8A4A28699F1FE5E2787AC3B81A" unitRef="usd">-58000</us-gaap:TreasuryStockRetiredParValueMethodAmount>
	<us-gaap:TreasuryStockRetiredParValueMethodAmount contextRef="FD2015Q4YTD" decimals="-3" id="Fact-D16275CA8F716CC027D3E2787AFED7E5" unitRef="usd">0</us-gaap:TreasuryStockRetiredParValueMethodAmount>
	<us-gaap:TreasuryStockRetiredParValueMethodAmount contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-AE155EBC84CE16B33F9AE2787BCF6542" unitRef="usd">48000</us-gaap:TreasuryStockRetiredParValueMethodAmount>
	<us-gaap:TreasuryStockRetiredParValueMethodAmount contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-D7D7EC7364B4847DBE5AE2787AF49B57" unitRef="usd">-48000</us-gaap:TreasuryStockRetiredParValueMethodAmount>
	<us-gaap:TreasuryStockRetiredParValueMethodAmount contextRef="FD2016Q4YTD" decimals="-3" id="Fact-C027BE10F6298DB45D1DE2787BD242EC" unitRef="usd">0</us-gaap:TreasuryStockRetiredParValueMethodAmount>
	<us-gaap:TreasuryStockRetiredParValueMethodAmount contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-8F8C55D0F0DB570D0000E2787BDD215D" unitRef="usd">39000</us-gaap:TreasuryStockRetiredParValueMethodAmount>
	<us-gaap:TreasuryStockRetiredParValueMethodAmount contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-968CFCC1145D791AF107E2787B4A8DF4" unitRef="usd">-39000</us-gaap:TreasuryStockRetiredParValueMethodAmount>
	<us-gaap:TreasuryStockSharesRetired contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-5286B90DCAABC2AE5A7AE2787AC64644" unitRef="shares">14381</us-gaap:TreasuryStockSharesRetired>
	<us-gaap:TreasuryStockSharesRetired contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-95B996999E720CB44331E2787BED3C78" unitRef="shares">1790</us-gaap:TreasuryStockSharesRetired>
	<us-gaap:TreasuryStockSharesRetired contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-C1EA3EDB9A4889876AAE814665FA6B9B" unitRef="shares">1862</us-gaap:TreasuryStockSharesRetired>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2014Q4YTD" decimals="INF" id="Fact-CD8A69B99CA66C6C1F886D906446BAD3" unitRef="usd">0</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2015Q4YTD" decimals="-3" id="Fact-70FD9A3BBB4D2878694563E99FA9339C" unitRef="usd">-5000</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-71D233E9E6C115C8F87563E96BA8DD8E" unitRef="usd">-5000</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2016Q4YTD" decimals="-3" id="Fact-330A2BA61D18682527B7E2787ADD851A" unitRef="usd">-77000</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-E0DA486186859108E7ADE2787AFB8A50" unitRef="usd">-77000</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2013Q4" decimals="-3" id="Fact-7CE2C4815613DFE8B788E2787BD27F67" unitRef="usd">1708000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2014Q4" decimals="-3" id="Fact-F0E16E8B2303D33704C4E2787BF1E2CF" unitRef="usd">2047000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2015Q4" decimals="-3" id="Fact-60FAB0F79E344042979AE2787BE4D8AB" unitRef="usd">2425000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2016Q4" decimals="-3" id="Fact-11C9FB49CAC884E8FD77E2787BE04EB1" unitRef="usd">2465000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="FD2014Q4YTD" decimals="INF" id="Fact-604000F42868530111FCE2787C0B6623" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="FD2015Q4YTD" decimals="INF" id="Fact-B6B968A5DB5017F80EE7E2787C044814" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="FD2016Q4YTD" decimals="INF" id="Fact-9E22E6070ED572047E94E2787B3D4238" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2014Q4YTD" decimals="-3" id="Fact-2DB2D08FCBDF7440BA2FE2787BE176F5" unitRef="usd">242000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2015Q4YTD" decimals="-3" id="Fact-229392637A0669D2AD71E2787AD5099A" unitRef="usd">357000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2016Q4YTD" decimals="-3" id="Fact-653CE9C5FD2E268729FCE2787B929E52" unitRef="usd">308000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2014Q4YTD" decimals="-3" id="Fact-FDC7518432AB7ABEECBCE2787BFF1720" unitRef="usd">97000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2015Q4YTD" decimals="-3" id="Fact-6B033AD8B6B76E8436B3E2787BE4F14A" unitRef="usd">21000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2016Q4YTD" decimals="-3" id="Fact-84CBDD21F10F826E80A3E2787BF4A86D" unitRef="usd">-268000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="FI2015Q4" decimals="-5" id="Fact-ECEF46FB03E5D4F671CBE2787B35DB6D" unitRef="usd">2400000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
	<us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="FI2016Q4" decimals="-5" id="Fact-61A9C9392D70B88275A7E2787B28D5F5" unitRef="usd">2500000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2014Q4YTD" decimals="0" id="Fact-B7FC40B57FC9651E920FE2787AEF5F45" unitRef="shares">27384990</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2015Q4YTD" decimals="0" id="Fact-FA103237A0226AA36535E2787AEE9A3D" unitRef="shares">31801645</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2016Q4YTD" decimals="0" id="Fact-228201701611324E4498E2787AF3AE94" unitRef="shares">34685274</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2014Q4YTD" decimals="0" id="Fact-8CAA0DBF7E08C61295C5E2787BEEA4B2" unitRef="shares">27384990</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2015Q4YTD" decimals="0" id="Fact-4F63075B666E111187FCE2787B1F270E" unitRef="shares">31801645</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q4YTD" decimals="0" id="Fact-E14AF3A4AE75F0AC0147E2787B239E7B" unitRef="shares">34685274</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2014Q4YTD" decimals="0" id="Fact-DEF2B2FFFDB562A2B7FFE2787AF2B28D" unitRef="shares">27384990</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2015Q4YTD" decimals="0" id="Fact-97E9D95408529670081EE2787AF00CB4" unitRef="shares">31801645</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2016Q4YTD" decimals="0" id="Fact-D8C87CA5A97E9B481536E2787AEEEADF" unitRef="shares">34685274</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-AF91197B61589C687CF0E2787B203F58">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Collaboration and Other Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Janssen&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company entered into a collaboration and license agreement with Janssen for the development and commercialization of MGD011 (also known as JNJ-64052781 or duvortuxizumab), a product candidate that incorporates the Company's proprietary DART technology to simultaneously target CD19 and CD3 for the potential treatment of B-cell hematological malignancies (MGD011 Agreement). The Company contemporaneously entered into an agreement with JJDC under which JJDC agreed to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,923,077&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; new shares of the Company's common stock for proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160;&amp;#160;Upon closing the transaction in January 2015, the Company received a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront payment from Janssen as well as the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; investment in the Company's common stock.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the MGD011 Agreement, the Company granted an exclusive license to Janssen to develop and commercialize duvortuxizumab. Following the Company's submission of the Investigational New Drug (IND) application, Janssen became fully responsible for the development and commercialization of duvortuxizumab.&amp;#160;&amp;#160; Assuming successful development and commercialization, the agreement entitles the Company to receive up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$205.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in development milestone payments, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$220.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in regulatory milestone payments and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in sales milestone payments. The Company determined that each potential future clinical and regulatory milestone is substantive.&amp;#160; Although the sales milestones are not considered substantive, they will be recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time.&amp;#160; The Company may elect to fund a portion of late-stage clinical development in exchange for a profit share with Janssen in the U.S. and Canada. If commercialized, the Company would be eligible to receive low double-digit royalties on any global net sales and has the option to co-promote the molecule with Janssen in the United States.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluated the MGD011 Agreement with Janssen and determined that it is a revenue arrangement with multiple deliverables, or performance obligations.&amp;#160; The Company's substantive performance obligations under the collaboration and license agreement include the delivery of an exclusive license and research and development services during the preclinical research period (through the filing of the IND for duvortuxizumab). &amp;#160; The Company evaluated the MGD011 Agreement and determined that the license and preclinical research and development activities each represented separate deliverables and were accounted for as separate units of accounting.&amp;#160; The Company concluded that the license had standalone value to Janssen and was separable from the research and development services because the license was sublicensable, there were no restrictions as to Janssen's use of the license and Janssen or other third parties have significant research capabilities in this field.&amp;#160; Thus, the total arrangement consideration for these two deliverables was allocated using the relative best estimate of selling price method to each deliverable.&amp;#160; The best estimate of selling price for the exclusive license was determined using a discounted cash flow model that includes Level 3 fair value measurements. The best estimate of selling price for the research and development services was determined using third party evidence of other similar research and development arrangements, which are Level 2 fair value measurements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluated the stock purchase agreement and the collaboration and license agreement as one arrangement and determined that the stock purchase price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$39.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share exceeded the fair value of the common stock by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. This excess was recognized in the same manner as the upfront payment allocated to the license and preclinical research and development activities.&amp;#160; Of the total arrangement consideration of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$125.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company allocated &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$62.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to equity (representing the fair value of common stock purchased), &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$62.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to the license and preclinical research and development activities, and a de minimis amount to the ongoing research and development activities.&amp;#160; The Company submitted the IND application and therefore met its performance obligation during the year ended December&amp;#160;31, 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2015, Janssen dosed the first patient in an open-label Phase 1 study of duvortuxizumab which triggered a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; milestone to the Company.&amp;#160; During the years ended December&amp;#160;31, 2016 and 2015, the Company recognized revenue of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$72.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, under the MGD011 agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2016, the Company entered into a separate collaboration and license agreement with Janssen, a related party through ownership of the Company's common stock, for the development and commercialization of MGD015, a product candidate that incorporates the Company's proprietary DART technology to simultaneously target CD3 and an undisclosed tumor target for the potential treatment of various hematological malignancies and solid tumors (MGD015 Agreement). The transaction closed in June 2016, and the Company received the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront payment from Janssen in July 2016.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the MGD015 Agreement, the Company granted an exclusive license to Janssen to develop and commercialize MGD015. Janssen will complete the IND-enabling activities and will be fully responsible for the future clinical development and commercialization of MGD015.&amp;#160;&amp;#160; Assuming successful development and commercialization, the agreement entitles the Company to receive up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in development milestone payments, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$265.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in regulatory milestone payments and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in sales milestone payments. The Company determined that each potential future clinical and regulatory milestone is substantive.&amp;#160; Although the sales milestones are not considered substantive, they will be recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time.&amp;#160; The Company may elect to fund a portion of late-stage clinical development in exchange for a profit share with Janssen in the U.S. and Canada. If commercialized, the Company would be eligible to receive low double-digit royalties on any global net sales and has the option to co-promote the molecule with Janssen in the United States.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluated the MGD015 Agreement with Janssen and determined that it is a revenue arrangement with multiple deliverables, or performance obligations.&amp;#160; The Company's substantive performance obligations under the MGD015 Agreement include the delivery of an exclusive license and research and development services during the preclinical research period. &amp;#160; The Company evaluated the MGD015 Agreement with Janssen and determined that the license and preclinical research and development activities each represented separate deliverables and were accounted for as two separate units of accounting.&amp;#160; The Company concluded that the license had standalone value to Janssen and was separable from the research and development services because the license was sublicensable, there were no restrictions as to Janssen's use of the license and Janssen or other third parties have significant research capabilities in this field.&amp;#160; Thus, the total arrangement consideration for these two deliverables was allocated using the best estimate of relative selling price method to each deliverable.&amp;#160; The best estimate of selling price for the exclusive license was determined using information from the previous collaboration and license agreement with Janssen as well as other third party collaboration and license agreements, which are Level 2 fair value measurements. The best estimate of selling price for the research and development services was determined using other similar research and development arrangements, which are also Level 2 fair value measurements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized revenue of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$75.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, including the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront fee for the exclusive license under the MGD015 Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Takeda&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;May 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company entered into a license and option agreement with Takeda for the development and commercialization of MGD010, a product candidate that incorporates the Company's proprietary DART technology to simultaneously engage CD32B and CD79B, which are two B-cell surface proteins.&amp;#160;&amp;#160;MGD010 is being developed for the treatment of autoimmune disorders.&amp;#160; Upon execution of the agreement, Takeda made a non-refundable payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to the Company.&amp;#160;&amp;#160;Takeda had an option to obtain an exclusive worldwide license for MGD010 following the completion of a pre-defined Phase 1a study.&amp;#160; Following the announcement of its therapeutic area re-prioritization, Takeda gave formal notification in September 2016 that it did not intend to exercise this option.&amp;#160; As a result of Takeda not exercising the option, the Company regained worldwide development and commercialization rights to MGD010. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At the inception of the license and option agreement with Takeda, the Company evaluated it and determined that it was a revenue arrangement with multiple deliverables, or performance obligations. The Company's substantive performance obligations under the license and option agreement included exclusivity, research and development services through the Phase 1a study and delivery of a future license for an initial research compound.&amp;#160;&amp;#160;The Company concluded that the MGD010 option was substantive and that the license fee payable upon exercise of the option was not a deliverable at the inception of the arrangement as there was considerable uncertainty that the option would be exercised. The Company determined that each potential future clinical and regulatory milestone was substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time.&amp;#160;&amp;#160;&amp;#160;The Company determined that these performance obligations represent a single unit of accounting, because the exclusivity clause does not have stand-alone value to Takeda without the Company's technical expertise and development through the pre-defined Phase 1a study.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;After identifying the deliverables included within the arrangement, the Company determined its best estimate of selling price.&amp;#160;&amp;#160;The Company allocated &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to the exclusivity clause to its technology and the research and development services and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to the exclusive license for the initial research compound.&amp;#160;&amp;#160;The Company's determination of best estimate of selling price for the research and development services relied upon other similar transactions.&amp;#160;&amp;#160;The Company relied upon the income approach (e.g., discounted future cash flows) to determine the value of the license of the to-be-delivered compound along with other similar license transactions with differing indications but similar stage of development. The portion of the up-front fee allocated to the MGD010 option was being recognized over an initial &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-month period, which represented the expected period of development through the completion of a pre-defined Phase 1a study.&amp;#160;&amp;#160;During the first quarter of 2016, the Company determined that the development period would be extended by eight months, and prospectively adjusted the MGD010 option fee recognition period.&amp;#160; The portion of the up-front fee allocated to the license for the initial research compound was deferred until the research collaboration and license option agreement was executed and the license delivered in September 2014.&amp;#160; Upon the notification that Takeda would not exercise the option to obtain an exclusive worldwide license for MGD010 during the three months ended September 30, 2016, the Company's performance obligation to Takeda ceased, and the remaining deferred revenue under the MGD010 agreement was recognized in full.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognized revenue of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; under the MGD010 agreement during the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&amp;#160; Revenue recognized during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; included a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; milestone payment received upon initiation of a Phase 1a trial of MGD010.&amp;#160;&amp;#160;&amp;#160;At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; revenue was deferred under this agreement.&amp;#160; At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of revenue was deferred under this agreement, all of which was current.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company and Takeda executed a research collaboration and license option agreement, which formalized the license for the initial research compound contemplated in the May 2014 arrangement. Under the terms of the agreement, Takeda may nominate up to three additional compounds on or before September 25, 2017, which will be subject to separate research and development plans.&amp;#160;&amp;#160;The Company determined that it could recognize the entire license fee allocated to this agreement as (1) the executed contract constituted persuasive evidence of an arrangement, (2) the delivery of the license occurred and the Company had no current or future performance obligations, (3) the total consideration for the license was fixed and known at the time of its execution and there were not any extended payment terms or rights of return, and (4) the cash was received. &amp;#160;The Company is also entitled to receive reimbursements for research and development services provided to Takeda with respect to the initial research compound under a separate research plan.&amp;#160; The Company recognized revenue of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; under this agreement during the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&amp;#160; Revenue during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; includes the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; license fee.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;text-indent:26px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Takeda terminated its option to license the first program under this research collaboration agreement in 2015 and retains an option for three others.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Servier&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September 2012&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company entered into a right-to-develop collaboration agreement with Servier and granted it options to obtain three separate exclusive licenses to develop and commercialize DART molecules, consisting of those designated by the Company as MGD006 (or flotetuzumab) (also known as S80880) and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India.  During 2014, Servier exercised its exclusive option to develop and commercialize flotetuzumab, and during 2016 Servier notified the Company that it did not intend to exercise the option for the third DART molecule.  Servier retains the option to obtain a license for MGD007.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upon execution of the agreement, Servier made a nonrefundable payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to the Company. In addition, the Company will be eligible to receive up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$40.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in license fees, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$63.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in clinical milestone payments, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$188.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in regulatory milestone payments and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$420.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in sales milestone payments if Servier exercises the remaining available options and successfully develops, obtains regulatory approval for, and commercializes a product under each license. In addition to these milestones, the Company and Servier will share Phase 2 and Phase 3 development costs. The Company has determined that each potential future clinical and regulatory milestone is substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. Under this agreement, Servier would be obligated to pay the Company from low double-digit to mid-teen royalties on net product sales in its territories.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluated the research collaboration agreement with Servier and determined that it is a revenue arrangement with multiple deliverables, or performance obligations. The Company concluded that each option is substantive and that the license fees for each option are not deliverables at the inception of the arrangement and were not issued with a substantial discount. The Company's substantive performance obligations under this research collaboration include an exclusivity clause to its technology, technical, scientific and intellectual property support to the research plan and participation on an executive committee and a research and development committee. The Company determined that the performance obligations with respect to the preclinical development represent a single unit of accounting, since the license does not have stand-alone value to Servier without the Company's technical expertise and committee participation. As such, the initial upfront license payment was deferred and initially recognized ratably over a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-month period, which represented the expected development period. During 2014, the Company and Servier further refined the research plan related to the three DART molecules and as such, the development period was extended.&amp;#160;&amp;#160;Based on this revised development period, the Company prospectively adjusted its period of recognition of the upfront payment to a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;75&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-month period. The impact of this change in accounting estimate reduced revenue that would have been recognized in 2014 by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As a result of Servier exercising its option in 2014, the Company received a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; payment from Servier for its license to develop and commercialize flotetuzumab in its territories.&amp;#160;&amp;#160;Upon exercise of the option, the Company evaluated its performance obligations with respect to the license for flotetuzumab. The Company's substantive performance obligations under this research collaboration include an exclusive license to its technology, technical, scientific and intellectual property support to the research plan and participation on an executive committee and a research and development committee. The Company determined that the performance obligations with respect to the clinical development represent a single unit of accounting, since the license does not have stand-alone value to Servier without the Company's technical expertise and committee participation. As such, the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; license fee was deferred and is being recognized ratably over a period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;82 months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which represents the expected development period for flotetuzumab.&amp;#160;&amp;#160;In accordance with the agreement, the Company and Servier will share costs incurred to develop flotetuzumab.&amp;#160;&amp;#160;Reimbursement of research and development expenses received in connection with this collaborative cost-sharing agreement is recorded as a reduction to research and development expense.&amp;#160;&amp;#160;During the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; the Company recorded approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as an offset to research and development costs under this collaboration arrangement, respectively.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; the Company recognized revenue of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$16.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, under this agreement.&amp;#160;&amp;#160;Revenue during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; includes &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; milestone payments from Servier upon the achievement of clinical milestones related to the IND applications for flotetuzumab and MGD007 clearing the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-day review period by the U.S. FDA.&amp;#160;&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; milestones were recognized under this agreement during the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$11.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of revenue was deferred under this agreement, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of which was current and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of which was non-current. At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$14.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of revenue was deferred under this agreement, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of which was current and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$11.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of which was non-current.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Boehringer&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;October 2010&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; the Company entered into a collaboration and license agreement with Boehringer to discover, develop and commercialize multiple DART molecules that were to be evaluated during a five-year period that ended in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;October 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Under the terms of the agreement, the Company granted Boehringer an exclusive, worldwide, royalty-bearing, license under its intellectual property to research, develop, and market DART molecules generated under the agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upon execution of the agreement, the Company received an upfront payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company subsequently received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; annual maintenance payments. These maintenance payments were being recognized over the estimated period of development. The Company has the potential to earn additional milestone payments of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$34.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; related to preclinical and clinical development, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$88.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; related to regulatory milestones and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$82.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; related to sales milestones for each of the two ongoing programs under this agreement. The Company determined that each potential future preclinical, clinical and regulatory milestone is substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. Boehringer would be required to pay the Company mid-single digit royalties on product sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company determined that the deliverables under the Boehringer agreement include the license, the research and development services to be performed by the Company, and the co-promotion/manufacturing services. The Company concluded that the co-promotional activities were optional and were subject to further negotiation upon reaching regulatory approval. As such, the co-promotional period is not included in the expected obligation period to perform services.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company concluded that the undelivered element of research and development services had fair value. The Company concluded that the license did not have value on a standalone basis (e.g. absent the provision of the research and development services) and therefore did not represent a separate unit of accounting. The Company concluded that because the drug candidate had not yet been developed, the license was of no value to Boehringer without the ensuing research and development activities using the DART technology, which is proprietary to the Company. Likewise, Boehringer could not sell the license to another party (without the Company agreeing to provide the research and development activities for the other party). Therefore, the upfront license fee and research and development services were treated as a combined unit of accounting and recognized over the expected obligation period associated with the research and development services through October 2015, which represented the estimated period of development.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company and Boehringer also agreed to establish a joint research committee to facilitate the governance and oversight of the parties' activities under the agreements. Management considered whether participation on the joint committee may be a deliverable and determined that it was not a deliverable. However, had management considered participation on the joint committee as a deliverable, it would not have had a material impact on the accounting for the arrangement as the period of participation in this committee matched the obligation period for the research and development services.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; revenue under this agreement during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  The Company recognized revenue of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$13.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, under this agreement. Revenue recognized during the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; included milestone payments of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, for the achievement of clinical milestones.  &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; revenue was deferred under this agreement at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Green Cross&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June 2010&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company entered into a collaboration agreement with Green Cross Corp. (Green Cross) for the development of the Company's anti-HER2 antibody margetuximab. This arrangement grants Green Cross an exclusive license to conduct specified Phase 1 and Phase 2 clinical trials and commercialize margetuximab in South Korea. In March 2014, the Company and Green Cross entered into an amendment to the original agreement, causing the terms of the original agreement to be materially modified.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upon execution of the amendment, the Company became eligible to receive reimbursement for costs incurred for Phase 2 and Phase 3 clinical trials up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as well as clinical development and commercial milestone payments of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company determined that each potential clinical development and commercial milestone is substantive. The Company is also entitled to receive royalties on net sales of margetuximab in South Korea. The Company and Green Cross have formed a joint steering committee to coordinate and oversee activities on which the companies collaborate under the agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluated the collaboration agreement with Green Cross and determined that it is a revenue arrangement with multiple deliverables or performance obligations. As a result of the material modification to the arrangement in March 2014, the Company reassessed the entire arrangement in accordance with the guidance provided by ASC 605-25, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Multiple Element Arrangements (Revenue Recognition)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as the original agreement was accounted for prior to adopting ASU 2009-13&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The Company's substantive performance obligations under this agreement include an exclusive license to its technologies, research and development services, and participation in a joint steering committee. The Company concluded that the license and the reimbursements for research and development services do not have value on a standalone basis and therefore do not represent separate units of accounting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The initial &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront payment received by the Company upon execution of the original agreement is non-refundable; as such, there is no right of return for the license. Therefore, the upfront license fee and participation on the joint steering committee were treated as a combined unit of accounting and will be recognized over the term of the agreement through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June 2020&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Further, due to the fact the research and development services are not deemed to have stand-alone value, revenue for those services will be recognized over the entire term of the agreement (through June 2020). As a result of reassessing the arrangement in accordance with ASC 605-25, the Company was required to record an adjustment on the date of the material modification to reflect the revenue that would have resulted had the entity applied the requirements of ASC 605-25 from the inception of the agreement.&amp;#160;&amp;#160;As a result, the Company recorded an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of revenue during 2014.  The Company has received a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for reimbursement of research and development services, which is also being recognized over the remaining term of the agreement.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognized revenues of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; under this agreement during the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&amp;#160;&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; milestones were achieved under this agreement during the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of revenue was deferred under this agreement, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of which was current and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of which was non-current.&amp;#160; At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of revenue was deferred under this agreement, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of which was current and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of which was non-current.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;NIAID Contract&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;15, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;,&amp;#160;to perform product development and to advance up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; DART molecules, including MGD014. Under this contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. This contract includes a base period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to support development of MGD014 through IND application submission with the FDA, as well as up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$17.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$24.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The total potential period of performance under the award is from September 15, 2015 through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;14, 2022&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in revenue under this contract during the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock>
	<mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock contextRef="FD2016Q4YTD" id="Fact-BDB07435D22F1340376DE2787AF954C7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation is computed using the straight-line method over the following estimated useful lives:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Laboratory and office equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shorter of lease term or useful life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock>
	<mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock contextRef="FD2016Q4YTD" id="Fact-A0918590C8150ADCF935E2787AEC998C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes stock option and restricted stock unit (RSU) activity for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Contractual Term&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Aggregate Intrinsic Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,146,064&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;399,949&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised or RSUs vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(526,715&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited or expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(181,238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,838,060&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,862&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,292,923&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,458&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,651,523&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,496&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock>
	<us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="FD2016Q4YTD" id="Fact-D1CAAC7DEA35F4AAC381E2787BE1C69F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;Available-for-sale marketable securities as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt; were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,825&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Government-sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,764&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;166,376&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;166,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;200,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;56&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;200,884&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,354&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,349&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Government-sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;111,473&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;111,481&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;142,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;142,877&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;The contractual maturities of the available-for-sale marketable securities as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt; were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Mature in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;192,985&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;192,898&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Mature between one and five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,981&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,986&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;200,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;200,884&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-8E94BAF6124B476E4549E2787B03C7C8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation and Principles of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited.&amp;#160; All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; segment, which is developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-F8EE62A4C3443D1C0311E2787AFF1303">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash, Cash Equivalents and Marketable Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income (expense).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. The Company considers factors including: the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not that it will be required to sell a security prior to recovery of its fair value.&amp;#160; An impairment loss is recognized at the time the Company determines that a decline in the fair value below its cost basis is other-than-temporary. There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt; unrealized losses at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt; or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt; that the Company determined to be other-than-temporary.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-90F8ADEF6C0E096716F0E2787B649D6E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Operating Leases&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company leases manufacturing, office and laboratory space in Rockville, Maryland under &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; leases that have terms that expire between &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; unless renewed.&amp;#160;&amp;#160;&amp;#160;This includes a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;seven&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year lease executed in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;July 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for additional space that the Company intends to use as mixed-use office, laboratory and manufacturing space.&amp;#160;&amp;#160; Under the terms of the lease, which commenced on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January&amp;#160;1, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company received an assignment fee from the former tenant and a tenant improvement allowance from the landlord totaling &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which has been recorded as deferred rent and will be recognized over the lease term.&amp;#160;&amp;#160; The Company also leases office and laboratory space in South San Francisco under a lease that expires on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;February&amp;#160;28, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  During the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company entered into a sublease agreement for a portion of the South San Francisco space (see Note 8). Future payments to be received by the Company under this sublease total approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All of the leases contain rent escalation clauses and certain leases contain rent abatements.&amp;#160;&amp;#160;For financial reporting purposes, rent expense is charged to operations on a straight-line basis over the term of the lease.&amp;#160;&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had recorded a deferred rent liability of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. Rent expense for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Future minimum lease payments under noncancelable operating leases as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:88%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,314&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,210&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,803&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,574&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,679&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company does not believe it is currently subject to any material matters where there is at least a reasonable possibility that a material loss may be incurred.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-1D1CA0BD7332C08C2318E2787B06EBE8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based payments are accounted for in accordance with the provisions of ASC 718, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation &amp;#8211; Stock Compensation&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
	<us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-60198EE616BEBD62EE2BE2787B012234">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale securities.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Comprehensive loss equals net loss for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; unrealized gains or losses in that period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2016Q4YTD" id="Fact-9843F651ED7C2F015418E2787B0E73E1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;We maintain our cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, we have not experienced any losses on related accounts to date.&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;Our investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The counterparties are various corporations, financial institutions and government agencies of high credit standing.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2016Q4YTD" id="Fact-1C3997EEC398F4CE7A7CE2787ACBB6F8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock-based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. The 2003 Plan originally allowed for the grant of awards in respect of an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,051,644&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's common stock. Between 2006 and 2012, the maximum number of shares of common stock authorized to be issued by the Company under the 2003 Plan was increased to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,336,730&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan. Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Plan, up to a specified number of shares.&amp;#160; As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, under the 2003 Plan, there were options to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,193,941&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock outstanding at a weighted average exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.81&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2013, the Company implemented the 2013 Stock Incentive Plan (2013 Plan).&amp;#160;&amp;#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards. The aggregate number of shares of common stock initially available for issuance pursuant to awards under the 2013 Plan was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,960,168&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares.&amp;#160;&amp;#160;The number of shares of common stock reserved for issuance will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,960,168&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares, (b) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Board of Directors. During the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,375,064&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160;&amp;#160;If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, under the 2013 Plan, there were options to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,644,119&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock outstanding at a weighted average exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$26.66&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following stock-based compensation amounts were recognized for the periods indicated (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,778&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,387&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,224&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,682&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,165&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,847&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,244&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Employee Stock Options&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;64% - 69%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;73% - 75%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.2% - 2.4%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.6% - 2.1%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.8% - 2.3%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.25 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.25 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.25 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Expected Dividend Yield&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8211; The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Expected Volatility&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8211; Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period.&amp;#160;&amp;#160;As the Company does not yet have sufficient history of its own volatility, the Company has identified several public entities of similar size, complexity and stage of development and estimates volatility based on the volatility of these companies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Risk-Free Interest Rate&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8211; This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Expected Term&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8211; This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ten years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company uses a simplified method to calculate the average expected term.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In addition to the assumptions above, the Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.&amp;#160;&amp;#160;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes stock option and restricted stock unit (RSU) activity for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Contractual Term&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Aggregate Intrinsic Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,146,064&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;399,949&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised or RSUs vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(526,715&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited or expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(181,238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,838,060&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,862&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,292,923&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,458&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,651,523&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,496&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; the Company issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;526,715&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;374,214&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;568,906&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; net shares of common stock, respectively, in conjunction with stock option exercises and RSU lapses.&amp;#160;&amp;#160;The Company received cash proceeds from the exercise of stock options of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The weighted-average grant-date fair value of options granted during &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.17&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20.90&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$17.41&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, respectively. The total intrinsic value of options exercised during &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$14.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&amp;#160;&amp;#160;The total fair value of stock options which vested during &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$11.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&amp;#160;&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the total unrecognized compensation expense related to non-vested stock options and RSUs, net of related forfeiture estimates, was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$22.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which the Company expects to recognize over a weighted-average period of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.5 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-73FAC4EF3F92CD157A4DE2787B0CDE3F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants.  &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="FD2016Q4YTD" id="Fact-9962440838AD05F85084E2787AF7AFF9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.34146341463415%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:38%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurement at December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quoted Prices in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Active Markets for&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Identical Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Observable Inputs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,781&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,781&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S Treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Government-sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;166,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;166,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets measured at fair value &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;251,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,781&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;204,885&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(a) Total assets measured at fair value at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; includes approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; reported in cash and cash equivalents on the balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.24390243902438%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurement at December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quoted Prices in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Active Markets for&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Identical Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Observable Inputs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62,353&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62,353&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S Treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,348&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,348&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Government-sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,202&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,202&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;137,928&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;137,928&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets measured at fair value &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;250,831&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62,353&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;188,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(a) Total assets measured at fair value at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; includes approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$108.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; reported in cash and cash equivalents on the balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2016Q4YTD" id="Fact-63C4198478D7BD6DDC53E2787AFA6B35">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements and Disclosures&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1 &amp;#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2 &amp;#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3 &amp;#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &amp;#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of Level 2 securities is determined from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data.  There were no transfers between Level 1 and Level 2 investments during the periods presented.  &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-5213590F8D56AB09EA46E2787AF9C25A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company determined that there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; impaired assets and had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; assets held-for-sale.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-D7A51D9BDD781E355467E2787B39640D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; there was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; provision for income taxes due to taxable losses generated, fully offset by a valuation allowance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred income tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal U.S. net operating loss carryforward&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;75,377&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,949&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State net operating loss carryforward&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,583&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,907&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development credit, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,829&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,278&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Orphan drug credit, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,855&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred rent&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,497&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,947&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,098&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,632&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,926&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,597&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,085&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,532&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gross deferred income tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;130,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;105,126&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(128,844&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(104,399&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net deferred income tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,406&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred income tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenditures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,406&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gross deferred income tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,406&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net deferred income tax asset/(liability)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i) future reversals of existing taxable temporary differences; (ii) future taxable income exclusive of reversing temporary difference and carryforwards; (iii) taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv) tax planning strategies. The Company's net deferred income tax asset is not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. The net increase in the valuation allowance in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is due to the fact the Company generated research and development and orphan drug credits and NOL carryforwards which increased the net deferred tax asset.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company has U.S. federal and state NOL carryforwards of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$215.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; that will expire in various years beginning in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2036&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In addition, the Company has U.S. federal tax credits of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$32.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; which will expire in various years beginning in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2036&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The use of the Company's U.S. federal NOL and tax credit carryforwards in future years are restricted due to changes in the Company's ownership and tax attributes acquired through the Company's acquisitions. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$13.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the Company's US Federal NOLs are limited for use over the years &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8211; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2029&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in which a range of such amounts could be utilized on an annual basis of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The remaining &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$201.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of NOLs is not limited and can be offset against future taxable income.&amp;#160;&amp;#160;Additionally, approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$18.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of NOLs will be recognized as a benefit through additional-paid-in-capital when realized.&amp;#160;&amp;#160;Further, despite the NOL and credit carryforwards, the Company may have a future tax liability due to an alternative minimum tax or state tax requirements in which net operating losses do not exist.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;United States federal tax at statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(20,489&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,049&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State taxes (net of federal benefit)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,116&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,608&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred income tax adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred state blended rate adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,034&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research credit, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,551&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,228&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Transaction cost deduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(379&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Transaction cost deduction - prior year adjustment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(564&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Orphan drug credit, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(571&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(106&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(139&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;145&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(382&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Equity-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,997&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,102&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;756&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,444&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,920&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income tax expense/(benefit)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,708&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Increases/(decreases) for current year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;357&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;242&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Increases/(decreases) for prior year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(268&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,465&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, of the total gross unrecognized tax benefits, approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; would favorably impact the Company's effective income tax rate, respectively. Although, due to the Company's determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance would be recorded, therefore, zero net impact would result within the Company's effective income tax rate. The Company's uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute carryforward amounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company has &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;not&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recognized any interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within the next twelve months.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company's U.S. Federal and state income tax returns from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2001&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;forward remain open to examination due to the carryover of unused net operating losses and tax credits.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-4371472E2AE9FD788D76E2787B09BF76">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company's policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-C809C289A8F527EA7A34E2787BDBE9A0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;font-weight:bold;"&gt;Marketable Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;Available-for-sale marketable securities as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt; were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,825&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Government-sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,764&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;166,376&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;166,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;200,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;56&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;200,884&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,354&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,349&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Government-sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;111,473&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;111,481&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;142,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;142,877&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;The contractual maturities of the available-for-sale marketable securities as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt; were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Mature in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;192,985&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;192,898&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Mature between one and five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,981&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,986&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;200,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;200,884&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All of the Company's available-for-sale securities held at December 31, 2015 had maturity dates of less than one year.  All available-for-sale securities in an unrealized loss position as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were in a loss position for less than twelve months.&amp;#160; There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; unrealized losses at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; that the Company determined to be other-than-temporary.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-27D0E9FFBD3729EBB8C6E2787B07A4EC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recently Issued Accounting Standards&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the FASB issued ASU No. 2014-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;"&gt;(Topic 606)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(ASU 2014-09).  ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract.  ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017 and interim periods therein, with early adoption permitted for interim and annual reporting periods beginning after December 15, 2016.  ASU 2014-09 may be adopted either retrospectively or on a modified retrospective basis&amp;#160;whereby ASU 2014-09 would be applied to new contracts and existing contracts with remaining performance obligations&amp;#160;as of the effective date, with a cumulative catch-up adjustment recorded to beginning retained&amp;#160;earnings at the effective date for existing contracts with remaining performance obligations.  &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;In 2016, the FASB issued ASU 2016-08, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;"&gt;Revenue from Contracts with Customers: Principal versus Agent Considerations&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;, ASU 2016-10,&amp;#160; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;"&gt;Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;, and ASU 2016-12, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;"&gt;Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt; &amp;#160;to provide supplemental adoption guidance and clarification to ASU 2014-09.  The effective date for these new standards is the same as the effective date and transition requirements for ASU 2014-09.  &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Management has begun an initial review of each of the Company's collaboration and license agreements and is performing an assessment of the potential effects of the standard on the Company's consolidated financial statements, accounting policies, and internal controls over financial reporting. The Company anticipates that the adoption of the new revenue recognition standard will have primarily two impacts on its contract revenues generated by its collaborative research and license agreements: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(i) Changes in the model for distinct licenses of functional intellectual property which may result in a timing difference of revenue recognition.&amp;#160;&amp;#160;Whereas revenue from these arrangements was previously recognized over a period of time pursuant to revenue recognition guidance that was in place for the arrangements at the time such arrangements commenced, revenue from these arrangements may now be recognized at point in time under the new guidance. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(ii) Assessments of milestone payments, which are linked to events that are in the Company&amp;#8217;s control, will result in variable consideration that may be recognized at an earlier point in time under the new guidance, when it is probable that the milestone will be achieved without a significant future reversal of cumulative revenue expected. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has not yet completed its final review of the impact of this guidance. The Company has also not concluded on the implementation approach to be used.&amp;#160;&amp;#160;Management plans to adopt the new standard effective January 1, 2018. The Company continues to monitor additional changes, modifications, clarifications or interpretations being undertaken by the FASB, which may impact the implementation approach management decides to use. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;In August 2014, the FASB issued ASU 2014-15, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;"&gt;Presentation of Financial Statements - Going Concern, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;which requires management of an entity to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&amp;#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued or available to be issued.  ASU 2014-15 is effective for annual periods ending after December&amp;#160;15, 2016, and interim periods within &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;annual periods beginning after December 15, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;. The Company&amp;#8217;s adoption of this new standard for the year ended December&amp;#160;31, 2016 had no impact on the Company&amp;#8217;s &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In November 2015, the FASB issued ASU No. 2015-17, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Taxes, Balance Sheet Classification of Deferred Taxes&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (ASU 2015-17).&amp;#160; ASU 2015-17 requires entities to present deferred tax assets and deferred tax liabilities as noncurrent on a classified balance sheet. ASU 2015-17 is effective for annual and interim reporting periods after December 15, 2016 and companies are permitted to apply ASU 2015-17 either prospectively or retrospectively. Early adoption of ASU 2015-17 is permitted. The Company adopted ASU 2015-17 on a prospective basis in the first quarter of 2016.&amp;#160; The prior reporting period was not retrospectively adjusted. The adoption of this guidance had no impact on the Company's results of operations or cash flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (ASU 2016-02) that provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors.&amp;#160; ASU 2016-02 requires a lessee to recognize assets and liabilities on the balance sheet for operating leases and changes many key definitions, including the definition of a lease. ASU 2016-02 includes a short-term lease exception for leases with a term of 12 months or less, in which a lessee can make an accounting policy election not to recognize lease assets and lease liabilities. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous guidance. ASU 2016-02 is effective for fiscal years beginning after December&amp;#160;15, 2018, and interim periods within those fiscal years, with earlier application permitted. The Company is currently evaluating the effect of the standard on its consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March&amp;#160;2016, the FASB issued ASU 2016-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Improvements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;to Employee Share-Based Payment Accounting &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(ASU 2016-09). This amendment addresses several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within that year. Early adoption is permitted. The Company is evaluating the impact&amp;#160;of the standard on its consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-D152BD0DCB0B21B4DBF4E2787B4ED056">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Future minimum lease payments under noncancelable operating leases as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:88%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,314&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,210&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,803&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,574&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,679&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-B3B9398A52E8097D0084E2787BC1F2F8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Organization and Nature of Operations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;MacroGenics, Inc. (the Company) was incorporated in Delaware on August 14, 2000. The Company is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. These product candidates, which the Company has identified through its understanding of disease biology and immune-mediated mechanisms, may address disease-specific challenges which are not currently being met by existing therapies.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
	<us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-E984CF98BF0BB7CD7E11E2787B7FB45B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Employee Benefit Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section 401(k) of the IRC. Under this Plan, all employees at least &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years of age are eligible to participate in the Plan, starting on the first day of each month. Employees may contribute up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of their salary, subject to government maximums.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employees are &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; vested in their contributions to the Plan. The Company's contribution to the Plan, as determined by the Board of Directors, is discretionary. The Company's contributions to the Plan totaled &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-3958D3D56D415DE1FF3AE2787B74195E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment consists of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,069&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,352&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and office equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;919&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lab equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,306&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,807&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,936&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43,784&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(25,823&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(20,190&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,961&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,841&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment balance at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; includes approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in assets that were purchased in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; but were not paid for by year end.&amp;#160; Depreciation expense for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-FC9AFE46ABA41E4781DAE2787B0D31DD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="FD2016Q4YTD" id="Fact-ED776AEACF08B4D8F2ACE2787B74DE38">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment consists of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,069&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,352&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and office equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;919&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lab equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,306&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,807&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,936&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43,784&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(25,823&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(20,190&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,961&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,841&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:QuarterlyFinancialInformationTextBlock contextRef="FD2016Q4YTD" id="Fact-68984CA5408C2717A343E2787AFBD43D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quarterly Financial Information (unaudited)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1st Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2nd Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3rd Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;4th Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(in thousands, except per share data)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80,673&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,106&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(30,363&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40,464&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(33,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34,783&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;71,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,716&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,681&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,178&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,129&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(21,376&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15,442&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(28,451&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2016Q4YTD" id="Fact-A2B485CD10564262E370E2787B0A04A1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities.&amp;#160; Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-4C659565D9261FB16398E2787C029F85">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Lease Exit Liability&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In 2008, the Company acquired Raven Biotechnologies, Inc. (Raven), a private South San Francisco-based company focused on the development of monoclonal antibody therapeutics for treating cancer. The Company undertook restructuring activities related to the acquisition of Raven. In connection with these restructuring activities, as part of the cost of acquisition, the Company established a restructuring liability attributed to an existing operating lease.&amp;#160; During the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company entered into an agreement to sublease a portion of the space subject to this operating lease.&amp;#160; The Company will receive approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in sublease payments over its term, which ends at the same time as the original lease in February 2018.&amp;#160; No sublease income was contemplated when the restructuring liability was recorded in 2008; therefore, the Company adjusted the liability to reflect the future sublease income during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and recorded an offset to research and development expenses of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the same period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Changes in the lease exit liability are as follows (in thousands): &lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:88%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrual balance at December&amp;#160;31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Principal payments and other adjustments &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,293&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrual balance at December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,713&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Principal payments and other adjustments (net of sublease receipts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,822&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrual balance at December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,891&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During 2015, the Company corrected an immaterial error attributed to the estimated lease term that resulted in a reduction of research and development expense of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Future principal payments to be made under the lease agreement as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, net of the sublease amounts, are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:88%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,593&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;298&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,891&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-B88E0E5F17C4B5FA718EE2787B0E4BEE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenues&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company enters into collaboration and license agreements with collaborators for the development of monoclonal antibody-based therapeutics to treat cancer and other complex diseases. The terms of these agreements contain multiple deliverables which may include (i) licenses, or options to obtain licenses, to the Company's technological platforms, such as its Fc Optimization and Dual-Affinity Re-Targeting (DART) technologies, (ii) rights to future technological improvements, (iii) research and development activities to be performed on behalf of the collaborator or as part of the collaboration, and (iv) the manufacture of preclinical or clinical materials for the collaborator. Payments to the Company under these agreements may include nonrefundable license fees, option fees, exercise fees, payments for research and development activities, payments for the manufacture of preclinical or clinical materials, license maintenance payments, payments based upon the achievement of certain milestones and royalties on product sales. Other benefits to the Company of these agreements include the right to sell products resulting from the collaborative efforts of the parties in specific geographic territories. The Company follows the provisions of FASB ASC Topic 605-25, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition &amp;#8211; Multiple-Element Arrangements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and FASB ASC Topic 605-28, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition&amp;#8211;Milestone Method&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, in accounting for these agreements. In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For the periods presented, the Company had the following two types of agreements: 1) exclusive development and commercialization licenses to use the Company's technology and/or certain other intellectual property to develop compounds against specified targets (referred to herein as exclusive licenses); and 2) option/research agreements to secure on established terms, development and commercialization licenses to therapeutic product candidates to collaborator-selected targets developed by the Company during an option period (referred to herein as right-to-develop agreements).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There are no performance, cancellation, termination or refund provisions in any of the arrangements that contain material financial consequences to the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Exclusive Licenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The deliverables under an exclusive license agreement generally include the exclusive license to the Company's DART technology with respect to a specified antigen target, and may also include deliverables related to rights to future technological improvements, research and preclinical development activities to be performed on behalf of the collaborator. In some cases the Company may have an option to participate in the co-development of product candidates that result from such agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Generally, exclusive license agreements contain nonrefundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i) at the collaborator's request, provide research and preclinical development services at negotiated prices which are generally consistent with what other third parties would charge, (ii) earn payments upon the achievement of certain milestones, (iii) earn royalty payments, and (iv) in some cases grant the Company an option to participate in the development and commercialization of products that result from such agreements. Royalty rates may vary over the royalty term depending on the Company's intellectual property rights and whether the Company exercises any co-development and co-commercialization rights.The Company does not directly control when any collaborator will achieve milestones or become liable for royalty payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;When entering into a new collaboration arrangement or materially modifying an existing arrangement, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator.&amp;#160;&amp;#160;The selling prices of deliverables under an arrangement may be derived using third-party evidence (TPE), or a best estimate of selling price (BESP), if vendor specific objective evidence (VSOE) is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the license agreement was sold on a standalone basis. Establishing BESP involves management's judgment and considers multiple factors, including market conditions, company-specific factors, and factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i) the delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the Company's control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of accounting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In determining the separate units of accounting, the Company evaluates whether the exclusive license has standalone value to the collaborator based on consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research and development capabilities of the collaborator and the availability of relevant research expertise in the marketplace. In addition, the Company considers whether or not (i) the collaborator could use the license for its intended purpose without the receipt of the remaining deliverables, (ii) the value of the license was dependent on the undelivered items and (iii) the collaborator or other vendors could provide the undelivered items. If the Company concludes that the license has stand-alone value and therefore will be accounted for as a separate unit of accounting, the Company then determines the estimated selling prices of the license and all other units of accounting based on market conditions, similar arrangements entered into by third parties, and entity-specific factors such as the terms of the Company's previous collaboration agreements, recent preclinical and clinical testing results of therapeutic product candidates that use the Company's technology platforms, the Company's pricing practices and pricing objectives, the likelihood that technological improvements will be made, the likelihood that technological improvements made will be used by the Company's collaborators and the nature of the research services to be performed on behalf of its collaborators and market rates for similar services. Total arrangement consideration is then allocated to each of the units of accounting using the relative-selling-price method.&amp;#160;&amp;#160;If facts and circumstances dictate that the exclusive license does not have stand-alone value, then the related payments are deferred and revenue is recognized throughout the period of performance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Management reassesses the period of performance over which the Company recognizes deferred upfront license fees and makes adjustments as appropriate in the period in which a change in the estimated period of performance is identified. In the event a collaborator elects to discontinue development of a specific product candidate under a single target license, but retains its right to use the Company's technology to develop an alternative product candidate to the same target or a target substitute, the Company would cease amortization of any remaining portion of the upfront fee until there is substantial preclinical activity on another product candidate and its remaining period of substantial involvement can be estimated. In the event that a single target license were to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination or through the remaining substantial involvement in the wind down of the agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upfront payments on exclusive licenses may be recognized upon delivery of the license if facts and circumstances dictate that the license has stand-alone value from the undelivered elements, which generally include rights to future technological improvements, research services and the manufacture of preclinical and clinical materials.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue related to research and preclinical development services that represent separate units of accounting as they are performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection is reasonably assured. The Company recognizes revenue related to the rights to future technological improvements over the estimated term of the applicable license.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company typically performs research activities and preclinical development services, including generating and engineering product candidates, on behalf of its licensees during the early evaluation and preclinical testing stages of drug development under its exclusive licenses. The Company records amounts received for research materials produced or services performed as revenue from collaborative agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company's license agreements have milestone payments which for reporting purposes are aggregated into three categories: (i) development milestones, (ii) regulatory milestones, and (iii) sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the U.S. Food and Drug Administration (FDA) or other countries' regulatory authorities or on receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At the inception of each agreement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (i) the consideration is commensurate with either (a) the entity's performance to achieve the milestone, or (b) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity's performance to achieve the milestone, (ii) the consideration relates solely to past performance and (iii) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-refundable development and regulatory milestones that are expected to be achieved as a result of the Company's efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute effort to their achievement are generally recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligations, assuming all other revenue recognition criteria are met.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Right-to-Develop Agreements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company's right-to-develop agreements provide collaborators with an exclusive option to obtain licenses to develop and commercialize in specified geographic territories product candidates developed by the Company under agreed upon research and preclinical development product programs. The product candidates resulting from each program are all directed to a specific target selected by the collaborator. Under these agreements, fees may be due to the Company (i) at the inception of the arrangement (referred to as "upfront" fees or payments), (ii) the selection of a target for a program, (iii) upon the exercise of an option to acquire a development and commercialization license (referred to as exercise fees or payments earned) for a program, or (iv) some combination of all of these fees.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accounting for right-to-develop agreements is dependent on the nature of the options granted to the collaborator. Options are considered substantive if, at the inception of a right-to-develop agreement, the Company is at risk as to whether the collaborator will choose to exercise the options to secure development and commercialization licenses. Factors that are considered in evaluating whether options are substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the total upfront consideration, and the additional financial commitments imposed on the collaborator as a result of exercising the options.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For right-to-develop agreements where the options to secure development and commercialization licenses to a product program are considered substantive, the Company does not consider the development and commercialization licenses to be a deliverable at the inception of the agreement, and therefore defers any upfront payments received and recognizes this revenue over the period during which the collaborator could elect to exercise options for development and commercialization licenses. These periods are specific to each collaboration agreement. If a collaborator selects a target for a product program, any substantive option fee is deferred and recognized over the life of the option. For right-to-develop agreements that include multiple deliverables, the Company determines the selling prices of deliverables under the arrangement using TPE or a BESP, if VSOE is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the right-to-develop agreement was sold on a standalone basis. Establishing BESP involves management's judgment and considers multiple factors, including market conditions and company-specific factors, including those factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the right-to-develop agreement. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i) the delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the Company's control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of accounting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;If a collaborator exercises an option and acquires a development and commercialization license to a product program, the Company attributes the exercise fee to the development and commercialization license. The Company determines the selling price of the option license, upon exercise, through management's best estimate using the process for an exclusive license as described above.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upon exercise of an option to acquire a development and commercialization license, the Company would also attribute any remaining deferred option fee, in addition to the consideration received for the license upon exercise of the option, to the development and commercialization license.&amp;#160;&amp;#160;The Company then applies the multiple-element revenue recognition criteria to the development and commercialization license and other deliverables, if any, to determine the appropriate revenue recognition method. This model is consistent with the Company's accounting policy for upfront payments on exclusive licenses (discussed above).&amp;#160;&amp;#160;In the event a right-to-develop agreement were to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination. The Company's right-to-develop agreements have been determined to contain substantive options.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For right-to-develop agreements where the options to secure development and commercialization licenses to product programs are not considered substantive, the Company considers the development and commercialization licenses to be a deliverable at the inception of the agreement and applies the multiple-element revenue recognition criteria to determine the appropriate revenue recognition. The Company does not directly control when any collaborator will exercise its options for development and commercialization licenses.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2016Q4YTD" id="Fact-97016F69F9F56BB320D0E2787B0916FD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following common stock equivalents were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,394,608&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,955,398&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,094,904&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="FD2016Q4YTD" id="Fact-CA2EEF323C5EE22B7E92E2787B3569F7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred income tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal U.S. net operating loss carryforward&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;75,377&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,949&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State net operating loss carryforward&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,583&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,907&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development credit, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,829&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,278&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Orphan drug credit, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,855&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred rent&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,497&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,947&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,098&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,632&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,926&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,597&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,085&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,532&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gross deferred income tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;130,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;105,126&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(128,844&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(104,399&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net deferred income tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,406&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred income tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenditures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,406&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gross deferred income tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,406&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net deferred income tax asset/(liability)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2016Q4YTD" id="Fact-962CA0B340C03FF35FF9E2787AF882C6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted loss per common share is computed as follows (in thousands except share and per share data):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.97560975609755%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss used for calculation of basic and diluted EPS&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(58,528&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(20,140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(38,313&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average shares outstanding, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,685,274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,801,645&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,384,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options and restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average shares outstanding, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,685,274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,801,645&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,384,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2016Q4YTD" id="Fact-8BA2EB0B29032863AC6CE2787B380210">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;United States federal tax at statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(20,489&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,049&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State taxes (net of federal benefit)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,116&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,608&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred income tax adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred state blended rate adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,034&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research credit, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,551&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,228&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Transaction cost deduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(379&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Transaction cost deduction - prior year adjustment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(564&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Orphan drug credit, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(571&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(106&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(139&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;145&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(382&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Equity-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,997&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,102&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;756&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,444&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,920&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income tax expense/(benefit)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2016Q4YTD" id="Fact-D3812E1EDD265D30700FE2787AE26399">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following stock-based compensation amounts were recognized for the periods indicated (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,778&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,387&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,224&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,682&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,165&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,847&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,244&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2016Q4YTD" id="Fact-21832ADD532320B445D8E2787AE48E53">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Future principal payments to be made under the lease agreement as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, net of the sublease amounts, are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:88%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,593&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;298&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,891&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="FD2016Q4YTD" id="Fact-832EBD3894BD26B54BD0E2787AFA1A6C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1st Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2nd Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3rd Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;4th Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(in thousands, except per share data)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80,673&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,106&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(30,363&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40,464&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(33,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34,783&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;71,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,716&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,681&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,178&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,129&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(21,376&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15,442&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(28,451&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
	<us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="FD2016Q4YTD" id="Fact-175A305FA47ECF8C8EB0E2787AD7A7FF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Changes in the lease exit liability are as follows (in thousands): &lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:88%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrual balance at December&amp;#160;31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Principal payments and other adjustments &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,293&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrual balance at December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,713&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Principal payments and other adjustments (net of sublease receipts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,822&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrual balance at December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,891&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2016Q4YTD" id="Fact-2FFC0F53D4666F9554AEE2787ADF8BBF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;64% - 69%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;73% - 75%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.2% - 2.4%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.6% - 2.1%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.8% - 2.3%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.25 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.25 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.25 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="FD2016Q4YTD" id="Fact-B12352A69A3EF201AFC8E2787B2A63ED">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,708&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Increases/(decreases) for current year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;357&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;242&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Increases/(decreases) for prior year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(268&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,465&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
	<us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" id="Fact-37F7D4FB3114E1261BB984370703AE1D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table includes those collaborators that represent more than 10% of total revenue earned in the periods indicated:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Janssen Biotech, Inc. (Janssen)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Les Laboratoires Servier and Institut de Reserches Servier (collectively, Servier) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Boehringer Ingelheim GmbH (Boehringer)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Takeda Pharmaceutical Company Limited (Takeda)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gilead Sciences, Inc. (Gilead)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table includes those collaborators that represent more than 10% of accounts receivable at the date indicated:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Janssen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. government&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Servier&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Takeda&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Eli Lilly&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;* Balance is less than 10%&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2016Q4YTD" id="Fact-B1A498E2865344EACC69E2787B09044F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation and Principles of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited.&amp;#160; All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; segment, which is developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, stock-based compensation, income taxes, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash, Cash Equivalents and Marketable Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income (expense).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. The Company considers factors including: the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not that it will be required to sell a security prior to recovery of its fair value.&amp;#160; An impairment loss is recognized at the time the Company determines that a decline in the fair value below its cost basis is other-than-temporary. There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt; unrealized losses at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt; or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt; that the Company determined to be other-than-temporary.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accounts Receivable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; allowance was recorded as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, as the Company has a history of collecting on all outstanding accounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements and Disclosures&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1 &amp;#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2 &amp;#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3 &amp;#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &amp;#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.34146341463415%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:38%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurement at December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quoted Prices in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Active Markets for&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Identical Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Observable Inputs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,781&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,781&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S Treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Government-sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;166,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;166,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets measured at fair value &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;251,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,781&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;204,885&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(a) Total assets measured at fair value at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; includes approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; reported in cash and cash equivalents on the balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.24390243902438%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurement at December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quoted Prices in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Active Markets for&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Identical Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Observable Inputs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62,353&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62,353&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S Treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,348&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,348&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Government-sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,202&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,202&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;137,928&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;137,928&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets measured at fair value &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;250,831&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62,353&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;188,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(a) Total assets measured at fair value at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; includes approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$108.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; reported in cash and cash equivalents on the balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of Level 2 securities is determined from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data.  There were no transfers between Level 1 and Level 2 investments during the periods presented.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;We maintain our cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, we have not experienced any losses on related accounts to date.&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;Our investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The counterparties are various corporations, financial institutions and government agencies of high credit standing.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company's revenue relates to agreements with various collaborators and&amp;#160;contracts and research grants received from U.S. government agencies.&amp;#160;The following table includes those collaborators that represent more than 10% of total revenue earned in the periods indicated:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Janssen Biotech, Inc. (Janssen)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Les Laboratoires Servier and Institut de Reserches Servier (collectively, Servier) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Boehringer Ingelheim GmbH (Boehringer)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Takeda Pharmaceutical Company Limited (Takeda)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gilead Sciences, Inc. (Gilead)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table includes those collaborators that represent more than 10% of accounts receivable at the date indicated:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Janssen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. government&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Servier&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Takeda&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Eli Lilly&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;* Balance is less than 10%&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred. Depreciation is computed using the straight-line method over the following estimated useful lives:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Laboratory and office equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shorter of lease term or useful life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company determined that there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; impaired assets and had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; assets held-for-sale.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company's policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenues&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company enters into collaboration and license agreements with collaborators for the development of monoclonal antibody-based therapeutics to treat cancer and other complex diseases. The terms of these agreements contain multiple deliverables which may include (i) licenses, or options to obtain licenses, to the Company's technological platforms, such as its Fc Optimization and Dual-Affinity Re-Targeting (DART) technologies, (ii) rights to future technological improvements, (iii) research and development activities to be performed on behalf of the collaborator or as part of the collaboration, and (iv) the manufacture of preclinical or clinical materials for the collaborator. Payments to the Company under these agreements may include nonrefundable license fees, option fees, exercise fees, payments for research and development activities, payments for the manufacture of preclinical or clinical materials, license maintenance payments, payments based upon the achievement of certain milestones and royalties on product sales. Other benefits to the Company of these agreements include the right to sell products resulting from the collaborative efforts of the parties in specific geographic territories. The Company follows the provisions of FASB ASC Topic 605-25, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition &amp;#8211; Multiple-Element Arrangements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and FASB ASC Topic 605-28, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition&amp;#8211;Milestone Method&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, in accounting for these agreements. In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For the periods presented, the Company had the following two types of agreements: 1) exclusive development and commercialization licenses to use the Company's technology and/or certain other intellectual property to develop compounds against specified targets (referred to herein as exclusive licenses); and 2) option/research agreements to secure on established terms, development and commercialization licenses to therapeutic product candidates to collaborator-selected targets developed by the Company during an option period (referred to herein as right-to-develop agreements).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There are no performance, cancellation, termination or refund provisions in any of the arrangements that contain material financial consequences to the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Exclusive Licenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The deliverables under an exclusive license agreement generally include the exclusive license to the Company's DART technology with respect to a specified antigen target, and may also include deliverables related to rights to future technological improvements, research and preclinical development activities to be performed on behalf of the collaborator. In some cases the Company may have an option to participate in the co-development of product candidates that result from such agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Generally, exclusive license agreements contain nonrefundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i) at the collaborator's request, provide research and preclinical development services at negotiated prices which are generally consistent with what other third parties would charge, (ii) earn payments upon the achievement of certain milestones, (iii) earn royalty payments, and (iv) in some cases grant the Company an option to participate in the development and commercialization of products that result from such agreements. Royalty rates may vary over the royalty term depending on the Company's intellectual property rights and whether the Company exercises any co-development and co-commercialization rights.The Company does not directly control when any collaborator will achieve milestones or become liable for royalty payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;When entering into a new collaboration arrangement or materially modifying an existing arrangement, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator.&amp;#160;&amp;#160;The selling prices of deliverables under an arrangement may be derived using third-party evidence (TPE), or a best estimate of selling price (BESP), if vendor specific objective evidence (VSOE) is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the license agreement was sold on a standalone basis. Establishing BESP involves management's judgment and considers multiple factors, including market conditions, company-specific factors, and factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i) the delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the Company's control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of accounting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In determining the separate units of accounting, the Company evaluates whether the exclusive license has standalone value to the collaborator based on consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research and development capabilities of the collaborator and the availability of relevant research expertise in the marketplace. In addition, the Company considers whether or not (i) the collaborator could use the license for its intended purpose without the receipt of the remaining deliverables, (ii) the value of the license was dependent on the undelivered items and (iii) the collaborator or other vendors could provide the undelivered items. If the Company concludes that the license has stand-alone value and therefore will be accounted for as a separate unit of accounting, the Company then determines the estimated selling prices of the license and all other units of accounting based on market conditions, similar arrangements entered into by third parties, and entity-specific factors such as the terms of the Company's previous collaboration agreements, recent preclinical and clinical testing results of therapeutic product candidates that use the Company's technology platforms, the Company's pricing practices and pricing objectives, the likelihood that technological improvements will be made, the likelihood that technological improvements made will be used by the Company's collaborators and the nature of the research services to be performed on behalf of its collaborators and market rates for similar services. Total arrangement consideration is then allocated to each of the units of accounting using the relative-selling-price method.&amp;#160;&amp;#160;If facts and circumstances dictate that the exclusive license does not have stand-alone value, then the related payments are deferred and revenue is recognized throughout the period of performance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Management reassesses the period of performance over which the Company recognizes deferred upfront license fees and makes adjustments as appropriate in the period in which a change in the estimated period of performance is identified. In the event a collaborator elects to discontinue development of a specific product candidate under a single target license, but retains its right to use the Company's technology to develop an alternative product candidate to the same target or a target substitute, the Company would cease amortization of any remaining portion of the upfront fee until there is substantial preclinical activity on another product candidate and its remaining period of substantial involvement can be estimated. In the event that a single target license were to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination or through the remaining substantial involvement in the wind down of the agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upfront payments on exclusive licenses may be recognized upon delivery of the license if facts and circumstances dictate that the license has stand-alone value from the undelivered elements, which generally include rights to future technological improvements, research services and the manufacture of preclinical and clinical materials.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue related to research and preclinical development services that represent separate units of accounting as they are performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection is reasonably assured. The Company recognizes revenue related to the rights to future technological improvements over the estimated term of the applicable license.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company typically performs research activities and preclinical development services, including generating and engineering product candidates, on behalf of its licensees during the early evaluation and preclinical testing stages of drug development under its exclusive licenses. The Company records amounts received for research materials produced or services performed as revenue from collaborative agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company's license agreements have milestone payments which for reporting purposes are aggregated into three categories: (i) development milestones, (ii) regulatory milestones, and (iii) sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the U.S. Food and Drug Administration (FDA) or other countries' regulatory authorities or on receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At the inception of each agreement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (i) the consideration is commensurate with either (a) the entity's performance to achieve the milestone, or (b) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity's performance to achieve the milestone, (ii) the consideration relates solely to past performance and (iii) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-refundable development and regulatory milestones that are expected to be achieved as a result of the Company's efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute effort to their achievement are generally recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligations, assuming all other revenue recognition criteria are met.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Right-to-Develop Agreements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company's right-to-develop agreements provide collaborators with an exclusive option to obtain licenses to develop and commercialize in specified geographic territories product candidates developed by the Company under agreed upon research and preclinical development product programs. The product candidates resulting from each program are all directed to a specific target selected by the collaborator. Under these agreements, fees may be due to the Company (i) at the inception of the arrangement (referred to as "upfront" fees or payments), (ii) the selection of a target for a program, (iii) upon the exercise of an option to acquire a development and commercialization license (referred to as exercise fees or payments earned) for a program, or (iv) some combination of all of these fees.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accounting for right-to-develop agreements is dependent on the nature of the options granted to the collaborator. Options are considered substantive if, at the inception of a right-to-develop agreement, the Company is at risk as to whether the collaborator will choose to exercise the options to secure development and commercialization licenses. Factors that are considered in evaluating whether options are substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the total upfront consideration, and the additional financial commitments imposed on the collaborator as a result of exercising the options.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For right-to-develop agreements where the options to secure development and commercialization licenses to a product program are considered substantive, the Company does not consider the development and commercialization licenses to be a deliverable at the inception of the agreement, and therefore defers any upfront payments received and recognizes this revenue over the period during which the collaborator could elect to exercise options for development and commercialization licenses. These periods are specific to each collaboration agreement. If a collaborator selects a target for a product program, any substantive option fee is deferred and recognized over the life of the option. For right-to-develop agreements that include multiple deliverables, the Company determines the selling prices of deliverables under the arrangement using TPE or a BESP, if VSOE is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the right-to-develop agreement was sold on a standalone basis. Establishing BESP involves management's judgment and considers multiple factors, including market conditions and company-specific factors, including those factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the right-to-develop agreement. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i) the delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the Company's control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of accounting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;If a collaborator exercises an option and acquires a development and commercialization license to a product program, the Company attributes the exercise fee to the development and commercialization license. The Company determines the selling price of the option license, upon exercise, through management's best estimate using the process for an exclusive license as described above.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upon exercise of an option to acquire a development and commercialization license, the Company would also attribute any remaining deferred option fee, in addition to the consideration received for the license upon exercise of the option, to the development and commercialization license.&amp;#160;&amp;#160;The Company then applies the multiple-element revenue recognition criteria to the development and commercialization license and other deliverables, if any, to determine the appropriate revenue recognition method. This model is consistent with the Company's accounting policy for upfront payments on exclusive licenses (discussed above).&amp;#160;&amp;#160;In the event a right-to-develop agreement were to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination. The Company's right-to-develop agreements have been determined to contain substantive options.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For right-to-develop agreements where the options to secure development and commercialization licenses to product programs are not considered substantive, the Company considers the development and commercialization licenses to be a deliverable at the inception of the agreement and applies the multiple-element revenue recognition criteria to determine the appropriate revenue recognition. The Company does not directly control when any collaborator will exercise its options for development and commercialization licenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities.&amp;#160; Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale securities.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Comprehensive loss equals net loss for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; unrealized gains or losses in that period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based payments are accounted for in accordance with the provisions of ASC 718, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation &amp;#8211; Stock Compensation&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted loss per common share is computed as follows (in thousands except share and per share data):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.97560975609755%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss used for calculation of basic and diluted EPS&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(58,528&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(20,140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(38,313&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average shares outstanding, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,685,274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,801,645&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,384,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options and restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average shares outstanding, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,685,274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,801,645&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,384,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following common stock equivalents were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,394,608&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,955,398&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,094,904&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recently Issued Accounting Standards&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the FASB issued ASU No. 2014-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;"&gt;(Topic 606)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(ASU 2014-09).  ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract.  ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017 and interim periods therein, with early adoption permitted for interim and annual reporting periods beginning after December 15, 2016.  ASU 2014-09 may be adopted either retrospectively or on a modified retrospective basis&amp;#160;whereby ASU 2014-09 would be applied to new contracts and existing contracts with remaining performance obligations&amp;#160;as of the effective date, with a cumulative catch-up adjustment recorded to beginning retained&amp;#160;earnings at the effective date for existing contracts with remaining performance obligations.  &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;In 2016, the FASB issued ASU 2016-08, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;"&gt;Revenue from Contracts with Customers: Principal versus Agent Considerations&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;, ASU 2016-10,&amp;#160; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;"&gt;Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;, and ASU 2016-12, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;"&gt;Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt; &amp;#160;to provide supplemental adoption guidance and clarification to ASU 2014-09.  The effective date for these new standards is the same as the effective date and transition requirements for ASU 2014-09.  &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Management has begun an initial review of each of the Company's collaboration and license agreements and is performing an assessment of the potential effects of the standard on the Company's consolidated financial statements, accounting policies, and internal controls over financial reporting. The Company anticipates that the adoption of the new revenue recognition standard will have primarily two impacts on its contract revenues generated by its collaborative research and license agreements: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(i) Changes in the model for distinct licenses of functional intellectual property which may result in a timing difference of revenue recognition.&amp;#160;&amp;#160;Whereas revenue from these arrangements was previously recognized over a period of time pursuant to revenue recognition guidance that was in place for the arrangements at the time such arrangements commenced, revenue from these arrangements may now be recognized at point in time under the new guidance. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(ii) Assessments of milestone payments, which are linked to events that are in the Company&amp;#8217;s control, will result in variable consideration that may be recognized at an earlier point in time under the new guidance, when it is probable that the milestone will be achieved without a significant future reversal of cumulative revenue expected. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has not yet completed its final review of the impact of this guidance. The Company has also not concluded on the implementation approach to be used.&amp;#160;&amp;#160;Management plans to adopt the new standard effective January 1, 2018. The Company continues to monitor additional changes, modifications, clarifications or interpretations being undertaken by the FASB, which may impact the implementation approach management decides to use. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;In August 2014, the FASB issued ASU 2014-15, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;"&gt;Presentation of Financial Statements - Going Concern, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;which requires management of an entity to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&amp;#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued or available to be issued.  ASU 2014-15 is effective for annual periods ending after December&amp;#160;15, 2016, and interim periods within &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;annual periods beginning after December 15, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;. The Company&amp;#8217;s adoption of this new standard for the year ended December&amp;#160;31, 2016 had no impact on the Company&amp;#8217;s &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In November 2015, the FASB issued ASU No. 2015-17, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Taxes, Balance Sheet Classification of Deferred Taxes&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (ASU 2015-17).&amp;#160; ASU 2015-17 requires entities to present deferred tax assets and deferred tax liabilities as noncurrent on a classified balance sheet. ASU 2015-17 is effective for annual and interim reporting periods after December 15, 2016 and companies are permitted to apply ASU 2015-17 either prospectively or retrospectively. Early adoption of ASU 2015-17 is permitted. The Company adopted ASU 2015-17 on a prospective basis in the first quarter of 2016.&amp;#160; The prior reporting period was not retrospectively adjusted. The adoption of this guidance had no impact on the Company's results of operations or cash flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (ASU 2016-02) that provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors.&amp;#160; ASU 2016-02 requires a lessee to recognize assets and liabilities on the balance sheet for operating leases and changes many key definitions, including the definition of a lease. ASU 2016-02 includes a short-term lease exception for leases with a term of 12 months or less, in which a lessee can make an accounting policy election not to recognize lease assets and lease liabilities. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous guidance. ASU 2016-02 is effective for fiscal years beginning after December&amp;#160;15, 2018, and interim periods within those fiscal years, with earlier application permitted. The Company is currently evaluating the effect of the standard on its consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March&amp;#160;2016, the FASB issued ASU 2016-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Improvements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;to Employee Share-Based Payment Accounting &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(ASU 2016-09). This amendment addresses several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within that year. Early adoption is permitted. The Company is evaluating the impact&amp;#160;of the standard on its consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-19F7A28E10A70DEE706BE2787B3DD775">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stockholders' Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;The Company's amended and restated certificate of incorporation authorizes &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;125,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of undesignated preferred stock, both with a par value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.01&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share.&amp;#160;&amp;#160;There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of undesignated preferred stock issued or outstanding as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2014, the Company completed an equity offering, in which the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,800,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$36.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share.&amp;#160;&amp;#160;Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;450,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's common stock at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$36.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share.&amp;#160;&amp;#160;The Company received proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$76.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from this offering, net of underwriting discounts and commissions and other offering expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2015, the Company's stock purchase agreement and investor agreement, each with Johnson &amp;amp; Johnson Innovation &amp;#8211; JJDC, Inc. (JJDC) became effective (See Note 9 for additional information).&amp;#160; Under these agreements, JJDC purchased &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,923,077&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; new shares of the Company's common stock at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$39.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, representing proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2015, the Company completed an equity offering, in which the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,525,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$37.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share.&amp;#160; Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;528,750&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's common stock at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$37.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share.&amp;#160; The Company received net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$141.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from this offering, net of underwriting discounts and commissions and other estimated offering expenses.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="FD2016Q4YTD" id="Fact-74E00B7BF6DB19AE951FE2787B0648E2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accounts Receivable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; allowance was recorded as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, as the Company has a history of collecting on all outstanding accounts.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
	<us-gaap:UseOfEstimates contextRef="FD2016Q4YTD" id="Fact-7FD51F8FF9EFB0B08E7CE2787B0C0EFB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, stock-based compensation, income taxes, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>mgnx-20161231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://macrogenics.com/20161231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgnx="http://macrogenics.com/20161231" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-roles-2015-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-types-2015-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2015-01-31" schemaLocation="http://xbrl.sec.gov/exch/2015/exch-2015-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20161231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20161231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20161231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20161231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="CollaborationAndOtherAgreements" roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreements">
        <link:definition>2112100 - Disclosure - Collaboration and Other Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndOtherAgreementsBoehringerDetails" roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsBoehringerDetails">
        <link:definition>2412404 - Disclosure - Collaboration and Other Agreements, Boehringer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndOtherAgreementsGreenCrossDetails" roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsGreenCrossDetails">
        <link:definition>2412405 - Disclosure - Collaboration and Other Agreements, Green Cross (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndOtherAgreementsJanssenBiotechIncDetails" roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsJanssenBiotechIncDetails">
        <link:definition>2412401 - Disclosure - Collaboration and Other Agreements, Janssen Biotech, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndOtherAgreementsNiaidContractDetails" roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsNiaidContractDetails">
        <link:definition>2412406 - Disclosure - Collaboration and Other Agreements, NIAID Contract (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndOtherAgreementsServierDetails" roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsServierDetails">
        <link:definition>2412403 - Disclosure - Collaboration and Other Agreements, Servier (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndOtherAgreementsTakedaDetails" roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsTakedaDetails">
        <link:definition>2412402 - Disclosure - Collaboration and Other Agreements, Takeda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://macrogenics.com/role/CommitmentsAndContingencies">
        <link:definition>2113100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesDetails" roleURI="http://macrogenics.com/role/CommitmentsAndContingenciesDetails">
        <link:definition>2413402 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://macrogenics.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2313301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://macrogenics.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://macrogenics.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://macrogenics.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://macrogenics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfStockholdersEquity" roleURI="http://macrogenics.com/role/ConsolidatedStatementsOfStockholdersEquity">
        <link:definition>1003000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://macrogenics.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://macrogenics.com/role/EmployeeBenefitPlan">
        <link:definition>2114100 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanDetails" roleURI="http://macrogenics.com/role/EmployeeBenefitPlanDetails">
        <link:definition>2414401 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://macrogenics.com/role/IncomeTaxes">
        <link:definition>2110100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsOfCompanysDeferredTaxAssetsLiabilitiesDetails" roleURI="http://macrogenics.com/role/IncomeTaxesComponentsOfCompanysDeferredTaxAssetsLiabilitiesDetails">
        <link:definition>2410402 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails" roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>2410404 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefitDetails" roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefitDetails">
        <link:definition>2410403 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://macrogenics.com/role/IncomeTaxesTables">
        <link:definition>2310301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseExitLiability" roleURI="http://macrogenics.com/role/LeaseExitLiability">
        <link:definition>2111100 - Disclosure - Lease Exit Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseExitLiabilityChangesInLeaseExitLiabilityDetails" roleURI="http://macrogenics.com/role/LeaseExitLiabilityChangesInLeaseExitLiabilityDetails">
        <link:definition>2411403 - Disclosure - Lease Exit Liability - Changes in Lease Exit Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreementDetails" roleURI="http://macrogenics.com/role/LeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreementDetails">
        <link:definition>2411404 - Disclosure - Lease Exit Liability - Future Principal Payments Under Lease Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseExitLiabilityLeaseExitLiabilityNarrativeDetails" roleURI="http://macrogenics.com/role/LeaseExitLiabilityLeaseExitLiabilityNarrativeDetails">
        <link:definition>2411402 - Disclosure - Lease Exit Liability Lease Exit Liability - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseExitLiabilityTables" roleURI="http://macrogenics.com/role/LeaseExitLiabilityTables">
        <link:definition>2311301 - Disclosure - Lease Exit Liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://macrogenics.com/role/MarketableSecurities">
        <link:definition>2103100 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails">
        <link:definition>2403402 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetailsCalc2" roleURI="http://macrogenics.com/role/MarketableSecuritiesDetailsCalc2">
        <link:definition>2403402 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://macrogenics.com/role/MarketableSecuritiesTables">
        <link:definition>2303301 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndNatureOfOperations" roleURI="http://macrogenics.com/role/OrganizationAndNatureOfOperations">
        <link:definition>2101100 - Disclosure - Organization and Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipment" roleURI="http://macrogenics.com/role/PropertyAndEquipment">
        <link:definition>2104100 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentDetails" roleURI="http://macrogenics.com/role/PropertyAndEquipmentDetails">
        <link:definition>2404402 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentTables" roleURI="http://macrogenics.com/role/PropertyAndEquipmentTables">
        <link:definition>2304301 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnaudited" roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited">
        <link:definition>2115100 - Disclosure - Quarterly Financial Information (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnauditedDetails" roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails">
        <link:definition>2415402 - Disclosure - Quarterly Financial Information (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnauditedTables" roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables">
        <link:definition>2315301 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://macrogenics.com/role/StockBasedCompensation">
        <link:definition>2106100 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationOptionPricingAssumptionsDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails">
        <link:definition>2406403 - Disclosure - Stock- based Compensation - Option Pricing Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2406402 - Disclosure - Stock- based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails">
        <link:definition>2406404 - Disclosure - Stock- based Compensation - Stock Option and Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://macrogenics.com/role/StockBasedCompensationTables">
        <link:definition>2306301 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://macrogenics.com/role/StockholdersEquity">
        <link:definition>2105100 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://macrogenics.com/role/StockholdersEquityDetails">
        <link:definition>2405401 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShareDetails" roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShareDetails">
        <link:definition>2402408 - Disclosure - Summary of Significant Accounting Policies - Computation of Basic and Diluted Income (Loss) Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>2402403 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails">
        <link:definition>2402407 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedLossPerShareDetails" roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedLossPerShareDetails">
        <link:definition>2402409 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivableDetails" roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivableDetails">
        <link:definition>2402406 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarnedDetails" roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarnedDetails">
        <link:definition>2402405 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilitiesDetails" roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilitiesDetails">
        <link:definition>2402404 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" name="AdditionalDevelopmentFundingOptionsUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement" name="AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" name="AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement" name="AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement" name="AdditionalPotentialSalesMilestonePaymentsUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification" name="AdjustmentToRevenueUnderAccountingStandardsCodification" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_AggregatePotentialFutureCostReimbursement" name="AggregatePotentialFutureCostReimbursement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_AmountAllocatedToEquity" name="AmountAllocatedToEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_AmountAllocatedToLicenseAndRD" name="AmountAllocatedToLicenseAndRD" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_AmountOfImmaterialErrorCorrection" name="AmountOfImmaterialErrorCorrection" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_BoehringerIngelheimMember" name="BoehringerIngelheimMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_ChangeInAccountingEstimateCurrentYearImpact" name="ChangeInAccountingEstimateCurrentYearImpact" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_ClinicalMilestoneEarnedDuringPeriod" name="ClinicalMilestoneEarnedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="mgnx_CollaborationAndLicenseAgreementsAbstract" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" name="CollaborationAndLicenseAgreementsDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" name="CollaborationArrangementOffsetToResearchAndDevelopmentCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" name="CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" name="DefinedContributionPlanEmployeesContributionVestedPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" name="DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" name="EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount" name="EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_EliLillyMember" name="EliLillyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" name="EmployeesEligibleAgeToParticipateInBenefitPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_EquityIncentivePlan2003Member" name="EquityIncentivePlan2003Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_FundedValueOfBasePeriod" name="FundedValueOfBasePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_FurnitureAndOfficeEquipmentMember" name="FurnitureAndOfficeEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_GileadSciencesIncMember" name="GileadSciencesIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_GreenCrossCorporationMember" name="GreenCrossCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_IncomeTaxRateReconciliationDeductionPriorYearAdjustment" name="IncomeTaxRateReconciliationDeductionPriorYearAdjustment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_IncreaseDecreaseInDeferredRent" name="IncreaseDecreaseInDeferredRent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_JanssenBiotechIncMember" name="JanssenBiotechIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_JanssenMGD011AgreementMember" name="JanssenMGD011AgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_JanssenMGD015AgreementMember" name="JanssenMGD015AgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_JohnsonAndJohnsonDevelopmentCorporationMember" name="JohnsonAndJohnsonDevelopmentCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_LaboratoryAndOfficeEquipmentMember" name="LaboratoryAndOfficeEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_MixedUseOfficeLaboratoryAndManufacturingSpaceMember" name="MixedUseOfficeLaboratoryAndManufacturingSpaceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_NonRefundableUpfrontFees" name="NonRefundableUpfrontFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_NumberOfAnnualMaintenancePaymentReceived" name="NumberOfAnnualMaintenancePaymentReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_NumberOfLease" name="NumberOfLease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_NumberOfMilestonesAchieved" name="NumberOfMilestonesAchieved" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" name="NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" name="OperatingLossCarryforwardsAnnualLimitationAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" name="OperatingLossCarryforwardsLimitationsOnUseAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" name="OperatingLossCarryforwardsNotSubjectToLimitation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_OptionExerciseFee" name="OptionExerciseFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_OptionExerciseFeeRecognitionPeriod" name="OptionExerciseFeeRecognitionPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_OriginalPeriodOfDevelopment" name="OriginalPeriodOfDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" name="PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_PotentialClinicalMilestonePaymentsUnderAgreement" name="PotentialClinicalMilestonePaymentsUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_PotentialLicenseFee" name="PotentialLicenseFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement" name="PotentialRegulatoryMilestonePaymentsUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_PotentialSalesMilestonePaymentsUnderAgreement" name="PotentialSalesMilestonePaymentsUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_PremiumReceivedOnStockPurchase" name="PremiumReceivedOnStockPurchase" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_ProceedsFromResearchAndDevelopmentServices" name="ProceedsFromResearchAndDevelopmentServices" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" name="PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_PropertyPlantAndEquipmentNonCashAdditions" name="PropertyPlantAndEquipmentNonCashAdditions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="mgnx_RavenBiotechnologiesIncMember" name="RavenBiotechnologiesIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_ReductionInResearchAndDevelopmentExpense" name="ReductionInResearchAndDevelopmentExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_ResearchCollaborationAndLicenseOptionAgreementMember" name="ResearchCollaborationAndLicenseOptionAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_ReviewPeriodByRegulatoryAuthority" name="ReviewPeriodByRegulatoryAuthority" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" name="ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_ServierDARTMember" name="ServierDARTMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_ServierMGA271Member" name="ServierMGA271Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_ServierMember" name="ServierMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_StockIncentivePlan2013Member" name="StockIncentivePlan2013Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" name="StockIssuedDuringPeriodSharesStockPlanActivity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" name="StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_StockIssuedDuringPeriodValueStockPlanActivity" name="StockIssuedDuringPeriodValueStockPlanActivity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_TakedaMGD010AgreementMember" name="TakedaMGD010AgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_TakedaMember" name="TakedaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_TakedaPharmaceuticalMember" name="TakedaPharmaceuticalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_TotalConsideration" name="TotalConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_TotalPotentialValueUnderAgreement" name="TotalPotentialValueUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_USGovernmentMember" name="USGovernmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_UndesignatedPreferredStockMember" name="UndesignatedPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward" name="UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_UpfrontFeeAllocatedToAgreement" name="UpfrontFeeAllocatedToAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_UpfrontPaymentRecognitionPeriod" name="UpfrontPaymentRecognitionPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>mgnx-20161231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreements" xlink:href="mgnx-20161231.xsd#CollaborationAndOtherAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsBoehringerDetails" xlink:href="mgnx-20161231.xsd#CollaborationAndOtherAgreementsBoehringerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsGreenCrossDetails" xlink:href="mgnx-20161231.xsd#CollaborationAndOtherAgreementsGreenCrossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsJanssenBiotechIncDetails" xlink:href="mgnx-20161231.xsd#CollaborationAndOtherAgreementsJanssenBiotechIncDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsNiaidContractDetails" xlink:href="mgnx-20161231.xsd#CollaborationAndOtherAgreementsNiaidContractDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsServierDetails" xlink:href="mgnx-20161231.xsd#CollaborationAndOtherAgreementsServierDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsTakedaDetails" xlink:href="mgnx-20161231.xsd#CollaborationAndOtherAgreementsTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsAndContingencies" xlink:href="mgnx-20161231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsAndContingenciesDetails" xlink:href="mgnx-20161231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsAndContingenciesTables" xlink:href="mgnx-20161231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedBalanceSheets" xlink:href="mgnx-20161231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="mgnx-20161231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="mgnx-20161231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="mgnx-20161231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="mgnx-20161231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/DocumentAndEntityInformation" xlink:href="mgnx-20161231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:href="mgnx-20161231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:href="mgnx-20161231.xsd#EmployeeBenefitPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxes" xlink:href="mgnx-20161231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesComponentsOfCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:href="mgnx-20161231.xsd#IncomeTaxesComponentsOfCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails" xlink:href="mgnx-20161231.xsd#IncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefitDetails" xlink:href="mgnx-20161231.xsd#IncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesTables" xlink:href="mgnx-20161231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiability" xlink:href="mgnx-20161231.xsd#LeaseExitLiability" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiabilityChangesInLeaseExitLiabilityDetails" xlink:href="mgnx-20161231.xsd#LeaseExitLiabilityChangesInLeaseExitLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreementDetails" xlink:href="mgnx-20161231.xsd#LeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiabilityLeaseExitLiabilityNarrativeDetails" xlink:href="mgnx-20161231.xsd#LeaseExitLiabilityLeaseExitLiabilityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiabilityTables" xlink:href="mgnx-20161231.xsd#LeaseExitLiabilityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:href="mgnx-20161231.xsd#MarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:href="mgnx-20161231.xsd#MarketableSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetailsCalc2" xlink:href="mgnx-20161231.xsd#MarketableSecuritiesDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:href="mgnx-20161231.xsd#MarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/OrganizationAndNatureOfOperations" xlink:href="mgnx-20161231.xsd#OrganizationAndNatureOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyAndEquipment" xlink:href="mgnx-20161231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyAndEquipmentDetails" xlink:href="mgnx-20161231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyAndEquipmentTables" xlink:href="mgnx-20161231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited" xlink:href="mgnx-20161231.xsd#QuarterlyFinancialInformationUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:href="mgnx-20161231.xsd#QuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:href="mgnx-20161231.xsd#QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensation" xlink:href="mgnx-20161231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:href="mgnx-20161231.xsd#StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:href="mgnx-20161231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails" xlink:href="mgnx-20161231.xsd#StockBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationTables" xlink:href="mgnx-20161231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:href="mgnx-20161231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:href="mgnx-20161231.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShareDetails" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedLossPerShareDetails" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivableDetails" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarnedDetails" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarnedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilitiesDetails" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsBoehringerDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsGreenCrossDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsJanssenBiotechIncDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsNiaidContractDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsServierDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsTakedaDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_6282e4c0-b0bd-9c84-bf43-857ac02b98fc" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8a0692b4-cb50-1eeb-12b4-1509099841b7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_6282e4c0-b0bd-9c84-bf43-857ac02b98fc" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8a0692b4-cb50-1eeb-12b4-1509099841b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_4c8190eb-f692-81f2-35bc-182f11d12444" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_6282e4c0-b0bd-9c84-bf43-857ac02b98fc" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_4c8190eb-f692-81f2-35bc-182f11d12444" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_baee32aa-bbe2-ead3-1f78-a80f542a97a2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_6282e4c0-b0bd-9c84-bf43-857ac02b98fc" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_baee32aa-bbe2-ead3-1f78-a80f542a97a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5e342c11-473b-4170-d672-935adcfdb463" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_6282e4c0-b0bd-9c84-bf43-857ac02b98fc" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5e342c11-473b-4170-d672-935adcfdb463" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_c48f63ae-e409-59ce-5794-cc7ae6139c21" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_6282e4c0-b0bd-9c84-bf43-857ac02b98fc" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_c48f63ae-e409-59ce-5794-cc7ae6139c21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_6adcb5b9-fb65-97ee-8a5b-2e780c178728" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_6282e4c0-b0bd-9c84-bf43-857ac02b98fc" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_6adcb5b9-fb65-97ee-8a5b-2e780c178728" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_effc14df-fd72-eec8-ede9-64e0071b91bc" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_39eaeb62-7ee3-5503-48f5-08c2dff05e50" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_effc14df-fd72-eec8-ede9-64e0071b91bc" xlink:to="loc_us-gaap_AssetsCurrent_39eaeb62-7ee3-5503-48f5-08c2dff05e50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cd34decb-53b6-e0a9-28d5-0a9741c4b0f8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39eaeb62-7ee3-5503-48f5-08c2dff05e50" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cd34decb-53b6-e0a9-28d5-0a9741c4b0f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_222b5a74-9526-7448-da46-fccf1775d7c0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39eaeb62-7ee3-5503-48f5-08c2dff05e50" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_222b5a74-9526-7448-da46-fccf1775d7c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4d24e56f-a5cb-07ba-0508-f5f1533ae24e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39eaeb62-7ee3-5503-48f5-08c2dff05e50" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4d24e56f-a5cb-07ba-0508-f5f1533ae24e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_b3090934-8a46-705d-b2a1-f192f64fe191" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39eaeb62-7ee3-5503-48f5-08c2dff05e50" xlink:to="loc_us-gaap_OtherAssets_b3090934-8a46-705d-b2a1-f192f64fe191" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_290bf57d-cf88-b5a0-ebfc-cf698dca5a98" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39eaeb62-7ee3-5503-48f5-08c2dff05e50" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_290bf57d-cf88-b5a0-ebfc-cf698dca5a98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7ce178a4-245f-fa78-36a1-552609a67554" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_effc14df-fd72-eec8-ede9-64e0071b91bc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7ce178a4-245f-fa78-36a1-552609a67554" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_392a46ef-05fd-68f8-e487-35e85a8f15a1" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_effc14df-fd72-eec8-ede9-64e0071b91bc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_392a46ef-05fd-68f8-e487-35e85a8f15a1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9b98e689-e6db-3e5b-e5c3-3324fffb4edf" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_effc14df-fd72-eec8-ede9-64e0071b91bc" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9b98e689-e6db-3e5b-e5c3-3324fffb4edf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4a314f0d-c6fa-5cf2-0be1-add747465af3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_4e70462c-e5f6-e2d9-0cf5-7f1332ddbc05" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4a314f0d-c6fa-5cf2-0be1-add747465af3" xlink:to="loc_us-gaap_Liabilities_4e70462c-e5f6-e2d9-0cf5-7f1332ddbc05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_1de50dbc-01a9-6657-f83f-d1e74edfdf18" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4e70462c-e5f6-e2d9-0cf5-7f1332ddbc05" xlink:to="loc_us-gaap_LiabilitiesCurrent_1de50dbc-01a9-6657-f83f-d1e74edfdf18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_22caddf9-3843-6329-6e39-dc458323b572" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1de50dbc-01a9-6657-f83f-d1e74edfdf18" xlink:to="loc_us-gaap_AccountsPayableCurrent_22caddf9-3843-6329-6e39-dc458323b572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_eaf92fb1-642d-2c65-5ba7-1a63a3697f47" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1de50dbc-01a9-6657-f83f-d1e74edfdf18" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_eaf92fb1-642d-2c65-5ba7-1a63a3697f47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_a33614ee-2047-2d07-d4dc-cd97b29aa0eb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1de50dbc-01a9-6657-f83f-d1e74edfdf18" xlink:to="loc_us-gaap_DeferredRevenueCurrent_a33614ee-2047-2d07-d4dc-cd97b29aa0eb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_ccc889c0-8c69-212f-757d-76e7bd4dae1a" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1de50dbc-01a9-6657-f83f-d1e74edfdf18" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_ccc889c0-8c69-212f-757d-76e7bd4dae1a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="loc_us-gaap_RestructuringReserveCurrent_998a81b7-ae3e-a966-e17e-0d0af3f84a28" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1de50dbc-01a9-6657-f83f-d1e74edfdf18" xlink:to="loc_us-gaap_RestructuringReserveCurrent_998a81b7-ae3e-a966-e17e-0d0af3f84a28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0d8009a1-9f3a-b52e-6afc-03d7b3b4df06" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1de50dbc-01a9-6657-f83f-d1e74edfdf18" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0d8009a1-9f3a-b52e-6afc-03d7b3b4df06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_4ca8aac1-2306-11d6-0ee3-d0bcb454b02f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4e70462c-e5f6-e2d9-0cf5-7f1332ddbc05" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_4ca8aac1-2306-11d6-0ee3-d0bcb454b02f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_837ff1b5-f4a9-6226-286b-ca7e18b0c168" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4e70462c-e5f6-e2d9-0cf5-7f1332ddbc05" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_837ff1b5-f4a9-6226-286b-ca7e18b0c168" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserveNoncurrent" xlink:label="loc_us-gaap_RestructuringReserveNoncurrent_13aa9312-f501-7060-14a4-f77735344ece" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4e70462c-e5f6-e2d9-0cf5-7f1332ddbc05" xlink:to="loc_us-gaap_RestructuringReserveNoncurrent_13aa9312-f501-7060-14a4-f77735344ece" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_d0f349aa-18e3-6323-86ad-665f8773c064" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4a314f0d-c6fa-5cf2-0be1-add747465af3" xlink:to="loc_us-gaap_StockholdersEquity_d0f349aa-18e3-6323-86ad-665f8773c064" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_ce40a301-9b6b-9fc3-bfb6-dfbb8fcdf29b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d0f349aa-18e3-6323-86ad-665f8773c064" xlink:to="loc_us-gaap_CommonStockValue_ce40a301-9b6b-9fc3-bfb6-dfbb8fcdf29b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8d1ec446-d346-e57d-d34b-0cb90bceaaba" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d0f349aa-18e3-6323-86ad-665f8773c064" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8d1ec446-d346-e57d-d34b-0cb90bceaaba" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1f8404e1-51ca-3815-5fb1-ababdf27715f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d0f349aa-18e3-6323-86ad-665f8773c064" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1f8404e1-51ca-3815-5fb1-ababdf27715f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1d565cd0-d7bf-de89-4dbe-a484007b1fe8" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d0f349aa-18e3-6323-86ad-665f8773c064" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1d565cd0-d7bf-de89-4dbe-a484007b1fe8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://macrogenics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ff5db18e-7b91-5a5d-e914-0527b02a8012" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ccd1614-9a87-83c1-3be9-8188ac1300a8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ff5db18e-7b91-5a5d-e914-0527b02a8012" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ccd1614-9a87-83c1-3be9-8188ac1300a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e62ce8b8-4401-2622-8598-3e644745e95e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ccd1614-9a87-83c1-3be9-8188ac1300a8" xlink:to="loc_us-gaap_NetIncomeLoss_e62ce8b8-4401-2622-8598-3e644745e95e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_783b94c5-664a-4bc7-f813-8c258cc934b7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ccd1614-9a87-83c1-3be9-8188ac1300a8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_783b94c5-664a-4bc7-f813-8c258cc934b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_d4c99b59-c44a-c4ac-309f-0bddfdb944a5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ccd1614-9a87-83c1-3be9-8188ac1300a8" xlink:to="loc_us-gaap_ShareBasedCompensation_d4c99b59-c44a-c4ac-309f-0bddfdb944a5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_91d80b53-6368-7466-a11d-02030d33de5c" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ccd1614-9a87-83c1-3be9-8188ac1300a8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_91d80b53-6368-7466-a11d-02030d33de5c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_e7628bfe-188d-34d3-32e9-4b04bae1ba2c" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ccd1614-9a87-83c1-3be9-8188ac1300a8" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_e7628bfe-188d-34d3-32e9-4b04bae1ba2c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_d93d5f02-d089-fb60-608e-73232ee32133" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ccd1614-9a87-83c1-3be9-8188ac1300a8" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_d93d5f02-d089-fb60-608e-73232ee32133" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6726a997-b874-a6f6-d79f-e0a4bde49905" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ccd1614-9a87-83c1-3be9-8188ac1300a8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6726a997-b874-a6f6-d79f-e0a4bde49905" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a167e25c-e8b1-aeb8-f355-3727e3f06f3e" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ccd1614-9a87-83c1-3be9-8188ac1300a8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a167e25c-e8b1-aeb8-f355-3727e3f06f3e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1ea297cc-8653-7155-6fa9-a3af7df49950" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ccd1614-9a87-83c1-3be9-8188ac1300a8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1ea297cc-8653-7155-6fa9-a3af7df49950" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:label="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_a2f0fc3c-ae40-b2f3-f31d-aabcc238c525" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ccd1614-9a87-83c1-3be9-8188ac1300a8" xlink:to="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_a2f0fc3c-ae40-b2f3-f31d-aabcc238c525" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_ccf69244-7aaf-19cf-90d6-269f163732c4" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ccd1614-9a87-83c1-3be9-8188ac1300a8" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_ccf69244-7aaf-19cf-90d6-269f163732c4" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_IncreaseDecreaseInDeferredRent" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent_43cbfe2f-a1c6-d855-b09b-e2782cc8efed" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ccd1614-9a87-83c1-3be9-8188ac1300a8" xlink:to="loc_mgnx_IncreaseDecreaseInDeferredRent_43cbfe2f-a1c6-d855-b09b-e2782cc8efed" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_d4a99ec2-3e43-bbed-7f30-a333136d697a" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ccd1614-9a87-83c1-3be9-8188ac1300a8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_d4a99ec2-3e43-bbed-7f30-a333136d697a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1399ec7f-d333-641c-d0c0-2d49567c2e2a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ff5db18e-7b91-5a5d-e914-0527b02a8012" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1399ec7f-d333-641c-d0c0-2d49567c2e2a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_a2a2354e-ae02-73fb-dfbd-8a5cf012f928" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1399ec7f-d333-641c-d0c0-2d49567c2e2a" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_a2a2354e-ae02-73fb-dfbd-8a5cf012f928" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_198988d2-2f05-3f47-d4f0-bce81f98eaf0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1399ec7f-d333-641c-d0c0-2d49567c2e2a" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_198988d2-2f05-3f47-d4f0-bce81f98eaf0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_386292ff-155c-0309-455a-2b91b395b3da" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1399ec7f-d333-641c-d0c0-2d49567c2e2a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_386292ff-155c-0309-455a-2b91b395b3da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_e5890061-8327-8e2a-3fbd-6d1690a72b44" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ff5db18e-7b91-5a5d-e914-0527b02a8012" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_e5890061-8327-8e2a-3fbd-6d1690a72b44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8c608436-f07c-e907-aa0d-bfd819a80a12" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_e5890061-8327-8e2a-3fbd-6d1690a72b44" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8c608436-f07c-e907-aa0d-bfd819a80a12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f1b85fa1-97cd-57cc-5318-fb8dd976eb81" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_e5890061-8327-8e2a-3fbd-6d1690a72b44" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f1b85fa1-97cd-57cc-5318-fb8dd976eb81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2660b777-f313-aa0f-f2f0-b727ebbc5b13" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_e5890061-8327-8e2a-3fbd-6d1690a72b44" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2660b777-f313-aa0f-f2f0-b727ebbc5b13" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://macrogenics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_58e3e908-4af5-683d-5a7a-0ca47c8e456d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e62ce8b8-4401-2622-8598-3e644745e95e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_58e3e908-4af5-683d-5a7a-0ca47c8e456d" xlink:to="loc_us-gaap_NetIncomeLoss_e62ce8b8-4401-2622-8598-3e644745e95e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_0ea1551e-1643-5e21-4c6e-6431fd87aa68" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e62ce8b8-4401-2622-8598-3e644745e95e" xlink:to="loc_us-gaap_OperatingIncomeLoss_0ea1551e-1643-5e21-4c6e-6431fd87aa68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_ba59260a-e348-d7f8-5375-fde11baf79c1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0ea1551e-1643-5e21-4c6e-6431fd87aa68" xlink:to="loc_us-gaap_Revenues_ba59260a-e348-d7f8-5375-fde11baf79c1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_us-gaap_LicenseAndServicesRevenue_6bca522f-8408-bde3-e226-12503ce2a855" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_ba59260a-e348-d7f8-5375-fde11baf79c1" xlink:to="loc_us-gaap_LicenseAndServicesRevenue_6bca522f-8408-bde3-e226-12503ce2a855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_2b5d2ad3-ca0c-6d78-453f-044abdb8cc4b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_ba59260a-e348-d7f8-5375-fde11baf79c1" xlink:to="loc_us-gaap_RevenueFromGrants_2b5d2ad3-ca0c-6d78-453f-044abdb8cc4b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_8281466b-86c7-ec9c-c7fc-3723705ba526" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0ea1551e-1643-5e21-4c6e-6431fd87aa68" xlink:to="loc_us-gaap_CostsAndExpenses_8281466b-86c7-ec9c-c7fc-3723705ba526" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6a3cb05a-f9c0-32f6-d20f-a948f53d0ee5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8281466b-86c7-ec9c-c7fc-3723705ba526" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6a3cb05a-f9c0-32f6-d20f-a948f53d0ee5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_69f193f1-2583-2a25-604c-cc949229c2d8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8281466b-86c7-ec9c-c7fc-3723705ba526" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_69f193f1-2583-2a25-604c-cc949229c2d8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_51486ac3-3cfb-dff4-43ca-0d3980775a1d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e62ce8b8-4401-2622-8598-3e644745e95e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_51486ac3-3cfb-dff4-43ca-0d3980775a1d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8449f638-e094-e8fc-6726-9e09a5f21c54" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_58e3e908-4af5-683d-5a7a-0ca47c8e456d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8449f638-e094-e8fc-6726-9e09a5f21c54" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://macrogenics.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesComponentsOfCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_7ab95885-50a1-f3b5-4737-49b616fc51d6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_c9103802-e01c-0411-2da8-2206c8e6cbaf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_7ab95885-50a1-f3b5-4737-49b616fc51d6" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_c9103802-e01c-0411-2da8-2206c8e6cbaf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ae76b0a4-0e26-3d8f-4ecb-c8186dd802d0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c9103802-e01c-0411-2da8-2206c8e6cbaf" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_ae76b0a4-0e26-3d8f-4ecb-c8186dd802d0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_a6e95cb9-f84e-2901-2770-7715240e3c97" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ae76b0a4-0e26-3d8f-4ecb-c8186dd802d0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_a6e95cb9-f84e-2901-2770-7715240e3c97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_04d3fcc1-7adb-59a6-41b5-75bbb47801f6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ae76b0a4-0e26-3d8f-4ecb-c8186dd802d0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_04d3fcc1-7adb-59a6-41b5-75bbb47801f6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d5eac5d2-09a1-57ad-5162-7ab7e28ad31e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ae76b0a4-0e26-3d8f-4ecb-c8186dd802d0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d5eac5d2-09a1-57ad-5162-7ab7e28ad31e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_d8cacd9e-0a7b-9cca-cdec-c155c3204e34" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ae76b0a4-0e26-3d8f-4ecb-c8186dd802d0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_d8cacd9e-0a7b-9cca-cdec-c155c3204e34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_40627278-dad4-5a0f-329b-5115a45ba8df" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ae76b0a4-0e26-3d8f-4ecb-c8186dd802d0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_40627278-dad4-5a0f-329b-5115a45ba8df" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_2bda83ba-0db3-98b0-761b-d8fe7c271584" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ae76b0a4-0e26-3d8f-4ecb-c8186dd802d0" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_2bda83ba-0db3-98b0-761b-d8fe7c271584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_78b16c0c-fb0d-d9ad-6dd8-2191ea4cf06a" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ae76b0a4-0e26-3d8f-4ecb-c8186dd802d0" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_78b16c0c-fb0d-d9ad-6dd8-2191ea4cf06a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_d2894808-c556-546c-7bdb-cf4d5d84446f" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ae76b0a4-0e26-3d8f-4ecb-c8186dd802d0" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_d2894808-c556-546c-7bdb-cf4d5d84446f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_43429341-a7f8-3d28-8300-64e1feef8fa0" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c9103802-e01c-0411-2da8-2206c8e6cbaf" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_43429341-a7f8-3d28-8300-64e1feef8fa0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_3e14f64d-d2f6-3fdd-a49d-772a2e1ab66a" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_7ab95885-50a1-f3b5-4737-49b616fc51d6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_3e14f64d-d2f6-3fdd-a49d-772a2e1ab66a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_e40fbc7e-e577-3a13-10f2-03285653a3e0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_3e14f64d-d2f6-3fdd-a49d-772a2e1ab66a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_e40fbc7e-e577-3a13-10f2-03285653a3e0" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b8dcf191-083d-828d-7b9f-e2d2969b89f4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_23dfa76f-a323-ebe5-1756-72b60cc125de" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b8dcf191-083d-828d-7b9f-e2d2969b89f4" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_23dfa76f-a323-ebe5-1756-72b60cc125de" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_9a82a053-a83b-f7b5-55e1-2d615631a3f2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b8dcf191-083d-828d-7b9f-e2d2969b89f4" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_9a82a053-a83b-f7b5-55e1-2d615631a3f2" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_a7fd9c6e-7934-2fee-b7c2-e2782cc94d8c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b8dcf191-083d-828d-7b9f-e2d2969b89f4" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_a7fd9c6e-7934-2fee-b7c2-e2782cc94d8c" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount" xlink:label="loc_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_42ec4868-3e9b-2831-2d29-e2782cc9b129" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b8dcf191-083d-828d-7b9f-e2d2969b89f4" xlink:to="loc_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_42ec4868-3e9b-2831-2d29-e2782cc9b129" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_35e98a8c-9478-3929-cd2c-46ed8c45d1ed" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b8dcf191-083d-828d-7b9f-e2d2969b89f4" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_35e98a8c-9478-3929-cd2c-46ed8c45d1ed" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationDeductions" xlink:label="loc_us-gaap_IncomeTaxReconciliationDeductions_ca033ed0-807e-e080-f101-1f481438546b" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b8dcf191-083d-828d-7b9f-e2d2969b89f4" xlink:to="loc_us-gaap_IncomeTaxReconciliationDeductions_ca033ed0-807e-e080-f101-1f481438546b" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_IncomeTaxRateReconciliationDeductionPriorYearAdjustment" xlink:label="loc_mgnx_IncomeTaxRateReconciliationDeductionPriorYearAdjustment_6ef364f9-2308-f55c-9ff3-e2782cc96500" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b8dcf191-083d-828d-7b9f-e2d2969b89f4" xlink:to="loc_mgnx_IncomeTaxRateReconciliationDeductionPriorYearAdjustment_6ef364f9-2308-f55c-9ff3-e2782cc96500" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_773c2f6c-ade4-828e-9605-5067295b6dbf" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b8dcf191-083d-828d-7b9f-e2d2969b89f4" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_773c2f6c-ade4-828e-9605-5067295b6dbf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_1fdefd2f-d853-0a9a-f5f8-180343aa3e64" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b8dcf191-083d-828d-7b9f-e2d2969b89f4" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_1fdefd2f-d853-0a9a-f5f8-180343aa3e64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_c5d5e46a-1f68-96cb-22d6-ccc29d0c2a99" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b8dcf191-083d-828d-7b9f-e2d2969b89f4" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_c5d5e46a-1f68-96cb-22d6-ccc29d0c2a99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_38b23e59-fe3b-da98-561d-a315421d29db" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b8dcf191-083d-828d-7b9f-e2d2969b89f4" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_38b23e59-fe3b-da98-561d-a315421d29db" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/LeaseExitLiability" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/LeaseExitLiabilityChangesInLeaseExitLiabilityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/LeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_6282e4c0-b0bd-9c84-bf43-857ac02b98fc" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8a0692b4-cb50-1eeb-12b4-1509099841b7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_6282e4c0-b0bd-9c84-bf43-857ac02b98fc" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8a0692b4-cb50-1eeb-12b4-1509099841b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_4c8190eb-f692-81f2-35bc-182f11d12444" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_6282e4c0-b0bd-9c84-bf43-857ac02b98fc" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_4c8190eb-f692-81f2-35bc-182f11d12444" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://macrogenics.com/role/LeaseExitLiabilityLeaseExitLiabilityNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/LeaseExitLiabilityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9361d00b-bf28-09e2-175e-2f8c5c8d39ac" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_23f4b68d-024f-b771-52d7-9c6fb8b84fd6" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9361d00b-bf28-09e2-175e-2f8c5c8d39ac" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_23f4b68d-024f-b771-52d7-9c6fb8b84fd6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_71eca22f-9f1c-f22f-4df6-b11a94d2b626" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9361d00b-bf28-09e2-175e-2f8c5c8d39ac" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_71eca22f-9f1c-f22f-4df6-b11a94d2b626" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dc625d98-2316-5835-4481-320b95705dbb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9361d00b-bf28-09e2-175e-2f8c5c8d39ac" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dc625d98-2316-5835-4481-320b95705dbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_465ba6e6-2b33-45fe-3e73-c5293643fc38" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dc625d98-2316-5835-4481-320b95705dbb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_465ba6e6-2b33-45fe-3e73-c5293643fc38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_73b022da-9054-5e1b-96dd-04e339313a48" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dc625d98-2316-5835-4481-320b95705dbb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_73b022da-9054-5e1b-96dd-04e339313a48" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_65C1861AEFC4D901E92D80A2409F7ABF_9361d00b-bf28-09e2-175e-2f8c5c8d39ac" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_65C1861AEFC4D901E92D80A2409F7ABF_0c84ece3-1f8c-2bb3-6d4d-e7a215e4c9c1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_65C1861AEFC4D901E92D80A2409F7ABF_9361d00b-bf28-09e2-175e-2f8c5c8d39ac" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_65C1861AEFC4D901E92D80A2409F7ABF_0c84ece3-1f8c-2bb3-6d4d-e7a215e4c9c1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_65C1861AEFC4D901E92D80A2409F7ABF_0936fe34-b1c6-5f4e-1eee-fa338ed8b930" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_65C1861AEFC4D901E92D80A2409F7ABF_9361d00b-bf28-09e2-175e-2f8c5c8d39ac" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_65C1861AEFC4D901E92D80A2409F7ABF_0936fe34-b1c6-5f4e-1eee-fa338ed8b930" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/OrganizationAndNatureOfOperations" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7ce178a4-245f-fa78-36a1-552609a67554" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6591f040-08b3-69a1-a560-c70736475ada" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_7ce178a4-245f-fa78-36a1-552609a67554" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6591f040-08b3-69a1-a560-c70736475ada" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b84a1570-30ad-4e3a-2391-9767a64e15fd" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_7ce178a4-245f-fa78-36a1-552609a67554" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b84a1570-30ad-4e3a-2391-9767a64e15fd" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://macrogenics.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ca9bebe4-4073-b721-7b75-1a0086593d58" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8afbf9ec-40f2-ac04-dde9-64f96fdfbf74" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ca9bebe4-4073-b721-7b75-1a0086593d58" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8afbf9ec-40f2-ac04-dde9-64f96fdfbf74" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedLossPerShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivableDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarnedDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_97f92a73-40d1-2a43-0127-cd282f325367" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_074f42d4-7f64-aa49-46b6-c8bd9ead085f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_97f92a73-40d1-2a43-0127-cd282f325367" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_074f42d4-7f64-aa49-46b6-c8bd9ead085f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_a6e76a34-fa42-d66f-a2a4-5865ce92446b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_97f92a73-40d1-2a43-0127-cd282f325367" xlink:to="loc_us-gaap_AvailableForSaleSecurities_a6e76a34-fa42-d66f-a2a4-5865ce92446b" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>mgnx-20161231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreements" xlink:href="mgnx-20161231.xsd#CollaborationAndOtherAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsBoehringerDetails" xlink:href="mgnx-20161231.xsd#CollaborationAndOtherAgreementsBoehringerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsGreenCrossDetails" xlink:href="mgnx-20161231.xsd#CollaborationAndOtherAgreementsGreenCrossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsJanssenBiotechIncDetails" xlink:href="mgnx-20161231.xsd#CollaborationAndOtherAgreementsJanssenBiotechIncDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsNiaidContractDetails" xlink:href="mgnx-20161231.xsd#CollaborationAndOtherAgreementsNiaidContractDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsServierDetails" xlink:href="mgnx-20161231.xsd#CollaborationAndOtherAgreementsServierDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsTakedaDetails" xlink:href="mgnx-20161231.xsd#CollaborationAndOtherAgreementsTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsAndContingencies" xlink:href="mgnx-20161231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsAndContingenciesDetails" xlink:href="mgnx-20161231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsAndContingenciesTables" xlink:href="mgnx-20161231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedBalanceSheets" xlink:href="mgnx-20161231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="mgnx-20161231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="mgnx-20161231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="mgnx-20161231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="mgnx-20161231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/DocumentAndEntityInformation" xlink:href="mgnx-20161231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:href="mgnx-20161231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:href="mgnx-20161231.xsd#EmployeeBenefitPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxes" xlink:href="mgnx-20161231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesComponentsOfCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:href="mgnx-20161231.xsd#IncomeTaxesComponentsOfCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails" xlink:href="mgnx-20161231.xsd#IncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefitDetails" xlink:href="mgnx-20161231.xsd#IncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesTables" xlink:href="mgnx-20161231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiability" xlink:href="mgnx-20161231.xsd#LeaseExitLiability" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiabilityChangesInLeaseExitLiabilityDetails" xlink:href="mgnx-20161231.xsd#LeaseExitLiabilityChangesInLeaseExitLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreementDetails" xlink:href="mgnx-20161231.xsd#LeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiabilityLeaseExitLiabilityNarrativeDetails" xlink:href="mgnx-20161231.xsd#LeaseExitLiabilityLeaseExitLiabilityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiabilityTables" xlink:href="mgnx-20161231.xsd#LeaseExitLiabilityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:href="mgnx-20161231.xsd#MarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:href="mgnx-20161231.xsd#MarketableSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:href="mgnx-20161231.xsd#MarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/OrganizationAndNatureOfOperations" xlink:href="mgnx-20161231.xsd#OrganizationAndNatureOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyAndEquipment" xlink:href="mgnx-20161231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyAndEquipmentDetails" xlink:href="mgnx-20161231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyAndEquipmentTables" xlink:href="mgnx-20161231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited" xlink:href="mgnx-20161231.xsd#QuarterlyFinancialInformationUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:href="mgnx-20161231.xsd#QuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:href="mgnx-20161231.xsd#QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensation" xlink:href="mgnx-20161231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:href="mgnx-20161231.xsd#StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:href="mgnx-20161231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails" xlink:href="mgnx-20161231.xsd#StockBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationTables" xlink:href="mgnx-20161231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:href="mgnx-20161231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:href="mgnx-20161231.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShareDetails" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedLossPerShareDetails" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivableDetails" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarnedDetails" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarnedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilitiesDetails" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsBoehringerDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DF63ACAB5591470CA75371703D62C48A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3D74486496ED4E42280671703D61D6C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DF63ACAB5591470CA75371703D62C48A" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3D74486496ED4E42280671703D61D6C9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_FB8460116201758788A871703D615EAC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3D74486496ED4E42280671703D61D6C9" xlink:to="loc_us-gaap_CounterpartyNameAxis_FB8460116201758788A871703D615EAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_469C92AAE54196AC7AA171703D61656D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_FB8460116201758788A871703D615EAC" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_469C92AAE54196AC7AA171703D61656D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_469C92AAE54196AC7AA171703D61656D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_FB8460116201758788A871703D615EAC" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_469C92AAE54196AC7AA171703D61656D" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_BoehringerIngelheimMember" xlink:label="loc_mgnx_BoehringerIngelheimMember_5469441C8D05CE6BB6B871703D610228" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_469C92AAE54196AC7AA171703D61656D" xlink:to="loc_mgnx_BoehringerIngelheimMember_5469441C8D05CE6BB6B871703D610228" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_AA8B19DA3215EA1BF38771703D6203E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DF63ACAB5591470CA75371703D62C48A" xlink:to="loc_mgnx_NonRefundableUpfrontFees_AA8B19DA3215EA1BF38771703D6203E4" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NumberOfAnnualMaintenancePaymentReceived" xlink:label="loc_mgnx_NumberOfAnnualMaintenancePaymentReceived_A4893ABF8CECFE444CD871703D62AFEC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DF63ACAB5591470CA75371703D62C48A" xlink:to="loc_mgnx_NumberOfAnnualMaintenancePaymentReceived_A4893ABF8CECFE444CD871703D62AFEC" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_B7193704E669B021ED0D71703D674EAD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DF63ACAB5591470CA75371703D62C48A" xlink:to="loc_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_B7193704E669B021ED0D71703D674EAD" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_9A94F7724CE89A9C1BC171703D67DCB3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DF63ACAB5591470CA75371703D62C48A" xlink:to="loc_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_9A94F7724CE89A9C1BC171703D67DCB3" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_64E84716F49477A2F0A771703D67AC48" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DF63ACAB5591470CA75371703D62C48A" xlink:to="loc_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_64E84716F49477A2F0A771703D67AC48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_CB8313AF8055E9B36C6F71703D67F24A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DF63ACAB5591470CA75371703D62C48A" xlink:to="loc_us-gaap_LicensesRevenue_CB8313AF8055E9B36C6F71703D67F24A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_2EA8E108E3EEF5034E7A71703D676712" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DF63ACAB5591470CA75371703D62C48A" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_2EA8E108E3EEF5034E7A71703D676712" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_F9E15538F6959CC4199071703D67133C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DF63ACAB5591470CA75371703D62C48A" xlink:to="loc_us-gaap_DeferredRevenue_F9E15538F6959CC4199071703D67133C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsGreenCrossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D2CD24B3D5A099A2EC88018CA054235" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1CFECE300B963EAC580B8018CA05539C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D2CD24B3D5A099A2EC88018CA054235" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1CFECE300B963EAC580B8018CA05539C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_1E4E2D82EC780C55D16A8018CA05FA6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1CFECE300B963EAC580B8018CA05539C" xlink:to="loc_us-gaap_CounterpartyNameAxis_1E4E2D82EC780C55D16A8018CA05FA6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_0038A4F31402BDC101B78018CA051135_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_1E4E2D82EC780C55D16A8018CA05FA6B" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_0038A4F31402BDC101B78018CA051135_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_0038A4F31402BDC101B78018CA051135" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_1E4E2D82EC780C55D16A8018CA05FA6B" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_0038A4F31402BDC101B78018CA051135" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_GreenCrossCorporationMember" xlink:label="loc_mgnx_GreenCrossCorporationMember_39BD72A01460905243098018CA05821D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_0038A4F31402BDC101B78018CA051135" xlink:to="loc_mgnx_GreenCrossCorporationMember_39BD72A01460905243098018CA05821D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_D22603F806F49CB527178018CA0529D7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1CFECE300B963EAC580B8018CA05539C" xlink:to="loc_us-gaap_RangeAxis_D22603F806F49CB527178018CA0529D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_4F96BED787BB2542B0528018CA05B0D8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_D22603F806F49CB527178018CA0529D7" xlink:to="loc_us-gaap_RangeMember_4F96BED787BB2542B0528018CA05B0D8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_4F96BED787BB2542B0528018CA05B0D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_D22603F806F49CB527178018CA0529D7" xlink:to="loc_us-gaap_RangeMember_4F96BED787BB2542B0528018CA05B0D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_62A7DACEE04079F508D38018CA05A4DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_4F96BED787BB2542B0528018CA05B0D8" xlink:to="loc_us-gaap_MaximumMember_62A7DACEE04079F508D38018CA05A4DB" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AggregatePotentialFutureCostReimbursement" xlink:label="loc_mgnx_AggregatePotentialFutureCostReimbursement_4E117FBF3158001C814D8018CA052BED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D2CD24B3D5A099A2EC88018CA054235" xlink:to="loc_mgnx_AggregatePotentialFutureCostReimbursement_4E117FBF3158001C814D8018CA052BED" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_035119394DDC37C666F58018CA0518D5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D2CD24B3D5A099A2EC88018CA054235" xlink:to="loc_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_035119394DDC37C666F58018CA0518D5" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_4394788CBBFC7A06801A8018CA051905" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D2CD24B3D5A099A2EC88018CA054235" xlink:to="loc_mgnx_NonRefundableUpfrontFees_4394788CBBFC7A06801A8018CA051905" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification" xlink:label="loc_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_23BF567B7586791A86A68018CA0598FA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D2CD24B3D5A099A2EC88018CA054235" xlink:to="loc_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_23BF567B7586791A86A68018CA0598FA" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ProceedsFromResearchAndDevelopmentServices" xlink:label="loc_mgnx_ProceedsFromResearchAndDevelopmentServices_CE28AEA80A8565601BA38018CA05EDF2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D2CD24B3D5A099A2EC88018CA054235" xlink:to="loc_mgnx_ProceedsFromResearchAndDevelopmentServices_CE28AEA80A8565601BA38018CA05EDF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_83BB800A2A08F749D3A88018CA05BCA3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D2CD24B3D5A099A2EC88018CA054235" xlink:to="loc_us-gaap_LicensesRevenue_83BB800A2A08F749D3A88018CA05BCA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_62C17DC13C2C2B3ED5DF8018CA05A30B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D2CD24B3D5A099A2EC88018CA054235" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_62C17DC13C2C2B3ED5DF8018CA05A30B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_88004F56E46ADF8135D08018CA059D05" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D2CD24B3D5A099A2EC88018CA054235" xlink:to="loc_us-gaap_DeferredRevenue_88004F56E46ADF8135D08018CA059D05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_B126390B9A454993DD198018CA052F5A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D2CD24B3D5A099A2EC88018CA054235" xlink:to="loc_us-gaap_DeferredRevenueCurrent_B126390B9A454993DD198018CA052F5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_E1C18CD823AF736A89668018CA059D7D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D2CD24B3D5A099A2EC88018CA054235" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_E1C18CD823AF736A89668018CA059D7D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsJanssenBiotechIncDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_48C2509E04AD749AAE047B56E5B202C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_48C2509E04AD749AAE047B56E5B202C8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E81694074AE68E92E4887B56E5B2727B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_48C2509E04AD749AAE047B56E5B202C8" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E81694074AE68E92E4887B56E5B2727B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_E41145BACC315758EEFB7B56E5B25F50_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E81694074AE68E92E4887B56E5B2727B" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_E41145BACC315758EEFB7B56E5B25F50_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_E41145BACC315758EEFB7B56E5B25F50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E81694074AE68E92E4887B56E5B2727B" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_E41145BACC315758EEFB7B56E5B25F50" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_JanssenMGD011AgreementMember" xlink:label="loc_mgnx_JanssenMGD011AgreementMember_73F55F2702F5E907FFB57B56E5B2907D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_E41145BACC315758EEFB7B56E5B25F50" xlink:to="loc_mgnx_JanssenMGD011AgreementMember_73F55F2702F5E907FFB57B56E5B2907D" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_JanssenMGD015AgreementMember" xlink:label="loc_mgnx_JanssenMGD015AgreementMember_CB4C3521CF1FDD65E28D7B56E5B24FC4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_E41145BACC315758EEFB7B56E5B25F50" xlink:to="loc_mgnx_JanssenMGD015AgreementMember_CB4C3521CF1FDD65E28D7B56E5B24FC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_8BAEF8803012296591EE7B56E5B291C7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_48C2509E04AD749AAE047B56E5B202C8" xlink:to="loc_us-gaap_CounterpartyNameAxis_8BAEF8803012296591EE7B56E5B291C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_B705433F480AE1C0EF257B56E5B2E1C1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_8BAEF8803012296591EE7B56E5B291C7" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_B705433F480AE1C0EF257B56E5B2E1C1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_B705433F480AE1C0EF257B56E5B2E1C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_8BAEF8803012296591EE7B56E5B291C7" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_B705433F480AE1C0EF257B56E5B2E1C1" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_JanssenBiotechIncMember" xlink:label="loc_mgnx_JanssenBiotechIncMember_ECD474B40DB42AE394F27B56E5B34C78" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_B705433F480AE1C0EF257B56E5B2E1C1" xlink:to="loc_mgnx_JanssenBiotechIncMember_ECD474B40DB42AE394F27B56E5B34C78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_4DEBE84C3BD1CFA03E0B7B56E5B38D11" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_48C2509E04AD749AAE047B56E5B202C8" xlink:to="loc_us-gaap_RangeAxis_4DEBE84C3BD1CFA03E0B7B56E5B38D11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9CEAAE11413472DFEDA27B56E5B38995_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_4DEBE84C3BD1CFA03E0B7B56E5B38D11" xlink:to="loc_us-gaap_RangeMember_9CEAAE11413472DFEDA27B56E5B38995_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9CEAAE11413472DFEDA27B56E5B38995" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_4DEBE84C3BD1CFA03E0B7B56E5B38D11" xlink:to="loc_us-gaap_RangeMember_9CEAAE11413472DFEDA27B56E5B38995" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9FC330C081F75498AC477B56E5B34D84" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9CEAAE11413472DFEDA27B56E5B38995" xlink:to="loc_us-gaap_MaximumMember_9FC330C081F75498AC477B56E5B34D84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7280D67ADA2259D3E50D7B56E5B36F5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7280D67ADA2259D3E50D7B56E5B36F5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_22BC30B8F2DE70A4F2647B56E5B4C816" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_22BC30B8F2DE70A4F2647B56E5B4C816" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_DC28316E7DD1B2475BAE7B56E5B52C58" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_mgnx_NonRefundableUpfrontFees_DC28316E7DD1B2475BAE7B56E5B52C58" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PotentialClinicalMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_061A4BFA2FA3CA989ECF7B56E5B43C53" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_061A4BFA2FA3CA989ECF7B56E5B43C53" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_801977226E250240E59F7B56E5B4CAB9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_801977226E250240E59F7B56E5B4CAB9" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PotentialSalesMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_31A98A22CC274496C5967B56E5B43A6E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_31A98A22CC274496C5967B56E5B43A6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_920B2DFD6F0F39514DBA7B56E5B4CA18" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_920B2DFD6F0F39514DBA7B56E5B4CA18" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PremiumReceivedOnStockPurchase" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase_72880FFB1CA4476A50627B56E5B441A8" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_mgnx_PremiumReceivedOnStockPurchase_72880FFB1CA4476A50627B56E5B441A8" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_TotalConsideration" xlink:label="loc_mgnx_TotalConsideration_C93C1F1C55BE1FDCF5977B56E5B4EF2C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_mgnx_TotalConsideration_C93C1F1C55BE1FDCF5977B56E5B4EF2C" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AmountAllocatedToEquity" xlink:label="loc_mgnx_AmountAllocatedToEquity_9FC85C98CDBDF4E9AD4E7B56E5B4E95E" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_mgnx_AmountAllocatedToEquity_9FC85C98CDBDF4E9AD4E7B56E5B4E95E" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AmountAllocatedToLicenseAndRD" xlink:label="loc_mgnx_AmountAllocatedToLicenseAndRD_E17E4BC8DDC31D1683977B56E5B42580" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_mgnx_AmountAllocatedToLicenseAndRD_E17E4BC8DDC31D1683977B56E5B42580" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ClinicalMilestoneEarnedDuringPeriod" xlink:label="loc_mgnx_ClinicalMilestoneEarnedDuringPeriod_4E21EAAC25907AFDE4767B56E5B5015C" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_mgnx_ClinicalMilestoneEarnedDuringPeriod_4E21EAAC25907AFDE4767B56E5B5015C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_B5921C027F2C604ACDC37B56E5B5A805" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_us-gaap_LicensesRevenue_B5921C027F2C604ACDC37B56E5B5A805" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsNiaidContractDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D508F0E755FB3D0D3B6B6EBE6C782A16" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3A3F6FB2BBC7D7A045E26EBE6C77B077" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D508F0E755FB3D0D3B6B6EBE6C782A16" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3A3F6FB2BBC7D7A045E26EBE6C77B077" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_F863BB68622C0BAA71E66EBE6C780AC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3A3F6FB2BBC7D7A045E26EBE6C77B077" xlink:to="loc_us-gaap_CounterpartyNameAxis_F863BB68622C0BAA71E66EBE6C780AC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_2C384615DABE8AAAF8BF6EBE6C782993_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_F863BB68622C0BAA71E66EBE6C780AC4" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_2C384615DABE8AAAF8BF6EBE6C782993_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_2C384615DABE8AAAF8BF6EBE6C782993" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_F863BB68622C0BAA71E66EBE6C780AC4" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_2C384615DABE8AAAF8BF6EBE6C782993" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_D8EDD228C76C59964A5D6EBE6C784C9F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_2C384615DABE8AAAF8BF6EBE6C782993" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_D8EDD228C76C59964A5D6EBE6C784C9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_61197FE0BA62791EBF986EBE6C784EE3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3A3F6FB2BBC7D7A045E26EBE6C77B077" xlink:to="loc_us-gaap_RangeAxis_61197FE0BA62791EBF986EBE6C784EE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_C575C1ADEBC011FD19CF6EBE6C78FA41_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_61197FE0BA62791EBF986EBE6C784EE3" xlink:to="loc_us-gaap_RangeMember_C575C1ADEBC011FD19CF6EBE6C78FA41_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_C575C1ADEBC011FD19CF6EBE6C78FA41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_61197FE0BA62791EBF986EBE6C784EE3" xlink:to="loc_us-gaap_RangeMember_C575C1ADEBC011FD19CF6EBE6C78FA41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_10AFFA39E58502420E336EBE6C781323" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_C575C1ADEBC011FD19CF6EBE6C78FA41" xlink:to="loc_us-gaap_MaximumMember_10AFFA39E58502420E336EBE6C781323" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_62971F88F7CB7D51FE796EBE6C78ECA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D508F0E755FB3D0D3B6B6EBE6C782A16" xlink:to="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_62971F88F7CB7D51FE796EBE6C78ECA0" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_FundedValueOfBasePeriod" xlink:label="loc_mgnx_FundedValueOfBasePeriod_393F92E19CC540F2B0586EBE6C784D97" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D508F0E755FB3D0D3B6B6EBE6C782A16" xlink:to="loc_mgnx_FundedValueOfBasePeriod_393F92E19CC540F2B0586EBE6C784D97" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:label="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_2062BC623B5F3439583B6EBE6C7836E2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D508F0E755FB3D0D3B6B6EBE6C782A16" xlink:to="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_2062BC623B5F3439583B6EBE6C7836E2" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_TotalPotentialValueUnderAgreement" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_0BA545EAB14FE9CC5BA16EBE6C784822" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D508F0E755FB3D0D3B6B6EBE6C782A16" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_0BA545EAB14FE9CC5BA16EBE6C784822" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_1253D8ED1F879ED2BECD6EBE6C78B541" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D508F0E755FB3D0D3B6B6EBE6C782A16" xlink:to="loc_us-gaap_LicensesRevenue_1253D8ED1F879ED2BECD6EBE6C78B541" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsServierDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F4F1501FF422B41F997F71703B7AFB4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F4F1501FF422B41F997F71703B7AFB4E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_A09F588E6ACCF09F8A1971703B7A5659" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F4F1501FF422B41F997F71703B7AFB4E" xlink:to="loc_us-gaap_CounterpartyNameAxis_A09F588E6ACCF09F8A1971703B7A5659" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_6F03D20BCCA3A953FF9371703B7A6450_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_A09F588E6ACCF09F8A1971703B7A5659" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_6F03D20BCCA3A953FF9371703B7A6450_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_6F03D20BCCA3A953FF9371703B7A6450" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_A09F588E6ACCF09F8A1971703B7A5659" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_6F03D20BCCA3A953FF9371703B7A6450" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ServierMember" xlink:label="loc_mgnx_ServierMember_E850E973D4548F6A614C71703B7A486F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_6F03D20BCCA3A953FF9371703B7A6450" xlink:to="loc_mgnx_ServierMember_E850E973D4548F6A614C71703B7A486F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2F04D245E467693C0AA871703B7A215D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F4F1501FF422B41F997F71703B7AFB4E" xlink:to="loc_us-gaap_RangeAxis_2F04D245E467693C0AA871703B7A215D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1137A52A97FA2D4B5AAF71703B7A748F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_2F04D245E467693C0AA871703B7A215D" xlink:to="loc_us-gaap_RangeMember_1137A52A97FA2D4B5AAF71703B7A748F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1137A52A97FA2D4B5AAF71703B7A748F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_2F04D245E467693C0AA871703B7A215D" xlink:to="loc_us-gaap_RangeMember_1137A52A97FA2D4B5AAF71703B7A748F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_74E4AAD6012E9306AFF371703B7A9085" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_1137A52A97FA2D4B5AAF71703B7A748F" xlink:to="loc_us-gaap_MaximumMember_74E4AAD6012E9306AFF371703B7A9085" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C66929EC5FCB2B9CE20D71703B7AC91B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F4F1501FF422B41F997F71703B7AFB4E" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C66929EC5FCB2B9CE20D71703B7AC91B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B2D1C6FAFF3386693BA671703B7AA891_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C66929EC5FCB2B9CE20D71703B7AC91B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B2D1C6FAFF3386693BA671703B7AA891_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B2D1C6FAFF3386693BA671703B7AA891" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C66929EC5FCB2B9CE20D71703B7AC91B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B2D1C6FAFF3386693BA671703B7AA891" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ServierDARTMember" xlink:label="loc_mgnx_ServierDARTMember_E4780B4BEA24DC1CE9D271703B7AAB38" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B2D1C6FAFF3386693BA671703B7AA891" xlink:to="loc_mgnx_ServierDARTMember_E4780B4BEA24DC1CE9D271703B7AAB38" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_C256648B20CF61B4E41A71703B7B66F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_NonRefundableUpfrontFees_C256648B20CF61B4E41A71703B7B66F3" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PotentialLicenseFee" xlink:label="loc_mgnx_PotentialLicenseFee_A94510199FED7ADC837A71703B7BC210" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_PotentialLicenseFee_A94510199FED7ADC837A71703B7BC210" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PotentialClinicalMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_3C09C9A27B1DF524BA3271703B7B85D5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_3C09C9A27B1DF524BA3271703B7B85D5" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_3FC1331EAE3E6D4A633A71703B805B82" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_3FC1331EAE3E6D4A633A71703B805B82" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PotentialSalesMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_2D5C15569E488E586FD871703B80464A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_2D5C15569E488E586FD871703B80464A" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_OriginalPeriodOfDevelopment" xlink:label="loc_mgnx_OriginalPeriodOfDevelopment_FC2DE2FB50165E29972C71703B8048D1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_OriginalPeriodOfDevelopment_FC2DE2FB50165E29972C71703B8048D1" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod_7DE7AFFC080898A9BCBB71703B815ADA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_UpfrontPaymentRecognitionPeriod_7DE7AFFC080898A9BCBB71703B815ADA" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ChangeInAccountingEstimateCurrentYearImpact" xlink:label="loc_mgnx_ChangeInAccountingEstimateCurrentYearImpact_C30BFBAD7454E3E6EAE971703B81C787" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_ChangeInAccountingEstimateCurrentYearImpact_C30BFBAD7454E3E6EAE971703B81C787" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_OptionExerciseFee" xlink:label="loc_mgnx_OptionExerciseFee_DF9A45F6B99AEE085A0171703B8166F7" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_OptionExerciseFee_DF9A45F6B99AEE085A0171703B8166F7" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_OptionExerciseFeeRecognitionPeriod" xlink:label="loc_mgnx_OptionExerciseFeeRecognitionPeriod_4FA6749FC178CFDBB79E71703B811F27" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_OptionExerciseFeeRecognitionPeriod_4FA6749FC178CFDBB79E71703B811F27" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:label="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_6D24ECE892386EDFFC0071703B8153AD" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_6D24ECE892386EDFFC0071703B8153AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_7383F69EF38B63EC15D271703B81D4D1" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_us-gaap_LicensesRevenue_7383F69EF38B63EC15D271703B81D4D1" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NumberOfMilestonesAchieved" xlink:label="loc_mgnx_NumberOfMilestonesAchieved_2575BBE1DBEF99F840F171703B8129D5" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_NumberOfMilestonesAchieved_2575BBE1DBEF99F840F171703B8129D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_D38F8F8F88CBE120D5A071703B815237" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_D38F8F8F88CBE120D5A071703B815237" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ReviewPeriodByRegulatoryAuthority" xlink:label="loc_mgnx_ReviewPeriodByRegulatoryAuthority_93EF9F959AAAA3C6536B71703B819E5D" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_ReviewPeriodByRegulatoryAuthority_93EF9F959AAAA3C6536B71703B819E5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_23A3ED0695096E9F000A71703B8266B2" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_us-gaap_DeferredRevenue_23A3ED0695096E9F000A71703B8266B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_8C0C03B0A13F78CC9BF571703B82CF02" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_us-gaap_DeferredRevenueCurrent_8C0C03B0A13F78CC9BF571703B82CF02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_063CB7EF9BB0B1F449E471703B82E257" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_063CB7EF9BB0B1F449E471703B82E257" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsTakedaDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BC20E45152D5A1CFF2ED8238ADE15087" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BC20E45152D5A1CFF2ED8238ADE15087" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_BF37B0471873E9213FB68238ADE1196F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BC20E45152D5A1CFF2ED8238ADE15087" xlink:to="loc_us-gaap_CounterpartyNameAxis_BF37B0471873E9213FB68238ADE1196F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9E9F8B73172DFA1D70068238ADE1873F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_BF37B0471873E9213FB68238ADE1196F" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9E9F8B73172DFA1D70068238ADE1873F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9E9F8B73172DFA1D70068238ADE1873F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_BF37B0471873E9213FB68238ADE1196F" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9E9F8B73172DFA1D70068238ADE1873F" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_TakedaMember" xlink:label="loc_mgnx_TakedaMember_B5912AB689FB276D427E8238ADE12923" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9E9F8B73172DFA1D70068238ADE1873F" xlink:to="loc_mgnx_TakedaMember_B5912AB689FB276D427E8238ADE12923" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_65B970DDA5286C692A148238ADE1F821" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BC20E45152D5A1CFF2ED8238ADE15087" xlink:to="loc_us-gaap_TypeOfArrangementAxis_65B970DDA5286C692A148238ADE1F821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A04E4DBBCA122957CF328238ADE2B7C5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_65B970DDA5286C692A148238ADE1F821" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A04E4DBBCA122957CF328238ADE2B7C5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A04E4DBBCA122957CF328238ADE2B7C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_65B970DDA5286C692A148238ADE1F821" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A04E4DBBCA122957CF328238ADE2B7C5" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_TakedaMGD010AgreementMember" xlink:label="loc_mgnx_TakedaMGD010AgreementMember_157CC58203FFF1CF37EB8238ADE22FCD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A04E4DBBCA122957CF328238ADE2B7C5" xlink:to="loc_mgnx_TakedaMGD010AgreementMember_157CC58203FFF1CF37EB8238ADE22FCD" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ResearchCollaborationAndLicenseOptionAgreementMember" xlink:label="loc_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_C053AF6554CF0972C8B28238ADE2035C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A04E4DBBCA122957CF328238ADE2B7C5" xlink:to="loc_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_C053AF6554CF0972C8B28238ADE2035C" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_D098FF2B9C5BF5D160988238ADE7B0E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0" xlink:to="loc_mgnx_NonRefundableUpfrontFees_D098FF2B9C5BF5D160988238ADE7B0E4" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_UpfrontFeeAllocatedToAgreement" xlink:label="loc_mgnx_UpfrontFeeAllocatedToAgreement_A95AB039EAC88A6FBD7E8238ADE7AEF4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0" xlink:to="loc_mgnx_UpfrontFeeAllocatedToAgreement_A95AB039EAC88A6FBD7E8238ADE7AEF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_6E93102F9055D0DDC0608238ADE725AA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0" xlink:to="loc_us-gaap_DeferredRevenueCurrent_6E93102F9055D0DDC0608238ADE725AA" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod_CAAE10E950DA18A6540B8238ADE78F53" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0" xlink:to="loc_mgnx_UpfrontPaymentRecognitionPeriod_CAAE10E950DA18A6540B8238ADE78F53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_EA6F33BD660EFB2B6D598238ADE7108F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0" xlink:to="loc_us-gaap_LicensesRevenue_EA6F33BD660EFB2B6D598238ADE7108F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_DCD414A4858D99BA3C078238ADE7451A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_DCD414A4858D99BA3C078238ADE7451A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_2ADACD9D5E2E8B47C5E38238ADE72628" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0" xlink:to="loc_us-gaap_DeferredRevenue_2ADACD9D5E2E8B47C5E38238ADE72628" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_3160BB29052DE84ED0F37B56E5071EFD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8AA50227AAB823E1190A7B56E507F957" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3160BB29052DE84ED0F37B56E5071EFD" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8AA50227AAB823E1190A7B56E507F957" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_63ACEAFB4D5665F356F87B56E5077BA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8AA50227AAB823E1190A7B56E507F957" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_63ACEAFB4D5665F356F87B56E5077BA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_570C5969C5ABA7764E977B56E5079DD5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_63ACEAFB4D5665F356F87B56E5077BA9" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_570C5969C5ABA7764E977B56E5079DD5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_570C5969C5ABA7764E977B56E5079DD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_63ACEAFB4D5665F356F87B56E5077BA9" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_570C5969C5ABA7764E977B56E5079DD5" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_MixedUseOfficeLaboratoryAndManufacturingSpaceMember" xlink:label="loc_mgnx_MixedUseOfficeLaboratoryAndManufacturingSpaceMember_2665B3EB7E84B56469C87B56E5072908" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_570C5969C5ABA7764E977B56E5079DD5" xlink:to="loc_mgnx_MixedUseOfficeLaboratoryAndManufacturingSpaceMember_2665B3EB7E84B56469C87B56E5072908" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NumberOfLease" xlink:label="loc_mgnx_NumberOfLease_3B367D9D07B40BBB4F247B56E5070FFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3160BB29052DE84ED0F37B56E5071EFD" xlink:to="loc_mgnx_NumberOfLease_3B367D9D07B40BBB4F247B56E5070FFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_1B1C749BC293E726192A7B56E5079A61" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3160BB29052DE84ED0F37B56E5071EFD" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_1B1C749BC293E726192A7B56E5079A61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_7C0A76B6C64BDA3D3F397B56E508C9C4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3160BB29052DE84ED0F37B56E5071EFD" xlink:to="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_7C0A76B6C64BDA3D3F397B56E508C9C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_4E10FA8708C3EF65FCE27B56E508734C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3160BB29052DE84ED0F37B56E5071EFD" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_4E10FA8708C3EF65FCE27B56E508734C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="loc_us-gaap_DeferredRentCredit_614B74843CB30FD418217B56E5083E88" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3160BB29052DE84ED0F37B56E5071EFD" xlink:to="loc_us-gaap_DeferredRentCredit_614B74843CB30FD418217B56E5083E88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_9E07358DC21403B4F7557B56E5086C34" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3160BB29052DE84ED0F37B56E5071EFD" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_9E07358DC21403B4F7557B56E5086C34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3160BB29052DE84ED0F37B56E5071EFD" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2995A349938A715636AA7B56E508373D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2995A349938A715636AA7B56E508373D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6430BDB28797900FF89E7B56E5086BDF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6430BDB28797900FF89E7B56E5086BDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D2823456275B7A2B3BD97B56E5086AB7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D2823456275B7A2B3BD97B56E5086AB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_F4F55BC0FB941EF7887A7B56E5085E15" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_F4F55BC0FB941EF7887A7B56E5085E15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_13BED0A565F3150CA30E7B56E509DFA5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_13BED0A565F3150CA30E7B56E509DFA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_4292863D1F681A36BF577B56E50947BD" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_4292863D1F681A36BF577B56E50947BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_400C731C66A28487E1727B56E5097BD5" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_400C731C66A28487E1727B56E5097BD5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_CB012FC7D17ECAF1D98D812472AE03FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_us-gaap_StatementTable_CB012FC7D17ECAF1D98D812472AE03FA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3E30EB4C37F1FBA69FC2812472AFD33B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_CB012FC7D17ECAF1D98D812472AE03FA" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3E30EB4C37F1FBA69FC2812472AFD33B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7DD98188CF4E40B00F26812472AF783C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3E30EB4C37F1FBA69FC2812472AFD33B" xlink:to="loc_us-gaap_EquityComponentDomain_7DD98188CF4E40B00F26812472AF783C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7DD98188CF4E40B00F26812472AF783C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3E30EB4C37F1FBA69FC2812472AFD33B" xlink:to="loc_us-gaap_EquityComponentDomain_7DD98188CF4E40B00F26812472AF783C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_EAB849A9C2EF27DEAC5B812472AFFFE8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7DD98188CF4E40B00F26812472AF783C" xlink:to="loc_us-gaap_CommonStockMember_EAB849A9C2EF27DEAC5B812472AFFFE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_91153E58E9C0BA63A8D9812472AFBCD3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7DD98188CF4E40B00F26812472AF783C" xlink:to="loc_us-gaap_TreasuryStockMember_91153E58E9C0BA63A8D9812472AFBCD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_D4ED1AE3823319913B8B812472AF5CDA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7DD98188CF4E40B00F26812472AF783C" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_D4ED1AE3823319913B8B812472AF5CDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_7C0B8DAB0BB0E5854450812472AF0651" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7DD98188CF4E40B00F26812472AF783C" xlink:to="loc_us-gaap_RetainedEarningsMember_7C0B8DAB0BB0E5854450812472AF0651" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_E5DAE027960D171B5AD0812472AF02F0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7DD98188CF4E40B00F26812472AF783C" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_E5DAE027960D171B5AD0812472AF02F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_F727B14C93D590FE552A812472AFBC30" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_us-gaap_StockholdersEquity_F727B14C93D590FE552A812472AFBC30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_6A83F1C077272DC9D425812472AFDB53" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_us-gaap_SharesIssued_6A83F1C077272DC9D425812472AFDB53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B03E9348503C1070A72E812472AFE834" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B03E9348503C1070A72E812472AFE834" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_B21ECA21EEE56EA6E248812472AF3818" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_B21ECA21EEE56EA6E248812472AF3818" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1CFD1A7B08354C02D850812472AF0DE6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1CFD1A7B08354C02D850812472AF0DE6" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_C64BEDAE35EDCDB1003C812472AF4DB5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_C64BEDAE35EDCDB1003C812472AF4DB5" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_C9CE46E1290B160E8D63812472B01F90" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_C9CE46E1290B160E8D63812472B01F90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockRetiredParValueMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredParValueMethodAmount_C2E22CD0C3EBB04A8218812472B08B39" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_us-gaap_TreasuryStockRetiredParValueMethodAmount_C2E22CD0C3EBB04A8218812472B08B39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_19921DC2C6E051F66B0A812472B03CBF" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_19921DC2C6E051F66B0A812472B03CBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_01DF964CA6C6BBB09F1B812472B07A21" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_01DF964CA6C6BBB09F1B812472B07A21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_CC07DC98AD90155B960B812472B06EED" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_us-gaap_NetIncomeLoss_CC07DC98AD90155B960B812472B06EED" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/IncomeTaxesComponentsOfCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_1CD103690CE608C95F3981C6E1A534E8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_40B5303C872265F55CED81C6E1A4F618" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1CD103690CE608C95F3981C6E1A534E8" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_40B5303C872265F55CED81C6E1A4F618" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_510B41AF2D058E96AF6881C6E1A44AA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_40B5303C872265F55CED81C6E1A4F618" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_510B41AF2D058E96AF6881C6E1A44AA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_EC1D365044E18BDEAE2281C6E1A43DD3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_510B41AF2D058E96AF6881C6E1A44AA0" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_EC1D365044E18BDEAE2281C6E1A43DD3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_EC1D365044E18BDEAE2281C6E1A43DD3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_510B41AF2D058E96AF6881C6E1A44AA0" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_EC1D365044E18BDEAE2281C6E1A43DD3" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:label="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_776783359C4089381E1981ED191F79E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_EC1D365044E18BDEAE2281C6E1A43DD3" xlink:to="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_776783359C4089381E1981ED191F79E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_F03722A839302225399781C6E1A472BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_776783359C4089381E1981ED191F79E3" xlink:to="loc_us-gaap_DomesticCountryMember_F03722A839302225399781C6E1A472BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_717FE463C50F4A28505981C6E1A44E18" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_40B5303C872265F55CED81C6E1A4F618" xlink:to="loc_us-gaap_RangeAxis_717FE463C50F4A28505981C6E1A44E18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6AF5D61EB7DF11616CF181C6E1A42DB2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_717FE463C50F4A28505981C6E1A44E18" xlink:to="loc_us-gaap_RangeMember_6AF5D61EB7DF11616CF181C6E1A42DB2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6AF5D61EB7DF11616CF181C6E1A42DB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_717FE463C50F4A28505981C6E1A44E18" xlink:to="loc_us-gaap_RangeMember_6AF5D61EB7DF11616CF181C6E1A42DB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_99F2AB32A7C2B1EA9F0481C6E1A54C64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6AF5D61EB7DF11616CF181C6E1A42DB2" xlink:to="loc_us-gaap_MinimumMember_99F2AB32A7C2B1EA9F0481C6E1A54C64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7E923DA38AC5DED1D4DC81C6E1A5597E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6AF5D61EB7DF11616CF181C6E1A42DB2" xlink:to="loc_us-gaap_MaximumMember_7E923DA38AC5DED1D4DC81C6E1A5597E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_8CFDB9ED3AEB1B05545181C6E1A56D96" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1CD103690CE608C95F3981C6E1A534E8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_8CFDB9ED3AEB1B05545181C6E1A56D96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_286E23E1C27FCFA05A5C81C6E1A586AD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1CD103690CE608C95F3981C6E1A534E8" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_286E23E1C27FCFA05A5C81C6E1A586AD" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:label="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_F0C98CE41305590010BA81C6E1A57810" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1CD103690CE608C95F3981C6E1A534E8" xlink:to="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_F0C98CE41305590010BA81C6E1A57810" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:label="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_4D7952121C7C9CE8AA8E81C6E1A53B90" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1CD103690CE608C95F3981C6E1A534E8" xlink:to="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_4D7952121C7C9CE8AA8E81C6E1A53B90" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:label="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_51B20E90CB071CE5DE9281C6E1A57752" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1CD103690CE608C95F3981C6E1A534E8" xlink:to="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_51B20E90CB071CE5DE9281C6E1A57752" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward" xlink:label="loc_mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward_6493347ECFFEF59F32EB81C6E1A5CBCE" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1CD103690CE608C95F3981C6E1A534E8" xlink:to="loc_mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward_6493347ECFFEF59F32EB81C6E1A5CBCE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_F9B05C39BDF3059A3B6C8018CA94CADE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_4A4D59B9B69314686D848018CA945B85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_F9B05C39BDF3059A3B6C8018CA94CADE" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_4A4D59B9B69314686D848018CA945B85" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_1B49703A559E18AA6DA18018CA94E53E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_4A4D59B9B69314686D848018CA945B85" xlink:to="loc_us-gaap_RangeAxis_1B49703A559E18AA6DA18018CA94E53E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_ADD781FFFE74204F5CE88018CA9463D1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_1B49703A559E18AA6DA18018CA94E53E" xlink:to="loc_us-gaap_RangeMember_ADD781FFFE74204F5CE88018CA9463D1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_ADD781FFFE74204F5CE88018CA9463D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_1B49703A559E18AA6DA18018CA94E53E" xlink:to="loc_us-gaap_RangeMember_ADD781FFFE74204F5CE88018CA9463D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_921BB6AE79A9B86976128018CA94091B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_ADD781FFFE74204F5CE88018CA9463D1" xlink:to="loc_us-gaap_MinimumMember_921BB6AE79A9B86976128018CA94091B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5ADE9C145D8D296C3AAA8018CA948BE7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_F9B05C39BDF3059A3B6C8018CA94CADE" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5ADE9C145D8D296C3AAA8018CA948BE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_AC8CFE953714493042428018CA9482EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5ADE9C145D8D296C3AAA8018CA948BE7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_AC8CFE953714493042428018CA9482EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_16F9DB270951F92FB7208018CA94E54B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5ADE9C145D8D296C3AAA8018CA948BE7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_16F9DB270951F92FB7208018CA94E54B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_62F2F528ED3CAD6BF0088018CA940926" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5ADE9C145D8D296C3AAA8018CA948BE7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_62F2F528ED3CAD6BF0088018CA940926" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_E10A48273BC6188F932B8018CA94885C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_F9B05C39BDF3059A3B6C8018CA94CADE" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_E10A48273BC6188F932B8018CA94885C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_F292DA0D667F85CF2FAB8018CA948C71" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_F9B05C39BDF3059A3B6C8018CA94CADE" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_F292DA0D667F85CF2FAB8018CA948C71" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefitDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/LeaseExitLiability" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/LeaseExitLiabilityChangesInLeaseExitLiabilityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_C2E992743828C37A7B6B8018CA638C0F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_38F8D4F870F2D4DE3A5E8018CA63D026" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_C2E992743828C37A7B6B8018CA638C0F" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_38F8D4F870F2D4DE3A5E8018CA63D026" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_2C55C490960A9CF58B158018CA63C71F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_38F8D4F870F2D4DE3A5E8018CA63D026" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_2C55C490960A9CF58B158018CA63C71F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1AED901A6271EA9CDF338018CA631BBB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2C55C490960A9CF58B158018CA63C71F" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1AED901A6271EA9CDF338018CA631BBB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1AED901A6271EA9CDF338018CA631BBB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2C55C490960A9CF58B158018CA63C71F" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1AED901A6271EA9CDF338018CA631BBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="loc_us-gaap_ContractTerminationMember_1F161CB294C08B579DC68018CA63B3D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1AED901A6271EA9CDF338018CA631BBB" xlink:to="loc_us-gaap_ContractTerminationMember_1F161CB294C08B579DC68018CA63B3D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="loc_us-gaap_RestructuringReserveRollForward_0FBDBF0127E7351BFCB48018CA639368" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_C2E992743828C37A7B6B8018CA638C0F" xlink:to="loc_us-gaap_RestructuringReserveRollForward_0FBDBF0127E7351BFCB48018CA639368" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_73C38AFC16A871A175D98018CA635730" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_0FBDBF0127E7351BFCB48018CA639368" xlink:to="loc_us-gaap_RestructuringReserve_73C38AFC16A871A175D98018CA635730" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_D1E1EB3CCC36B0E398578018CA63B128" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_0FBDBF0127E7351BFCB48018CA639368" xlink:to="loc_us-gaap_PaymentsForRestructuring_D1E1EB3CCC36B0E398578018CA63B128" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/LeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_C8A0C2EADD76B0573144812471BBE802" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_37B4D4340C0CA2E8624D812471B69C30" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_C8A0C2EADD76B0573144812471BBE802" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_37B4D4340C0CA2E8624D812471B69C30" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6A18AC626DCAB38E62A4812471B6C2B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_37B4D4340C0CA2E8624D812471B69C30" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6A18AC626DCAB38E62A4812471B6C2B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9106B0EC1ADE2E684459812471B688DA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6A18AC626DCAB38E62A4812471B6C2B7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9106B0EC1ADE2E684459812471B688DA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9106B0EC1ADE2E684459812471B688DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6A18AC626DCAB38E62A4812471B6C2B7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9106B0EC1ADE2E684459812471B688DA" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_RavenBiotechnologiesIncMember" xlink:label="loc_mgnx_RavenBiotechnologiesIncMember_BB6DE7899F67C6EA219A812471B63B85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9106B0EC1ADE2E684459812471B688DA" xlink:to="loc_mgnx_RavenBiotechnologiesIncMember_BB6DE7899F67C6EA219A812471B63B85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_C269ACC848F57FD78B00812471BB89A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_C8A0C2EADD76B0573144812471BBE802" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_C269ACC848F57FD78B00812471BB89A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_82D2020FE174074D2FC1812471BB0636" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_C8A0C2EADD76B0573144812471BBE802" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_82D2020FE174074D2FC1812471BB0636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_72CDF964293A0694D171812471BB2B7B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_C8A0C2EADD76B0573144812471BBE802" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_72CDF964293A0694D171812471BB2B7B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/LeaseExitLiabilityLeaseExitLiabilityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_BCF1267D87C2CD55082D81C6E18DDAC5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_DC6900296FEC981F37B381C6E18DF5AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_BCF1267D87C2CD55082D81C6E18DDAC5" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_DC6900296FEC981F37B381C6E18DF5AF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A41A0515B8E36AAD010881C6E18DD0A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_DC6900296FEC981F37B381C6E18DF5AF" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_A41A0515B8E36AAD010881C6E18DD0A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9CC60582D4F86AE5E54781C6E18DCB08_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A41A0515B8E36AAD010881C6E18DD0A4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9CC60582D4F86AE5E54781C6E18DCB08_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9CC60582D4F86AE5E54781C6E18DCB08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A41A0515B8E36AAD010881C6E18DD0A4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9CC60582D4F86AE5E54781C6E18DCB08" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_RavenBiotechnologiesIncMember" xlink:label="loc_mgnx_RavenBiotechnologiesIncMember_13966769A856E0A24FD881C6E18DD0C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9CC60582D4F86AE5E54781C6E18DCB08" xlink:to="loc_mgnx_RavenBiotechnologiesIncMember_13966769A856E0A24FD881C6E18DD0C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_2869C850FBA4F21BA03881C6E18D3AB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_BCF1267D87C2CD55082D81C6E18DDAC5" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_2869C850FBA4F21BA03881C6E18D3AB5" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ReductionInResearchAndDevelopmentExpense" xlink:label="loc_mgnx_ReductionInResearchAndDevelopmentExpense_FCD6959F4C8ACE54059681C6E18DE47F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_BCF1267D87C2CD55082D81C6E18DDAC5" xlink:to="loc_mgnx_ReductionInResearchAndDevelopmentExpense_FCD6959F4C8ACE54059681C6E18DE47F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/LeaseExitLiabilityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_BB49FAD207D8226B9460808A11B4F365" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_BB49FAD207D8226B9460808A11B4F365" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_1125C6A89C8BA82328A8808A11B4CA88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_BB49FAD207D8226B9460808A11B4F365" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_1125C6A89C8BA82328A8808A11B4CA88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F4DC206234262356C0808A11B4812C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_1125C6A89C8BA82328A8808A11B4CA88" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F4DC206234262356C0808A11B4812C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F4DC206234262356C0808A11B4812C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_1125C6A89C8BA82328A8808A11B4CA88" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F4DC206234262356C0808A11B4812C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_E90435EC2490BC47F381808A11B498AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F4DC206234262356C0808A11B4812C" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_E90435EC2490BC47F381808A11B498AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_177B9BB360367B46F05D808A11B4940D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F4DC206234262356C0808A11B4812C" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_177B9BB360367B46F05D808A11B4940D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0F099DB89ACFC2075843808A11B44FCB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F4DC206234262356C0808A11B4812C" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0F099DB89ACFC2075843808A11B44FCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C8C1CEE60C6F06A8E6F9808A11B4EECE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C8C1CEE60C6F06A8E6F9808A11B4EECE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F3F5752648435ABAF6BA808A11B5C5D0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F3F5752648435ABAF6BA808A11B5C5D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7FADE19E9D0723723777808A11B523F1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7FADE19E9D0723723777808A11B523F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9A6276B9FBC7C4ABE083808A11B57EB9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9A6276B9FBC7C4ABE083808A11B57EB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_71F09AC3BB9E5A9F6964808A11B580BC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_71F09AC3BB9E5A9F6964808A11B580BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9747A2003B12801932CD808A11B5B032" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9747A2003B12801932CD808A11B5B032" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_F0BF150ABF4436229C3C808A11B526E8" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_F0BF150ABF4436229C3C808A11B526E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A681F5C975571D0FFD19808A11B5AA1C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A681F5C975571D0FFD19808A11B5AA1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_5924FD30A8C541C4EA55808A11B52DA0" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_5924FD30A8C541C4EA55808A11B52DA0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/OrganizationAndNatureOfOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_FB9B7AD9E97D540768648018CB5197AE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E82984389698DE5BE55D8018CB5113E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_FB9B7AD9E97D540768648018CB5197AE" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E82984389698DE5BE55D8018CB5113E9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2415B3DBA13379FBFDF08018CB5129F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E82984389698DE5BE55D8018CB5113E9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2415B3DBA13379FBFDF08018CB5129F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CE3F58E789395BAF7FE68018CB5166A3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2415B3DBA13379FBFDF08018CB5129F0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CE3F58E789395BAF7FE68018CB5166A3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CE3F58E789395BAF7FE68018CB5166A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2415B3DBA13379FBFDF08018CB5129F0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CE3F58E789395BAF7FE68018CB5166A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_3BFAA0DB1CC1045D92F98018CB51EC85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CE3F58E789395BAF7FE68018CB5166A3" xlink:to="loc_us-gaap_ComputerEquipmentMember_3BFAA0DB1CC1045D92F98018CB51EC85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_523FC8E441EBF69253FF8018CB51A947" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CE3F58E789395BAF7FE68018CB5166A3" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_523FC8E441EBF69253FF8018CB51A947" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_FurnitureAndOfficeEquipmentMember" xlink:label="loc_mgnx_FurnitureAndOfficeEquipmentMember_846C2E01D468B5EA36F58018CB51F410" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CE3F58E789395BAF7FE68018CB5166A3" xlink:to="loc_mgnx_FurnitureAndOfficeEquipmentMember_846C2E01D468B5EA36F58018CB51F410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_1758D66CF0322FBD5FB88018CB513891" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CE3F58E789395BAF7FE68018CB5166A3" xlink:to="loc_us-gaap_EquipmentMember_1758D66CF0322FBD5FB88018CB513891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_0D6214C3126F10B3D9728018CB5168D7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CE3F58E789395BAF7FE68018CB5166A3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_0D6214C3126F10B3D9728018CB5168D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_753E23109D5D5622D98C8018CB514C8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_FB9B7AD9E97D540768648018CB5197AE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_753E23109D5D5622D98C8018CB514C8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7BFB6E2A5DD48AC048BD8018CB51F01A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_FB9B7AD9E97D540768648018CB5197AE" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7BFB6E2A5DD48AC048BD8018CB51F01A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_13E9FB46BD42434591088018CB514FCB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_FB9B7AD9E97D540768648018CB5197AE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_13E9FB46BD42434591088018CB514FCB" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PropertyPlantAndEquipmentNonCashAdditions" xlink:label="loc_mgnx_PropertyPlantAndEquipmentNonCashAdditions_CE6EAB1697DD94DBABD38018CB513695" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_FB9B7AD9E97D540768648018CB5197AE" xlink:to="loc_mgnx_PropertyPlantAndEquipmentNonCashAdditions_CE6EAB1697DD94DBABD38018CB513695" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_77196894B8CD1D105BEB804EBB57C326" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_FB9B7AD9E97D540768648018CB5197AE" xlink:to="loc_us-gaap_Depreciation_77196894B8CD1D105BEB804EBB57C326" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3E8834644647A0BD6D1673428EDF099" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E13D86877DBF5543034673428ECE628" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3E8834644647A0BD6D1673428EDF099" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E13D86877DBF5543034673428ECE628" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8FA79C5B5EF803F4727D673428ECE8DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E13D86877DBF5543034673428ECE628" xlink:to="loc_us-gaap_RangeAxis_8FA79C5B5EF803F4727D673428ECE8DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_2EBDA709F8AC64020E3C673428ED6F37_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_8FA79C5B5EF803F4727D673428ECE8DB" xlink:to="loc_us-gaap_RangeMember_2EBDA709F8AC64020E3C673428ED6F37_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_2EBDA709F8AC64020E3C673428ED6F37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_8FA79C5B5EF803F4727D673428ECE8DB" xlink:to="loc_us-gaap_RangeMember_2EBDA709F8AC64020E3C673428ED6F37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8091E1FE8C247E7ABF2B673428ED63DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_2EBDA709F8AC64020E3C673428ED6F37" xlink:to="loc_us-gaap_MinimumMember_8091E1FE8C247E7ABF2B673428ED63DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_D2FCB28BB7549EE88794673428ED6FDD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_2EBDA709F8AC64020E3C673428ED6F37" xlink:to="loc_us-gaap_MaximumMember_D2FCB28BB7549EE88794673428ED6FDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_92C15AAB943544456CA0673428EDF4AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3E8834644647A0BD6D1673428EDF099" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_92C15AAB943544456CA0673428EDF4AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0CB2AD4BFFFDACDB139D673428ED0886" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3E8834644647A0BD6D1673428EDF099" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0CB2AD4BFFFDACDB139D673428ED0886" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7492F944870E0E516F0E673428EDE89E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3E8834644647A0BD6D1673428EDF099" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7492F944870E0E516F0E673428EDE89E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_88927E134E8DC0355032673428ED8C6F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3E8834644647A0BD6D1673428EDF099" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_88927E134E8DC0355032673428ED8C6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_505DE5B4FD23329F6C5E673428EDEED8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3E8834644647A0BD6D1673428EDF099" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_505DE5B4FD23329F6C5E673428EDEED8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64FE7CEDA350F41A05F663E495159CE5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_978F5271B4C77BEE44E363E495148792" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64FE7CEDA350F41A05F663E495159CE5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_978F5271B4C77BEE44E363E495148792" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_56AC8DD130394A1B23D963E495141D14" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_978F5271B4C77BEE44E363E495148792" xlink:to="loc_us-gaap_PlanNameAxis_56AC8DD130394A1B23D963E495141D14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_853BB81E67641DB1603863E495149159_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_56AC8DD130394A1B23D963E495141D14" xlink:to="loc_us-gaap_PlanNameDomain_853BB81E67641DB1603863E495149159_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_853BB81E67641DB1603863E495149159" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_56AC8DD130394A1B23D963E495141D14" xlink:to="loc_us-gaap_PlanNameDomain_853BB81E67641DB1603863E495149159" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_EquityIncentivePlan2003Member" xlink:label="loc_mgnx_EquityIncentivePlan2003Member_91A0426E2C014FFD9A2F63E49515FCC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_853BB81E67641DB1603863E495149159" xlink:to="loc_mgnx_EquityIncentivePlan2003Member_91A0426E2C014FFD9A2F63E49515FCC4" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_StockIncentivePlan2013Member" xlink:label="loc_mgnx_StockIncentivePlan2013Member_ABEA052196814BE419DD63E495154370" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_853BB81E67641DB1603863E495149159" xlink:to="loc_mgnx_StockIncentivePlan2013Member_ABEA052196814BE419DD63E495154370" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_929D5BD1E813114172E663E495150A6C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64FE7CEDA350F41A05F663E495159CE5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_929D5BD1E813114172E663E495150A6C" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_7CCD6C53024196770D8D63E4951559A0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64FE7CEDA350F41A05F663E495159CE5" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_7CCD6C53024196770D8D63E4951559A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A4E40369EF3630711DD263E49515B27B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64FE7CEDA350F41A05F663E495159CE5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A4E40369EF3630711DD263E49515B27B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0332A992136B608133E963E495159E38" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64FE7CEDA350F41A05F663E495159CE5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0332A992136B608133E963E495159E38" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_13AF18F7A9CB013067D563E495159883" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64FE7CEDA350F41A05F663E495159CE5" xlink:to="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_13AF18F7A9CB013067D563E495159883" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_ED966013549DE49DF97963E49515CDC0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64FE7CEDA350F41A05F663E495159CE5" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_ED966013549DE49DF97963E49515CDC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_769CE96B9271E4F8510563E495158287" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D1188F814F9C0F3450AF63E49515F04B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_769CE96B9271E4F8510563E495158287" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D1188F814F9C0F3450AF63E49515F04B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_200974DA9209CB4AC09C63E49515EB5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D1188F814F9C0F3450AF63E49515F04B" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_200974DA9209CB4AC09C63E49515EB5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_DDDFC1198BCD575519DF63E49515290B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_200974DA9209CB4AC09C63E49515EB5B" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_DDDFC1198BCD575519DF63E49515290B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_DDDFC1198BCD575519DF63E49515290B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_200974DA9209CB4AC09C63E49515EB5B" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_DDDFC1198BCD575519DF63E49515290B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0E7C9CDDC339470CCBB263E495154973" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_DDDFC1198BCD575519DF63E49515290B" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0E7C9CDDC339470CCBB263E495154973" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8711CA27533F6975AA7563E49515D3B3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_DDDFC1198BCD575519DF63E49515290B" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8711CA27533F6975AA7563E49515D3B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_274BA5AD719D68171A5563E4951603BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_769CE96B9271E4F8510563E495158287" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_274BA5AD719D68171A5563E4951603BF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_B207023914F0BC0A77CE6731121901A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_B207023914F0BC0A77CE6731121901A9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5A5D72C29CCF1E89832D6731121ADE2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B207023914F0BC0A77CE6731121901A9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5A5D72C29CCF1E89832D6731121ADE2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_33C08EB2B9C599B241296731121A8896_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5A5D72C29CCF1E89832D6731121ADE2B" xlink:to="loc_us-gaap_ClassOfStockDomain_33C08EB2B9C599B241296731121A8896_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_33C08EB2B9C599B241296731121A8896" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5A5D72C29CCF1E89832D6731121ADE2B" xlink:to="loc_us-gaap_ClassOfStockDomain_33C08EB2B9C599B241296731121A8896" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_UndesignatedPreferredStockMember" xlink:label="loc_mgnx_UndesignatedPreferredStockMember_63955DD124B708CDB3866731121B5A7D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_33C08EB2B9C599B241296731121A8896" xlink:to="loc_mgnx_UndesignatedPreferredStockMember_63955DD124B708CDB3866731121B5A7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_8FC97911EC45EC562E376731121BAB19" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B207023914F0BC0A77CE6731121901A9" xlink:to="loc_us-gaap_CounterpartyNameAxis_8FC97911EC45EC562E376731121BAB19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_21B0D94AB5B50117A2226731121B95EF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_8FC97911EC45EC562E376731121BAB19" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_21B0D94AB5B50117A2226731121B95EF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_21B0D94AB5B50117A2226731121B95EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_8FC97911EC45EC562E376731121BAB19" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_21B0D94AB5B50117A2226731121B95EF" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_JohnsonAndJohnsonDevelopmentCorporationMember" xlink:label="loc_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_42C168924B28B39DA7DD6731121CF31F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_21B0D94AB5B50117A2226731121B95EF" xlink:to="loc_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_42C168924B28B39DA7DD6731121CF31F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_CFC831A81881CAFF8BCE6731121C4B7A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_CFC831A81881CAFF8BCE6731121C4B7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_09D6E4942D15259EA1E767328883DF3C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_09D6E4942D15259EA1E767328883DF3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_E786C0A21C5BBD3247906731121CA5E0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_E786C0A21C5BBD3247906731121CA5E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4C4D506E935E099656786731121C466C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4C4D506E935E099656786731121C466C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_0ADD0109B59EDC9018846731121CB0ED" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_PreferredStockSharesIssued_0ADD0109B59EDC9018846731121CB0ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4E33E8BDB04C14B8F9886731121D84D3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4E33E8BDB04C14B8F9886731121D84D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6E51CCAE2109FC4D4BA86731121DF60D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6E51CCAE2109FC4D4BA86731121DF60D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1EE3BB423EEC586A286A6731121D323A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_SharePrice_1EE3BB423EEC586A286A6731121D323A" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_6FAFAA138BEB817F3DD16731121DE905" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_6FAFAA138BEB817F3DD16731121DE905" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5B6A4B37B853453B99706731121D279F" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5B6A4B37B853453B99706731121D279F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_F8D2464407F90002241F6731121DA17A" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_F8D2464407F90002241F6731121DA17A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_39C87424A7B71C2FD3EB6731121D6D61" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_39C87424A7B71C2FD3EB6731121D6D61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_709BBE6EFB27EFC4FD656731121D626D" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_709BBE6EFB27EFC4FD656731121D626D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShareDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8A704005B0D9FC46C2BE63E49557FD6B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D4F3F871D42EE1735D6363E49556208C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8A704005B0D9FC46C2BE63E49557FD6B" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D4F3F871D42EE1735D6363E49556208C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_57B2295176832915C96663E49557317A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D4F3F871D42EE1735D6363E49556208C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_57B2295176832915C96663E49557317A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_51E692DA7411274736E563E495578A4C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_57B2295176832915C96663E49557317A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_51E692DA7411274736E563E495578A4C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_51E692DA7411274736E563E495578A4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_57B2295176832915C96663E49557317A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_51E692DA7411274736E563E495578A4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_C92A4561BC3D32E2D81763E495577F1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_51E692DA7411274736E563E495578A4C" xlink:to="loc_us-gaap_ComputerEquipmentMember_C92A4561BC3D32E2D81763E495577F1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_3F625C2325D42F7245FC63E495576CB5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_51E692DA7411274736E563E495578A4C" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_3F625C2325D42F7245FC63E495576CB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_EC32FCF036863127E69963E495572981" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_51E692DA7411274736E563E495578A4C" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_EC32FCF036863127E69963E495572981" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember" xlink:label="loc_mgnx_LaboratoryAndOfficeEquipmentMember_BBCB0AECF7DED513648A63E49557E20F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_51E692DA7411274736E563E495578A4C" xlink:to="loc_mgnx_LaboratoryAndOfficeEquipmentMember_BBCB0AECF7DED513648A63E49557E20F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_FBE4E5FA4FCE67380CD763E495577A9E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_51E692DA7411274736E563E495578A4C" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_FBE4E5FA4FCE67380CD763E495577A9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_54E703147FF9A7A6510963E495578764" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8A704005B0D9FC46C2BE63E49557FD6B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_54E703147FF9A7A6510963E495578764" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_50CBA480ACD6DD15170E63E49557455C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8A704005B0D9FC46C2BE63E49557FD6B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_50CBA480ACD6DD15170E63E49557455C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_626FCC2872220606EDBD638FF1407563" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44E6AE20B46507C0FEAD638FF140D79E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_626FCC2872220606EDBD638FF1407563" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44E6AE20B46507C0FEAD638FF140D79E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B8D2EFE9515A8A0C31C0638FF14080F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44E6AE20B46507C0FEAD638FF140D79E" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B8D2EFE9515A8A0C31C0638FF14080F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_514D8098635ACCBC65B3638FF140CC7C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B8D2EFE9515A8A0C31C0638FF14080F3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_514D8098635ACCBC65B3638FF140CC7C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_514D8098635ACCBC65B3638FF140CC7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B8D2EFE9515A8A0C31C0638FF14080F3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_514D8098635ACCBC65B3638FF140CC7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_413CBF2979B2F627F89D638FF140939E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_514D8098635ACCBC65B3638FF140CC7C" xlink:to="loc_us-gaap_StockOptionMember_413CBF2979B2F627F89D638FF140939E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_CE18C4907B6D5CAFA693638FF1412F16" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_626FCC2872220606EDBD638FF1407563" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_CE18C4907B6D5CAFA693638FF1412F16" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_7011D199E2E3FEFAF1E47B56E68FD13B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_830CA0832FF5D1E51A657B56E68EC2FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7011D199E2E3FEFAF1E47B56E68FD13B" xlink:to="loc_us-gaap_ConcentrationRiskTable_830CA0832FF5D1E51A657B56E68EC2FA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_98CDDC13DE79DB5CD4B57B7818A290BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_830CA0832FF5D1E51A657B56E68EC2FA" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_98CDDC13DE79DB5CD4B57B7818A290BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_D53353D50589AD690A4B7B7818A4407A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_98CDDC13DE79DB5CD4B57B7818A290BD" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_D53353D50589AD690A4B7B7818A4407A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_D53353D50589AD690A4B7B7818A4407A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_98CDDC13DE79DB5CD4B57B7818A290BD" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_D53353D50589AD690A4B7B7818A4407A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_8684ED2D85016101FD657B785871E99C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_D53353D50589AD690A4B7B7818A4407A" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_8684ED2D85016101FD657B785871E99C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_B59D52C436E3334F18637B56E68FE813" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_830CA0832FF5D1E51A657B56E68EC2FA" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_B59D52C436E3334F18637B56E68FE813" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_C5FACD804694095898747B56E68FCE0B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_B59D52C436E3334F18637B56E68FE813" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_C5FACD804694095898747B56E68FCE0B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_C5FACD804694095898747B56E68FCE0B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_B59D52C436E3334F18637B56E68FE813" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_C5FACD804694095898747B56E68FCE0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_C0FDAE2E35ADCBAC1CB97B56E68F7E2F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_C5FACD804694095898747B56E68FCE0B" xlink:to="loc_us-gaap_AccountsReceivableMember_C0FDAE2E35ADCBAC1CB97B56E68F7E2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_CA35D66F1AA36C03E2527B773C643F7A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_830CA0832FF5D1E51A657B56E68EC2FA" xlink:to="loc_us-gaap_MajorCustomersAxis_CA35D66F1AA36C03E2527B773C643F7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_BDC7FD69F97C7195455B7B773C655C47_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_CA35D66F1AA36C03E2527B773C643F7A" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_BDC7FD69F97C7195455B7B773C655C47_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_BDC7FD69F97C7195455B7B773C655C47" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_CA35D66F1AA36C03E2527B773C643F7A" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_BDC7FD69F97C7195455B7B773C655C47" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_JanssenBiotechIncMember" xlink:label="loc_mgnx_JanssenBiotechIncMember_BCA41E3259A93EBE39B37B56E68EB735" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_BDC7FD69F97C7195455B7B773C655C47" xlink:to="loc_mgnx_JanssenBiotechIncMember_BCA41E3259A93EBE39B37B56E68EB735" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_USGovernmentMember" xlink:label="loc_mgnx_USGovernmentMember_DEBB654B9B3D9EB24B737B56E68E5DF9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_BDC7FD69F97C7195455B7B773C655C47" xlink:to="loc_mgnx_USGovernmentMember_DEBB654B9B3D9EB24B737B56E68E5DF9" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ServierMGA271Member" xlink:label="loc_mgnx_ServierMGA271Member_9C3881DF5CD41E5BE5287B56E68EBC76" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_BDC7FD69F97C7195455B7B773C655C47" xlink:to="loc_mgnx_ServierMGA271Member_9C3881DF5CD41E5BE5287B56E68EBC76" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_TakedaPharmaceuticalMember" xlink:label="loc_mgnx_TakedaPharmaceuticalMember_854CA0EB57ECDBB226477B56E68FE2EA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_BDC7FD69F97C7195455B7B773C655C47" xlink:to="loc_mgnx_TakedaPharmaceuticalMember_854CA0EB57ECDBB226477B56E68FE2EA" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_EliLillyMember" xlink:label="loc_mgnx_EliLillyMember_7C80B0302D969AD07EB97B56E68F6929" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_BDC7FD69F97C7195455B7B773C655C47" xlink:to="loc_mgnx_EliLillyMember_7C80B0302D969AD07EB97B56E68F6929" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_A556BB80165F62D4F9297B56E68FA2F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7011D199E2E3FEFAF1E47B56E68FD13B" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_A556BB80165F62D4F9297B56E68FA2F7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarnedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_7AD9DD650C18420841767B56E697A51C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_43BA862DCBAD768C975C7B56E696AB48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7AD9DD650C18420841767B56E697A51C" xlink:to="loc_us-gaap_ConcentrationRiskTable_43BA862DCBAD768C975C7B56E696AB48" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_07BE13EA2959E7EA27177B73CBCD3194" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_43BA862DCBAD768C975C7B56E696AB48" xlink:to="loc_us-gaap_MajorCustomersAxis_07BE13EA2959E7EA27177B73CBCD3194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_A29A835F36C18B10096A7B745E5FBAA6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_07BE13EA2959E7EA27177B73CBCD3194" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_A29A835F36C18B10096A7B745E5FBAA6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_A29A835F36C18B10096A7B745E5FBAA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_07BE13EA2959E7EA27177B73CBCD3194" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_A29A835F36C18B10096A7B745E5FBAA6" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_JanssenBiotechIncMember" xlink:label="loc_mgnx_JanssenBiotechIncMember_E281E1086157CC82109B7B56E69667BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_A29A835F36C18B10096A7B745E5FBAA6" xlink:to="loc_mgnx_JanssenBiotechIncMember_E281E1086157CC82109B7B56E69667BB" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ServierMGA271Member" xlink:label="loc_mgnx_ServierMGA271Member_C8D9CEA9E87E4AB6228C7B56E697EB7B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_A29A835F36C18B10096A7B745E5FBAA6" xlink:to="loc_mgnx_ServierMGA271Member_C8D9CEA9E87E4AB6228C7B56E697EB7B" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_BoehringerIngelheimMember" xlink:label="loc_mgnx_BoehringerIngelheimMember_6EBCCDD78C51F9F252387B56E6978C95" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_A29A835F36C18B10096A7B745E5FBAA6" xlink:to="loc_mgnx_BoehringerIngelheimMember_6EBCCDD78C51F9F252387B56E6978C95" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_TakedaMember" xlink:label="loc_mgnx_TakedaMember_DBDC5DF685460F5AC9C27B56E69713EF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_A29A835F36C18B10096A7B745E5FBAA6" xlink:to="loc_mgnx_TakedaMember_DBDC5DF685460F5AC9C27B56E69713EF" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_GileadSciencesIncMember" xlink:label="loc_mgnx_GileadSciencesIncMember_6A7D55D22D59797D08E27B56E6979C00" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_A29A835F36C18B10096A7B745E5FBAA6" xlink:to="loc_mgnx_GileadSciencesIncMember_6A7D55D22D59797D08E27B56E6979C00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4D5D1F6F441E477FB3B37B56E696D144" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_43BA862DCBAD768C975C7B56E696AB48" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4D5D1F6F441E477FB3B37B56E696D144" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D7A8FC63FA56849CC4D87B56E696FA5D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4D5D1F6F441E477FB3B37B56E696D144" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D7A8FC63FA56849CC4D87B56E696FA5D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D7A8FC63FA56849CC4D87B56E696FA5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4D5D1F6F441E477FB3B37B56E696D144" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D7A8FC63FA56849CC4D87B56E696FA5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_DAF92DF9A928DA9F6A7E7B56E6964620" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D7A8FC63FA56849CC4D87B56E696FA5D" xlink:to="loc_us-gaap_SalesRevenueNetMember_DAF92DF9A928DA9F6A7E7B56E6964620" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_04CD0F2F60F54839667A7B75FDA27C36" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_43BA862DCBAD768C975C7B56E696AB48" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_04CD0F2F60F54839667A7B75FDA27C36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6024FAD4B4039D2D23A37B75FDACF891_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_04CD0F2F60F54839667A7B75FDA27C36" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6024FAD4B4039D2D23A37B75FDACF891_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6024FAD4B4039D2D23A37B75FDACF891" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_04CD0F2F60F54839667A7B75FDA27C36" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6024FAD4B4039D2D23A37B75FDACF891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_245C45882796D6599FDC7B769818AA2C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6024FAD4B4039D2D23A37B75FDACF891" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_245C45882796D6599FDC7B769818AA2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_E364BEC392BBEEE0CE127B56E69734C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7AD9DD650C18420841767B56E697A51C" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_E364BEC392BBEEE0CE127B56E69734C8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BC5E68AB294794EB1AB48018CBA40B37" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B413E47485BFCE7A3DE8018CBA4912B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BC5E68AB294794EB1AB48018CBA40B37" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B413E47485BFCE7A3DE8018CBA4912B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7BC33C99C84E65DE1B7D8018CBA44917" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B413E47485BFCE7A3DE8018CBA4912B" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7BC33C99C84E65DE1B7D8018CBA44917" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2682C61220E20BF841D68018CBA4EFD9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7BC33C99C84E65DE1B7D8018CBA44917" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2682C61220E20BF841D68018CBA4EFD9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2682C61220E20BF841D68018CBA4EFD9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7BC33C99C84E65DE1B7D8018CBA44917" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2682C61220E20BF841D68018CBA4EFD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_B5DBD561D842C95B47C78018CBA41259" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2682C61220E20BF841D68018CBA4EFD9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_B5DBD561D842C95B47C78018CBA41259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_73D62F05E6F270316E918018CBA46D97" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2682C61220E20BF841D68018CBA4EFD9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_73D62F05E6F270316E918018CBA46D97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_02C11550F502326B8F738018CBA47976" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2682C61220E20BF841D68018CBA4EFD9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_02C11550F502326B8F738018CBA47976" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_AF45F04F818BF4D3584F8018CBA4E03D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B413E47485BFCE7A3DE8018CBA4912B" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_AF45F04F818BF4D3584F8018CBA4E03D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_964663B78865213C473A8018CBA4DB09_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_AF45F04F818BF4D3584F8018CBA4E03D" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_964663B78865213C473A8018CBA4DB09_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_964663B78865213C473A8018CBA4DB09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_AF45F04F818BF4D3584F8018CBA4E03D" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_964663B78865213C473A8018CBA4DB09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4B7E392130FF6BF9B82F8018CBA479C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_964663B78865213C473A8018CBA4DB09" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4B7E392130FF6BF9B82F8018CBA479C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8A2DF76D2FEAB42A4F928018CBA485E2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_964663B78865213C473A8018CBA4DB09" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_8A2DF76D2FEAB42A4F928018CBA485E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_C7DACE2B6FE4F2F9046F8018CBA49E97" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_964663B78865213C473A8018CBA4DB09" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_C7DACE2B6FE4F2F9046F8018CBA49E97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1649A5829E7615E676F18018CBA4549E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_964663B78865213C473A8018CBA4DB09" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1649A5829E7615E676F18018CBA4549E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_DF899FF79A7627DA2A658018CBA440F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BC5E68AB294794EB1AB48018CBA40B37" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_DF899FF79A7627DA2A658018CBA440F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_AADA64B60DD226F70B2A8018CBA488CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_DF899FF79A7627DA2A658018CBA440F0" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_AADA64B60DD226F70B2A8018CBA488CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_345FB15D60A5117D7E248056A7E3BD0E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_DF899FF79A7627DA2A658018CBA440F0" xlink:to="loc_us-gaap_AvailableForSaleSecurities_345FB15D60A5117D7E248056A7E3BD0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_756F209E6DCECDEFA26C8018CBA41B55" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_DF899FF79A7627DA2A658018CBA440F0" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_756F209E6DCECDEFA26C8018CBA41B55" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_B1622573C18985F8FAC07B56E6A81D99" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_D15C1B9E2C2DEE2E7ADE7B56E6A8A035" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_B1622573C18985F8FAC07B56E6A81D99" xlink:to="loc_us-gaap_StatementTable_D15C1B9E2C2DEE2E7ADE7B56E6A8A035" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5D1973B5220C851EA5D97B56E6A899F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_D15C1B9E2C2DEE2E7ADE7B56E6A8A035" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5D1973B5220C851EA5D97B56E6A899F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_765D81CBD2A127EEA52A7B56E6A89348_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5D1973B5220C851EA5D97B56E6A899F3" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_765D81CBD2A127EEA52A7B56E6A89348_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_765D81CBD2A127EEA52A7B56E6A89348" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5D1973B5220C851EA5D97B56E6A899F3" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_765D81CBD2A127EEA52A7B56E6A89348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_AA2FC870675E9A8E95C67B56E6A8863F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_765D81CBD2A127EEA52A7B56E6A89348" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_AA2FC870675E9A8E95C67B56E6A8863F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_A44E65E1F3652B59B7807B56E6A99644" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B1622573C18985F8FAC07B56E6A81D99" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_A44E65E1F3652B59B7807B56E6A99644" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_7C3BCB9B6A10F8A33B397B56E6A9CDA9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B1622573C18985F8FAC07B56E6A81D99" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_7C3BCB9B6A10F8A33B397B56E6A9CDA9" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_43800C20444245D457577B56E6A91CDF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B1622573C18985F8FAC07B56E6A81D99" xlink:to="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_43800C20444245D457577B56E6A91CDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_36C18D17463432E8ED567B56E6A9BA85" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B1622573C18985F8FAC07B56E6A81D99" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_36C18D17463432E8ED567B56E6A9BA85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0F5DE2CA29F8C45F39327B56E6A9E024" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B1622573C18985F8FAC07B56E6A81D99" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0F5DE2CA29F8C45F39327B56E6A9E024" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>mgnx-20161231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B91022CD614125FB1B63673428EC6691_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B91022CD614125FB1B63673428EC6691" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B91022CD614125FB1B63673428EC6691" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B91022CD614125FB1B63673428EC6691" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B91022CD614125FB1B63673428EC6691" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E13D86877DBF5543034673428ECE628_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E13D86877DBF5543034673428ECE628" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E13D86877DBF5543034673428ECE628_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E13D86877DBF5543034673428ECE628" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E13D86877DBF5543034673428ECE628" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E13D86877DBF5543034673428ECE628" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E13D86877DBF5543034673428ECE628" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_8FA79C5B5EF803F4727D673428ECE8DB_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_8FA79C5B5EF803F4727D673428ECE8DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_8FA79C5B5EF803F4727D673428ECE8DB_label_en-US" xlink:label="lab_us-gaap_RangeAxis_8FA79C5B5EF803F4727D673428ECE8DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8FA79C5B5EF803F4727D673428ECE8DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_8FA79C5B5EF803F4727D673428ECE8DB" xlink:to="lab_us-gaap_RangeAxis_8FA79C5B5EF803F4727D673428ECE8DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_2EBDA709F8AC64020E3C673428ED6F37_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_2EBDA709F8AC64020E3C673428ED6F37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range</link:label>
    <link:label id="lab_us-gaap_RangeMember_2EBDA709F8AC64020E3C673428ED6F37_label_en-US" xlink:label="lab_us-gaap_RangeMember_2EBDA709F8AC64020E3C673428ED6F37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_2EBDA709F8AC64020E3C673428ED6F37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_2EBDA709F8AC64020E3C673428ED6F37" xlink:to="lab_us-gaap_RangeMember_2EBDA709F8AC64020E3C673428ED6F37" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_8091E1FE8C247E7ABF2B673428ED63DC_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_8091E1FE8C247E7ABF2B673428ED63DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_8091E1FE8C247E7ABF2B673428ED63DC_label_en-US" xlink:label="lab_us-gaap_MinimumMember_8091E1FE8C247E7ABF2B673428ED63DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8091E1FE8C247E7ABF2B673428ED63DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_8091E1FE8C247E7ABF2B673428ED63DC" xlink:to="lab_us-gaap_MinimumMember_8091E1FE8C247E7ABF2B673428ED63DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_D2FCB28BB7549EE88794673428ED6FDD_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_D2FCB28BB7549EE88794673428ED6FDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_D2FCB28BB7549EE88794673428ED6FDD_label_en-US" xlink:label="lab_us-gaap_MaximumMember_D2FCB28BB7549EE88794673428ED6FDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_D2FCB28BB7549EE88794673428ED6FDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_D2FCB28BB7549EE88794673428ED6FDD" xlink:to="lab_us-gaap_MaximumMember_D2FCB28BB7549EE88794673428ED6FDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3E8834644647A0BD6D1673428EDF099_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3E8834644647A0BD6D1673428EDF099" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3E8834644647A0BD6D1673428EDF099_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3E8834644647A0BD6D1673428EDF099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3E8834644647A0BD6D1673428EDF099" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3E8834644647A0BD6D1673428EDF099" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3E8834644647A0BD6D1673428EDF099" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_92C15AAB943544456CA0673428EDF4AF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_92C15AAB943544456CA0673428EDF4AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_92C15AAB943544456CA0673428EDF4AF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_92C15AAB943544456CA0673428EDF4AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_92C15AAB943544456CA0673428EDF4AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_92C15AAB943544456CA0673428EDF4AF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_92C15AAB943544456CA0673428EDF4AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0CB2AD4BFFFDACDB139D673428ED0886_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0CB2AD4BFFFDACDB139D673428ED0886" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0CB2AD4BFFFDACDB139D673428ED0886_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0CB2AD4BFFFDACDB139D673428ED0886" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0CB2AD4BFFFDACDB139D673428ED0886" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0CB2AD4BFFFDACDB139D673428ED0886" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0CB2AD4BFFFDACDB139D673428ED0886" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7492F944870E0E516F0E673428EDE89E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7492F944870E0E516F0E673428EDE89E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7492F944870E0E516F0E673428EDE89E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7492F944870E0E516F0E673428EDE89E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7492F944870E0E516F0E673428EDE89E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7492F944870E0E516F0E673428EDE89E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7492F944870E0E516F0E673428EDE89E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_88927E134E8DC0355032673428ED8C6F_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_88927E134E8DC0355032673428ED8C6F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_88927E134E8DC0355032673428ED8C6F_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_88927E134E8DC0355032673428ED8C6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_88927E134E8DC0355032673428ED8C6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_88927E134E8DC0355032673428ED8C6F" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_88927E134E8DC0355032673428ED8C6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_505DE5B4FD23329F6C5E673428EDEED8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_505DE5B4FD23329F6C5E673428EDEED8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted, maximum term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_505DE5B4FD23329F6C5E673428EDEED8_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_505DE5B4FD23329F6C5E673428EDEED8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_505DE5B4FD23329F6C5E673428EDEED8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_505DE5B4FD23329F6C5E673428EDEED8" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_505DE5B4FD23329F6C5E673428EDEED8" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_FC05C2BBC0BB4ED9AB76638FF13937B3_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_FC05C2BBC0BB4ED9AB76638FF13937B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_FC05C2BBC0BB4ED9AB76638FF13937B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_FC05C2BBC0BB4ED9AB76638FF13937B3" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_FC05C2BBC0BB4ED9AB76638FF13937B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_3042DB7951241700CBE1638FF139D43C_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_3042DB7951241700CBE1638FF139D43C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_3042DB7951241700CBE1638FF139D43C_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_3042DB7951241700CBE1638FF139D43C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_3042DB7951241700CBE1638FF139D43C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_3042DB7951241700CBE1638FF139D43C" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_3042DB7951241700CBE1638FF139D43C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_1B4AFF033B74CE3BD325808A11FADE30_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_1B4AFF033B74CE3BD325808A11FADE30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1B4AFF033B74CE3BD325808A11FADE30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1B4AFF033B74CE3BD325808A11FADE30" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_1B4AFF033B74CE3BD325808A11FADE30" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_25A31435B346C570CAD7808A11FA6671_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_25A31435B346C570CAD7808A11FA6671" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_25A31435B346C570CAD7808A11FA6671_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_25A31435B346C570CAD7808A11FA6671" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_25A31435B346C570CAD7808A11FA6671" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_25A31435B346C570CAD7808A11FA6671" xlink:to="lab_us-gaap_AssetsAbstract_25A31435B346C570CAD7808A11FA6671" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_F01C084948379B61DC29808A11FAE2AE_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_F01C084948379B61DC29808A11FAE2AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_F01C084948379B61DC29808A11FAE2AE_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_F01C084948379B61DC29808A11FAE2AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_F01C084948379B61DC29808A11FAE2AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F01C084948379B61DC29808A11FAE2AE" xlink:to="lab_us-gaap_AssetsCurrentAbstract_F01C084948379B61DC29808A11FAE2AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5DC084A376A8E4520966808A11FAEA65_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5DC084A376A8E4520966808A11FAEA65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5DC084A376A8E4520966808A11FAEA65_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5DC084A376A8E4520966808A11FAEA65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5DC084A376A8E4520966808A11FAEA65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5DC084A376A8E4520966808A11FAEA65" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5DC084A376A8E4520966808A11FAEA65" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_9E4BA4E95977DB1DE035808A11FA98C7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_9E4BA4E95977DB1DE035808A11FA98C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_9E4BA4E95977DB1DE035808A11FA98C7_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_9E4BA4E95977DB1DE035808A11FA98C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_9E4BA4E95977DB1DE035808A11FA98C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent_9E4BA4E95977DB1DE035808A11FA98C7" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent_9E4BA4E95977DB1DE035808A11FA98C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_561BE652A48B1D38FF2A808A11FA5D4F_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_561BE652A48B1D38FF2A808A11FA5D4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_561BE652A48B1D38FF2A808A11FA5D4F_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_561BE652A48B1D38FF2A808A11FA5D4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_561BE652A48B1D38FF2A808A11FA5D4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_561BE652A48B1D38FF2A808A11FA5D4F" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_561BE652A48B1D38FF2A808A11FA5D4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_2C7B2A52B4AEBAFE38B7808A11FA8C97_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_2C7B2A52B4AEBAFE38B7808A11FA8C97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_2C7B2A52B4AEBAFE38B7808A11FA8C97_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_2C7B2A52B4AEBAFE38B7808A11FA8C97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_2C7B2A52B4AEBAFE38B7808A11FA8C97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_2C7B2A52B4AEBAFE38B7808A11FA8C97" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_2C7B2A52B4AEBAFE38B7808A11FA8C97" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssets_065482757E2A07F321FE808A11FA37A0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets_065482757E2A07F321FE808A11FA37A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_065482757E2A07F321FE808A11FA37A0_label_en-US" xlink:label="lab_us-gaap_OtherAssets_065482757E2A07F321FE808A11FA37A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_065482757E2A07F321FE808A11FA37A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets_065482757E2A07F321FE808A11FA37A0" xlink:to="lab_us-gaap_OtherAssets_065482757E2A07F321FE808A11FA37A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_B434CA824E903C62E2E1808A11FA78DC_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_B434CA824E903C62E2E1808A11FA78DC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_B434CA824E903C62E2E1808A11FA78DC_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_B434CA824E903C62E2E1808A11FA78DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_B434CA824E903C62E2E1808A11FA78DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_B434CA824E903C62E2E1808A11FA78DC" xlink:to="lab_us-gaap_AssetsCurrent_B434CA824E903C62E2E1808A11FA78DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2724F6590851B6128A67808A11FAAEBF_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_2724F6590851B6128A67808A11FAAEBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2724F6590851B6128A67808A11FAAEBF_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_2724F6590851B6128A67808A11FAAEBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2724F6590851B6128A67808A11FAAEBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_2724F6590851B6128A67808A11FAAEBF" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_2724F6590851B6128A67808A11FAAEBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_B5B0BB4BFB06699D9BDA808A11FA7EF5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_B5B0BB4BFB06699D9BDA808A11FA7EF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, non-current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_B5B0BB4BFB06699D9BDA808A11FA7EF5_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_B5B0BB4BFB06699D9BDA808A11FA7EF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_B5B0BB4BFB06699D9BDA808A11FA7EF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_B5B0BB4BFB06699D9BDA808A11FA7EF5" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_B5B0BB4BFB06699D9BDA808A11FA7EF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_A00A9A8ECA9FE03CEA27808A11FA57BF_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_A00A9A8ECA9FE03CEA27808A11FA57BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_A00A9A8ECA9FE03CEA27808A11FA57BF_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_A00A9A8ECA9FE03CEA27808A11FA57BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_A00A9A8ECA9FE03CEA27808A11FA57BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_A00A9A8ECA9FE03CEA27808A11FA57BF" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_A00A9A8ECA9FE03CEA27808A11FA57BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_15713F371DFF9F1563DB808A11FB6825_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_15713F371DFF9F1563DB808A11FB6825" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_15713F371DFF9F1563DB808A11FB6825_label_en-US" xlink:label="lab_us-gaap_Assets_15713F371DFF9F1563DB808A11FB6825" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_15713F371DFF9F1563DB808A11FB6825" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_15713F371DFF9F1563DB808A11FB6825" xlink:to="lab_us-gaap_Assets_15713F371DFF9F1563DB808A11FB6825" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D15243FF1B983FDCFFB1808A11FB526C_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D15243FF1B983FDCFFB1808A11FB526C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D15243FF1B983FDCFFB1808A11FB526C_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D15243FF1B983FDCFFB1808A11FB526C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D15243FF1B983FDCFFB1808A11FB526C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D15243FF1B983FDCFFB1808A11FB526C" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D15243FF1B983FDCFFB1808A11FB526C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_105782DD12EB16B7B5C7808A11FBFBEF_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_105782DD12EB16B7B5C7808A11FBFBEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_105782DD12EB16B7B5C7808A11FBFBEF_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_105782DD12EB16B7B5C7808A11FBFBEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_105782DD12EB16B7B5C7808A11FBFBEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_105782DD12EB16B7B5C7808A11FBFBEF" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_105782DD12EB16B7B5C7808A11FBFBEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_F3CDEB13CBDF4AD119BE808A11FBB130_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_F3CDEB13CBDF4AD119BE808A11FBB130" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_F3CDEB13CBDF4AD119BE808A11FBB130_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_F3CDEB13CBDF4AD119BE808A11FBB130" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_F3CDEB13CBDF4AD119BE808A11FBB130" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_F3CDEB13CBDF4AD119BE808A11FBB130" xlink:to="lab_us-gaap_AccountsPayableCurrent_F3CDEB13CBDF4AD119BE808A11FBB130" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_B972298D63EA9E640B9E808A11FBACFB_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_B972298D63EA9E640B9E808A11FBACFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_B972298D63EA9E640B9E808A11FBACFB_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_B972298D63EA9E640B9E808A11FBACFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_B972298D63EA9E640B9E808A11FBACFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_B972298D63EA9E640B9E808A11FBACFB" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_B972298D63EA9E640B9E808A11FBACFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_105B67F184003A914A05808A11FB7118_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_105B67F184003A914A05808A11FB7118" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_105B67F184003A914A05808A11FB7118_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_105B67F184003A914A05808A11FB7118" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_105B67F184003A914A05808A11FB7118" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_105B67F184003A914A05808A11FB7118" xlink:to="lab_us-gaap_DeferredRevenueCurrent_105B67F184003A914A05808A11FB7118" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_AA6073BD186E0E4991A9808A11FB1DE1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent_AA6073BD186E0E4991A9808A11FB1DE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_AA6073BD186E0E4991A9808A11FB1DE1_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent_AA6073BD186E0E4991A9808A11FB1DE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Credit, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_AA6073BD186E0E4991A9808A11FB1DE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditCurrent_AA6073BD186E0E4991A9808A11FB1DE1" xlink:to="lab_us-gaap_DeferredRentCreditCurrent_AA6073BD186E0E4991A9808A11FB1DE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserveCurrent_9893F4C12C61B4899CAD808A11FB841D_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveCurrent_9893F4C12C61B4899CAD808A11FB841D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease exit liability</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveCurrent_9893F4C12C61B4899CAD808A11FB841D_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveCurrent_9893F4C12C61B4899CAD808A11FB841D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="loc_us-gaap_RestructuringReserveCurrent_9893F4C12C61B4899CAD808A11FB841D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveCurrent_9893F4C12C61B4899CAD808A11FB841D" xlink:to="lab_us-gaap_RestructuringReserveCurrent_9893F4C12C61B4899CAD808A11FB841D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_5851DF0C02889FE2F985808A11FBC445_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_5851DF0C02889FE2F985808A11FBC445" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_5851DF0C02889FE2F985808A11FBC445_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_5851DF0C02889FE2F985808A11FBC445" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5851DF0C02889FE2F985808A11FBC445" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_5851DF0C02889FE2F985808A11FBC445" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_5851DF0C02889FE2F985808A11FBC445" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_C2F9EBA08AEA7C0D7AD0808A11FB1F71_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_C2F9EBA08AEA7C0D7AD0808A11FB1F71" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_C2F9EBA08AEA7C0D7AD0808A11FB1F71_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_C2F9EBA08AEA7C0D7AD0808A11FB1F71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_C2F9EBA08AEA7C0D7AD0808A11FB1F71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_C2F9EBA08AEA7C0D7AD0808A11FB1F71" xlink:to="lab_us-gaap_LiabilitiesCurrent_C2F9EBA08AEA7C0D7AD0808A11FB1F71" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_29CAF2319E6DAC4AECBC808A11FB4CAF_positiveLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_29CAF2319E6DAC4AECBC808A11FB4CAF" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_29CAF2319E6DAC4AECBC808A11FB4CAF_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_29CAF2319E6DAC4AECBC808A11FB4CAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_29CAF2319E6DAC4AECBC808A11FB4CAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent_29CAF2319E6DAC4AECBC808A11FB4CAF" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent_29CAF2319E6DAC4AECBC808A11FB4CAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_26D1FFBD8AC4446DE67A808A11FBFCDF_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_26D1FFBD8AC4446DE67A808A11FBFCDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_26D1FFBD8AC4446DE67A808A11FBFCDF_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_26D1FFBD8AC4446DE67A808A11FBFCDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_26D1FFBD8AC4446DE67A808A11FBFCDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent_26D1FFBD8AC4446DE67A808A11FBFCDF" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent_26D1FFBD8AC4446DE67A808A11FBFCDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserveNoncurrent_A953FD5E0F60224EC86D808A11FBBE3E_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveNoncurrent_A953FD5E0F60224EC86D808A11FBBE3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease exit liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveNoncurrent_A953FD5E0F60224EC86D808A11FBBE3E_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveNoncurrent_A953FD5E0F60224EC86D808A11FBBE3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserveNoncurrent" xlink:label="loc_us-gaap_RestructuringReserveNoncurrent_A953FD5E0F60224EC86D808A11FBBE3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveNoncurrent_A953FD5E0F60224EC86D808A11FBBE3E" xlink:to="lab_us-gaap_RestructuringReserveNoncurrent_A953FD5E0F60224EC86D808A11FBBE3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_2216168CBB0FA1305BDF808A11FBF81D_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_2216168CBB0FA1305BDF808A11FBF81D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_2216168CBB0FA1305BDF808A11FBF81D_label_en-US" xlink:label="lab_us-gaap_Liabilities_2216168CBB0FA1305BDF808A11FBF81D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_2216168CBB0FA1305BDF808A11FBF81D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_2216168CBB0FA1305BDF808A11FBF81D" xlink:to="lab_us-gaap_Liabilities_2216168CBB0FA1305BDF808A11FBF81D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_3445B970731179141A8C808A11FBAB4F_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_3445B970731179141A8C808A11FBAB4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_3445B970731179141A8C808A11FBAB4F_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_3445B970731179141A8C808A11FBAB4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_3445B970731179141A8C808A11FBAB4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3445B970731179141A8C808A11FBAB4F" xlink:to="lab_us-gaap_StockholdersEquityAbstract_3445B970731179141A8C808A11FBAB4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_65C7F60AA6E8206FD389808A11FBA410_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_65C7F60AA6E8206FD389808A11FBA410" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value &#8211; 125,000,000 shares authorized, 34,870,607 and 34,345,754 shares outstanding at December 31, 2016 and 2015, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_65C7F60AA6E8206FD389808A11FBA410_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_65C7F60AA6E8206FD389808A11FBA410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_65C7F60AA6E8206FD389808A11FBA410" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_65C7F60AA6E8206FD389808A11FBA410" xlink:to="lab_us-gaap_CommonStockValue_65C7F60AA6E8206FD389808A11FBA410" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1B710D45A8D1204E4D37808A11FC6061_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1B710D45A8D1204E4D37808A11FC6061" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1B710D45A8D1204E4D37808A11FC6061_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1B710D45A8D1204E4D37808A11FC6061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1B710D45A8D1204E4D37808A11FC6061" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1B710D45A8D1204E4D37808A11FC6061" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1B710D45A8D1204E4D37808A11FC6061" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7A949151E7B4CE3DC143808A11FC4589_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7A949151E7B4CE3DC143808A11FC4589" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7A949151E7B4CE3DC143808A11FC4589_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7A949151E7B4CE3DC143808A11FC4589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7A949151E7B4CE3DC143808A11FC4589" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7A949151E7B4CE3DC143808A11FC4589" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7A949151E7B4CE3DC143808A11FC4589" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8DE9E7BDCDE1FF3736AD808A11FC497C_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8DE9E7BDCDE1FF3736AD808A11FC497C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8DE9E7BDCDE1FF3736AD808A11FC497C_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8DE9E7BDCDE1FF3736AD808A11FC497C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8DE9E7BDCDE1FF3736AD808A11FC497C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8DE9E7BDCDE1FF3736AD808A11FC497C" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8DE9E7BDCDE1FF3736AD808A11FC497C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_2461818DBE9A5D8D903C808A11FC562F_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_2461818DBE9A5D8D903C808A11FC562F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2461818DBE9A5D8D903C808A11FC562F_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_2461818DBE9A5D8D903C808A11FC562F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2461818DBE9A5D8D903C808A11FC562F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_2461818DBE9A5D8D903C808A11FC562F" xlink:to="lab_us-gaap_StockholdersEquity_2461818DBE9A5D8D903C808A11FC562F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_FE87D4753BF4C3E772BE808A11FCDBA7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_FE87D4753BF4C3E772BE808A11FCDBA7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_FE87D4753BF4C3E772BE808A11FCDBA7_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_FE87D4753BF4C3E772BE808A11FCDBA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_FE87D4753BF4C3E772BE808A11FCDBA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_FE87D4753BF4C3E772BE808A11FCDBA7" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_FE87D4753BF4C3E772BE808A11FCDBA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_EB043F46E54A5DA57D9EE2787DDEA600_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_EB043F46E54A5DA57D9EE2787DDEA600" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_EB043F46E54A5DA57D9EE2787DDEA600" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_EB043F46E54A5DA57D9EE2787DDEA600" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_EB043F46E54A5DA57D9EE2787DDEA600" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_52129109A3A778930DA5E2787DDE04E2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_52129109A3A778930DA5E2787DDE04E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_52129109A3A778930DA5E2787DDE04E2_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_52129109A3A778930DA5E2787DDE04E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_52129109A3A778930DA5E2787DDE04E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_52129109A3A778930DA5E2787DDE04E2" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_52129109A3A778930DA5E2787DDE04E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_9D14D7B94ED5B7DBFACFE2787D4DAA37_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_9D14D7B94ED5B7DBFACFE2787D4DAA37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation and Retirement Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9D14D7B94ED5B7DBFACFE2787D4DAA37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9D14D7B94ED5B7DBFACFE2787D4DAA37" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_9D14D7B94ED5B7DBFACFE2787D4DAA37" xlink:type="arc" />
    <link:label id="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_19927230061B7767DD80E2787D4D52F8_terseLabel_en-US" xlink:label="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_19927230061B7767DD80E2787D4D52F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eligible age to participate in plan</link:label>
    <link:label id="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_19927230061B7767DD80E2787D4D52F8_label_en-US" xlink:label="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_19927230061B7767DD80E2787D4D52F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employees Eligible Age To Participate In Benefit Plan</link:label>
    <link:label id="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_19927230061B7767DD80E2787D4D52F8_documentation_en-US" xlink:label="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_19927230061B7767DD80E2787D4D52F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to minimum eligible age of employee to participate in benefit plan.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:label="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_19927230061B7767DD80E2787D4D52F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_19927230061B7767DD80E2787D4D52F8" xlink:to="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_19927230061B7767DD80E2787D4D52F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_C44C36974A56F3BAFA14E2787D4DEA3E_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_C44C36974A56F3BAFA14E2787D4DEA3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of employee contribution to salary</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_C44C36974A56F3BAFA14E2787D4DEA3E_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_C44C36974A56F3BAFA14E2787D4DEA3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_C44C36974A56F3BAFA14E2787D4DEA3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_C44C36974A56F3BAFA14E2787D4DEA3E" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_C44C36974A56F3BAFA14E2787D4DEA3E" xlink:type="arc" />
    <link:label id="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_B463028AA8D91064B1F9E2787D4DF230_terseLabel_en-US" xlink:label="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_B463028AA8D91064B1F9E2787D4DF230" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of employee vested contribution</link:label>
    <link:label id="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_B463028AA8D91064B1F9E2787D4DF230_label_en-US" xlink:label="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_B463028AA8D91064B1F9E2787D4DF230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employees Contribution, Vested Percentage</link:label>
    <link:label id="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_B463028AA8D91064B1F9E2787D4DF230_documentation_en-US" xlink:label="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_B463028AA8D91064B1F9E2787D4DF230" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage vested of employee's contributions to defined contribution plan</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:label="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_B463028AA8D91064B1F9E2787D4DF230" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_B463028AA8D91064B1F9E2787D4DF230" xlink:to="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_B463028AA8D91064B1F9E2787D4DF230" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_F61C1D12380744382B08E2787D4D521A_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_F61C1D12380744382B08E2787D4D521A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined contribution plan, employer discretionary contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_F61C1D12380744382B08E2787D4D521A_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_F61C1D12380744382B08E2787D4D521A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_F61C1D12380744382B08E2787D4D521A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_F61C1D12380744382B08E2787D4D521A" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_F61C1D12380744382B08E2787D4D521A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8204643397B901A9972EE2787DBD58DA_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8204643397B901A9972EE2787DBD58DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8204643397B901A9972EE2787DBD58DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8204643397B901A9972EE2787DBD58DA" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8204643397B901A9972EE2787DBD58DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_229A4C979FCD37B5758EE2787DBE472D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_229A4C979FCD37B5758EE2787DBE472D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Minimum Future Lease Payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_229A4C979FCD37B5758EE2787DBE472D_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_229A4C979FCD37B5758EE2787DBE472D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases of Lessee Disclosure [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_229A4C979FCD37B5758EE2787DBE472D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_229A4C979FCD37B5758EE2787DBE472D" xlink:to="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_229A4C979FCD37B5758EE2787DBE472D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_FE1E6CAB2083FAF5E21A8018CBA4BB55_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_FE1E6CAB2083FAF5E21A8018CBA4BB55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_FE1E6CAB2083FAF5E21A8018CBA4BB55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_FE1E6CAB2083FAF5E21A8018CBA4BB55" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_FE1E6CAB2083FAF5E21A8018CBA4BB55" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_728904E35B41FB08BEF18018CBA4D1C9_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_728904E35B41FB08BEF18018CBA4D1C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_728904E35B41FB08BEF18018CBA4D1C9_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_728904E35B41FB08BEF18018CBA4D1C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_728904E35B41FB08BEF18018CBA4D1C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_728904E35B41FB08BEF18018CBA4D1C9" xlink:to="lab_us-gaap_NumberOfOperatingSegments_728904E35B41FB08BEF18018CBA4D1C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_0A4289BB06FC2211BF808022384AD314_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_0A4289BB06FC2211BF808022384AD314" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, other than temporary impairment losses</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_0A4289BB06FC2211BF808022384AD314_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_0A4289BB06FC2211BF808022384AD314" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other than Temporary Impairment Losses, Investments, Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_0A4289BB06FC2211BF808022384AD314" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_0A4289BB06FC2211BF808022384AD314" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_0A4289BB06FC2211BF808022384AD314" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_9DE688A86883A7819E468018CBA41B64_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_9DE688A86883A7819E468018CBA41B64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance recorded</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_9DE688A86883A7819E468018CBA41B64_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_9DE688A86883A7819E468018CBA41B64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for Doubtful Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_9DE688A86883A7819E468018CBA41B64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_9DE688A86883A7819E468018CBA41B64" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_9DE688A86883A7819E468018CBA41B64" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_5E60E4DCAF0A24C970708018CBB4445D_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_5E60E4DCAF0A24C970708018CBB4445D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impaired assets</link:label>
    <link:label id="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_5E60E4DCAF0A24C970708018CBB4445D_label_en-US" xlink:label="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_5E60E4DCAF0A24C970708018CBB4445D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impaired Assets to be Disposed of by Method Other than Sale, Carrying Value of Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" xlink:label="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_5E60E4DCAF0A24C970708018CBB4445D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_5E60E4DCAF0A24C970708018CBB4445D" xlink:to="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_5E60E4DCAF0A24C970708018CBB4445D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_445157DCC2C2A34434958018CBB4BD6E_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_445157DCC2C2A34434958018CBB4BD6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets held-for-sale</link:label>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_445157DCC2C2A34434958018CBB4BD6E_label_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_445157DCC2C2A34434958018CBB4BD6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Held-for-sale, Not Part of Disposal Group</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_445157DCC2C2A34434958018CBB4BD6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_445157DCC2C2A34434958018CBB4BD6E" xlink:to="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_445157DCC2C2A34434958018CBB4BD6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_497CE14224AD403799A68018CBB405C7_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments_497CE14224AD403799A68018CBB405C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_497CE14224AD403799A68018CBB405C7_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments_497CE14224AD403799A68018CBB405C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_497CE14224AD403799A68018CBB405C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments_497CE14224AD403799A68018CBB405C7" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments_497CE14224AD403799A68018CBB405C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_567842EC6187CCC3E4F163E495B957B7_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_567842EC6187CCC3E4F163E495B957B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_567842EC6187CCC3E4F163E495B957B7_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_567842EC6187CCC3E4F163E495B957B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_567842EC6187CCC3E4F163E495B957B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_567842EC6187CCC3E4F163E495B957B7" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_567842EC6187CCC3E4F163E495B957B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_843E596D70660202500763E495B9872B_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_843E596D70660202500763E495B9872B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_843E596D70660202500763E495B9872B_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_843E596D70660202500763E495B9872B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_843E596D70660202500763E495B9872B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_843E596D70660202500763E495B9872B" xlink:to="lab_us-gaap_UseOfEstimates_843E596D70660202500763E495B9872B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6A2CC57D550A25F24FAD63E495B9A3F6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6A2CC57D550A25F24FAD63E495B9A3F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6A2CC57D550A25F24FAD63E495B9A3F6_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6A2CC57D550A25F24FAD63E495B9A3F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6A2CC57D550A25F24FAD63E495B9A3F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6A2CC57D550A25F24FAD63E495B9A3F6" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6A2CC57D550A25F24FAD63E495B9A3F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_727F91711C6395948DCE63E495BA2F78_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_727F91711C6395948DCE63E495BA2F78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_727F91711C6395948DCE63E495BA2F78_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_727F91711C6395948DCE63E495BA2F78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and Other Accounts Receivable, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_727F91711C6395948DCE63E495BA2F78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_727F91711C6395948DCE63E495BA2F78" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_727F91711C6395948DCE63E495BA2F78" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_C62E212730177D72B5EA63E495BA7E9B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_C62E212730177D72B5EA63E495BA7E9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_C62E212730177D72B5EA63E495BA7E9B_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_C62E212730177D72B5EA63E495BA7E9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_C62E212730177D72B5EA63E495BA7E9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_C62E212730177D72B5EA63E495BA7E9B" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_C62E212730177D72B5EA63E495BA7E9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_D128F2A5E36EF947C35563E495BA9C90_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_D128F2A5E36EF947C35563E495BA9C90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_D128F2A5E36EF947C35563E495BA9C90_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_D128F2A5E36EF947C35563E495BA9C90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_D128F2A5E36EF947C35563E495BA9C90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_D128F2A5E36EF947C35563E495BA9C90" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_D128F2A5E36EF947C35563E495BA9C90" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2E6593C49FB557352BFB63E495BAF812_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2E6593C49FB557352BFB63E495BAF812" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2E6593C49FB557352BFB63E495BAF812_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2E6593C49FB557352BFB63E495BAF812" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2E6593C49FB557352BFB63E495BAF812" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2E6593C49FB557352BFB63E495BAF812" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2E6593C49FB557352BFB63E495BAF812" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_84E94F984DBE5B9CC59D63E495BA21B1_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_84E94F984DBE5B9CC59D63E495BA21B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_84E94F984DBE5B9CC59D63E495BA21B1_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_84E94F984DBE5B9CC59D63E495BA21B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_84E94F984DBE5B9CC59D63E495BA21B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_84E94F984DBE5B9CC59D63E495BA21B1" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_84E94F984DBE5B9CC59D63E495BA21B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_133D3D214E69411A480563E495BA1BEC_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_133D3D214E69411A480563E495BA1BEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_133D3D214E69411A480563E495BA1BEC_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_133D3D214E69411A480563E495BA1BEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_133D3D214E69411A480563E495BA1BEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_133D3D214E69411A480563E495BA1BEC" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_133D3D214E69411A480563E495BA1BEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_2C51FD9FC84FBA407B8F63E495BA6EEE_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_2C51FD9FC84FBA407B8F63E495BA6EEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_2C51FD9FC84FBA407B8F63E495BA6EEE_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_2C51FD9FC84FBA407B8F63E495BA6EEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_2C51FD9FC84FBA407B8F63E495BA6EEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_2C51FD9FC84FBA407B8F63E495BA6EEE" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_2C51FD9FC84FBA407B8F63E495BA6EEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_EF03E0E0560D0784614863E495BA6D71_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_EF03E0E0560D0784614863E495BA6D71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_EF03E0E0560D0784614863E495BA6D71_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_EF03E0E0560D0784614863E495BA6D71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_EF03E0E0560D0784614863E495BA6D71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_EF03E0E0560D0784614863E495BA6D71" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_EF03E0E0560D0784614863E495BA6D71" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_62DAD705B5F7146F51D163E495BAE5CE_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_62DAD705B5F7146F51D163E495BAE5CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_62DAD705B5F7146F51D163E495BAE5CE_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_62DAD705B5F7146F51D163E495BAE5CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_62DAD705B5F7146F51D163E495BAE5CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_62DAD705B5F7146F51D163E495BAE5CE" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_62DAD705B5F7146F51D163E495BAE5CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_FEA53C4DEBDD9EE291D063E495BA891A_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_FEA53C4DEBDD9EE291D063E495BA891A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_FEA53C4DEBDD9EE291D063E495BA891A_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_FEA53C4DEBDD9EE291D063E495BA891A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_FEA53C4DEBDD9EE291D063E495BA891A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_FEA53C4DEBDD9EE291D063E495BA891A" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_FEA53C4DEBDD9EE291D063E495BA891A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_BB7FE586CCF3164055E363E495BA73CE_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_BB7FE586CCF3164055E363E495BA73CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_BB7FE586CCF3164055E363E495BA73CE_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_BB7FE586CCF3164055E363E495BA73CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_BB7FE586CCF3164055E363E495BA73CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_BB7FE586CCF3164055E363E495BA73CE" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_BB7FE586CCF3164055E363E495BA73CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_FB39D65C7EA2488ED99563E495BAA488_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_FB39D65C7EA2488ED99563E495BAA488" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_FB39D65C7EA2488ED99563E495BAA488_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_FB39D65C7EA2488ED99563E495BAA488" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_FB39D65C7EA2488ED99563E495BAA488" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_FB39D65C7EA2488ED99563E495BAA488" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_FB39D65C7EA2488ED99563E495BAA488" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EE0F63FF01DBF4E087A1E2787E3F2EDD_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EE0F63FF01DBF4E087A1E2787E3F2EDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EE0F63FF01DBF4E087A1E2787E3F2EDD_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EE0F63FF01DBF4E087A1E2787E3F2EDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EE0F63FF01DBF4E087A1E2787E3F2EDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EE0F63FF01DBF4E087A1E2787E3F2EDD" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EE0F63FF01DBF4E087A1E2787E3F2EDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_26F03D73AEF76B51649281C6E18DA719_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_26F03D73AEF76B51649281C6E18DA719" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_26F03D73AEF76B51649281C6E18DA719" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_26F03D73AEF76B51649281C6E18DA719" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_26F03D73AEF76B51649281C6E18DA719" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_DC6900296FEC981F37B381C6E18DF5AF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_DC6900296FEC981F37B381C6E18DF5AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_DC6900296FEC981F37B381C6E18DF5AF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_DC6900296FEC981F37B381C6E18DF5AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_DC6900296FEC981F37B381C6E18DF5AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_DC6900296FEC981F37B381C6E18DF5AF" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_DC6900296FEC981F37B381C6E18DF5AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_A41A0515B8E36AAD010881C6E18DD0A4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_A41A0515B8E36AAD010881C6E18DD0A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_A41A0515B8E36AAD010881C6E18DD0A4_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_A41A0515B8E36AAD010881C6E18DD0A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A41A0515B8E36AAD010881C6E18DD0A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A41A0515B8E36AAD010881C6E18DD0A4" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_A41A0515B8E36AAD010881C6E18DD0A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_9CC60582D4F86AE5E54781C6E18DCB08_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_9CC60582D4F86AE5E54781C6E18DCB08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_9CC60582D4F86AE5E54781C6E18DCB08_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_9CC60582D4F86AE5E54781C6E18DCB08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9CC60582D4F86AE5E54781C6E18DCB08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9CC60582D4F86AE5E54781C6E18DCB08" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_9CC60582D4F86AE5E54781C6E18DCB08" xlink:type="arc" />
    <link:label id="lab_mgnx_RavenBiotechnologiesIncMember_13966769A856E0A24FD881C6E18DD0C9_terseLabel_en-US" xlink:label="lab_mgnx_RavenBiotechnologiesIncMember_13966769A856E0A24FD881C6E18DD0C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raven Biotechnologies Inc.</link:label>
    <link:label id="lab_mgnx_RavenBiotechnologiesIncMember_13966769A856E0A24FD881C6E18DD0C9_label_en-US" xlink:label="lab_mgnx_RavenBiotechnologiesIncMember_13966769A856E0A24FD881C6E18DD0C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Raven Biotechnologies Inc [Member]</link:label>
    <link:label id="lab_mgnx_RavenBiotechnologiesIncMember_13966769A856E0A24FD881C6E18DD0C9_documentation_en-US" xlink:label="lab_mgnx_RavenBiotechnologiesIncMember_13966769A856E0A24FD881C6E18DD0C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Raven Biotechnologies, Inc.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_RavenBiotechnologiesIncMember" xlink:label="loc_mgnx_RavenBiotechnologiesIncMember_13966769A856E0A24FD881C6E18DD0C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RavenBiotechnologiesIncMember_13966769A856E0A24FD881C6E18DD0C9" xlink:to="lab_mgnx_RavenBiotechnologiesIncMember_13966769A856E0A24FD881C6E18DD0C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_BCF1267D87C2CD55082D81C6E18DDAC5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_BCF1267D87C2CD55082D81C6E18DDAC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_BCF1267D87C2CD55082D81C6E18DDAC5_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_BCF1267D87C2CD55082D81C6E18DDAC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_BCF1267D87C2CD55082D81C6E18DDAC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_BCF1267D87C2CD55082D81C6E18DDAC5" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems_BCF1267D87C2CD55082D81C6E18DDAC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_2869C850FBA4F21BA03881C6E18D3AB5_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_2869C850FBA4F21BA03881C6E18D3AB5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Future sublease payments to be received</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_2869C850FBA4F21BA03881C6E18D3AB5_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_2869C850FBA4F21BA03881C6E18D3AB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_2869C850FBA4F21BA03881C6E18D3AB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_2869C850FBA4F21BA03881C6E18D3AB5" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_2869C850FBA4F21BA03881C6E18D3AB5" xlink:type="arc" />
    <link:label id="lab_mgnx_ReductionInResearchAndDevelopmentExpense_FCD6959F4C8ACE54059681C6E18DE47F_terseLabel_en-US" xlink:label="lab_mgnx_ReductionInResearchAndDevelopmentExpense_FCD6959F4C8ACE54059681C6E18DE47F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in research and development expense</link:label>
    <link:label id="lab_mgnx_ReductionInResearchAndDevelopmentExpense_FCD6959F4C8ACE54059681C6E18DE47F_label_en-US" xlink:label="lab_mgnx_ReductionInResearchAndDevelopmentExpense_FCD6959F4C8ACE54059681C6E18DE47F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction In Research And Development Expense</link:label>
    <link:label id="lab_mgnx_ReductionInResearchAndDevelopmentExpense_FCD6959F4C8ACE54059681C6E18DE47F_documentation_en-US" xlink:label="lab_mgnx_ReductionInResearchAndDevelopmentExpense_FCD6959F4C8ACE54059681C6E18DE47F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction In Research And Development Expense</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ReductionInResearchAndDevelopmentExpense" xlink:label="loc_mgnx_ReductionInResearchAndDevelopmentExpense_FCD6959F4C8ACE54059681C6E18DE47F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ReductionInResearchAndDevelopmentExpense_FCD6959F4C8ACE54059681C6E18DE47F" xlink:to="lab_mgnx_ReductionInResearchAndDevelopmentExpense_FCD6959F4C8ACE54059681C6E18DE47F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_EFDC16996F49DEA0C363E2787CA35A64_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_EFDC16996F49DEA0C363E2787CA35A64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_EFDC16996F49DEA0C363E2787CA35A64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_EFDC16996F49DEA0C363E2787CA35A64" xlink:to="lab_us-gaap_EquityAbstract_EFDC16996F49DEA0C363E2787CA35A64" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A2C5708B1A05F62C00A3E2787CA3F182_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A2C5708B1A05F62C00A3E2787CA3F182" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A2C5708B1A05F62C00A3E2787CA3F182_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A2C5708B1A05F62C00A3E2787CA3F182" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A2C5708B1A05F62C00A3E2787CA3F182" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A2C5708B1A05F62C00A3E2787CA3F182" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A2C5708B1A05F62C00A3E2787CA3F182" xlink:type="arc" />
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_FEC6281BDDCB29DB15148238ADDCF2FC_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_FEC6281BDDCB29DB15148238ADDCF2FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_FEC6281BDDCB29DB15148238ADDCF2FC_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_FEC6281BDDCB29DB15148238ADDCF2FC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_FEC6281BDDCB29DB15148238ADDCF2FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_FEC6281BDDCB29DB15148238ADDCF2FC" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_FEC6281BDDCB29DB15148238ADDCF2FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BC20E45152D5A1CFF2ED8238ADE15087_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BC20E45152D5A1CFF2ED8238ADE15087" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BC20E45152D5A1CFF2ED8238ADE15087_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BC20E45152D5A1CFF2ED8238ADE15087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BC20E45152D5A1CFF2ED8238ADE15087" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BC20E45152D5A1CFF2ED8238ADE15087" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BC20E45152D5A1CFF2ED8238ADE15087" xlink:type="arc" />
    <link:label id="lab_us-gaap_CounterpartyNameAxis_BF37B0471873E9213FB68238ADE1196F_terseLabel_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_BF37B0471873E9213FB68238ADE1196F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_us-gaap_CounterpartyNameAxis_BF37B0471873E9213FB68238ADE1196F_label_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_BF37B0471873E9213FB68238ADE1196F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_BF37B0471873E9213FB68238ADE1196F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CounterpartyNameAxis_BF37B0471873E9213FB68238ADE1196F" xlink:to="lab_us-gaap_CounterpartyNameAxis_BF37B0471873E9213FB68238ADE1196F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9E9F8B73172DFA1D70068238ADE1873F_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9E9F8B73172DFA1D70068238ADE1873F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9E9F8B73172DFA1D70068238ADE1873F_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9E9F8B73172DFA1D70068238ADE1873F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9E9F8B73172DFA1D70068238ADE1873F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9E9F8B73172DFA1D70068238ADE1873F" xlink:to="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9E9F8B73172DFA1D70068238ADE1873F" xlink:type="arc" />
    <link:label id="lab_mgnx_TakedaMember_B5912AB689FB276D427E8238ADE12923_terseLabel_en-US" xlink:label="lab_mgnx_TakedaMember_B5912AB689FB276D427E8238ADE12923" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Takeda Pharmaceutical Company Limited (Takeda)</link:label>
    <link:label id="lab_mgnx_TakedaMember_B5912AB689FB276D427E8238ADE12923_label_en-US" xlink:label="lab_mgnx_TakedaMember_B5912AB689FB276D427E8238ADE12923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Takeda [Member]</link:label>
    <link:label id="lab_mgnx_TakedaMember_B5912AB689FB276D427E8238ADE12923_documentation_en-US" xlink:label="lab_mgnx_TakedaMember_B5912AB689FB276D427E8238ADE12923" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Counterparty in collaboration agreement</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_TakedaMember" xlink:label="loc_mgnx_TakedaMember_B5912AB689FB276D427E8238ADE12923" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TakedaMember_B5912AB689FB276D427E8238ADE12923" xlink:to="lab_mgnx_TakedaMember_B5912AB689FB276D427E8238ADE12923" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_65B970DDA5286C692A148238ADE1F821_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_65B970DDA5286C692A148238ADE1F821" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_65B970DDA5286C692A148238ADE1F821_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_65B970DDA5286C692A148238ADE1F821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_65B970DDA5286C692A148238ADE1F821" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_65B970DDA5286C692A148238ADE1F821" xlink:to="lab_us-gaap_TypeOfArrangementAxis_65B970DDA5286C692A148238ADE1F821" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A04E4DBBCA122957CF328238ADE2B7C5_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A04E4DBBCA122957CF328238ADE2B7C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A04E4DBBCA122957CF328238ADE2B7C5_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A04E4DBBCA122957CF328238ADE2B7C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A04E4DBBCA122957CF328238ADE2B7C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A04E4DBBCA122957CF328238ADE2B7C5" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A04E4DBBCA122957CF328238ADE2B7C5" xlink:type="arc" />
    <link:label id="lab_mgnx_TakedaMGD010AgreementMember_157CC58203FFF1CF37EB8238ADE22FCD_terseLabel_en-US" xlink:label="lab_mgnx_TakedaMGD010AgreementMember_157CC58203FFF1CF37EB8238ADE22FCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Takeda MGD010 Agreement</link:label>
    <link:label id="lab_mgnx_TakedaMGD010AgreementMember_157CC58203FFF1CF37EB8238ADE22FCD_label_en-US" xlink:label="lab_mgnx_TakedaMGD010AgreementMember_157CC58203FFF1CF37EB8238ADE22FCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Takeda MGD010 Agreement [Member]</link:label>
    <link:label id="lab_mgnx_TakedaMGD010AgreementMember_157CC58203FFF1CF37EB8238ADE22FCD_documentation_en-US" xlink:label="lab_mgnx_TakedaMGD010AgreementMember_157CC58203FFF1CF37EB8238ADE22FCD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents agreement with Takeda for MGD010</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_TakedaMGD010AgreementMember" xlink:label="loc_mgnx_TakedaMGD010AgreementMember_157CC58203FFF1CF37EB8238ADE22FCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TakedaMGD010AgreementMember_157CC58203FFF1CF37EB8238ADE22FCD" xlink:to="lab_mgnx_TakedaMGD010AgreementMember_157CC58203FFF1CF37EB8238ADE22FCD" xlink:type="arc" />
    <link:label id="lab_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_C053AF6554CF0972C8B28238ADE2035C_terseLabel_en-US" xlink:label="lab_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_C053AF6554CF0972C8B28238ADE2035C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Collaboration and License Option Agreement</link:label>
    <link:label id="lab_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_C053AF6554CF0972C8B28238ADE2035C_label_en-US" xlink:label="lab_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_C053AF6554CF0972C8B28238ADE2035C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Collaboration And License Option Agreement [Member]</link:label>
    <link:label id="lab_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_C053AF6554CF0972C8B28238ADE2035C_documentation_en-US" xlink:label="lab_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_C053AF6554CF0972C8B28238ADE2035C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents agreement with Takeda for research</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ResearchCollaborationAndLicenseOptionAgreementMember" xlink:label="loc_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_C053AF6554CF0972C8B28238ADE2035C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_C053AF6554CF0972C8B28238ADE2035C" xlink:to="lab_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_C053AF6554CF0972C8B28238ADE2035C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and Other Agreements [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0" xlink:type="arc" />
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_D098FF2B9C5BF5D160988238ADE7B0E4_terseLabel_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees_D098FF2B9C5BF5D160988238ADE7B0E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrefundable upfront payment</link:label>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_D098FF2B9C5BF5D160988238ADE7B0E4_label_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees_D098FF2B9C5BF5D160988238ADE7B0E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-refundable upfront payment</link:label>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_D098FF2B9C5BF5D160988238ADE7B0E4_documentation_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees_D098FF2B9C5BF5D160988238ADE7B0E4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial fee received from collaboration or license agreement.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_D098FF2B9C5BF5D160988238ADE7B0E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonRefundableUpfrontFees_D098FF2B9C5BF5D160988238ADE7B0E4" xlink:to="lab_mgnx_NonRefundableUpfrontFees_D098FF2B9C5BF5D160988238ADE7B0E4" xlink:type="arc" />
    <link:label id="lab_mgnx_UpfrontFeeAllocatedToAgreement_A95AB039EAC88A6FBD7E8238ADE7AEF4_terseLabel_en-US" xlink:label="lab_mgnx_UpfrontFeeAllocatedToAgreement_A95AB039EAC88A6FBD7E8238ADE7AEF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount allocated to agreement</link:label>
    <link:label id="lab_mgnx_UpfrontFeeAllocatedToAgreement_A95AB039EAC88A6FBD7E8238ADE7AEF4_label_en-US" xlink:label="lab_mgnx_UpfrontFeeAllocatedToAgreement_A95AB039EAC88A6FBD7E8238ADE7AEF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Fee Allocated To Agreement</link:label>
    <link:label id="lab_mgnx_UpfrontFeeAllocatedToAgreement_A95AB039EAC88A6FBD7E8238ADE7AEF4_documentation_en-US" xlink:label="lab_mgnx_UpfrontFeeAllocatedToAgreement_A95AB039EAC88A6FBD7E8238ADE7AEF4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Portion of upfront fee allocated to agreement.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_UpfrontFeeAllocatedToAgreement" xlink:label="loc_mgnx_UpfrontFeeAllocatedToAgreement_A95AB039EAC88A6FBD7E8238ADE7AEF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UpfrontFeeAllocatedToAgreement_A95AB039EAC88A6FBD7E8238ADE7AEF4" xlink:to="lab_mgnx_UpfrontFeeAllocatedToAgreement_A95AB039EAC88A6FBD7E8238ADE7AEF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_6E93102F9055D0DDC0608238ADE725AA_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_6E93102F9055D0DDC0608238ADE725AA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue included in current liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_6E93102F9055D0DDC0608238ADE725AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_6E93102F9055D0DDC0608238ADE725AA" xlink:to="lab_us-gaap_DeferredRevenueCurrent_6E93102F9055D0DDC0608238ADE725AA" xlink:type="arc" />
    <link:label id="lab_mgnx_UpfrontPaymentRecognitionPeriod_CAAE10E950DA18A6540B8238ADE78F53_terseLabel_en-US" xlink:label="lab_mgnx_UpfrontPaymentRecognitionPeriod_CAAE10E950DA18A6540B8238ADE78F53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected period of development</link:label>
    <link:label id="lab_mgnx_UpfrontPaymentRecognitionPeriod_CAAE10E950DA18A6540B8238ADE78F53_label_en-US" xlink:label="lab_mgnx_UpfrontPaymentRecognitionPeriod_CAAE10E950DA18A6540B8238ADE78F53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payment Recognition Period</link:label>
    <link:label id="lab_mgnx_UpfrontPaymentRecognitionPeriod_CAAE10E950DA18A6540B8238ADE78F53_documentation_en-US" xlink:label="lab_mgnx_UpfrontPaymentRecognitionPeriod_CAAE10E950DA18A6540B8238ADE78F53" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to upfront payment recognition period.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod_CAAE10E950DA18A6540B8238ADE78F53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UpfrontPaymentRecognitionPeriod_CAAE10E950DA18A6540B8238ADE78F53" xlink:to="lab_mgnx_UpfrontPaymentRecognitionPeriod_CAAE10E950DA18A6540B8238ADE78F53" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicensesRevenue_EA6F33BD660EFB2B6D598238ADE7108F_terseLabel_en-US" xlink:label="lab_us-gaap_LicensesRevenue_EA6F33BD660EFB2B6D598238ADE7108F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognized revenue under agreement</link:label>
    <link:label id="lab_us-gaap_LicensesRevenue_EA6F33BD660EFB2B6D598238ADE7108F_label_en-US" xlink:label="lab_us-gaap_LicensesRevenue_EA6F33BD660EFB2B6D598238ADE7108F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licenses Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_EA6F33BD660EFB2B6D598238ADE7108F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensesRevenue_EA6F33BD660EFB2B6D598238ADE7108F" xlink:to="lab_us-gaap_LicensesRevenue_EA6F33BD660EFB2B6D598238ADE7108F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_DCD414A4858D99BA3C078238ADE7451A_netLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_DCD414A4858D99BA3C078238ADE7451A" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Milestone received</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_DCD414A4858D99BA3C078238ADE7451A_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_DCD414A4858D99BA3C078238ADE7451A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_DCD414A4858D99BA3C078238ADE7451A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_DCD414A4858D99BA3C078238ADE7451A" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_DCD414A4858D99BA3C078238ADE7451A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenue_2ADACD9D5E2E8B47C5E38238ADE72628_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue_2ADACD9D5E2E8B47C5E38238ADE72628" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenue_2ADACD9D5E2E8B47C5E38238ADE72628_label_en-US" xlink:label="lab_us-gaap_DeferredRevenue_2ADACD9D5E2E8B47C5E38238ADE72628" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_2ADACD9D5E2E8B47C5E38238ADE72628" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue_2ADACD9D5E2E8B47C5E38238ADE72628" xlink:to="lab_us-gaap_DeferredRevenue_2ADACD9D5E2E8B47C5E38238ADE72628" xlink:type="arc" />
    <link:label id="lab_mgnx_BoehringerIngelheimMember_5469441C8D05CE6BB6B871703D610228_terseLabel_en-US" xlink:label="lab_mgnx_BoehringerIngelheimMember_5469441C8D05CE6BB6B871703D610228" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Boehringer Ingelheim GmbH (Boehringer)</link:label>
    <link:label id="lab_mgnx_BoehringerIngelheimMember_5469441C8D05CE6BB6B871703D610228_label_en-US" xlink:label="lab_mgnx_BoehringerIngelheimMember_5469441C8D05CE6BB6B871703D610228" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Boehringer Ingelheim [Member]</link:label>
    <link:label id="lab_mgnx_BoehringerIngelheimMember_5469441C8D05CE6BB6B871703D610228_documentation_en-US" xlink:label="lab_mgnx_BoehringerIngelheimMember_5469441C8D05CE6BB6B871703D610228" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents a collaborators with which entity has an agreement related to contracts and research grants received from U.S. government agencies.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_BoehringerIngelheimMember" xlink:label="loc_mgnx_BoehringerIngelheimMember_5469441C8D05CE6BB6B871703D610228" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_BoehringerIngelheimMember_5469441C8D05CE6BB6B871703D610228" xlink:to="lab_mgnx_BoehringerIngelheimMember_5469441C8D05CE6BB6B871703D610228" xlink:type="arc" />
    <link:label id="lab_mgnx_NumberOfAnnualMaintenancePaymentReceived_A4893ABF8CECFE444CD871703D62AFEC_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfAnnualMaintenancePaymentReceived_A4893ABF8CECFE444CD871703D62AFEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of annual maintenance payments received</link:label>
    <link:label id="lab_mgnx_NumberOfAnnualMaintenancePaymentReceived_A4893ABF8CECFE444CD871703D62AFEC_label_en-US" xlink:label="lab_mgnx_NumberOfAnnualMaintenancePaymentReceived_A4893ABF8CECFE444CD871703D62AFEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Annual Maintenance Payment Received</link:label>
    <link:label id="lab_mgnx_NumberOfAnnualMaintenancePaymentReceived_A4893ABF8CECFE444CD871703D62AFEC_documentation_en-US" xlink:label="lab_mgnx_NumberOfAnnualMaintenancePaymentReceived_A4893ABF8CECFE444CD871703D62AFEC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of annual maintenance payment received.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NumberOfAnnualMaintenancePaymentReceived" xlink:label="loc_mgnx_NumberOfAnnualMaintenancePaymentReceived_A4893ABF8CECFE444CD871703D62AFEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfAnnualMaintenancePaymentReceived_A4893ABF8CECFE444CD871703D62AFEC" xlink:to="lab_mgnx_NumberOfAnnualMaintenancePaymentReceived_A4893ABF8CECFE444CD871703D62AFEC" xlink:type="arc" />
    <link:label id="lab_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_B7193704E669B021ED0D71703D674EAD_terseLabel_en-US" xlink:label="lab_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_B7193704E669B021ED0D71703D674EAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical milestone payments</link:label>
    <link:label id="lab_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_B7193704E669B021ED0D71703D674EAD_label_en-US" xlink:label="lab_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_B7193704E669B021ED0D71703D674EAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Potential Clinical Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_B7193704E669B021ED0D71703D674EAD_documentation_en-US" xlink:label="lab_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_B7193704E669B021ED0D71703D674EAD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate potential clinical milestone payments available to be earned under collaboration agreement.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_B7193704E669B021ED0D71703D674EAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_B7193704E669B021ED0D71703D674EAD" xlink:to="lab_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_B7193704E669B021ED0D71703D674EAD" xlink:type="arc" />
    <link:label id="lab_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_9A94F7724CE89A9C1BC171703D67DCB3_terseLabel_en-US" xlink:label="lab_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_9A94F7724CE89A9C1BC171703D67DCB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional potential regulatory milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_9A94F7724CE89A9C1BC171703D67DCB3_label_en-US" xlink:label="lab_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_9A94F7724CE89A9C1BC171703D67DCB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Potential Regulatory Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_9A94F7724CE89A9C1BC171703D67DCB3_documentation_en-US" xlink:label="lab_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_9A94F7724CE89A9C1BC171703D67DCB3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate potential regulatory milestone payments available to be earned under a collaboration arrangement.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_9A94F7724CE89A9C1BC171703D67DCB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_9A94F7724CE89A9C1BC171703D67DCB3" xlink:to="lab_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_9A94F7724CE89A9C1BC171703D67DCB3" xlink:type="arc" />
    <link:label id="lab_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_64E84716F49477A2F0A771703D67AC48_terseLabel_en-US" xlink:label="lab_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_64E84716F49477A2F0A771703D67AC48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional potential sales milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_64E84716F49477A2F0A771703D67AC48_label_en-US" xlink:label="lab_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_64E84716F49477A2F0A771703D67AC48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Potential Sales Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_64E84716F49477A2F0A771703D67AC48_documentation_en-US" xlink:label="lab_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_64E84716F49477A2F0A771703D67AC48" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate potential sales milestone payments available to be earned under collaboration agreement.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_64E84716F49477A2F0A771703D67AC48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_64E84716F49477A2F0A771703D67AC48" xlink:to="lab_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_64E84716F49477A2F0A771703D67AC48" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_2EA8E108E3EEF5034E7A71703D676712_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_2EA8E108E3EEF5034E7A71703D676712" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_2EA8E108E3EEF5034E7A71703D676712" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_2EA8E108E3EEF5034E7A71703D676712" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_2EA8E108E3EEF5034E7A71703D676712" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_E4EDB04CB8F45498A12884277070DDD4_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_E4EDB04CB8F45498A12884277070DDD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_E4EDB04CB8F45498A12884277070DDD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_E4EDB04CB8F45498A12884277070DDD4" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_E4EDB04CB8F45498A12884277070DDD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2746EFBDCF79410F6F31842770709D79_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2746EFBDCF79410F6F31842770709D79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company's Consolidated Quarterly Results of Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2746EFBDCF79410F6F31842770709D79_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2746EFBDCF79410F6F31842770709D79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2746EFBDCF79410F6F31842770709D79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2746EFBDCF79410F6F31842770709D79" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2746EFBDCF79410F6F31842770709D79" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTable_830CA0832FF5D1E51A657B56E68EC2FA_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_830CA0832FF5D1E51A657B56E68EC2FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_830CA0832FF5D1E51A657B56E68EC2FA_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_830CA0832FF5D1E51A657B56E68EC2FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_830CA0832FF5D1E51A657B56E68EC2FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable_830CA0832FF5D1E51A657B56E68EC2FA" xlink:to="lab_us-gaap_ConcentrationRiskTable_830CA0832FF5D1E51A657B56E68EC2FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_98CDDC13DE79DB5CD4B57B7818A290BD_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_98CDDC13DE79DB5CD4B57B7818A290BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_98CDDC13DE79DB5CD4B57B7818A290BD_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_98CDDC13DE79DB5CD4B57B7818A290BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_98CDDC13DE79DB5CD4B57B7818A290BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_98CDDC13DE79DB5CD4B57B7818A290BD" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_98CDDC13DE79DB5CD4B57B7818A290BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_D53353D50589AD690A4B7B7818A4407A_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_D53353D50589AD690A4B7B7818A4407A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_D53353D50589AD690A4B7B7818A4407A_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_D53353D50589AD690A4B7B7818A4407A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_D53353D50589AD690A4B7B7818A4407A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_D53353D50589AD690A4B7B7818A4407A" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_D53353D50589AD690A4B7B7818A4407A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_8684ED2D85016101FD657B785871E99C_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_8684ED2D85016101FD657B785871E99C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_8684ED2D85016101FD657B785871E99C_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_8684ED2D85016101FD657B785871E99C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_8684ED2D85016101FD657B785871E99C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_8684ED2D85016101FD657B785871E99C" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_8684ED2D85016101FD657B785871E99C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_B59D52C436E3334F18637B56E68FE813_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_B59D52C436E3334F18637B56E68FE813" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_B59D52C436E3334F18637B56E68FE813_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_B59D52C436E3334F18637B56E68FE813" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_B59D52C436E3334F18637B56E68FE813" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_B59D52C436E3334F18637B56E68FE813" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_B59D52C436E3334F18637B56E68FE813" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_C5FACD804694095898747B56E68FCE0B_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_C5FACD804694095898747B56E68FCE0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_C5FACD804694095898747B56E68FCE0B_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_C5FACD804694095898747B56E68FCE0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_C5FACD804694095898747B56E68FCE0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_C5FACD804694095898747B56E68FCE0B" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_C5FACD804694095898747B56E68FCE0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_C0FDAE2E35ADCBAC1CB97B56E68F7E2F_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_C0FDAE2E35ADCBAC1CB97B56E68F7E2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_C0FDAE2E35ADCBAC1CB97B56E68F7E2F_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_C0FDAE2E35ADCBAC1CB97B56E68F7E2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_C0FDAE2E35ADCBAC1CB97B56E68F7E2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_C0FDAE2E35ADCBAC1CB97B56E68F7E2F" xlink:to="lab_us-gaap_AccountsReceivableMember_C0FDAE2E35ADCBAC1CB97B56E68F7E2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorCustomersAxis_CA35D66F1AA36C03E2527B773C643F7A_terseLabel_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_CA35D66F1AA36C03E2527B773C643F7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorCustomersAxis_CA35D66F1AA36C03E2527B773C643F7A_label_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_CA35D66F1AA36C03E2527B773C643F7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_CA35D66F1AA36C03E2527B773C643F7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersAxis_CA35D66F1AA36C03E2527B773C643F7A" xlink:to="lab_us-gaap_MajorCustomersAxis_CA35D66F1AA36C03E2527B773C643F7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_BDC7FD69F97C7195455B7B773C655C47_terseLabel_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_BDC7FD69F97C7195455B7B773C655C47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_BDC7FD69F97C7195455B7B773C655C47_label_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_BDC7FD69F97C7195455B7B773C655C47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_BDC7FD69F97C7195455B7B773C655C47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_BDC7FD69F97C7195455B7B773C655C47" xlink:to="lab_us-gaap_NameOfMajorCustomerDomain_BDC7FD69F97C7195455B7B773C655C47" xlink:type="arc" />
    <link:label id="lab_mgnx_JanssenBiotechIncMember_BCA41E3259A93EBE39B37B56E68EB735_verboseLabel_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember_BCA41E3259A93EBE39B37B56E68EB735" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Janssen Biotech, Inc. (Janssen)</link:label>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_BCA41E3259A93EBE39B37B56E68EB735_label_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember_BCA41E3259A93EBE39B37B56E68EB735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Janssen Biotech Inc [Member]</link:label>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_BCA41E3259A93EBE39B37B56E68EB735_documentation_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember_BCA41E3259A93EBE39B37B56E68EB735" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Counterparty in collaboration agreement</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_JanssenBiotechIncMember" xlink:label="loc_mgnx_JanssenBiotechIncMember_BCA41E3259A93EBE39B37B56E68EB735" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenBiotechIncMember_BCA41E3259A93EBE39B37B56E68EB735" xlink:to="lab_mgnx_JanssenBiotechIncMember_BCA41E3259A93EBE39B37B56E68EB735" xlink:type="arc" />
    <link:label id="lab_mgnx_USGovernmentMember_DEBB654B9B3D9EB24B737B56E68E5DF9_terseLabel_en-US" xlink:label="lab_mgnx_USGovernmentMember_DEBB654B9B3D9EB24B737B56E68E5DF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government</link:label>
    <link:label id="lab_mgnx_USGovernmentMember_DEBB654B9B3D9EB24B737B56E68E5DF9_label_en-US" xlink:label="lab_mgnx_USGovernmentMember_DEBB654B9B3D9EB24B737B56E68E5DF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">USGovernment [Member]</link:label>
    <link:label id="lab_mgnx_USGovernmentMember_DEBB654B9B3D9EB24B737B56E68E5DF9_documentation_en-US" xlink:label="lab_mgnx_USGovernmentMember_DEBB654B9B3D9EB24B737B56E68E5DF9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents counterparty in contractual arrangement</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_USGovernmentMember" xlink:label="loc_mgnx_USGovernmentMember_DEBB654B9B3D9EB24B737B56E68E5DF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_USGovernmentMember_DEBB654B9B3D9EB24B737B56E68E5DF9" xlink:to="lab_mgnx_USGovernmentMember_DEBB654B9B3D9EB24B737B56E68E5DF9" xlink:type="arc" />
    <link:label id="lab_mgnx_ServierMGA271Member_9C3881DF5CD41E5BE5287B56E68EBC76_terseLabel_en-US" xlink:label="lab_mgnx_ServierMGA271Member_9C3881DF5CD41E5BE5287B56E68EBC76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Les Laboratoires Servier and Institut de Reserches Servier (collectively, Servier)</link:label>
    <link:label id="lab_mgnx_ServierMGA271Member_9C3881DF5CD41E5BE5287B56E68EBC76_label_en-US" xlink:label="lab_mgnx_ServierMGA271Member_9C3881DF5CD41E5BE5287B56E68EBC76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Servier MGA271 [Member]</link:label>
    <link:label id="lab_mgnx_ServierMGA271Member_9C3881DF5CD41E5BE5287B56E68EBC76_documentation_en-US" xlink:label="lab_mgnx_ServierMGA271Member_9C3881DF5CD41E5BE5287B56E68EBC76" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents agreement with Servier for enoblituzumab</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ServierMGA271Member" xlink:label="loc_mgnx_ServierMGA271Member_9C3881DF5CD41E5BE5287B56E68EBC76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ServierMGA271Member_9C3881DF5CD41E5BE5287B56E68EBC76" xlink:to="lab_mgnx_ServierMGA271Member_9C3881DF5CD41E5BE5287B56E68EBC76" xlink:type="arc" />
    <link:label id="lab_mgnx_TakedaPharmaceuticalMember_854CA0EB57ECDBB226477B56E68FE2EA_terseLabel_en-US" xlink:label="lab_mgnx_TakedaPharmaceuticalMember_854CA0EB57ECDBB226477B56E68FE2EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Takeda</link:label>
    <link:label id="lab_mgnx_TakedaPharmaceuticalMember_854CA0EB57ECDBB226477B56E68FE2EA_label_en-US" xlink:label="lab_mgnx_TakedaPharmaceuticalMember_854CA0EB57ECDBB226477B56E68FE2EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Takeda Pharmaceutical [Member]</link:label>
    <link:label id="lab_mgnx_TakedaPharmaceuticalMember_854CA0EB57ECDBB226477B56E68FE2EA_documentation_en-US" xlink:label="lab_mgnx_TakedaPharmaceuticalMember_854CA0EB57ECDBB226477B56E68FE2EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Takeda Pharmaceutical Company Limited (Takeda)</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_TakedaPharmaceuticalMember" xlink:label="loc_mgnx_TakedaPharmaceuticalMember_854CA0EB57ECDBB226477B56E68FE2EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TakedaPharmaceuticalMember_854CA0EB57ECDBB226477B56E68FE2EA" xlink:to="lab_mgnx_TakedaPharmaceuticalMember_854CA0EB57ECDBB226477B56E68FE2EA" xlink:type="arc" />
    <link:label id="lab_mgnx_EliLillyMember_7C80B0302D969AD07EB97B56E68F6929_terseLabel_en-US" xlink:label="lab_mgnx_EliLillyMember_7C80B0302D969AD07EB97B56E68F6929" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eli Lilly</link:label>
    <link:label id="lab_mgnx_EliLillyMember_7C80B0302D969AD07EB97B56E68F6929_label_en-US" xlink:label="lab_mgnx_EliLillyMember_7C80B0302D969AD07EB97B56E68F6929" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eli Lilly [Member]</link:label>
    <link:label id="lab_mgnx_EliLillyMember_7C80B0302D969AD07EB97B56E68F6929_documentation_en-US" xlink:label="lab_mgnx_EliLillyMember_7C80B0302D969AD07EB97B56E68F6929" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents a collaborators with which entity has an agreement related to contracts and research grants received from U.S. government agencies.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_EliLillyMember" xlink:label="loc_mgnx_EliLillyMember_7C80B0302D969AD07EB97B56E68F6929" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EliLillyMember_7C80B0302D969AD07EB97B56E68F6929" xlink:to="lab_mgnx_EliLillyMember_7C80B0302D969AD07EB97B56E68F6929" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_7011D199E2E3FEFAF1E47B56E68FD13B_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_7011D199E2E3FEFAF1E47B56E68FD13B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_7011D199E2E3FEFAF1E47B56E68FD13B_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_7011D199E2E3FEFAF1E47B56E68FD13B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_7011D199E2E3FEFAF1E47B56E68FD13B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7011D199E2E3FEFAF1E47B56E68FD13B" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_7011D199E2E3FEFAF1E47B56E68FD13B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_A556BB80165F62D4F9297B56E68FA2F7_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_A556BB80165F62D4F9297B56E68FA2F7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of significant accounts receivable</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_A556BB80165F62D4F9297B56E68FA2F7_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_A556BB80165F62D4F9297B56E68FA2F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_A556BB80165F62D4F9297B56E68FA2F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_A556BB80165F62D4F9297B56E68FA2F7" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_A556BB80165F62D4F9297B56E68FA2F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_9D3F6242DAA32A9F88888018CBC451A0_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_9D3F6242DAA32A9F88888018CBC451A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_9D3F6242DAA32A9F88888018CBC451A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9D3F6242DAA32A9F88888018CBC451A0" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_9D3F6242DAA32A9F88888018CBC451A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7DF655EC6C8C444C6A578018CBC4F397_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7DF655EC6C8C444C6A578018CBC4F397" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7DF655EC6C8C444C6A578018CBC4F397_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7DF655EC6C8C444C6A578018CBC4F397" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7DF655EC6C8C444C6A578018CBC4F397" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7DF655EC6C8C444C6A578018CBC4F397" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7DF655EC6C8C444C6A578018CBC4F397" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_9018C24AEE60D0A5C5838018CBC41448_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_9018C24AEE60D0A5C5838018CBC41448" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9018C24AEE60D0A5C5838018CBC41448_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_9018C24AEE60D0A5C5838018CBC41448" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9018C24AEE60D0A5C5838018CBC41448" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_9018C24AEE60D0A5C5838018CBC41448" xlink:to="lab_us-gaap_NetIncomeLoss_9018C24AEE60D0A5C5838018CBC41448" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A269F14C8CB4EED337308018CBC4DE7F_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A269F14C8CB4EED337308018CBC4DE7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A269F14C8CB4EED337308018CBC4DE7F_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A269F14C8CB4EED337308018CBC4DE7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A269F14C8CB4EED337308018CBC4DE7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A269F14C8CB4EED337308018CBC4DE7F" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A269F14C8CB4EED337308018CBC4DE7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_39EF082F114C8797CECA803426F9A8DA_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_39EF082F114C8797CECA803426F9A8DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_39EF082F114C8797CECA803426F9A8DA_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_39EF082F114C8797CECA803426F9A8DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_39EF082F114C8797CECA803426F9A8DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_39EF082F114C8797CECA803426F9A8DA" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_39EF082F114C8797CECA803426F9A8DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_5FF06C63256D3962A57B8018CBC45E07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_5FF06C63256D3962A57B8018CBC45E07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_5FF06C63256D3962A57B8018CBC45E07_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_5FF06C63256D3962A57B8018CBC45E07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_5FF06C63256D3962A57B8018CBC45E07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_5FF06C63256D3962A57B8018CBC45E07" xlink:to="lab_us-gaap_ShareBasedCompensation_5FF06C63256D3962A57B8018CBC45E07" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_095CE971AAD59AD73D468018CBC47326_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_095CE971AAD59AD73D468018CBC47326" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_095CE971AAD59AD73D468018CBC47326_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_095CE971AAD59AD73D468018CBC47326" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_095CE971AAD59AD73D468018CBC47326" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_095CE971AAD59AD73D468018CBC47326" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_095CE971AAD59AD73D468018CBC47326" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_512D2EE9140E5FC7CCA18018CBC43541_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_512D2EE9140E5FC7CCA18018CBC43541" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_512D2EE9140E5FC7CCA18018CBC43541_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_512D2EE9140E5FC7CCA18018CBC43541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_512D2EE9140E5FC7CCA18018CBC43541" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_512D2EE9140E5FC7CCA18018CBC43541" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_512D2EE9140E5FC7CCA18018CBC43541" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_BE632F1BA842331F5E438018CBC49CEA_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_BE632F1BA842331F5E438018CBC49CEA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_BE632F1BA842331F5E438018CBC49CEA_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_BE632F1BA842331F5E438018CBC49CEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_BE632F1BA842331F5E438018CBC49CEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_BE632F1BA842331F5E438018CBC49CEA" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_BE632F1BA842331F5E438018CBC49CEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_CDE6DCF6ECA24FFFC1938018CBC4B949_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_CDE6DCF6ECA24FFFC1938018CBC4B949" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_CDE6DCF6ECA24FFFC1938018CBC4B949_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_CDE6DCF6ECA24FFFC1938018CBC4B949" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Restricted Cash for Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_CDE6DCF6ECA24FFFC1938018CBC4B949" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_CDE6DCF6ECA24FFFC1938018CBC4B949" xlink:to="lab_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_CDE6DCF6ECA24FFFC1938018CBC4B949" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8F58F3B524C2C878FEBE8018CBC4BC6B_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8F58F3B524C2C878FEBE8018CBC4BC6B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8F58F3B524C2C878FEBE8018CBC4BC6B_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8F58F3B524C2C878FEBE8018CBC4BC6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8F58F3B524C2C878FEBE8018CBC4BC6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8F58F3B524C2C878FEBE8018CBC4BC6B" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8F58F3B524C2C878FEBE8018CBC4BC6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D2926A01F683C9BD99A28018CBC41456_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D2926A01F683C9BD99A28018CBC41456" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D2926A01F683C9BD99A28018CBC41456_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D2926A01F683C9BD99A28018CBC41456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_D2926A01F683C9BD99A28018CBC41456" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_D2926A01F683C9BD99A28018CBC41456" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D2926A01F683C9BD99A28018CBC41456" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_BF28C5128A49CF086FB68018CBC4212E_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_BF28C5128A49CF086FB68018CBC4212E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_BF28C5128A49CF086FB68018CBC4212E_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_BF28C5128A49CF086FB68018CBC4212E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_BF28C5128A49CF086FB68018CBC4212E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_BF28C5128A49CF086FB68018CBC4212E" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_BF28C5128A49CF086FB68018CBC4212E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestructuringReserve_0F4C761627E3ADBE3C048018CBC4BD47_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestructuringReserve_0F4C761627E3ADBE3C048018CBC4BD47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease exit liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestructuringReserve_0F4C761627E3ADBE3C048018CBC4BD47_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestructuringReserve_0F4C761627E3ADBE3C048018CBC4BD47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Restructuring Reserve</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:label="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_0F4C761627E3ADBE3C048018CBC4BD47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_0F4C761627E3ADBE3C048018CBC4BD47" xlink:to="lab_us-gaap_IncreaseDecreaseInRestructuringReserve_0F4C761627E3ADBE3C048018CBC4BD47" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_C301B4647F4D801DC9C18018CBC44E1D_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_C301B4647F4D801DC9C18018CBC44E1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_C301B4647F4D801DC9C18018CBC44E1D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_C301B4647F4D801DC9C18018CBC44E1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_C301B4647F4D801DC9C18018CBC44E1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_C301B4647F4D801DC9C18018CBC44E1D" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_C301B4647F4D801DC9C18018CBC44E1D" xlink:type="arc" />
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_D13246876CA4760E1BFE8018CBC4B7B4_terseLabel_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent_D13246876CA4760E1BFE8018CBC4B7B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_D13246876CA4760E1BFE8018CBC4B7B4_label_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent_D13246876CA4760E1BFE8018CBC4B7B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Rent</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_D13246876CA4760E1BFE8018CBC4B7B4_documentation_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent_D13246876CA4760E1BFE8018CBC4B7B4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) during the reporting period in deferred rent.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_IncreaseDecreaseInDeferredRent" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent_D13246876CA4760E1BFE8018CBC4B7B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncreaseDecreaseInDeferredRent_D13246876CA4760E1BFE8018CBC4B7B4" xlink:to="lab_mgnx_IncreaseDecreaseInDeferredRent_D13246876CA4760E1BFE8018CBC4B7B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1562E9F32556DBE0DB898018CBC4F261_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1562E9F32556DBE0DB898018CBC4F261" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1562E9F32556DBE0DB898018CBC4F261_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1562E9F32556DBE0DB898018CBC4F261" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1562E9F32556DBE0DB898018CBC4F261" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1562E9F32556DBE0DB898018CBC4F261" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1562E9F32556DBE0DB898018CBC4F261" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_814798065B10DAD46F278018CBC47E66_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_814798065B10DAD46F278018CBC47E66" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_814798065B10DAD46F278018CBC47E66_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_814798065B10DAD46F278018CBC47E66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_814798065B10DAD46F278018CBC47E66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_814798065B10DAD46F278018CBC47E66" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_814798065B10DAD46F278018CBC47E66" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_24AADBDD614F0726DAC58018CBC4CA33_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_24AADBDD614F0726DAC58018CBC4CA33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_24AADBDD614F0726DAC58018CBC4CA33_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_24AADBDD614F0726DAC58018CBC4CA33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_24AADBDD614F0726DAC58018CBC4CA33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_24AADBDD614F0726DAC58018CBC4CA33" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_24AADBDD614F0726DAC58018CBC4CA33" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9EFE2054AA8DF18E93F68018CBC4F7CC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9EFE2054AA8DF18E93F68018CBC4F7CC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9EFE2054AA8DF18E93F68018CBC4F7CC_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9EFE2054AA8DF18E93F68018CBC4F7CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Available-for-sale Securities, Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9EFE2054AA8DF18E93F68018CBC4F7CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9EFE2054AA8DF18E93F68018CBC4F7CC" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9EFE2054AA8DF18E93F68018CBC4F7CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6BADE614DB515FB436488028669424AA_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6BADE614DB515FB436488028669424AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6BADE614DB515FB436488028669424AA_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6BADE614DB515FB436488028669424AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6BADE614DB515FB436488028669424AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6BADE614DB515FB436488028669424AA" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6BADE614DB515FB436488028669424AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_04BEC89FD7E092942CEE8018CBC45EA2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_04BEC89FD7E092942CEE8018CBC45EA2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_04BEC89FD7E092942CEE8018CBC45EA2_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_04BEC89FD7E092942CEE8018CBC45EA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_04BEC89FD7E092942CEE8018CBC45EA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_04BEC89FD7E092942CEE8018CBC45EA2" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_04BEC89FD7E092942CEE8018CBC45EA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1BE4AB881CA07ED4659A8018CBC41316_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1BE4AB881CA07ED4659A8018CBC41316" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1BE4AB881CA07ED4659A8018CBC41316_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1BE4AB881CA07ED4659A8018CBC41316" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1BE4AB881CA07ED4659A8018CBC41316" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1BE4AB881CA07ED4659A8018CBC41316" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1BE4AB881CA07ED4659A8018CBC41316" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_554E87F42A18F3AC5D968018CBC4DEC1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_554E87F42A18F3AC5D968018CBC4DEC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_554E87F42A18F3AC5D968018CBC4DEC1_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_554E87F42A18F3AC5D968018CBC4DEC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_554E87F42A18F3AC5D968018CBC4DEC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_554E87F42A18F3AC5D968018CBC4DEC1" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_554E87F42A18F3AC5D968018CBC4DEC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_870837F8B232B56932578018CBC4B2A5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_870837F8B232B56932578018CBC4B2A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_870837F8B232B56932578018CBC4B2A5_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_870837F8B232B56932578018CBC4B2A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_870837F8B232B56932578018CBC4B2A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_870837F8B232B56932578018CBC4B2A5" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_870837F8B232B56932578018CBC4B2A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_383587A6525F7A64C7E08018CBC47AE4_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_383587A6525F7A64C7E08018CBC47AE4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_383587A6525F7A64C7E08018CBC47AE4_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_383587A6525F7A64C7E08018CBC47AE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_383587A6525F7A64C7E08018CBC47AE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_383587A6525F7A64C7E08018CBC47AE4" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_383587A6525F7A64C7E08018CBC47AE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2CAC9C07A2820A2108DD8018CBC41643_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2CAC9C07A2820A2108DD8018CBC41643" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2CAC9C07A2820A2108DD8018CBC41643_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2CAC9C07A2820A2108DD8018CBC41643" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2CAC9C07A2820A2108DD8018CBC41643" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2CAC9C07A2820A2108DD8018CBC41643" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2CAC9C07A2820A2108DD8018CBC41643" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_D922CEC9097012EEF8808018CBC4B3BD_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_D922CEC9097012EEF8808018CBC4B3BD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_D922CEC9097012EEF8808018CBC4B3BD_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_D922CEC9097012EEF8808018CBC4B3BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_D922CEC9097012EEF8808018CBC4B3BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_D922CEC9097012EEF8808018CBC4B3BD" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_D922CEC9097012EEF8808018CBC4B3BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CCC1106BA4CBC5DA560F8018CBC405C5_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CCC1106BA4CBC5DA560F8018CBC405C5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CCC1106BA4CBC5DA560F8018CBC405C5_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CCC1106BA4CBC5DA560F8018CBC405C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CCC1106BA4CBC5DA560F8018CBC405C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CCC1106BA4CBC5DA560F8018CBC405C5" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CCC1106BA4CBC5DA560F8018CBC405C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_BE10972E16F476B3AAD88018CBC4DF5B_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_BE10972E16F476B3AAD88018CBC4DF5B" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_BE10972E16F476B3AAD88018CBC4DF5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_BE10972E16F476B3AAD88018CBC4DF5B" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_BE10972E16F476B3AAD88018CBC4DF5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1DF9250410612F46735B8018CBC4DCC0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1DF9250410612F46735B8018CBC4DCC0" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1DF9250410612F46735B8018CBC4DCC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1DF9250410612F46735B8018CBC4DCC0" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1DF9250410612F46735B8018CBC4DCC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_041D13D4AE30F83A40BFE2787CC3DD70_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_041D13D4AE30F83A40BFE2787CC3DD70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_041D13D4AE30F83A40BFE2787CC3DD70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_041D13D4AE30F83A40BFE2787CC3DD70" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_041D13D4AE30F83A40BFE2787CC3DD70" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_5269A452BF51CB479C99E2787CC4CF87_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_5269A452BF51CB479C99E2787CC4CF87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_5269A452BF51CB479C99E2787CC4CF87_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_5269A452BF51CB479C99E2787CC4CF87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5269A452BF51CB479C99E2787CC4CF87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5269A452BF51CB479C99E2787CC4CF87" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_5269A452BF51CB479C99E2787CC4CF87" xlink:type="arc" />
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_63293D1927DD12970AF78018CA4439C3_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_63293D1927DD12970AF78018CA4439C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and Other Agreements</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_63293D1927DD12970AF78018CA4439C3_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_63293D1927DD12970AF78018CA4439C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration And License Agreements Disclosure [Text Block]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_63293D1927DD12970AF78018CA4439C3_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_63293D1927DD12970AF78018CA4439C3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for collaboration and license agreements.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_63293D1927DD12970AF78018CA4439C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_63293D1927DD12970AF78018CA4439C3" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_63293D1927DD12970AF78018CA4439C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_879DD350AFA6943C655881C6E1A344A1_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_879DD350AFA6943C655881C6E1A344A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for federal or state income taxes</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_879DD350AFA6943C655881C6E1A344A1_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_879DD350AFA6943C655881C6E1A344A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_879DD350AFA6943C655881C6E1A344A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_879DD350AFA6943C655881C6E1A344A1" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_879DD350AFA6943C655881C6E1A344A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_53712308FF7471173D4381C6E1A3D2F0_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_53712308FF7471173D4381C6E1A3D2F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_53712308FF7471173D4381C6E1A3D2F0_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_53712308FF7471173D4381C6E1A3D2F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_53712308FF7471173D4381C6E1A3D2F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_53712308FF7471173D4381C6E1A3D2F0" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_53712308FF7471173D4381C6E1A3D2F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_03CE8AB92825231542CA81C6E1A32213_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_03CE8AB92825231542CA81C6E1A32213" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal U.S. net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_03CE8AB92825231542CA81C6E1A32213_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_03CE8AB92825231542CA81C6E1A32213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_03CE8AB92825231542CA81C6E1A32213" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_03CE8AB92825231542CA81C6E1A32213" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_03CE8AB92825231542CA81C6E1A32213" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_93B1EB2946C3CDA42E4281C6E1A30D7C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_93B1EB2946C3CDA42E4281C6E1A30D7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_93B1EB2946C3CDA42E4281C6E1A30D7C_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_93B1EB2946C3CDA42E4281C6E1A30D7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_93B1EB2946C3CDA42E4281C6E1A30D7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_93B1EB2946C3CDA42E4281C6E1A30D7C" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_93B1EB2946C3CDA42E4281C6E1A30D7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_50E2A852CC99B744CDE181C6E1A32B8B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_50E2A852CC99B744CDE181C6E1A32B8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credit, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_50E2A852CC99B744CDE181C6E1A32B8B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_50E2A852CC99B744CDE181C6E1A32B8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_50E2A852CC99B744CDE181C6E1A32B8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_50E2A852CC99B744CDE181C6E1A32B8B" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_50E2A852CC99B744CDE181C6E1A32B8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_ECDB30D3197B3311A20E81C6E1A3CFD5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_ECDB30D3197B3311A20E81C6E1A3CFD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Orphan drug credit, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_ECDB30D3197B3311A20E81C6E1A3CFD5_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_ECDB30D3197B3311A20E81C6E1A3CFD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_ECDB30D3197B3311A20E81C6E1A3CFD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_ECDB30D3197B3311A20E81C6E1A3CFD5" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_ECDB30D3197B3311A20E81C6E1A3CFD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_1E421C3931F08C37CE4C81C6E1A32269_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_1E421C3931F08C37CE4C81C6E1A32269" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_1E421C3931F08C37CE4C81C6E1A32269_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_1E421C3931F08C37CE4C81C6E1A32269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_1E421C3931F08C37CE4C81C6E1A32269" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_1E421C3931F08C37CE4C81C6E1A32269" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_1E421C3931F08C37CE4C81C6E1A32269" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_AAAA4A255B69A81EE36681C6E1A31063_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_AAAA4A255B69A81EE36681C6E1A31063" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_AAAA4A255B69A81EE36681C6E1A31063_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_AAAA4A255B69A81EE36681C6E1A31063" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_AAAA4A255B69A81EE36681C6E1A31063" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome_AAAA4A255B69A81EE36681C6E1A31063" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome_AAAA4A255B69A81EE36681C6E1A31063" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_54649D9CD3703A8C6CDF81C6E1A3C993_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_54649D9CD3703A8C6CDF81C6E1A3C993" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_54649D9CD3703A8C6CDF81C6E1A3C993_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_54649D9CD3703A8C6CDF81C6E1A3C993" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_54649D9CD3703A8C6CDF81C6E1A3C993" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_54649D9CD3703A8C6CDF81C6E1A3C993" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_54649D9CD3703A8C6CDF81C6E1A3C993" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_C31E09E4165396325AA781C6E1A36947_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_C31E09E4165396325AA781C6E1A36947" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_C31E09E4165396325AA781C6E1A36947_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_C31E09E4165396325AA781C6E1A36947" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_C31E09E4165396325AA781C6E1A36947" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_C31E09E4165396325AA781C6E1A36947" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_C31E09E4165396325AA781C6E1A36947" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_F88424B3002FA00589A981C6E1A338EF_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_F88424B3002FA00589A981C6E1A338EF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_F88424B3002FA00589A981C6E1A338EF_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_F88424B3002FA00589A981C6E1A338EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_F88424B3002FA00589A981C6E1A338EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_F88424B3002FA00589A981C6E1A338EF" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_F88424B3002FA00589A981C6E1A338EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5DFBE74631E7026CE3A081C6E1A302C5_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5DFBE74631E7026CE3A081C6E1A302C5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5DFBE74631E7026CE3A081C6E1A302C5_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5DFBE74631E7026CE3A081C6E1A302C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5DFBE74631E7026CE3A081C6E1A302C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5DFBE74631E7026CE3A081C6E1A302C5" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5DFBE74631E7026CE3A081C6E1A302C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_C503D0B3E94B126683CD81C6E1A3E43E_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_C503D0B3E94B126683CD81C6E1A3E43E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_C503D0B3E94B126683CD81C6E1A3E43E_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_C503D0B3E94B126683CD81C6E1A3E43E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_C503D0B3E94B126683CD81C6E1A3E43E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_C503D0B3E94B126683CD81C6E1A3E43E" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_C503D0B3E94B126683CD81C6E1A3E43E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_33F1D6A09011A13CB0C181C6E1A4F1FC_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_33F1D6A09011A13CB0C181C6E1A4F1FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_33F1D6A09011A13CB0C181C6E1A4F1FC_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_33F1D6A09011A13CB0C181C6E1A4F1FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_33F1D6A09011A13CB0C181C6E1A4F1FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_33F1D6A09011A13CB0C181C6E1A4F1FC" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_33F1D6A09011A13CB0C181C6E1A4F1FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_5EC25EC9A75D2FC0FFF381C6E1A48735_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_5EC25EC9A75D2FC0FFF381C6E1A48735" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenditures</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_5EC25EC9A75D2FC0FFF381C6E1A48735_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_5EC25EC9A75D2FC0FFF381C6E1A48735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_5EC25EC9A75D2FC0FFF381C6E1A48735" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_5EC25EC9A75D2FC0FFF381C6E1A48735" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_5EC25EC9A75D2FC0FFF381C6E1A48735" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_002C66F88F9576ECCEC081C6E1A493EC_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_002C66F88F9576ECCEC081C6E1A493EC" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_002C66F88F9576ECCEC081C6E1A493EC_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_002C66F88F9576ECCEC081C6E1A493EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_002C66F88F9576ECCEC081C6E1A493EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_002C66F88F9576ECCEC081C6E1A493EC" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_002C66F88F9576ECCEC081C6E1A493EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_6D5AD4E8575CDF798DFA81C6E1A40584_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_6D5AD4E8575CDF798DFA81C6E1A40584" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred income tax asset/(liability)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_6D5AD4E8575CDF798DFA81C6E1A40584_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_6D5AD4E8575CDF798DFA81C6E1A40584" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6D5AD4E8575CDF798DFA81C6E1A40584" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6D5AD4E8575CDF798DFA81C6E1A40584" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_6D5AD4E8575CDF798DFA81C6E1A40584" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_40B5303C872265F55CED81C6E1A4F618_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_40B5303C872265F55CED81C6E1A4F618" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_40B5303C872265F55CED81C6E1A4F618_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_40B5303C872265F55CED81C6E1A4F618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_40B5303C872265F55CED81C6E1A4F618" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_40B5303C872265F55CED81C6E1A4F618" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable_40B5303C872265F55CED81C6E1A4F618" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_510B41AF2D058E96AF6881C6E1A44AA0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_510B41AF2D058E96AF6881C6E1A44AA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_510B41AF2D058E96AF6881C6E1A44AA0_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_510B41AF2D058E96AF6881C6E1A44AA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_510B41AF2D058E96AF6881C6E1A44AA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_510B41AF2D058E96AF6881C6E1A44AA0" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_510B41AF2D058E96AF6881C6E1A44AA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_EC1D365044E18BDEAE2281C6E1A43DD3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_EC1D365044E18BDEAE2281C6E1A43DD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_EC1D365044E18BDEAE2281C6E1A43DD3_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_EC1D365044E18BDEAE2281C6E1A43DD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_EC1D365044E18BDEAE2281C6E1A43DD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_EC1D365044E18BDEAE2281C6E1A43DD3" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_EC1D365044E18BDEAE2281C6E1A43DD3" xlink:type="arc" />
    <link:label id="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_776783359C4089381E1981ED191F79E3_terseLabel_en-US" xlink:label="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_776783359C4089381E1981ED191F79E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Federal and State</link:label>
    <link:label id="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_776783359C4089381E1981ED191F79E3_label_en-US" xlink:label="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_776783359C4089381E1981ED191F79E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]</link:label>
    <link:label id="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_776783359C4089381E1981ED191F79E3_documentation_en-US" xlink:label="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_776783359C4089381E1981ED191F79E3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:label="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_776783359C4089381E1981ED191F79E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_776783359C4089381E1981ED191F79E3" xlink:to="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_776783359C4089381E1981ED191F79E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_F03722A839302225399781C6E1A472BC_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_F03722A839302225399781C6E1A472BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Federal Government</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_F03722A839302225399781C6E1A472BC_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_F03722A839302225399781C6E1A472BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_F03722A839302225399781C6E1A472BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_F03722A839302225399781C6E1A472BC" xlink:to="lab_us-gaap_DomesticCountryMember_F03722A839302225399781C6E1A472BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_1CD103690CE608C95F3981C6E1A534E8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_1CD103690CE608C95F3981C6E1A534E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_1CD103690CE608C95F3981C6E1A534E8_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_1CD103690CE608C95F3981C6E1A534E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_1CD103690CE608C95F3981C6E1A534E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1CD103690CE608C95F3981C6E1A534E8" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems_1CD103690CE608C95F3981C6E1A534E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_8CFDB9ED3AEB1B05545181C6E1A56D96_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_8CFDB9ED3AEB1B05545181C6E1A56D96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_8CFDB9ED3AEB1B05545181C6E1A56D96_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_8CFDB9ED3AEB1B05545181C6E1A56D96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_8CFDB9ED3AEB1B05545181C6E1A56D96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_8CFDB9ED3AEB1B05545181C6E1A56D96" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_8CFDB9ED3AEB1B05545181C6E1A56D96" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_286E23E1C27FCFA05A5C81C6E1A586AD_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_286E23E1C27FCFA05A5C81C6E1A586AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US Federal tax credits carry forward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_286E23E1C27FCFA05A5C81C6E1A586AD_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_286E23E1C27FCFA05A5C81C6E1A586AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_286E23E1C27FCFA05A5C81C6E1A586AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_286E23E1C27FCFA05A5C81C6E1A586AD" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_286E23E1C27FCFA05A5C81C6E1A586AD" xlink:type="arc" />
    <link:label id="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_F0C98CE41305590010BA81C6E1A57810_terseLabel_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_F0C98CE41305590010BA81C6E1A57810" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss for limited use</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_F0C98CE41305590010BA81C6E1A57810_label_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_F0C98CE41305590010BA81C6E1A57810" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards Limitations On Use Amount</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_F0C98CE41305590010BA81C6E1A57810_documentation_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_F0C98CE41305590010BA81C6E1A57810" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of net operating loss carryforward, which are limited for use over the range of years.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:label="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_F0C98CE41305590010BA81C6E1A57810" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_F0C98CE41305590010BA81C6E1A57810" xlink:to="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_F0C98CE41305590010BA81C6E1A57810" xlink:type="arc" />
    <link:label id="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_4D7952121C7C9CE8AA8E81C6E1A53B90_terseLabel_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_4D7952121C7C9CE8AA8E81C6E1A53B90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses limited for use utilized on an annual basis</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_4D7952121C7C9CE8AA8E81C6E1A53B90_label_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_4D7952121C7C9CE8AA8E81C6E1A53B90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards Annual Limitation Amount</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_4D7952121C7C9CE8AA8E81C6E1A53B90_documentation_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_4D7952121C7C9CE8AA8E81C6E1A53B90" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of net operating loss which are limited for use, utilized on a annual basis.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:label="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_4D7952121C7C9CE8AA8E81C6E1A53B90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_4D7952121C7C9CE8AA8E81C6E1A53B90" xlink:to="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_4D7952121C7C9CE8AA8E81C6E1A53B90" xlink:type="arc" />
    <link:label id="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_51B20E90CB071CE5DE9281C6E1A57752_terseLabel_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_51B20E90CB071CE5DE9281C6E1A57752" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining portion of net operating losses</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_51B20E90CB071CE5DE9281C6E1A57752_label_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_51B20E90CB071CE5DE9281C6E1A57752" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards Not Subject To Limitation</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_51B20E90CB071CE5DE9281C6E1A57752_documentation_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_51B20E90CB071CE5DE9281C6E1A57752" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards not subject to limitation.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:label="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_51B20E90CB071CE5DE9281C6E1A57752" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_51B20E90CB071CE5DE9281C6E1A57752" xlink:to="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_51B20E90CB071CE5DE9281C6E1A57752" xlink:type="arc" />
    <link:label id="lab_mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward_6493347ECFFEF59F32EB81C6E1A5CBCE_terseLabel_en-US" xlink:label="lab_mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward_6493347ECFFEF59F32EB81C6E1A5CBCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses, recognized as a benefit through additional-paid-in-capital</link:label>
    <link:label id="lab_mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward_6493347ECFFEF59F32EB81C6E1A5CBCE_label_en-US" xlink:label="lab_mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward_6493347ECFFEF59F32EB81C6E1A5CBCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits Resulting In Net Operating Losses Carryforward</link:label>
    <link:label id="lab_mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward_6493347ECFFEF59F32EB81C6E1A5CBCE_documentation_en-US" xlink:label="lab_mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward_6493347ECFFEF59F32EB81C6E1A5CBCE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits resulting in net operating losses carryforward.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward" xlink:label="loc_mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward_6493347ECFFEF59F32EB81C6E1A5CBCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward_6493347ECFFEF59F32EB81C6E1A5CBCE" xlink:to="lab_mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward_6493347ECFFEF59F32EB81C6E1A5CBCE" xlink:type="arc" />
    <link:label id="lab_mgnx_DocumentAndEntityInformationAbstract_6A75FD2103DF3DF543BB6A261067E995_label_en-US" xlink:label="lab_mgnx_DocumentAndEntityInformationAbstract_6A75FD2103DF3DF543BB6A261067E995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_mgnx_DocumentAndEntityInformationAbstract_6A75FD2103DF3DF543BB6A261067E995_documentation_en-US" xlink:label="lab_mgnx_DocumentAndEntityInformationAbstract_6A75FD2103DF3DF543BB6A261067E995" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and entity information.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_DocumentAndEntityInformationAbstract" xlink:label="loc_mgnx_DocumentAndEntityInformationAbstract_6A75FD2103DF3DF543BB6A261067E995" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_6A75FD2103DF3DF543BB6A261067E995" xlink:to="lab_mgnx_DocumentAndEntityInformationAbstract_6A75FD2103DF3DF543BB6A261067E995" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_4CF786137F5030F8C3966A261067638C_terseLabel_en-US" xlink:label="lab_dei_DocumentType_4CF786137F5030F8C3966A261067638C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_4CF786137F5030F8C3966A261067638C_label_en-US" xlink:label="lab_dei_DocumentType_4CF786137F5030F8C3966A261067638C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_4CF786137F5030F8C3966A261067638C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_4CF786137F5030F8C3966A261067638C" xlink:to="lab_dei_DocumentType_4CF786137F5030F8C3966A261067638C" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_7B3F485F6C9EFE60D9B96A261067C630_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_7B3F485F6C9EFE60D9B96A261067C630" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_7B3F485F6C9EFE60D9B96A261067C630_label_en-US" xlink:label="lab_dei_AmendmentFlag_7B3F485F6C9EFE60D9B96A261067C630" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_7B3F485F6C9EFE60D9B96A261067C630" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_7B3F485F6C9EFE60D9B96A261067C630" xlink:to="lab_dei_AmendmentFlag_7B3F485F6C9EFE60D9B96A261067C630" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_847E69D2FDDDF7BFFA496A2610678996_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_847E69D2FDDDF7BFFA496A2610678996" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_847E69D2FDDDF7BFFA496A2610678996_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_847E69D2FDDDF7BFFA496A2610678996" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_847E69D2FDDDF7BFFA496A2610678996" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_847E69D2FDDDF7BFFA496A2610678996" xlink:to="lab_dei_DocumentPeriodEndDate_847E69D2FDDDF7BFFA496A2610678996" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_692BF6714A64F118DE756A261067B8F3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_692BF6714A64F118DE756A261067B8F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_692BF6714A64F118DE756A261067B8F3_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_692BF6714A64F118DE756A261067B8F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_692BF6714A64F118DE756A261067B8F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_692BF6714A64F118DE756A261067B8F3" xlink:to="lab_dei_DocumentFiscalYearFocus_692BF6714A64F118DE756A261067B8F3" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_2C42F24801854C3CB9A46A261067D061_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_2C42F24801854C3CB9A46A261067D061" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_2C42F24801854C3CB9A46A261067D061_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_2C42F24801854C3CB9A46A261067D061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_2C42F24801854C3CB9A46A261067D061" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_2C42F24801854C3CB9A46A261067D061" xlink:to="lab_dei_DocumentFiscalPeriodFocus_2C42F24801854C3CB9A46A261067D061" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_A55D0FCBC18A7AE38BA76A2610676B00_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_A55D0FCBC18A7AE38BA76A2610676B00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_A55D0FCBC18A7AE38BA76A2610676B00_label_en-US" xlink:label="lab_dei_EntityRegistrantName_A55D0FCBC18A7AE38BA76A2610676B00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_A55D0FCBC18A7AE38BA76A2610676B00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_A55D0FCBC18A7AE38BA76A2610676B00" xlink:to="lab_dei_EntityRegistrantName_A55D0FCBC18A7AE38BA76A2610676B00" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_8A301F505B78F55F49546A26106765F7_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_8A301F505B78F55F49546A26106765F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_8A301F505B78F55F49546A26106765F7_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_8A301F505B78F55F49546A26106765F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_8A301F505B78F55F49546A26106765F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_8A301F505B78F55F49546A26106765F7" xlink:to="lab_dei_EntityCentralIndexKey_8A301F505B78F55F49546A26106765F7" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_EA2EFA21290ED300C1F66A261067E37E_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_EA2EFA21290ED300C1F66A261067E37E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_EA2EFA21290ED300C1F66A261067E37E_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_EA2EFA21290ED300C1F66A261067E37E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_EA2EFA21290ED300C1F66A261067E37E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_EA2EFA21290ED300C1F66A261067E37E" xlink:to="lab_dei_CurrentFiscalYearEndDate_EA2EFA21290ED300C1F66A261067E37E" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_C9CD0FE44474D41A9CE16A26106728E7_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_C9CD0FE44474D41A9CE16A26106728E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_C9CD0FE44474D41A9CE16A26106728E7_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_C9CD0FE44474D41A9CE16A26106728E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_C9CD0FE44474D41A9CE16A26106728E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_C9CD0FE44474D41A9CE16A26106728E7" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_C9CD0FE44474D41A9CE16A26106728E7" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_12A84E4208A99E793DB06A2610682C42_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_12A84E4208A99E793DB06A2610682C42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_12A84E4208A99E793DB06A2610682C42_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_12A84E4208A99E793DB06A2610682C42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_12A84E4208A99E793DB06A2610682C42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_12A84E4208A99E793DB06A2610682C42" xlink:to="lab_dei_EntityCurrentReportingStatus_12A84E4208A99E793DB06A2610682C42" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_870AAC14A26B2AA1CDE26A261068DBB2_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_870AAC14A26B2AA1CDE26A261068DBB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_870AAC14A26B2AA1CDE26A261068DBB2_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_870AAC14A26B2AA1CDE26A261068DBB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_870AAC14A26B2AA1CDE26A261068DBB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_870AAC14A26B2AA1CDE26A261068DBB2" xlink:to="lab_dei_EntityVoluntaryFilers_870AAC14A26B2AA1CDE26A261068DBB2" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_EFCDD22130183AE44F756A2610687EB9_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_EFCDD22130183AE44F756A2610687EB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_EFCDD22130183AE44F756A2610687EB9_label_en-US" xlink:label="lab_dei_EntityFilerCategory_EFCDD22130183AE44F756A2610687EB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_EFCDD22130183AE44F756A2610687EB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_EFCDD22130183AE44F756A2610687EB9" xlink:to="lab_dei_EntityFilerCategory_EFCDD22130183AE44F756A2610687EB9" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_DB7AFFA463CA6A3A3A8E6A26106875EC_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_DB7AFFA463CA6A3A3A8E6A26106875EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_DB7AFFA463CA6A3A3A8E6A26106875EC_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_DB7AFFA463CA6A3A3A8E6A26106875EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_DB7AFFA463CA6A3A3A8E6A26106875EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_DB7AFFA463CA6A3A3A8E6A26106875EC" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_DB7AFFA463CA6A3A3A8E6A26106875EC" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_516E188A526E66BA87756A261068428A_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_516E188A526E66BA87756A261068428A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_516E188A526E66BA87756A261068428A_label_en-US" xlink:label="lab_dei_EntityPublicFloat_516E188A526E66BA87756A261068428A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_516E188A526E66BA87756A261068428A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_516E188A526E66BA87756A261068428A" xlink:to="lab_dei_EntityPublicFloat_516E188A526E66BA87756A261068428A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EAFE48F6EC3D813636EA6B043516CEBE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EAFE48F6EC3D813636EA6B043516CEBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EAFE48F6EC3D813636EA6B043516CEBE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EAFE48F6EC3D813636EA6B043516CEBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EAFE48F6EC3D813636EA6B043516CEBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EAFE48F6EC3D813636EA6B043516CEBE" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EAFE48F6EC3D813636EA6B043516CEBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_80328F733D7962010FD36B0435164415_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_80328F733D7962010FD36B0435164415" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Stock Options Award Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_80328F733D7962010FD36B0435164415_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_80328F733D7962010FD36B0435164415" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_80328F733D7962010FD36B0435164415" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_80328F733D7962010FD36B0435164415" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_80328F733D7962010FD36B0435164415" xlink:type="arc" />
    <link:label id="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_4A4F72B4DA428816CD226B04351670AF_terseLabel_en-US" xlink:label="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_4A4F72B4DA428816CD226B04351670AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option and Restricted Stock Unit Activity</link:label>
    <link:label id="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_4A4F72B4DA428816CD226B04351670AF_label_en-US" xlink:label="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_4A4F72B4DA428816CD226B04351670AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Share Based Compensation Stock Options And Restricted Stock Units Activity Table [Text Block]</link:label>
    <link:label id="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_4A4F72B4DA428816CD226B04351670AF_documentation_en-US" xlink:label="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_4A4F72B4DA428816CD226B04351670AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Share Based Compensation Stock Options And Restricted Stock Units Activity Table [Text Block]</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_4A4F72B4DA428816CD226B04351670AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_4A4F72B4DA428816CD226B04351670AF" xlink:to="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_4A4F72B4DA428816CD226B04351670AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_2C55C490960A9CF58B158018CA63C71F_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis_2C55C490960A9CF58B158018CA63C71F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_2C55C490960A9CF58B158018CA63C71F_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis_2C55C490960A9CF58B158018CA63C71F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_2C55C490960A9CF58B158018CA63C71F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2C55C490960A9CF58B158018CA63C71F" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis_2C55C490960A9CF58B158018CA63C71F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_1AED901A6271EA9CDF338018CA631BBB_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain_1AED901A6271EA9CDF338018CA631BBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_1AED901A6271EA9CDF338018CA631BBB_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain_1AED901A6271EA9CDF338018CA631BBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1AED901A6271EA9CDF338018CA631BBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1AED901A6271EA9CDF338018CA631BBB" xlink:to="lab_us-gaap_TypeOfRestructuringDomain_1AED901A6271EA9CDF338018CA631BBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractTerminationMember_1F161CB294C08B579DC68018CA63B3D8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractTerminationMember_1F161CB294C08B579DC68018CA63B3D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract termination</link:label>
    <link:label id="lab_us-gaap_ContractTerminationMember_1F161CB294C08B579DC68018CA63B3D8_label_en-US" xlink:label="lab_us-gaap_ContractTerminationMember_1F161CB294C08B579DC68018CA63B3D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Termination [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="loc_us-gaap_ContractTerminationMember_1F161CB294C08B579DC68018CA63B3D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractTerminationMember_1F161CB294C08B579DC68018CA63B3D8" xlink:to="lab_us-gaap_ContractTerminationMember_1F161CB294C08B579DC68018CA63B3D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_0FBDBF0127E7351BFCB48018CA639368_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward_0FBDBF0127E7351BFCB48018CA639368" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_0FBDBF0127E7351BFCB48018CA639368_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward_0FBDBF0127E7351BFCB48018CA639368" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="loc_us-gaap_RestructuringReserveRollForward_0FBDBF0127E7351BFCB48018CA639368" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward_0FBDBF0127E7351BFCB48018CA639368" xlink:to="lab_us-gaap_RestructuringReserveRollForward_0FBDBF0127E7351BFCB48018CA639368" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_73C38AFC16A871A175D98018CA635730_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_73C38AFC16A871A175D98018CA635730" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Accrual beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_73C38AFC16A871A175D98018CA635730_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve_73C38AFC16A871A175D98018CA635730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_73C38AFC16A871A175D98018CA635730" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_73C38AFC16A871A175D98018CA635730" xlink:to="lab_us-gaap_RestructuringReserve_73C38AFC16A871A175D98018CA635730" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRestructuring_D1E1EB3CCC36B0E398578018CA63B128_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring_D1E1EB3CCC36B0E398578018CA63B128" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Principal payments and other adjustments (net of sublease receipts)</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_D1E1EB3CCC36B0E398578018CA63B128_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring_D1E1EB3CCC36B0E398578018CA63B128" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_D1E1EB3CCC36B0E398578018CA63B128" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring_D1E1EB3CCC36B0E398578018CA63B128" xlink:to="lab_us-gaap_PaymentsForRestructuring_D1E1EB3CCC36B0E398578018CA63B128" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_382B92F67ED01270AFE18018CA63D9C8_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_382B92F67ED01270AFE18018CA63D9C8" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Accrual ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_382B92F67ED01270AFE18018CA63D9C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_382B92F67ED01270AFE18018CA63D9C8" xlink:to="lab_us-gaap_RestructuringReserve_382B92F67ED01270AFE18018CA63D9C8" xlink:type="arc" />
    <link:label id="lab_mgnx_AmountOfImmaterialErrorCorrection_807916E24E4D53B913218018CA63C9F6_terseLabel_en-US" xlink:label="lab_mgnx_AmountOfImmaterialErrorCorrection_807916E24E4D53B913218018CA63C9F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of research and development expense</link:label>
    <link:label id="lab_mgnx_AmountOfImmaterialErrorCorrection_807916E24E4D53B913218018CA63C9F6_label_en-US" xlink:label="lab_mgnx_AmountOfImmaterialErrorCorrection_807916E24E4D53B913218018CA63C9F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount of immaterial error correction</link:label>
    <link:label id="lab_mgnx_AmountOfImmaterialErrorCorrection_807916E24E4D53B913218018CA63C9F6_documentation_en-US" xlink:label="lab_mgnx_AmountOfImmaterialErrorCorrection_807916E24E4D53B913218018CA63C9F6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of immaterial error correction made during period</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AmountOfImmaterialErrorCorrection" xlink:label="loc_mgnx_AmountOfImmaterialErrorCorrection_807916E24E4D53B913218018CA63C9F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AmountOfImmaterialErrorCorrection_807916E24E4D53B913218018CA63C9F6" xlink:to="lab_mgnx_AmountOfImmaterialErrorCorrection_807916E24E4D53B913218018CA63C9F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8FA25C58EA1ADEAEC4D4E2787DC5654D_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8FA25C58EA1ADEAEC4D4E2787DC5654D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8FA25C58EA1ADEAEC4D4E2787DC5654D_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8FA25C58EA1ADEAEC4D4E2787DC5654D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8FA25C58EA1ADEAEC4D4E2787DC5654D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8FA25C58EA1ADEAEC4D4E2787DC5654D" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8FA25C58EA1ADEAEC4D4E2787DC5654D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_4A4D59B9B69314686D848018CA945B85_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable_4A4D59B9B69314686D848018CA945B85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_4A4D59B9B69314686D848018CA945B85_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable_4A4D59B9B69314686D848018CA945B85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_4A4D59B9B69314686D848018CA945B85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_4A4D59B9B69314686D848018CA945B85" xlink:to="lab_us-gaap_IncomeTaxExaminationTable_4A4D59B9B69314686D848018CA945B85" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_F9B05C39BDF3059A3B6C8018CA94CADE_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems_F9B05C39BDF3059A3B6C8018CA94CADE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_F9B05C39BDF3059A3B6C8018CA94CADE_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems_F9B05C39BDF3059A3B6C8018CA94CADE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_F9B05C39BDF3059A3B6C8018CA94CADE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_F9B05C39BDF3059A3B6C8018CA94CADE" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems_F9B05C39BDF3059A3B6C8018CA94CADE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5ADE9C145D8D296C3AAA8018CA948BE7_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5ADE9C145D8D296C3AAA8018CA948BE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5ADE9C145D8D296C3AAA8018CA948BE7_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5ADE9C145D8D296C3AAA8018CA948BE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5ADE9C145D8D296C3AAA8018CA948BE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5ADE9C145D8D296C3AAA8018CA948BE7" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5ADE9C145D8D296C3AAA8018CA948BE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_AC8CFE953714493042428018CA9482EF_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_AC8CFE953714493042428018CA9482EF" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_AC8CFE953714493042428018CA9482EF_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_AC8CFE953714493042428018CA9482EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_AC8CFE953714493042428018CA9482EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_AC8CFE953714493042428018CA9482EF" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_AC8CFE953714493042428018CA9482EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_16F9DB270951F92FB7208018CA94E54B_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_16F9DB270951F92FB7208018CA94E54B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases/(decreases) for current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_16F9DB270951F92FB7208018CA94E54B_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_16F9DB270951F92FB7208018CA94E54B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_16F9DB270951F92FB7208018CA94E54B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_16F9DB270951F92FB7208018CA94E54B" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_16F9DB270951F92FB7208018CA94E54B" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_62F2F528ED3CAD6BF0088018CA940926_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_62F2F528ED3CAD6BF0088018CA940926" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases/(decreases) for prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_62F2F528ED3CAD6BF0088018CA940926_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_62F2F528ED3CAD6BF0088018CA940926" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_62F2F528ED3CAD6BF0088018CA940926" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_62F2F528ED3CAD6BF0088018CA940926" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_62F2F528ED3CAD6BF0088018CA940926" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_D9CD93D5A3101E2626E08018CA947366_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_D9CD93D5A3101E2626E08018CA947366" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_D9CD93D5A3101E2626E08018CA947366" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_D9CD93D5A3101E2626E08018CA947366" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_D9CD93D5A3101E2626E08018CA947366" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_E10A48273BC6188F932B8018CA94885C_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_E10A48273BC6188F932B8018CA94885C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_E10A48273BC6188F932B8018CA94885C_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_E10A48273BC6188F932B8018CA94885C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_E10A48273BC6188F932B8018CA94885C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_E10A48273BC6188F932B8018CA94885C" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_E10A48273BC6188F932B8018CA94885C" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_F292DA0D667F85CF2FAB8018CA948C71_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_F292DA0D667F85CF2FAB8018CA948C71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized interest or penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_F292DA0D667F85CF2FAB8018CA948C71_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_F292DA0D667F85CF2FAB8018CA948C71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_F292DA0D667F85CF2FAB8018CA948C71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_F292DA0D667F85CF2FAB8018CA948C71" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_F292DA0D667F85CF2FAB8018CA948C71" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_E010B41A86E0B2D3828EE2787D591783_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_E010B41A86E0B2D3828EE2787D591783" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of the Company's Deferred Income Tax Assets (Liabilities)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_E010B41A86E0B2D3828EE2787D591783_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_E010B41A86E0B2D3828EE2787D591783" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_E010B41A86E0B2D3828EE2787D591783" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_E010B41A86E0B2D3828EE2787D591783" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_E010B41A86E0B2D3828EE2787D591783" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D2A27CAD5D43B88FE0BAE2787D599DA4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D2A27CAD5D43B88FE0BAE2787D599DA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Reported Estimated Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D2A27CAD5D43B88FE0BAE2787D599DA4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D2A27CAD5D43B88FE0BAE2787D599DA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D2A27CAD5D43B88FE0BAE2787D599DA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D2A27CAD5D43B88FE0BAE2787D599DA4" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D2A27CAD5D43B88FE0BAE2787D599DA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_680CA14A2719374ED000E2787D59E5F5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_680CA14A2719374ED000E2787D59E5F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_680CA14A2719374ED000E2787D59E5F5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_680CA14A2719374ED000E2787D59E5F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_680CA14A2719374ED000E2787D59E5F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_680CA14A2719374ED000E2787D59E5F5" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_680CA14A2719374ED000E2787D59E5F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_F395594DEAE0EF6F9E3FE2787D342D3B_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_F395594DEAE0EF6F9E3FE2787D342D3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Exit Liability</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_F395594DEAE0EF6F9E3FE2787D342D3B_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_F395594DEAE0EF6F9E3FE2787D342D3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_F395594DEAE0EF6F9E3FE2787D342D3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_F395594DEAE0EF6F9E3FE2787D342D3B" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_F395594DEAE0EF6F9E3FE2787D342D3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44E6AE20B46507C0FEAD638FF140D79E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44E6AE20B46507C0FEAD638FF140D79E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44E6AE20B46507C0FEAD638FF140D79E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44E6AE20B46507C0FEAD638FF140D79E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44E6AE20B46507C0FEAD638FF140D79E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44E6AE20B46507C0FEAD638FF140D79E" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44E6AE20B46507C0FEAD638FF140D79E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B8D2EFE9515A8A0C31C0638FF14080F3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B8D2EFE9515A8A0C31C0638FF14080F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B8D2EFE9515A8A0C31C0638FF14080F3_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B8D2EFE9515A8A0C31C0638FF14080F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B8D2EFE9515A8A0C31C0638FF14080F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B8D2EFE9515A8A0C31C0638FF14080F3" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B8D2EFE9515A8A0C31C0638FF14080F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_514D8098635ACCBC65B3638FF140CC7C_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_514D8098635ACCBC65B3638FF140CC7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_514D8098635ACCBC65B3638FF140CC7C_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_514D8098635ACCBC65B3638FF140CC7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_514D8098635ACCBC65B3638FF140CC7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_514D8098635ACCBC65B3638FF140CC7C" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_514D8098635ACCBC65B3638FF140CC7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockOptionMember_413CBF2979B2F627F89D638FF140939E_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember_413CBF2979B2F627F89D638FF140939E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_413CBF2979B2F627F89D638FF140939E_label_en-US" xlink:label="lab_us-gaap_StockOptionMember_413CBF2979B2F627F89D638FF140939E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_413CBF2979B2F627F89D638FF140939E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember_413CBF2979B2F627F89D638FF140939E" xlink:to="lab_us-gaap_StockOptionMember_413CBF2979B2F627F89D638FF140939E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_626FCC2872220606EDBD638FF1407563_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_626FCC2872220606EDBD638FF1407563" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_626FCC2872220606EDBD638FF1407563_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_626FCC2872220606EDBD638FF1407563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_626FCC2872220606EDBD638FF1407563" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_626FCC2872220606EDBD638FF1407563" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_626FCC2872220606EDBD638FF1407563" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_CE18C4907B6D5CAFA693638FF1412F16_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_CE18C4907B6D5CAFA693638FF1412F16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_CE18C4907B6D5CAFA693638FF1412F16_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_CE18C4907B6D5CAFA693638FF1412F16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_CE18C4907B6D5CAFA693638FF1412F16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_CE18C4907B6D5CAFA693638FF1412F16" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_CE18C4907B6D5CAFA693638FF1412F16" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_BB49FAD207D8226B9460808A11B4F365_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_BB49FAD207D8226B9460808A11B4F365" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_BB49FAD207D8226B9460808A11B4F365_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_BB49FAD207D8226B9460808A11B4F365" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_BB49FAD207D8226B9460808A11B4F365" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_BB49FAD207D8226B9460808A11B4F365" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_BB49FAD207D8226B9460808A11B4F365" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_1125C6A89C8BA82328A8808A11B4CA88_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_1125C6A89C8BA82328A8808A11B4CA88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_1125C6A89C8BA82328A8808A11B4CA88_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_1125C6A89C8BA82328A8808A11B4CA88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_1125C6A89C8BA82328A8808A11B4CA88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_1125C6A89C8BA82328A8808A11B4CA88" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_1125C6A89C8BA82328A8808A11B4CA88" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F4DC206234262356C0808A11B4812C_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F4DC206234262356C0808A11B4812C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F4DC206234262356C0808A11B4812C_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F4DC206234262356C0808A11B4812C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F4DC206234262356C0808A11B4812C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F4DC206234262356C0808A11B4812C" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F4DC206234262356C0808A11B4812C" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_E90435EC2490BC47F381808A11B498AC_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_E90435EC2490BC47F381808A11B498AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_E90435EC2490BC47F381808A11B498AC_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_E90435EC2490BC47F381808A11B498AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_E90435EC2490BC47F381808A11B498AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember_E90435EC2490BC47F381808A11B498AC" xlink:to="lab_us-gaap_USTreasurySecuritiesMember_E90435EC2490BC47F381808A11B498AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_177B9BB360367B46F05D808A11B4940D_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_177B9BB360367B46F05D808A11B4940D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_177B9BB360367B46F05D808A11B4940D_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_177B9BB360367B46F05D808A11B4940D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_177B9BB360367B46F05D808A11B4940D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_177B9BB360367B46F05D808A11B4940D" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_177B9BB360367B46F05D808A11B4940D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_0F099DB89ACFC2075843808A11B44FCB_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_0F099DB89ACFC2075843808A11B44FCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_0F099DB89ACFC2075843808A11B44FCB_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_0F099DB89ACFC2075843808A11B44FCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0F099DB89ACFC2075843808A11B44FCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_0F099DB89ACFC2075843808A11B44FCB" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_0F099DB89ACFC2075843808A11B44FCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C8C1CEE60C6F06A8E6F9808A11B4EECE_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C8C1CEE60C6F06A8E6F9808A11B4EECE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C8C1CEE60C6F06A8E6F9808A11B4EECE_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C8C1CEE60C6F06A8E6F9808A11B4EECE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C8C1CEE60C6F06A8E6F9808A11B4EECE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C8C1CEE60C6F06A8E6F9808A11B4EECE" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C8C1CEE60C6F06A8E6F9808A11B4EECE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F3F5752648435ABAF6BA808A11B5C5D0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F3F5752648435ABAF6BA808A11B5C5D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F3F5752648435ABAF6BA808A11B5C5D0_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F3F5752648435ABAF6BA808A11B5C5D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F3F5752648435ABAF6BA808A11B5C5D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F3F5752648435ABAF6BA808A11B5C5D0" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F3F5752648435ABAF6BA808A11B5C5D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7FADE19E9D0723723777808A11B523F1_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7FADE19E9D0723723777808A11B523F1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7FADE19E9D0723723777808A11B523F1_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7FADE19E9D0723723777808A11B523F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7FADE19E9D0723723777808A11B523F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7FADE19E9D0723723777808A11B523F1" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7FADE19E9D0723723777808A11B523F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9A6276B9FBC7C4ABE083808A11B57EB9_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9A6276B9FBC7C4ABE083808A11B57EB9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9A6276B9FBC7C4ABE083808A11B57EB9_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9A6276B9FBC7C4ABE083808A11B57EB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9A6276B9FBC7C4ABE083808A11B57EB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9A6276B9FBC7C4ABE083808A11B57EB9" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9A6276B9FBC7C4ABE083808A11B57EB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_71F09AC3BB9E5A9F6964808A11B580BC_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_71F09AC3BB9E5A9F6964808A11B580BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, mature in one year or less, amortized cost basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_71F09AC3BB9E5A9F6964808A11B580BC_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_71F09AC3BB9E5A9F6964808A11B580BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_71F09AC3BB9E5A9F6964808A11B580BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_71F09AC3BB9E5A9F6964808A11B580BC" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_71F09AC3BB9E5A9F6964808A11B580BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9747A2003B12801932CD808A11B5B032_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9747A2003B12801932CD808A11B5B032" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, mature in one year or less, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9747A2003B12801932CD808A11B5B032_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9747A2003B12801932CD808A11B5B032" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9747A2003B12801932CD808A11B5B032" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9747A2003B12801932CD808A11B5B032" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9747A2003B12801932CD808A11B5B032" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_F0BF150ABF4436229C3C808A11B526E8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_F0BF150ABF4436229C3C808A11B526E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, maturing between one and five years, amortized cost basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_F0BF150ABF4436229C3C808A11B526E8_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_F0BF150ABF4436229C3C808A11B526E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_F0BF150ABF4436229C3C808A11B526E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_F0BF150ABF4436229C3C808A11B526E8" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_F0BF150ABF4436229C3C808A11B526E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A681F5C975571D0FFD19808A11B5AA1C_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A681F5C975571D0FFD19808A11B5AA1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, maturing between one and five years, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A681F5C975571D0FFD19808A11B5AA1C_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A681F5C975571D0FFD19808A11B5AA1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A681F5C975571D0FFD19808A11B5AA1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A681F5C975571D0FFD19808A11B5AA1C" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A681F5C975571D0FFD19808A11B5AA1C" xlink:type="arc" />
    <link:label id="lab_mgnx_GreenCrossCorporationMember_39BD72A01460905243098018CA05821D_terseLabel_en-US" xlink:label="lab_mgnx_GreenCrossCorporationMember_39BD72A01460905243098018CA05821D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Green Cross</link:label>
    <link:label id="lab_mgnx_GreenCrossCorporationMember_39BD72A01460905243098018CA05821D_label_en-US" xlink:label="lab_mgnx_GreenCrossCorporationMember_39BD72A01460905243098018CA05821D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Green Cross Corporation [Member]</link:label>
    <link:label id="lab_mgnx_GreenCrossCorporationMember_39BD72A01460905243098018CA05821D_documentation_en-US" xlink:label="lab_mgnx_GreenCrossCorporationMember_39BD72A01460905243098018CA05821D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Counterparty in collaboration agreement</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_GreenCrossCorporationMember" xlink:label="loc_mgnx_GreenCrossCorporationMember_39BD72A01460905243098018CA05821D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_GreenCrossCorporationMember_39BD72A01460905243098018CA05821D" xlink:to="lab_mgnx_GreenCrossCorporationMember_39BD72A01460905243098018CA05821D" xlink:type="arc" />
    <link:label id="lab_mgnx_AggregatePotentialFutureCostReimbursement_4E117FBF3158001C814D8018CA052BED_terseLabel_en-US" xlink:label="lab_mgnx_AggregatePotentialFutureCostReimbursement_4E117FBF3158001C814D8018CA052BED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate potential future cost reimbursement</link:label>
    <link:label id="lab_mgnx_AggregatePotentialFutureCostReimbursement_4E117FBF3158001C814D8018CA052BED_label_en-US" xlink:label="lab_mgnx_AggregatePotentialFutureCostReimbursement_4E117FBF3158001C814D8018CA052BED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Potential Future Cost Reimbursement</link:label>
    <link:label id="lab_mgnx_AggregatePotentialFutureCostReimbursement_4E117FBF3158001C814D8018CA052BED_documentation_en-US" xlink:label="lab_mgnx_AggregatePotentialFutureCostReimbursement_4E117FBF3158001C814D8018CA052BED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate potential future cost reimbursement from collaborator</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AggregatePotentialFutureCostReimbursement" xlink:label="loc_mgnx_AggregatePotentialFutureCostReimbursement_4E117FBF3158001C814D8018CA052BED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AggregatePotentialFutureCostReimbursement_4E117FBF3158001C814D8018CA052BED" xlink:to="lab_mgnx_AggregatePotentialFutureCostReimbursement_4E117FBF3158001C814D8018CA052BED" xlink:type="arc" />
    <link:label id="lab_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_035119394DDC37C666F58018CA0518D5_terseLabel_en-US" xlink:label="lab_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_035119394DDC37C666F58018CA0518D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical and commercial milestone payments</link:label>
    <link:label id="lab_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_035119394DDC37C666F58018CA0518D5_label_en-US" xlink:label="lab_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_035119394DDC37C666F58018CA0518D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Potential Clinical And Commercial Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_035119394DDC37C666F58018CA0518D5_documentation_en-US" xlink:label="lab_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_035119394DDC37C666F58018CA0518D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate potential clinical and commercial milestone payments available to be earned under collaboration agreement.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_035119394DDC37C666F58018CA0518D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_035119394DDC37C666F58018CA0518D5" xlink:to="lab_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_035119394DDC37C666F58018CA0518D5" xlink:type="arc" />
    <link:label id="lab_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_23BF567B7586791A86A68018CA0598FA_terseLabel_en-US" xlink:label="lab_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_23BF567B7586791A86A68018CA0598FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to revenue from contract material modification</link:label>
    <link:label id="lab_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_23BF567B7586791A86A68018CA0598FA_label_en-US" xlink:label="lab_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_23BF567B7586791A86A68018CA0598FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To Revenue Under Accounting Standards Codification</link:label>
    <link:label id="lab_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_23BF567B7586791A86A68018CA0598FA_documentation_en-US" xlink:label="lab_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_23BF567B7586791A86A68018CA0598FA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the adjustment to revenue under the accounting standards codification.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification" xlink:label="loc_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_23BF567B7586791A86A68018CA0598FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_23BF567B7586791A86A68018CA0598FA" xlink:to="lab_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_23BF567B7586791A86A68018CA0598FA" xlink:type="arc" />
    <link:label id="lab_mgnx_ProceedsFromResearchAndDevelopmentServices_CE28AEA80A8565601BA38018CA05EDF2_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsFromResearchAndDevelopmentServices_CE28AEA80A8565601BA38018CA05EDF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from research and development services</link:label>
    <link:label id="lab_mgnx_ProceedsFromResearchAndDevelopmentServices_CE28AEA80A8565601BA38018CA05EDF2_label_en-US" xlink:label="lab_mgnx_ProceedsFromResearchAndDevelopmentServices_CE28AEA80A8565601BA38018CA05EDF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Research And Development Services</link:label>
    <link:label id="lab_mgnx_ProceedsFromResearchAndDevelopmentServices_CE28AEA80A8565601BA38018CA05EDF2_documentation_en-US" xlink:label="lab_mgnx_ProceedsFromResearchAndDevelopmentServices_CE28AEA80A8565601BA38018CA05EDF2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Research And Development Services</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ProceedsFromResearchAndDevelopmentServices" xlink:label="loc_mgnx_ProceedsFromResearchAndDevelopmentServices_CE28AEA80A8565601BA38018CA05EDF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsFromResearchAndDevelopmentServices_CE28AEA80A8565601BA38018CA05EDF2" xlink:to="lab_mgnx_ProceedsFromResearchAndDevelopmentServices_CE28AEA80A8565601BA38018CA05EDF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_62C17DC13C2C2B3ED5DF8018CA05A30B_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_62C17DC13C2C2B3ED5DF8018CA05A30B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone achieved</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_62C17DC13C2C2B3ED5DF8018CA05A30B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_62C17DC13C2C2B3ED5DF8018CA05A30B" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_62C17DC13C2C2B3ED5DF8018CA05A30B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_E1C18CD823AF736A89668018CA059D7D_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_E1C18CD823AF736A89668018CA059D7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue included in long-term liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_E1C18CD823AF736A89668018CA059D7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent_E1C18CD823AF736A89668018CA059D7D" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent_E1C18CD823AF736A89668018CA059D7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_D3A6DDCCC3BD3439E60A66981228D1F3_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues_D3A6DDCCC3BD3439E60A66981228D1F3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_D3A6DDCCC3BD3439E60A66981228D1F3_label_en-US" xlink:label="lab_us-gaap_Revenues_D3A6DDCCC3BD3439E60A66981228D1F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_D3A6DDCCC3BD3439E60A66981228D1F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_D3A6DDCCC3BD3439E60A66981228D1F3" xlink:to="lab_us-gaap_Revenues_D3A6DDCCC3BD3439E60A66981228D1F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_BED7A8D862F9EABE6EB86698122ECE37_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_BED7A8D862F9EABE6EB86698122ECE37" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_BED7A8D862F9EABE6EB86698122ECE37_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_BED7A8D862F9EABE6EB86698122ECE37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_BED7A8D862F9EABE6EB86698122ECE37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_BED7A8D862F9EABE6EB86698122ECE37" xlink:to="lab_us-gaap_EarningsPerShareBasic_BED7A8D862F9EABE6EB86698122ECE37" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_427C2CEF93379AA84A3E6698122FC8E6_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_427C2CEF93379AA84A3E6698122FC8E6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_427C2CEF93379AA84A3E6698122FC8E6_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_427C2CEF93379AA84A3E6698122FC8E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_427C2CEF93379AA84A3E6698122FC8E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_427C2CEF93379AA84A3E6698122FC8E6" xlink:to="lab_us-gaap_EarningsPerShareDiluted_427C2CEF93379AA84A3E6698122FC8E6" xlink:type="arc" />
    <link:label id="lab_mgnx_ServierMember_E850E973D4548F6A614C71703B7A486F_terseLabel_en-US" xlink:label="lab_mgnx_ServierMember_E850E973D4548F6A614C71703B7A486F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Servier</link:label>
    <link:label id="lab_mgnx_ServierMember_E850E973D4548F6A614C71703B7A486F_label_en-US" xlink:label="lab_mgnx_ServierMember_E850E973D4548F6A614C71703B7A486F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Servier [Member]</link:label>
    <link:label id="lab_mgnx_ServierMember_E850E973D4548F6A614C71703B7A486F_documentation_en-US" xlink:label="lab_mgnx_ServierMember_E850E973D4548F6A614C71703B7A486F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Counterparty in collaboration agreement</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ServierMember" xlink:label="loc_mgnx_ServierMember_E850E973D4548F6A614C71703B7A486F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ServierMember_E850E973D4548F6A614C71703B7A486F" xlink:to="lab_mgnx_ServierMember_E850E973D4548F6A614C71703B7A486F" xlink:type="arc" />
    <link:label id="lab_mgnx_ServierDARTMember_E4780B4BEA24DC1CE9D271703B7AAB38_terseLabel_en-US" xlink:label="lab_mgnx_ServierDARTMember_E4780B4BEA24DC1CE9D271703B7AAB38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Servier DART</link:label>
    <link:label id="lab_mgnx_ServierDARTMember_E4780B4BEA24DC1CE9D271703B7AAB38_label_en-US" xlink:label="lab_mgnx_ServierDARTMember_E4780B4BEA24DC1CE9D271703B7AAB38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Servier DART [Member]</link:label>
    <link:label id="lab_mgnx_ServierDARTMember_E4780B4BEA24DC1CE9D271703B7AAB38_documentation_en-US" xlink:label="lab_mgnx_ServierDARTMember_E4780B4BEA24DC1CE9D271703B7AAB38" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents agreement with Servier for DARTs</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ServierDARTMember" xlink:label="loc_mgnx_ServierDARTMember_E4780B4BEA24DC1CE9D271703B7AAB38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ServierDARTMember_E4780B4BEA24DC1CE9D271703B7AAB38" xlink:to="lab_mgnx_ServierDARTMember_E4780B4BEA24DC1CE9D271703B7AAB38" xlink:type="arc" />
    <link:label id="lab_mgnx_PotentialLicenseFee_A94510199FED7ADC837A71703B7BC210_verboseLabel_en-US" xlink:label="lab_mgnx_PotentialLicenseFee_A94510199FED7ADC837A71703B7BC210" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Potential License Fee</link:label>
    <link:label id="lab_mgnx_PotentialLicenseFee_A94510199FED7ADC837A71703B7BC210_label_en-US" xlink:label="lab_mgnx_PotentialLicenseFee_A94510199FED7ADC837A71703B7BC210" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential License Fee</link:label>
    <link:label id="lab_mgnx_PotentialLicenseFee_A94510199FED7ADC837A71703B7BC210_documentation_en-US" xlink:label="lab_mgnx_PotentialLicenseFee_A94510199FED7ADC837A71703B7BC210" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential license fee company could earn under agreement</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PotentialLicenseFee" xlink:label="loc_mgnx_PotentialLicenseFee_A94510199FED7ADC837A71703B7BC210" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialLicenseFee_A94510199FED7ADC837A71703B7BC210" xlink:to="lab_mgnx_PotentialLicenseFee_A94510199FED7ADC837A71703B7BC210" xlink:type="arc" />
    <link:label id="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_3C09C9A27B1DF524BA3271703B7B85D5_terseLabel_en-US" xlink:label="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_3C09C9A27B1DF524BA3271703B7B85D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential clinical milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_3C09C9A27B1DF524BA3271703B7B85D5_label_en-US" xlink:label="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_3C09C9A27B1DF524BA3271703B7B85D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Clinical Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_3C09C9A27B1DF524BA3271703B7B85D5_documentation_en-US" xlink:label="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_3C09C9A27B1DF524BA3271703B7B85D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total potential clinical milestone payments company could earn under agreement.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PotentialClinicalMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_3C09C9A27B1DF524BA3271703B7B85D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_3C09C9A27B1DF524BA3271703B7B85D5" xlink:to="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_3C09C9A27B1DF524BA3271703B7B85D5" xlink:type="arc" />
    <link:label id="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_3FC1331EAE3E6D4A633A71703B805B82_terseLabel_en-US" xlink:label="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_3FC1331EAE3E6D4A633A71703B805B82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential regulatory milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_3FC1331EAE3E6D4A633A71703B805B82_label_en-US" xlink:label="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_3FC1331EAE3E6D4A633A71703B805B82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Regulatory Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_3FC1331EAE3E6D4A633A71703B805B82_documentation_en-US" xlink:label="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_3FC1331EAE3E6D4A633A71703B805B82" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total potential regulatory milestones company could earn under agreement</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_3FC1331EAE3E6D4A633A71703B805B82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_3FC1331EAE3E6D4A633A71703B805B82" xlink:to="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_3FC1331EAE3E6D4A633A71703B805B82" xlink:type="arc" />
    <link:label id="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_2D5C15569E488E586FD871703B80464A_verboseLabel_en-US" xlink:label="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_2D5C15569E488E586FD871703B80464A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Potential sales milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_2D5C15569E488E586FD871703B80464A_label_en-US" xlink:label="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_2D5C15569E488E586FD871703B80464A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Sales Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_2D5C15569E488E586FD871703B80464A_documentation_en-US" xlink:label="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_2D5C15569E488E586FD871703B80464A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total potential sales milestones company could earn under agreement</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PotentialSalesMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_2D5C15569E488E586FD871703B80464A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_2D5C15569E488E586FD871703B80464A" xlink:to="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_2D5C15569E488E586FD871703B80464A" xlink:type="arc" />
    <link:label id="lab_mgnx_OriginalPeriodOfDevelopment_FC2DE2FB50165E29972C71703B8048D1_terseLabel_en-US" xlink:label="lab_mgnx_OriginalPeriodOfDevelopment_FC2DE2FB50165E29972C71703B8048D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Original period of development</link:label>
    <link:label id="lab_mgnx_OriginalPeriodOfDevelopment_FC2DE2FB50165E29972C71703B8048D1_label_en-US" xlink:label="lab_mgnx_OriginalPeriodOfDevelopment_FC2DE2FB50165E29972C71703B8048D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Original period of development</link:label>
    <link:label id="lab_mgnx_OriginalPeriodOfDevelopment_FC2DE2FB50165E29972C71703B8048D1_documentation_en-US" xlink:label="lab_mgnx_OriginalPeriodOfDevelopment_FC2DE2FB50165E29972C71703B8048D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Original recognition period for development.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_OriginalPeriodOfDevelopment" xlink:label="loc_mgnx_OriginalPeriodOfDevelopment_FC2DE2FB50165E29972C71703B8048D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OriginalPeriodOfDevelopment_FC2DE2FB50165E29972C71703B8048D1" xlink:to="lab_mgnx_OriginalPeriodOfDevelopment_FC2DE2FB50165E29972C71703B8048D1" xlink:type="arc" />
    <link:label id="lab_mgnx_ChangeInAccountingEstimateCurrentYearImpact_C30BFBAD7454E3E6EAE971703B81C787_terseLabel_en-US" xlink:label="lab_mgnx_ChangeInAccountingEstimateCurrentYearImpact_C30BFBAD7454E3E6EAE971703B81C787" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in accounting estimate, current year impact</link:label>
    <link:label id="lab_mgnx_ChangeInAccountingEstimateCurrentYearImpact_C30BFBAD7454E3E6EAE971703B81C787_label_en-US" xlink:label="lab_mgnx_ChangeInAccountingEstimateCurrentYearImpact_C30BFBAD7454E3E6EAE971703B81C787" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Accounting Estimate Current Year Impact</link:label>
    <link:label id="lab_mgnx_ChangeInAccountingEstimateCurrentYearImpact_C30BFBAD7454E3E6EAE971703B81C787_documentation_en-US" xlink:label="lab_mgnx_ChangeInAccountingEstimateCurrentYearImpact_C30BFBAD7454E3E6EAE971703B81C787" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of the effect of a change in accounting estimate on current year operations.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ChangeInAccountingEstimateCurrentYearImpact" xlink:label="loc_mgnx_ChangeInAccountingEstimateCurrentYearImpact_C30BFBAD7454E3E6EAE971703B81C787" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ChangeInAccountingEstimateCurrentYearImpact_C30BFBAD7454E3E6EAE971703B81C787" xlink:to="lab_mgnx_ChangeInAccountingEstimateCurrentYearImpact_C30BFBAD7454E3E6EAE971703B81C787" xlink:type="arc" />
    <link:label id="lab_mgnx_OptionExerciseFee_DF9A45F6B99AEE085A0171703B8166F7_terseLabel_en-US" xlink:label="lab_mgnx_OptionExerciseFee_DF9A45F6B99AEE085A0171703B8166F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option exercise fee</link:label>
    <link:label id="lab_mgnx_OptionExerciseFee_DF9A45F6B99AEE085A0171703B8166F7_label_en-US" xlink:label="lab_mgnx_OptionExerciseFee_DF9A45F6B99AEE085A0171703B8166F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Exercise Fee</link:label>
    <link:label id="lab_mgnx_OptionExerciseFee_DF9A45F6B99AEE085A0171703B8166F7_documentation_en-US" xlink:label="lab_mgnx_OptionExerciseFee_DF9A45F6B99AEE085A0171703B8166F7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment from collaborator upon exercise of option to develop and commercialize product.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_OptionExerciseFee" xlink:label="loc_mgnx_OptionExerciseFee_DF9A45F6B99AEE085A0171703B8166F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OptionExerciseFee_DF9A45F6B99AEE085A0171703B8166F7" xlink:to="lab_mgnx_OptionExerciseFee_DF9A45F6B99AEE085A0171703B8166F7" xlink:type="arc" />
    <link:label id="lab_mgnx_OptionExerciseFeeRecognitionPeriod_4FA6749FC178CFDBB79E71703B811F27_terseLabel_en-US" xlink:label="lab_mgnx_OptionExerciseFeeRecognitionPeriod_4FA6749FC178CFDBB79E71703B811F27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option exercise fee recognition period</link:label>
    <link:label id="lab_mgnx_OptionExerciseFeeRecognitionPeriod_4FA6749FC178CFDBB79E71703B811F27_label_en-US" xlink:label="lab_mgnx_OptionExerciseFeeRecognitionPeriod_4FA6749FC178CFDBB79E71703B811F27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Exercise Fee Recognition Period</link:label>
    <link:label id="lab_mgnx_OptionExerciseFeeRecognitionPeriod_4FA6749FC178CFDBB79E71703B811F27_documentation_en-US" xlink:label="lab_mgnx_OptionExerciseFeeRecognitionPeriod_4FA6749FC178CFDBB79E71703B811F27" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to option exercise fee recognition period.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_OptionExerciseFeeRecognitionPeriod" xlink:label="loc_mgnx_OptionExerciseFeeRecognitionPeriod_4FA6749FC178CFDBB79E71703B811F27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OptionExerciseFeeRecognitionPeriod_4FA6749FC178CFDBB79E71703B811F27" xlink:to="lab_mgnx_OptionExerciseFeeRecognitionPeriod_4FA6749FC178CFDBB79E71703B811F27" xlink:type="arc" />
    <link:label id="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_6D24ECE892386EDFFC0071703B8153AD_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_6D24ECE892386EDFFC0071703B8153AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offset to research and development costs under collaboration arrangement</link:label>
    <link:label id="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_6D24ECE892386EDFFC0071703B8153AD_label_en-US" xlink:label="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_6D24ECE892386EDFFC0071703B8153AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement Offset to Research and Development Costs</link:label>
    <link:label id="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_6D24ECE892386EDFFC0071703B8153AD_documentation_en-US" xlink:label="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_6D24ECE892386EDFFC0071703B8153AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to collaboration arrangement offset to research and development costs.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:label="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_6D24ECE892386EDFFC0071703B8153AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_6D24ECE892386EDFFC0071703B8153AD" xlink:to="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_6D24ECE892386EDFFC0071703B8153AD" xlink:type="arc" />
    <link:label id="lab_mgnx_NumberOfMilestonesAchieved_2575BBE1DBEF99F840F171703B8129D5_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfMilestonesAchieved_2575BBE1DBEF99F840F171703B8129D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of milestones achieved</link:label>
    <link:label id="lab_mgnx_NumberOfMilestonesAchieved_2575BBE1DBEF99F840F171703B8129D5_label_en-US" xlink:label="lab_mgnx_NumberOfMilestonesAchieved_2575BBE1DBEF99F840F171703B8129D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Milestones Achieved</link:label>
    <link:label id="lab_mgnx_NumberOfMilestonesAchieved_2575BBE1DBEF99F840F171703B8129D5_documentation_en-US" xlink:label="lab_mgnx_NumberOfMilestonesAchieved_2575BBE1DBEF99F840F171703B8129D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of clinical milestones achieved during period.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NumberOfMilestonesAchieved" xlink:label="loc_mgnx_NumberOfMilestonesAchieved_2575BBE1DBEF99F840F171703B8129D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfMilestonesAchieved_2575BBE1DBEF99F840F171703B8129D5" xlink:to="lab_mgnx_NumberOfMilestonesAchieved_2575BBE1DBEF99F840F171703B8129D5" xlink:type="arc" />
    <link:label id="lab_mgnx_ReviewPeriodByRegulatoryAuthority_93EF9F959AAAA3C6536B71703B819E5D_terseLabel_en-US" xlink:label="lab_mgnx_ReviewPeriodByRegulatoryAuthority_93EF9F959AAAA3C6536B71703B819E5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Review period</link:label>
    <link:label id="lab_mgnx_ReviewPeriodByRegulatoryAuthority_93EF9F959AAAA3C6536B71703B819E5D_label_en-US" xlink:label="lab_mgnx_ReviewPeriodByRegulatoryAuthority_93EF9F959AAAA3C6536B71703B819E5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Review Period By Regulatory Authority</link:label>
    <link:label id="lab_mgnx_ReviewPeriodByRegulatoryAuthority_93EF9F959AAAA3C6536B71703B819E5D_documentation_en-US" xlink:label="lab_mgnx_ReviewPeriodByRegulatoryAuthority_93EF9F959AAAA3C6536B71703B819E5D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to review period by regulatory authority.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ReviewPeriodByRegulatoryAuthority" xlink:label="loc_mgnx_ReviewPeriodByRegulatoryAuthority_93EF9F959AAAA3C6536B71703B819E5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ReviewPeriodByRegulatoryAuthority_93EF9F959AAAA3C6536B71703B819E5D" xlink:to="lab_mgnx_ReviewPeriodByRegulatoryAuthority_93EF9F959AAAA3C6536B71703B819E5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_C2D36E5D1E0F273716487B56E68377FD_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_C2D36E5D1E0F273716487B56E68377FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_C2D36E5D1E0F273716487B56E68377FD_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_C2D36E5D1E0F273716487B56E68377FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_C2D36E5D1E0F273716487B56E68377FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_C2D36E5D1E0F273716487B56E68377FD" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_C2D36E5D1E0F273716487B56E68377FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_F3FF3790F43F1D9599DD7B56E683A053_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_F3FF3790F43F1D9599DD7B56E683A053" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss used for calculation of basic and diluted EPS</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F3FF3790F43F1D9599DD7B56E683A053" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_F3FF3790F43F1D9599DD7B56E683A053" xlink:to="lab_us-gaap_NetIncomeLoss_F3FF3790F43F1D9599DD7B56E683A053" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_22DC60629221A0529F307B56E683C7DB_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_22DC60629221A0529F307B56E683C7DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_22DC60629221A0529F307B56E683C7DB_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_22DC60629221A0529F307B56E683C7DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_22DC60629221A0529F307B56E683C7DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_22DC60629221A0529F307B56E683C7DB" xlink:to="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_22DC60629221A0529F307B56E683C7DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9B373F9AF8DBD30265FA7B56E6835A0B_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9B373F9AF8DBD30265FA7B56E6835A0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9B373F9AF8DBD30265FA7B56E6835A0B_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9B373F9AF8DBD30265FA7B56E6835A0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9B373F9AF8DBD30265FA7B56E6835A0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9B373F9AF8DBD30265FA7B56E6835A0B" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9B373F9AF8DBD30265FA7B56E6835A0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_0A9348EFBCA132C16AF67B56E6834CD7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_0A9348EFBCA132C16AF67B56E6834CD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_0A9348EFBCA132C16AF67B56E6834CD7_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_0A9348EFBCA132C16AF67B56E6834CD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_0A9348EFBCA132C16AF67B56E6834CD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_0A9348EFBCA132C16AF67B56E6834CD7" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_0A9348EFBCA132C16AF67B56E6834CD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_439A0716C9BAB11775DB7B56E684F1C0_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_439A0716C9BAB11775DB7B56E684F1C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options and restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_439A0716C9BAB11775DB7B56E684F1C0_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_439A0716C9BAB11775DB7B56E684F1C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_439A0716C9BAB11775DB7B56E684F1C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_439A0716C9BAB11775DB7B56E684F1C0" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_439A0716C9BAB11775DB7B56E684F1C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_94E496E3783B945335B77B56E6848F11_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_94E496E3783B945335B77B56E6848F11" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_94E496E3783B945335B77B56E6848F11_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_94E496E3783B945335B77B56E6848F11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_94E496E3783B945335B77B56E6848F11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_94E496E3783B945335B77B56E6848F11" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_94E496E3783B945335B77B56E6848F11" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_91D582F3A76C78B7FB167B56E684A2B7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_91D582F3A76C78B7FB167B56E684A2B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_91D582F3A76C78B7FB167B56E684A2B7_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_91D582F3A76C78B7FB167B56E684A2B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_91D582F3A76C78B7FB167B56E684A2B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_91D582F3A76C78B7FB167B56E684A2B7" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_91D582F3A76C78B7FB167B56E684A2B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_DEF7CB17733A9B27BF5F638FF13B8C43_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_DEF7CB17733A9B27BF5F638FF13B8C43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_DEF7CB17733A9B27BF5F638FF13B8C43_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_DEF7CB17733A9B27BF5F638FF13B8C43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_DEF7CB17733A9B27BF5F638FF13B8C43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_DEF7CB17733A9B27BF5F638FF13B8C43" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_DEF7CB17733A9B27BF5F638FF13B8C43" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E81694074AE68E92E4887B56E5B2727B_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E81694074AE68E92E4887B56E5B2727B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E81694074AE68E92E4887B56E5B2727B_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E81694074AE68E92E4887B56E5B2727B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E81694074AE68E92E4887B56E5B2727B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E81694074AE68E92E4887B56E5B2727B" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E81694074AE68E92E4887B56E5B2727B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_E41145BACC315758EEFB7B56E5B25F50_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_E41145BACC315758EEFB7B56E5B25F50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_E41145BACC315758EEFB7B56E5B25F50_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_E41145BACC315758EEFB7B56E5B25F50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_E41145BACC315758EEFB7B56E5B25F50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_E41145BACC315758EEFB7B56E5B25F50" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_E41145BACC315758EEFB7B56E5B25F50" xlink:type="arc" />
    <link:label id="lab_mgnx_JanssenMGD011AgreementMember_73F55F2702F5E907FFB57B56E5B2907D_terseLabel_en-US" xlink:label="lab_mgnx_JanssenMGD011AgreementMember_73F55F2702F5E907FFB57B56E5B2907D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Janssen MGD011 Agreement</link:label>
    <link:label id="lab_mgnx_JanssenMGD011AgreementMember_73F55F2702F5E907FFB57B56E5B2907D_label_en-US" xlink:label="lab_mgnx_JanssenMGD011AgreementMember_73F55F2702F5E907FFB57B56E5B2907D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Janssen MGD011 Agreement [Member]</link:label>
    <link:label id="lab_mgnx_JanssenMGD011AgreementMember_73F55F2702F5E907FFB57B56E5B2907D_documentation_en-US" xlink:label="lab_mgnx_JanssenMGD011AgreementMember_73F55F2702F5E907FFB57B56E5B2907D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Janssen MGD011 Agreement [Member]</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_JanssenMGD011AgreementMember" xlink:label="loc_mgnx_JanssenMGD011AgreementMember_73F55F2702F5E907FFB57B56E5B2907D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenMGD011AgreementMember_73F55F2702F5E907FFB57B56E5B2907D" xlink:to="lab_mgnx_JanssenMGD011AgreementMember_73F55F2702F5E907FFB57B56E5B2907D" xlink:type="arc" />
    <link:label id="lab_mgnx_JanssenMGD015AgreementMember_CB4C3521CF1FDD65E28D7B56E5B24FC4_terseLabel_en-US" xlink:label="lab_mgnx_JanssenMGD015AgreementMember_CB4C3521CF1FDD65E28D7B56E5B24FC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Janssen MGD015 Agreement</link:label>
    <link:label id="lab_mgnx_JanssenMGD015AgreementMember_CB4C3521CF1FDD65E28D7B56E5B24FC4_label_en-US" xlink:label="lab_mgnx_JanssenMGD015AgreementMember_CB4C3521CF1FDD65E28D7B56E5B24FC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Janssen MGD015 Agreement [Member]</link:label>
    <link:label id="lab_mgnx_JanssenMGD015AgreementMember_CB4C3521CF1FDD65E28D7B56E5B24FC4_documentation_en-US" xlink:label="lab_mgnx_JanssenMGD015AgreementMember_CB4C3521CF1FDD65E28D7B56E5B24FC4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Janssen MGD015 Agreement [Member]</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_JanssenMGD015AgreementMember" xlink:label="loc_mgnx_JanssenMGD015AgreementMember_CB4C3521CF1FDD65E28D7B56E5B24FC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenMGD015AgreementMember_CB4C3521CF1FDD65E28D7B56E5B24FC4" xlink:to="lab_mgnx_JanssenMGD015AgreementMember_CB4C3521CF1FDD65E28D7B56E5B24FC4" xlink:type="arc" />
    <link:label id="lab_mgnx_JanssenBiotechIncMember_ECD474B40DB42AE394F27B56E5B34C78_terseLabel_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember_ECD474B40DB42AE394F27B56E5B34C78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Janssen Biotech Inc.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_JanssenBiotechIncMember" xlink:label="loc_mgnx_JanssenBiotechIncMember_ECD474B40DB42AE394F27B56E5B34C78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenBiotechIncMember_ECD474B40DB42AE394F27B56E5B34C78" xlink:to="lab_mgnx_JanssenBiotechIncMember_ECD474B40DB42AE394F27B56E5B34C78" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7280D67ADA2259D3E50D7B56E5B36F5B_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7280D67ADA2259D3E50D7B56E5B36F5B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7280D67ADA2259D3E50D7B56E5B36F5B_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7280D67ADA2259D3E50D7B56E5B36F5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7280D67ADA2259D3E50D7B56E5B36F5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7280D67ADA2259D3E50D7B56E5B36F5B" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7280D67ADA2259D3E50D7B56E5B36F5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_22BC30B8F2DE70A4F2647B56E5B4C816_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_22BC30B8F2DE70A4F2647B56E5B4C816" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds of stock sale</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_22BC30B8F2DE70A4F2647B56E5B4C816_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_22BC30B8F2DE70A4F2647B56E5B4C816" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_22BC30B8F2DE70A4F2647B56E5B4C816" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_22BC30B8F2DE70A4F2647B56E5B4C816" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_22BC30B8F2DE70A4F2647B56E5B4C816" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_920B2DFD6F0F39514DBA7B56E5B4CA18_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_920B2DFD6F0F39514DBA7B56E5B4CA18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_920B2DFD6F0F39514DBA7B56E5B4CA18_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_920B2DFD6F0F39514DBA7B56E5B4CA18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_920B2DFD6F0F39514DBA7B56E5B4CA18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_920B2DFD6F0F39514DBA7B56E5B4CA18" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_920B2DFD6F0F39514DBA7B56E5B4CA18" xlink:type="arc" />
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_72880FFB1CA4476A50627B56E5B441A8_terseLabel_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase_72880FFB1CA4476A50627B56E5B441A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Premium received on stock purchase</link:label>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_72880FFB1CA4476A50627B56E5B441A8_label_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase_72880FFB1CA4476A50627B56E5B441A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Premium received on stock purchase</link:label>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_72880FFB1CA4476A50627B56E5B441A8_documentation_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase_72880FFB1CA4476A50627B56E5B441A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount by which purchase price exceeds fair value for common stock purchased by collaborator.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PremiumReceivedOnStockPurchase" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase_72880FFB1CA4476A50627B56E5B441A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PremiumReceivedOnStockPurchase_72880FFB1CA4476A50627B56E5B441A8" xlink:to="lab_mgnx_PremiumReceivedOnStockPurchase_72880FFB1CA4476A50627B56E5B441A8" xlink:type="arc" />
    <link:label id="lab_mgnx_TotalConsideration_C93C1F1C55BE1FDCF5977B56E5B4EF2C_terseLabel_en-US" xlink:label="lab_mgnx_TotalConsideration_C93C1F1C55BE1FDCF5977B56E5B4EF2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_mgnx_TotalConsideration_C93C1F1C55BE1FDCF5977B56E5B4EF2C_label_en-US" xlink:label="lab_mgnx_TotalConsideration_C93C1F1C55BE1FDCF5977B56E5B4EF2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_mgnx_TotalConsideration_C93C1F1C55BE1FDCF5977B56E5B4EF2C_documentation_en-US" xlink:label="lab_mgnx_TotalConsideration_C93C1F1C55BE1FDCF5977B56E5B4EF2C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total consideration received under agreement.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_TotalConsideration" xlink:label="loc_mgnx_TotalConsideration_C93C1F1C55BE1FDCF5977B56E5B4EF2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TotalConsideration_C93C1F1C55BE1FDCF5977B56E5B4EF2C" xlink:to="lab_mgnx_TotalConsideration_C93C1F1C55BE1FDCF5977B56E5B4EF2C" xlink:type="arc" />
    <link:label id="lab_mgnx_AmountAllocatedToEquity_9FC85C98CDBDF4E9AD4E7B56E5B4E95E_terseLabel_en-US" xlink:label="lab_mgnx_AmountAllocatedToEquity_9FC85C98CDBDF4E9AD4E7B56E5B4E95E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount allocated to equity</link:label>
    <link:label id="lab_mgnx_AmountAllocatedToEquity_9FC85C98CDBDF4E9AD4E7B56E5B4E95E_label_en-US" xlink:label="lab_mgnx_AmountAllocatedToEquity_9FC85C98CDBDF4E9AD4E7B56E5B4E95E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount allocated to equity</link:label>
    <link:label id="lab_mgnx_AmountAllocatedToEquity_9FC85C98CDBDF4E9AD4E7B56E5B4E95E_documentation_en-US" xlink:label="lab_mgnx_AmountAllocatedToEquity_9FC85C98CDBDF4E9AD4E7B56E5B4E95E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Portion of consideration allocated to equity.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AmountAllocatedToEquity" xlink:label="loc_mgnx_AmountAllocatedToEquity_9FC85C98CDBDF4E9AD4E7B56E5B4E95E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AmountAllocatedToEquity_9FC85C98CDBDF4E9AD4E7B56E5B4E95E" xlink:to="lab_mgnx_AmountAllocatedToEquity_9FC85C98CDBDF4E9AD4E7B56E5B4E95E" xlink:type="arc" />
    <link:label id="lab_mgnx_AmountAllocatedToLicenseAndRD_E17E4BC8DDC31D1683977B56E5B42580_terseLabel_en-US" xlink:label="lab_mgnx_AmountAllocatedToLicenseAndRD_E17E4BC8DDC31D1683977B56E5B42580" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount allocated to license and R&amp;D</link:label>
    <link:label id="lab_mgnx_AmountAllocatedToLicenseAndRD_E17E4BC8DDC31D1683977B56E5B42580_label_en-US" xlink:label="lab_mgnx_AmountAllocatedToLicenseAndRD_E17E4BC8DDC31D1683977B56E5B42580" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount allocated to license and R&amp;D</link:label>
    <link:label id="lab_mgnx_AmountAllocatedToLicenseAndRD_E17E4BC8DDC31D1683977B56E5B42580_documentation_en-US" xlink:label="lab_mgnx_AmountAllocatedToLicenseAndRD_E17E4BC8DDC31D1683977B56E5B42580" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Portion of consideration allocated to license and pre-clinical research and development.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AmountAllocatedToLicenseAndRD" xlink:label="loc_mgnx_AmountAllocatedToLicenseAndRD_E17E4BC8DDC31D1683977B56E5B42580" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AmountAllocatedToLicenseAndRD_E17E4BC8DDC31D1683977B56E5B42580" xlink:to="lab_mgnx_AmountAllocatedToLicenseAndRD_E17E4BC8DDC31D1683977B56E5B42580" xlink:type="arc" />
    <link:label id="lab_mgnx_ClinicalMilestoneEarnedDuringPeriod_4E21EAAC25907AFDE4767B56E5B5015C_terseLabel_en-US" xlink:label="lab_mgnx_ClinicalMilestoneEarnedDuringPeriod_4E21EAAC25907AFDE4767B56E5B5015C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical milestone earned during period</link:label>
    <link:label id="lab_mgnx_ClinicalMilestoneEarnedDuringPeriod_4E21EAAC25907AFDE4767B56E5B5015C_label_en-US" xlink:label="lab_mgnx_ClinicalMilestoneEarnedDuringPeriod_4E21EAAC25907AFDE4767B56E5B5015C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical milestone earned during period</link:label>
    <link:label id="lab_mgnx_ClinicalMilestoneEarnedDuringPeriod_4E21EAAC25907AFDE4767B56E5B5015C_documentation_en-US" xlink:label="lab_mgnx_ClinicalMilestoneEarnedDuringPeriod_4E21EAAC25907AFDE4767B56E5B5015C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical milestone earned during the period</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ClinicalMilestoneEarnedDuringPeriod" xlink:label="loc_mgnx_ClinicalMilestoneEarnedDuringPeriod_4E21EAAC25907AFDE4767B56E5B5015C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ClinicalMilestoneEarnedDuringPeriod_4E21EAAC25907AFDE4767B56E5B5015C" xlink:to="lab_mgnx_ClinicalMilestoneEarnedDuringPeriod_4E21EAAC25907AFDE4767B56E5B5015C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_56AC8DD130394A1B23D963E495141D14_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_56AC8DD130394A1B23D963E495141D14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_56AC8DD130394A1B23D963E495141D14_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_56AC8DD130394A1B23D963E495141D14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_56AC8DD130394A1B23D963E495141D14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_56AC8DD130394A1B23D963E495141D14" xlink:to="lab_us-gaap_PlanNameAxis_56AC8DD130394A1B23D963E495141D14" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_853BB81E67641DB1603863E495149159_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_853BB81E67641DB1603863E495149159" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_853BB81E67641DB1603863E495149159_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_853BB81E67641DB1603863E495149159" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_853BB81E67641DB1603863E495149159" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_853BB81E67641DB1603863E495149159" xlink:to="lab_us-gaap_PlanNameDomain_853BB81E67641DB1603863E495149159" xlink:type="arc" />
    <link:label id="lab_mgnx_EquityIncentivePlan2003Member_91A0426E2C014FFD9A2F63E49515FCC4_terseLabel_en-US" xlink:label="lab_mgnx_EquityIncentivePlan2003Member_91A0426E2C014FFD9A2F63E49515FCC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2003</link:label>
    <link:label id="lab_mgnx_EquityIncentivePlan2003Member_91A0426E2C014FFD9A2F63E49515FCC4_label_en-US" xlink:label="lab_mgnx_EquityIncentivePlan2003Member_91A0426E2C014FFD9A2F63E49515FCC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2003 [Member]</link:label>
    <link:label id="lab_mgnx_EquityIncentivePlan2003Member_91A0426E2C014FFD9A2F63E49515FCC4_documentation_en-US" xlink:label="lab_mgnx_EquityIncentivePlan2003Member_91A0426E2C014FFD9A2F63E49515FCC4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2003</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_EquityIncentivePlan2003Member" xlink:label="loc_mgnx_EquityIncentivePlan2003Member_91A0426E2C014FFD9A2F63E49515FCC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EquityIncentivePlan2003Member_91A0426E2C014FFD9A2F63E49515FCC4" xlink:to="lab_mgnx_EquityIncentivePlan2003Member_91A0426E2C014FFD9A2F63E49515FCC4" xlink:type="arc" />
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_ABEA052196814BE419DD63E495154370_terseLabel_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member_ABEA052196814BE419DD63E495154370" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan 2013</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_ABEA052196814BE419DD63E495154370_label_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member_ABEA052196814BE419DD63E495154370" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan 2013 [Member]</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_ABEA052196814BE419DD63E495154370_documentation_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member_ABEA052196814BE419DD63E495154370" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan 2013 [Member]</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_StockIncentivePlan2013Member" xlink:label="loc_mgnx_StockIncentivePlan2013Member_ABEA052196814BE419DD63E495154370" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIncentivePlan2013Member_ABEA052196814BE419DD63E495154370" xlink:to="lab_mgnx_StockIncentivePlan2013Member_ABEA052196814BE419DD63E495154370" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_929D5BD1E813114172E663E495150A6C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_929D5BD1E813114172E663E495150A6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation, number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_929D5BD1E813114172E663E495150A6C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_929D5BD1E813114172E663E495150A6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_929D5BD1E813114172E663E495150A6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_929D5BD1E813114172E663E495150A6C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_929D5BD1E813114172E663E495150A6C" xlink:type="arc" />
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_7CCD6C53024196770D8D63E4951559A0_terseLabel_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_7CCD6C53024196770D8D63E4951559A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increased number of shares authorized (in shares)</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_7CCD6C53024196770D8D63E4951559A0_label_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_7CCD6C53024196770D8D63E4951559A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized After Increase</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_7CCD6C53024196770D8D63E4951559A0_documentation_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_7CCD6C53024196770D8D63E4951559A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award number of shares authorized after increase.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_7CCD6C53024196770D8D63E4951559A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_7CCD6C53024196770D8D63E4951559A0" xlink:to="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_7CCD6C53024196770D8D63E4951559A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A4E40369EF3630711DD263E49515B27B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A4E40369EF3630711DD263E49515B27B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A4E40369EF3630711DD263E49515B27B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A4E40369EF3630711DD263E49515B27B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A4E40369EF3630711DD263E49515B27B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A4E40369EF3630711DD263E49515B27B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A4E40369EF3630711DD263E49515B27B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0332A992136B608133E963E495159E38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0332A992136B608133E963E495159E38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0332A992136B608133E963E495159E38_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0332A992136B608133E963E495159E38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0332A992136B608133E963E495159E38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0332A992136B608133E963E495159E38" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0332A992136B608133E963E495159E38" xlink:type="arc" />
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_13AF18F7A9CB013067D563E495159883_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_13AF18F7A9CB013067D563E495159883" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock reserved for future issuance (in shares)</link:label>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_13AF18F7A9CB013067D563E495159883_label_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_13AF18F7A9CB013067D563E495159883" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Capital Shares Minimum Increase In Shares Reserved For Future Issuance</link:label>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_13AF18F7A9CB013067D563E495159883_documentation_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_13AF18F7A9CB013067D563E495159883" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Capital Shares Minimum Increase In Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_13AF18F7A9CB013067D563E495159883" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_13AF18F7A9CB013067D563E495159883" xlink:to="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_13AF18F7A9CB013067D563E495159883" xlink:type="arc" />
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_ED966013549DE49DF97963E49515CDC0_terseLabel_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_ED966013549DE49DF97963E49515CDC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of common stock share outstanding</link:label>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_ED966013549DE49DF97963E49515CDC0_label_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_ED966013549DE49DF97963E49515CDC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Shares Of Companys Common Stock Outstanding For Increase In Shares Reserved For Issuance Under Stock Plan</link:label>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_ED966013549DE49DF97963E49515CDC0_documentation_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_ED966013549DE49DF97963E49515CDC0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of shares of company's common stock outstanding for increase in shares reserved for issuance under stock plan.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_ED966013549DE49DF97963E49515CDC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_ED966013549DE49DF97963E49515CDC0" xlink:to="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_ED966013549DE49DF97963E49515CDC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D1188F814F9C0F3450AF63E49515F04B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D1188F814F9C0F3450AF63E49515F04B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D1188F814F9C0F3450AF63E49515F04B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D1188F814F9C0F3450AF63E49515F04B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D1188F814F9C0F3450AF63E49515F04B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D1188F814F9C0F3450AF63E49515F04B" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D1188F814F9C0F3450AF63E49515F04B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_200974DA9209CB4AC09C63E49515EB5B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_200974DA9209CB4AC09C63E49515EB5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_200974DA9209CB4AC09C63E49515EB5B_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_200974DA9209CB4AC09C63E49515EB5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_200974DA9209CB4AC09C63E49515EB5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_200974DA9209CB4AC09C63E49515EB5B" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_200974DA9209CB4AC09C63E49515EB5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_DDDFC1198BCD575519DF63E49515290B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_DDDFC1198BCD575519DF63E49515290B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_DDDFC1198BCD575519DF63E49515290B_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_DDDFC1198BCD575519DF63E49515290B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_DDDFC1198BCD575519DF63E49515290B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_DDDFC1198BCD575519DF63E49515290B" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_DDDFC1198BCD575519DF63E49515290B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0E7C9CDDC339470CCBB263E495154973_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0E7C9CDDC339470CCBB263E495154973" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0E7C9CDDC339470CCBB263E495154973_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0E7C9CDDC339470CCBB263E495154973" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0E7C9CDDC339470CCBB263E495154973" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0E7C9CDDC339470CCBB263E495154973" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0E7C9CDDC339470CCBB263E495154973" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_8711CA27533F6975AA7563E49515D3B3_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_8711CA27533F6975AA7563E49515D3B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_8711CA27533F6975AA7563E49515D3B3_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_8711CA27533F6975AA7563E49515D3B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8711CA27533F6975AA7563E49515D3B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8711CA27533F6975AA7563E49515D3B3" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_8711CA27533F6975AA7563E49515D3B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_769CE96B9271E4F8510563E495158287_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_769CE96B9271E4F8510563E495158287" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_769CE96B9271E4F8510563E495158287_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_769CE96B9271E4F8510563E495158287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_769CE96B9271E4F8510563E495158287" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_769CE96B9271E4F8510563E495158287" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_769CE96B9271E4F8510563E495158287" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_274BA5AD719D68171A5563E4951603BF_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_274BA5AD719D68171A5563E4951603BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_274BA5AD719D68171A5563E4951603BF_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_274BA5AD719D68171A5563E4951603BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_274BA5AD719D68171A5563E4951603BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_274BA5AD719D68171A5563E4951603BF" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_274BA5AD719D68171A5563E4951603BF" xlink:type="arc" />
    <link:label id="lab_mgnx_GileadSciencesIncMember_6A7D55D22D59797D08E27B56E6979C00_terseLabel_en-US" xlink:label="lab_mgnx_GileadSciencesIncMember_6A7D55D22D59797D08E27B56E6979C00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gilead Sciences, Inc. (Gilead)</link:label>
    <link:label id="lab_mgnx_GileadSciencesIncMember_6A7D55D22D59797D08E27B56E6979C00_label_en-US" xlink:label="lab_mgnx_GileadSciencesIncMember_6A7D55D22D59797D08E27B56E6979C00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gilead Sciences Inc [Member]</link:label>
    <link:label id="lab_mgnx_GileadSciencesIncMember_6A7D55D22D59797D08E27B56E6979C00_documentation_en-US" xlink:label="lab_mgnx_GileadSciencesIncMember_6A7D55D22D59797D08E27B56E6979C00" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Counterparty in collaboration agreement</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_GileadSciencesIncMember" xlink:label="loc_mgnx_GileadSciencesIncMember_6A7D55D22D59797D08E27B56E6979C00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_GileadSciencesIncMember_6A7D55D22D59797D08E27B56E6979C00" xlink:to="lab_mgnx_GileadSciencesIncMember_6A7D55D22D59797D08E27B56E6979C00" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueNetMember_DAF92DF9A928DA9F6A7E7B56E6964620_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember_DAF92DF9A928DA9F6A7E7B56E6964620" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales revenue, net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_DAF92DF9A928DA9F6A7E7B56E6964620_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember_DAF92DF9A928DA9F6A7E7B56E6964620" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Net [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_DAF92DF9A928DA9F6A7E7B56E6964620" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember_DAF92DF9A928DA9F6A7E7B56E6964620" xlink:to="lab_us-gaap_SalesRevenueNetMember_DAF92DF9A928DA9F6A7E7B56E6964620" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_E364BEC392BBEEE0CE127B56E69734C8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_E364BEC392BBEEE0CE127B56E69734C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of all significant revenue earned</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_E364BEC392BBEEE0CE127B56E69734C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_E364BEC392BBEEE0CE127B56E69734C8" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_E364BEC392BBEEE0CE127B56E69734C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_F7EC33085915A0EBBC1CE2787CDD6379_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_F7EC33085915A0EBBC1CE2787CDD6379" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_F7EC33085915A0EBBC1CE2787CDD6379_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_F7EC33085915A0EBBC1CE2787CDD6379" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_F7EC33085915A0EBBC1CE2787CDD6379" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_F7EC33085915A0EBBC1CE2787CDD6379" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_F7EC33085915A0EBBC1CE2787CDD6379" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_CCC654BE1B5CC3FB073684277071C446_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_CCC654BE1B5CC3FB073684277071C446" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_CCC654BE1B5CC3FB073684277071C446_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_CCC654BE1B5CC3FB073684277071C446" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_CCC654BE1B5CC3FB073684277071C446" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock_CCC654BE1B5CC3FB073684277071C446" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock_CCC654BE1B5CC3FB073684277071C446" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1B5C61E61D7076780A31638FF17F473B_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_1B5C61E61D7076780A31638FF17F473B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1B5C61E61D7076780A31638FF17F473B_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_1B5C61E61D7076780A31638FF17F473B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1B5C61E61D7076780A31638FF17F473B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_1B5C61E61D7076780A31638FF17F473B" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_1B5C61E61D7076780A31638FF17F473B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_38FFB1E8107F63EA08F6638FF17F2ECF_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_38FFB1E8107F63EA08F6638FF17F2ECF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_38FFB1E8107F63EA08F6638FF17F2ECF_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_38FFB1E8107F63EA08F6638FF17F2ECF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_38FFB1E8107F63EA08F6638FF17F2ECF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_38FFB1E8107F63EA08F6638FF17F2ECF" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_38FFB1E8107F63EA08F6638FF17F2ECF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_CF068793853E8492F2FD638FF17F7EFC_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_CF068793853E8492F2FD638FF17F7EFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_CF068793853E8492F2FD638FF17F7EFC_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_CF068793853E8492F2FD638FF17F7EFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_CF068793853E8492F2FD638FF17F7EFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_CF068793853E8492F2FD638FF17F7EFC" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_CF068793853E8492F2FD638FF17F7EFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E82984389698DE5BE55D8018CB5113E9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E82984389698DE5BE55D8018CB5113E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E82984389698DE5BE55D8018CB5113E9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E82984389698DE5BE55D8018CB5113E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E82984389698DE5BE55D8018CB5113E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E82984389698DE5BE55D8018CB5113E9" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E82984389698DE5BE55D8018CB5113E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2415B3DBA13379FBFDF08018CB5129F0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2415B3DBA13379FBFDF08018CB5129F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2415B3DBA13379FBFDF08018CB5129F0_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2415B3DBA13379FBFDF08018CB5129F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2415B3DBA13379FBFDF08018CB5129F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2415B3DBA13379FBFDF08018CB5129F0" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2415B3DBA13379FBFDF08018CB5129F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_CE3F58E789395BAF7FE68018CB5166A3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_CE3F58E789395BAF7FE68018CB5166A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_CE3F58E789395BAF7FE68018CB5166A3_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_CE3F58E789395BAF7FE68018CB5166A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CE3F58E789395BAF7FE68018CB5166A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CE3F58E789395BAF7FE68018CB5166A3" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_CE3F58E789395BAF7FE68018CB5166A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerEquipmentMember_3BFAA0DB1CC1045D92F98018CB51EC85_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_3BFAA0DB1CC1045D92F98018CB51EC85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_3BFAA0DB1CC1045D92F98018CB51EC85_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_3BFAA0DB1CC1045D92F98018CB51EC85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_3BFAA0DB1CC1045D92F98018CB51EC85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_3BFAA0DB1CC1045D92F98018CB51EC85" xlink:to="lab_us-gaap_ComputerEquipmentMember_3BFAA0DB1CC1045D92F98018CB51EC85" xlink:type="arc" />
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_523FC8E441EBF69253FF8018CB51A947_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_523FC8E441EBF69253FF8018CB51A947" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_523FC8E441EBF69253FF8018CB51A947_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_523FC8E441EBF69253FF8018CB51A947" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_523FC8E441EBF69253FF8018CB51A947" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_523FC8E441EBF69253FF8018CB51A947" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_523FC8E441EBF69253FF8018CB51A947" xlink:type="arc" />
    <link:label id="lab_mgnx_FurnitureAndOfficeEquipmentMember_846C2E01D468B5EA36F58018CB51F410_terseLabel_en-US" xlink:label="lab_mgnx_FurnitureAndOfficeEquipmentMember_846C2E01D468B5EA36F58018CB51F410" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and office equipment</link:label>
    <link:label id="lab_mgnx_FurnitureAndOfficeEquipmentMember_846C2E01D468B5EA36F58018CB51F410_label_en-US" xlink:label="lab_mgnx_FurnitureAndOfficeEquipmentMember_846C2E01D468B5EA36F58018CB51F410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture And Office Equipment [Member]</link:label>
    <link:label id="lab_mgnx_FurnitureAndOfficeEquipmentMember_846C2E01D468B5EA36F58018CB51F410_documentation_en-US" xlink:label="lab_mgnx_FurnitureAndOfficeEquipmentMember_846C2E01D468B5EA36F58018CB51F410" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Furniture and office equipment are movable furniture, fixtures, or other equipment that have no permanent connection to the structure of a building or utilities. These items depreciate substantially but definitely are important costs to consider when valuing a company, especially in liquidation.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_FurnitureAndOfficeEquipmentMember" xlink:label="loc_mgnx_FurnitureAndOfficeEquipmentMember_846C2E01D468B5EA36F58018CB51F410" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FurnitureAndOfficeEquipmentMember_846C2E01D468B5EA36F58018CB51F410" xlink:to="lab_mgnx_FurnitureAndOfficeEquipmentMember_846C2E01D468B5EA36F58018CB51F410" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquipmentMember_1758D66CF0322FBD5FB88018CB513891_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember_1758D66CF0322FBD5FB88018CB513891" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_1758D66CF0322FBD5FB88018CB513891_label_en-US" xlink:label="lab_us-gaap_EquipmentMember_1758D66CF0322FBD5FB88018CB513891" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_1758D66CF0322FBD5FB88018CB513891" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember_1758D66CF0322FBD5FB88018CB513891" xlink:to="lab_us-gaap_EquipmentMember_1758D66CF0322FBD5FB88018CB513891" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_0D6214C3126F10B3D9728018CB5168D7_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_0D6214C3126F10B3D9728018CB5168D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_0D6214C3126F10B3D9728018CB5168D7_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_0D6214C3126F10B3D9728018CB5168D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_0D6214C3126F10B3D9728018CB5168D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_0D6214C3126F10B3D9728018CB5168D7" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_0D6214C3126F10B3D9728018CB5168D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_FB9B7AD9E97D540768648018CB5197AE_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_FB9B7AD9E97D540768648018CB5197AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_FB9B7AD9E97D540768648018CB5197AE_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_FB9B7AD9E97D540768648018CB5197AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_FB9B7AD9E97D540768648018CB5197AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_FB9B7AD9E97D540768648018CB5197AE" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_FB9B7AD9E97D540768648018CB5197AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_753E23109D5D5622D98C8018CB514C8E_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_753E23109D5D5622D98C8018CB514C8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_753E23109D5D5622D98C8018CB514C8E_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_753E23109D5D5622D98C8018CB514C8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_753E23109D5D5622D98C8018CB514C8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_753E23109D5D5622D98C8018CB514C8E" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_753E23109D5D5622D98C8018CB514C8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7BFB6E2A5DD48AC048BD8018CB51F01A_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7BFB6E2A5DD48AC048BD8018CB51F01A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7BFB6E2A5DD48AC048BD8018CB51F01A_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7BFB6E2A5DD48AC048BD8018CB51F01A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7BFB6E2A5DD48AC048BD8018CB51F01A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7BFB6E2A5DD48AC048BD8018CB51F01A" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7BFB6E2A5DD48AC048BD8018CB51F01A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_13E9FB46BD42434591088018CB514FCB_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_13E9FB46BD42434591088018CB514FCB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_13E9FB46BD42434591088018CB514FCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_13E9FB46BD42434591088018CB514FCB" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_13E9FB46BD42434591088018CB514FCB" xlink:type="arc" />
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentNonCashAdditions_CE6EAB1697DD94DBABD38018CB513695_terseLabel_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentNonCashAdditions_CE6EAB1697DD94DBABD38018CB513695" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment purchased but not yet paid</link:label>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentNonCashAdditions_CE6EAB1697DD94DBABD38018CB513695_label_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentNonCashAdditions_CE6EAB1697DD94DBABD38018CB513695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Non-cash Additions</link:label>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentNonCashAdditions_CE6EAB1697DD94DBABD38018CB513695_documentation_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentNonCashAdditions_CE6EAB1697DD94DBABD38018CB513695" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PropertyPlantAndEquipmentNonCashAdditions" xlink:label="loc_mgnx_PropertyPlantAndEquipmentNonCashAdditions_CE6EAB1697DD94DBABD38018CB513695" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PropertyPlantAndEquipmentNonCashAdditions_CE6EAB1697DD94DBABD38018CB513695" xlink:to="lab_mgnx_PropertyPlantAndEquipmentNonCashAdditions_CE6EAB1697DD94DBABD38018CB513695" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_77196894B8CD1D105BEB804EBB57C326_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_77196894B8CD1D105BEB804EBB57C326" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_77196894B8CD1D105BEB804EBB57C326_label_en-US" xlink:label="lab_us-gaap_Depreciation_77196894B8CD1D105BEB804EBB57C326" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_77196894B8CD1D105BEB804EBB57C326" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_77196894B8CD1D105BEB804EBB57C326" xlink:to="lab_us-gaap_Depreciation_77196894B8CD1D105BEB804EBB57C326" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_37B4D4340C0CA2E8624D812471B69C30_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_37B4D4340C0CA2E8624D812471B69C30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_37B4D4340C0CA2E8624D812471B69C30_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_37B4D4340C0CA2E8624D812471B69C30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_37B4D4340C0CA2E8624D812471B69C30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_37B4D4340C0CA2E8624D812471B69C30" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_37B4D4340C0CA2E8624D812471B69C30" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_C8A0C2EADD76B0573144812471BBE802_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_C8A0C2EADD76B0573144812471BBE802" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_C8A0C2EADD76B0573144812471BBE802_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_C8A0C2EADD76B0573144812471BBE802" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_C8A0C2EADD76B0573144812471BBE802" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_C8A0C2EADD76B0573144812471BBE802" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems_C8A0C2EADD76B0573144812471BBE802" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_C269ACC848F57FD78B00812471BB89A5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_C269ACC848F57FD78B00812471BB89A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_C269ACC848F57FD78B00812471BB89A5_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_C269ACC848F57FD78B00812471BB89A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_C269ACC848F57FD78B00812471BB89A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_C269ACC848F57FD78B00812471BB89A5" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_C269ACC848F57FD78B00812471BB89A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_82D2020FE174074D2FC1812471BB0636_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_82D2020FE174074D2FC1812471BB0636" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_82D2020FE174074D2FC1812471BB0636_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_82D2020FE174074D2FC1812471BB0636" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_82D2020FE174074D2FC1812471BB0636" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_82D2020FE174074D2FC1812471BB0636" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_82D2020FE174074D2FC1812471BB0636" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_72CDF964293A0694D171812471BB2B7B_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_72CDF964293A0694D171812471BB2B7B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_72CDF964293A0694D171812471BB2B7B_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_72CDF964293A0694D171812471BB2B7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_72CDF964293A0694D171812471BB2B7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_72CDF964293A0694D171812471BB2B7B" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_72CDF964293A0694D171812471BB2B7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5D6DEF850A9ED5C536BFE2787D327DB1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5D6DEF850A9ED5C536BFE2787D327DB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in Lease Exit Liability</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5D6DEF850A9ED5C536BFE2787D327DB1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5D6DEF850A9ED5C536BFE2787D327DB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5D6DEF850A9ED5C536BFE2787D327DB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5D6DEF850A9ED5C536BFE2787D327DB1" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5D6DEF850A9ED5C536BFE2787D327DB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_70AE22279AA3B04C08BBE2787D3214AE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_70AE22279AA3B04C08BBE2787D3214AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Principal Payments Under Lease Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_70AE22279AA3B04C08BBE2787D3214AE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_70AE22279AA3B04C08BBE2787D3214AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_70AE22279AA3B04C08BBE2787D3214AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_70AE22279AA3B04C08BBE2787D3214AE" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_70AE22279AA3B04C08BBE2787D3214AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_851A7489017F12832D7E7B947AA87804_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_851A7489017F12832D7E7B947AA87804" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_851A7489017F12832D7E7B947AA87804_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_851A7489017F12832D7E7B947AA87804" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_851A7489017F12832D7E7B947AA87804" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_851A7489017F12832D7E7B947AA87804" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_851A7489017F12832D7E7B947AA87804" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DD05EF0ED197DE18A3787B56E63DBC71_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DD05EF0ED197DE18A3787B56E63DBC71" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Shares, Outstanding, Beginning balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DD05EF0ED197DE18A3787B56E63DBC71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DD05EF0ED197DE18A3787B56E63DBC71" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DD05EF0ED197DE18A3787B56E63DBC71" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6D7EEF4CED71CD0E1C297B56E63D2097_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6D7EEF4CED71CD0E1C297B56E63D2097" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6D7EEF4CED71CD0E1C297B56E63D2097_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6D7EEF4CED71CD0E1C297B56E63D2097" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6D7EEF4CED71CD0E1C297B56E63D2097" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6D7EEF4CED71CD0E1C297B56E63D2097" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6D7EEF4CED71CD0E1C297B56E63D2097" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_68F0C88F63F8A3A825457B56E63D206E_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_68F0C88F63F8A3A825457B56E63D206E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares, Exercised or RSUs vested (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_68F0C88F63F8A3A825457B56E63D206E_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_68F0C88F63F8A3A825457B56E63D206E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_68F0C88F63F8A3A825457B56E63D206E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_68F0C88F63F8A3A825457B56E63D206E" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_68F0C88F63F8A3A825457B56E63D206E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B768B984CE56DF297B897B56E63DE238_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B768B984CE56DF297B897B56E63DE238" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares, Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B768B984CE56DF297B897B56E63DE238_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B768B984CE56DF297B897B56E63DE238" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B768B984CE56DF297B897B56E63DE238" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B768B984CE56DF297B897B56E63DE238" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B768B984CE56DF297B897B56E63DE238" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C9D9A5A14F474EF9AD387B56E63D463F_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C9D9A5A14F474EF9AD387B56E63D463F" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Shares, Outstanding, Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C9D9A5A14F474EF9AD387B56E63D463F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C9D9A5A14F474EF9AD387B56E63D463F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C9D9A5A14F474EF9AD387B56E63D463F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_18D73DC35AE70636F3937B56E63DF654_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_18D73DC35AE70636F3937B56E63DF654" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_18D73DC35AE70636F3937B56E63DF654_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_18D73DC35AE70636F3937B56E63DF654" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_18D73DC35AE70636F3937B56E63DF654" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_18D73DC35AE70636F3937B56E63DF654" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_18D73DC35AE70636F3937B56E63DF654" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8F80C4E194B814E473E57B56E63E19C8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8F80C4E194B814E473E57B56E63E19C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8F80C4E194B814E473E57B56E63E19C8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8F80C4E194B814E473E57B56E63E19C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8F80C4E194B814E473E57B56E63E19C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8F80C4E194B814E473E57B56E63E19C8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8F80C4E194B814E473E57B56E63E19C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2734643E0AC45C6279867B951C6E7529_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2734643E0AC45C6279867B951C6E7529" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2734643E0AC45C6279867B951C6E7529_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2734643E0AC45C6279867B951C6E7529" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2734643E0AC45C6279867B951C6E7529" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2734643E0AC45C6279867B951C6E7529" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2734643E0AC45C6279867B951C6E7529" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0450B510BD3844030D927B56E63E873B_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0450B510BD3844030D927B56E63E873B" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price, Outstanding, Beginning balance (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0450B510BD3844030D927B56E63E873B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0450B510BD3844030D927B56E63E873B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0450B510BD3844030D927B56E63E873B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FB8284067CC06111ED067B56E63EDE63_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FB8284067CC06111ED067B56E63EDE63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FB8284067CC06111ED067B56E63EDE63_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FB8284067CC06111ED067B56E63EDE63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FB8284067CC06111ED067B56E63EDE63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FB8284067CC06111ED067B56E63EDE63" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FB8284067CC06111ED067B56E63EDE63" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_FCAFC3A7018FCC78AC8A7B56E63E370A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_FCAFC3A7018FCC78AC8A7B56E63E370A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price, Exercised or RSUs vested(in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_FCAFC3A7018FCC78AC8A7B56E63E370A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_FCAFC3A7018FCC78AC8A7B56E63E370A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_FCAFC3A7018FCC78AC8A7B56E63E370A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_FCAFC3A7018FCC78AC8A7B56E63E370A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_FCAFC3A7018FCC78AC8A7B56E63E370A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_445F6506932803F74E707B56E63EFCA6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_445F6506932803F74E707B56E63EFCA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price, Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_445F6506932803F74E707B56E63EFCA6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_445F6506932803F74E707B56E63EFCA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_445F6506932803F74E707B56E63EFCA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_445F6506932803F74E707B56E63EFCA6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_445F6506932803F74E707B56E63EFCA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B244C0C700E6C3A24A1E7B56E63E8B68_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B244C0C700E6C3A24A1E7B56E63E8B68" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price, Outstanding, Ending balance (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B244C0C700E6C3A24A1E7B56E63E8B68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B244C0C700E6C3A24A1E7B56E63E8B68" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B244C0C700E6C3A24A1E7B56E63E8B68" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_293DA9994CEED7C221A37B56E63E9B16_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_293DA9994CEED7C221A37B56E63E9B16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_293DA9994CEED7C221A37B56E63E9B16_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_293DA9994CEED7C221A37B56E63E9B16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_293DA9994CEED7C221A37B56E63E9B16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_293DA9994CEED7C221A37B56E63E9B16" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_293DA9994CEED7C221A37B56E63E9B16" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_CFA6EE6595037656C18B7B56E63EE8A6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_CFA6EE6595037656C18B7B56E63EE8A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price, Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_CFA6EE6595037656C18B7B56E63EE8A6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_CFA6EE6595037656C18B7B56E63EE8A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_CFA6EE6595037656C18B7B56E63EE8A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_CFA6EE6595037656C18B7B56E63EE8A6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_CFA6EE6595037656C18B7B56E63EE8A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_DE754664C527E1387D117B56E63EF0AE_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_DE754664C527E1387D117B56E63EF0AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contractual term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_DE754664C527E1387D117B56E63EF0AE_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_DE754664C527E1387D117B56E63EF0AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_DE754664C527E1387D117B56E63EF0AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_DE754664C527E1387D117B56E63EF0AE" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_DE754664C527E1387D117B56E63EF0AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BEC67134B7253D13945C7B56E63E4176_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BEC67134B7253D13945C7B56E63E4176" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contractual term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BEC67134B7253D13945C7B56E63E4176_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BEC67134B7253D13945C7B56E63E4176" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BEC67134B7253D13945C7B56E63E4176" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BEC67134B7253D13945C7B56E63E4176" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BEC67134B7253D13945C7B56E63E4176" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_16F0B7749EEE29FE46E17B56E63E30F1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_16F0B7749EEE29FE46E17B56E63E30F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contractual term, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_16F0B7749EEE29FE46E17B56E63E30F1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_16F0B7749EEE29FE46E17B56E63E30F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_16F0B7749EEE29FE46E17B56E63E30F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_16F0B7749EEE29FE46E17B56E63E30F1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_16F0B7749EEE29FE46E17B56E63E30F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F055DFAF49551D7DF1D97B56E63E3491_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F055DFAF49551D7DF1D97B56E63E3491" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, Outstanding, Ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F055DFAF49551D7DF1D97B56E63E3491_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F055DFAF49551D7DF1D97B56E63E3491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F055DFAF49551D7DF1D97B56E63E3491" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F055DFAF49551D7DF1D97B56E63E3491" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F055DFAF49551D7DF1D97B56E63E3491" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_430E4D033624174A32367B56E63E787F_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_430E4D033624174A32367B56E63E787F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_430E4D033624174A32367B56E63E787F_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_430E4D033624174A32367B56E63E787F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_430E4D033624174A32367B56E63E787F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_430E4D033624174A32367B56E63E787F" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_430E4D033624174A32367B56E63E787F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6C75B4315B3D529C96DA7B56E63F55C1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6C75B4315B3D529C96DA7B56E63F55C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6C75B4315B3D529C96DA7B56E63F55C1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6C75B4315B3D529C96DA7B56E63F55C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6C75B4315B3D529C96DA7B56E63F55C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6C75B4315B3D529C96DA7B56E63F55C1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6C75B4315B3D529C96DA7B56E63F55C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5FEA54D2C9D5B73DF3597B56E63FE1E2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5FEA54D2C9D5B73DF3597B56E63FE1E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5FEA54D2C9D5B73DF3597B56E63FE1E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5FEA54D2C9D5B73DF3597B56E63FE1E2" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5FEA54D2C9D5B73DF3597B56E63FE1E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_265A6A6CFDF4208AD2357B56E63FDBDE_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_265A6A6CFDF4208AD2357B56E63FDBDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash proceeds from exercise of stock options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_265A6A6CFDF4208AD2357B56E63FDBDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_265A6A6CFDF4208AD2357B56E63FDBDE" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_265A6A6CFDF4208AD2357B56E63FDBDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4F3F217E21ABB28D066F7B56E63F85B1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4F3F217E21ABB28D066F7B56E63F85B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant-date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4F3F217E21ABB28D066F7B56E63F85B1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4F3F217E21ABB28D066F7B56E63F85B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4F3F217E21ABB28D066F7B56E63F85B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4F3F217E21ABB28D066F7B56E63F85B1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4F3F217E21ABB28D066F7B56E63F85B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9ABE874D1097CA20F3907B56E63FCE83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9ABE874D1097CA20F3907B56E63FCE83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9ABE874D1097CA20F3907B56E63FCE83_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9ABE874D1097CA20F3907B56E63FCE83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9ABE874D1097CA20F3907B56E63FCE83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9ABE874D1097CA20F3907B56E63FCE83" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9ABE874D1097CA20F3907B56E63FCE83" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_5423C16DE41918B87F907B56E63F52A3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_5423C16DE41918B87F907B56E63F52A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_5423C16DE41918B87F907B56E63F52A3_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_5423C16DE41918B87F907B56E63F52A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_5423C16DE41918B87F907B56E63F52A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_5423C16DE41918B87F907B56E63F52A3" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_5423C16DE41918B87F907B56E63F52A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5C339C5D89567D2417F77B56E63FA6D3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5C339C5D89567D2417F77B56E63FA6D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to non-vested stock-based compensation arrangements</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5C339C5D89567D2417F77B56E63FA6D3_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5C339C5D89567D2417F77B56E63FA6D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5C339C5D89567D2417F77B56E63FA6D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5C339C5D89567D2417F77B56E63FA6D3" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5C339C5D89567D2417F77B56E63FA6D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F49F6C23E9408B5AF6DA7B56E63FBDE0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F49F6C23E9408B5AF6DA7B56E63FBDE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F49F6C23E9408B5AF6DA7B56E63FBDE0_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F49F6C23E9408B5AF6DA7B56E63FBDE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F49F6C23E9408B5AF6DA7B56E63FBDE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F49F6C23E9408B5AF6DA7B56E63FBDE0" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F49F6C23E9408B5AF6DA7B56E63FBDE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B413E47485BFCE7A3DE8018CBA4912B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B413E47485BFCE7A3DE8018CBA4912B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B413E47485BFCE7A3DE8018CBA4912B_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B413E47485BFCE7A3DE8018CBA4912B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B413E47485BFCE7A3DE8018CBA4912B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B413E47485BFCE7A3DE8018CBA4912B" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B413E47485BFCE7A3DE8018CBA4912B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_7BC33C99C84E65DE1B7D8018CBA44917_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_7BC33C99C84E65DE1B7D8018CBA44917" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_7BC33C99C84E65DE1B7D8018CBA44917_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_7BC33C99C84E65DE1B7D8018CBA44917" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7BC33C99C84E65DE1B7D8018CBA44917" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7BC33C99C84E65DE1B7D8018CBA44917" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_7BC33C99C84E65DE1B7D8018CBA44917" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2682C61220E20BF841D68018CBA4EFD9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2682C61220E20BF841D68018CBA4EFD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2682C61220E20BF841D68018CBA4EFD9_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2682C61220E20BF841D68018CBA4EFD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2682C61220E20BF841D68018CBA4EFD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2682C61220E20BF841D68018CBA4EFD9" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2682C61220E20BF841D68018CBA4EFD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_B5DBD561D842C95B47C78018CBA41259_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_B5DBD561D842C95B47C78018CBA41259" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_B5DBD561D842C95B47C78018CBA41259_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_B5DBD561D842C95B47C78018CBA41259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_B5DBD561D842C95B47C78018CBA41259" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_B5DBD561D842C95B47C78018CBA41259" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_B5DBD561D842C95B47C78018CBA41259" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_73D62F05E6F270316E918018CBA46D97_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_73D62F05E6F270316E918018CBA46D97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_73D62F05E6F270316E918018CBA46D97_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_73D62F05E6F270316E918018CBA46D97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_73D62F05E6F270316E918018CBA46D97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_73D62F05E6F270316E918018CBA46D97" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_73D62F05E6F270316E918018CBA46D97" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_02C11550F502326B8F738018CBA47976_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_02C11550F502326B8F738018CBA47976" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_02C11550F502326B8F738018CBA47976_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_02C11550F502326B8F738018CBA47976" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_02C11550F502326B8F738018CBA47976" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_02C11550F502326B8F738018CBA47976" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_02C11550F502326B8F738018CBA47976" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_AF45F04F818BF4D3584F8018CBA4E03D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_AF45F04F818BF4D3584F8018CBA4E03D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_AF45F04F818BF4D3584F8018CBA4E03D_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_AF45F04F818BF4D3584F8018CBA4E03D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_AF45F04F818BF4D3584F8018CBA4E03D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_AF45F04F818BF4D3584F8018CBA4E03D" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_AF45F04F818BF4D3584F8018CBA4E03D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_964663B78865213C473A8018CBA4DB09_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_964663B78865213C473A8018CBA4DB09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_964663B78865213C473A8018CBA4DB09_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_964663B78865213C473A8018CBA4DB09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_964663B78865213C473A8018CBA4DB09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_964663B78865213C473A8018CBA4DB09" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_964663B78865213C473A8018CBA4DB09" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_4B7E392130FF6BF9B82F8018CBA479C6_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_4B7E392130FF6BF9B82F8018CBA479C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_4B7E392130FF6BF9B82F8018CBA479C6_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_4B7E392130FF6BF9B82F8018CBA479C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4B7E392130FF6BF9B82F8018CBA479C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_4B7E392130FF6BF9B82F8018CBA479C6" xlink:to="lab_us-gaap_MoneyMarketFundsMember_4B7E392130FF6BF9B82F8018CBA479C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_8A2DF76D2FEAB42A4F928018CBA485E2_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_8A2DF76D2FEAB42A4F928018CBA485E2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S Treasury securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8A2DF76D2FEAB42A4F928018CBA485E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember_8A2DF76D2FEAB42A4F928018CBA485E2" xlink:to="lab_us-gaap_USTreasurySecuritiesMember_8A2DF76D2FEAB42A4F928018CBA485E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_C7DACE2B6FE4F2F9046F8018CBA49E97_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_C7DACE2B6FE4F2F9046F8018CBA49E97" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government-sponsored enterprises</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_C7DACE2B6FE4F2F9046F8018CBA49E97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_C7DACE2B6FE4F2F9046F8018CBA49E97" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_C7DACE2B6FE4F2F9046F8018CBA49E97" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_1649A5829E7615E676F18018CBA4549E_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_1649A5829E7615E676F18018CBA4549E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1649A5829E7615E676F18018CBA4549E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_1649A5829E7615E676F18018CBA4549E" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_1649A5829E7615E676F18018CBA4549E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BC5E68AB294794EB1AB48018CBA40B37_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BC5E68AB294794EB1AB48018CBA40B37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BC5E68AB294794EB1AB48018CBA40B37_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BC5E68AB294794EB1AB48018CBA40B37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BC5E68AB294794EB1AB48018CBA40B37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BC5E68AB294794EB1AB48018CBA40B37" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BC5E68AB294794EB1AB48018CBA40B37" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_DF899FF79A7627DA2A658018CBA440F0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_DF899FF79A7627DA2A658018CBA440F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_DF899FF79A7627DA2A658018CBA440F0_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_DF899FF79A7627DA2A658018CBA440F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_DF899FF79A7627DA2A658018CBA440F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_DF899FF79A7627DA2A658018CBA440F0" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_DF899FF79A7627DA2A658018CBA440F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_AADA64B60DD226F70B2A8018CBA488CE_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_AADA64B60DD226F70B2A8018CBA488CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_AADA64B60DD226F70B2A8018CBA488CE_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_AADA64B60DD226F70B2A8018CBA488CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_AADA64B60DD226F70B2A8018CBA488CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_AADA64B60DD226F70B2A8018CBA488CE" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_AADA64B60DD226F70B2A8018CBA488CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_345FB15D60A5117D7E248056A7E3BD0E_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_345FB15D60A5117D7E248056A7E3BD0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_345FB15D60A5117D7E248056A7E3BD0E_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_345FB15D60A5117D7E248056A7E3BD0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_345FB15D60A5117D7E248056A7E3BD0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_345FB15D60A5117D7E248056A7E3BD0E" xlink:to="lab_us-gaap_AvailableForSaleSecurities_345FB15D60A5117D7E248056A7E3BD0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_756F209E6DCECDEFA26C8018CBA41B55_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_756F209E6DCECDEFA26C8018CBA41B55" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_756F209E6DCECDEFA26C8018CBA41B55_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_756F209E6DCECDEFA26C8018CBA41B55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_756F209E6DCECDEFA26C8018CBA41B55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_756F209E6DCECDEFA26C8018CBA41B55" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_756F209E6DCECDEFA26C8018CBA41B55" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_63ACEAFB4D5665F356F87B56E5077BA9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_63ACEAFB4D5665F356F87B56E5077BA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_63ACEAFB4D5665F356F87B56E5077BA9_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_63ACEAFB4D5665F356F87B56E5077BA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_63ACEAFB4D5665F356F87B56E5077BA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_63ACEAFB4D5665F356F87B56E5077BA9" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_63ACEAFB4D5665F356F87B56E5077BA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_570C5969C5ABA7764E977B56E5079DD5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_570C5969C5ABA7764E977B56E5079DD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property Subject to or Available for Operating Lease [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_570C5969C5ABA7764E977B56E5079DD5_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_570C5969C5ABA7764E977B56E5079DD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property Subject to or Available for Operating Lease [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_570C5969C5ABA7764E977B56E5079DD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_570C5969C5ABA7764E977B56E5079DD5" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_570C5969C5ABA7764E977B56E5079DD5" xlink:type="arc" />
    <link:label id="lab_mgnx_MixedUseOfficeLaboratoryAndManufacturingSpaceMember_2665B3EB7E84B56469C87B56E5072908_terseLabel_en-US" xlink:label="lab_mgnx_MixedUseOfficeLaboratoryAndManufacturingSpaceMember_2665B3EB7E84B56469C87B56E5072908" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office, laboratory and manufacturing space</link:label>
    <link:label id="lab_mgnx_MixedUseOfficeLaboratoryAndManufacturingSpaceMember_2665B3EB7E84B56469C87B56E5072908_label_en-US" xlink:label="lab_mgnx_MixedUseOfficeLaboratoryAndManufacturingSpaceMember_2665B3EB7E84B56469C87B56E5072908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mixed Use Office, Laboratory and Manufacturing Space [Member]</link:label>
    <link:label id="lab_mgnx_MixedUseOfficeLaboratoryAndManufacturingSpaceMember_2665B3EB7E84B56469C87B56E5072908_documentation_en-US" xlink:label="lab_mgnx_MixedUseOfficeLaboratoryAndManufacturingSpaceMember_2665B3EB7E84B56469C87B56E5072908" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to mixed use office, laboratory and manufacturing space property subject to an operating lease.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_MixedUseOfficeLaboratoryAndManufacturingSpaceMember" xlink:label="loc_mgnx_MixedUseOfficeLaboratoryAndManufacturingSpaceMember_2665B3EB7E84B56469C87B56E5072908" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_MixedUseOfficeLaboratoryAndManufacturingSpaceMember_2665B3EB7E84B56469C87B56E5072908" xlink:to="lab_mgnx_MixedUseOfficeLaboratoryAndManufacturingSpaceMember_2665B3EB7E84B56469C87B56E5072908" xlink:type="arc" />
    <link:label id="lab_mgnx_NumberOfLease_3B367D9D07B40BBB4F247B56E5070FFE_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfLease_3B367D9D07B40BBB4F247B56E5070FFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of leases</link:label>
    <link:label id="lab_mgnx_NumberOfLease_3B367D9D07B40BBB4F247B56E5070FFE_label_en-US" xlink:label="lab_mgnx_NumberOfLease_3B367D9D07B40BBB4F247B56E5070FFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Lease</link:label>
    <link:label id="lab_mgnx_NumberOfLease_3B367D9D07B40BBB4F247B56E5070FFE_documentation_en-US" xlink:label="lab_mgnx_NumberOfLease_3B367D9D07B40BBB4F247B56E5070FFE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of lease during the period.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NumberOfLease" xlink:label="loc_mgnx_NumberOfLease_3B367D9D07B40BBB4F247B56E5070FFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfLease_3B367D9D07B40BBB4F247B56E5070FFE" xlink:to="lab_mgnx_NumberOfLease_3B367D9D07B40BBB4F247B56E5070FFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_1B1C749BC293E726192A7B56E5079A61_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_1B1C749BC293E726192A7B56E5079A61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee leasing arrangements, term of operating leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_1B1C749BC293E726192A7B56E5079A61_label_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_1B1C749BC293E726192A7B56E5079A61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Leasing Arrangements, Operating Leases, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_1B1C749BC293E726192A7B56E5079A61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_1B1C749BC293E726192A7B56E5079A61" xlink:to="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_1B1C749BC293E726192A7B56E5079A61" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_7C0A76B6C64BDA3D3F397B56E508C9C4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_7C0A76B6C64BDA3D3F397B56E508C9C4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Lease incentives</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_7C0A76B6C64BDA3D3F397B56E508C9C4_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_7C0A76B6C64BDA3D3F397B56E508C9C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Tenant Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_7C0A76B6C64BDA3D3F397B56E508C9C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_7C0A76B6C64BDA3D3F397B56E508C9C4" xlink:to="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_7C0A76B6C64BDA3D3F397B56E508C9C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRentCredit_614B74843CB30FD418217B56E5083E88_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCredit_614B74843CB30FD418217B56E5083E88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent liability</link:label>
    <link:label id="lab_us-gaap_DeferredRentCredit_614B74843CB30FD418217B56E5083E88_label_en-US" xlink:label="lab_us-gaap_DeferredRentCredit_614B74843CB30FD418217B56E5083E88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Credit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="loc_us-gaap_DeferredRentCredit_614B74843CB30FD418217B56E5083E88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCredit_614B74843CB30FD418217B56E5083E88" xlink:to="lab_us-gaap_DeferredRentCredit_614B74843CB30FD418217B56E5083E88" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_9E07358DC21403B4F7557B56E5086C34_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_9E07358DC21403B4F7557B56E5086C34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_9E07358DC21403B4F7557B56E5086C34_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_9E07358DC21403B4F7557B56E5086C34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_9E07358DC21403B4F7557B56E5086C34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_9E07358DC21403B4F7557B56E5086C34" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet_9E07358DC21403B4F7557B56E5086C34" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum rental payments required under all non-cancelable operating leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D2823456275B7A2B3BD97B56E5086AB7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D2823456275B7A2B3BD97B56E5086AB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D2823456275B7A2B3BD97B56E5086AB7_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D2823456275B7A2B3BD97B56E5086AB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D2823456275B7A2B3BD97B56E5086AB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D2823456275B7A2B3BD97B56E5086AB7" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D2823456275B7A2B3BD97B56E5086AB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_F4F55BC0FB941EF7887A7B56E5085E15_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_F4F55BC0FB941EF7887A7B56E5085E15" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_F4F55BC0FB941EF7887A7B56E5085E15_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_F4F55BC0FB941EF7887A7B56E5085E15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_F4F55BC0FB941EF7887A7B56E5085E15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_F4F55BC0FB941EF7887A7B56E5085E15" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_F4F55BC0FB941EF7887A7B56E5085E15" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_13BED0A565F3150CA30E7B56E509DFA5_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_13BED0A565F3150CA30E7B56E509DFA5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_13BED0A565F3150CA30E7B56E509DFA5_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_13BED0A565F3150CA30E7B56E509DFA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_13BED0A565F3150CA30E7B56E509DFA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_13BED0A565F3150CA30E7B56E509DFA5" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_13BED0A565F3150CA30E7B56E509DFA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_4292863D1F681A36BF577B56E50947BD_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_4292863D1F681A36BF577B56E50947BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_4292863D1F681A36BF577B56E50947BD_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_4292863D1F681A36BF577B56E50947BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_4292863D1F681A36BF577B56E50947BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_4292863D1F681A36BF577B56E50947BD" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_4292863D1F681A36BF577B56E50947BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_3C6D53EE6F5C1F1474B8E2787D60B1A3_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_3C6D53EE6F5C1F1474B8E2787D60B1A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_3C6D53EE6F5C1F1474B8E2787D60B1A3_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_3C6D53EE6F5C1F1474B8E2787D60B1A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_3C6D53EE6F5C1F1474B8E2787D60B1A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_3C6D53EE6F5C1F1474B8E2787D60B1A3" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_3C6D53EE6F5C1F1474B8E2787D60B1A3" xlink:type="arc" />
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_D8EDD228C76C59964A5D6EBE6C784C9F_terseLabel_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_D8EDD228C76C59964A5D6EBE6C784C9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NIAID</link:label>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_D8EDD228C76C59964A5D6EBE6C784C9F_label_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_D8EDD228C76C59964A5D6EBE6C784C9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">National Institute of Allergy and Infectious Diseases [Member]</link:label>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_D8EDD228C76C59964A5D6EBE6C784C9F_documentation_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_D8EDD228C76C59964A5D6EBE6C784C9F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents a collaborators with which entity has an agreement related to contracts and research grants received from U.S. government agencies.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_D8EDD228C76C59964A5D6EBE6C784C9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_D8EDD228C76C59964A5D6EBE6C784C9F" xlink:to="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_D8EDD228C76C59964A5D6EBE6C784C9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D508F0E755FB3D0D3B6B6EBE6C782A16_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D508F0E755FB3D0D3B6B6EBE6C782A16" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaboration And Other Agreements [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D508F0E755FB3D0D3B6B6EBE6C782A16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D508F0E755FB3D0D3B6B6EBE6C782A16" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D508F0E755FB3D0D3B6B6EBE6C782A16" xlink:type="arc" />
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_62971F88F7CB7D51FE796EBE6C78ECA0_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_62971F88F7CB7D51FE796EBE6C78ECA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercialization of molecules</link:label>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_62971F88F7CB7D51FE796EBE6C78ECA0_label_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_62971F88F7CB7D51FE796EBE6C78ECA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Molecules To Be Developed And Commercialized Under Agreement</link:label>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_62971F88F7CB7D51FE796EBE6C78ECA0_documentation_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_62971F88F7CB7D51FE796EBE6C78ECA0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of molecules to be developed and commercialized as per collaboration.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_62971F88F7CB7D51FE796EBE6C78ECA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_62971F88F7CB7D51FE796EBE6C78ECA0" xlink:to="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_62971F88F7CB7D51FE796EBE6C78ECA0" xlink:type="arc" />
    <link:label id="lab_mgnx_FundedValueOfBasePeriod_393F92E19CC540F2B0586EBE6C784D97_verboseLabel_en-US" xlink:label="lab_mgnx_FundedValueOfBasePeriod_393F92E19CC540F2B0586EBE6C784D97" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Base period value</link:label>
    <link:label id="lab_mgnx_FundedValueOfBasePeriod_393F92E19CC540F2B0586EBE6C784D97_label_en-US" xlink:label="lab_mgnx_FundedValueOfBasePeriod_393F92E19CC540F2B0586EBE6C784D97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Funded Value of Base Period</link:label>
    <link:label id="lab_mgnx_FundedValueOfBasePeriod_393F92E19CC540F2B0586EBE6C784D97_documentation_en-US" xlink:label="lab_mgnx_FundedValueOfBasePeriod_393F92E19CC540F2B0586EBE6C784D97" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Funded value of base period</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_FundedValueOfBasePeriod" xlink:label="loc_mgnx_FundedValueOfBasePeriod_393F92E19CC540F2B0586EBE6C784D97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FundedValueOfBasePeriod_393F92E19CC540F2B0586EBE6C784D97" xlink:to="lab_mgnx_FundedValueOfBasePeriod_393F92E19CC540F2B0586EBE6C784D97" xlink:type="arc" />
    <link:label id="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_2062BC623B5F3439583B6EBE6C7836E2_terseLabel_en-US" xlink:label="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_2062BC623B5F3439583B6EBE6C7836E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional development funding options</link:label>
    <link:label id="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_2062BC623B5F3439583B6EBE6C7836E2_label_en-US" xlink:label="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_2062BC623B5F3439583B6EBE6C7836E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional development funding options under agreement</link:label>
    <link:label id="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_2062BC623B5F3439583B6EBE6C7836E2_documentation_en-US" xlink:label="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_2062BC623B5F3439583B6EBE6C7836E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional funding available under agreement at counterparty's option</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:label="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_2062BC623B5F3439583B6EBE6C7836E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_2062BC623B5F3439583B6EBE6C7836E2" xlink:to="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_2062BC623B5F3439583B6EBE6C7836E2" xlink:type="arc" />
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_0BA545EAB14FE9CC5BA16EBE6C784822_terseLabel_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement_0BA545EAB14FE9CC5BA16EBE6C784822" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total potential value</link:label>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_0BA545EAB14FE9CC5BA16EBE6C784822_label_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement_0BA545EAB14FE9CC5BA16EBE6C784822" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total potential value of agreement</link:label>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_0BA545EAB14FE9CC5BA16EBE6C784822_documentation_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement_0BA545EAB14FE9CC5BA16EBE6C784822" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to total potential value under agreement.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_TotalPotentialValueUnderAgreement" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_0BA545EAB14FE9CC5BA16EBE6C784822" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TotalPotentialValueUnderAgreement_0BA545EAB14FE9CC5BA16EBE6C784822" xlink:to="lab_mgnx_TotalPotentialValueUnderAgreement_0BA545EAB14FE9CC5BA16EBE6C784822" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_295D2948086B003D4FA6E2787D5F8A42_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_295D2948086B003D4FA6E2787D5F8A42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_295D2948086B003D4FA6E2787D5F8A42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_295D2948086B003D4FA6E2787D5F8A42" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_295D2948086B003D4FA6E2787D5F8A42" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6F28D96450988C6605BBE2787D5FE780_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6F28D96450988C6605BBE2787D5FE780" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Nature of Operations</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6F28D96450988C6605BBE2787D5FE780_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6F28D96450988C6605BBE2787D5FE780" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6F28D96450988C6605BBE2787D5FE780" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6F28D96450988C6605BBE2787D5FE780" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6F28D96450988C6605BBE2787D5FE780" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_EC32FCF036863127E69963E495572981_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_EC32FCF036863127E69963E495572981" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_EC32FCF036863127E69963E495572981_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_EC32FCF036863127E69963E495572981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_EC32FCF036863127E69963E495572981" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_EC32FCF036863127E69963E495572981" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_EC32FCF036863127E69963E495572981" xlink:type="arc" />
    <link:label id="lab_mgnx_LaboratoryAndOfficeEquipmentMember_BBCB0AECF7DED513648A63E49557E20F_terseLabel_en-US" xlink:label="lab_mgnx_LaboratoryAndOfficeEquipmentMember_BBCB0AECF7DED513648A63E49557E20F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory and office equipment</link:label>
    <link:label id="lab_mgnx_LaboratoryAndOfficeEquipmentMember_BBCB0AECF7DED513648A63E49557E20F_label_en-US" xlink:label="lab_mgnx_LaboratoryAndOfficeEquipmentMember_BBCB0AECF7DED513648A63E49557E20F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory and Office Equipment [Member]</link:label>
    <link:label id="lab_mgnx_LaboratoryAndOfficeEquipmentMember_BBCB0AECF7DED513648A63E49557E20F_documentation_en-US" xlink:label="lab_mgnx_LaboratoryAndOfficeEquipmentMember_BBCB0AECF7DED513648A63E49557E20F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A facility that provides controlled conditions in which scientific or technological research, experiments, and measurement may be performed. and tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember" xlink:label="loc_mgnx_LaboratoryAndOfficeEquipmentMember_BBCB0AECF7DED513648A63E49557E20F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LaboratoryAndOfficeEquipmentMember_BBCB0AECF7DED513648A63E49557E20F" xlink:to="lab_mgnx_LaboratoryAndOfficeEquipmentMember_BBCB0AECF7DED513648A63E49557E20F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_54E703147FF9A7A6510963E495578764_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_54E703147FF9A7A6510963E495578764" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_54E703147FF9A7A6510963E495578764_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_54E703147FF9A7A6510963E495578764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_54E703147FF9A7A6510963E495578764" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_54E703147FF9A7A6510963E495578764" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_54E703147FF9A7A6510963E495578764" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_50CBA480ACD6DD15170E63E49557455C_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_50CBA480ACD6DD15170E63E49557455C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_50CBA480ACD6DD15170E63E49557455C_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_50CBA480ACD6DD15170E63E49557455C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_50CBA480ACD6DD15170E63E49557455C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_50CBA480ACD6DD15170E63E49557455C" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_50CBA480ACD6DD15170E63E49557455C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5207DB836497731954558018CAA47E11_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5207DB836497731954558018CAA47E11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States federal tax at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5207DB836497731954558018CAA47E11_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5207DB836497731954558018CAA47E11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5207DB836497731954558018CAA47E11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5207DB836497731954558018CAA47E11" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5207DB836497731954558018CAA47E11" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E740E90F54431FFCDC708018CAA420C4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E740E90F54431FFCDC708018CAA420C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State taxes (net of federal benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E740E90F54431FFCDC708018CAA420C4_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E740E90F54431FFCDC708018CAA420C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E740E90F54431FFCDC708018CAA420C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E740E90F54431FFCDC708018CAA420C4" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E740E90F54431FFCDC708018CAA420C4" xlink:type="arc" />
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_F2AE1D12755FD3FE082F8018CAA474E2_terseLabel_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_F2AE1D12755FD3FE082F8018CAA474E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax adjustments</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_F2AE1D12755FD3FE082F8018CAA474E2_label_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_F2AE1D12755FD3FE082F8018CAA474E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deferred Tax Adjustments, Amount</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_F2AE1D12755FD3FE082F8018CAA474E2_documentation_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_F2AE1D12755FD3FE082F8018CAA474E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_F2AE1D12755FD3FE082F8018CAA474E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_F2AE1D12755FD3FE082F8018CAA474E2" xlink:to="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_F2AE1D12755FD3FE082F8018CAA474E2" xlink:type="arc" />
    <link:label id="lab_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_10E66059BF31040CAA528018CAA417A4_negatedLabel_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_10E66059BF31040CAA528018CAA417A4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred state blended rate adjustments</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_10E66059BF31040CAA528018CAA417A4_label_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_10E66059BF31040CAA528018CAA417A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation State Deferred Taxes Adjustments, Amount</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_10E66059BF31040CAA528018CAA417A4_documentation_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_10E66059BF31040CAA528018CAA417A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred state blended rate adjustments.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount" xlink:label="loc_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_10E66059BF31040CAA528018CAA417A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_10E66059BF31040CAA528018CAA417A4" xlink:to="lab_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_10E66059BF31040CAA528018CAA417A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_042867A45153AA38A82A8018CAA43C3E_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_042867A45153AA38A82A8018CAA43C3E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research credit, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_042867A45153AA38A82A8018CAA43C3E_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_042867A45153AA38A82A8018CAA43C3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_042867A45153AA38A82A8018CAA43C3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_042867A45153AA38A82A8018CAA43C3E" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_042867A45153AA38A82A8018CAA43C3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDeductions_40CFBB72049A940D74C58018CAA481C3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDeductions_40CFBB72049A940D74C58018CAA481C3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Transaction cost deduction</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDeductions_40CFBB72049A940D74C58018CAA481C3_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDeductions_40CFBB72049A940D74C58018CAA481C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationDeductions" xlink:label="loc_us-gaap_IncomeTaxReconciliationDeductions_40CFBB72049A940D74C58018CAA481C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationDeductions_40CFBB72049A940D74C58018CAA481C3" xlink:to="lab_us-gaap_IncomeTaxReconciliationDeductions_40CFBB72049A940D74C58018CAA481C3" xlink:type="arc" />
    <link:label id="lab_mgnx_IncomeTaxRateReconciliationDeductionPriorYearAdjustment_AA6C336EE00B251F7B0A8018CAA495FD_negatedLabel_en-US" xlink:label="lab_mgnx_IncomeTaxRateReconciliationDeductionPriorYearAdjustment_AA6C336EE00B251F7B0A8018CAA495FD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Transaction cost deduction - prior year adjustment</link:label>
    <link:label id="lab_mgnx_IncomeTaxRateReconciliationDeductionPriorYearAdjustment_AA6C336EE00B251F7B0A8018CAA495FD_label_en-US" xlink:label="lab_mgnx_IncomeTaxRateReconciliationDeductionPriorYearAdjustment_AA6C336EE00B251F7B0A8018CAA495FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Rate Reconciliation, Deduction, Prior Year Adjustment</link:label>
    <link:label id="lab_mgnx_IncomeTaxRateReconciliationDeductionPriorYearAdjustment_AA6C336EE00B251F7B0A8018CAA495FD_documentation_en-US" xlink:label="lab_mgnx_IncomeTaxRateReconciliationDeductionPriorYearAdjustment_AA6C336EE00B251F7B0A8018CAA495FD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deductions. Including, but not limited to, extraterritorial income exclusion deduction, qualified production activity deduction, dividend deduction, deduction for dividend paid to employee stock ownership plan, Medicare prescription drug benefit subsidy deduction, and other deductions related to prior year adjustment.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_IncomeTaxRateReconciliationDeductionPriorYearAdjustment" xlink:label="loc_mgnx_IncomeTaxRateReconciliationDeductionPriorYearAdjustment_AA6C336EE00B251F7B0A8018CAA495FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncomeTaxRateReconciliationDeductionPriorYearAdjustment_AA6C336EE00B251F7B0A8018CAA495FD" xlink:to="lab_mgnx_IncomeTaxRateReconciliationDeductionPriorYearAdjustment_AA6C336EE00B251F7B0A8018CAA495FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther_55BB7F646AD2C37C377D8018CAA4673C_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther_55BB7F646AD2C37C377D8018CAA4673C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Orphan drug credit, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther_55BB7F646AD2C37C377D8018CAA4673C_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther_55BB7F646AD2C37C377D8018CAA4673C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_55BB7F646AD2C37C377D8018CAA4673C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_55BB7F646AD2C37C377D8018CAA4673C" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther_55BB7F646AD2C37C377D8018CAA4673C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_1386738EA87E943054C98018CAA43DC2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_1386738EA87E943054C98018CAA43DC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other permanent items</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_1386738EA87E943054C98018CAA43DC2_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_1386738EA87E943054C98018CAA43DC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_1386738EA87E943054C98018CAA43DC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_1386738EA87E943054C98018CAA43DC2" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_1386738EA87E943054C98018CAA43DC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_A909826D5CE136827D508018CAA45E21_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_A909826D5CE136827D508018CAA45E21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_A909826D5CE136827D508018CAA45E21_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_A909826D5CE136827D508018CAA45E21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_A909826D5CE136827D508018CAA45E21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_A909826D5CE136827D508018CAA45E21" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_A909826D5CE136827D508018CAA45E21" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9DEA007CF00BC5EBE8C48018CAA48F46_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9DEA007CF00BC5EBE8C48018CAA48F46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9DEA007CF00BC5EBE8C48018CAA48F46_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9DEA007CF00BC5EBE8C48018CAA48F46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9DEA007CF00BC5EBE8C48018CAA48F46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9DEA007CF00BC5EBE8C48018CAA48F46" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9DEA007CF00BC5EBE8C48018CAA48F46" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_E5F76B92E7917EAC3AFA8018CAA4677C_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_E5F76B92E7917EAC3AFA8018CAA4677C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax expense/(benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_E5F76B92E7917EAC3AFA8018CAA4677C_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_E5F76B92E7917EAC3AFA8018CAA4677C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_E5F76B92E7917EAC3AFA8018CAA4677C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_E5F76B92E7917EAC3AFA8018CAA4677C" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_E5F76B92E7917EAC3AFA8018CAA4677C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_10264E3D242ED685916D812472AE891F_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_10264E3D242ED685916D812472AE891F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_10264E3D242ED685916D812472AE891F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_10264E3D242ED685916D812472AE891F" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_10264E3D242ED685916D812472AE891F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_CB012FC7D17ECAF1D98D812472AE03FA_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_CB012FC7D17ECAF1D98D812472AE03FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_CB012FC7D17ECAF1D98D812472AE03FA_label_en-US" xlink:label="lab_us-gaap_StatementTable_CB012FC7D17ECAF1D98D812472AE03FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_CB012FC7D17ECAF1D98D812472AE03FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_CB012FC7D17ECAF1D98D812472AE03FA" xlink:to="lab_us-gaap_StatementTable_CB012FC7D17ECAF1D98D812472AE03FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3E30EB4C37F1FBA69FC2812472AFD33B_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_3E30EB4C37F1FBA69FC2812472AFD33B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3E30EB4C37F1FBA69FC2812472AFD33B_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_3E30EB4C37F1FBA69FC2812472AFD33B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3E30EB4C37F1FBA69FC2812472AFD33B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3E30EB4C37F1FBA69FC2812472AFD33B" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_3E30EB4C37F1FBA69FC2812472AFD33B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_7DD98188CF4E40B00F26812472AF783C_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_7DD98188CF4E40B00F26812472AF783C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_7DD98188CF4E40B00F26812472AF783C_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_7DD98188CF4E40B00F26812472AF783C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7DD98188CF4E40B00F26812472AF783C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_7DD98188CF4E40B00F26812472AF783C" xlink:to="lab_us-gaap_EquityComponentDomain_7DD98188CF4E40B00F26812472AF783C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_EAB849A9C2EF27DEAC5B812472AFFFE8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_EAB849A9C2EF27DEAC5B812472AFFFE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_EAB849A9C2EF27DEAC5B812472AFFFE8_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_EAB849A9C2EF27DEAC5B812472AFFFE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_EAB849A9C2EF27DEAC5B812472AFFFE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_EAB849A9C2EF27DEAC5B812472AFFFE8" xlink:to="lab_us-gaap_CommonStockMember_EAB849A9C2EF27DEAC5B812472AFFFE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_91153E58E9C0BA63A8D9812472AFBCD3_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_91153E58E9C0BA63A8D9812472AFBCD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_91153E58E9C0BA63A8D9812472AFBCD3_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_91153E58E9C0BA63A8D9812472AFBCD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_91153E58E9C0BA63A8D9812472AFBCD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_91153E58E9C0BA63A8D9812472AFBCD3" xlink:to="lab_us-gaap_TreasuryStockMember_91153E58E9C0BA63A8D9812472AFBCD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_D4ED1AE3823319913B8B812472AF5CDA_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_D4ED1AE3823319913B8B812472AF5CDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_D4ED1AE3823319913B8B812472AF5CDA_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_D4ED1AE3823319913B8B812472AF5CDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_D4ED1AE3823319913B8B812472AF5CDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_D4ED1AE3823319913B8B812472AF5CDA" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_D4ED1AE3823319913B8B812472AF5CDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_7C0B8DAB0BB0E5854450812472AF0651_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_7C0B8DAB0BB0E5854450812472AF0651" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_7C0B8DAB0BB0E5854450812472AF0651_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_7C0B8DAB0BB0E5854450812472AF0651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_7C0B8DAB0BB0E5854450812472AF0651" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_7C0B8DAB0BB0E5854450812472AF0651" xlink:to="lab_us-gaap_RetainedEarningsMember_7C0B8DAB0BB0E5854450812472AF0651" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_E5DAE027960D171B5AD0812472AF02F0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_E5DAE027960D171B5AD0812472AF02F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_E5DAE027960D171B5AD0812472AF02F0_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_E5DAE027960D171B5AD0812472AF02F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_E5DAE027960D171B5AD0812472AF02F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_E5DAE027960D171B5AD0812472AF02F0" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_E5DAE027960D171B5AD0812472AF02F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="lab_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_F727B14C93D590FE552A812472AFBC30_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_F727B14C93D590FE552A812472AFBC30" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_F727B14C93D590FE552A812472AFBC30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_F727B14C93D590FE552A812472AFBC30" xlink:to="lab_us-gaap_StockholdersEquity_F727B14C93D590FE552A812472AFBC30" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_6A83F1C077272DC9D425812472AFDB53_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_6A83F1C077272DC9D425812472AFDB53" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_6A83F1C077272DC9D425812472AFDB53_label_en-US" xlink:label="lab_us-gaap_SharesIssued_6A83F1C077272DC9D425812472AFDB53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_6A83F1C077272DC9D425812472AFDB53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_6A83F1C077272DC9D425812472AFDB53" xlink:to="lab_us-gaap_SharesIssued_6A83F1C077272DC9D425812472AFDB53" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B03E9348503C1070A72E812472AFE834_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B03E9348503C1070A72E812472AFE834" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B03E9348503C1070A72E812472AFE834_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B03E9348503C1070A72E812472AFE834" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B03E9348503C1070A72E812472AFE834" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B03E9348503C1070A72E812472AFE834" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B03E9348503C1070A72E812472AFE834" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_B21ECA21EEE56EA6E248812472AF3818_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_B21ECA21EEE56EA6E248812472AF3818" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_B21ECA21EEE56EA6E248812472AF3818_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_B21ECA21EEE56EA6E248812472AF3818" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_B21ECA21EEE56EA6E248812472AF3818" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_B21ECA21EEE56EA6E248812472AF3818" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_B21ECA21EEE56EA6E248812472AF3818" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1CFD1A7B08354C02D850812472AF0DE6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1CFD1A7B08354C02D850812472AF0DE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1CFD1A7B08354C02D850812472AF0DE6_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1CFD1A7B08354C02D850812472AF0DE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1CFD1A7B08354C02D850812472AF0DE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1CFD1A7B08354C02D850812472AF0DE6" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1CFD1A7B08354C02D850812472AF0DE6" xlink:type="arc" />
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_C64BEDAE35EDCDB1003C812472AF4DB5_terseLabel_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_C64BEDAE35EDCDB1003C812472AF4DB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock plan related activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_C64BEDAE35EDCDB1003C812472AF4DB5_label_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_C64BEDAE35EDCDB1003C812472AF4DB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Value Stock Plan Activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_C64BEDAE35EDCDB1003C812472AF4DB5_documentation_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_C64BEDAE35EDCDB1003C812472AF4DB5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of shares issued due to stock plan related activity.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_C64BEDAE35EDCDB1003C812472AF4DB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_C64BEDAE35EDCDB1003C812472AF4DB5" xlink:to="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_C64BEDAE35EDCDB1003C812472AF4DB5" xlink:type="arc" />
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_C9CE46E1290B160E8D63812472B01F90_terseLabel_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_C9CE46E1290B160E8D63812472B01F90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock plan related activity (in shares)</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_C9CE46E1290B160E8D63812472B01F90_label_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_C9CE46E1290B160E8D63812472B01F90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Stock Plan Activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_C9CE46E1290B160E8D63812472B01F90_documentation_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_C9CE46E1290B160E8D63812472B01F90" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares issued due to stock plan related activity.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_C9CE46E1290B160E8D63812472B01F90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_C9CE46E1290B160E8D63812472B01F90" xlink:to="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_C9CE46E1290B160E8D63812472B01F90" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockRetiredParValueMethodAmount_C2E22CD0C3EBB04A8218812472B08B39_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredParValueMethodAmount_C2E22CD0C3EBB04A8218812472B08B39" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Retirement of treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredParValueMethodAmount_C2E22CD0C3EBB04A8218812472B08B39_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredParValueMethodAmount_C2E22CD0C3EBB04A8218812472B08B39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Retired, Par Value Method, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockRetiredParValueMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredParValueMethodAmount_C2E22CD0C3EBB04A8218812472B08B39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredParValueMethodAmount_C2E22CD0C3EBB04A8218812472B08B39" xlink:to="lab_us-gaap_TreasuryStockRetiredParValueMethodAmount_C2E22CD0C3EBB04A8218812472B08B39" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_19921DC2C6E051F66B0A812472B03CBF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired_19921DC2C6E051F66B0A812472B03CBF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Retirement of treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_19921DC2C6E051F66B0A812472B03CBF_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired_19921DC2C6E051F66B0A812472B03CBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Retired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_19921DC2C6E051F66B0A812472B03CBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesRetired_19921DC2C6E051F66B0A812472B03CBF" xlink:to="lab_us-gaap_TreasuryStockSharesRetired_19921DC2C6E051F66B0A812472B03CBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_E7F230EDC3C7568A9EC3812472B0C9DC_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_E7F230EDC3C7568A9EC3812472B0C9DC" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_E7F230EDC3C7568A9EC3812472B0C9DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_E7F230EDC3C7568A9EC3812472B0C9DC" xlink:to="lab_us-gaap_StockholdersEquity_E7F230EDC3C7568A9EC3812472B0C9DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_42FFF9A771B152A0DD2E812472B0335A_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_42FFF9A771B152A0DD2E812472B0335A" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_42FFF9A771B152A0DD2E812472B0335A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_42FFF9A771B152A0DD2E812472B0335A" xlink:to="lab_us-gaap_SharesIssued_42FFF9A771B152A0DD2E812472B0335A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_998361EE925BA3DD137CE2787D4FA9C4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_998361EE925BA3DD137CE2787D4FA9C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_998361EE925BA3DD137CE2787D4FA9C4_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_998361EE925BA3DD137CE2787D4FA9C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_998361EE925BA3DD137CE2787D4FA9C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_998361EE925BA3DD137CE2787D4FA9C4" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_998361EE925BA3DD137CE2787D4FA9C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_A44E65E1F3652B59B7807B56E6A99644_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_A44E65E1F3652B59B7807B56E6A99644" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Fair Value Measurement Financial Assets</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_A44E65E1F3652B59B7807B56E6A99644_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_A44E65E1F3652B59B7807B56E6A99644" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_A44E65E1F3652B59B7807B56E6A99644" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_A44E65E1F3652B59B7807B56E6A99644" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_A44E65E1F3652B59B7807B56E6A99644" xlink:type="arc" />
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_7C3BCB9B6A10F8A33B397B56E6A9CDA9_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_7C3BCB9B6A10F8A33B397B56E6A9CDA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Percentage of Customer Concentration</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_7C3BCB9B6A10F8A33B397B56E6A9CDA9_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_7C3BCB9B6A10F8A33B397B56E6A9CDA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_7C3BCB9B6A10F8A33B397B56E6A9CDA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_7C3BCB9B6A10F8A33B397B56E6A9CDA9" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_7C3BCB9B6A10F8A33B397B56E6A9CDA9" xlink:type="arc" />
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_43800C20444245D457577B56E6A91CDF_terseLabel_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_43800C20444245D457577B56E6A91CDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Useful Lives</link:label>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_43800C20444245D457577B56E6A91CDF_label_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_43800C20444245D457577B56E6A91CDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property Plant And Equipment Estimated Useful Life Table [Text Block]</link:label>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_43800C20444245D457577B56E6A91CDF_documentation_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_43800C20444245D457577B56E6A91CDF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property plant and equipment estimated useful life.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_43800C20444245D457577B56E6A91CDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_43800C20444245D457577B56E6A91CDF" xlink:to="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_43800C20444245D457577B56E6A91CDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_36C18D17463432E8ED567B56E6A9BA85_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_36C18D17463432E8ED567B56E6A9BA85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computation of Basic and Diluted Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_36C18D17463432E8ED567B56E6A9BA85_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_36C18D17463432E8ED567B56E6A9BA85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_36C18D17463432E8ED567B56E6A9BA85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_36C18D17463432E8ED567B56E6A9BA85" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_36C18D17463432E8ED567B56E6A9BA85" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0F5DE2CA29F8C45F39327B56E6A9E024_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0F5DE2CA29F8C45F39327B56E6A9E024" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0F5DE2CA29F8C45F39327B56E6A9E024_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0F5DE2CA29F8C45F39327B56E6A9E024" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0F5DE2CA29F8C45F39327B56E6A9E024" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0F5DE2CA29F8C45F39327B56E6A9E024" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0F5DE2CA29F8C45F39327B56E6A9E024" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_A251F9BBA0CFC6E0E4F626B2D012FA7E_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_A251F9BBA0CFC6E0E4F626B2D012FA7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_A251F9BBA0CFC6E0E4F626B2D012FA7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_A251F9BBA0CFC6E0E4F626B2D012FA7E" xlink:to="lab_us-gaap_IncomeStatementAbstract_A251F9BBA0CFC6E0E4F626B2D012FA7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_99BF6E2A0DC539297AD826B2D0128E83_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_99BF6E2A0DC539297AD826B2D0128E83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_99BF6E2A0DC539297AD826B2D0128E83_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_99BF6E2A0DC539297AD826B2D0128E83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_99BF6E2A0DC539297AD826B2D0128E83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_99BF6E2A0DC539297AD826B2D0128E83" xlink:to="lab_us-gaap_RevenuesAbstract_99BF6E2A0DC539297AD826B2D0128E83" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseAndServicesRevenue_514D4E54A6D3676F623C26B2D0127A05_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServicesRevenue_514D4E54A6D3676F623C26B2D0127A05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from collaborative agreements</link:label>
    <link:label id="lab_us-gaap_LicenseAndServicesRevenue_514D4E54A6D3676F623C26B2D0127A05_label_en-US" xlink:label="lab_us-gaap_LicenseAndServicesRevenue_514D4E54A6D3676F623C26B2D0127A05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License and Services Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_us-gaap_LicenseAndServicesRevenue_514D4E54A6D3676F623C26B2D0127A05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServicesRevenue_514D4E54A6D3676F623C26B2D0127A05" xlink:to="lab_us-gaap_LicenseAndServicesRevenue_514D4E54A6D3676F623C26B2D0127A05" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromGrants_5212E45723619D6F674526B2D012D568_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromGrants_5212E45723619D6F674526B2D012D568" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from government agreements</link:label>
    <link:label id="lab_us-gaap_RevenueFromGrants_5212E45723619D6F674526B2D012D568_label_en-US" xlink:label="lab_us-gaap_RevenueFromGrants_5212E45723619D6F674526B2D012D568" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Grants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_5212E45723619D6F674526B2D012D568" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromGrants_5212E45723619D6F674526B2D012D568" xlink:to="lab_us-gaap_RevenueFromGrants_5212E45723619D6F674526B2D012D568" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_E79DF91D7A4386087EA626B2D012F769_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_E79DF91D7A4386087EA626B2D012F769" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_E79DF91D7A4386087EA626B2D012F769" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_E79DF91D7A4386087EA626B2D012F769" xlink:to="lab_us-gaap_Revenues_E79DF91D7A4386087EA626B2D012F769" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_21F26896F3E4AF08852F26B2D012B77A_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_21F26896F3E4AF08852F26B2D012B77A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_21F26896F3E4AF08852F26B2D012B77A_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_21F26896F3E4AF08852F26B2D012B77A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_21F26896F3E4AF08852F26B2D012B77A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_21F26896F3E4AF08852F26B2D012B77A" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_21F26896F3E4AF08852F26B2D012B77A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_EFA83C6A7B3AF59B898D26B2D0122BA9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_EFA83C6A7B3AF59B898D26B2D0122BA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_EFA83C6A7B3AF59B898D26B2D0122BA9_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_EFA83C6A7B3AF59B898D26B2D0122BA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_EFA83C6A7B3AF59B898D26B2D0122BA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_EFA83C6A7B3AF59B898D26B2D0122BA9" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_EFA83C6A7B3AF59B898D26B2D0122BA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_8F4344F6B29BDCA39B7A26B2D0129E8D_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_8F4344F6B29BDCA39B7A26B2D0129E8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_8F4344F6B29BDCA39B7A26B2D0129E8D_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_8F4344F6B29BDCA39B7A26B2D0129E8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8F4344F6B29BDCA39B7A26B2D0129E8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_8F4344F6B29BDCA39B7A26B2D0129E8D" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_8F4344F6B29BDCA39B7A26B2D0129E8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_154ED61BE0EE5AFDDFFF26B2D012B228_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_154ED61BE0EE5AFDDFFF26B2D012B228" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_154ED61BE0EE5AFDDFFF26B2D012B228_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_154ED61BE0EE5AFDDFFF26B2D012B228" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_154ED61BE0EE5AFDDFFF26B2D012B228" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_154ED61BE0EE5AFDDFFF26B2D012B228" xlink:to="lab_us-gaap_CostsAndExpenses_154ED61BE0EE5AFDDFFF26B2D012B228" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_138C342C7E90BF0ABAB826B2D012F0FF_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_138C342C7E90BF0ABAB826B2D012F0FF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_138C342C7E90BF0ABAB826B2D012F0FF_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_138C342C7E90BF0ABAB826B2D012F0FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_138C342C7E90BF0ABAB826B2D012F0FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_138C342C7E90BF0ABAB826B2D012F0FF" xlink:to="lab_us-gaap_OperatingIncomeLoss_138C342C7E90BF0ABAB826B2D012F0FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_2D0F2DE87641DB4107A126B2D012AB58_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_2D0F2DE87641DB4107A126B2D012AB58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_2D0F2DE87641DB4107A126B2D012AB58_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_2D0F2DE87641DB4107A126B2D012AB58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2D0F2DE87641DB4107A126B2D012AB58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_2D0F2DE87641DB4107A126B2D012AB58" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_2D0F2DE87641DB4107A126B2D012AB58" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_ABA9FBEC640B3E3C46F126B2D0129803_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_ABA9FBEC640B3E3C46F126B2D0129803" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_ABA9FBEC640B3E3C46F126B2D0129803" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_ABA9FBEC640B3E3C46F126B2D0129803" xlink:to="lab_us-gaap_NetIncomeLoss_ABA9FBEC640B3E3C46F126B2D0129803" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_04EEB99C3F40D9056FB426B2D0125F36_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_04EEB99C3F40D9056FB426B2D0125F36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_04EEB99C3F40D9056FB426B2D0125F36_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_04EEB99C3F40D9056FB426B2D0125F36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_04EEB99C3F40D9056FB426B2D0125F36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_04EEB99C3F40D9056FB426B2D0125F36" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_04EEB99C3F40D9056FB426B2D0125F36" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_32FD8983FF9A80C1B4AC26B2D01298F5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_32FD8983FF9A80C1B4AC26B2D01298F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_32FD8983FF9A80C1B4AC26B2D01298F5_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_32FD8983FF9A80C1B4AC26B2D01298F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_32FD8983FF9A80C1B4AC26B2D01298F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_32FD8983FF9A80C1B4AC26B2D01298F5" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_32FD8983FF9A80C1B4AC26B2D01298F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_DEAB840EC61402F9078426B2D012C554_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_DEAB840EC61402F9078426B2D012C554" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_DEAB840EC61402F9078426B2D012C554_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_DEAB840EC61402F9078426B2D012C554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_DEAB840EC61402F9078426B2D012C554" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_DEAB840EC61402F9078426B2D012C554" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_DEAB840EC61402F9078426B2D012C554" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_3BC54984B0F6A5387A4926B2D012DEB3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_3BC54984B0F6A5387A4926B2D012DEB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_3BC54984B0F6A5387A4926B2D012DEB3_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_3BC54984B0F6A5387A4926B2D012DEB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic and Diluted Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_3BC54984B0F6A5387A4926B2D012DEB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_3BC54984B0F6A5387A4926B2D012DEB3" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_3BC54984B0F6A5387A4926B2D012DEB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C77EA85973542266F1FA26B2D01FE3EE_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C77EA85973542266F1FA26B2D01FE3EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted weighted average number of common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C77EA85973542266F1FA26B2D01FE3EE_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C77EA85973542266F1FA26B2D01FE3EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C77EA85973542266F1FA26B2D01FE3EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C77EA85973542266F1FA26B2D01FE3EE" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C77EA85973542266F1FA26B2D01FE3EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_B207023914F0BC0A77CE6731121901A9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_B207023914F0BC0A77CE6731121901A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_B207023914F0BC0A77CE6731121901A9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_B207023914F0BC0A77CE6731121901A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_B207023914F0BC0A77CE6731121901A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B207023914F0BC0A77CE6731121901A9" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_B207023914F0BC0A77CE6731121901A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_5A5D72C29CCF1E89832D6731121ADE2B_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_5A5D72C29CCF1E89832D6731121ADE2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_5A5D72C29CCF1E89832D6731121ADE2B_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_5A5D72C29CCF1E89832D6731121ADE2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5A5D72C29CCF1E89832D6731121ADE2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5A5D72C29CCF1E89832D6731121ADE2B" xlink:to="lab_us-gaap_StatementClassOfStockAxis_5A5D72C29CCF1E89832D6731121ADE2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_33C08EB2B9C599B241296731121A8896_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_33C08EB2B9C599B241296731121A8896" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_33C08EB2B9C599B241296731121A8896_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_33C08EB2B9C599B241296731121A8896" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_33C08EB2B9C599B241296731121A8896" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_33C08EB2B9C599B241296731121A8896" xlink:to="lab_us-gaap_ClassOfStockDomain_33C08EB2B9C599B241296731121A8896" xlink:type="arc" />
    <link:label id="lab_mgnx_UndesignatedPreferredStockMember_63955DD124B708CDB3866731121B5A7D_terseLabel_en-US" xlink:label="lab_mgnx_UndesignatedPreferredStockMember_63955DD124B708CDB3866731121B5A7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated Preferred Stock</link:label>
    <link:label id="lab_mgnx_UndesignatedPreferredStockMember_63955DD124B708CDB3866731121B5A7D_label_en-US" xlink:label="lab_mgnx_UndesignatedPreferredStockMember_63955DD124B708CDB3866731121B5A7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
    <link:label id="lab_mgnx_UndesignatedPreferredStockMember_63955DD124B708CDB3866731121B5A7D_documentation_en-US" xlink:label="lab_mgnx_UndesignatedPreferredStockMember_63955DD124B708CDB3866731121B5A7D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_UndesignatedPreferredStockMember" xlink:label="loc_mgnx_UndesignatedPreferredStockMember_63955DD124B708CDB3866731121B5A7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UndesignatedPreferredStockMember_63955DD124B708CDB3866731121B5A7D" xlink:to="lab_mgnx_UndesignatedPreferredStockMember_63955DD124B708CDB3866731121B5A7D" xlink:type="arc" />
    <link:label id="lab_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_42C168924B28B39DA7DD6731121CF31F_terseLabel_en-US" xlink:label="lab_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_42C168924B28B39DA7DD6731121CF31F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Johnson &amp; Johnson Innovation JJDC, Inc,</link:label>
    <link:label id="lab_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_42C168924B28B39DA7DD6731121CF31F_label_en-US" xlink:label="lab_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_42C168924B28B39DA7DD6731121CF31F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Johnson And Johnson Development Corporation [Member]</link:label>
    <link:label id="lab_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_42C168924B28B39DA7DD6731121CF31F_documentation_en-US" xlink:label="lab_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_42C168924B28B39DA7DD6731121CF31F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents counter party in stock purchase arrangement</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_JohnsonAndJohnsonDevelopmentCorporationMember" xlink:label="loc_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_42C168924B28B39DA7DD6731121CF31F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_42C168924B28B39DA7DD6731121CF31F" xlink:to="lab_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_42C168924B28B39DA7DD6731121CF31F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="lab_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_09D6E4942D15259EA1E767328883DF3C_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_09D6E4942D15259EA1E767328883DF3C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_09D6E4942D15259EA1E767328883DF3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_09D6E4942D15259EA1E767328883DF3C" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_09D6E4942D15259EA1E767328883DF3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_E786C0A21C5BBD3247906731121CA5E0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_E786C0A21C5BBD3247906731121CA5E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_E786C0A21C5BBD3247906731121CA5E0_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_E786C0A21C5BBD3247906731121CA5E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_E786C0A21C5BBD3247906731121CA5E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_E786C0A21C5BBD3247906731121CA5E0" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_E786C0A21C5BBD3247906731121CA5E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_4C4D506E935E099656786731121C466C_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_4C4D506E935E099656786731121C466C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_4C4D506E935E099656786731121C466C_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_4C4D506E935E099656786731121C466C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4C4D506E935E099656786731121C466C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4C4D506E935E099656786731121C466C" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_4C4D506E935E099656786731121C466C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_0ADD0109B59EDC9018846731121CB0ED_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_0ADD0109B59EDC9018846731121CB0ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_0ADD0109B59EDC9018846731121CB0ED_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_0ADD0109B59EDC9018846731121CB0ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_0ADD0109B59EDC9018846731121CB0ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_0ADD0109B59EDC9018846731121CB0ED" xlink:to="lab_us-gaap_PreferredStockSharesIssued_0ADD0109B59EDC9018846731121CB0ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_4E33E8BDB04C14B8F9886731121D84D3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_4E33E8BDB04C14B8F9886731121D84D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_4E33E8BDB04C14B8F9886731121D84D3_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_4E33E8BDB04C14B8F9886731121D84D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4E33E8BDB04C14B8F9886731121D84D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_4E33E8BDB04C14B8F9886731121D84D3" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_4E33E8BDB04C14B8F9886731121D84D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6E51CCAE2109FC4D4BA86731121DF60D_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6E51CCAE2109FC4D4BA86731121DF60D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued or sold (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6E51CCAE2109FC4D4BA86731121DF60D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6E51CCAE2109FC4D4BA86731121DF60D" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6E51CCAE2109FC4D4BA86731121DF60D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_1EE3BB423EEC586A286A6731121D323A_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_1EE3BB423EEC586A286A6731121D323A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_1EE3BB423EEC586A286A6731121D323A_label_en-US" xlink:label="lab_us-gaap_SharePrice_1EE3BB423EEC586A286A6731121D323A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1EE3BB423EEC586A286A6731121D323A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_1EE3BB423EEC586A286A6731121D323A" xlink:to="lab_us-gaap_SharePrice_1EE3BB423EEC586A286A6731121D323A" xlink:type="arc" />
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_6FAFAA138BEB817F3DD16731121DE905_terseLabel_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_6FAFAA138BEB817F3DD16731121DE905" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional shares sold under over-allotments option to underwriter (in shares)</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_6FAFAA138BEB817F3DD16731121DE905_label_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_6FAFAA138BEB817F3DD16731121DE905" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares To Underwriters For Exercise Of Over Allotment Option</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_6FAFAA138BEB817F3DD16731121DE905_documentation_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_6FAFAA138BEB817F3DD16731121DE905" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock issued during period, shares to underwriters for exercise of over allotment option.</link:label>
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_6FAFAA138BEB817F3DD16731121DE905" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_6FAFAA138BEB817F3DD16731121DE905" xlink:to="lab_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_6FAFAA138BEB817F3DD16731121DE905" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5B6A4B37B853453B99706731121D279F_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5B6A4B37B853453B99706731121D279F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5B6A4B37B853453B99706731121D279F_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5B6A4B37B853453B99706731121D279F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5B6A4B37B853453B99706731121D279F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5B6A4B37B853453B99706731121D279F" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5B6A4B37B853453B99706731121D279F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_F8D2464407F90002241F6731121DA17A_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_F8D2464407F90002241F6731121DA17A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_F8D2464407F90002241F6731121DA17A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_F8D2464407F90002241F6731121DA17A" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_F8D2464407F90002241F6731121DA17A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_709BBE6EFB27EFC4FD656731121D626D_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_709BBE6EFB27EFC4FD656731121D626D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds of stock sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_709BBE6EFB27EFC4FD656731121D626D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_709BBE6EFB27EFC4FD656731121D626D" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_709BBE6EFB27EFC4FD656731121D626D" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>mgnx-20161231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreements" xlink:href="mgnx-20161231.xsd#CollaborationAndOtherAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsBoehringerDetails" xlink:href="mgnx-20161231.xsd#CollaborationAndOtherAgreementsBoehringerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsGreenCrossDetails" xlink:href="mgnx-20161231.xsd#CollaborationAndOtherAgreementsGreenCrossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsJanssenBiotechIncDetails" xlink:href="mgnx-20161231.xsd#CollaborationAndOtherAgreementsJanssenBiotechIncDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsNiaidContractDetails" xlink:href="mgnx-20161231.xsd#CollaborationAndOtherAgreementsNiaidContractDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsServierDetails" xlink:href="mgnx-20161231.xsd#CollaborationAndOtherAgreementsServierDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsTakedaDetails" xlink:href="mgnx-20161231.xsd#CollaborationAndOtherAgreementsTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsAndContingencies" xlink:href="mgnx-20161231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsAndContingenciesDetails" xlink:href="mgnx-20161231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsAndContingenciesTables" xlink:href="mgnx-20161231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedBalanceSheets" xlink:href="mgnx-20161231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="mgnx-20161231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="mgnx-20161231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="mgnx-20161231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="mgnx-20161231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/DocumentAndEntityInformation" xlink:href="mgnx-20161231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:href="mgnx-20161231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:href="mgnx-20161231.xsd#EmployeeBenefitPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxes" xlink:href="mgnx-20161231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesComponentsOfCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:href="mgnx-20161231.xsd#IncomeTaxesComponentsOfCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails" xlink:href="mgnx-20161231.xsd#IncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefitDetails" xlink:href="mgnx-20161231.xsd#IncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesTables" xlink:href="mgnx-20161231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiability" xlink:href="mgnx-20161231.xsd#LeaseExitLiability" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiabilityChangesInLeaseExitLiabilityDetails" xlink:href="mgnx-20161231.xsd#LeaseExitLiabilityChangesInLeaseExitLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreementDetails" xlink:href="mgnx-20161231.xsd#LeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiabilityLeaseExitLiabilityNarrativeDetails" xlink:href="mgnx-20161231.xsd#LeaseExitLiabilityLeaseExitLiabilityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiabilityTables" xlink:href="mgnx-20161231.xsd#LeaseExitLiabilityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:href="mgnx-20161231.xsd#MarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:href="mgnx-20161231.xsd#MarketableSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:href="mgnx-20161231.xsd#MarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/OrganizationAndNatureOfOperations" xlink:href="mgnx-20161231.xsd#OrganizationAndNatureOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyAndEquipment" xlink:href="mgnx-20161231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyAndEquipmentDetails" xlink:href="mgnx-20161231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyAndEquipmentTables" xlink:href="mgnx-20161231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited" xlink:href="mgnx-20161231.xsd#QuarterlyFinancialInformationUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:href="mgnx-20161231.xsd#QuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:href="mgnx-20161231.xsd#QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensation" xlink:href="mgnx-20161231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:href="mgnx-20161231.xsd#StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:href="mgnx-20161231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails" xlink:href="mgnx-20161231.xsd#StockBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationTables" xlink:href="mgnx-20161231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:href="mgnx-20161231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:href="mgnx-20161231.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShareDetails" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedLossPerShareDetails" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivableDetails" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarnedDetails" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarnedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilitiesDetails" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="mgnx-20161231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreements" xlink:type="extended">
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_25D237BC0A2795A3E59F8018CA446231" xlink:type="locator" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_63293D1927DD12970AF78018CA4439C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_25D237BC0A2795A3E59F8018CA446231" xlink:to="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_63293D1927DD12970AF78018CA4439C3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsBoehringerDetails" xlink:type="extended">
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_C3299A2E8FA94954969E71703D61072A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3D74486496ED4E42280671703D61D6C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_C3299A2E8FA94954969E71703D61072A" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3D74486496ED4E42280671703D61D6C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_FB8460116201758788A871703D615EAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3D74486496ED4E42280671703D61D6C9" xlink:to="loc_us-gaap_CounterpartyNameAxis_FB8460116201758788A871703D615EAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_469C92AAE54196AC7AA171703D61656D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_FB8460116201758788A871703D615EAC" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_469C92AAE54196AC7AA171703D61656D" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_BoehringerIngelheimMember" xlink:label="loc_mgnx_BoehringerIngelheimMember_5469441C8D05CE6BB6B871703D610228" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_469C92AAE54196AC7AA171703D61656D" xlink:to="loc_mgnx_BoehringerIngelheimMember_5469441C8D05CE6BB6B871703D610228" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DF63ACAB5591470CA75371703D62C48A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3D74486496ED4E42280671703D61D6C9" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DF63ACAB5591470CA75371703D62C48A" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_AA8B19DA3215EA1BF38771703D6203E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DF63ACAB5591470CA75371703D62C48A" xlink:to="loc_mgnx_NonRefundableUpfrontFees_AA8B19DA3215EA1BF38771703D6203E4" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NumberOfAnnualMaintenancePaymentReceived" xlink:label="loc_mgnx_NumberOfAnnualMaintenancePaymentReceived_A4893ABF8CECFE444CD871703D62AFEC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DF63ACAB5591470CA75371703D62C48A" xlink:to="loc_mgnx_NumberOfAnnualMaintenancePaymentReceived_A4893ABF8CECFE444CD871703D62AFEC" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_B7193704E669B021ED0D71703D674EAD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DF63ACAB5591470CA75371703D62C48A" xlink:to="loc_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_B7193704E669B021ED0D71703D674EAD" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_9A94F7724CE89A9C1BC171703D67DCB3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DF63ACAB5591470CA75371703D62C48A" xlink:to="loc_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_9A94F7724CE89A9C1BC171703D67DCB3" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_64E84716F49477A2F0A771703D67AC48" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DF63ACAB5591470CA75371703D62C48A" xlink:to="loc_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_64E84716F49477A2F0A771703D67AC48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_CB8313AF8055E9B36C6F71703D67F24A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DF63ACAB5591470CA75371703D62C48A" xlink:to="loc_us-gaap_LicensesRevenue_CB8313AF8055E9B36C6F71703D67F24A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_2EA8E108E3EEF5034E7A71703D676712" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DF63ACAB5591470CA75371703D62C48A" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_2EA8E108E3EEF5034E7A71703D676712" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_F9E15538F6959CC4199071703D67133C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DF63ACAB5591470CA75371703D62C48A" xlink:to="loc_us-gaap_DeferredRevenue_F9E15538F6959CC4199071703D67133C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsGreenCrossDetails" xlink:type="extended">
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_CFD2BCF6C741F9462FAB8018CA053BE4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1CFECE300B963EAC580B8018CA05539C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_CFD2BCF6C741F9462FAB8018CA053BE4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1CFECE300B963EAC580B8018CA05539C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_1E4E2D82EC780C55D16A8018CA05FA6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1CFECE300B963EAC580B8018CA05539C" xlink:to="loc_us-gaap_CounterpartyNameAxis_1E4E2D82EC780C55D16A8018CA05FA6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_0038A4F31402BDC101B78018CA051135" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_1E4E2D82EC780C55D16A8018CA05FA6B" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_0038A4F31402BDC101B78018CA051135" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_GreenCrossCorporationMember" xlink:label="loc_mgnx_GreenCrossCorporationMember_39BD72A01460905243098018CA05821D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_0038A4F31402BDC101B78018CA051135" xlink:to="loc_mgnx_GreenCrossCorporationMember_39BD72A01460905243098018CA05821D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_D22603F806F49CB527178018CA0529D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1CFECE300B963EAC580B8018CA05539C" xlink:to="loc_us-gaap_RangeAxis_D22603F806F49CB527178018CA0529D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_4F96BED787BB2542B0528018CA05B0D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_D22603F806F49CB527178018CA0529D7" xlink:to="loc_us-gaap_RangeMember_4F96BED787BB2542B0528018CA05B0D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_62A7DACEE04079F508D38018CA05A4DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_4F96BED787BB2542B0528018CA05B0D8" xlink:to="loc_us-gaap_MaximumMember_62A7DACEE04079F508D38018CA05A4DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D2CD24B3D5A099A2EC88018CA054235" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1CFECE300B963EAC580B8018CA05539C" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D2CD24B3D5A099A2EC88018CA054235" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AggregatePotentialFutureCostReimbursement" xlink:label="loc_mgnx_AggregatePotentialFutureCostReimbursement_4E117FBF3158001C814D8018CA052BED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D2CD24B3D5A099A2EC88018CA054235" xlink:to="loc_mgnx_AggregatePotentialFutureCostReimbursement_4E117FBF3158001C814D8018CA052BED" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_035119394DDC37C666F58018CA0518D5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D2CD24B3D5A099A2EC88018CA054235" xlink:to="loc_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_035119394DDC37C666F58018CA0518D5" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_4394788CBBFC7A06801A8018CA051905" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D2CD24B3D5A099A2EC88018CA054235" xlink:to="loc_mgnx_NonRefundableUpfrontFees_4394788CBBFC7A06801A8018CA051905" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification" xlink:label="loc_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_23BF567B7586791A86A68018CA0598FA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D2CD24B3D5A099A2EC88018CA054235" xlink:to="loc_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_23BF567B7586791A86A68018CA0598FA" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ProceedsFromResearchAndDevelopmentServices" xlink:label="loc_mgnx_ProceedsFromResearchAndDevelopmentServices_CE28AEA80A8565601BA38018CA05EDF2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D2CD24B3D5A099A2EC88018CA054235" xlink:to="loc_mgnx_ProceedsFromResearchAndDevelopmentServices_CE28AEA80A8565601BA38018CA05EDF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_83BB800A2A08F749D3A88018CA05BCA3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D2CD24B3D5A099A2EC88018CA054235" xlink:to="loc_us-gaap_LicensesRevenue_83BB800A2A08F749D3A88018CA05BCA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_62C17DC13C2C2B3ED5DF8018CA05A30B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D2CD24B3D5A099A2EC88018CA054235" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_62C17DC13C2C2B3ED5DF8018CA05A30B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_88004F56E46ADF8135D08018CA059D05" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D2CD24B3D5A099A2EC88018CA054235" xlink:to="loc_us-gaap_DeferredRevenue_88004F56E46ADF8135D08018CA059D05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_B126390B9A454993DD198018CA052F5A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D2CD24B3D5A099A2EC88018CA054235" xlink:to="loc_us-gaap_DeferredRevenueCurrent_B126390B9A454993DD198018CA052F5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_E1C18CD823AF736A89668018CA059D7D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D2CD24B3D5A099A2EC88018CA054235" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_E1C18CD823AF736A89668018CA059D7D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsJanssenBiotechIncDetails" xlink:type="extended">
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_9A0DBB248DE274CDFA327B56E5B2859C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_48C2509E04AD749AAE047B56E5B202C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_9A0DBB248DE274CDFA327B56E5B2859C" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_48C2509E04AD749AAE047B56E5B202C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E81694074AE68E92E4887B56E5B2727B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_48C2509E04AD749AAE047B56E5B202C8" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E81694074AE68E92E4887B56E5B2727B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_E41145BACC315758EEFB7B56E5B25F50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E81694074AE68E92E4887B56E5B2727B" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_E41145BACC315758EEFB7B56E5B25F50" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_JanssenMGD011AgreementMember" xlink:label="loc_mgnx_JanssenMGD011AgreementMember_73F55F2702F5E907FFB57B56E5B2907D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_E41145BACC315758EEFB7B56E5B25F50" xlink:to="loc_mgnx_JanssenMGD011AgreementMember_73F55F2702F5E907FFB57B56E5B2907D" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_JanssenMGD015AgreementMember" xlink:label="loc_mgnx_JanssenMGD015AgreementMember_CB4C3521CF1FDD65E28D7B56E5B24FC4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_E41145BACC315758EEFB7B56E5B25F50" xlink:to="loc_mgnx_JanssenMGD015AgreementMember_CB4C3521CF1FDD65E28D7B56E5B24FC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_8BAEF8803012296591EE7B56E5B291C7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_48C2509E04AD749AAE047B56E5B202C8" xlink:to="loc_us-gaap_CounterpartyNameAxis_8BAEF8803012296591EE7B56E5B291C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_B705433F480AE1C0EF257B56E5B2E1C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_8BAEF8803012296591EE7B56E5B291C7" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_B705433F480AE1C0EF257B56E5B2E1C1" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_JanssenBiotechIncMember" xlink:label="loc_mgnx_JanssenBiotechIncMember_ECD474B40DB42AE394F27B56E5B34C78" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_B705433F480AE1C0EF257B56E5B2E1C1" xlink:to="loc_mgnx_JanssenBiotechIncMember_ECD474B40DB42AE394F27B56E5B34C78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_4DEBE84C3BD1CFA03E0B7B56E5B38D11" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_48C2509E04AD749AAE047B56E5B202C8" xlink:to="loc_us-gaap_RangeAxis_4DEBE84C3BD1CFA03E0B7B56E5B38D11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9CEAAE11413472DFEDA27B56E5B38995" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_4DEBE84C3BD1CFA03E0B7B56E5B38D11" xlink:to="loc_us-gaap_RangeMember_9CEAAE11413472DFEDA27B56E5B38995" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9FC330C081F75498AC477B56E5B34D84" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9CEAAE11413472DFEDA27B56E5B38995" xlink:to="loc_us-gaap_MaximumMember_9FC330C081F75498AC477B56E5B34D84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_48C2509E04AD749AAE047B56E5B202C8" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7280D67ADA2259D3E50D7B56E5B36F5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7280D67ADA2259D3E50D7B56E5B36F5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_22BC30B8F2DE70A4F2647B56E5B4C816" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_22BC30B8F2DE70A4F2647B56E5B4C816" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_DC28316E7DD1B2475BAE7B56E5B52C58" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_mgnx_NonRefundableUpfrontFees_DC28316E7DD1B2475BAE7B56E5B52C58" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PotentialClinicalMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_061A4BFA2FA3CA989ECF7B56E5B43C53" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_061A4BFA2FA3CA989ECF7B56E5B43C53" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_801977226E250240E59F7B56E5B4CAB9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_801977226E250240E59F7B56E5B4CAB9" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PotentialSalesMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_31A98A22CC274496C5967B56E5B43A6E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_31A98A22CC274496C5967B56E5B43A6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_920B2DFD6F0F39514DBA7B56E5B4CA18" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_920B2DFD6F0F39514DBA7B56E5B4CA18" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PremiumReceivedOnStockPurchase" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase_72880FFB1CA4476A50627B56E5B441A8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_mgnx_PremiumReceivedOnStockPurchase_72880FFB1CA4476A50627B56E5B441A8" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_TotalConsideration" xlink:label="loc_mgnx_TotalConsideration_C93C1F1C55BE1FDCF5977B56E5B4EF2C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_mgnx_TotalConsideration_C93C1F1C55BE1FDCF5977B56E5B4EF2C" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AmountAllocatedToEquity" xlink:label="loc_mgnx_AmountAllocatedToEquity_9FC85C98CDBDF4E9AD4E7B56E5B4E95E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_mgnx_AmountAllocatedToEquity_9FC85C98CDBDF4E9AD4E7B56E5B4E95E" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AmountAllocatedToLicenseAndRD" xlink:label="loc_mgnx_AmountAllocatedToLicenseAndRD_E17E4BC8DDC31D1683977B56E5B42580" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_mgnx_AmountAllocatedToLicenseAndRD_E17E4BC8DDC31D1683977B56E5B42580" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ClinicalMilestoneEarnedDuringPeriod" xlink:label="loc_mgnx_ClinicalMilestoneEarnedDuringPeriod_4E21EAAC25907AFDE4767B56E5B5015C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_mgnx_ClinicalMilestoneEarnedDuringPeriod_4E21EAAC25907AFDE4767B56E5B5015C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_B5921C027F2C604ACDC37B56E5B5A805" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7A6F75B7598954EA715B7B56E5B321B1" xlink:to="loc_us-gaap_LicensesRevenue_B5921C027F2C604ACDC37B56E5B5A805" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsNiaidContractDetails" xlink:type="extended">
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_36370C08B4337CAFFA916EBE6C776DDE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3A3F6FB2BBC7D7A045E26EBE6C77B077" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_36370C08B4337CAFFA916EBE6C776DDE" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3A3F6FB2BBC7D7A045E26EBE6C77B077" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_F863BB68622C0BAA71E66EBE6C780AC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3A3F6FB2BBC7D7A045E26EBE6C77B077" xlink:to="loc_us-gaap_CounterpartyNameAxis_F863BB68622C0BAA71E66EBE6C780AC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_2C384615DABE8AAAF8BF6EBE6C782993" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_F863BB68622C0BAA71E66EBE6C780AC4" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_2C384615DABE8AAAF8BF6EBE6C782993" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_D8EDD228C76C59964A5D6EBE6C784C9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_2C384615DABE8AAAF8BF6EBE6C782993" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_D8EDD228C76C59964A5D6EBE6C784C9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_61197FE0BA62791EBF986EBE6C784EE3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3A3F6FB2BBC7D7A045E26EBE6C77B077" xlink:to="loc_us-gaap_RangeAxis_61197FE0BA62791EBF986EBE6C784EE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_C575C1ADEBC011FD19CF6EBE6C78FA41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_61197FE0BA62791EBF986EBE6C784EE3" xlink:to="loc_us-gaap_RangeMember_C575C1ADEBC011FD19CF6EBE6C78FA41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_10AFFA39E58502420E336EBE6C781323" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_C575C1ADEBC011FD19CF6EBE6C78FA41" xlink:to="loc_us-gaap_MaximumMember_10AFFA39E58502420E336EBE6C781323" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D508F0E755FB3D0D3B6B6EBE6C782A16" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3A3F6FB2BBC7D7A045E26EBE6C77B077" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D508F0E755FB3D0D3B6B6EBE6C782A16" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_62971F88F7CB7D51FE796EBE6C78ECA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D508F0E755FB3D0D3B6B6EBE6C782A16" xlink:to="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_62971F88F7CB7D51FE796EBE6C78ECA0" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_FundedValueOfBasePeriod" xlink:label="loc_mgnx_FundedValueOfBasePeriod_393F92E19CC540F2B0586EBE6C784D97" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D508F0E755FB3D0D3B6B6EBE6C782A16" xlink:to="loc_mgnx_FundedValueOfBasePeriod_393F92E19CC540F2B0586EBE6C784D97" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:label="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_2062BC623B5F3439583B6EBE6C7836E2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D508F0E755FB3D0D3B6B6EBE6C782A16" xlink:to="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_2062BC623B5F3439583B6EBE6C7836E2" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_TotalPotentialValueUnderAgreement" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_0BA545EAB14FE9CC5BA16EBE6C784822" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D508F0E755FB3D0D3B6B6EBE6C782A16" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_0BA545EAB14FE9CC5BA16EBE6C784822" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_1253D8ED1F879ED2BECD6EBE6C78B541" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D508F0E755FB3D0D3B6B6EBE6C782A16" xlink:to="loc_us-gaap_LicensesRevenue_1253D8ED1F879ED2BECD6EBE6C78B541" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsServierDetails" xlink:type="extended">
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_C36DF39BF727C2CBC82171703B7A8267" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F4F1501FF422B41F997F71703B7AFB4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_C36DF39BF727C2CBC82171703B7A8267" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F4F1501FF422B41F997F71703B7AFB4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_A09F588E6ACCF09F8A1971703B7A5659" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F4F1501FF422B41F997F71703B7AFB4E" xlink:to="loc_us-gaap_CounterpartyNameAxis_A09F588E6ACCF09F8A1971703B7A5659" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_6F03D20BCCA3A953FF9371703B7A6450" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_A09F588E6ACCF09F8A1971703B7A5659" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_6F03D20BCCA3A953FF9371703B7A6450" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ServierMember" xlink:label="loc_mgnx_ServierMember_E850E973D4548F6A614C71703B7A486F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_6F03D20BCCA3A953FF9371703B7A6450" xlink:to="loc_mgnx_ServierMember_E850E973D4548F6A614C71703B7A486F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2F04D245E467693C0AA871703B7A215D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F4F1501FF422B41F997F71703B7AFB4E" xlink:to="loc_us-gaap_RangeAxis_2F04D245E467693C0AA871703B7A215D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1137A52A97FA2D4B5AAF71703B7A748F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_2F04D245E467693C0AA871703B7A215D" xlink:to="loc_us-gaap_RangeMember_1137A52A97FA2D4B5AAF71703B7A748F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_74E4AAD6012E9306AFF371703B7A9085" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_1137A52A97FA2D4B5AAF71703B7A748F" xlink:to="loc_us-gaap_MaximumMember_74E4AAD6012E9306AFF371703B7A9085" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C66929EC5FCB2B9CE20D71703B7AC91B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F4F1501FF422B41F997F71703B7AFB4E" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C66929EC5FCB2B9CE20D71703B7AC91B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B2D1C6FAFF3386693BA671703B7AA891" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C66929EC5FCB2B9CE20D71703B7AC91B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B2D1C6FAFF3386693BA671703B7AA891" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ServierDARTMember" xlink:label="loc_mgnx_ServierDARTMember_E4780B4BEA24DC1CE9D271703B7AAB38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B2D1C6FAFF3386693BA671703B7AA891" xlink:to="loc_mgnx_ServierDARTMember_E4780B4BEA24DC1CE9D271703B7AAB38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F4F1501FF422B41F997F71703B7AFB4E" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_C256648B20CF61B4E41A71703B7B66F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_NonRefundableUpfrontFees_C256648B20CF61B4E41A71703B7B66F3" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PotentialLicenseFee" xlink:label="loc_mgnx_PotentialLicenseFee_A94510199FED7ADC837A71703B7BC210" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_PotentialLicenseFee_A94510199FED7ADC837A71703B7BC210" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PotentialClinicalMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_3C09C9A27B1DF524BA3271703B7B85D5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_3C09C9A27B1DF524BA3271703B7B85D5" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_3FC1331EAE3E6D4A633A71703B805B82" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_3FC1331EAE3E6D4A633A71703B805B82" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PotentialSalesMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_2D5C15569E488E586FD871703B80464A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_2D5C15569E488E586FD871703B80464A" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_OriginalPeriodOfDevelopment" xlink:label="loc_mgnx_OriginalPeriodOfDevelopment_FC2DE2FB50165E29972C71703B8048D1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_OriginalPeriodOfDevelopment_FC2DE2FB50165E29972C71703B8048D1" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod_7DE7AFFC080898A9BCBB71703B815ADA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_UpfrontPaymentRecognitionPeriod_7DE7AFFC080898A9BCBB71703B815ADA" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ChangeInAccountingEstimateCurrentYearImpact" xlink:label="loc_mgnx_ChangeInAccountingEstimateCurrentYearImpact_C30BFBAD7454E3E6EAE971703B81C787" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_ChangeInAccountingEstimateCurrentYearImpact_C30BFBAD7454E3E6EAE971703B81C787" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_OptionExerciseFee" xlink:label="loc_mgnx_OptionExerciseFee_DF9A45F6B99AEE085A0171703B8166F7" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_OptionExerciseFee_DF9A45F6B99AEE085A0171703B8166F7" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_OptionExerciseFeeRecognitionPeriod" xlink:label="loc_mgnx_OptionExerciseFeeRecognitionPeriod_4FA6749FC178CFDBB79E71703B811F27" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_OptionExerciseFeeRecognitionPeriod_4FA6749FC178CFDBB79E71703B811F27" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:label="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_6D24ECE892386EDFFC0071703B8153AD" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_6D24ECE892386EDFFC0071703B8153AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_7383F69EF38B63EC15D271703B81D4D1" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_us-gaap_LicensesRevenue_7383F69EF38B63EC15D271703B81D4D1" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NumberOfMilestonesAchieved" xlink:label="loc_mgnx_NumberOfMilestonesAchieved_2575BBE1DBEF99F840F171703B8129D5" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_NumberOfMilestonesAchieved_2575BBE1DBEF99F840F171703B8129D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_D38F8F8F88CBE120D5A071703B815237" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_D38F8F8F88CBE120D5A071703B815237" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ReviewPeriodByRegulatoryAuthority" xlink:label="loc_mgnx_ReviewPeriodByRegulatoryAuthority_93EF9F959AAAA3C6536B71703B819E5D" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_mgnx_ReviewPeriodByRegulatoryAuthority_93EF9F959AAAA3C6536B71703B819E5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_23A3ED0695096E9F000A71703B8266B2" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_us-gaap_DeferredRevenue_23A3ED0695096E9F000A71703B8266B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_8C0C03B0A13F78CC9BF571703B82CF02" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_us-gaap_DeferredRevenueCurrent_8C0C03B0A13F78CC9BF571703B82CF02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_063CB7EF9BB0B1F449E471703B82E257" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_298C876CB7C8E13F274771703B7B2420" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_063CB7EF9BB0B1F449E471703B82E257" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsTakedaDetails" xlink:type="extended">
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_FEC6281BDDCB29DB15148238ADDCF2FC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BC20E45152D5A1CFF2ED8238ADE15087" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_FEC6281BDDCB29DB15148238ADDCF2FC" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BC20E45152D5A1CFF2ED8238ADE15087" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_BF37B0471873E9213FB68238ADE1196F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BC20E45152D5A1CFF2ED8238ADE15087" xlink:to="loc_us-gaap_CounterpartyNameAxis_BF37B0471873E9213FB68238ADE1196F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9E9F8B73172DFA1D70068238ADE1873F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_BF37B0471873E9213FB68238ADE1196F" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9E9F8B73172DFA1D70068238ADE1873F" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_TakedaMember" xlink:label="loc_mgnx_TakedaMember_B5912AB689FB276D427E8238ADE12923" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9E9F8B73172DFA1D70068238ADE1873F" xlink:to="loc_mgnx_TakedaMember_B5912AB689FB276D427E8238ADE12923" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_65B970DDA5286C692A148238ADE1F821" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BC20E45152D5A1CFF2ED8238ADE15087" xlink:to="loc_us-gaap_TypeOfArrangementAxis_65B970DDA5286C692A148238ADE1F821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A04E4DBBCA122957CF328238ADE2B7C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_65B970DDA5286C692A148238ADE1F821" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A04E4DBBCA122957CF328238ADE2B7C5" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_TakedaMGD010AgreementMember" xlink:label="loc_mgnx_TakedaMGD010AgreementMember_157CC58203FFF1CF37EB8238ADE22FCD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A04E4DBBCA122957CF328238ADE2B7C5" xlink:to="loc_mgnx_TakedaMGD010AgreementMember_157CC58203FFF1CF37EB8238ADE22FCD" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ResearchCollaborationAndLicenseOptionAgreementMember" xlink:label="loc_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_C053AF6554CF0972C8B28238ADE2035C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A04E4DBBCA122957CF328238ADE2B7C5" xlink:to="loc_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_C053AF6554CF0972C8B28238ADE2035C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BC20E45152D5A1CFF2ED8238ADE15087" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_D098FF2B9C5BF5D160988238ADE7B0E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0" xlink:to="loc_mgnx_NonRefundableUpfrontFees_D098FF2B9C5BF5D160988238ADE7B0E4" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_UpfrontFeeAllocatedToAgreement" xlink:label="loc_mgnx_UpfrontFeeAllocatedToAgreement_A95AB039EAC88A6FBD7E8238ADE7AEF4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0" xlink:to="loc_mgnx_UpfrontFeeAllocatedToAgreement_A95AB039EAC88A6FBD7E8238ADE7AEF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_6E93102F9055D0DDC0608238ADE725AA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0" xlink:to="loc_us-gaap_DeferredRevenueCurrent_6E93102F9055D0DDC0608238ADE725AA" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod_CAAE10E950DA18A6540B8238ADE78F53" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0" xlink:to="loc_mgnx_UpfrontPaymentRecognitionPeriod_CAAE10E950DA18A6540B8238ADE78F53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_EA6F33BD660EFB2B6D598238ADE7108F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0" xlink:to="loc_us-gaap_LicensesRevenue_EA6F33BD660EFB2B6D598238ADE7108F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_DCD414A4858D99BA3C078238ADE7451A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_DCD414A4858D99BA3C078238ADE7451A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_2ADACD9D5E2E8B47C5E38238ADE72628" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B1BA1E35877F76AE34D58238ADE29AF0" xlink:to="loc_us-gaap_DeferredRevenue_2ADACD9D5E2E8B47C5E38238ADE72628" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6E9E10995513CFB82307E2787DC55628" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8FA25C58EA1ADEAEC4D4E2787DC5654D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6E9E10995513CFB82307E2787DC55628" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8FA25C58EA1ADEAEC4D4E2787DC5654D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_EDA6002F41A2044259297B56E507C0F6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8AA50227AAB823E1190A7B56E507F957" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_EDA6002F41A2044259297B56E507C0F6" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8AA50227AAB823E1190A7B56E507F957" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_63ACEAFB4D5665F356F87B56E5077BA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8AA50227AAB823E1190A7B56E507F957" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_63ACEAFB4D5665F356F87B56E5077BA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_570C5969C5ABA7764E977B56E5079DD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_63ACEAFB4D5665F356F87B56E5077BA9" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_570C5969C5ABA7764E977B56E5079DD5" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_MixedUseOfficeLaboratoryAndManufacturingSpaceMember" xlink:label="loc_mgnx_MixedUseOfficeLaboratoryAndManufacturingSpaceMember_2665B3EB7E84B56469C87B56E5072908" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_570C5969C5ABA7764E977B56E5079DD5" xlink:to="loc_mgnx_MixedUseOfficeLaboratoryAndManufacturingSpaceMember_2665B3EB7E84B56469C87B56E5072908" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_3160BB29052DE84ED0F37B56E5071EFD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8AA50227AAB823E1190A7B56E507F957" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_3160BB29052DE84ED0F37B56E5071EFD" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_NumberOfLease" xlink:label="loc_mgnx_NumberOfLease_3B367D9D07B40BBB4F247B56E5070FFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3160BB29052DE84ED0F37B56E5071EFD" xlink:to="loc_mgnx_NumberOfLease_3B367D9D07B40BBB4F247B56E5070FFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_1B1C749BC293E726192A7B56E5079A61" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3160BB29052DE84ED0F37B56E5071EFD" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_1B1C749BC293E726192A7B56E5079A61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_7C0A76B6C64BDA3D3F397B56E508C9C4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3160BB29052DE84ED0F37B56E5071EFD" xlink:to="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_7C0A76B6C64BDA3D3F397B56E508C9C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_4E10FA8708C3EF65FCE27B56E508734C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3160BB29052DE84ED0F37B56E5071EFD" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_4E10FA8708C3EF65FCE27B56E508734C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="loc_us-gaap_DeferredRentCredit_614B74843CB30FD418217B56E5083E88" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3160BB29052DE84ED0F37B56E5071EFD" xlink:to="loc_us-gaap_DeferredRentCredit_614B74843CB30FD418217B56E5083E88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_9E07358DC21403B4F7557B56E5086C34" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3160BB29052DE84ED0F37B56E5071EFD" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_9E07358DC21403B4F7557B56E5086C34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3160BB29052DE84ED0F37B56E5071EFD" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2995A349938A715636AA7B56E508373D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2995A349938A715636AA7B56E508373D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6430BDB28797900FF89E7B56E5086BDF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6430BDB28797900FF89E7B56E5086BDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D2823456275B7A2B3BD97B56E5086AB7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D2823456275B7A2B3BD97B56E5086AB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_F4F55BC0FB941EF7887A7B56E5085E15" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_F4F55BC0FB941EF7887A7B56E5085E15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_13BED0A565F3150CA30E7B56E509DFA5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_13BED0A565F3150CA30E7B56E509DFA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_4292863D1F681A36BF577B56E50947BD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_4292863D1F681A36BF577B56E50947BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_400C731C66A28487E1727B56E5097BD5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B127C8039D567B471D1C7B56E508CE7F" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_400C731C66A28487E1727B56E5097BD5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8204643397B901A9972EE2787DBD58DA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_229A4C979FCD37B5758EE2787DBE472D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8204643397B901A9972EE2787DBD58DA" xlink:to="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_229A4C979FCD37B5758EE2787DBE472D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1B4AFF033B74CE3BD325808A11FADE30" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_25A31435B346C570CAD7808A11FA6671" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1B4AFF033B74CE3BD325808A11FADE30" xlink:to="loc_us-gaap_AssetsAbstract_25A31435B346C570CAD7808A11FA6671" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_F01C084948379B61DC29808A11FAE2AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_25A31435B346C570CAD7808A11FA6671" xlink:to="loc_us-gaap_AssetsCurrentAbstract_F01C084948379B61DC29808A11FAE2AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5DC084A376A8E4520966808A11FAEA65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F01C084948379B61DC29808A11FAE2AE" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5DC084A376A8E4520966808A11FAEA65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_9E4BA4E95977DB1DE035808A11FA98C7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F01C084948379B61DC29808A11FAE2AE" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_9E4BA4E95977DB1DE035808A11FA98C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_561BE652A48B1D38FF2A808A11FA5D4F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F01C084948379B61DC29808A11FAE2AE" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_561BE652A48B1D38FF2A808A11FA5D4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_2C7B2A52B4AEBAFE38B7808A11FA8C97" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F01C084948379B61DC29808A11FAE2AE" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_2C7B2A52B4AEBAFE38B7808A11FA8C97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_065482757E2A07F321FE808A11FA37A0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F01C084948379B61DC29808A11FAE2AE" xlink:to="loc_us-gaap_OtherAssets_065482757E2A07F321FE808A11FA37A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_B434CA824E903C62E2E1808A11FA78DC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F01C084948379B61DC29808A11FAE2AE" xlink:to="loc_us-gaap_AssetsCurrent_B434CA824E903C62E2E1808A11FA78DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2724F6590851B6128A67808A11FAAEBF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_25A31435B346C570CAD7808A11FA6671" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2724F6590851B6128A67808A11FAAEBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_B5B0BB4BFB06699D9BDA808A11FA7EF5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_25A31435B346C570CAD7808A11FA6671" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_B5B0BB4BFB06699D9BDA808A11FA7EF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_A00A9A8ECA9FE03CEA27808A11FA57BF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_25A31435B346C570CAD7808A11FA6671" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_A00A9A8ECA9FE03CEA27808A11FA57BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_15713F371DFF9F1563DB808A11FB6825" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_25A31435B346C570CAD7808A11FA6671" xlink:to="loc_us-gaap_Assets_15713F371DFF9F1563DB808A11FB6825" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D15243FF1B983FDCFFB1808A11FB526C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1B4AFF033B74CE3BD325808A11FADE30" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D15243FF1B983FDCFFB1808A11FB526C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_105782DD12EB16B7B5C7808A11FBFBEF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D15243FF1B983FDCFFB1808A11FB526C" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_105782DD12EB16B7B5C7808A11FBFBEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_F3CDEB13CBDF4AD119BE808A11FBB130" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_105782DD12EB16B7B5C7808A11FBFBEF" xlink:to="loc_us-gaap_AccountsPayableCurrent_F3CDEB13CBDF4AD119BE808A11FBB130" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_B972298D63EA9E640B9E808A11FBACFB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_105782DD12EB16B7B5C7808A11FBFBEF" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_B972298D63EA9E640B9E808A11FBACFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_105B67F184003A914A05808A11FB7118" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_105782DD12EB16B7B5C7808A11FBFBEF" xlink:to="loc_us-gaap_DeferredRevenueCurrent_105B67F184003A914A05808A11FB7118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_AA6073BD186E0E4991A9808A11FB1DE1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_105782DD12EB16B7B5C7808A11FBFBEF" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_AA6073BD186E0E4991A9808A11FB1DE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="loc_us-gaap_RestructuringReserveCurrent_9893F4C12C61B4899CAD808A11FB841D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_105782DD12EB16B7B5C7808A11FBFBEF" xlink:to="loc_us-gaap_RestructuringReserveCurrent_9893F4C12C61B4899CAD808A11FB841D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5851DF0C02889FE2F985808A11FBC445" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_105782DD12EB16B7B5C7808A11FBFBEF" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5851DF0C02889FE2F985808A11FBC445" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_C2F9EBA08AEA7C0D7AD0808A11FB1F71" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_105782DD12EB16B7B5C7808A11FBFBEF" xlink:to="loc_us-gaap_LiabilitiesCurrent_C2F9EBA08AEA7C0D7AD0808A11FB1F71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_29CAF2319E6DAC4AECBC808A11FB4CAF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D15243FF1B983FDCFFB1808A11FB526C" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_29CAF2319E6DAC4AECBC808A11FB4CAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_26D1FFBD8AC4446DE67A808A11FBFCDF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D15243FF1B983FDCFFB1808A11FB526C" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_26D1FFBD8AC4446DE67A808A11FBFCDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserveNoncurrent" xlink:label="loc_us-gaap_RestructuringReserveNoncurrent_A953FD5E0F60224EC86D808A11FBBE3E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D15243FF1B983FDCFFB1808A11FB526C" xlink:to="loc_us-gaap_RestructuringReserveNoncurrent_A953FD5E0F60224EC86D808A11FBBE3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_2216168CBB0FA1305BDF808A11FBF81D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D15243FF1B983FDCFFB1808A11FB526C" xlink:to="loc_us-gaap_Liabilities_2216168CBB0FA1305BDF808A11FBF81D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_3445B970731179141A8C808A11FBAB4F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D15243FF1B983FDCFFB1808A11FB526C" xlink:to="loc_us-gaap_StockholdersEquityAbstract_3445B970731179141A8C808A11FBAB4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_65C7F60AA6E8206FD389808A11FBA410" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3445B970731179141A8C808A11FBAB4F" xlink:to="loc_us-gaap_CommonStockValue_65C7F60AA6E8206FD389808A11FBA410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1B710D45A8D1204E4D37808A11FC6061" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3445B970731179141A8C808A11FBAB4F" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1B710D45A8D1204E4D37808A11FC6061" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7A949151E7B4CE3DC143808A11FC4589" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3445B970731179141A8C808A11FBAB4F" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7A949151E7B4CE3DC143808A11FC4589" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8DE9E7BDCDE1FF3736AD808A11FC497C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3445B970731179141A8C808A11FBAB4F" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8DE9E7BDCDE1FF3736AD808A11FC497C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2461818DBE9A5D8D903C808A11FC562F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3445B970731179141A8C808A11FBAB4F" xlink:to="loc_us-gaap_StockholdersEquity_2461818DBE9A5D8D903C808A11FC562F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_FE87D4753BF4C3E772BE808A11FCDBA7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D15243FF1B983FDCFFB1808A11FB526C" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_FE87D4753BF4C3E772BE808A11FCDBA7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_B2566C28E646DBD5B71C638FF17FF146" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1B5C61E61D7076780A31638FF17F473B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B2566C28E646DBD5B71C638FF17FF146" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1B5C61E61D7076780A31638FF17F473B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_38FFB1E8107F63EA08F6638FF17F2ECF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B2566C28E646DBD5B71C638FF17FF146" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_38FFB1E8107F63EA08F6638FF17F2ECF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_CF068793853E8492F2FD638FF17F7EFC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B2566C28E646DBD5B71C638FF17FF146" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_CF068793853E8492F2FD638FF17F7EFC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_9D3F6242DAA32A9F88888018CBC451A0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7DF655EC6C8C444C6A578018CBC4F397" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9D3F6242DAA32A9F88888018CBC451A0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7DF655EC6C8C444C6A578018CBC4F397" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9018C24AEE60D0A5C5838018CBC41448" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7DF655EC6C8C444C6A578018CBC4F397" xlink:to="loc_us-gaap_NetIncomeLoss_9018C24AEE60D0A5C5838018CBC41448" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A269F14C8CB4EED337308018CBC4DE7F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7DF655EC6C8C444C6A578018CBC4F397" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A269F14C8CB4EED337308018CBC4DE7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_39EF082F114C8797CECA803426F9A8DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A269F14C8CB4EED337308018CBC4DE7F" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_39EF082F114C8797CECA803426F9A8DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_5FF06C63256D3962A57B8018CBC45E07" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A269F14C8CB4EED337308018CBC4DE7F" xlink:to="loc_us-gaap_ShareBasedCompensation_5FF06C63256D3962A57B8018CBC45E07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_095CE971AAD59AD73D468018CBC47326" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A269F14C8CB4EED337308018CBC4DE7F" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_095CE971AAD59AD73D468018CBC47326" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_512D2EE9140E5FC7CCA18018CBC43541" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_095CE971AAD59AD73D468018CBC47326" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_512D2EE9140E5FC7CCA18018CBC43541" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_BE632F1BA842331F5E438018CBC49CEA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_095CE971AAD59AD73D468018CBC47326" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_BE632F1BA842331F5E438018CBC49CEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_CDE6DCF6ECA24FFFC1938018CBC4B949" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_095CE971AAD59AD73D468018CBC47326" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_CDE6DCF6ECA24FFFC1938018CBC4B949" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8F58F3B524C2C878FEBE8018CBC4BC6B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_095CE971AAD59AD73D468018CBC47326" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8F58F3B524C2C878FEBE8018CBC4BC6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_D2926A01F683C9BD99A28018CBC41456" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_095CE971AAD59AD73D468018CBC47326" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_D2926A01F683C9BD99A28018CBC41456" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_BF28C5128A49CF086FB68018CBC4212E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_095CE971AAD59AD73D468018CBC47326" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_BF28C5128A49CF086FB68018CBC4212E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:label="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_0F4C761627E3ADBE3C048018CBC4BD47" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_095CE971AAD59AD73D468018CBC47326" xlink:to="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_0F4C761627E3ADBE3C048018CBC4BD47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_C301B4647F4D801DC9C18018CBC44E1D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_095CE971AAD59AD73D468018CBC47326" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_C301B4647F4D801DC9C18018CBC44E1D" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_IncreaseDecreaseInDeferredRent" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent_D13246876CA4760E1BFE8018CBC4B7B4" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_095CE971AAD59AD73D468018CBC47326" xlink:to="loc_mgnx_IncreaseDecreaseInDeferredRent_D13246876CA4760E1BFE8018CBC4B7B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1562E9F32556DBE0DB898018CBC4F261" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_095CE971AAD59AD73D468018CBC47326" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1562E9F32556DBE0DB898018CBC4F261" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_814798065B10DAD46F278018CBC47E66" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7DF655EC6C8C444C6A578018CBC4F397" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_814798065B10DAD46F278018CBC47E66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_24AADBDD614F0726DAC58018CBC4CA33" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9D3F6242DAA32A9F88888018CBC451A0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_24AADBDD614F0726DAC58018CBC4CA33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9EFE2054AA8DF18E93F68018CBC4F7CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_24AADBDD614F0726DAC58018CBC4CA33" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9EFE2054AA8DF18E93F68018CBC4F7CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6BADE614DB515FB436488028669424AA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_24AADBDD614F0726DAC58018CBC4CA33" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6BADE614DB515FB436488028669424AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_04BEC89FD7E092942CEE8018CBC45EA2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_24AADBDD614F0726DAC58018CBC4CA33" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_04BEC89FD7E092942CEE8018CBC45EA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1BE4AB881CA07ED4659A8018CBC41316" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_24AADBDD614F0726DAC58018CBC4CA33" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1BE4AB881CA07ED4659A8018CBC41316" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_554E87F42A18F3AC5D968018CBC4DEC1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9D3F6242DAA32A9F88888018CBC451A0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_554E87F42A18F3AC5D968018CBC4DEC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_870837F8B232B56932578018CBC4B2A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_554E87F42A18F3AC5D968018CBC4DEC1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_870837F8B232B56932578018CBC4B2A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_383587A6525F7A64C7E08018CBC47AE4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_554E87F42A18F3AC5D968018CBC4DEC1" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_383587A6525F7A64C7E08018CBC47AE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2CAC9C07A2820A2108DD8018CBC41643" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_554E87F42A18F3AC5D968018CBC4DEC1" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2CAC9C07A2820A2108DD8018CBC41643" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_D922CEC9097012EEF8808018CBC4B3BD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_554E87F42A18F3AC5D968018CBC4DEC1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_D922CEC9097012EEF8808018CBC4B3BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CCC1106BA4CBC5DA560F8018CBC405C5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9D3F6242DAA32A9F88888018CBC451A0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CCC1106BA4CBC5DA560F8018CBC405C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_BE10972E16F476B3AAD88018CBC4DF5B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9D3F6242DAA32A9F88888018CBC451A0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_BE10972E16F476B3AAD88018CBC4DF5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1DF9250410612F46735B8018CBC4DCC0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9D3F6242DAA32A9F88888018CBC451A0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1DF9250410612F46735B8018CBC4DCC0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_A251F9BBA0CFC6E0E4F626B2D012FA7E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_99BF6E2A0DC539297AD826B2D0128E83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_A251F9BBA0CFC6E0E4F626B2D012FA7E" xlink:to="loc_us-gaap_RevenuesAbstract_99BF6E2A0DC539297AD826B2D0128E83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_us-gaap_LicenseAndServicesRevenue_514D4E54A6D3676F623C26B2D0127A05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_99BF6E2A0DC539297AD826B2D0128E83" xlink:to="loc_us-gaap_LicenseAndServicesRevenue_514D4E54A6D3676F623C26B2D0127A05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_5212E45723619D6F674526B2D012D568" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_99BF6E2A0DC539297AD826B2D0128E83" xlink:to="loc_us-gaap_RevenueFromGrants_5212E45723619D6F674526B2D012D568" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_E79DF91D7A4386087EA626B2D012F769" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_99BF6E2A0DC539297AD826B2D0128E83" xlink:to="loc_us-gaap_Revenues_E79DF91D7A4386087EA626B2D012F769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_21F26896F3E4AF08852F26B2D012B77A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_A251F9BBA0CFC6E0E4F626B2D012FA7E" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_21F26896F3E4AF08852F26B2D012B77A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_EFA83C6A7B3AF59B898D26B2D0122BA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_21F26896F3E4AF08852F26B2D012B77A" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_EFA83C6A7B3AF59B898D26B2D0122BA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8F4344F6B29BDCA39B7A26B2D0129E8D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_21F26896F3E4AF08852F26B2D012B77A" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8F4344F6B29BDCA39B7A26B2D0129E8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_154ED61BE0EE5AFDDFFF26B2D012B228" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_21F26896F3E4AF08852F26B2D012B77A" xlink:to="loc_us-gaap_CostsAndExpenses_154ED61BE0EE5AFDDFFF26B2D012B228" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_138C342C7E90BF0ABAB826B2D012F0FF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_A251F9BBA0CFC6E0E4F626B2D012FA7E" xlink:to="loc_us-gaap_OperatingIncomeLoss_138C342C7E90BF0ABAB826B2D012F0FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2D0F2DE87641DB4107A126B2D012AB58" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_A251F9BBA0CFC6E0E4F626B2D012FA7E" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2D0F2DE87641DB4107A126B2D012AB58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_ABA9FBEC640B3E3C46F126B2D0129803" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_A251F9BBA0CFC6E0E4F626B2D012FA7E" xlink:to="loc_us-gaap_NetIncomeLoss_ABA9FBEC640B3E3C46F126B2D0129803" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_04EEB99C3F40D9056FB426B2D0125F36" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_A251F9BBA0CFC6E0E4F626B2D012FA7E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_04EEB99C3F40D9056FB426B2D0125F36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_32FD8983FF9A80C1B4AC26B2D01298F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_04EEB99C3F40D9056FB426B2D0125F36" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_32FD8983FF9A80C1B4AC26B2D01298F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_DEAB840EC61402F9078426B2D012C554" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_A251F9BBA0CFC6E0E4F626B2D012FA7E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_DEAB840EC61402F9078426B2D012C554" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_3BC54984B0F6A5387A4926B2D012DEB3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_A251F9BBA0CFC6E0E4F626B2D012FA7E" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_3BC54984B0F6A5387A4926B2D012DEB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C77EA85973542266F1FA26B2D01FE3EE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_A251F9BBA0CFC6E0E4F626B2D012FA7E" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C77EA85973542266F1FA26B2D01FE3EE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_10264E3D242ED685916D812472AE891F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_CB012FC7D17ECAF1D98D812472AE03FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_10264E3D242ED685916D812472AE891F" xlink:to="loc_us-gaap_StatementTable_CB012FC7D17ECAF1D98D812472AE03FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3E30EB4C37F1FBA69FC2812472AFD33B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_CB012FC7D17ECAF1D98D812472AE03FA" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3E30EB4C37F1FBA69FC2812472AFD33B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7DD98188CF4E40B00F26812472AF783C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3E30EB4C37F1FBA69FC2812472AFD33B" xlink:to="loc_us-gaap_EquityComponentDomain_7DD98188CF4E40B00F26812472AF783C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_EAB849A9C2EF27DEAC5B812472AFFFE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7DD98188CF4E40B00F26812472AF783C" xlink:to="loc_us-gaap_CommonStockMember_EAB849A9C2EF27DEAC5B812472AFFFE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_91153E58E9C0BA63A8D9812472AFBCD3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7DD98188CF4E40B00F26812472AF783C" xlink:to="loc_us-gaap_TreasuryStockMember_91153E58E9C0BA63A8D9812472AFBCD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_D4ED1AE3823319913B8B812472AF5CDA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7DD98188CF4E40B00F26812472AF783C" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_D4ED1AE3823319913B8B812472AF5CDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_7C0B8DAB0BB0E5854450812472AF0651" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7DD98188CF4E40B00F26812472AF783C" xlink:to="loc_us-gaap_RetainedEarningsMember_7C0B8DAB0BB0E5854450812472AF0651" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_E5DAE027960D171B5AD0812472AF02F0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7DD98188CF4E40B00F26812472AF783C" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_E5DAE027960D171B5AD0812472AF02F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_CB012FC7D17ECAF1D98D812472AE03FA" xlink:to="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_F727B14C93D590FE552A812472AFBC30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_us-gaap_StockholdersEquity_F727B14C93D590FE552A812472AFBC30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_6A83F1C077272DC9D425812472AFDB53" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_us-gaap_SharesIssued_6A83F1C077272DC9D425812472AFDB53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B03E9348503C1070A72E812472AFE834" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B03E9348503C1070A72E812472AFE834" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_B21ECA21EEE56EA6E248812472AF3818" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_B21ECA21EEE56EA6E248812472AF3818" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1CFD1A7B08354C02D850812472AF0DE6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1CFD1A7B08354C02D850812472AF0DE6" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_C64BEDAE35EDCDB1003C812472AF4DB5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_C64BEDAE35EDCDB1003C812472AF4DB5" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_C9CE46E1290B160E8D63812472B01F90" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_C9CE46E1290B160E8D63812472B01F90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockRetiredParValueMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredParValueMethodAmount_C2E22CD0C3EBB04A8218812472B08B39" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_us-gaap_TreasuryStockRetiredParValueMethodAmount_C2E22CD0C3EBB04A8218812472B08B39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_19921DC2C6E051F66B0A812472B03CBF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_19921DC2C6E051F66B0A812472B03CBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_01DF964CA6C6BBB09F1B812472B07A21" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_01DF964CA6C6BBB09F1B812472B07A21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_CC07DC98AD90155B960B812472B06EED" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_us-gaap_NetIncomeLoss_CC07DC98AD90155B960B812472B06EED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_E7F230EDC3C7568A9EC3812472B0C9DC" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_us-gaap_StockholdersEquity_E7F230EDC3C7568A9EC3812472B0C9DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_42FFF9A771B152A0DD2E812472B0335A" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3281C8137DA23BC234AA812472AFDD41" xlink:to="loc_us-gaap_SharesIssued_42FFF9A771B152A0DD2E812472B0335A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_DocumentAndEntityInformationAbstract" xlink:label="loc_mgnx_DocumentAndEntityInformationAbstract_6A75FD2103DF3DF543BB6A261067E995" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_4CF786137F5030F8C3966A261067638C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_6A75FD2103DF3DF543BB6A261067E995" xlink:to="loc_dei_DocumentType_4CF786137F5030F8C3966A261067638C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_7B3F485F6C9EFE60D9B96A261067C630" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_6A75FD2103DF3DF543BB6A261067E995" xlink:to="loc_dei_AmendmentFlag_7B3F485F6C9EFE60D9B96A261067C630" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_847E69D2FDDDF7BFFA496A2610678996" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_6A75FD2103DF3DF543BB6A261067E995" xlink:to="loc_dei_DocumentPeriodEndDate_847E69D2FDDDF7BFFA496A2610678996" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_692BF6714A64F118DE756A261067B8F3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_6A75FD2103DF3DF543BB6A261067E995" xlink:to="loc_dei_DocumentFiscalYearFocus_692BF6714A64F118DE756A261067B8F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_2C42F24801854C3CB9A46A261067D061" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_6A75FD2103DF3DF543BB6A261067E995" xlink:to="loc_dei_DocumentFiscalPeriodFocus_2C42F24801854C3CB9A46A261067D061" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_A55D0FCBC18A7AE38BA76A2610676B00" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_6A75FD2103DF3DF543BB6A261067E995" xlink:to="loc_dei_EntityRegistrantName_A55D0FCBC18A7AE38BA76A2610676B00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_8A301F505B78F55F49546A26106765F7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_6A75FD2103DF3DF543BB6A261067E995" xlink:to="loc_dei_EntityCentralIndexKey_8A301F505B78F55F49546A26106765F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_EA2EFA21290ED300C1F66A261067E37E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_6A75FD2103DF3DF543BB6A261067E995" xlink:to="loc_dei_CurrentFiscalYearEndDate_EA2EFA21290ED300C1F66A261067E37E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_C9CD0FE44474D41A9CE16A26106728E7" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_6A75FD2103DF3DF543BB6A261067E995" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_C9CD0FE44474D41A9CE16A26106728E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_12A84E4208A99E793DB06A2610682C42" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_6A75FD2103DF3DF543BB6A261067E995" xlink:to="loc_dei_EntityCurrentReportingStatus_12A84E4208A99E793DB06A2610682C42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_870AAC14A26B2AA1CDE26A261068DBB2" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_6A75FD2103DF3DF543BB6A261067E995" xlink:to="loc_dei_EntityVoluntaryFilers_870AAC14A26B2AA1CDE26A261068DBB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_EFCDD22130183AE44F756A2610687EB9" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_6A75FD2103DF3DF543BB6A261067E995" xlink:to="loc_dei_EntityFilerCategory_EFCDD22130183AE44F756A2610687EB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_DB7AFFA463CA6A3A3A8E6A26106875EC" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_6A75FD2103DF3DF543BB6A261067E995" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_DB7AFFA463CA6A3A3A8E6A26106875EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_516E188A526E66BA87756A261068428A" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_6A75FD2103DF3DF543BB6A261067E995" xlink:to="loc_dei_EntityPublicFloat_516E188A526E66BA87756A261068428A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5E7AA2736CB2792ECB4CE2787D60524B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_3C6D53EE6F5C1F1474B8E2787D60B1A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5E7AA2736CB2792ECB4CE2787D60524B" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_3C6D53EE6F5C1F1474B8E2787D60B1A3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9D14D7B94ED5B7DBFACFE2787D4DAA37" xlink:type="locator" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:label="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_19927230061B7767DD80E2787D4D52F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9D14D7B94ED5B7DBFACFE2787D4DAA37" xlink:to="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_19927230061B7767DD80E2787D4D52F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_C44C36974A56F3BAFA14E2787D4DEA3E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9D14D7B94ED5B7DBFACFE2787D4DAA37" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_C44C36974A56F3BAFA14E2787D4DEA3E" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:label="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_B463028AA8D91064B1F9E2787D4DF230" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9D14D7B94ED5B7DBFACFE2787D4DAA37" xlink:to="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_B463028AA8D91064B1F9E2787D4DF230" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_F61C1D12380744382B08E2787D4D521A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9D14D7B94ED5B7DBFACFE2787D4DAA37" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_F61C1D12380744382B08E2787D4D521A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_EB043F46E54A5DA57D9EE2787DDEA600" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_52129109A3A778930DA5E2787DDE04E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_EB043F46E54A5DA57D9EE2787DDEA600" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_52129109A3A778930DA5E2787DDE04E2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesComponentsOfCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_884A5348A0F52DD0884881C6E1A3A8C4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_879DD350AFA6943C655881C6E1A344A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_884A5348A0F52DD0884881C6E1A3A8C4" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_879DD350AFA6943C655881C6E1A344A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_53712308FF7471173D4381C6E1A3D2F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_884A5348A0F52DD0884881C6E1A3A8C4" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_53712308FF7471173D4381C6E1A3D2F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_03CE8AB92825231542CA81C6E1A32213" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_53712308FF7471173D4381C6E1A3D2F0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_03CE8AB92825231542CA81C6E1A32213" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_93B1EB2946C3CDA42E4281C6E1A30D7C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_53712308FF7471173D4381C6E1A3D2F0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_93B1EB2946C3CDA42E4281C6E1A30D7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_50E2A852CC99B744CDE181C6E1A32B8B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_53712308FF7471173D4381C6E1A3D2F0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_50E2A852CC99B744CDE181C6E1A32B8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_ECDB30D3197B3311A20E81C6E1A3CFD5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_53712308FF7471173D4381C6E1A3D2F0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_ECDB30D3197B3311A20E81C6E1A3CFD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_1E421C3931F08C37CE4C81C6E1A32269" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_53712308FF7471173D4381C6E1A3D2F0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_1E421C3931F08C37CE4C81C6E1A32269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_AAAA4A255B69A81EE36681C6E1A31063" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_53712308FF7471173D4381C6E1A3D2F0" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_AAAA4A255B69A81EE36681C6E1A31063" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_54649D9CD3703A8C6CDF81C6E1A3C993" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_53712308FF7471173D4381C6E1A3D2F0" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_54649D9CD3703A8C6CDF81C6E1A3C993" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_C31E09E4165396325AA781C6E1A36947" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_53712308FF7471173D4381C6E1A3D2F0" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_C31E09E4165396325AA781C6E1A36947" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_F88424B3002FA00589A981C6E1A338EF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_53712308FF7471173D4381C6E1A3D2F0" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_F88424B3002FA00589A981C6E1A338EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5DFBE74631E7026CE3A081C6E1A302C5" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_53712308FF7471173D4381C6E1A3D2F0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5DFBE74631E7026CE3A081C6E1A302C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_C503D0B3E94B126683CD81C6E1A3E43E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_53712308FF7471173D4381C6E1A3D2F0" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_C503D0B3E94B126683CD81C6E1A3E43E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_33F1D6A09011A13CB0C181C6E1A4F1FC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_884A5348A0F52DD0884881C6E1A3A8C4" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_33F1D6A09011A13CB0C181C6E1A4F1FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_5EC25EC9A75D2FC0FFF381C6E1A48735" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_33F1D6A09011A13CB0C181C6E1A4F1FC" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_5EC25EC9A75D2FC0FFF381C6E1A48735" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_002C66F88F9576ECCEC081C6E1A493EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_33F1D6A09011A13CB0C181C6E1A4F1FC" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_002C66F88F9576ECCEC081C6E1A493EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6D5AD4E8575CDF798DFA81C6E1A40584" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_33F1D6A09011A13CB0C181C6E1A4F1FC" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6D5AD4E8575CDF798DFA81C6E1A40584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_40B5303C872265F55CED81C6E1A4F618" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_884A5348A0F52DD0884881C6E1A3A8C4" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_40B5303C872265F55CED81C6E1A4F618" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_510B41AF2D058E96AF6881C6E1A44AA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_40B5303C872265F55CED81C6E1A4F618" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_510B41AF2D058E96AF6881C6E1A44AA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_EC1D365044E18BDEAE2281C6E1A43DD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_510B41AF2D058E96AF6881C6E1A44AA0" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_EC1D365044E18BDEAE2281C6E1A43DD3" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:label="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_776783359C4089381E1981ED191F79E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_EC1D365044E18BDEAE2281C6E1A43DD3" xlink:to="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_776783359C4089381E1981ED191F79E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_F03722A839302225399781C6E1A472BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_776783359C4089381E1981ED191F79E3" xlink:to="loc_us-gaap_DomesticCountryMember_F03722A839302225399781C6E1A472BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_717FE463C50F4A28505981C6E1A44E18" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_40B5303C872265F55CED81C6E1A4F618" xlink:to="loc_us-gaap_RangeAxis_717FE463C50F4A28505981C6E1A44E18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6AF5D61EB7DF11616CF181C6E1A42DB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_717FE463C50F4A28505981C6E1A44E18" xlink:to="loc_us-gaap_RangeMember_6AF5D61EB7DF11616CF181C6E1A42DB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_99F2AB32A7C2B1EA9F0481C6E1A54C64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6AF5D61EB7DF11616CF181C6E1A42DB2" xlink:to="loc_us-gaap_MinimumMember_99F2AB32A7C2B1EA9F0481C6E1A54C64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7E923DA38AC5DED1D4DC81C6E1A5597E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6AF5D61EB7DF11616CF181C6E1A42DB2" xlink:to="loc_us-gaap_MaximumMember_7E923DA38AC5DED1D4DC81C6E1A5597E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_1CD103690CE608C95F3981C6E1A534E8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_40B5303C872265F55CED81C6E1A4F618" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_1CD103690CE608C95F3981C6E1A534E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_8CFDB9ED3AEB1B05545181C6E1A56D96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1CD103690CE608C95F3981C6E1A534E8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_8CFDB9ED3AEB1B05545181C6E1A56D96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_286E23E1C27FCFA05A5C81C6E1A586AD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1CD103690CE608C95F3981C6E1A534E8" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_286E23E1C27FCFA05A5C81C6E1A586AD" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:label="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_F0C98CE41305590010BA81C6E1A57810" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1CD103690CE608C95F3981C6E1A534E8" xlink:to="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_F0C98CE41305590010BA81C6E1A57810" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:label="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_4D7952121C7C9CE8AA8E81C6E1A53B90" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1CD103690CE608C95F3981C6E1A534E8" xlink:to="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_4D7952121C7C9CE8AA8E81C6E1A53B90" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:label="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_51B20E90CB071CE5DE9281C6E1A57752" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1CD103690CE608C95F3981C6E1A534E8" xlink:to="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_51B20E90CB071CE5DE9281C6E1A57752" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward" xlink:label="loc_mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward_6493347ECFFEF59F32EB81C6E1A5CBCE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1CD103690CE608C95F3981C6E1A534E8" xlink:to="loc_mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward_6493347ECFFEF59F32EB81C6E1A5CBCE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1D7724517777E7B3BA4E8018CA8562AA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_4A4D59B9B69314686D848018CA945B85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1D7724517777E7B3BA4E8018CA8562AA" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_4A4D59B9B69314686D848018CA945B85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_1B49703A559E18AA6DA18018CA94E53E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_4A4D59B9B69314686D848018CA945B85" xlink:to="loc_us-gaap_RangeAxis_1B49703A559E18AA6DA18018CA94E53E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_ADD781FFFE74204F5CE88018CA9463D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_1B49703A559E18AA6DA18018CA94E53E" xlink:to="loc_us-gaap_RangeMember_ADD781FFFE74204F5CE88018CA9463D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_921BB6AE79A9B86976128018CA94091B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_ADD781FFFE74204F5CE88018CA9463D1" xlink:to="loc_us-gaap_MinimumMember_921BB6AE79A9B86976128018CA94091B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_F9B05C39BDF3059A3B6C8018CA94CADE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_4A4D59B9B69314686D848018CA945B85" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_F9B05C39BDF3059A3B6C8018CA94CADE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5ADE9C145D8D296C3AAA8018CA948BE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_F9B05C39BDF3059A3B6C8018CA94CADE" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5ADE9C145D8D296C3AAA8018CA948BE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_AC8CFE953714493042428018CA9482EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5ADE9C145D8D296C3AAA8018CA948BE7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_AC8CFE953714493042428018CA9482EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_16F9DB270951F92FB7208018CA94E54B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5ADE9C145D8D296C3AAA8018CA948BE7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_16F9DB270951F92FB7208018CA94E54B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_62F2F528ED3CAD6BF0088018CA940926" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5ADE9C145D8D296C3AAA8018CA948BE7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_62F2F528ED3CAD6BF0088018CA940926" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_D9CD93D5A3101E2626E08018CA947366" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5ADE9C145D8D296C3AAA8018CA948BE7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_D9CD93D5A3101E2626E08018CA947366" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_E10A48273BC6188F932B8018CA94885C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_F9B05C39BDF3059A3B6C8018CA94CADE" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_E10A48273BC6188F932B8018CA94885C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_F292DA0D667F85CF2FAB8018CA948C71" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_F9B05C39BDF3059A3B6C8018CA94CADE" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_F292DA0D667F85CF2FAB8018CA948C71" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_84034C46CE6B3CE2B5378018CAA41D10" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5207DB836497731954558018CAA47E11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_84034C46CE6B3CE2B5378018CAA41D10" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5207DB836497731954558018CAA47E11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E740E90F54431FFCDC708018CAA420C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_84034C46CE6B3CE2B5378018CAA41D10" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_E740E90F54431FFCDC708018CAA420C4" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_F2AE1D12755FD3FE082F8018CAA474E2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_84034C46CE6B3CE2B5378018CAA41D10" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_F2AE1D12755FD3FE082F8018CAA474E2" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount" xlink:label="loc_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_10E66059BF31040CAA528018CAA417A4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_84034C46CE6B3CE2B5378018CAA41D10" xlink:to="loc_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_10E66059BF31040CAA528018CAA417A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_042867A45153AA38A82A8018CAA43C3E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_84034C46CE6B3CE2B5378018CAA41D10" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_042867A45153AA38A82A8018CAA43C3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationDeductions" xlink:label="loc_us-gaap_IncomeTaxReconciliationDeductions_40CFBB72049A940D74C58018CAA481C3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_84034C46CE6B3CE2B5378018CAA41D10" xlink:to="loc_us-gaap_IncomeTaxReconciliationDeductions_40CFBB72049A940D74C58018CAA481C3" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_IncomeTaxRateReconciliationDeductionPriorYearAdjustment" xlink:label="loc_mgnx_IncomeTaxRateReconciliationDeductionPriorYearAdjustment_AA6C336EE00B251F7B0A8018CAA495FD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_84034C46CE6B3CE2B5378018CAA41D10" xlink:to="loc_mgnx_IncomeTaxRateReconciliationDeductionPriorYearAdjustment_AA6C336EE00B251F7B0A8018CAA495FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_55BB7F646AD2C37C377D8018CAA4673C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_84034C46CE6B3CE2B5378018CAA41D10" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_55BB7F646AD2C37C377D8018CAA4673C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_1386738EA87E943054C98018CAA43DC2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_84034C46CE6B3CE2B5378018CAA41D10" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_1386738EA87E943054C98018CAA43DC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_A909826D5CE136827D508018CAA45E21" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_84034C46CE6B3CE2B5378018CAA41D10" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_A909826D5CE136827D508018CAA45E21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9DEA007CF00BC5EBE8C48018CAA48F46" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_84034C46CE6B3CE2B5378018CAA41D10" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9DEA007CF00BC5EBE8C48018CAA48F46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_E5F76B92E7917EAC3AFA8018CAA4677C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_84034C46CE6B3CE2B5378018CAA41D10" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_E5F76B92E7917EAC3AFA8018CAA4677C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_FFFC96C421105CB8C517E2787D593F7F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_E010B41A86E0B2D3828EE2787D591783" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_FFFC96C421105CB8C517E2787D593F7F" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_E010B41A86E0B2D3828EE2787D591783" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D2A27CAD5D43B88FE0BAE2787D599DA4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_FFFC96C421105CB8C517E2787D593F7F" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D2A27CAD5D43B88FE0BAE2787D599DA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_680CA14A2719374ED000E2787D59E5F5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_FFFC96C421105CB8C517E2787D593F7F" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_680CA14A2719374ED000E2787D59E5F5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/LeaseExitLiability" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5A7C323899F256E195A2E2787D344A68" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_F395594DEAE0EF6F9E3FE2787D342D3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5A7C323899F256E195A2E2787D344A68" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_F395594DEAE0EF6F9E3FE2787D342D3B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/LeaseExitLiabilityChangesInLeaseExitLiabilityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6606CA6565E774CEFF0C8018CA637FF6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_38F8D4F870F2D4DE3A5E8018CA63D026" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6606CA6565E774CEFF0C8018CA637FF6" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_38F8D4F870F2D4DE3A5E8018CA63D026" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_2C55C490960A9CF58B158018CA63C71F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_38F8D4F870F2D4DE3A5E8018CA63D026" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_2C55C490960A9CF58B158018CA63C71F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1AED901A6271EA9CDF338018CA631BBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2C55C490960A9CF58B158018CA63C71F" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1AED901A6271EA9CDF338018CA631BBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="loc_us-gaap_ContractTerminationMember_1F161CB294C08B579DC68018CA63B3D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1AED901A6271EA9CDF338018CA631BBB" xlink:to="loc_us-gaap_ContractTerminationMember_1F161CB294C08B579DC68018CA63B3D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_C2E992743828C37A7B6B8018CA638C0F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_38F8D4F870F2D4DE3A5E8018CA63D026" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_C2E992743828C37A7B6B8018CA638C0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="loc_us-gaap_RestructuringReserveRollForward_0FBDBF0127E7351BFCB48018CA639368" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_C2E992743828C37A7B6B8018CA638C0F" xlink:to="loc_us-gaap_RestructuringReserveRollForward_0FBDBF0127E7351BFCB48018CA639368" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_73C38AFC16A871A175D98018CA635730" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_0FBDBF0127E7351BFCB48018CA639368" xlink:to="loc_us-gaap_RestructuringReserve_73C38AFC16A871A175D98018CA635730" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_D1E1EB3CCC36B0E398578018CA63B128" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_0FBDBF0127E7351BFCB48018CA639368" xlink:to="loc_us-gaap_PaymentsForRestructuring_D1E1EB3CCC36B0E398578018CA63B128" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_382B92F67ED01270AFE18018CA63D9C8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_0FBDBF0127E7351BFCB48018CA639368" xlink:to="loc_us-gaap_RestructuringReserve_382B92F67ED01270AFE18018CA63D9C8" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_AmountOfImmaterialErrorCorrection" xlink:label="loc_mgnx_AmountOfImmaterialErrorCorrection_807916E24E4D53B913218018CA63C9F6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6606CA6565E774CEFF0C8018CA637FF6" xlink:to="loc_mgnx_AmountOfImmaterialErrorCorrection_807916E24E4D53B913218018CA63C9F6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/LeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_B78B47F8EF9616475D24812471B6FBB8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_37B4D4340C0CA2E8624D812471B69C30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_B78B47F8EF9616475D24812471B6FBB8" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_37B4D4340C0CA2E8624D812471B69C30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6A18AC626DCAB38E62A4812471B6C2B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_37B4D4340C0CA2E8624D812471B69C30" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6A18AC626DCAB38E62A4812471B6C2B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9106B0EC1ADE2E684459812471B688DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6A18AC626DCAB38E62A4812471B6C2B7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9106B0EC1ADE2E684459812471B688DA" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_RavenBiotechnologiesIncMember" xlink:label="loc_mgnx_RavenBiotechnologiesIncMember_BB6DE7899F67C6EA219A812471B63B85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9106B0EC1ADE2E684459812471B688DA" xlink:to="loc_mgnx_RavenBiotechnologiesIncMember_BB6DE7899F67C6EA219A812471B63B85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_C8A0C2EADD76B0573144812471BBE802" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_37B4D4340C0CA2E8624D812471B69C30" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_C8A0C2EADD76B0573144812471BBE802" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_C269ACC848F57FD78B00812471BB89A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_C8A0C2EADD76B0573144812471BBE802" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_C269ACC848F57FD78B00812471BB89A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_82D2020FE174074D2FC1812471BB0636" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_C8A0C2EADD76B0573144812471BBE802" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_82D2020FE174074D2FC1812471BB0636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_72CDF964293A0694D171812471BB2B7B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_C8A0C2EADD76B0573144812471BBE802" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_72CDF964293A0694D171812471BB2B7B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/LeaseExitLiabilityLeaseExitLiabilityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_26F03D73AEF76B51649281C6E18DA719" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_DC6900296FEC981F37B381C6E18DF5AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_26F03D73AEF76B51649281C6E18DA719" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_DC6900296FEC981F37B381C6E18DF5AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A41A0515B8E36AAD010881C6E18DD0A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_DC6900296FEC981F37B381C6E18DF5AF" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_A41A0515B8E36AAD010881C6E18DD0A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9CC60582D4F86AE5E54781C6E18DCB08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A41A0515B8E36AAD010881C6E18DD0A4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9CC60582D4F86AE5E54781C6E18DCB08" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_RavenBiotechnologiesIncMember" xlink:label="loc_mgnx_RavenBiotechnologiesIncMember_13966769A856E0A24FD881C6E18DD0C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9CC60582D4F86AE5E54781C6E18DCB08" xlink:to="loc_mgnx_RavenBiotechnologiesIncMember_13966769A856E0A24FD881C6E18DD0C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_BCF1267D87C2CD55082D81C6E18DDAC5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_DC6900296FEC981F37B381C6E18DF5AF" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_BCF1267D87C2CD55082D81C6E18DDAC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_2869C850FBA4F21BA03881C6E18D3AB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_BCF1267D87C2CD55082D81C6E18DDAC5" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_2869C850FBA4F21BA03881C6E18D3AB5" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ReductionInResearchAndDevelopmentExpense" xlink:label="loc_mgnx_ReductionInResearchAndDevelopmentExpense_FCD6959F4C8ACE54059681C6E18DE47F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_BCF1267D87C2CD55082D81C6E18DDAC5" xlink:to="loc_mgnx_ReductionInResearchAndDevelopmentExpense_FCD6959F4C8ACE54059681C6E18DE47F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/LeaseExitLiabilityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_753248D83CDC34D13FEEE2787D327E3F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5D6DEF850A9ED5C536BFE2787D327DB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_753248D83CDC34D13FEEE2787D327E3F" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5D6DEF850A9ED5C536BFE2787D327DB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_70AE22279AA3B04C08BBE2787D3214AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_753248D83CDC34D13FEEE2787D327E3F" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_70AE22279AA3B04C08BBE2787D3214AE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8CAA7B5BC40038AA54F2638FF13BA937" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_DEF7CB17733A9B27BF5F638FF13B8C43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8CAA7B5BC40038AA54F2638FF13BA937" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_DEF7CB17733A9B27BF5F638FF13B8C43" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_DE0828D04810DE3419E6808A11B4F35C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_BB49FAD207D8226B9460808A11B4F365" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_DE0828D04810DE3419E6808A11B4F35C" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_BB49FAD207D8226B9460808A11B4F365" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_1125C6A89C8BA82328A8808A11B4CA88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_BB49FAD207D8226B9460808A11B4F365" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_1125C6A89C8BA82328A8808A11B4CA88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F4DC206234262356C0808A11B4812C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_1125C6A89C8BA82328A8808A11B4CA88" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F4DC206234262356C0808A11B4812C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_E90435EC2490BC47F381808A11B498AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F4DC206234262356C0808A11B4812C" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_E90435EC2490BC47F381808A11B498AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_177B9BB360367B46F05D808A11B4940D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F4DC206234262356C0808A11B4812C" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_177B9BB360367B46F05D808A11B4940D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0F099DB89ACFC2075843808A11B44FCB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F4DC206234262356C0808A11B4812C" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0F099DB89ACFC2075843808A11B44FCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_BB49FAD207D8226B9460808A11B4F365" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C8C1CEE60C6F06A8E6F9808A11B4EECE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C8C1CEE60C6F06A8E6F9808A11B4EECE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F3F5752648435ABAF6BA808A11B5C5D0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F3F5752648435ABAF6BA808A11B5C5D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7FADE19E9D0723723777808A11B523F1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7FADE19E9D0723723777808A11B523F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9A6276B9FBC7C4ABE083808A11B57EB9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9A6276B9FBC7C4ABE083808A11B57EB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_71F09AC3BB9E5A9F6964808A11B580BC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_71F09AC3BB9E5A9F6964808A11B580BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9747A2003B12801932CD808A11B5B032" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9747A2003B12801932CD808A11B5B032" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_F0BF150ABF4436229C3C808A11B526E8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_F0BF150ABF4436229C3C808A11B526E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A681F5C975571D0FFD19808A11B5AA1C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A681F5C975571D0FFD19808A11B5AA1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_5924FD30A8C541C4EA55808A11B52DA0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2F342C2500FA586F3810808A11B4E6D5" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_5924FD30A8C541C4EA55808A11B52DA0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_FC05C2BBC0BB4ED9AB76638FF13937B3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_3042DB7951241700CBE1638FF139D43C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_FC05C2BBC0BB4ED9AB76638FF13937B3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_3042DB7951241700CBE1638FF139D43C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/OrganizationAndNatureOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_295D2948086B003D4FA6E2787D5F8A42" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6F28D96450988C6605BBE2787D5FE780" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_295D2948086B003D4FA6E2787D5F8A42" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6F28D96450988C6605BBE2787D5FE780" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/PropertyAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_EDA3E4DE374648B5E593E2787D4F9CE6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_998361EE925BA3DD137CE2787D4FA9C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_EDA3E4DE374648B5E593E2787D4F9CE6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_998361EE925BA3DD137CE2787D4FA9C4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_22D81B54F19CE3C74F688018CB51A807" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E82984389698DE5BE55D8018CB5113E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_22D81B54F19CE3C74F688018CB51A807" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E82984389698DE5BE55D8018CB5113E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2415B3DBA13379FBFDF08018CB5129F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E82984389698DE5BE55D8018CB5113E9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2415B3DBA13379FBFDF08018CB5129F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CE3F58E789395BAF7FE68018CB5166A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2415B3DBA13379FBFDF08018CB5129F0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CE3F58E789395BAF7FE68018CB5166A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_3BFAA0DB1CC1045D92F98018CB51EC85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CE3F58E789395BAF7FE68018CB5166A3" xlink:to="loc_us-gaap_ComputerEquipmentMember_3BFAA0DB1CC1045D92F98018CB51EC85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_523FC8E441EBF69253FF8018CB51A947" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CE3F58E789395BAF7FE68018CB5166A3" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_523FC8E441EBF69253FF8018CB51A947" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_FurnitureAndOfficeEquipmentMember" xlink:label="loc_mgnx_FurnitureAndOfficeEquipmentMember_846C2E01D468B5EA36F58018CB51F410" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CE3F58E789395BAF7FE68018CB5166A3" xlink:to="loc_mgnx_FurnitureAndOfficeEquipmentMember_846C2E01D468B5EA36F58018CB51F410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_1758D66CF0322FBD5FB88018CB513891" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CE3F58E789395BAF7FE68018CB5166A3" xlink:to="loc_us-gaap_EquipmentMember_1758D66CF0322FBD5FB88018CB513891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_0D6214C3126F10B3D9728018CB5168D7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CE3F58E789395BAF7FE68018CB5166A3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_0D6214C3126F10B3D9728018CB5168D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_FB9B7AD9E97D540768648018CB5197AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E82984389698DE5BE55D8018CB5113E9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_FB9B7AD9E97D540768648018CB5197AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_753E23109D5D5622D98C8018CB514C8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_FB9B7AD9E97D540768648018CB5197AE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_753E23109D5D5622D98C8018CB514C8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7BFB6E2A5DD48AC048BD8018CB51F01A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_FB9B7AD9E97D540768648018CB5197AE" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7BFB6E2A5DD48AC048BD8018CB51F01A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_13E9FB46BD42434591088018CB514FCB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_FB9B7AD9E97D540768648018CB5197AE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_13E9FB46BD42434591088018CB514FCB" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PropertyPlantAndEquipmentNonCashAdditions" xlink:label="loc_mgnx_PropertyPlantAndEquipmentNonCashAdditions_CE6EAB1697DD94DBABD38018CB513695" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_FB9B7AD9E97D540768648018CB5197AE" xlink:to="loc_mgnx_PropertyPlantAndEquipmentNonCashAdditions_CE6EAB1697DD94DBABD38018CB513695" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_77196894B8CD1D105BEB804EBB57C326" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_FB9B7AD9E97D540768648018CB5197AE" xlink:to="loc_us-gaap_Depreciation_77196894B8CD1D105BEB804EBB57C326" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/PropertyAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_041D13D4AE30F83A40BFE2787CC3DD70" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5269A452BF51CB479C99E2787CC4CF87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_041D13D4AE30F83A40BFE2787CC3DD70" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5269A452BF51CB479C99E2787CC4CF87" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_5F996D59CFC5FD88C7EF84277071DB34" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_CCC654BE1B5CC3FB073684277071C446" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_5F996D59CFC5FD88C7EF84277071DB34" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_CCC654BE1B5CC3FB073684277071C446" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_E007C02446E3BCF8DEAA669812288A27" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_D3A6DDCCC3BD3439E60A66981228D1F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_E007C02446E3BCF8DEAA669812288A27" xlink:to="loc_us-gaap_Revenues_D3A6DDCCC3BD3439E60A66981228D1F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_883AD24B528F0DDE6CE3669812285306" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_E007C02446E3BCF8DEAA669812288A27" xlink:to="loc_us-gaap_NetIncomeLoss_883AD24B528F0DDE6CE3669812285306" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_BED7A8D862F9EABE6EB86698122ECE37" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_E007C02446E3BCF8DEAA669812288A27" xlink:to="loc_us-gaap_EarningsPerShareBasic_BED7A8D862F9EABE6EB86698122ECE37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_427C2CEF93379AA84A3E6698122FC8E6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_E007C02446E3BCF8DEAA669812288A27" xlink:to="loc_us-gaap_EarningsPerShareDiluted_427C2CEF93379AA84A3E6698122FC8E6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_E4EDB04CB8F45498A12884277070DDD4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2746EFBDCF79410F6F31842770709D79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_E4EDB04CB8F45498A12884277070DDD4" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2746EFBDCF79410F6F31842770709D79" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8A7C1D36FEA614BE8C86E2787E3FC606" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EE0F63FF01DBF4E087A1E2787E3F2EDD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8A7C1D36FEA614BE8C86E2787E3FC606" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EE0F63FF01DBF4E087A1E2787E3F2EDD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B91022CD614125FB1B63673428EC6691" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E13D86877DBF5543034673428ECE628" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B91022CD614125FB1B63673428EC6691" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E13D86877DBF5543034673428ECE628" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8FA79C5B5EF803F4727D673428ECE8DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E13D86877DBF5543034673428ECE628" xlink:to="loc_us-gaap_RangeAxis_8FA79C5B5EF803F4727D673428ECE8DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_2EBDA709F8AC64020E3C673428ED6F37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_8FA79C5B5EF803F4727D673428ECE8DB" xlink:to="loc_us-gaap_RangeMember_2EBDA709F8AC64020E3C673428ED6F37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8091E1FE8C247E7ABF2B673428ED63DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_2EBDA709F8AC64020E3C673428ED6F37" xlink:to="loc_us-gaap_MinimumMember_8091E1FE8C247E7ABF2B673428ED63DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_D2FCB28BB7549EE88794673428ED6FDD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_2EBDA709F8AC64020E3C673428ED6F37" xlink:to="loc_us-gaap_MaximumMember_D2FCB28BB7549EE88794673428ED6FDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3E8834644647A0BD6D1673428EDF099" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E13D86877DBF5543034673428ECE628" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3E8834644647A0BD6D1673428EDF099" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_92C15AAB943544456CA0673428EDF4AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3E8834644647A0BD6D1673428EDF099" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_92C15AAB943544456CA0673428EDF4AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0CB2AD4BFFFDACDB139D673428ED0886" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3E8834644647A0BD6D1673428EDF099" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0CB2AD4BFFFDACDB139D673428ED0886" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7492F944870E0E516F0E673428EDE89E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3E8834644647A0BD6D1673428EDF099" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7492F944870E0E516F0E673428EDE89E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_88927E134E8DC0355032673428ED8C6F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3E8834644647A0BD6D1673428EDF099" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_88927E134E8DC0355032673428ED8C6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_505DE5B4FD23329F6C5E673428EDEED8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3E8834644647A0BD6D1673428EDF099" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_505DE5B4FD23329F6C5E673428EDEED8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4784989109C6B8D9DEC963E49514B3A7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_978F5271B4C77BEE44E363E495148792" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4784989109C6B8D9DEC963E49514B3A7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_978F5271B4C77BEE44E363E495148792" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_56AC8DD130394A1B23D963E495141D14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_978F5271B4C77BEE44E363E495148792" xlink:to="loc_us-gaap_PlanNameAxis_56AC8DD130394A1B23D963E495141D14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_853BB81E67641DB1603863E495149159" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_56AC8DD130394A1B23D963E495141D14" xlink:to="loc_us-gaap_PlanNameDomain_853BB81E67641DB1603863E495149159" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_EquityIncentivePlan2003Member" xlink:label="loc_mgnx_EquityIncentivePlan2003Member_91A0426E2C014FFD9A2F63E49515FCC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_853BB81E67641DB1603863E495149159" xlink:to="loc_mgnx_EquityIncentivePlan2003Member_91A0426E2C014FFD9A2F63E49515FCC4" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_StockIncentivePlan2013Member" xlink:label="loc_mgnx_StockIncentivePlan2013Member_ABEA052196814BE419DD63E495154370" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_853BB81E67641DB1603863E495149159" xlink:to="loc_mgnx_StockIncentivePlan2013Member_ABEA052196814BE419DD63E495154370" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64FE7CEDA350F41A05F663E495159CE5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_978F5271B4C77BEE44E363E495148792" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64FE7CEDA350F41A05F663E495159CE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_929D5BD1E813114172E663E495150A6C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64FE7CEDA350F41A05F663E495159CE5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_929D5BD1E813114172E663E495150A6C" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_7CCD6C53024196770D8D63E4951559A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64FE7CEDA350F41A05F663E495159CE5" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_7CCD6C53024196770D8D63E4951559A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A4E40369EF3630711DD263E49515B27B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64FE7CEDA350F41A05F663E495159CE5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A4E40369EF3630711DD263E49515B27B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0332A992136B608133E963E495159E38" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64FE7CEDA350F41A05F663E495159CE5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0332A992136B608133E963E495159E38" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_13AF18F7A9CB013067D563E495159883" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64FE7CEDA350F41A05F663E495159CE5" xlink:to="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_13AF18F7A9CB013067D563E495159883" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_ED966013549DE49DF97963E49515CDC0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64FE7CEDA350F41A05F663E495159CE5" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_ED966013549DE49DF97963E49515CDC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D1188F814F9C0F3450AF63E49515F04B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4784989109C6B8D9DEC963E49514B3A7" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D1188F814F9C0F3450AF63E49515F04B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_200974DA9209CB4AC09C63E49515EB5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D1188F814F9C0F3450AF63E49515F04B" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_200974DA9209CB4AC09C63E49515EB5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_DDDFC1198BCD575519DF63E49515290B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_200974DA9209CB4AC09C63E49515EB5B" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_DDDFC1198BCD575519DF63E49515290B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0E7C9CDDC339470CCBB263E495154973" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_DDDFC1198BCD575519DF63E49515290B" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0E7C9CDDC339470CCBB263E495154973" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8711CA27533F6975AA7563E49515D3B3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_DDDFC1198BCD575519DF63E49515290B" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8711CA27533F6975AA7563E49515D3B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_769CE96B9271E4F8510563E495158287" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D1188F814F9C0F3450AF63E49515F04B" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_769CE96B9271E4F8510563E495158287" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_274BA5AD719D68171A5563E4951603BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_769CE96B9271E4F8510563E495158287" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_274BA5AD719D68171A5563E4951603BF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CA4D5294752DE80260637B56E63DDA90" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_851A7489017F12832D7E7B947AA87804" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CA4D5294752DE80260637B56E63DDA90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_851A7489017F12832D7E7B947AA87804" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DD05EF0ED197DE18A3787B56E63DBC71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_851A7489017F12832D7E7B947AA87804" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DD05EF0ED197DE18A3787B56E63DBC71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6D7EEF4CED71CD0E1C297B56E63D2097" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_851A7489017F12832D7E7B947AA87804" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6D7EEF4CED71CD0E1C297B56E63D2097" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_68F0C88F63F8A3A825457B56E63D206E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_851A7489017F12832D7E7B947AA87804" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_68F0C88F63F8A3A825457B56E63D206E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B768B984CE56DF297B897B56E63DE238" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_851A7489017F12832D7E7B947AA87804" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B768B984CE56DF297B897B56E63DE238" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C9D9A5A14F474EF9AD387B56E63D463F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_851A7489017F12832D7E7B947AA87804" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C9D9A5A14F474EF9AD387B56E63D463F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_18D73DC35AE70636F3937B56E63DF654" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CA4D5294752DE80260637B56E63DDA90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_18D73DC35AE70636F3937B56E63DF654" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8F80C4E194B814E473E57B56E63E19C8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CA4D5294752DE80260637B56E63DDA90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8F80C4E194B814E473E57B56E63E19C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2734643E0AC45C6279867B951C6E7529" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CA4D5294752DE80260637B56E63DDA90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2734643E0AC45C6279867B951C6E7529" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0450B510BD3844030D927B56E63E873B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2734643E0AC45C6279867B951C6E7529" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0450B510BD3844030D927B56E63E873B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FB8284067CC06111ED067B56E63EDE63" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2734643E0AC45C6279867B951C6E7529" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FB8284067CC06111ED067B56E63EDE63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_FCAFC3A7018FCC78AC8A7B56E63E370A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2734643E0AC45C6279867B951C6E7529" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_FCAFC3A7018FCC78AC8A7B56E63E370A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_445F6506932803F74E707B56E63EFCA6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2734643E0AC45C6279867B951C6E7529" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_445F6506932803F74E707B56E63EFCA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B244C0C700E6C3A24A1E7B56E63E8B68" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2734643E0AC45C6279867B951C6E7529" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B244C0C700E6C3A24A1E7B56E63E8B68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_293DA9994CEED7C221A37B56E63E9B16" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CA4D5294752DE80260637B56E63DDA90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_293DA9994CEED7C221A37B56E63E9B16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_CFA6EE6595037656C18B7B56E63EE8A6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CA4D5294752DE80260637B56E63DDA90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_CFA6EE6595037656C18B7B56E63EE8A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_DE754664C527E1387D117B56E63EF0AE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CA4D5294752DE80260637B56E63DDA90" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_DE754664C527E1387D117B56E63EF0AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BEC67134B7253D13945C7B56E63E4176" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CA4D5294752DE80260637B56E63DDA90" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BEC67134B7253D13945C7B56E63E4176" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_16F0B7749EEE29FE46E17B56E63E30F1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CA4D5294752DE80260637B56E63DDA90" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_16F0B7749EEE29FE46E17B56E63E30F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F055DFAF49551D7DF1D97B56E63E3491" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CA4D5294752DE80260637B56E63DDA90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F055DFAF49551D7DF1D97B56E63E3491" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_430E4D033624174A32367B56E63E787F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CA4D5294752DE80260637B56E63DDA90" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_430E4D033624174A32367B56E63E787F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6C75B4315B3D529C96DA7B56E63F55C1" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CA4D5294752DE80260637B56E63DDA90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6C75B4315B3D529C96DA7B56E63F55C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5FEA54D2C9D5B73DF3597B56E63FE1E2" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CA4D5294752DE80260637B56E63DDA90" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5FEA54D2C9D5B73DF3597B56E63FE1E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_265A6A6CFDF4208AD2357B56E63FDBDE" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CA4D5294752DE80260637B56E63DDA90" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_265A6A6CFDF4208AD2357B56E63FDBDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4F3F217E21ABB28D066F7B56E63F85B1" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CA4D5294752DE80260637B56E63DDA90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4F3F217E21ABB28D066F7B56E63F85B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9ABE874D1097CA20F3907B56E63FCE83" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CA4D5294752DE80260637B56E63DDA90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9ABE874D1097CA20F3907B56E63FCE83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_5423C16DE41918B87F907B56E63F52A3" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CA4D5294752DE80260637B56E63DDA90" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_5423C16DE41918B87F907B56E63F52A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5C339C5D89567D2417F77B56E63FA6D3" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CA4D5294752DE80260637B56E63DDA90" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5C339C5D89567D2417F77B56E63FA6D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F49F6C23E9408B5AF6DA7B56E63FBDE0" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CA4D5294752DE80260637B56E63DDA90" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F49F6C23E9408B5AF6DA7B56E63FBDE0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9909C21CC10AB66476C96B043516C03A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EAFE48F6EC3D813636EA6B043516CEBE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9909C21CC10AB66476C96B043516C03A" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EAFE48F6EC3D813636EA6B043516CEBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_80328F733D7962010FD36B0435164415" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9909C21CC10AB66476C96B043516C03A" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_80328F733D7962010FD36B0435164415" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_4A4F72B4DA428816CD226B04351670AF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9909C21CC10AB66476C96B043516C03A" xlink:to="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_4A4F72B4DA428816CD226B04351670AF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_EFDC16996F49DEA0C363E2787CA35A64" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A2C5708B1A05F62C00A3E2787CA3F182" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_EFDC16996F49DEA0C363E2787CA35A64" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A2C5708B1A05F62C00A3E2787CA3F182" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_6996FE3BF76DC90AF2DE673112169867" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_B207023914F0BC0A77CE6731121901A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6996FE3BF76DC90AF2DE673112169867" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_B207023914F0BC0A77CE6731121901A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5A5D72C29CCF1E89832D6731121ADE2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B207023914F0BC0A77CE6731121901A9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5A5D72C29CCF1E89832D6731121ADE2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_33C08EB2B9C599B241296731121A8896" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5A5D72C29CCF1E89832D6731121ADE2B" xlink:to="loc_us-gaap_ClassOfStockDomain_33C08EB2B9C599B241296731121A8896" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_UndesignatedPreferredStockMember" xlink:label="loc_mgnx_UndesignatedPreferredStockMember_63955DD124B708CDB3866731121B5A7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_33C08EB2B9C599B241296731121A8896" xlink:to="loc_mgnx_UndesignatedPreferredStockMember_63955DD124B708CDB3866731121B5A7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_8FC97911EC45EC562E376731121BAB19" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B207023914F0BC0A77CE6731121901A9" xlink:to="loc_us-gaap_CounterpartyNameAxis_8FC97911EC45EC562E376731121BAB19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_21B0D94AB5B50117A2226731121B95EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_8FC97911EC45EC562E376731121BAB19" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_21B0D94AB5B50117A2226731121B95EF" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_JohnsonAndJohnsonDevelopmentCorporationMember" xlink:label="loc_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_42C168924B28B39DA7DD6731121CF31F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_21B0D94AB5B50117A2226731121B95EF" xlink:to="loc_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_42C168924B28B39DA7DD6731121CF31F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B207023914F0BC0A77CE6731121901A9" xlink:to="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_CFC831A81881CAFF8BCE6731121C4B7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_CFC831A81881CAFF8BCE6731121C4B7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_09D6E4942D15259EA1E767328883DF3C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_09D6E4942D15259EA1E767328883DF3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_E786C0A21C5BBD3247906731121CA5E0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_E786C0A21C5BBD3247906731121CA5E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4C4D506E935E099656786731121C466C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4C4D506E935E099656786731121C466C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_0ADD0109B59EDC9018846731121CB0ED" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_PreferredStockSharesIssued_0ADD0109B59EDC9018846731121CB0ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4E33E8BDB04C14B8F9886731121D84D3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4E33E8BDB04C14B8F9886731121D84D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6E51CCAE2109FC4D4BA86731121DF60D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6E51CCAE2109FC4D4BA86731121DF60D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1EE3BB423EEC586A286A6731121D323A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_SharePrice_1EE3BB423EEC586A286A6731121D323A" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_6FAFAA138BEB817F3DD16731121DE905" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_6FAFAA138BEB817F3DD16731121DE905" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5B6A4B37B853453B99706731121D279F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5B6A4B37B853453B99706731121D279F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_F8D2464407F90002241F6731121DA17A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_F8D2464407F90002241F6731121DA17A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_39C87424A7B71C2FD3EB6731121D6D61" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_39C87424A7B71C2FD3EB6731121D6D61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_709BBE6EFB27EFC4FD656731121D626D" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_F8B08DB204410ECE1B296731121C7C07" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_709BBE6EFB27EFC4FD656731121D626D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_DD52AF74DD04461717F1E2787CDD5739" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_F7EC33085915A0EBBC1CE2787CDD6379" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DD52AF74DD04461717F1E2787CDD5739" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_F7EC33085915A0EBBC1CE2787CDD6379" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0938807D4F6B977603127B56E683EC61" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_C2D36E5D1E0F273716487B56E68377FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0938807D4F6B977603127B56E683EC61" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_C2D36E5D1E0F273716487B56E68377FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F3FF3790F43F1D9599DD7B56E683A053" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_C2D36E5D1E0F273716487B56E68377FD" xlink:to="loc_us-gaap_NetIncomeLoss_F3FF3790F43F1D9599DD7B56E683A053" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_22DC60629221A0529F307B56E683C7DB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0938807D4F6B977603127B56E683EC61" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_22DC60629221A0529F307B56E683C7DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9B373F9AF8DBD30265FA7B56E6835A0B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_22DC60629221A0529F307B56E683C7DB" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9B373F9AF8DBD30265FA7B56E6835A0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_0A9348EFBCA132C16AF67B56E6834CD7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0938807D4F6B977603127B56E683EC61" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_0A9348EFBCA132C16AF67B56E6834CD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_439A0716C9BAB11775DB7B56E684F1C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_0A9348EFBCA132C16AF67B56E6834CD7" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_439A0716C9BAB11775DB7B56E684F1C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_94E496E3783B945335B77B56E6848F11" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0938807D4F6B977603127B56E683EC61" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_94E496E3783B945335B77B56E6848F11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_91D582F3A76C78B7FB167B56E684A2B7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0938807D4F6B977603127B56E683EC61" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_91D582F3A76C78B7FB167B56E684A2B7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_FE1E6CAB2083FAF5E21A8018CBA4BB55" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_728904E35B41FB08BEF18018CBA4D1C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_FE1E6CAB2083FAF5E21A8018CBA4BB55" xlink:to="loc_us-gaap_NumberOfOperatingSegments_728904E35B41FB08BEF18018CBA4D1C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_0A4289BB06FC2211BF808022384AD314" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_FE1E6CAB2083FAF5E21A8018CBA4BB55" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_0A4289BB06FC2211BF808022384AD314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_9DE688A86883A7819E468018CBA41B64" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_FE1E6CAB2083FAF5E21A8018CBA4BB55" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_9DE688A86883A7819E468018CBA41B64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" xlink:label="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_5E60E4DCAF0A24C970708018CBB4445D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_FE1E6CAB2083FAF5E21A8018CBA4BB55" xlink:to="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_5E60E4DCAF0A24C970708018CBB4445D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_445157DCC2C2A34434958018CBB4BD6E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_FE1E6CAB2083FAF5E21A8018CBA4BB55" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_445157DCC2C2A34434958018CBB4BD6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_497CE14224AD403799A68018CBB405C7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_FE1E6CAB2083FAF5E21A8018CBA4BB55" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_497CE14224AD403799A68018CBB405C7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_F68B6A1128C92661403963E49556688F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D4F3F871D42EE1735D6363E49556208C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F68B6A1128C92661403963E49556688F" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D4F3F871D42EE1735D6363E49556208C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_57B2295176832915C96663E49557317A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D4F3F871D42EE1735D6363E49556208C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_57B2295176832915C96663E49557317A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_51E692DA7411274736E563E495578A4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_57B2295176832915C96663E49557317A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_51E692DA7411274736E563E495578A4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_C92A4561BC3D32E2D81763E495577F1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_51E692DA7411274736E563E495578A4C" xlink:to="loc_us-gaap_ComputerEquipmentMember_C92A4561BC3D32E2D81763E495577F1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_3F625C2325D42F7245FC63E495576CB5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_51E692DA7411274736E563E495578A4C" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_3F625C2325D42F7245FC63E495576CB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_EC32FCF036863127E69963E495572981" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_51E692DA7411274736E563E495578A4C" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_EC32FCF036863127E69963E495572981" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember" xlink:label="loc_mgnx_LaboratoryAndOfficeEquipmentMember_BBCB0AECF7DED513648A63E49557E20F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_51E692DA7411274736E563E495578A4C" xlink:to="loc_mgnx_LaboratoryAndOfficeEquipmentMember_BBCB0AECF7DED513648A63E49557E20F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_FBE4E5FA4FCE67380CD763E495577A9E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_51E692DA7411274736E563E495578A4C" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_FBE4E5FA4FCE67380CD763E495577A9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8A704005B0D9FC46C2BE63E49557FD6B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D4F3F871D42EE1735D6363E49556208C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8A704005B0D9FC46C2BE63E49557FD6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_54E703147FF9A7A6510963E495578764" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8A704005B0D9FC46C2BE63E49557FD6B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_54E703147FF9A7A6510963E495578764" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_50CBA480ACD6DD15170E63E49557455C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8A704005B0D9FC46C2BE63E49557FD6B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_50CBA480ACD6DD15170E63E49557455C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_26659BC834C447BF20B463E495B91C26" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_567842EC6187CCC3E4F163E495B957B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26659BC834C447BF20B463E495B91C26" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_567842EC6187CCC3E4F163E495B957B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_843E596D70660202500763E495B9872B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26659BC834C447BF20B463E495B91C26" xlink:to="loc_us-gaap_UseOfEstimates_843E596D70660202500763E495B9872B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6A2CC57D550A25F24FAD63E495B9A3F6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26659BC834C447BF20B463E495B91C26" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6A2CC57D550A25F24FAD63E495B9A3F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_727F91711C6395948DCE63E495BA2F78" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26659BC834C447BF20B463E495B91C26" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_727F91711C6395948DCE63E495BA2F78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_C62E212730177D72B5EA63E495BA7E9B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26659BC834C447BF20B463E495B91C26" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_C62E212730177D72B5EA63E495BA7E9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_D128F2A5E36EF947C35563E495BA9C90" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26659BC834C447BF20B463E495B91C26" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_D128F2A5E36EF947C35563E495BA9C90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2E6593C49FB557352BFB63E495BAF812" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26659BC834C447BF20B463E495B91C26" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2E6593C49FB557352BFB63E495BAF812" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_84E94F984DBE5B9CC59D63E495BA21B1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26659BC834C447BF20B463E495B91C26" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_84E94F984DBE5B9CC59D63E495BA21B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_133D3D214E69411A480563E495BA1BEC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26659BC834C447BF20B463E495B91C26" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_133D3D214E69411A480563E495BA1BEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_2C51FD9FC84FBA407B8F63E495BA6EEE" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26659BC834C447BF20B463E495B91C26" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_2C51FD9FC84FBA407B8F63E495BA6EEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_EF03E0E0560D0784614863E495BA6D71" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26659BC834C447BF20B463E495B91C26" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_EF03E0E0560D0784614863E495BA6D71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_62DAD705B5F7146F51D163E495BAE5CE" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26659BC834C447BF20B463E495B91C26" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_62DAD705B5F7146F51D163E495BAE5CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_FEA53C4DEBDD9EE291D063E495BA891A" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26659BC834C447BF20B463E495B91C26" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_FEA53C4DEBDD9EE291D063E495BA891A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_BB7FE586CCF3164055E363E495BA73CE" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26659BC834C447BF20B463E495B91C26" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_BB7FE586CCF3164055E363E495BA73CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_FB39D65C7EA2488ED99563E495BAA488" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26659BC834C447BF20B463E495B91C26" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_FB39D65C7EA2488ED99563E495BAA488" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5B42E5617CECE574BAC7638FF140CA72" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44E6AE20B46507C0FEAD638FF140D79E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5B42E5617CECE574BAC7638FF140CA72" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44E6AE20B46507C0FEAD638FF140D79E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B8D2EFE9515A8A0C31C0638FF14080F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44E6AE20B46507C0FEAD638FF140D79E" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B8D2EFE9515A8A0C31C0638FF14080F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_514D8098635ACCBC65B3638FF140CC7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B8D2EFE9515A8A0C31C0638FF14080F3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_514D8098635ACCBC65B3638FF140CC7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_413CBF2979B2F627F89D638FF140939E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_514D8098635ACCBC65B3638FF140CC7C" xlink:to="loc_us-gaap_StockOptionMember_413CBF2979B2F627F89D638FF140939E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_626FCC2872220606EDBD638FF1407563" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44E6AE20B46507C0FEAD638FF140D79E" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_626FCC2872220606EDBD638FF1407563" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_CE18C4907B6D5CAFA693638FF1412F16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_626FCC2872220606EDBD638FF1407563" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_CE18C4907B6D5CAFA693638FF1412F16" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2095465284EF9716504F7B56E68EBA7A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_830CA0832FF5D1E51A657B56E68EC2FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2095465284EF9716504F7B56E68EBA7A" xlink:to="loc_us-gaap_ConcentrationRiskTable_830CA0832FF5D1E51A657B56E68EC2FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_98CDDC13DE79DB5CD4B57B7818A290BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_830CA0832FF5D1E51A657B56E68EC2FA" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_98CDDC13DE79DB5CD4B57B7818A290BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_D53353D50589AD690A4B7B7818A4407A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_98CDDC13DE79DB5CD4B57B7818A290BD" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_D53353D50589AD690A4B7B7818A4407A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_8684ED2D85016101FD657B785871E99C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_D53353D50589AD690A4B7B7818A4407A" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_8684ED2D85016101FD657B785871E99C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_B59D52C436E3334F18637B56E68FE813" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_830CA0832FF5D1E51A657B56E68EC2FA" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_B59D52C436E3334F18637B56E68FE813" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_C5FACD804694095898747B56E68FCE0B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_B59D52C436E3334F18637B56E68FE813" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_C5FACD804694095898747B56E68FCE0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_C0FDAE2E35ADCBAC1CB97B56E68F7E2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_C5FACD804694095898747B56E68FCE0B" xlink:to="loc_us-gaap_AccountsReceivableMember_C0FDAE2E35ADCBAC1CB97B56E68F7E2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_CA35D66F1AA36C03E2527B773C643F7A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_830CA0832FF5D1E51A657B56E68EC2FA" xlink:to="loc_us-gaap_MajorCustomersAxis_CA35D66F1AA36C03E2527B773C643F7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_BDC7FD69F97C7195455B7B773C655C47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_CA35D66F1AA36C03E2527B773C643F7A" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_BDC7FD69F97C7195455B7B773C655C47" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_JanssenBiotechIncMember" xlink:label="loc_mgnx_JanssenBiotechIncMember_BCA41E3259A93EBE39B37B56E68EB735" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_BDC7FD69F97C7195455B7B773C655C47" xlink:to="loc_mgnx_JanssenBiotechIncMember_BCA41E3259A93EBE39B37B56E68EB735" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_USGovernmentMember" xlink:label="loc_mgnx_USGovernmentMember_DEBB654B9B3D9EB24B737B56E68E5DF9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_BDC7FD69F97C7195455B7B773C655C47" xlink:to="loc_mgnx_USGovernmentMember_DEBB654B9B3D9EB24B737B56E68E5DF9" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ServierMGA271Member" xlink:label="loc_mgnx_ServierMGA271Member_9C3881DF5CD41E5BE5287B56E68EBC76" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_BDC7FD69F97C7195455B7B773C655C47" xlink:to="loc_mgnx_ServierMGA271Member_9C3881DF5CD41E5BE5287B56E68EBC76" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_TakedaPharmaceuticalMember" xlink:label="loc_mgnx_TakedaPharmaceuticalMember_854CA0EB57ECDBB226477B56E68FE2EA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_BDC7FD69F97C7195455B7B773C655C47" xlink:to="loc_mgnx_TakedaPharmaceuticalMember_854CA0EB57ECDBB226477B56E68FE2EA" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_EliLillyMember" xlink:label="loc_mgnx_EliLillyMember_7C80B0302D969AD07EB97B56E68F6929" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_BDC7FD69F97C7195455B7B773C655C47" xlink:to="loc_mgnx_EliLillyMember_7C80B0302D969AD07EB97B56E68F6929" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_7011D199E2E3FEFAF1E47B56E68FD13B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_830CA0832FF5D1E51A657B56E68EC2FA" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_7011D199E2E3FEFAF1E47B56E68FD13B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_A556BB80165F62D4F9297B56E68FA2F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7011D199E2E3FEFAF1E47B56E68FD13B" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_A556BB80165F62D4F9297B56E68FA2F7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarnedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_D56293813EE9EA23C0037B56E696A812" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_43BA862DCBAD768C975C7B56E696AB48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D56293813EE9EA23C0037B56E696A812" xlink:to="loc_us-gaap_ConcentrationRiskTable_43BA862DCBAD768C975C7B56E696AB48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_07BE13EA2959E7EA27177B73CBCD3194" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_43BA862DCBAD768C975C7B56E696AB48" xlink:to="loc_us-gaap_MajorCustomersAxis_07BE13EA2959E7EA27177B73CBCD3194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_A29A835F36C18B10096A7B745E5FBAA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_07BE13EA2959E7EA27177B73CBCD3194" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_A29A835F36C18B10096A7B745E5FBAA6" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_JanssenBiotechIncMember" xlink:label="loc_mgnx_JanssenBiotechIncMember_E281E1086157CC82109B7B56E69667BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_A29A835F36C18B10096A7B745E5FBAA6" xlink:to="loc_mgnx_JanssenBiotechIncMember_E281E1086157CC82109B7B56E69667BB" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_ServierMGA271Member" xlink:label="loc_mgnx_ServierMGA271Member_C8D9CEA9E87E4AB6228C7B56E697EB7B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_A29A835F36C18B10096A7B745E5FBAA6" xlink:to="loc_mgnx_ServierMGA271Member_C8D9CEA9E87E4AB6228C7B56E697EB7B" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_BoehringerIngelheimMember" xlink:label="loc_mgnx_BoehringerIngelheimMember_6EBCCDD78C51F9F252387B56E6978C95" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_A29A835F36C18B10096A7B745E5FBAA6" xlink:to="loc_mgnx_BoehringerIngelheimMember_6EBCCDD78C51F9F252387B56E6978C95" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_TakedaMember" xlink:label="loc_mgnx_TakedaMember_DBDC5DF685460F5AC9C27B56E69713EF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_A29A835F36C18B10096A7B745E5FBAA6" xlink:to="loc_mgnx_TakedaMember_DBDC5DF685460F5AC9C27B56E69713EF" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_GileadSciencesIncMember" xlink:label="loc_mgnx_GileadSciencesIncMember_6A7D55D22D59797D08E27B56E6979C00" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_A29A835F36C18B10096A7B745E5FBAA6" xlink:to="loc_mgnx_GileadSciencesIncMember_6A7D55D22D59797D08E27B56E6979C00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4D5D1F6F441E477FB3B37B56E696D144" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_43BA862DCBAD768C975C7B56E696AB48" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4D5D1F6F441E477FB3B37B56E696D144" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D7A8FC63FA56849CC4D87B56E696FA5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4D5D1F6F441E477FB3B37B56E696D144" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D7A8FC63FA56849CC4D87B56E696FA5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_DAF92DF9A928DA9F6A7E7B56E6964620" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D7A8FC63FA56849CC4D87B56E696FA5D" xlink:to="loc_us-gaap_SalesRevenueNetMember_DAF92DF9A928DA9F6A7E7B56E6964620" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_04CD0F2F60F54839667A7B75FDA27C36" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_43BA862DCBAD768C975C7B56E696AB48" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_04CD0F2F60F54839667A7B75FDA27C36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1C48846CCE187EF67EC67B56E69645B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_04CD0F2F60F54839667A7B75FDA27C36" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1C48846CCE187EF67EC67B56E69645B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_B5C1E9750CD7AD03E7F47B769817C696" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1C48846CCE187EF67EC67B56E69645B4" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_B5C1E9750CD7AD03E7F47B769817C696" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_7AD9DD650C18420841767B56E697A51C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_43BA862DCBAD768C975C7B56E696AB48" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_7AD9DD650C18420841767B56E697A51C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_E364BEC392BBEEE0CE127B56E69734C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7AD9DD650C18420841767B56E697A51C" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_E364BEC392BBEEE0CE127B56E69734C8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_92AA5F39AFCC33B901668018CBA45E24" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B413E47485BFCE7A3DE8018CBA4912B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92AA5F39AFCC33B901668018CBA45E24" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B413E47485BFCE7A3DE8018CBA4912B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7BC33C99C84E65DE1B7D8018CBA44917" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B413E47485BFCE7A3DE8018CBA4912B" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7BC33C99C84E65DE1B7D8018CBA44917" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2682C61220E20BF841D68018CBA4EFD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7BC33C99C84E65DE1B7D8018CBA44917" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2682C61220E20BF841D68018CBA4EFD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_B5DBD561D842C95B47C78018CBA41259" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2682C61220E20BF841D68018CBA4EFD9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_B5DBD561D842C95B47C78018CBA41259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_73D62F05E6F270316E918018CBA46D97" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2682C61220E20BF841D68018CBA4EFD9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_73D62F05E6F270316E918018CBA46D97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_02C11550F502326B8F738018CBA47976" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2682C61220E20BF841D68018CBA4EFD9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_02C11550F502326B8F738018CBA47976" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_AF45F04F818BF4D3584F8018CBA4E03D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B413E47485BFCE7A3DE8018CBA4912B" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_AF45F04F818BF4D3584F8018CBA4E03D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_964663B78865213C473A8018CBA4DB09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_AF45F04F818BF4D3584F8018CBA4E03D" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_964663B78865213C473A8018CBA4DB09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4B7E392130FF6BF9B82F8018CBA479C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_964663B78865213C473A8018CBA4DB09" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4B7E392130FF6BF9B82F8018CBA479C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8A2DF76D2FEAB42A4F928018CBA485E2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_964663B78865213C473A8018CBA4DB09" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_8A2DF76D2FEAB42A4F928018CBA485E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_C7DACE2B6FE4F2F9046F8018CBA49E97" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_964663B78865213C473A8018CBA4DB09" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_C7DACE2B6FE4F2F9046F8018CBA49E97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1649A5829E7615E676F18018CBA4549E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_964663B78865213C473A8018CBA4DB09" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1649A5829E7615E676F18018CBA4549E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BC5E68AB294794EB1AB48018CBA40B37" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7B413E47485BFCE7A3DE8018CBA4912B" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BC5E68AB294794EB1AB48018CBA40B37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_DF899FF79A7627DA2A658018CBA440F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BC5E68AB294794EB1AB48018CBA40B37" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_DF899FF79A7627DA2A658018CBA440F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_AADA64B60DD226F70B2A8018CBA488CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_DF899FF79A7627DA2A658018CBA440F0" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_AADA64B60DD226F70B2A8018CBA488CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_345FB15D60A5117D7E248056A7E3BD0E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_DF899FF79A7627DA2A658018CBA440F0" xlink:to="loc_us-gaap_AvailableForSaleSecurities_345FB15D60A5117D7E248056A7E3BD0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_756F209E6DCECDEFA26C8018CBA41B55" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_DF899FF79A7627DA2A658018CBA440F0" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_756F209E6DCECDEFA26C8018CBA41B55" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_778A90049DB93AE425B17B56E6A8FAD9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_D15C1B9E2C2DEE2E7ADE7B56E6A8A035" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_778A90049DB93AE425B17B56E6A8FAD9" xlink:to="loc_us-gaap_StatementTable_D15C1B9E2C2DEE2E7ADE7B56E6A8A035" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5D1973B5220C851EA5D97B56E6A899F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_D15C1B9E2C2DEE2E7ADE7B56E6A8A035" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5D1973B5220C851EA5D97B56E6A899F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_765D81CBD2A127EEA52A7B56E6A89348" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5D1973B5220C851EA5D97B56E6A899F3" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_765D81CBD2A127EEA52A7B56E6A89348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_AA2FC870675E9A8E95C67B56E6A8863F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_765D81CBD2A127EEA52A7B56E6A89348" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_AA2FC870675E9A8E95C67B56E6A8863F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_B1622573C18985F8FAC07B56E6A81D99" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_D15C1B9E2C2DEE2E7ADE7B56E6A8A035" xlink:to="loc_us-gaap_StatementLineItems_B1622573C18985F8FAC07B56E6A81D99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_A44E65E1F3652B59B7807B56E6A99644" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B1622573C18985F8FAC07B56E6A81D99" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_A44E65E1F3652B59B7807B56E6A99644" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_7C3BCB9B6A10F8A33B397B56E6A9CDA9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B1622573C18985F8FAC07B56E6A81D99" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_7C3BCB9B6A10F8A33B397B56E6A9CDA9" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20161231.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_43800C20444245D457577B56E6A91CDF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B1622573C18985F8FAC07B56E6A81D99" xlink:to="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_43800C20444245D457577B56E6A91CDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_36C18D17463432E8ED567B56E6A9BA85" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B1622573C18985F8FAC07B56E6A81D99" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_36C18D17463432E8ED567B56E6A9BA85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0F5DE2CA29F8C45F39327B56E6A9E024" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B1622573C18985F8FAC07B56E6A81D99" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0F5DE2CA29F8C45F39327B56E6A9E024" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>form10k2016image1.jpg
<TEXT>
begin 644 form10k2016image1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X )D%D
M;V)E &3      0, %00#!@H-   U%@  TOL  0WC  %*(O_; (0  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @("
M @(" P,# P,# P,# P$! 0$! 0$" 0$" @(! @(# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\( $0@!.@*\ P$1
M  (1 0,1 ?_$ 3\  0 # 0 # 0$!           '" D&! 4* P(! 0$  @,!
M 0$!            !@<$!0@) P(!$   !@$" @D"!@$$ P$    " P0%!@<!
M  A -1 @,!(3%#0V-Q$54#$S%A<X(6" H#)P(B,8$0 !! $"! ,#" 8$"08(
M#P$" 0,$!081$@ A$P<Q(A1!(Q40,%$R0K46=B! 83,D=5*RM AQ@6)R0S1T
M)1>14W.&ML9@L8+31#4FEE!P@*'ADJ)C@Y.S5-4G-Q@2  $! P8'"PD' P4!
M 0    $" !$#$"$Q01($0%%A<;$R$S"!D:'!T7*R,W,44/#A(D)28B-T(/&"
M)#0%%<+2)8"@DD-CHE03 0 ! P(#" ,!  ,! 0    $1 "$Q05$087$@,$#P
M@9&AL5#!T>%@@/&@</_:  P# 0 "$0,1   !W\
M
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M?(=[^:;HTD_/Z   \(^5*:QKU/2--<WI]CIWR[>'"_G]1!M\'3F/[31G^?T
M>D/7G2E#2^)_A^AQ!V! )_A8H  X$[4B4X M">*?V<2?F0@263,  5B*.4U.
M;^1?;8TVW#+MR_256X&Z2M954QSG[!H_Z%>D*K[\  &#4;VL[>=?4/0:_)I'
MZ$\RV(FL?ME1U@31KLK,>_*YW!V&,  (7,.Y?HKV[C SFBNZTOT6QP-Z,I^3
M9Y%8^I>R/JVI^PY9  !@_L,3//J2C?<['#[7FBZ=$HION?G,<FS+^%4H')=[
M<3[@"A92,T0,_2/SJ"!CMS2\K"2X:7@ &3)4<UJ,_B.R*COBP9YIPQIT3^
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M>L=:41I3Q;?5YZ LJ@?2E4[9]>TC84_@^<FN)3>_S\Z7X_;X4/\ HIR]'O\
M&P]*SSA\GY9^7E7VZ&?C@   "M)C!*=-?;?:RANFV%WHCO,.+RK"3+6@<7UE
M-OIVH2U;4 ^9N0Z>"NH*1\?X_2W7+EX^/B9-V)Q'/7?G]5A@TC^@;%^P
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M?\X^II"C^R\GT\Y'H)QO>FCW.UH55]$N8/UV^!J[34YI))-7(5SP71W]?P
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MS2-"R7@         #. @KS8ZLZS59GJ/3SD>G7%E]Z$4#9-9?1?ES=:=1X
M        4@/G7ZBH[L9!J=4>/>A\4KPK&9+8@5DN8[L^CR)[\
M5))X(>)P.O           !G 05YL=6=9JLSU'IYR/3KBR^]"*!LFM?HYRSNA
M-="          *0'SK]14=U^_P!5JSQ]T-B9>%8S);$"LES'=GT>1/?@
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M"$"%M@           0X<V6'..*ZEN3^@          1R>B)+(9)F/\/[/;
M                                      &?1PI48\LC8YPF(WW
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ME3IC] >.>0         97%.C0D_4Y [$C(S)-6B/3PR="S1G>>W-6#V
M !E<58+NGNB,B6B'C.\T*/0GYEA"Q1GD>V-03I0     97%2"^IYYP!(Q%!F
MX:7'+GH3V!,9[,G0IV=D:3@      RH/'*R$T$7DVDV$&'KSNSVI2P^@<Q^(
MR-L3I0     #*@Z0H\6:*W%J21CCR&"63WQ30WW,JR"S9 D@     &5!YQ4(
ML 0<6,)8(N(_)3/:D?'"G\FM)DD2*:\       CLD0CLD0   $9DF
M $=DB$=DB    C,DP       $=DB$=DB               RC.I)X../<GJ"
M*"_ACL2Z20:4@        S3.8+.'$GDGX$7&AIB*6)(\-FSR      0J92EX
MS^STYV1"Q*A9 SI.J)&)P.#.+.G(L/2'/'.DQ&BX      ,\R'RH9/1Z8J,7
M^+K&<Q_)WQL2        "EY4,@,DLYXJF:!FAYCL>Q)@-:#J      #%HJX:
M*&1Q:HZ$[HN*9NFAA7<D@H03^>$6&*W'7'4'L#5L        @$CTN   5^+
M@         $(D.ET  "OQ8$       'XF<QH,>Y      /6$2$W
M
M                      __V@ ( 0$  04"_P!AN<X#A9=U2(%C:Z-KRB[1
MYLZNH\M:7EH?D7:N-U5.TK&AZ9Y A[1\L> 1E6RR!BDB+\*W.RU_?)0@HRN$
M:%E<W3;3.T2Q*XH^RW(V\YL>H_0,,2-Z@MUVXRL@XI23V>[>Q7EM FAK$03
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M"4:Y$=^CLJ^+(IZC6U7YSXAXJ^N9 N4;<:V.DR>G*H2G8Q@..(W8?"4"]C2
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M8:HXHH!)8QX!C"G_ #^#(A8$1I8G\,6,YQEF<L."?4B:_"'UT20U<H3)RTI
MQ@+ Z. W%2  C!$E!)!H[.!&]=1C/?T09]>AT1>5-TSKOKV!YP$Y2@\:DW&,
MBRW(\)"<YQC!@\C%HO&< _!2#LDC"+ PB#@83BLDC1+#$*A.H+5$F%@- YH!
MMZGJXQG.69LPWI]2)T\06DB?P0Z6J/IV(P8&'.,ASC/TT6/OA/) H*4$#3&X
MSD.6]9A83UG1=YHW3.AZ#S.]G1!?U_"$:CP\Z4$X/!G&0Y87/R9VG1O XIC
M#*'U(XU][.GMS\@1^>D2?Z]"H_P09S]>R.+[^- 'D L9QG#FB\T5I(J$D.+,
M":#J/"[PPZ;D659V,8Q@\SZ=!9?B"_+\)1*/$#I:G[V-1]S\R5J1-?B!Z6EN
M$XJ0A" *M44C(5JC5AZ8C)X\8QC!@PE@-,$:/LSR_IT$&=W.GA#W!::%W@CZ
M5JL*0D8Q&"**&<8E3@2DF#[@<Y^NL8R+( 8 '@/IGZ<0$60"(.P<#2Q/X0B3
MC$YK>M+7IOST]MGD%&B23%!K>A+0)M/CGY\\ !&"**"2#2I1XP^T_/1@.X+1
M!G>P,(1A6I!)#M-2WS)6AB" *Y6)8=IJ0^7+SG <#'D8M$E]S' 1]$4L69
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M1K0H:TFAK*J"UDT,+Q"JI&,8F3'@SH4&,*('H4'%C"/9F=)QCT5_:<*6>O\
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M&B<-V5':5]Q7O:HU.K)D>=$-4TW"+\9QQI2'7FFNJ?/.5\[/\:;ELKM=;;L
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MKANO(W&:0?Z;\A41/V(O&,XZIHXM#C]-2JX.JBXM771H.]%71="Z&OZ)HV2
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MWD2>847>R>[<TZ.K3C2HJ+IIK\.I.K9VD_2)%:ALNO%U9"]($;$0W/ODI:
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MN%-RB-71IA&=$#.,NU[]:L>JG(Z\V!R3E.,@8DO2Y[N.X62779<<PKK*XO\
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MZJ3;&N06E@@"(NY#+=RUTV\^(.=8)T;M^ZE^EJEL:NR=K8SL27&:M8]X,:1
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M.C?=<KGA:4+!.G7N;=O(N6GCQ@K%2W,%[-LWH&:F+.B/0IZ([$M6]ST)\1<
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MA'VZ7#SM+1?3@ 3C)%%!B"@BY&@B4N+@BE[E>8-Z\0_JH$;2"VOL8(R-%0*
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M\"=?_8:BU('&U!_S]O"5QZ)I4_P^S;*8D48TO1JLQ4J]@6)&$,BH0 $-I B
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MPAR@@(0(%C,:4!F&^E'JYCF'XEVWX(\I0%97'([T(I-8X?Y-GCVNDX=;_/\
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M;_>FA-<X"$=+%Z\&WK("%>@(D0PP)0)!-HTJ7J/'BPR\&E 8!T# 8DF;SE=
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MAA\1Q-"Q5NX1QQF' A1+:3<L'R"D5X(CL<0QZYV91616CXCK",M6%<I6&(X
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MVW6+8X0IWX'0Z3OMIF:D5DNA!\W])K2+G7GZY_\ E3__V@ , P$  A$#$0
M$
M
M                (      (      !      !
MJ@    !E@     .L     %2    (!(  () ( (     !LZ    (?P     .L
M@   !,?     )   (( !  )    H+QP   "T:2   &9B>    FC^@     !(
M   )  !(  (OJ.(   !ASD  !)@X=    ;,O@ !! (!   ()!!)(  !I^R@
M +ONNH   #*JXP !P4!C    !(      )      -RYP0!#\EVP   !&DA6
M2.\B    !  ! !         !/9?H K)E"    !!I 1 /6I=     ! !/)!(
M       !?3*4'FD8@     ),#<P202\     ! !$PD4         )8,<!VYU
M      !.F]Y"A<(     !  /CVR          _I/+X^\       !X 829N
M !  ! !+?&M          "1/+XK    (   )] 92:8   !( !!)#+L+
M      !/+X    !)    ! 8B0     ! !( !R!D((         !/+X
M    !(8B0        ! N8#KP          !/'X           *8B0
M  "_0!-H          !/-X           *8C          #\7+W<
M  !/-X           *8C0        !$1ABE6           ?-X
M *8C0         ( P_)(          !O-^           *XC0
M)(            !O-V           +HC0           ((            !C
M-V           +HC0          ( )(           )M-           !*PI
M@          ! (!           !(!            )             )!
M                                        !
M                         !        !  !  ((!( (  !(  ( !! ) !
M    !   ! ())    !!)))!)) !)(   ! )) ))!!!)(    !!!  )))
M !( !  )!! !!(    !! ((((( )        (!
M                                (  !!()(      ! !!()!)
M!    !(!(       !)!!((!       ! ( !  ((     !(((! ())
M((   !        !!    (       !!               (( !)
M)   )      !( (  !(!!(        )!)!(         )))(!        ! (
M) )))!        !   (          (  !                !
M
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M7=4/QV.[YRXNU:>$2%,F\\6_<(Z;@&HQM0B$ H%M^C9*;-J84:@)@   @ @
M"Q3LBA*YA G)>M:6(%1^T+R4;31+.&/=48\8:D[K1Y0D<(%C 0 V:RA?@IX.
MB]I2)$-8J%Z!X'%/,6=V T+IXV@_J>\=V/U2@U*$6<HET(+$UE0>8(.\<<.F
M4<$4E'HZ/N-K50 08FSCKBBL?;N+!1 0(<O)G#!:F>*)YSI+(:JL%]T)0M$0
M  $%"V0.X9TH-C&VVQG*NC(Y([%(54L)R(26)@P'9UT4T&6X(X\:XH:S$$"8
M4.F=EYMH#?\ *)]Y$8H^P.0>"!>#0"F4P%OH8HFN 5"HS2A]@UJ;U**=X(LH
M*$5"&@#116=RB10F%"XC4J25#%5]0(HU=Z QV/8U/$Q3$@6B$\@)R%1 '#%+
MW;2N[)=H_L7FP$2Y"Q* (2BHFA,#:(*LE"9I8Q$HBVIP_($G+RL66H9K<E=^
M,F6.O"@Z#GAR@  E6P4<@58 -$$X93<J;*9O$AH@I<L-.?0_+URE@E5$?DQD
MA H !K*;W'R#:X28;3<?92?CPEJ2P"'9,>L9TXP 0$34W9M 4D@74M>E#+*@
MU*IERO'>-3DRB33:IF'$DX](SLK3.$X9CY\%!RJ@B:3 >J\G!I)#?0^VL%GL
M(<9A<YU:5B&I,!"":-%TA7N,AFL%@"B H$'D,E"U:ZNJ-&8&;DP<0$=D-*5!
MYVA\!T^5P:D#* 14J))RH"TKA(&:X;B M1#VG')#%E L:,:#:E219YTLM84J
M'"#_ #-I"E2J?+GDJ\O)N 4VL(,AY/;N([0CPT1VQLQBEY(C'H,.9DHC)V4^
MWI,VDL<< RE@)*M8YL!>".<+,2@P#"<XS1Q"]4 %:0'>B(R19EIE68)I)6)O
MEX"IH;W_ +#,\%B(CFFP0 4  2HP !=J9>7 U,EOY*4/V03'"89B;,= #26-
M)_'N"UHMSI.M9F)VR>#AC0?\@ML!N28(KTOUV]"4@- (5::+&7/QV9>: +MG
M\ZO1*R<\$@I./F ACCT'"NJNC30"RZ<:8-*8+3&!HP/SG6:1"]2HL![(SVK#
M^-%E&ET9;5*Z\G:2'6E?(*2C8A/4HEX#;>7#5QR$+$@AD(2I\4:[!5CS+(2'
MFH$R)C/ V-Y9!!/1Y5B;(CON5 @Y:ZAT-RH8P5)6KG9+F;=PG9'=N^$N=5+@
M6,@00J,-2[$6,@,B"B'5K>9NQX6?@BY"BH  I+)I%-D ERJ+TX07<M/!YFU7
MDZ$S,QZPB0$@)[SIUQ&UHF"(!R3!M_&I2Z^TP3:=)X8]FM222')E)DK9N9.'
M( V"%,C3CIU<18XZ4 :<HJPW2"<05]3R*)#P4<L:"DH1I@]&21F11!?U=9R.
MX+?A%[]0 (!JIYH'/G8W?Y65("QN-GNL*U+0AD1#J6)#9I>GT:I0@S(!&/YP
MA56,Y-8T\2+58+R8GD4DM2*2#9&@_;#HAB.M)$*! >"W&M $% C'9A3Q(P94
MKZG"JC6B'CKO[B%:/"+8F2EB2)+3@CUQ%C*),2I%OI.G0B-^4K-X4 XRPA0>
M36;6I[J(R'4!R"!7W6-^8S?@A<H0)6P7P?\ \D;9Q .]DI.52W%)#H9"B'*6
M3Z9+0BCO.^'>(X&28!.@O4!LX+>:2<X09PO&4M>36@.QA48DVYY4>V*3&I24
M4A,_(//X(J\F)<P.N+;B4 *0A5,V)W2H[&SK!:0'*HC%A"OP%W?B+3C%G <!
M;<M@T/ )J1%H6/\ + )[B,-:X)=<59\VASAPX7C3WT0,@> !HD;XNRA?LB8'
M<V.F5\$*J<0;+B$##I-:=**54 OJ 1%Y72)9*BD+-KPQ:>K_ ._)(&)!:T5L
M<9IW@;128)<I<_($CXF*"1+)11J)"!\0!/&$0),9KG+S>)6#L*"N49-(0;I6
MQE0<B,OY]TXH\*)X27>,"I<APG1:)!RJ2S0QB (X9+7:GS/AP>@7/9RJ;&>Q
M12@FY,1W@#P^-!*I5T(RP1(19ZN@DO)1@25;-J*N@VG@5QF+Y4D"TS$X^)].
M($:N@&+%Z[/M@T2"#&"!RV&P11/#<E5'%0+,0@>!9MY?48V[X 50"H%Y68F_
M4J@@N"B?#T< *4K_ !6Q)4EN$.P)"1H$"6,B!$=@&HX N5%<F1KJZB@+YQ20
M'H!F;X"T'@MQK0!  JQ6*6?IF6[%5P%%IO[D< . P8J3)J0NI6%F35%EVRH%
M +T!]8*S' =:=85#O@0]YERIJ&"ABIZ';,"+*&JU9Y>&6W3Y%$(\[LF.X3L-
MVAG@.%<RH3=.Q*!\'&$(3#..YU&24O)T=HF"1&.V<JUAP"&PDI:>!,/ /'OD
MAAY)K/+!CI \,J<8*2>)64BG,](BD*+.1>4E0D)5V%+E%*LD5\*".D0*7*9J
M!R,T*L@D6*B44!K*@X)8PCD]*5\U9 X9DL" ,ADOPT:TL*:(#C(@!4&^ ^-4
MRT0MN,NVJI/IW)<;#*SN,U6T%HT\LB#D"!3@UV<H[!:&"UUT%A)+57+,U4^K
MZT7#RZ,%;'1C/<J U8#2D=<!C#K];)(*]8(4RPV0&6[-X)FW@SCB&P_X%\*8
M/)8$LH!5%%7Z)G# "$) ,(YHKT7;WM'RGE(/V;N?\%*]:*WH-A3MI*.)3C5.
M&[6S-K&4(D4U%'TZ\P8:.FVFH-"C\38P1&A0LFB;A?F^VHQHGE5[4B4EP5%.
M'P*H <0 "K%/)T;;[AO2IL+0.Z+Z-E)$-U0L8)(HJ:IL-I.F5^J *I@$ 6F;
M,A'S%?9+M>2)BBR3T3X$+'>6S0.[I=8) TBNB;+A)OJHN."Q3_K"SB-O-Q1[
MLX.@&S6,T,273#TD!;+/=7311!$01(1N(Y$U&HY8Y$N-0QH+46=<#ZAH8Q:0
M"%PZ.%ZJ$+9*12^VF69#DG* A)/3\\IW)5Q%BY:R[T315;']85$6;&ATV$HJ
M((T@"^H!%7@=*M@IC(F12A]Q7@NK!41X I$QD\_*392[/3M%O*4DM_7K-#,&
M"0!!8H)4^ "YK1DEX\>]LLM,4]4)PNW1>@LY8DH0**)^@QAWU0K1 -M'%%)'
M#4S,&RH -R )&P4I>'O./#TD\3P2&;<Z#GAR (!A&R45?T,V0#8856U2[Q0#
M3_:.F7E!;RT;"?-:RT/F=X>P,)=%S4!]T8[E#7U[3!&?U#5X(R4H;I)@FS"#
M7&@2!P 2N%%"H2)-M,_>#,L2"?"F%8D\W\+&&"FI&C!>[1C;/I$DZ@*\0\^&
MX=@&,;CTF1/"8'5TYG%=U+D_]\$+?:=G#42H$)&ER(X1X8=&D<IYC"45R_0A
MWZ3M50(Q ;BT'U18/.Q&ZMR7=#=R#,=. A2()9!$H.G8!PP$AFAS))39BYQ)
MA,?*P@9 ))P1H F4CDLN$2&D3F>2@%:ID6**V&AXG]AB_P#[@8O*SAT4+@?D
MD^XKN:<\$:8[A.PW:N> X>!Y4B+M)!*R)DF$,II'U>J"!![$ AI4NR3%1L+)
M*D)4[$2J-:$MA(B<62 RF@Q 9#@CX(8G EQ),0F$\'9MXW+H":,)YCQ$$!LX
MU>'P,C2V19-8,UJW^-Z,C(E$+A!TR)-B[0@T.(50OCKTD2CB5R+%'= S#%K
M&8I&0QD,L,'J<U"6%[P3_P!%W WP7KB2HZ4(B"U=LE[KXW[!X8DPSX[Z (!S
M!I$$ ! 4$B$B(V:1_J@I-$F\K%**$T^%+*:2 !VC\+0I]26MOL4MS(BP'"MV
M) D46FX!BFD)+"068( ITM61 'I-C$6$CN)5&::I2.&>,B;0HZZR-[J,"]I2
M=!SPY0  2K8*-F:)@S-T&@,R3*"@>0L<E8.3*T$F&&D+FV<800W9 /\ X8B\
MHE!I;([S@3*.I%*X"MO(6HI.SM20+5L,FC4A1.?U%VBT*!W:6L^:)M!#[ (
M#+B?[4\+DK4)X-FWZ*K\!30U]J9O.64AM9BT@*4AS/,(6GQA45">X$KM$0
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M,5&'WC5@  2_\\&VH(G!\<,T@-AY)U$[)G7_  T2,H;E>6+Z?V/](AP&H=&
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M)!31*VJHZ]"+-$!5F8X3QCA$\$>@MW.H!J;*"%F 4?Q2(14)0F IFY%U0GZ
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MIS$%D:1(@X /@ML2&@4!P+6@4A1"C6IJX+;LHE[B_L-ZG4"8/%X$"B5R$-:
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MF1HH6C)9QGOA',1M *RZ0&PD <R1\BP.W92J+,*[28,IF" 5!U" 0%:?5]!
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MU$N-%A'Q("@Q()V1A"*)G* Z=B-)HHM9E([9!(V4&BJ314\'=216WAUTV]H
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M:40%< R<H][S!NI4Y$]: ^$GPP!8()(-)0(;P+JK>AT7(HG+?*[^P<//=O9
M%_-4)J7(^<CA-2U$BB.1G5<?3W5\1 !H&@:>[*KX)&I$I$D[A)'O%!++*7T;
M'F<=GM)'R?8>7/C,O"2A.5(DIM9)ZR?7O1H.9<KN^$GU'%DN4&$2E<82*)XQ
M /VO-95U5:9Z05Z:'-P&K:H;4:>3 >A=C*>#T.CEH^GU-)<4SJ@D[N+O5U1X
MCSW;V0!?S7Y0[?S6@@QOG*<B_0;G"+NB4:Z>C5^W!;36.3J?LY6TX7ZM6Y^2
M.D>)\]V]D 7\UX@85)%Z@OLV\7_-:&5&6/D=^0AR<& ,9^C87><&M":DK3"(
M[H"-E3$DM06D-M,;H%,LQ8:**&A*SET_TZ)9K$7>VX\QMXCSW;Q &,7DO(0/
M27WX?->(/E?H\5_,2T #F_K=T+U$.H2MW_P-@#2GJ 2JX NKR*;.CB65R8;P
M=R!$-:OP-X ])CJ\-RBK+3MX$:B*,%J9$K<Q>.L#!X7ZO6Y?ZQUCQ'GNWL@)
M_P UX@^5^CL_YP(7HD^'PIP!:\HQU'#8-W 2:PF;*V%+DYY&$I</P^&ZR+S(
M2V&PI2<^CDO*'^GK2OPU.05^"OF"J9?+30T.X-D-E0YA8HX,KK<?V8:Q<S3C
M]H._J?,^'\]V]D!/^:\0?*_1XK]M,"9:@"E);")LI,D2C4&*V0II8P;JP<X%
M'I!7F[<C :%J"M+XS;'Z >E%A!"W1"QS]TQ%Z#E8?0)?1KTX(>E4.Q/<-+/O
M_P!CU^XJ%7+$,TRA#RFQ%AYY]_#AC"?U0]U7ZMV0$_YKQ!\K]'C?VS13<21$
MH"B]UY6WJ'J Y0,RRA7!=!)  !8"2(D(C9$LCFFJ,FX\DJDP %"ZDNI*Q@M(
MEC T+2<JGQQ\!/9DB/=;O6)\1\K]% !*!.4GY_\ ;'P$_P OW>(^5^BO+-GY
MO]L?<$&U< 3/8G^7[O$?*_17EFS\U^VB4:@!F8&%F "R%-AYB"5()31F)F$<
M!N"22"!$A0H1$A).92!:K""1D2$Y LPPWB0@%8"P)L0>(%; 1H$C#  0G(@C
M:#%#4F4A"HD#4%SBE=R@ A+-8"2V+@B9"EF0 IA;)Y0RZ7J4)*5S#*YJ5I+;
&_P"5/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>form10k2016image2.jpg
<TEXT>
begin 644 form10k2016image2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_[  11'5C:WD  0 $    /   _]L 0P "
M 0$" 0$" @(" @(" @,% P,# P,&! 0#!0<&!P<'!@<'" D+"0@("@@'!PH-
M"@H+# P,# <)#@\-# X+# P,_]L 0P$" @(# P,& P,&# @'" P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@#&@&0 P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'
M" D*"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R
M@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*
M4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2E
MIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S
M]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41
M  (! @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC
M,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:
M8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:
M  P# 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBO.?VKOCDW[,'[+7Q*^):Z7_ &V/AWX6U3Q-_9QN/LOV\65G+<^3
MYNU_+W^5MW;&VY^Z: /1J*_#WX7_ /!W7\3/C5X?EU;P7^PWXZ\8:7#<-:37
MFB^*;K4((YE56,;/#H[ -AT;:>?G!K[6_P""3?\ P5N^(W_!1GXA>+-$\;?L
MR^-O@3;>'-.BO;;4-;N[J>+4W>3884\ZQMAN'WN"U 'W917Y!_\ !5W_ (+)
M_M!0?\%.]#_8_P#V5]+\,Q^/KB*$ZEK6L0K<.D\UI]MV(K_NHH8;/]\\CK(S
M9PJC9\_L?@/]J_\ :>_X)N_\$]?C=\6OVPKOP+XPU3P*L,OAJV\,)';+J)D9
M(46:5(U"^9=3PQ_ZH,H1V^;(H _1FBOQ"_8+_:S_ ."HO_!17PAX;^,WA?5/
M@SX?^%OB+5_(BTVZTR)=]I'=>1<2Q1MNG:.)EE'S7"LQC.*_;V@ HHHH ***
MX?X^_'CPQ^S#\%_%'Q!\::E_9/A?PC82ZGJ5UL:79"BY^5%RS,?NA5^\U '<
M45PG[.?[0?A?]JOX)>&_B)X)O)=2\*>++-;W3+J:WDMWGB+,NXQN Z_=/WA7
M=T %%%% !1110 452U75;70-*N+R\N+>SL[.)I9YY7$<<$:C+,S'A5 YYK\C
MOV@?^#L;0;_XTW7P_P#V:/@?XX_:)UJU9@U[IIF@@GVG!DMX(;:XN)X^@W,D
M77O0!^OU%?E+^Q%_P<:^._CQ^V3X/^!OQ4_9.^)7PI\6^.)Y(K!YI)MR*D;2
MO-+;W=M;.L,<2%W=6?Y?X>U?JU0 445\F_\ !;_]KCQA^PI_P2_^)OQ6\ 3:
M?;>+O"O]E?8);VU%U!']HU6RM9-R'[W[J=_TH ^LJ*^-_P#@GA^VEXX_:3_X
M(R^'_C=XFFTV;QWJ7A/5M9FE@M!#:_:+:2[6(^5_=_<)Q7D__!M=_P %,?BC
M_P %/OV5_'7BWXJ7FBWFM>'_ !7_ &/:-IU@ME']G^QP2\JN=S;I'H _2"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "OG_P#X*O?\HM?VF/\ LE?BC_TT75?0%?/_ /P5>_Y1:_M,?]DK\4?^FBZH
M _$__@VA_P""V/[/'_!-K]A/Q7X'^+7BS4M!\1:MX[N]=M[>WT.[OD>UDL-.
M@5M\,;*#OMY?E/M7Z^_LI_\ !5#X;?\ !4_X9?%"U_9M\9+?>+O"&EI%%>ZU
MH-U;V>FWUY#<BRDECD5&FC$MN[.J?PICO7YQ?\&D/[$WP:_:3_X)P>--<^(G
MPC^%_C[6K'XE7^GPW_B/PO8ZI=0VZZ9I<@A62>)G6,/)(VW./G;CFOV*^!O[
M*/PM_9@?5&^&GPU\ _#L:WY0U'_A&?#UGI(O_)W^5YOV>-/,V>;+MW9V^8_K
M0!_-S!^SC^T]XA_X.9O$W@:'XZ:+8_M"FV$]QX_@T2..S,;>'H)Q&EKY>P8L
MV2#[G_+/=SUKZ^_X+M_LQ?MA?##_ ((Y:XWQ(_:"\*>-_!OAFULCXSMHO#BP
M:CXINIM?B%KMFV 10PK+9?+'L+-;ONW[ZS_!?_*\5XL_[!,?_J&6E?;W_!T;
M_P H)_CE_P!P#_U(--H ^6?^#;W]E']J@?L\_ 7XA?\ #06F_P##/WE7L_\
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M?_%^X\:_ ?XR>.O@#J%V[2?9;&W;4K>QW-EEMF2>WGCC_P!EI7Q_X[7[!T4
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M\4:XH;3M'N]4@@O]07+#]S [!Y.C?=4]* .NK\5_^#C3_@DQ^SC^RG_P2?\
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MDCKJ6I2?97_Y=8OW4'_?(^]_P*N6^;VKUZ.3W5ZK^2/,J9G?^&OO/H'Q)^W
MI++H^A_[LE[,.?\ @"?_ !5<7J_[6_C35/\ 57EC8*W\-O:+_P"S[J\R^;VH
M^;VKT*> P\=HKYZG%/&5I?:.IU#XX>,+[_6^)-67_KE.T7_H&*H2?$CQ%+)N
M;7M;=O[SWTG_ ,56+\WM1\WM70J,%LE]R_R,O:3ZMF[!\3_$EM_JO$.MKO\
M[M],O_LU:FG_ +0?C32WW1>(+U_^NNV7_P!#4UQWS>U'S>U'L:;W2^Y?Y#56
M:ZL]8T7]LGQ9IJK]J73=27^+S8-K_P#CC#_T&N[\,_MLZ3?A5U;2;RQ8_P <
M$BSI_P"RFOFSYO:CYO:N6>78>6\?N-J>-K1ZW/N'PC\5/#_CN-?[*U6RN9&Z
M1;]LO_?!PWZ5TE?GY'(T4FY?D9?NM7H?@']J#Q/X)VQ3W/\ :]FO_+*Z^9_^
M OUKSJV4-*])W]3NHYDGI47S/L"BO/\ X9_M&>'_ (D^7;QS?V=J3_\ +I<?
M*S_[AZ-^%>@5Y-2G*#Y9*QZ4*D9J\6%%%%04%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<?\
M4OC%HWPHT[S-0E\RZD7]S:1'][)_\2O^U7,?';]HZU^&4+:?IWEWFN,O*Y^2
MUS_$_O\ [-?+FMZW=^(M3FO+ZXDN[F9]SR2_,PKT\%E[J^_4TB>?BL=&'NPU
M9U'Q2^.NM_%*X=;J;[-IV_$=E%_J_P#@7]YJXSYO:CYO:CYO:OHZ=.,(\L%9
M'BSG*3O)A\WM1\WM1\WM1\WM5$A\WM1\WM1\WM3]E)NP#/F]J/F]JCO+RWL(
M]UQ-'"O]YY%7_P!"JA<>.=!M9-LNL:2C?W7NXU_]FIZAIU-/YO:CYO:J%OXQ
MT6__ ./?5=-F\SY/DNXV_P#9JO1R++'N5]Z_WDHU"ZZ"_-[4?-[4_93/F]J2
M=P#YO:CYO:CYO:CYO:F ?-[5Z[\(_P!JW5?![PV.N&75--QL\S[]S!^)^]_P
M*O(OF]J/F]JQK4858\LT:4ZLJ;YH,^[_  OXJL?&.C0W^FW,5U:S#*NG\CZ&
MM:OA_P"&OQ2U7X6ZY]LT^;]T_P#Q\6[_ .JG7_:_^*KZU^&/Q0TOXL:!]LT]
M_+D7Y)[=S^\@;T/Y<&OF\7@9T7S+6/<]S"XR-56>C.KHHHKA.P**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MO)?VC/V@%^&]C_9>F/&^N7*\G[PLE/\ $W^UZ5T7QS^+=O\ ";PDUP/*EU*[
M_=6<+?QMZG_9%?'6IZG<:[J<UY>327%S<.TLDC?>=C7J9?@O:/VDUIT\SS\;
MB_9^Y'<9>7DE_<//.\DTDS[Y)'^9I&/\35%\WM1\WM1\WM7T:5CPP^;VH^;V
MH^;VKS/XF?M,:7X2WVNEI'JM^GR;O^7>-O\ :;^+_@-:TZ<INT5<BI4C!<TC
MTB>XCM;=I97CAB3YVD?Y5CKSWQA^U!X9\+AXK5Y-8N$_AM_]5_WVW_LM> ^.
M/B9K7Q N=VJ7\DR?PPI\L4?^ZJUS_P WM7I4LM7_ "\?R1YU3'7T@OO/4/%'
M[8'B+5-ZZ;:V6E+_  MY?VB7_OIOE_\ ':X#7/BYXFU[_CZU[4F7^ZD[*O\
MWRN%K%?K5=^E=T,/3CLCEE6G+=LBO)&EDW,^]O[SU3N/ZU9N:K7']:W)*=Q_
M6H;?6+K1KCS;.YN;:3^]$[*W_CM37']:H7-/3J:=;G6^'_VE_'7A+9]E\2:E
M,J?PW<GVI?\ R)FO0O!__!135+#9%X@T&VOXOXIK*1K>7_OD[E;_ ,=KP&X_
MI6;<?UK*>%I5/BBC2-:<>I]__#/]JCP/\59$M]/UB.SOW^[9WO\ H\N[^ZN[
MY6_X"U>A_-[5^5EYUKT3X/\ [9GC+X-R);_;/[;TE/D^PZA(S>6O^Q)]Z/\
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MHWWPUMY-.NM2D\6VD]PNDP+#PL:[UEBFD>1XE^6YW<[MF* /T9HHHH ****
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M?V;?%FG^)KZ,>,M+TF0Z5?K\HU5F78G3_EHK.C?[2\^N?S5^/>L>=>6%FO\
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MM62^;ZMMZFEX\T]?$?A>:)?^/B']['_O"N T.\^Y7>0:A7#ZQ9_V-XDF5?\
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MPN88SVTN6/PK\^Y]-@<*Z2YI;L****\\[@HHHH **** "BBB@ HHHH ****
M*&L:O;:)IEQ>7<T=O:VL9EEED;:L: 9+$^W-?(GAO_@L;X%U'Q%=6NJ:#KVG
MV"3LEK>VVVZ6:,'Y7=/D=,C^'YJC_P""M_[2[> /AO:^ =*N%75O%*^;?E&P
M\%BK=/\ MJX*_P"ZDE?E_P#$#QHO@CP^]U^[>Z?Y+=6_Y:-7Q^><05:%=4<,
M_AWNKJ_;Y?J?T9X6^$>"SC*99CG$96J.U-*3BTHNSEV?,]%=-65^I^UW@S]N
MSX1^.X5:T\=Z!;,PSLOY_L+?E-LKM8_C/X/EL_M"^*O#;08_U@U.';_WUNK^
M>_1_VBU^[?Z;_O26\G_LK?\ Q5=#9_'#P_=?>N9+?_?@;_V7-<-/B^NE[]-/
MYM?YGTF(^CI@)3OA\54BNSC&3^]<OY&__P %0/ VC^#?VQ?%,WAO4M.U30]8
MF_M"UFL)DF@C:3YGCRK$?(WR[:^?8Y*[SXN>.-#\6Z/;+9W/G75L^]?W;+\I
M^]]Y17GV^OD:U15*DII6NV[=KG]$9/AIX7 TL+4DYN$8Q<FK-V5KOS98\RI-
M]5?-]Z=OK'E/6YF6O-]Z=OJOYE2;Z35BU.Y8\RL'X@1M_9\-POW87^;_ (%6
MMOI+B..Z@>*5=\3_ ",M>OP_FSRS,:6.2OR.[7=;2_!L^6XXX;CQ#D.*R=RY
M75@TGVDFI1>G122;\KG!V^H5?MM0JMKG@>\TN1VM?])M_P#8^]'_ ,!K*CU!
MHI-K?>K^N,HSW!YE2]M@JBDOQ7DUNGZG^8/$W!^;\/XKZIFU"5.5W9M>[+SC
M):27FF[;/70ZJVU"J?C"/[5IZ7"_>MO_ $$U0M]0JY'>+*FUONR?>KV.;F5C
MYGEL,T.\^Y73Z7<5Q.GNUK</%_<KI]+N*NC+4FI'J=59R5VWP:\2?V#XL2W9
M_P#1[_\ =-_O?PUP%G)5^.L\VRREF6!JX*M\-2+7IV?R>IZG#>>U\ES2AFN&
M^.E)2MW6S3\I)M/U/I+_ %E8MQ'Y4CK_ '*\K\-_%_5/#DGE--]LMT_Y9R_^
MRM7;:5\4-+\1O]_['</_ ,LY?_BJ_+.$>$<UR'&U:-:TZ-174H]&NZ=FFTWW
M]3]D\7N/<BXOR?#8S"7IXFC)ITY+7DDKMJ2O&24HQZIV;T-9^M=Q\-]8^WZ6
M]JW^MMON_P"Z:X=^M6_#>L?V#KD-Q_#]R3_=-='B/PS_ &YD=7#05ZD??A_B
MBMO^WDVO5GY#P7GG]EYI"O)VA+W9?X6]_D[/T3/6M/N/+DKH=+O*Y5'_ (EK
M8TN\K^#:M/\ F/ZRIR70ZW^R[/6?^/B'>W][^+_OJN0^+$B_"O1X=4V7-Y8/
M-Y4FS;N@S]WTKIM'O*O^)/#]OX]\'W^DW7^IOX63=_SS;^%O^ M6F4UL+1QU
M)YA%RH<RYTG9\KT;375)W7>UNI.84Z]3"5/JC4:MGRMJZYNB:?1GS]K'[5D-
MK;O_ &;IMR]Q_"UQM5?^^5S7BWCCQAJ'C?6'O]2N?M-P_P#WS&O]U5I^JV\E
MA<36\OR2PNR,O^TM9OV>2ZN$AB26:5_D54^9Y*_OSA7@3(\A;K992M.2UFWS
M2MO9-[)^7Z'\FYWQ5FF:)4\;4O%?922C==;+KZW,N\ZUDWM>Y?#O]BCQQ\1I
M(Y9;#^P;!_\ EXU#]TVW_9B^_P#]]5]*?!O]B/P?\*Y(;RZA_P"$AU:'YUNK
MV/\ =1M_L1?=7_@6ZOJ:^84:>E[OR/%IT92\CY3_ &?_ -A?Q-\;I(;_ %))
M/#WAQ_G^U2Q_Z1.O_3)&_P#0F^6ON?X3_!OP_P#!'PNFD^'[".SM_OS2?>EN
MV_YZ._\ $U=1\WM7>_";]GK6OBE<)<;/L.D_Q7<L?^L_W%_BKY_'9C*:YJCL
MNQZ.'PUG:*NSE?"'@S4O'6MPZ?I=M)<74W_?,:_WF;^%:^LO@K\#K'X1Z9N^
M2[U:9<3W9'_CB?W5K<^'OPSTGX8Z.+32[?R]W,LS?-).W]YF[UTE?(XS,)55
MR1TC^+]3Z#"X-4_>EN%%%%><=X4444 %%%% !1110 4444 %%%% !67X@\0V
MGA?0KS4M0FCM['3X7N;B5_NQQHNYF_ 5J5\A_P#!7/X[?\*X^ 47A:SE\O4/
M&DWV>3'WDM(]K2_]],8T^C-7+CL5'#T)5I?97X]#W.&<CJYSFM#+*.]225^R
MWD_E%-_(_/W]HSXT77Q^^-'B#Q9=>8JZI<_Z+"__ "QMT^6)/P1:^4OC!XT_
MX2CQ8ZQ/_HMA^ZA_WOXFKT_XJ>+/^$2\'W,JOLN)O]'A_P!X_P 7_ 5KP'?7
MY#.4JDW4ENW?[S_1K X*CA*$,-AURP@E&*[)))+\"Q]IJ3?57S?>CS?>IY3L
M1<\WWH\WWJKOJ3S*35BN9]2Y')4F^J>^G>;[U+5RN9=2Q4GF^]5HY*?YE2U8
MM.Q9CDI_F57WT[S?>I:N7&3+6^J6J>'[/6/^/B'YO^>B?*U/CDJ:.2M\+BJ^
M&JJMAYN,EU3L_P"O+8X\QRW!YA0EA<=2C4IRWC)*2^YG'ZI\/[JP^:S?[2O]
MU_D:L?[1):R;95D1D^\KUZ9OJKJ&EV^J1[;B&.:OU/(?%C%T&J>9Q]I'^9:2
M^:T3_ _F[C3Z,V58WFQ'#U7ZO/?DE>5-^2>LX_?)=HGGKW'^D))_P!JZ'1[B
MF:Q\-Y(?FLYM_P#TSE_^*JGH\C12;6^1D^1EK]KX?XDR_-8N>"J*35KK:2UM
MJOU5UV9_)'&7 &>\,UE1SB@X*3M&2:<)6UTDM/D[-+5I'9Z?<5L6\E<WI=Q6
M]9R5];1EH?"25G8-8'E1QR_]]56MM0K2N(UNK=E;^.N2^T-:W#Q-]Y/D:G4;
M3NA16ECT7P7\4+SPE(J[+:_M?XK>XW.O_?2L'7_@+5[9\/\ QQ\,_B7LM[^\
MU;P9J3_)_I$BW5A_WWM#+_P*OEJWU"KEOJ%<U;#TZNNS[H-.I]X:QX#_ .$#
MTRP6+4H]8L[F'=;WD4>U9%_X"S56L[CRY*^1? ?Q@UKP&Z+87DGV7?ODLWD9
M[>3_ (#7U+\/]<;X@^"[;7+.VD>UF^1MGS>1(/O1MMK^*_%SPVQN4X^>:8:/
M/AJLKWBO@D]6I)+1-W::TZ;K7^AN ^+,/C,+#!5Y<M6"MK]J*V:?5I;K?KU.
MSTN\KJM#N&ED15^\_P!VN/\ ">CZAKUPD-G9W-S+_=BC9J]:\#_"/5M*D26Z
ML[E[I_DCABCW?,?]VOS+AS@[&YWBXT:,7&G=<TWI%+J[]7T26MV?:9QQ)ALL
MP\JE1IRMI%:MOIIT7F]$>=:?^Q/X+BU2:\OTU+599IFE999]L6XMN_@56KT+
MP?\ #/P_X#CVZ-H^FZ:WW-UO JRR?[S?>:O4]$_9S\9:\JF+0KBW1NK76V#_
M ,==@U3Z?X'_ .$2O+J*Z>.:\A=HF9/F6/']VO[4K9E&E3Y>:]DE:_;34_F:
MC@YU)W:M=MOYZG&?V)>>7N\F1/\ ?K8\"_"W6OB'J\EGI=ON9/GD:5U58U_O
M<_\ LM;&I=ZY74-8NM!U".\LKF2VNH7WQS12;7C:O,_M6JULOZ^9W_V?"][L
M^DOAC^R/I'A,)=:T\6M7BCB-TQ;1_P# ?X_^!5Z]%$L,:JJ[57Y55:\M_9?^
M._\ PN3PQ-#?>6NM:852YV?*)E/W9%'\Z]6KS*U:I4E>H[GH4J,*:M!!1116
M)H%%%% !1110 4444 %%%% !1110 4444 %?D#_P4X^,[?%K]K#6X8IM^G>%
MC_8MM_=W1_Z\_A*S#\*_4OX[?$R'X.?![Q+XHF"L-!T^6[56Z.X4[%_%]J_C
M7X6ZWK[.]YJ%]-)+(WF75Q,WWG;[S-7Q?&&*:A##+KJ_EHOZ\C^DOH[9 JN,
MQ.<5%I32A'UEK*WHDE_V\>.?M >*?[4\40V"O^ZL$^;_ *Z/\W_H-</2:QJD
MFLZI<W4O^MN7:5OQJ+?7QT58_JESOJ2;ZD\RJ^^G>;[T-7*4[EK?3JKT[S*7
M*4G<L;Z^R?"W_!'K7-6^%/@WQ9JOQ4^%WA>S\::7;ZM81:UJ,EG(Z2PQR[?G
M3:S(LBYV^U?&6^OU1_;#^"'P[^,7[%?[*O\ PL#XM6_PK_LWP/#_ &?YVARZ
MI_:1>PTWS?\ 5NGE^6$C_P![S*]3+<+3JPJSG'F<4FO>Y>J6Y^?<=9]C,!B,
M%0PM5TXUI34FJ;JRM&FY*T(IR>J5[+17;T1\:?M;_P#!.KX@?L;Z!INN:\V@
MZYX7UB98+36]&NOM5F\A5G16RJNNY5?^';_M5Z9IG_!(K[=I]O/_ ,+Z^!</
MG(LOEOX@^9-R[MK?+7HO[?7AI?A9_P $O?AWX/\ AU=1_$'X76>JM?7GC1;N
M/BY+SXM_LPYA7S)6^]]WRPOWFKXY_8\_9[OOVJ?VC_"?@6S\R.'5KQ3?3)_R
MZ6<?SSR?@BOM_P!JKQ&%H4<0J,:;ES<MDY/1O>S6Z[/;0X,ISK-,?DLLQJXQ
M4?8RJ\TE37O0@]'*#=Z<DD[P=FKZI6/0_P!LO_@GIK7[%_@KPOKFI>,/"GB2
MQ\7/(E@VD322;XTC5_.5F4*T?SI\RUX+H]FVLZI;6:OY;W,RQ*S_ -XMMKZL
M_P""D?Q O_VOOVW(/AY\.])DU#2_ \/_  B7AK2['[C_ &=6\]D7_>1U_P!V
MW2O'?&'[)OQ'_9T\0^&;SQUX/U;PW;:CJ45O:O=(JK/(&5F5=K&N/&X6"KS^
MKQ?)%VOJU=63_$^BX7SNN\KH+.*T?K56+FH^[&5G>4?=3W4=&TOBOV+G[9/[
M(^M?L6?%Z/P?KVI:3JE]/81ZAYUAYGE;9&E55^=5.[Y*L>#/V.M<\;?L:^+/
MC1;ZKI,.A^$=4CTBZL7\S[9/([6B[DPNS;_IB_Q=J^]/^"JW[*?PN^-7[3MM
MK'C/X\:)\-=5CT2VMTTJ[T8WCR1K),1+O6>/&=Q'3M7-^)O@_P"$?@=_P1-^
M,>F>"_B)9?$S2[CQ'974NJVEB;-()C=:2C6^PN_141MV[_EI7I5<EC"O6NO<
MC&37O)O1::7O^!\1@/$RKB<IRWDE+ZS6J4(5+T9J+4YI3M)P5/5/1J5^Q\T_
M K_@FMJ'Q2^$.E^.O$WQ*^&OP[\-:\\B:;)KFL(LEWM;:>-P1?F_AW[O]FN:
M_;!_83\6_L;?V/>:M>:+X@\->)-SZ7KFD3^?:W>%W;?NC:VUMW]UOX6K$_96
M^!/@[X]OK$?C'XL:+\,XM*:W6S_M*U:Z^W^9YF_R\2+MV;$S_P!=*^E/^"I5
MAJ7PU_96^$?@/PS9R:Q\)-!9IM.\8I?6]U%X@O&21CCR6;RE&^7:K?>_X!7'
M'"T)X.57DM9*SYKMOS71?<EW/H*V>9EAN)*&7O$JI&I.2E"5+DC&'*Y+DJ/X
MYK32+DY:MJ*3M\,^97*^+++[!KB7"_<N?_0A71;ZI>)+/^U-*=5^\GSK^%>G
MP+G7]EYO3K2=H2]V7H[:_)V?I</&7A'_ %BX7KX:G&]6FO:4^[E'5Q7^*/-'
MU:;V*VCW%=)I]S7&:'>5T^ESU_7M&6I_F+4W-Z.2N5\>6_V"\2X7[LWR-_O"
MNDMY*K>*-+_MG0YHE_UWWX_]X5TU$Y0:1G&23U./M]0J_!J%<K;:A5RVU"N&
M-3L=$HG50:A7Z.?\$/?C\W@3X=?%+2YX_M:QW.G7&G1-'NC2:9;E)6;_ (#!
M%_W[K\R+?4*_27]@[X"ZE\!/@WI>K:U;R6>J>/K>/6DAE^5H[/=(EMN_WU5Y
M/]V2O XJQ$5@)4Y[R:MZIW.[*:+>(4ETN?6LOB2XU[4'NKJ;SIYOG9JOV\GF
MQUQFCZI70Z?>5^6'U1ZS\'/B]-H5Q_9>I3;K-_DMY)3_ *AOX5_W:\[N)&EW
ML_WGHCD\ZB3_ %= V[F1J?W*XOQ))]^NPUG_ %=<3XDD^_51$=9^Q-KDUC^T
M5;VZ_P"JU*SN(77V"[Q_Z!7VU7Q'^PXC2_M'P[?X+"Y=O_'5K[<K.6Y40HHH
MJ2@HHHH **** "BBB@ HHHH **** "BBB@#Y _X+'_%/_A$?V7K7089 L_BS
M5([=QZP1?O7_ /'UBK\@_C9KG]C?#^Y57^:\=;=?Q^9O_'5K[]_X+9?$#^U_
MCIX8\.QNIBT'2&N7 _AEN)/F!_X!#'7YJ_M*:Q_I&FV"_P "-<,OU^5?_07K
M\PXBK^US&45]FR_7]3^[?!G*?J'"%";7O5N:H_\ MYVC_P"2J)YOYOO3M]5_
M,J3?7F'Z+S%CS*7YO:JV^G>;[TBT[%K?3O-]ZJ[ZD\RD4IV+5?I=\;['X(?M
ML?LI_L^:+J_Q^\,^ =4^'/A."RO;633FOG>62SLDDC8>;'Y9C:U_VOTY_,FG
M;ZZ\-BO91E!Q4E*R=[]'?HT?/9]P^\QK8?$TJ\J-2@Y.,HJ#UE%Q=U.,D]&^
MA][?M0_M$_"'X _\$_7_ &??A;XLNOB-?:YJJZEK&M-8M;VL&R2.7*;E^\S0
MQ*H3?\H<[JYW_@GU\>_!?['/[+/Q5^(0\0::_P 6]:M/[ \-:4AW75I&^W-U
M_N^8=W_;G_MU\6^;[U)6KS"?ME622Y5RQ2VBNEKWU1P1X'PJRZ>73JSDJM3V
ME63:YJCNFU*R249<J322T5NIM>%?&VL^!?$]OK6BZQJ6BZQ:,S6]_97<D%U
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MD5G+<J.P4445)04444 %%%% !1110 4444 %%%% !1110!^+?_!2+QPWC?\
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MVI0R6]Y8S-%-"_WHV%?I57S?^W+^SZVO:9_PFFCP_P#$RTU/^)C&H_U]N/\
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M/,JOOHWTN4OF+'F5)OJ"/=-(BK\[/]U:]1^&GP+DNME_KR;(OOQVO\4G^_\
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M-=/LMTUBT>9O]GSEW5^D$4BS1JRMN5OF4U^:?A_][\1-'W?\_D?_ *%7VQ\
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M>/OB5\1?B(UA-IPU#Q#?1M;Q0R_ZS"+'O9C_ +<K4 ? '_!P!*ND_P#!SO\
ML8:G=LEMIT(\%^9<R/MBC$?BN^:3<QX^52":_?\ KXV_X*S_ /!%7X4_\%>/
M#>@Q^-KK6O#OB?PF)DTC7]%>-;B..3;O@E2162:'<H;;\K*P^5UWONC_ ."6
M/_!'C1O^"7^J^*]2L_BA\0OB5JWBZUM;*:;Q+=)+':0VS2F,0H%W+_K>?G-
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M#%EX3\*:3N:*SMRS,[M]^:65V+RR-WD=F8X'->8_\%"_^"M'P8_X)BV.@_\
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M]/\ "?A'1%5KG4+K=C<S86-(T!>21V^['&K,WI7Q7\"?^#GW]F/]H+XU^&?
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M[_V +1?'4ES)\3/A9J4O@WQ0UR?](NYK=5,5Q)_MO$RJ['[TL<U 'WI1110
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M_P#!>C]G+]J7Q9H5_P"-/AS<:)/X0CL-*,=UJUA>B.^7=;V;.'FVK?)+F/\
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M#,\GS<*@$'_!S#_P2C^/W_!5'Q#\)=+^%-GX;D\-^"X=1N-0DU/65L]]U=-
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M:YT/P<=5M9_[=O/.\^.(SPQ[UM?/;S<7$N$8?+%GYA^H7_!$[_@F%JG[#O\
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M&Y_=M<NY"0;_ .%?FD;CY-OS4 ?<E%?CI=_\'0OQ>\(:?_PD'BW]@/XW^'?
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MD>^!K4;D_A_>6,O>O-_^"_.G:Y_P3)_X+>_ K]LJ#1K[5/ MU]FTS6Y+./\
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M1\,O!.@PZ'X%T&R?3K+3([B658879F==[LTC,S.Y+,V[<>M>A44 >)_L3?\
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M#65U[S/[0MBWW0[S--<6S.H94D6>6+S/]8F=F_H_^#13_DZ7]NS_ +&K2/\
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MP(\7W-E<:EK>I2WM]?6;S21<RS,TLGE7,$P^8_*LL"U\*_M/?\%0/@W\0?\
M@YM/Q$^+_B2XL/A3^SDDVB>'OL]A-J2WVIV6Y=VR%7Z7TUQ,L@_AM(*A\'?\
M%6O@OX1_X.;?#?QF^#OB:ZU+X;_&ZSM/#7C-KC3YM-2TN[K;:[BLRK^[6:WL
M;EY/>>@#]?O^"L?[,7[3'[4?@WP;X<_9Z^,EC\'K.XOY8O%]\866_>S9,I);
M3HIE1D==OEQM$6\W_6JJG/YD_P#!1;_@FO\ M2?\$=?V8M4_:&\$_MM?%7QK
M>>";JQ?6]/UI[I8;\7-W#;+(L4UW<PS?OYTW0S(WRG[QQAOV[_:3TGQ]KOP
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MU\(?\'.W@*Q\<_\ !$SXR-=*OG:*NEZI9R%=WDS1ZG:#Y?\ >1G3_MI7JO\
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ML-?L >+O#7Q:M;>Z\<?&J::[\7V*W1G%M:R0M EB\H8K)((WF9V7^.X==SA
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MZ>T5ELC'YFQ3M#^6X_"OV'HH _&OQ;_P5T_X*0?'?29/#OPX_8AO_ 6O7ZM
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M=^P_\)?AO=B%=0\&>$].TJ_,0&Q[R.W3[0RX_O3;VKR_]H#_ ()1>'/VHO\
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MSXW?\$I/%'@>37)+75/A[XDO='T:[:-;AM-M;FWBN8&V/PVRXEN&"M\I "T
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M+:Y:_P#".+X%_P"$K-_OC9?^/3SL?W?,W_)L_O\ R]:_.O\ X,MOA)?>%/\
M@GC\0/%MY#-#%XP\;216>_[L\%K:01^8O_;5YD_[9TR7_@S[\(2%O"Z_M'?&
M=?@_]O\ MH\%[X]@;=G=YF?L_F?]-/LN:_5+]G']GCPA^R9\$O#7PY\!Z.FA
M>$?"5HMEI]E&S,(URS,S,>7D=V>1V;YF9RQY- 'Y?_\ !ZE_RBT\ _\ 94].
M_P#31K-?I_\ LH_\FL?#3_L5=+_](XJ\5_X*Y_\ !+KP_P#\%;?V<=$^&_B/
MQ5JWA&QT7Q)!XDCO-.@CGE>2*UN[<1E9.-I%TS>OR5]$_#/P/#\-?AKX?\-P
MS27$'A_3;;38YG^5IEAB6)6;'KMH ^8/^"^W_*&[]H7_ +%67_T9'7G_ /P:
MY?\ *"?X&_\ <?\ _4@U*OJC]MS]EJP_;9_92\<?"C5-4O=$T[QQIK:;<7UI
M&LD]JI96W*K?+_#6'_P3@_8CTS_@G)^QKX.^#.BZUJ'B/2_!IO?(U&]A6*>X
M%U?7-X=RIQ\K7!7CTH ]TK\7_P#@V=E7P_\ \%/O^"B.@ZGQKI\>1S;6.YBL
M6JZXLIW?[TL5?M!7XP_'^PE_X(X?\''6B_&;5#_9WP1_:KM#X=UK46&+31]7
M=8_];T6/=<06\WF-_P L[BZ/\#T >=?\'/,5[^R/_P %:OV2/VG+VQN;GPGX
M>FL-/U"2%-W_ "#=4>^DA]%>2"[EV>OEO_<K]P_AK\2M!^,'@32/%'A?5[/7
M?#NNVZ7FGZA9R++!=PNNY65A7$_M>?L<_#W]NCX$ZM\.?B9X=M_$'AG5V61X
MFD:*:UE7[EQ#*OS1RID[67UV_=)S^9.D_P#!I6/A==WFG_#+]K3XX> _!MY*
MTDFBV[Y:3/7>]O/;Q,VWY=WDT ?J-^U=(LW[+?Q.56W,GA;5%;'\+?8Y37YC
M?\&5O_*+3Q]_V5/4?_31HU?;7[#O_!+7PS^PQ^Q;XC^#&A^+/%GB.S\62ZC=
M:EK6M21R7LEQ>VZP22*$55VJJ+A6W'_:-?!?A'_@SV\._#_1)M+T7]ICXR:/
MIMQ(TL]GI\<5K;SL0%8LB. 25&W)]* ,7_@[M_;5\.^,_@GX._9A\%WT/BCX
MI>+O%-E?7VBZ:5NKBRA194@MW5<E;B>>6'9'][;&>,,F_P#5G]A7X#S?LN?L
M7_"?X<W?EMJ'@CPEI>B7CHVY)+B"UCCF9>3]Z17;\:^:O^"='_!O#^SK_P $
MXO&D/B[0=+UOQMX^M6:2U\0^*KJ.\N-.=EPS6\<<<<,;'G]YL,O^WUK[OH _
M$'_@MU_RLT?L-_\ <'_]/5S7[*?&#X4>'/CS\,-=\&^+M)M]>\->)K&33M3T
M^?<(KJ"1=KH=I!'7[P^9>HQ7S#^V!_P1_P##?[8'_!0WX._M#:EXPUK1]8^#
MOV3[%I-O:Q26VI>1>272^8[?,N6DV_+7U#\7? 3_ !2^%GB7PU%JE]H4OB+2
MKO3(]2LFVW5@T\+1"XB/_/1-VY3ZB@#\J=1_X-9_@W\ -)\2:A=_M$?&SP?\
M#U\W5=>\-'Q##8:7]E3YW%S/M"-"%7:69-VW^//S5YU_P:<_!K2?%_[1G[5'
MQN\&^'_^$;^%^M:ZGAKP5:+&R+'9K<2W/E[F&[=%!]AW?WFD.ZO6+S_@UQU#
MXPSV=C\;OVP/V@_BYX1M'61=#O=2F6)V7! S<SW2JO'\*!O]JOTL_9V_9V\%
M_LH?!W0_ ?P]\.V/A?PEX;A^SV5A: [8U/)9F8EY)&8[GDD8LS99B2: .^K^
M8W_@X8T&W_X*7_\ !4KQW9_LX^#KCQ'XB^#_ ()N7^)6NZ3-^[U'[%N\U-J_
MZV2"/;;?+F25OW>W;#FOZ0_C9X+U;XD_";Q%X?T'Q-J'@W6-;T^:QM-=LH5E
MNM)>1=OVB)6^7S$SE=W\0%?.W_!)[_@D9X#_ ."2GPH\0:#X5U'4O%&N>+M1
M%_K?B'5$5+R_" K#$=G"QQ;GP/[TDC=Z .2_X-Z/VB_A5\?O^"6OPZC^%6EV
M_ANR\&6G]@:WH0D\V;3=3C^>Y:1O^6GGM)]H$G\7VCG#;E'W+7Q#^Q?_ ,$4
M_#'_  3^_;F\?_%KX7^./$&@^%_B-YC:KX!%K"VCJS_O%,3<-'Y<Q=H\?<21
MXQ\M?;U '\__ /P;N?$#3?\ @G9_P69_:?\ V<?'EQ'X?U;QIJRQ:"UXRQ)J
M<UE=7,EI&C'^*XM;[SHQ_&/]HJ*_?N65;6-V9PJJ-S,WW5%?$G_!4?\ X(._
M!7_@JSJUCXB\41Z]X1^(6EPK;6OBC07CBNI(DW&.*Y1U9)HT9LC[D@QA9 O%
M?+=O_P &G<WC.UAT;XB?M=?'?QMX-@VH=%6<P(8QQY8\Z>XC7Y>/]50!+_P>
MI?\ *+3P#_V5/3O_ $T:S7Z9?LSZQ:>'OV0_A[?7]Q;V=G:^$--EFN)W6**%
M!9Q%F9CPJUY%_P %<_\ @EUX?_X*V_LXZ)\-_$?BK5O"-CHOB2#Q)'>:=!'/
M*\D5K=VXC*R<;2+IF]?DKXBC_P"#0'P3XH@MM-\9?M'_ !T\3^&8=O\ Q*_M
M4$2C;]W;YJS(N/\ <H \(F^)&F_\%BO^#K7P+XC^',H\1?#OX#Z=;_:O$%L-
MUF\6G-<W/G(ZXW1OJ-T(4;D/]X;HZ_9O]K+]B'X1_P#!0'P/IWAWXK^$]/\
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M?\%OM+_9?_9U\;>%?#__  D6@PWNFPZYI%K-;I,EC<WDYDG>"609CMWQP>U
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M.WGP7\2?"O7_  CX<N=?O?[8U+S9T:&ZL[?[.\#01/&W^EAOF_N>]>%?"/\
MX/'/@]I?@]+#XS?#/XI>!?B-I:+%K&EZ=ID-U:^>%^81>?/#-'EN?+E3Y<@;
MG^]7D7_!O=\6)/VR?^#@+]HWX_>'/"OC#2_ASXZ\):DVG7VJZ=Y2I+)J.D%(
M))(VDA$Q6&5MBR-]P^E '7_\[M'_ '*W_NLU^TWC/P9IOQ#\(ZIH.L6D5]I.
MM6DUA?6LHW1W$$J-')&P_NLI(K^>_P#X*!_MU^$?^";G_!UYK?Q<\=:;XCU3
MP[H'ARUMY[?0K>&XO7:XT%($VK-+$G#/D_/VKUW]I[_@Y*\??\%'_AAK/PM_
M8W^ ?Q9U3Q+XRMI-)D\1ZI8QJVC0S+LED1;>26&.3:S 333HL?WJ /#/^#</
MQYKGA'_@EK_P40TS1[FXU#2_"OA2YU/0Y(=V)[Q](U=69 OS;F6UM>GM7W%_
MP9UZ+9Z9_P $D;R>UDC>;4O'>J7%XJIMV3"WLXL'U_=QQ5ZY_P $6O\ @CC:
M_P#!/G_@F]K'PM\=-:ZAXL^*:W-UXU>S<-$GVFW^S_88I-OS1PP_Q<YDDF9?
ME(K\X_\ @F=_P4=G_P"#:/7/B=^SC^TMX(\<-HX\03Z_X5US0K)+J+5E=(X)
M)(O.EC5K>1((9%*,=DAD614;- 'K.NO_ ,(=_P 'L6CG2V\Y?%7AEQK!B7_4
M[?#,VW?C_KUM_O>HIG_!H(9/$W[0'[:7B#5&_P"*BO\ Q+I9O(I%/G0;[C67
M?+'GYW_6.KW_  0V\">-O^"E7_!8+XJ_MS^*O".J^$/ MU8MI/@B"_C97N]\
M,=G&T3-\KK%9P/YC1_*9;CY<_-7G&@?&/5/^#9+_ (*]?&[6/B!X)\5:I^SW
M\?[EM6TG6-"MUG6VF^T37,$2[V2)FM_M%W"\+,LFW9(N5^^ =[_P<:-_PAO_
M  6Z_8,\1Z6WG:Z_B&PMVMT7]X\<6N6C1J<<E7\Z9<?6L/\ ;U\0>)/^")O_
M  <%ZU^U7XA\#>*/%_P2^*^BKI]_J>BP>=)I+M:V\4L!+%8UF$UFDRK(R!XI
M/E;<K8SO@7\0-<_X.)/^"[GPU^-7AOP;XC\/_ #]GN*"XM=4U>U$9O;RUF:Z
MB^ZS1_:);IH?W:NVV"WW<-7Z4?\ !1+_ (+C_ W_ ()?_%G1_!OQ3F\5V^K:
M]I']M6;Z9I7VR!X/-DBPS!P5;=$W:@#\?/\ @XH_X*YVO_!5/]A7PVWPW^&/
MCK2?A)X9\96M[=^-/$UG'8)?:HUE=QP6%FBR/YO[J6YDD;=\OE)P 06_H _8
M^34HOV2?A>NK-OU5/"&E?;&7.UYOL<6_KS][-?C'\;_B3XW_ .#J+]J#X9^%
M?!/P_P#%_@O]E#X=:PNO>(?$OB*U^S/XAD'[MXXMC-%YGE>;#''&[LOVAY),
M#"#]WK:VCL;9(842..-=B(@VJBCL* /QD_X+[VW_  T1_P %P/V%/@[J1$GA
M^#54\17MM,/W%XLFH1^9&W][=%ISIC_II_M5]Q_\%]O^4-W[0O\ V*LO_HR.
MOAW_ (.+G_X9<_X*R?L1?M#7TGD^%=+UY- UR]Q\MA#'>Q2MN)X^:"ZNV7_K
M@]?<7_!?;_E#=^T+_P!BK+_Z,CH _+'_ ((W?M2?\%#OAG_P2Z^'>D? G]FW
MX<>//AG8Q:L="\0ZKKUM%<WS-J=[)/OMSJ4$GR7+2Q[?+7<L?OOKLO\ @WA\
M0:#XS_X*U_&;Q-\?-0\4Z/\ MF:[;7,=SX8U?0H],T^QM3Y4DHLV$KM+(L$5
MOC<L6(,[/-4N]>>?\$<?^#GGX$_\$[O^";'P\^#_ (N\(_%K6/%/@]=3^TW&
MC:;82:?.USJ=W>1A));R.3[EPBL3%][\Z[/_ ()1>!OBK_P51_X+Z7G[:M]\
M-];^&WPK\/6DT>G'549?[1W:/)I<,,3NJ^=)MD:9VC7RX\;=WW-X!^[FM:U:
M>&](NM0U"XM[.PL8FGN)Y7"1P1JNYG8G[J@"OQ/_ ."+UE=_\%>_^"U/QH_;
M*URUNI/ GPY<^%_AZD^_RHW:-H8BN?XDL]\TL?\ #+J8:O?O^#J3]O2Y_9>_
M8!_X5GX9N)/^$\^/-P_AFU@MVS<)IGR_;V4#/^L62*VQW^UG^[7U)_P2 _8.
MM?\ @G%_P3\^'OPQ\F%=>M[+^TO$DR;?](U:Y_>W/S+]X(S>2C?\\X(Z (?V
MEO\ @L[^S+^QU\8;_P  _$KXL:3X5\7Z9'#+=Z=<6%[*\"RQK+&Q:*!D^9&#
M?>KYI_X+]?M(^"OVN/\ @W&^+/Q"^'6N0>)O!OB#^Q_[/U.".2)+OR?$]C;R
M[5D57&V6)U^91TK["^-G_!,O]GS]I/X@WGB[Q]\&_AWXP\37Z1Q7&J:MHT-U
M=3K&JHBF1USPH"_2ODS_ (.(/@KX1_9Z_P"#>7XP>#_ GAW2/"?A;1_[%%EI
M6EVRVUK:^9XET^638B\+NDD=C_M$T ?&?_!,C]NO_@HI\-/V!?A9H?PK_97\
M&^-/AWINB+#H.MW=^J3ZC;^8VV1E^W)W/]Q>E?.7_!2#X_\ [2GQ_P#^"KO[
M)5Y^TI\)-%^$NN:?XETF'1[339_-2^MSJ]LSR-^_FZ/\O45^XG_! G_E#=^S
MU_V*L7_HR2OS@_X.;O\ E,_^P_\ ]A73O_3Y;4 ?LO\ M6>._''PS_9X\6:_
M\-?"<7CGQWI=@TVBZ#+<+;IJEQE?W;.S+M[\[J_!W_@KA^VG^U!^T=X,\/>!
M_P!K[X5>)/V;_P!G74-8MY=>U?P?H*^(KB^F1M\,$MR]WY,2[AN7;\VX?<EV
M;*_4S_@I/_P6_P# W_!*KXY>&_#?Q,\"_$*\\*^)])6_@\5:'81W5G:W'G2Q
MM;2AVC^8*B2?(S-^\'R5^>__  5T_P"#@OX;_P#!3W]D'Q!^SO\ L[>"/B1\
M2/&_Q.>TM,#066.QACO()V98U9I9)"T2*OR!%\S<7^78P!^R'[%;?#G_ (9+
M^&\?PBNK>^^&-KX<LK;PO/;N[I)81PJD6XOA]^T?/YGS[L[OFS7 ?\%6O^"=
M'AK_ (*?_L<^(/AGKOV6QU-O^)AX=U>2+>VB:G&K>3<>NP[FCD4?>CD?H<&J
M'_!&3]DCQ%^PI_P3(^$OPN\6R*WB;PYIT\^IQJPD6TN+N\GO7M]XX;R?M'E;
ME^4^7QQ7-_\ !;7_ (*G:3_P2G_8TU+Q8C6MWX]\1%]+\'Z;*-PNKTK\T[KU
M\F!3YC^OR)U<4 ?B?_P\Y_:6^(_['VG_ /!."W\.ZL/CTWB:3X?7^KO/\QT&
M$;?LAD!/&U75[C_5_88OXM^\?OQ_P32_8"\)_P#!-']D;PS\*_"L<<W]GQ_:
M=8U'9MEUO4I%7[1=/_O%=J+_  QHB?P5^(>K?\&_WQA\ ?\ !-+3_P!JJSUS
MQ1'^UYI^M-\4=0C><_;/L;_OVAV]6OD_X^GW==\D.W=U_8S_ ((Z_P#!3;P_
M_P %5/V--&\?6'V>Q\5:>%TKQ7HZ.,Z9J**N]E7KY,O^LC8_PG;]Y'H XO\
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MU=K728)45O,90K#<JM^]N)-N]=E &Y_P4K_;<_;5^ 'QFU71_@/^S+I'Q/\
M!MKIUO<6_B*ZU+YY+AU_>Q_94GCEDV'^[7R+_P &X_C3X??%#_@H+\9/''Q4
M\2^+/^&T/%$,T.N>&_$7AK^P8]&M4DB\^&Q022>9L\JW5O,\J58H_P#5;?-=
MO8/#_P#P=_\ [+@TJ;_A)=%^+W@_7K+<MUHM]X>C>XCF'WHU*3E>N1^\V?\
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M\5=:\#:+X\\':QXV\-IYNL:!9:S;SZII2?+\T]LCF6%?G3[ZC[XH [BBO/\
MX<_M-?#CXQ>.O$'A7PG\0/!?B;Q1X3FD@UO1M+UNUO+_ $61)&B=+F".1GA9
M9%9")%'S#'M71>/_ (C^'_A5X,U#Q%XIUS2?#>@Z1#]HOM3U6\CL[.QC[R2R
MR,$C7W8T ;U%<;\/_CUX%^+?PU/C3PMXR\)^)O!ZK,_]O:3JT%YINV+<)3]H
MC=H\)M;<=WRX.:Y_PG^VK\'/'WPOUOQOH?Q9^&NM>"_"[^7K'B"R\3V5QI>E
M-A3MN+E)3%%]]?OL.H]: /4J*Y?X4_%WPK\<O!%GXF\#^)M!\8>&]2,@M-6T
M74(M0L;LQNT3^7-$S(VUT93M/# BJ_Q?^.G@G]G;PC_PD'C[QAX7\#Z")DM_
M[2\0:M;Z99^:_P!U/-F94W'!PN[F@#J+FVCOK9X9D22.1=CHXW*ZGL:K:)X8
MT[PQ'(NGZ?96"S'<ZV\"Q*[>^T5!X)\9:3\1?"NG:]H&J:=K6AZU;QWFGZA8
M7"7-K?02+O2:*5"4DC=2&5EX(.:V* "BBB@ HHKPCXM?\%./V=_@-XOF\/\
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MNK5O[RK=SSPG_@49KYB_X/=O^36O@C_V-5[_ .D=?M]0!^'?_!#[]H;XF?\
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2BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>form10k2016image3.jpg
<TEXT>
begin 644 form10k2016image3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_[  11'5C:WD  0 $    /   _]L 0P "
M 0$" 0$" @(" @(" @,% P,# P,&! 0#!0<&!P<'!@<'" D+"0@("@@'!PH-
M"@H+# P,# <)#@\-# X+# P,_]L 0P$" @(# P,& P,&# @'" P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
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M>*;RW\17BW^I7>O7\=U=74R1[%/[N..-?E_NH*^>_P!JW_@V)^ '[1OQOO\
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M=-@-O'IJWMK_ &&5.F2:;\T7V;SL^3*6_P!?]_'\/RU];T44 %%%% !1110
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M_%7B#XR6#:7*KE9(]DD$38QS_K+FWH _62BBB@ HHHH **** "BBB@ HHHH
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M7[:ODWWQA\?>(/#?AV9][66K7TEU<R+S]RR#"*+I_P M-O\ N5YN'XJI8O\
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M/];! UG9C_>ED7<O_?JO#_B#_P %'OB]\2PRMXP^'GPITMOO16L\>HZEM/\
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M-<K\O[I:_(7P%^T/X]_8&^($UK;Z7JWANVFF\V^\(ZWN>SG7^*2UG_A_WO\
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M9V/L#]FCXH-XH^'%O%(^^\TO_1)/]T?<;_OFO4;/7.:^8OV"]8T<?'RPT'Q
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M?$2H58UH;Q::^1A6I1JP=.6S37WG._"/Q-'XG\ :;<*W[Z&%;>9?^FB?+_\
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ML+>_B_A66/[G^ZW5:\>\>_L46MR7G\,ZE)9R?PVMW\T7_ 7^\O\ X]7NU/\
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MAQ_87BVW\10)^XUC]U<?],YD7_V9:^I*YGXN> 8_B9\/M2TEO+\R9-UNS?\
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M^)XV*?[QL[#2%\O3(?9:N4Q$\J)5_NT^OU:G'E@H]D?(RE=W"BBBM"0HHHH
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MPJO/!/A*31(?!VM_Z'XG\2S%9=UY/;;0NU(KG;\KRM_H\'_ ?NWX]ZW\$O\
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M^%[%[%+1=TMXS;[B_F/WIIF_B9C^GRC"\4[Q'X!U+PR6:2+SK?\ YZQ?,O\
MP+^[7T$."L1DU&R3J7UE.]W*75O;[MELCXOBSQ0IY]5^IX*<HT(RO[_QU9;>
MTFT]7_+':$=$KW9Q-YX7DB.ZW?<O]W^*LUU:-]K+M:NQ^;VJ*YLH[J/9(NZO
M.=)'@4\;*.D]3E/F]J6MFX\+Q_\ +)]G^R]4)]#NK;^#?_N?-67LY+<ZXXJG
M/J5:D\WWIGS1?>I*DU:N6**C\WWJ2DU<@?\ -[4_?4-/^;VJ6K$-6):*;OIR
M(TGW?FI"';ZE^;VJ6V\/W5U_!L7_ &ZTK/PXD0_>-NK>GAJD]D<M3$0CU,F.
M-I)-JKN:M*S\.22_ZQMO^S_%6M;1K:Q[57:M31_[-=U' P2O/4X:F+D]M#E_
M&]E'I]I;K$O\;;JXW5)*[[XHZ1=:9'IS7$4D7G&7:K?>XV_PUY]JG]:_9.':
M+I8"$)*V[M:V[/S7.*JJ8N4D[[?DCC_$DG+UYOXLD_>5Z+XDD^_7F_BB3_2*
M]\\T]F\/WBQ6<*_W$6NJ\.:_<:%J=O>6S;9K=]P->;^']4_=)75:7J%0U8#Z
MU\">,+?QMX<AOH,*S?++'_SSD_B6MNOFWX0_$9O!.OHS?-8W/R7"_P#LW_ :
M^B[>>.\@26-O,B9=RLOW7!K-JQ:=R>BBBD,**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ JG?7T.DV<EQ<21PV\*F1WD;:J*.223T JY7PA_P4J_
M93_:3_:Q>72?"OB#P78?#Y6 71([^XMKS4L<[KES%L<?],]^S_>^]7+C,3.A
M2=2G!S?1(^DX3R+#9MF,,)C,7#"T]Y5)O1+LEUD^B;2[R2,7]K;_ (*Q:CXX
M\0WGP_\ V?88]8U1?W6H>,)8]VFZ5V/DY7;(P_YZ-\O]U9:\*^$_[/\ 9^ =
M3N->U:\N/$WC+47:6^UK4':6=Y#][;NR5_\ 0JDT/]GW]H3]GWP]#IQ^ 4=S
MI=K]UO#^JQ3[_5MJM+*S?[U8VK_M*ZEX$#+XR^&/Q,\),OWFO=%D6*/^+[S[
M?_0:_D?Q(K<;9O4E2JX6=.@MHJVJ\[._RM]_3^NLGR'"8'"/+^%?9RIR^*<*
MM*I5J^<W"3=NU.*4%U3=V6?VD?#?CSQWX?\ [&\'OIMA:WB?Z9>2W;13NO\
MSS3:IV_[35J?L]?&G]H3]ESX9:?X1\':/\(=-TFR!9F:UN&N+J5OO32OYGSR
M-_A_#6%H?[:GPWUGY?[>^QM_=N+29?\ Q[;M_P#'J]+_ +8M8M'^W--'#9^3
M]H::7Y5CCV[MS9^[7Y[E'%7$'#,%1PU+V/,]Y4VI2?75O5_@D=680Q-'!1RS
M,\#%T^;F2J4Y>]+:[;:YFD[+=)=AP_;-_:XD&[_A(?A=%N&[;]@D^3_R&:S/
MV=?VZ_VK_P!I_P".,G@WPGJ_@74H-,(;5M;M])+Z;IT9_B9SMW-_=51\W_CU
M<O\ "CX:^,O^"DWC>X\/^"YKGPW\+]-F\G7O%#1_-=]_L]NIQN8__M?W6_3S
M]GK]G?PG^R[\,['PGX-TN/2]*M/F./FEN96^_++)U=VQR3_*OZ8\.:/%>94E
MCL[KN--[12M)^KOI^GKM\'QSGG#O#>%EA*F78:>.FM(*E&U%/:51K>;WC2[.
M\[;%J#X21W/AZSBO[O[1JT,"K/?1P+ MU)CYG\H?*,G^&N=UWX5:II?S0K]N
MC_O1_>_*O7:*_3,?PS@<5JX\LN\=/^ ?S3ALZQ5%WO==GM\K;+R6GD?/\B-;
MMMD61&7[P:BO<=0T6SUF/;=6\,R^C+FN<U/X.:9='=;M/:-W ^9?R-?)8K@S
M%4V_824E]S_R_$][#\249+]ZG'\5_7R/+WBCD_UBQM_O5#)X?M9/^6.S_=KN
M-0^"VH(/]'NK>9?]O*M_6LF;X=:U9#YK&23_ '75OY5X-;)<=3_B4I?)7_*Y
M[%'-L//X*B^^WYV.7_X1:W/\<B4?\(G'_P ]9*W)/#VH6@_>:?>+_O0M4+6E
MQ%]Z&1?^ 5P2PLHNTH->J?\ D=D<:Y*\9W^9DQ^$XO\ GM)4T?A>W'\<C5J)
M8W$GW8I&_P" -5J#PUJ5Q]VQNU_[8M6E/!.6D(-_)_Y&<\<XJ[FOO,FVT.UC
M'^I_[ZJW'&L7W5V_[M;=K\-]7N1S;"%?5Y%K:T_X.S!?]*O(U_V8UW?SQ7J8
M?(<;4_ATFO73\SSZ^;8:.LZB?SO^5SCZL6&DW.K-MM8I)&_V:]$TSX::7IHW
M-#]H;UE.[].E;T,"VL.Q$557HJ]J^BP?!]5VEB)V\EJ_O/&Q'$4%I2C?S?\
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M3;:%9V46A0Z7_9MFD<Z7&^:-$EFFF\V']X_[Q6MPP;<<UX'\&_\ @CM^U_\
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M/^":_P"S[K&D^'M%TO5-8^%_AJ2^O+6QB@N+YFTNV<M*Z*&?YN?FKG?VSO\
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MK$NN^*4DET_0M.C6Y;S%BB8-))ML[MOFRO[H+M;?\@!^A5>!_P#!0G_@G/\
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M"_M86/PK\4:!\:MT&@^)O!J3PI:71^2.-?,$?F*)O*C='B5A]H1E<CY&]O\
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M2^'-EJ?A^Q\.3Z5<K<V?V&#=!$L4BD[E14"_A]:Q]9^/OP\\8? :Y\$^#_\
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M[]FGPOX%\6VOB3Q'X\\8^$[+PAJGV6W;<UG%9PYDFW-\R_,WSA/N+O>OW#H
M_![]D']@;X0_M\_\'!_[;&C_ !>\$V/C;3?#MS#>:?#<75Q MO*\D:,P,,B9
M^7UK]E?V;?V0/A?^Q[X.DT'X7>!/#/@729W66XATBQ6W:[<<*TKCYY6 XW2,
MQKH_#OP9\(^#_&>L>)-)\*^&]+\1>(/^0IJEGIL,%YJ6.GG3*H>3_@3&NIH
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MR_MVV*WY_P"6:=3_ -]5G)6143UVBBBLR@HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M (%^%OB1\3O$%]X?\,^,+B"UTQUTVXN;F22:W:X56AC5G7]VG.1\IXK\*/\
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M\U_XH^RJ-9\00V]O&MU+>3XWS&6XN8I%#-MCY6,*O%=S_P '-'Q@\3_LJ?\
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M3OCJ?A?Q;IL.JZ7=^4T7VBWF171MC@.N5;.UEKQ?]HW_ ()2_!G]L/\ 9N\
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MP;__ +=W_!0G4/ _@W]J3XW:';?"GP!Y4-K%:WB7UY)&B^7NBBA@C26X\O\
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MX7N/@[X3\+SZ)X8\*Z=-;S7%I=R7=O*EPTD-LAD5(TN%_>S,W[\?+UK]1**
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M_!T'^VGJGP1_8JT_X,^!_,O/B;^T=J2^$-,LK=LW)L7*I=E%_P"FOFQ6OO\
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MXL^!GP/U#4;:_P#$7BWQI!+;OJ,,3;XSM=$5XT;9)Y,'FLTD<?[U$W5^[5%
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8H **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>form10k2016image4.jpg
<TEXT>
begin 644 form10k2016image4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_[  11'5C:WD  0 $    /   _]L 0P "
M 0$" 0$" @(" @(" @,% P,# P,&! 0#!0<&!P<'!@<'" D+"0@("@@'!PH-
M"@H+# P,# <)#@\-# X+# P,_]L 0P$" @(# P,& P,&# @'" P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
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MF2=6*U\M_P#!ZE_RBT\ _P#94]._]-&LU]?_ /! G_E#=^SU_P!BK%_Z,DH
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M ?\ J0:;6!_P:@?\H3?AS_V%=:_].4];_P#P=&_\H)_CE_W /_4@TVL#_@U
M_P"4)OPY_P"PKK7_ *<IZ /T?HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH _*W_@[?_9^\??M*?\ !.+P7H/P[\$^+_'VN6?Q)L=0ET_PYHUQJEU#
M;KIFJ1M,T4",XC#R1KNQC,B\\U]3?\$2_ &O_"G_ ()1_ WPWXHT75O#?B+1
M_#4<%]I>JV<EG>6,GF2?NY8I%#QM[,M?5E% !7._%3X9Z+\:?AKX@\'^)+&+
M5/#OBC3I]*U.SE'RW5M/&T4L9^JL17144 ?S<C_@GA^W!_P;O?M8Z_XG_9V\
M/ZG\8OA?X@.SR;+39M6BU*V!+11W]A;L+B.XAR=LT/R\_*_SO%7L2?\ !P=_
MP4.^,4,>C^!?V+[^QUJ8^4]]=>$=<N8("?XLN8HX_K(^VOWDHH ^0?VW?V"-
M4_X*D?\ !*V#X7_$B:'P_P#$+6]!TW4I;WRU=-&\0PPQNS83*^7YWFQOY?\
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M6L/<:5KFFS:?>0*^H3R(6AF577<K!A\O>OOZB@ HHHH **** "BBB@ HHHH
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MT%\WM1\WM7RY>?\ !4C0?^7/PKJTW]WSIXXO_0=U0_\ #T"SEV;?!EU_M?\
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M\!KN*\F<)0?+)6/2A.,E>+"BBBI*"BBB@ HHHH **** "BBB@ HHHH ****
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M?O*>W5=O/T_(]W!XWF_=U-^Y[%1117CGIA1110 4444 %%%% !1110 4444
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M-]3A:WL+E[-/GDD\O;%Q_#N;Y:][\)_ /POX2V,MA]LN$_Y;7?[UO^^?N_\
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M  H/2D_NO/M_[_-76:EWK_.3C5RI\39@O^G]5_?-O]3^R.&[3R/"7_Y]4_\
MTE'&:7JE=#I^H5SWB#2_LMP]Q%_'_K%HTO5*\*<%)71Z49.+LSO+.\K8M_\
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M_0;QSHNC?M-?!RSU#0[^RU2QU2VBU30]1MY%E@N$=-\4B..L<B-U[@U^._\
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M-L4;^\D"JW_?2U6\4>$_[+C^T6OSV_\ $O\ SSK8TN2M7RUEM]K?.K_>KY3
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MY?#?]I[Q)<^(+"2]\$>)+Q_-N;G355[6\D/626W; \S_ &D9"W\6:\4\#_\
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MU"\KGM9U"KFJ:A7)>(-4^_32N!F^(-8^_5#P?9M?Z@]ZW^JA^2/_ 'JM> _
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MP<F?#.\EU_X5^+52233?)O='F;^&";=%+'_WVOF_]^Z]7)\\K8K&PI5-G?\
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<=\8_'W_  A/AS;
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MW*]%\/R?<KS'PO)Y4FVO1?#<G"5H2=MI<G"5]%_L\V;6OPVA9O\ EXGD=?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% %6_LEO[":W;[LR-$WXC%? WP'\#R
M0[]4NDV>2[10J_\ >'RLU?<_CWQA#X(\-S7TGS2#Y(8_^>DA^ZM?,>([6/:J
M1HO\*I5Q=B9#+RX\JL35+RK.H7E<UKFH4R2CKFJ??KC-4N)M4U"&UM4DFNKA
MUBAC3YGD8MM55JYXDUC[]>X_L$_ UM9U1O'&J0_Z/:NT6E1O_')]UYOP^ZM7
M)V5P/<OV:_@O#\#_ (;6VGMY<FIWG^D:C,O_ "TF/;_=3[M>B445@:!1110
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M[ =G85](? RX^T_"_3?]GS%_\B-7S;I\E?07[.MSYOP\V?\ /&YD3_QU6_\
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MZOI7_@RT^"$/P^_8@^+'Q,OE6T_X2_Q3'I@EE 4&UTZU5_,W?W?-O+A?^V=
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MO^8KV[_@]=^/VJQ>)O@9\(Q>W$FGV>FW7BK4,_*E_<N_V6"1E'R[D6*[Z?\
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MPYN/!WP%T3Q#)J7B6XU&PTR*?[++O,L:S.YEEW2X/[E6D&?O;: /WTK\%_\
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MU^&[_P 50Z_KD?B?3KG2C;RW6AZDRK]HBN+>9AOC>3S6W;6C*2;6P: /;O\
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M&2'P$_MGXZ_&[XGS1_+X?T.R\-6LC)]]KVX:XEV_[HL8L_\ 705RNC_L$_\
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M;RVXZKSTKO*_$W_@D[X/_P""B.L_\%F_$'B+XV7GQ&T_X16L^L#6[/6+]O\
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MKXSVOPWNOB1X"MOB)>G]QX7E\06BZU-F-I!LLS)YS?(I;[GW1FO1J "BBB@
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MB\>W5]J'B2ZTNY@DN[W<UQ=6\&H7-O9R2,WS.S6L5NWF'[V=W>OR$_X*1_\
M!'7]K7]E[PK'\=/C)X\\._M?^!?AJ1J&H^'/$_B#6G6SAW*KSK;"6+]VG\?E
MR_[T3KOK]I?^"07[>'A'_@HI^P=X/\>^#?#<7@NPMD;0KKPW"5\CP]<6H5/L
ML1157R1'Y31X5?W;I\J?= !]+:MJUMX?TNYOKR:.WM+.)KB:5_E6.-1EF/T
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M (+L:/\ \%4OC+XB\':;\)O''@";P_HO]L/>:V\;17"^?'%Y:[5'S?O0WX4
M>9_"'_@TN_99\)>)/$6L>/+?QI\6K_7M2N+Q%UOQ!=6:V,4DK,B!K62.:615
M.UI)96,C#=A<XK\__B]^R?H/_!(;_@YB_9[\&_LXZMK5AI/C*\T0Z]H?VV2]
M^P6E]J$MM>V<C-\SP_8XQ.!,S,O$F>$-?J1_P5L_X)U?M/?MF?%?0]8^!O[2
MFJ?!3P_8:#_9]_I5K?WUK]ONO/E?[1NMF&W]VZ+N^]^[K\N_V7-6\3?\&ZW_
M  5&\+Z;^TY\.?!/Q"UCXJRXM?C#:ZMJ&HZO;1W$GV>6=9+IMO[O?MF58(I_
M+D_ULJ[5< ^[/^#KC]D>7QU^Q7HOQ\\(S3:5\2OV?=7M=8L=4L_DNH[*2XC2
M4*P[PS_9YU)^[Y4G]\U]L?\ !,#]L:']OW]@?X7_ !958X[SQ9HZMJD<8VI#
MJ$+M;WBJ/[HN89MO^SBI_P#@IUX2L_''_!.#X^:3?)NMK[X=Z\K<?<;^SYRK
M#W##=^%?#'_!G/XMN_$/_!)"^L[K[3Y.@^/M4L+7SDVKY9M[.Y_=?WE\R=_^
M!;Z /U>HHHH _&C_ (.G?@9XU^,'[2G[%=UX3\'^*/%5KH'B;59=3FTC2+B^
MCTY'NM$*M.8E;RU/EO\ >Q]QZ]<_X.I?V&-:_:V_X)\6'BKP7H^JZQ\0/A'K
ML&L:7%I=M)<:C/:W#+;W4<"Q_/G)M[CY?^?.OT[HH _)O_@U?_8]\<?#SX0_
M%GXZ?%W2=?L?BG\;/%$TMT=<LI+.^>V@=G:9XI%4H9KJ:X8_+C$:5YC_ ,$@
M?@'XY\#?\'./[6GBW6O!?BW1_"NN:=XCCT_6;[2;B#3[YGUW39$6*=T$<FZ-
M&9=K'Y17[944 ?ES_P ''7_!$OQ%_P %)_!_AGXC?"AK>#XR?#J!K:UMY+A;
M1M=LC)YL<"3E@L4T,V]XF8JO[V3<PX(^6OA+_P '(/[8G[(_AFW\&_';]D+Q
MEXV\3Z1']F.L)#>Z%/?[./-DQ9W$,K'_ )Z0[4;K7[UT4 ?SP_L:/^T)_P %
M+O\ @X5^&7[3'B+]G3Q]\,?!^EP_9[N>^L;I;"UMX]-NH(Y/M4\,*RLSRK\J
M+WZ5[9_P>5_ 7QQ\>/AM\!H?!'@OQ9XRGTO4M:>\BT+2+C46M%>*SVL_DHVT
M-M/WO2OVRHH _$?3?^#CK]JK5?!&F^&/ _\ P3_^)L?B*ULXK:VN]0_M6_M_
MDCV;Y((]-@;;QG_6K5K_ ()@?\$6_CS^TS_P4!A_:\_;2DAL_%&FWD>H>'_"
M:R0M(EQ"NVUDECB9H[>WMOE:*%6\QI1NDQ\WF_M=10!^;O\ P<G_ /!)OQ!_
MP4X_8^T>^\ VL=W\3OA;>3:GHUFTJQMJUK*BK=6<;MPLK^5!(FX[2UN%_BW#
MXG\>?\%]_P!KSXN?LGWGP)C_ &2OB9;?'+6M&;PQJ'B+^S[[AI(_(EO5L3:#
MRYF5MWS2^4K'=]WY*_?JB@#X#_X-W/\ @E_K'_!+[]A2/1?&"V\/Q#\<:D?$
M'B&"*02IIS-&L4-GO'RMY<: L5S^\DDPS+MKTK_@N+X1U?X@?\$F/CMHN@Z7
MJ6M:SJ7AF2*TL;"U>ZNKJ3S(_E2-%+,W^[7UE10!^;?_  :M?"SQ/\'?^"3&
MCZ'XN\-Z_P"%]9C\3:K,UCK%A+8W*1O(NUO+E56VG%5O^"F/_!7;]H__ ()W
M_M:W>GZ3^S!X@^,7P5FTFVN[77-"@O(;BTN"K?:$EN(HKF+";=P5XHF_VB.:
M_2VB@#\ _P!M+_@M#^U%_P %;O@1KGP+^"_[(?Q#\,KXZMQIFLZQJ'GW6RV=
MEWPAWMH+>V5UPK332XVR?P\-7Z;?\$,_^"=NK?\ !,;_ ()]>&_AWXBO;6^\
M77EY<Z]K_P!E<O:V]Y<;!Y,3?Q+'%'$A;HS!V[U]C44 <#^U)\'U_:%_9G^(
MOP_=XXU\<>&=2\/LS_=3[7:R09/_ '\K\I?^#-;XQ26G[*WQ>^"^M1S67BKX
M:^-&O;BSF^62WANX4A:/;ZI<65QN_P"N@K]F*_.^Q_X(^^,/@)_P6HD_:<^#
MOB;POI'@_P"(%N]O\1?"FI^?$]^TK*9[BU,2,GF-)'%<XDV_OQ)\VV7Y #Y
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MQC\2O&<VEZMHMCHNHW\EOHNG);W/FNWD(\?GW$MNHW+M=8)^M?HC_P $T_\
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MG6\=I:6T";8H(HUVI&BC[JJHP* -*BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
B*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>form10k2016image5.jpg
<TEXT>
begin 644 form10k2016image5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_[  11'5C:WD  0 $    /   _]L 0P "
M 0$" 0$" @(" @(" @,% P,# P,&! 0#!0<&!P<'!@<'" D+"0@("@@'!PH-
M"@H+# P,# <)#@\-# X+# P,_]L 0P$" @(# P,& P,&# @'" P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
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M*V6.D_\ "92?LG^&9?#[CS!I2>&[MKS9CI]F74/MF[_@'7^'M0!^YE%?-_\
MP2Z_:V\=_MQ?L:^'?B-\0OA[_P *PU[6IKF)]%:YEE?9!,\/G,DD:/#O>-OW
M;[B% .XYKZ0H ***_$7_ (.+O^"A/QH_96_X*G_L^^#?AY\1?$GA/POXFT[3
MIM6TVQD5(+YI-7E@=I,J>L:A: /VZHK\QO\ @ZO_ &O/B9^Q;_P3U\&^*/A7
MXRUCP3X@O_B)9:5<7VFNJRRVKZ;JDK0G<#\I>&)O^V8KZU_X)3_$_7_C3_P3
M6^!WB[Q1JEUK7B/Q)X-TW4-2U"X.Z:[N)(%9Y&/]XL: /H2BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ K\ ?^#3G_E*5^UU_VV_].\U?O]7X _\
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M$7_!ZE_RBT\ _P#94]._]-&LU]N_\$5/^42'[.7_ &(&D_\ I*E 'U%1110
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MM2F1_O1^>R1?]\K\M>A3RFK+XFE^)QSS*FOA39]I:GXHTS05_P")AJ5C9_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:;I=G]Z1_OR-_#&B_>9F_NK7T]"@H)0IK[CPJE24Y<TCH9)%BCW-\BI7RO\
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MU53BY245U:-L+1=>M"A'>327S/2]#_X**>(O"4;Z;%'8^(?)^2.ZO=W[MO\
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MCJ_;QU BS;QU<MXZAMXZN6\=0W<4B:WCK['^$G_!2#P[XC^">G?#SXV>!/\
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MKJX?R;>V1I9)'_Y9J%W,U?@SX\\63?$OXB:]X@NO^/C7M2GU"3?_ 'I)&?\
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M[1:V=O\ NI8U/W9&?[R[O[JU0US_ ()#_#?1O.ETO5?%"7'WXX[N[CEMX_\
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M ]O]J\::/%]S?>0)^<BU]XU\CG&\%Y?Y'TV5[2"BBBO%/6"BBB@#\-?VD_\
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MJ?@?I_\ :GQ@\-Q?W+^.7_OAM_\ [+7VY7R/^R3I']I_&:SEV[EL;::X8_\
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M(9/O+7J/[;&CK%\9(=4A^>WUNP@NXY/^>F/D_P#052O<OVK/V?O!/C?X@?\
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MYOXTUC]V]=CXHU#RHWKRWQ)>?;]02+^^]?"Q/KCO/@G8?8-+>Z;_ %MX^_\
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MAE^]YG_?RM6STNQE^]#O_P"VC5S%O>-'6E9:I7X/*+MH?J\9)[G6Z?H>E_\
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MM9Z[(Z[P]X>M?#&AV^GV<7E6MFBQ1KZ**T***^5NV[L^B225D%%%% !1110
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MPC_O:E_Y _\ LJ_;_P#B)G#S5_K#_P# )_\ R)_'O_$O?'G-R_4EZ^UHV_\
M3AB?VI]:9>7$=U'\WW_X6KH8_A'&/O7\G_?NIH_A';_\_P#<_P#?M:QEXGY
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MKTDVK>'TCMM2^_-:_=BG_P!I?[K5^M<#^);CRX'-Y>2J/\I__)??W/YZ\7?
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M?%>;XV_&[Q-XJE\S;K5_)<0J_P!Y(=VV)?\ @,:HM?*GQL\0_P!O>/+E5?\
M=6'^CK_O#[W_ (]7M.L:HNC:7<W3?=MH6E;\%W5\S7%Y)=7CS2OOEF=G9O\
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MO_,S\S^JT?Y4>56G[(7@RV^]#J5S_OW1_IBMO3/V<_!6E#]WH-JW_79WG_\
M0V-=U16<L56>\W]Y4</26T49VB^&M/\ #D.VQL;*Q3^[! L?_H-:-%%8ZO5F
MRT/D'_@H'9^5\9-!N-G^NTI8MW^Y-*W_ +-7GOA7^"O5/^"B=IY?BKPE<?\
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M)M09-AN]>:)?]I4MX2#_ ./U]EU^J\/QY<!37D_S9_ _BUB%6XMQDUTE%?\
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M]5EO[4?P^3<?Z0FW_=67;7QO&%&\*=7LVOOV_(_JKZ+N:*.+QV6R?Q1C-?\
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M_P!E_P"%UUX4T>;6-3ADM[R^79%"XVM!#U^;ZUZY64C0****D HHHH _/O\
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MJ2JOF5)OH*YB:G>94/F^].WT%1D6-].\WWJYH_@?6->V?9=-OIE?^+R]J_\
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MA/\ [?@G]U[_ ('R]_PS7I?\-_J7_CO_ ,34UO\ LX:/%)^]O-2=?]B2-?\
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M$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>'_@QT_Y*E^T5_V"M"_]'7U?T/4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7X _'K_E=F\%_2Q_\ 49DK
M]_J_)WXI_P#!(OXR>+O^#E/PW^U!9V6@/\*],^S>=.^IJMX/+T5K-OW&W/\
MK30!^J'B/Q!9^$M OM5U*XCL]/TVWDNKF=^$AB1=SLWT45^'?[-G_!5+]N3_
M (+J_M!^-K7]FO7/ _P(^%/@B6))=6U328=2OS%,TGV<2^=%<+)=2+$[%84C
MCC4?,Q.QG_<7Q)X>LO%WA^_TG4(([G3]3MI+2ZA;[LD<B[74_56K\(?V:O\
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M>VAT^ZCM[A8'6.?R+AXUBEV,1]QCN'S+N7F@#ZDHHHH **** "BBB@ HHHH
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MK\0_^#U/XCZQ>_ #X*_#71[#4M277M>OO$=ZMI TOE_8K=((M^T?Q?;I<?\
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M?"&\CTWP'X:N]-\4^/[2>9DM](#-(]OY7E!(+B2-OL_,K-)YAVQJQROZ%_\
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M=4D74/B.DM[XHNHYV\V>SL5A58F)Y:.>XEWG/_/ICN:\J^-'_!OS\%?V6?\
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MSM\T;_-TH ^NJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSG:J01X??;1<YZ9KX _:N_Y72/@__P!@JT_],]]7[OT ?S%?\$Q/^"4?PO\
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M'C3_ (-UOB9K&J6OV'4]4TKPM>WMML*^1-)K6EO)'M/*[6./PKXM_P""2?\
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MOW:UN([=F20*\Y4[6_O+0!]/?\/]OV-_^CA?A_\ ^!$G_P 17T]\+_BCX?\
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M*SO()%25%=F:&;Y)E.UOE:,,NW@* ?#?_!#WXJ_\%"OAO_P3@\%VO[/'P5^
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MO"_A?4?"_P#:*>(]$U_:UMXCCF-H8%"R02Q[H_)F^;=&V)SM?K0!\$?M,?\
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MY=E?HU10!^5FN?!3_@K!\<O#;>&]4^)O[-GPSL+M1!=Z]H$%[+JR1GY7:'?
MZ"3_ '?*_P!EEKZA_P""0_\ P2K\*_\ !)C]FN7P3H6K7/BG7M?OO[5\1^(+
MJW^SOJMWM6-=D>YO+A15^1-S<EVW?/7UE10 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5[F)KBU=5>2%F7
M:'3;N3W&<BK%% 'SS^PU_P $S_A7_P $]KWQI>?#_3]5DUWXAZE_:GB+6]9O
MY-0U/59OF;]Y._S;=\DLG^_+(>]?0U%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>form10k2016image6.jpg
<TEXT>
begin 644 form10k2016image6.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $IO:&XN4V-A
M;&QO;@    60 P "    %   $*:0!  "    %   $+J2D0 "     S(V  "2
MD@ "     S(V  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_P"%U>(O^?+2_P#OU)_\<KSRDS1[6?</['R__GTCT3_A=7B+_GRTO_OU)_\
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M$2[41>BBNVE1Y'S7N?GN<9S];I>P47%IZ_(GHHHKI/E@HHHH **** "C%%%
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MQ'Q9\27GACP3]JT^\ALI9[J&W:XEB\WRD=L.P3^(@9.#[T >>Z=8^"];\9:
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M=!Y([B*,\.KQG!_$9%=W8Z[I>HQJUG?029[!QD?A04:%%&110 4444 %%%%
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MVE)#M=I=8U+:5LEXR%7J6/Y<5Z+5/5=)L-;T]['5[2*\M7(+0S+N5L'(X^M
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MO"R7>HWNI6D[PW-W:K;2IG"2A6R">^<9'T-8&G>"CILS7,]M:Q1D%72-5_>
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@!&&88_E6I110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>form10k2016pipeline.jpg
<TEXT>
begin 644 form10k2016pipeline.jpg
M_]C_X1.P17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  "OR    G$  *_(   "<0061O8F4@4&AO
M=&]S:&]P($-3-2XQ(%=I;F1O=W, ,C Q-SHP,CHQ-B Q,CHT-CHS,0   Z !
M  ,    !  $  * "  0    !   %9: #  0    !   "U@         & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M;'4OIRJO3%)/Z'90_(KLK_U_1JL.A?7:6_INJQ'N_7*003'T?UIV[;[OZ_\
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M?<\G;_G0>8;T/ZZDDVV]4!+B8JS*=L;G?1WY+7?1V[4W[!^NL&+^K$_FSET
M<=_UL_G+OWY8;;Z?I6DS&X,);P'?2^:>K(%CRST[&$"9>T@?YRE]Z7:/V,/
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MNEO(:S(J+G$- !$RX[6B/ZR8=5Z08C)IUX]S>Y#?^J<E1[*M)7BV,>'.NLL
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M;Z7T/\+ZWJ+QE)3X=S_-[?H[L>38?SN_T_2?8;_^8GKU^O\ ;_7G]'XS+?\
M1^SZ6S9O1.G?^-__ ,X</TOM?[5]5GH>I,;X/I;]OZ/9M7C22FCO^@P'8_/L
M_P#_V?_M&N!0:&]T;W-H;W @,RXP #A"24T$)0      $
M       X0DE-!#H      ),    0     0      "W!R:6YT3W5T<'5T
M!0    !#;')396YU;0    !#;')3     %)'0D,     26YT965N=6T
M26YT90    !#;')M     $UP0FQB;V]L 0    ]P<FEN=%-I>'1E96Y":71B
M;V]L      MP<FEN=&5R3F%M951%6%0    !    .$))300[      &R
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M9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!2
M"G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M    3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M        4V-L(%5N=$8C4')C0%D        X0DE- ^T      !  2     $
M 0!(     0 !.$))300F       .             #^    X0DE-! T
M  0   !X.$))3009       $    'CA"24T#\P      "0           0 X
M0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$         @ !.$))300"       $     #A"24T$,
M @$!.$))300M       &  $    ".$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      TD    &
M  +6   %90    H 50!N '0 :0!T &P 90!D "T ,0    $
M             0             %90   M8                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   M8     4F=H=&QO;F<   5E
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   +6     %)G:'1L;VYG   %90    -U<FQ415A4     0
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MYS _[;?_ .DT&OK6$7@#-!)G3[(!V_JJ(ZY@Q_3A_P"P@_\ (K-HUT^W'_\
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MK25XMC'ASKK+   6/+=I($;CLJ9_T5R'4_K37C=2RL<LZK--KF?H<=KJ]/\
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M "  4 !H &\ = !O ', : !O '     5 $$ 9 !O &( 90 @ %  : !O '0
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M("
M     !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T
M   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0    !1D
M;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #U
M "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#   $
M/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER:6=H
M=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P
M   2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V
M+3(N,0
M            6%E:(        /-1  $    !%LQ865H@
M     %A96B        !OH@  ./4   .06%E:(        &*9  "WA0  &-I8
M65H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W
M+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
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M<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H "T
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M.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^)
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MH@    8" P$             !P@&!00) PH" 0 + 0  !@,! 0$
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M;625;E$!X/X8'W;5VCK77%H-.D*KD%B3Q?\ L_FP]^U8SU[KF\;,I8ABVE6
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MA_C]3[WJU8/6NN0@75K(<-<'ZFW" C@_XW'O6H\.M]=HK:.5(.H<:;<:0/\
MB3[T23U[K$8VU:-#:7X9K&X %AZO]@/=]044ZUUY*<"<C3($475O5:_T_5[T
M6J*=;Z\1)_J&&DIILI_)9'//UX_XK[\6QU[KE+%?20KDE+,!>WUUVM_K^])2
MN>O=</!ZRNE]+:M1]7^O>_\ L/=R05/6NN'C=V!='  C'"L."06_WL^_!@%Z
M]UD5''B72Y D%R0UP#ZB23_C[T2,]>ZY%'Y]+?N#4_I/ZB]R/]X'NA !QUOK
MKQ-IUZ7UAHK"Q_'I/I_UO>R< =>ZY:&/&@V];?I/U8V/^\$^]>77NN!A) ?0
MVL(C_0_K+$L+'_6]W+8H.M=998O42 S7N_Y(U?4#_C7O2MY=>ZCB MK)1P0&
MTV#"]F '^OQ[MJ'7NLGA(!(5R25/()YU^]%B.'7NN2QDB34K?H++<']5V%A_
ML+>Z5-:];ZQ"-WTET<%53C2RBZ$J+C_6 ]WJI'6NNV20DJ48JVHDZ6_"AEY_
MU^/>RP QU[KD4=Y%5E;0S%V.DBQ%R.?P/=0>WK?61X[.KJK%O(3^6L"0I/\
MMK^]*<$=>ZXM&P4!58V"M]"?5:Q'^\GCWH9.>O=8V@(72JO8R7_)(M90;G_
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MY_WL^_5J:'AU[K)%'P258-J'!O\ 1K:OK_2Y]^+D]>ZQQQLVH.C $V^C"X<
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M?[VW^?KW^SM?,[_O+GY._P#H_.U?_KM[]_5WE_\ Y0;?_G#'_P! ]>^OOO\
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MM_\ G#'_ - ]>^OOO]_R?[VW^?KW^SM?,[_O+GY._P#H_.U?_KM[]_5WE_\
MY0;?_G#'_P! ]>^OOO\ ?\G^]M_GZ]_L[7S._P"\N?D[_P"C\[5_^NWOW]7>
M7_\ E!M_^<,?_0/7OK[[_?\ )_O;?Y^O?[.U\SO^\N?D[_Z/SM7_ .NWOW]7
M>7_^4&W_ .<,?_0/7OK[[_?\G^]M_GZ]_L[7S._[RY^3O_H_.U?_ *[>_?U=
MY?\ ^4&W_P"<,?\ T#U[Z^^_W_)_O;?Y^O?[.U\SO^\N?D[_ .C\[5_^NWOW
M]7>7_P#E!M_^<,?_ $#U[Z^^_P!_R?[VW^?KW^SM?,[_ +RY^3O_ */SM7_Z
M[>_?U=Y?_P"4&W_YPQ_] ]>^OOO]_P G^]M_GZ]_L[7S._[RY^3O_H_.U?\
MZ[>_?U=Y?_Y0;?\ YPQ_] ]>^OOO]_R?[VW^?KW^SM?,[_O+GY._^C\[5_\
MKM[]_5WE_P#Y0;?_ )PQ_P#0/7OK[[_?\G^]M_GZ]_L[7S._[RY^3O\ Z/SM
M7_Z[>_?U=Y?_ .4&W_YPQ_\ 0/7OK[[_ '_)_O;?Y^O?[.U\SO\ O+GY._\
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MZ*/K[[_?\G^]M_GZ]_L[7S._[RY^3O\ Z/SM7_Z[>_?U=Y?_ .4&W_YPQ_\
M0/7OK[[_ '_)_O;?Y^O?[.U\SO\ O+GY._\ H_.U?_KM[]_5WE__ )0;?_G#
M'_T#U[Z^^_W_ "?[VW^?KW^SM?,[_O+GY._^C\[5_P#KM[]_5WE__E!M_P#G
M#'_T#U[Z^^_W_)_O;?Y^O?[.U\SO^\N?D[_Z/SM7_P"NWOW]7>7_ /E!M_\
MG#'_ - ]>^OOO]_R?[VW^?KW^SM?,[_O+GY._P#H_.U?_KM[]_5WE_\ Y0;?
M_G#'_P! ]>^OOO\ ?\G^]M_GZ]_L[7S._P"\N?D[_P"C\[5_^NWOW]7>7_\
ME!M_^<,?_0/7OK[[_?\ )_O;?Y^O?[.U\SO^\N?D[_Z/SM7_ .NWOW]7>7_^
M4&W_ .<,?_0/7OK[[_?\G^]M_GZ]_L[7S._[RY^3O_H_.U?_ *[>_?U=Y?\
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M3O\ Z/SM7_Z[>_?U=Y?_ .4&W_YPQ_\ 0/7OK[[_ '_)_O;?Y^O?[.U\SO\
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MVOF=_P!Y<_)W_P!'YVK_ /7;W[^KO+__ "@V_P#SAC_Z!Z]]???[_D_WMO\
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MHD(5=*]J@K@?(4'1ON=W=I;VA25P6B!-&(J:G)SD]5@?[.U\SO\ O+GY._\
MH_.U?_KM[&7]7>7_ /E!M_\ G#'_ - ]%'U]]_O^3_>V_P _7O\ 9VOF=_WE
MS\G?_1^=J_\ UV]^_J[R_P#\H-O_ ,X8_P#H'KWU]]_O^3_>V_S]>_V=KYG?
M]Y<_)W_T?G:O_P!=O?OZN\O_ /*#;_\ .&/_ *!Z]]???[_D_P![;_/U[_9V
MOF=_WES\G?\ T?G:O_UV]^_J[R__ ,H-O_SAC_Z!Z]]???[_ )/][;_/U[_9
MVOF=_P!Y<_)W_P!'YVK_ /7;W[^KO+__ "@V_P#SAC_Z!Z]]???[_D_WMO\
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M_.&/_H'KWU]]_O\ D_WMO\_7O]G:^9W_ 'ES\G?_ $?G:O\ ]=O?OZN\O_\
M*#;_ /.&/_H'KWU]]_O^3_>V_P _4JA^;/S,:MI%;Y<?)QE:JIU96[[[5*LI
ME ((.6Y!]U;EWE_2?\1M_P#G#'_T#UX7]]7^VD_WMO\ /U99_./^4OR<Z[_F
M1?)/9O7_ ,C.]]B[0PU5U8N'VKL[M[L';&V\4M=TCMK)UHQN#PF0@I8!-4S3
M5$OBB77)(\C79F)"'(.R[/=\I6EQ=6D,DC>)5GB1F-)I *DJ2:  "IX"G1MO
MMY=Q;K+'%*ZJ-- &8#X%\@>JR?\ 9VOF=_WES\G?_1^=J_\ UV]C'^KO+_\
MR@V__.&/_H'HI^OOO]_R?[VW^?KW^SM?,[_O+GY._P#H_.U?_KM[]_5WE_\
MY0;?_G#'_P! ]>^OOO\ ?\G^]M_GZ]_L[7S._P"\N?D[_P"C\[5_^NWOW]7>
M7_\ E!M_^<,?_0/7OK[[_?\ )_O;?Y^O?[.U\SO^\N?D[_Z/SM7_ .NWOW]7
M>7_^4&W_ .<,?_0/7OK[[_?\G^]M_GZ]_L[7S._[RY^3O_H_.U?_ *[>_?U=
MY?\ ^4&W_P"<,?\ T#U[Z^^_W_)_O;?Y^O?[.U\SO^\N?D[_ .C\[5_^NWOW
M]7>7_P#E!M_^<,?_ $#U[Z^^_P!_R?[VW^?KW^SM?,[_ +RY^3O_ */SM7_Z
M[>_?U=Y?_P"4&W_YPQ_] ]>^OOO]_P G^]M_GZ]_L[7S._[RY^3O_H_.U?\
MZ[>_?U=Y?_Y0;?\ YPQ_] ]>^OOO]_R?[VW^?KW^SM?,[_O+GY._^C\[5_\
MKM[]_5WE_P#Y0;?_ )PQ_P#0/7OK[[_?\G^]M_GZ]_L[7S._[RY^3O\ Z/SM
M7_Z[>_?U=Y?_ .4&W_YPQ_\ 0/7OK[[_ '_)_O;?Y^O?[.U\SO\ O+GY._\
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M_7O]G:^9W_>7/R=_]'YVK_\ 7;W[^KO+_P#R@V__ #AC_P"@>O?7WW^_Y/\
M>V_S]>_V=KYG?]Y<_)W_ -'YVK_]=O?OZN\O_P#*#;_\X8_^@>O?7WW^_P"3
M_>V_S]>_V=KYG?\ >7/R=_\ 1^=J_P#UV]^_J[R__P H-O\ \X8_^@>O?7WW
M^_Y/][;_ #]>_P!G:^9W_>7/R=_]'YVK_P#7;W[^KO+_ /R@V_\ SAC_ .@>
MO?7WW^_Y/][;_/U[_9VOF=_WES\G?_1^=J__ %V]^_J[R_\ \H-O_P X8_\
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MA34<960L!ICD*@:\YKW;^LUURSLNVB\DM$@=V-S' -,\8=2?$32,ZEPY^&I
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M^#'_ &0-_-O_ /$2_&[_ -_/+[ _,G_*S;%_S5G_ .K0Z.]N_P"2;>_Z5/\
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M!!!((R.MS0S6\K07"-&Z$AE8%64CB"#0@CS!SU8G\?OAE\9-]].;?[A^1?\
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M.MCCU:E_/ _[>C?*7_J+ZB_]\)M7V"O;G_E3++[)?^KTG1SS#_R6)O\ :_\
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M@&1HWT/H5S)=FLKK;+O<-MO!,;+094:-HFTNZ1JR:B2_?(/(*0&*LQ1E /\
MS$^-W6G4^\_C[M/X]TWR(W35=L=']=[QRV+[@ZIW;LC=&4[*W;755%6XKK;
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M-K"_)_<=/1=1;JJ=A8'X\U'6U+B<PD+81]SX[L6IWO44E='!*!1)2OAJJ*4
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M[V_W#\GLQL!MS4^S,5))X=N[<V_UM+48V02PU>0IA-XJ1XA4/(YJ7$(A9O\
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MF_YX$_ZO]';?\J^G_-<_\<ZJ8]CCHDZ][]U[K8:_EC?Z$_\ AKO^99_LQ?\
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MKWOW7NK9OYD?_,@_Y67_ (H]A/\ WM*_V".4O^2GO7_/8W_'%Z.]V_W&L_\
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M;KOEC>2R36W[MG>9)23%',D4\EOI9@ )#+'&YB#'2\=NWAH909ES_,(^5_R
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ML7+O.',NYW<[/)="2VBL:,!;3K)=!IO$6D*FW,J!# %UM:P+0Q,/IUM_,/\
ME)\A>A/A;_*1V]TCV_OSJ6AW#\8<!NK<4W7FX\GM+)[@R>V-K;;I,!!F\KA)
M(:BJHJ9:RJ88^60TSO*7EBD98RAO:6-AN'O7S7)N,$=R+.2!HDE421@SS7?B
M%HGK&Y86\0JRDJNI5(61PP8$DD'M[810,8S=7%\KNA*2:8G30$D4AX\S.249
M22$)-46AZ>P]T9[ _P _CX<283.Y/;L?</Q=VG6=I4V#R57A*#L.KBV7OB6C
M7>%!CWBAR*Q28['M!%5(ZH]- R*&B0@EY:L;./DCGC;M :*UOIS C=PC:-+
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M=@O=SV>XG,5M/"MU;3MJ,<IC)1E<L5.E;E%*IK-)06D<HPCHW]RGT$.ML/\
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M/:(_!&X&<W'<[^(;FW%K-\;-HUP 1]FG3\2:7[NMW=Q-?6T%I='5';1+#&*
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M_J"OU$W:KA1KP.U=(C;9_F._-39O??8'R<VQWGEL/W5VIC\=B^Q-T4NU.O\
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M)-@+>Q#&BQ(L:"BJ  /D,#I+=W4]]=27MTVJ69V=S0"K.2S&@  J230  >0
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M^P=>_P"@8WHK_O)[MK_T$-G?]'^_?Z\6Y?\ *'%_O3]>_JC;?[^;]@Z]_P!
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MYOV#KW_0,;T5_P!Y/=M?^@AL[_H_W[_7BW+_ )0XO]Z?KW]4;;_?S?L'7O\
MH&-Z*_[R>[:_]!#9W_1_OW^O%N7_ "AQ?[T_7OZHVW^_F_8.O?\ 0,;T5_WD
M]VU_Z"&SO^C_ '[_ %XMR_Y0XO\ >GZ]_5&V_P!_-^P=>_Z!C>BO^\GNVO\
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M^P=>_P"@8WHK_O)[MK_T$-G?]'^_?Z\6Y?\ *'%_O3]>_JC;?[^;]@Z]_P!
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M$-G?]'^_?Z\6Y?\ *'%_O3]>_JC;?[^;]@Z]_P! QO17_>3W;7_H(;._Z/\
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MK_O)[MK_ -!#9W_1_OW^O%N7_*'%_O3]>_JC;?[^;]@Z]_T#&]%?]Y/=M?\
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M_P#00V=_T?[]_KQ;E_RAQ?[T_7OZHVW^_F_8.O?] QO17_>3W;7_ *"&SO\
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M]Y/=M?\ H(;._P"C_?O]>+<O^4.+_>GZ]_5&V_W\W[!U[_H&-Z*_[R>[:_\
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M *"&SO\ H_W[_7BW+_E#B_WI^O?U1MO]_-^P=>_Z!C>BO^\GNVO_ $$-G?\
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M&(AVQF,+.DTHBIR&FF=0C,IC#6*DG)/)R[U[E+R+S#XD 5)_%\,J)%DANK2
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MR)=[W8R2?O3;'TW4)*>&43N>2-0-:ZX7BN5!>31&)HV9GC)Z,>8]QGV+>]O
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MW*DB@]M+R"XRUS(&CCP3(L5M=I)0'%"\\48U4#L2JU*/I$SYW[:P^[?YUO\
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M ZY T7\5$'N4W^+<O[L'!MHO!5G!JJ&'<WN):TX*D,\4S-\ 1]5<-0['\_\
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M)[3DJ(?MYJG;V-V_C<1C8JDI=4KI:&2JB4LL4T8=PQ_N_N1S)NUB^W5CMH9
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MM9_[S-_T!U[_ (>NZ9_Y\[V=_P"=^U?_ *I]^_X,OD__ *-%Y_O4'_0?7O\
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M *#Z]_P('-O_ $=K/_>9O^@.O?\ #UW3/_/G>SO_ #OVK_\ 5/OW_!E\G_\
M1HO/]Z@_Z#Z]_P "!S;_ -':S_WF;_H#KW_#UW3/_/G>SO\ SOVK_P#5/OW_
M  9?)_\ T:+S_>H/^@^O?\"!S;_T=K/_ 'F;_H#KW_#UW3/_ #YWL[_SOVK_
M /5/OW_!E\G_ /1HO/\ >H/^@^O?\"!S;_T=K/\ WF;_ * Z]_P]=TS_ ,^=
M[._\[]J__5/OW_!E\G_]&B\_WJ#_ *#Z]_P('-O_ $=K/_>9O^@.O?\ #UW3
M/_/G>SO_ #OVK_\ 5/OW_!E\G_\ 1HO/]Z@_Z#Z]_P "!S;_ -':S_WF;_H#
MKW_#UW3/_/G>SO\ SOVK_P#5/OW_  9?)_\ T:+S_>H/^@^O?\"!S;_T=K/_
M 'F;_H#KW_#UW3/_ #YWL[_SOVK_ /5/OW_!E\G_ /1HO/\ >H/^@^O?\"!S
M;_T=K/\ WF;_ * Z]_P]=TS_ ,^=[._\[]J__5/OW_!E\G_]&B\_WJ#_ *#Z
M]_P('-O_ $=K/_>9O^@.O?\ #UW3/_/G>SO_ #OVK_\ 5/OW_!E\G_\ 1HO/
M]Z@_Z#Z]_P "!S;_ -':S_WF;_H#KW_#UW3/_/G>SO\ SOVK_P#5/OW_  9?
M)_\ T:+S_>H/^@^O?\"!S;_T=K/_ 'F;_H#H:>U?YH?6?5&VNG=RY7K;?64I
MNY.O:?L/#T^/J]OI/B,?45\E M!DC4SJK3!HRQ,1*V(YO[&7-'WF.6^5MNVC
M<KK;KF5=XM1=QA6BK&I8KI>K %JBO;4=!#EG[N',7,^X;MM]MN%M&VTW1M9"
MRRT=@H;4E%)TT-,T/0+?\/7=,_\ /G>SO_._:O\ ]4^P;_P9?)__ $:+S_>H
M/^@^A?\ \"!S;_T=K/\ WF;_ * Z]_P]=TS_ ,^=[._\[]J__5/OW_!E\G_]
M&B\_WJ#_ *#Z]_P('-O_ $=K/_>9O^@.O?\ #UW3/_/G>SO_ #OVK_\ 5/OW
M_!E\G_\ 1HO/]Z@_Z#Z]_P "!S;_ -':S_WF;_H#KW_#UW3/_/G>SO\ SOVK
M_P#5/OW_  9?)_\ T:+S_>H/^@^O?\"!S;_T=K/_ 'F;_H#KW_#UW3/_ #YW
ML[_SOVK_ /5/OW_!E\G_ /1HO/\ >H/^@^O?\"!S;_T=K/\ WF;_ * Z]_P]
M=TS_ ,^=[._\[]J__5/OW_!E\G_]&B\_WJ#_ *#Z]_P('-O_ $=K/_>9O^@.
MO?\ #UW3/_/G>SO_ #OVK_\ 5/OW_!E\G_\ 1HO/]Z@_Z#Z]_P "!S;_ -':
MS_WF;_H#KW_#UW3/_/G>SO\ SOVK_P#5/OW_  9?)_\ T:+S_>H/^@^O?\"!
MS;_T=K/_ 'F;_H#KW_#UW3/_ #YWL[_SOVK_ /5/OW_!E\G_ /1HO/\ >H/^
M@^O?\"!S;_T=K/\ WF;_ * Z]_P]=TS_ ,^=[._\[]J__5/OW_!E\G_]&B\_
MWJ#_ *#Z]_P('-O_ $=K/_>9O^@.O?\ #UW3/_/G>SO_ #OVK_\ 5/OW_!E\
MG_\ 1HO/]Z@_Z#Z]_P "!S;_ -':S_WF;_H#KW_#UW3/_/G>SO\ SOVK_P#5
M/OW_  9?)_\ T:+S_>H/^@^O?\"!S;_T=K/_ 'F;_H#KW_#UW3/_ #YWL[_S
MOVK_ /5/OW_!E\G_ /1HO/\ >H/^@^O?\"!S;_T=K/\ WF;_ * ZYQ?SJ^FI
M9(XQT]V:#(Z(":[:M@7;2"?\I]V7[Y7)[,%&T7F<?%!_T'U5ON@\VJI8[K:8
M_HS?] =71>\Q>L1NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO_5W^/?NO=>]^Z]U[W[KW6L1G?E+_,O[)C_ )G^Z>L_E#L[K38_P3[D
M[6J=L4%;T=UMN[=&]ML8"JR$E!U=)E<C2)2T./QM!B'FBRLV/J\C45%44FJ6
MC0&.0=JMN6+#DKE/F+>;1[NXWI+6"51*\2>)+);*]TVGNU@W2!88C%$41C17
MH627<-]N'.NX<J[3(+=8+*TN@[*'TO)923>&@/E-)'(97DUB+]+PETF1>O4_
MSC_F';(H_P"75\I>QN\.M-Q=1?-#M#9?7VX_C?M?IG 87&[1P6X:JGQ2[@H>
MQ*Z6HSM7DJB!IL@\7WM/34]5HA5*BG)"C*#E#E1^<;_D 6TC3"SFO(;IIFK&
MQCBEC@$2@*8XOJ84\1_$DD59"P#:68$W>];V_(K<Y02)$;2=;=HM&H7'A_4A
MY)')[&F-I)VQ*JQ^(A4]I0JGYW?/+Y,X[N;Y)4WQ#^0/<$^V/C%MJ";?NT^N
M/AGU/V3U?LW=N&Q4U;N+%]O=[=J9O'U=##))25*EL)C*IXU$HA2>2G96!?)V
MU;:VRV^\\P6\,L-_=B*VEGNI+=98F>..D$<".\CAW(4R%$D_1HZ+,K@9[PSO
MND6P[=(\=TEIX\Z0Q+-*I?Q98G?Q62)(F@\(DAB5 E8J6C=.E9W-_, ^9FX]
MF_RE<[T)E>O]J[_^;.!WQBM][9W)@:"LZYK=W56V\+B,'N"KJZVFK,S14&%K
M\A59J.DQM8DDX1:6=JE/2QO#R;LL?/O,W+=TS_1V&WV=Y"XS- LHGN9=%*)+
M+X$8@7QE:+4!)H6IZ((=]NO];Z'F.10]W^\X+2B]JR@SW4 1P20B3/%%XK)I
MD12_A.AIUE^4OR/^:/Q3W9\4>B^__FCA>HMJ;UVGVIN#M7YO8GXW;/W+2;AW
MSC<WD,CL_K#';*JL;4X7&K38LXV!I%QPJ)[F9I"=9)5M5ML',%YO-WM.W-XE
ME:VK6FW&=F-RYTI<3F2JRGOJ?#1E6/ (I-%I,+O][[9M]I-<RK*+V_ECFF"A
M190+;Q/ @'PDSRB9=<H8TJRT6WDJ6Z+^8I\].G/Y?V![V[/[2S&X^S_D=\E:
M;I?I_=_8?1NR]MX38/5U!0U=?)W+M_KW8> Q^0RTN61&%+1Y"GKE_8#T\,H?
MQS".XY5Y>W+G7:>4X85V\&RDOK\I,\\D;)+#$;0EF>,:/%21G55=HV<"A:-X
MR^VW&^M]EW[F<2F_M[.Y2SV]2JPQ71DB:9+IFHKJI6*XCIKTI*D>I6 D'0U_
M'[YL?*KL/>?R3^.F'^4,_>6+B^->XNVNI?E]G?A[F^DLELK>NV6@7<VQ,KU;
MF:7;E%6EJ6263'U9U>.3QRLU0%DI4#_-G+^R_P!2;S?Y;%;%[&<"6U2^6?ZV
MR:,EBLJM(UO(7(B+!24 D<+F)P:\O7EVO.&T;:9Q>Q[E6-BUNR+:77ZGA$JR
MH+B(!!*Z%AXFM(M::9-0;_R\\Q\I>EOY/';GR=P_R;ER&WJ'I;OW<G3?54_4
M&P//U+V'M_LG-U.3WM-V'DA65>XWR%9#4U34.8H6@B,^@!UC6XA]UFVJ'FG;
M]B6T F:?9(VG#LH-I*;>%K40 :% BE5!*I$@$=11F)!1[?+<[ON.\[G<RDJL
M>Z2RH1J,UXFVI<Q71DJ&4QE IB ,<A.IZY4F&[A^<'R:VK\0?Y379N#[13']
MA?)OM[H7;7=68.SNO*F7?&W-X8@U&[*1,16XJ2DQRSRM&6FQ%-2R1%E$3Q@@
M&UKREL$OO1>\J/;UVZ&RNI5BUR8DC^A\-O$U^(:>-+@N5.K(.E:,OO%^OM)>
M<S"3_'XKSPDDHN(_]VE1HIX9_P!QX,E">SCW-J0'\QO^8+\NOY?_ ,B=^]?T
M?8>U>T-F?)3K"&M^,E+N2BZQVYEOC7V#-N*';F0R&YY:''4CY+!PK+4U5#4;
M@-0DK1PQ23,M+7M,'>0.6-OYZL#L-#;[A97EN9;L:BL]I,7;P2E6CCGHOA,4
M12B:;@*3*D:"'F:_;EPVO,^DRV#P7*26E.XW5O'&RR(P(E,+:HRZ!P6:2:-3
M$$A8C[OWMGY0=+_,+^4_T)OONW'=IY'M7;O<,_>V[I>L^H:0[VW!0;:CRL3;
M6K\1@*>?#4%,\OVM*<-)225--'&:QIY&=BLV7;^6][W/F^:SLFM[?;["V:U0
MR2AT;7>*SRU>K-(84=HG+QQ-5449+%&Y3[I8<F[#N$\XDN=PW%UF*B-XQ%JV
MSPXHZ+H(C6XE G4"20N7U*OAI&4_._*7^9?V3'_,_P!T]9_*'9W6FQ_@GW)V
MM4[8H*WH[K;=VZ-[;8P%5D)*#JZ3*Y&D2EH<?C:#$/-%E9L?5Y&HJ*HI-4M&
M@,9?M5MRQ8<E<I\Q;S:/=W&]):P2J)7B3Q)9+97NFT]VL&Z0+#$8HBB,:*]"
MP@NX;[<.==PY5VF06ZP65I=!V4/I>2RDF\- ?*:2.0RO)K$7Z7A+I,B]>I_G
M'_,.V11_RZOE+V-WAUIN+J+YH=H;+Z^W'\;]K],X#"XW:."W#54^*7<%#V)7
M2U&=J\E40--D'B^]IZ:GJM$*I44Y(490<H<J/SC?\@"VD:86<UY#=-,U8V,<
M4L< B4!3'%]3"GB/XDDBK(6 ;2S F[WK>WY%;G*"1(C:3K;M%HU"X\/ZD/)(
MY/8TQM).V)56/Q$*GM*%4_.[YY?)G'=S?)*F^(?R![@GVQ\8MM03;]VGUQ\,
M^I^R>K]F[MPV*FK=Q8OM[O;M3-X^KH89)*2I4MA,95/&HE$*3R4[*P+Y.VK;
M6V6WWGF"WAEAO[L16TL]U);K+$SQQT@C@1WD<.Y"F0HDGZ-'19E<#/>&=]TB
MV';I'CNDM/'G2&)9I5+^++$[^*R1)$T'A$D,2H$K%2T;IT&WRV[@[>^364_D
M0=P;6R&S>O\ NKM[-[ORE)F\AAJK-[,VMO'.T6T\;7[@AVU-51254%/*9:RD
MQLM9ZV$=.\K LQ$^Q;!8<O>XW..SPO)]*FS6\E1I,HAE@OYR@)&DNJ.8PY6F
MH:RM.WH,W&[3;A[8VVX7R++*-\V] ,HCRPW5U#"7H2RH[HAF"'5I+B.C::6!
M_ KY'?*./YF?+'X*_*3M+ =_9SI+;>SNP]F]RX;K[;G65;D<%N:DQT]3@\UM
M?:*I01,J9:A>%%$DL;I4J]34(T7B#&X67+^[\@V_.FRVC6#B\ELY83*TRL4>
MY02!WHV#;,<!582*-*E"7,I7W3:>;H-CN[@7,-]8O>QGPQ&T?A2PPLA"DX+2
MM347+*B.&4.4!D94E["^:_?%=GBM1C/C?\:]CX/KS'22"2#';D[XDW!F>P-U
MQTS$A:N;'X#$8N*H"AD@%3&I"SR!@'N86T]M-ZO%_MK^>>U9J#MMK*PMKE8@
M:5I)<7[2RBM',%N2#X2T%%K()N>=@VI1^G;1K?OFFJXNKV:QA.D4U>!!97(0
MFNCZR8 #Q,UL[L[YWW+_ "9YMA-\2ODC!@A\&L-M[_2U-5?''_1N<=%UA3TB
M[S$<78;[C_A;H!4HO]WOOO$0#1++>(2[N^W6MQ[OVMU)?00N=]V]_"<7'B!E
MW.V81$I;O%XC$:%(D,>LBL@2K@DY6N);2TW2..![@%.8!JC,>D"1=Q#,?$DC
M:D.HF6BEJ(_AB0Z0Q@NT>N^M=_?.'LQ>Q/A#6_,M<7\5OB^V)AH\)\;<R>O6
MK-W=A"MED_V87=NUEC_BGBB _A)J2WVI^Y$0$'D#6TS7%ML6XR6M[^[F;>KD
M&35,OB ;?MA"?XNDCGPR2W>JJ-?:22P!/;4?8N3XI$\9#LTI\*BFI$]N!)WT
M3L!*_%J[\*1J*L/R8P'26V_D=55_87P1K/D'UWUC\!=FY>BZXP>Q_CWN:LZ.
MP.W>P<_-.E!A]\[BQZ0-34L H@NRWR,]H"L*21")G2[->7C;7S)<_O003R[K
MMZF]:6YB60R6MT*O/'$UQ&DK:97DDC5$2,R3F,H!T(/H4EAY?L+6SHC)NA%F
M%@)#?[J#01LXMF=*M&%64EGD"Q%PQ('38'370.#^$G3N[_F9!LKMK9W7NTL]
MNC;M+NK.;A[>Z]H]K=E;CDSW6^T<1M[<)DI-UY.@Q=5A]O8"LJ,3/7/(@AQQ
M3[@K)7F*ZW&SYIDM=N$C;D4M[&1HT6.XN+NWA$-Q)#I(,#7,ZS32-&\>I*27
M#A8JQH^6T@W/:Y)X&2+;+BXNK^%&8+#;6<LDDT23M\+16T#"J/KBA.I(@0JE
M@MJME;Z^/OQ9^*':FY:7-;8WWU;\K-K3;8VGDLK+D,]L?H'Y)]Y-L = YS(O
M+-]Q%B]K;@QL,E$\[PP5N-I$BD*T<+@TMY$O^>K#96F2YEOMO;;;V=>Z.ZNH
M-LDN?JJZ06*7]G&R3 !GC\62A,[@M7$(;E;F'<=NB^E@MYVW:P@8,O@QP7$0
MT4PT NK22\#0 :8!=^"4_24K='[CSH^Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NM=OJN7Y;93L7^:[M#I[X=?%7Y']89_YP]@X_/5G=GR,
MS>RMSUU=D?CGUY2YC;,/2U1U=G\'FZ1:<PO!'D=^XF*LDD>GFDH(U^Z8B>SE
MW3VCV[;[V/PXI?ZRI&\*+=3,C<V<P@R_3RR6:>-'(7$<7U0#A$?QT9RD:CZA
M++W)W"\LYF\:.+8G8,S6Z(Z['MQ0+<1I=2*K *6D%J[1DFD,ND:D[\<NR.U<
M'\9/Y+_QF^$O>N;VCLGMO97=_378O8O;'5FT*KL#;,/Q\Z\J'W9+0=?9&?/X
MZCS^ S6(RN%PF/BSU=AJ9S#-/-G\?1I3UPLW:Z;F7G^(P7;-M%QRH=WAF1ED
MN+F(3\I0;7>"::W2MQ<6NZ%KLSVRJPNKF0VRW*6YA)A<0[-M5S+/;)'N1YKN
M;"2V52EI#-,G,UY>V86.9BME:RV8>T,$QDD2TMH%GCAGF?H3/DU\LNV>K/DY
MLWX-9/Y4_+;9.%ZT^,.U^[>ROD]T;\$7^6OR*[@WEV%V)G=F;)VWEMN=*]/[
MVV%L_%TE+MW)5F7JIM@4;Y*62F@Q<E']M6M(3V=P-XN=WNP#:IMC;?:0PHCM
M%/<2VCSW=S<2R!R%4+;F.VBF@=I9YW#^#"D8.;BSFVG;-J#$7+[F^Y2R2R.B
MR00VTMJL,-O%'X89F:[D5IY(YDAAMH4D66XN_&1=]=_-?L#?/PCVKEOD7WGV
M;\0N[<[WUV=TMLO?> ^(F\*3Y"?)#:W6.Z,B-N=@])?#7M_:.>W%#DMT;7@H
M<_743[%R:XZU:_V,=,JF%1N92Y39)H=5I=WUF;R[L+:EW)"T+26MT@8+</':
M)=?3W EE#-';7-O;2SF69+ADUF?IYMXBU"YM+.XA@MKVY!MD<7,5K=0J]3;Q
MS72++/8,(2L4]U;3SP1F)/" 7],?*_YR]G?'SY^[-Z,W;VG\A.V/C7\C>H]B
M=7=C]S_&/&_&?Y0YKI#L+8^R>S.SZ[(?'OMC;O6F GWQMW$9O<8VA_%=M83%
M9AX,;+/33P3%ZO7B?6<N;3O-VC6T9W2_L+][$I<2_36?AR17444CSA)F^JMX
MKR*DKQQQW$]O:M.8K3I6L,%KO=U8PR&9IMFBO[..[5X81?2R[C:"W>>..(RV
M;2[?XT<L9HLDYM)[N,12W$(#?,'M7-]E?RLOYA]#M#^8K\K>Q]_]<[9V1#O[
M8W>'QYZ!^.7R0ZHQF[:_^!9?KSLOKI^I]HU"[>W12U<LM#EJ?;D+U(HG_AF<
MJ:5JD.\\<AO^4+^P=3%+S5L%K]5 VH,9]]V:#PYHY-1BN['QQ=QPRQPZS);B
M]M+BU9HIT]M,]O\ OR.\5XIEV'=KA()05TF#;[V?ZBVEC8":*7P1:M+%-.D8
M,Q@FBNQ%+;[&73NR=S];=<XG;>\.Y.R>^\W0K65E1V/VOB^H,-O3)P5<AJZ;
M'5M#T;M39>W5AHT(IZ9J? Q2M&JFHDGEU2LQO^Y1;=83W[1"EG%,[Z2VJ709
M)-3:F90^FD8\-432BDH7UNY5L43-8P-K)$JQ%5--,0,4:Z$H Y2H+UD:1]3L
M->@(JZVT]5GMR_R(:OY)XS'8S='<GRW^8_0WRJW'_>+,3;;I-S[X[&_F5[-;
M8.V-Q;HH*#)3T-#BL#0[=VM#4Q8VL-%0T,0AIZ@0I&[D-K>;+NOM;L5NJRS6
M<W+DI!=D2:^W"V_>NX2LY$K(+K<[ZZF9M+E%E "$*%Z%(2*???<B?<&\-$MN
M==OK&@<Q6>S;9NNRVBHI:,.4M+".0J70/.\KL^N1Y&,O_,4["_F YWH[K7&=
MX?%+XI]9]:5'S2^ !W!O/K7YR=H=Q[RQ3Q?-?8<N+7$]>;BZ&V71UPGJU@@G
M,NY*7PQ.\RB9HU@D7\LK;M[A\M&=V4B^E*!5#!G_ ';N':Q+KH73J.H!S4!=
M%&+*77+7*\I<R_3(KUV;<0VIRFE/ .IA1'U,/)#I#>;KQZ755G?E)AOYJ'SM
M7XY_'?X]=Z4U1T!\&3NN;O'Y+;Q^/\^W)XQV2,3%MVGVKU1V4N32I4U!J7FE
MH# 8XPJU'E8Q%7+K77]6-W5HT$(YFO"L@<EV<\N<IZT:/0 J(HC9'$C%R[J4
M30&D2;V+?^LVU,)&\7]Q)5- T:/WUO%'#ZZEB=0*>&   0YJ565\NNR.QNN_
MG;_*]W;DOBUO3N?L*I^,GSLIMV]&?&[=74.ZYMM9O(#IRHW!+MW>'R)S/5N*
MRN'Q=4KTR5\JT-;4(\4J8N/5+'#K;9+6WYVYF2R$MU;G8H%61HT1Q&N]6S+)
M)$)9"NH*(_#B>=@\BJ*IJ=3>XCDEY @>Y,<#IS'8D(&=O$_W2\T*H5A&!K*-
MXK!]"*%=0[N$$F#^6GU7U/\ )O _.'Y(;GZ+Z\VO\=/F+\@MM9[%?$7L#;VR
M=Q2]=[R^-F*INLNP=P]\];4L%5MS#;\R&[L"^0S&,I9:YJ:2@H*B>NFK"_B5
MV,,>R\D[0)IXYM5S<;[9SQD^#:6NXQ6DEK%;32+&ZM 8)[F<JD0MKR[N[<5:
M)Y'++^XN;[G/<-"RQ/;6,.PW<<FD2W$]K<;F]R\JQLZR0SVVXV]G S22?56-
MK;S"EO+#&HE=)X?%_([Y\[@^;?Q^VKAL;T9TS\8M^_%C9_8="E'M7;WR[[%W
M'V-B-WY"LP>4Q5+42UVR-B/MT8C#[D--/!4U^5RQQ<<U+2--6,[7+N-CR[ON
M\K$&EY@&VO96TSM%XB;<NY,-QN#HD: ;@;^*&S<Q/,]C;O=M&]M<V)>VZQ65
MSNVS[#JT_N*:_-[/&@?P7NDM(#ML)UH)7MOIY)[^)66&&Z6VM3*;N&]CM ?Z
M][<_F4U7\S+MO&YKXJ_%6DE/Q!^*C[GVG1?S >W<MMG:FSZSO;M:#^_NU:RI
M^/\ 2#)YVL\=;3U>'FQ^.C$5!0DY:;[EHZ!;RZEN^V[HMPQ$!W:U$TH4-)#7
M;XZK%&642KX?ZN98:R?ITI^KTIYA-U'LFRRVL*-+_N^\$%R@G=5V$E)W$;&%
M(F,8C=5N"1/.VB,Q 7!E>MHVZP_F]?([86WFCIMH_)+X:=/?)+<V$IY*..F@
M[AZL[+R?16=WBU##:5:G-;<GVQ0U-0ZVE7#0C4QC.E!RQ)JV?F397%4VS<MM
MO(#4D(-\L[]+J%<E53ZC81=>$NDB:[N)V!-SJ*3F&2/]Z\N7HU>/>V6\6DQK
MVO%L]SM$UF:'_1$._P!W$6!S"D$9Q$E!+[9_ES=0=T=P[Q[HWIV%W2^=WQOS
MX@[TS&V\?N+9D&SH\5\*MZY#LWJKK2AQU5M^>J3;=?N;)5&?W'2/6O4UE6(_
M#64M.O@+^S2R;'<07-J=;0;A>[D->0UQ>;.NRJ&TZ?T[*W4W%BBZ3%>N]R[2
MEM/3FYR2[I9R6$KM'')MS[;2,E=$,U\+V[E2M0+B]58[&Z<@J]A%'"B1R S,
M0K.;4W#_ "S?]FVW[WS\5-C?*CX5=L=\=H_*'L_Y%;$AVGN/OWJO;78F8&X=
MPK\B>D.PZ6!MV;<V3$TE+0YS:F>R&0@P=-3P+ML?9O+(7[!<VVS;)LW*V[.+
M']WSF*WOE_W'DGNMQEGM[J[(I+:7C37:QS7:K<1,\8NI9K96*1KMWL[KF#?+
MW>]FC^KDOK6!9;)J+,%LMN@M'MK,M6&>WECM3.EM(]NPEEDA19V=687NH=N]
M>_(K^;9\M=[]I8O;W8%9\:?CQ\1*'XG8S<^/HL_BMC[#[XQ&Y]Y]B]N]?X_)
MQO%1Y'<F4H(<)696"-:DTV(AI?*L1:-C38+:\VS:>8KNYC,6X_U@GVNX8C]6
M&TL-HV:ZMK37Y1276X7]U(J$+)+I236]HI4AW:]M]SN^7;2U8-MDFS?O.  $
M1W%U=[E?VLTK*0-3VME9;>L6L'PDO9?#"&:;7)R^S-I]'?SD^IZ;I7!8C9,'
MRJ^%'R/W5\G=K;0H*/$X/>6;Z%[#V)C>E^V=UX'%I'#_ !JF7=&=P29N6,35
M5+*E)+)*M+ L08+..5N>]@_Y9]KM=GN$2?@M]PN9K^UD\(<(CN-K%))/&M!.
MVV)-IUQ2LQKOT<;0<N;ZV+U]QNMO+_CFL?H&O"DAXR+:744!A9JM#]7*B%5G
M935[\:=A]U?-?^5'\&/BYL7X(]A;,KL7@_CCNG ?.+M[<OQ@Q'6O6%/UCO\
MQN]JSN7IR'8&^<_V549V:CQU128&EDVGB))):A8\E445*T]QRBG^M/*G,DK?
M11[/%L%W+JS<7$%MMMIXMI"L8DC*;G&#;R^/)$BV=Q*\@\=5MV<YT)%][@;#
M;$W$F[7W-UE&4H(8IKW<=TBBGG,NA@=NGE2X7PHY7-S;)X!"Z;E+#L)O#Y>;
M8_F9?S&(OC-T!T%W/C*O:'PEDW76]S?*;?7QXK<%7Q=9[B7&4N"QVT.I^R$R
M<4\9E>:>>IH6A9558I@Y= ERNUT=CWQ'11".:+THX<EV<\L<F^(K1Z %55$9
M1Q(Q<NZE(Q&K2%V[I:#FRSD21C.>7=N#H4 18QO_ #9X;+)K)9G8RAT,:",(
MC!Y#(RQ% [5S7<F?Z!_X4D9/OGKSKSJ[LB7X]X!,IL[J[MC/]U[/H:*+X-RQ
MXJIHNP-R[0V-5U,D\ 26>%]NPB%R8UDG"B1FMN2T3E& VLC.6YV!D#($"25Y
M1JB$.^M0H4ZR(R6++HHH9AART]RWNWM(N$5%7EZQ$95RQ=/WOS<2S@HOAMXA
M== ,@*JKZP7*(8O^99VOU#NY/@]\'>X<#VCO/IWM&CQ7?GRHVQU-\?N^/DCD
MJ[HWI7!T]1L+9>Z]D_'K;NYLQ2X_=/8$V!!J:S'K13TN)R5+++=UCD..9K6R
MY@]PM\L+TN+?:[?<)"R(2!N&Z?5;;MJE]+"*2"W;==T@?5')'=[;:/&=1#*!
M>4;N]V7VUV>[VUU2[W);&VC)D"NME:QVUWNTJ)QEC=#9;1<HI!,.],V55J+G
M^7=_<OYU_$3I'8/<>7[,RN]/Y>'R@I]JYW$[WV;NCJW=F_-S?&^&J7XT;_[?
MZV[AP5#N6C&9VME=H=B1TE70X^J&66F=W:"&:"<XW2:]WB7:/<JY98]QO[*Y
M>5H&C,=MNUS:7&S[VT2Q/)&LB2R[C]+%(7$-M>1-+ )1&(J06^W;:N^^WEE&
M1MHE@6V5UG5_W4;NUW;;8E,U'D2)((]KN9&\6.Z^ENPC,DH<6F_'#X_;$^+G
M36S^D.N9<W6;:VC_ !VL?-[GJ<=6[JW5N3=VY*S>>\]Y;KKL12T-+-D\QF,A
M79*ODIJ*"(S3OXH8H],:E;2+]+9V,*"."PM+.Q@C!8B.VL;:*TMHP79W;3#"
M@9F9F=JNQ+,3T9RA9=QO]TTTDW&\N[V6A)'BWEQ)<2*NHLPBC,GA0(S,8X$C
MB#$(.AQ]M]>Z][]U[I,;V_X\S=W_ (;&?_\ =5+[+-Z_Y(]W_P T9?\ CC=&
M.S_\E:U_YK1?\?7K1!]\.^NU77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO='Y^+_ /V2E\__ /PP>FO_
M 'Y$GN=O;/\ Z=;SY_SR[?\ ]I9ZA#W'_P"GF\C?\]-__P!H@Z(-[@GJ;^O>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z/SF?^W9>S/\ Q<K<7_OHU]SM>?\ B-UG_P"+!+_V@CJ$+3_Q
M(F[_ .E#%_VG'H@WN">IOZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H_/S*_P"94?!C_P 5CQO_ +TE
M5[G;W@_Y5;DC_I3)_P!7GZA#VE_Y6;G/_I;O_P!6DZ(-[@GJ;^O>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NL]
M)_P*IO\ J(A_ZV#VY%_:K]H_P]4E_LV^P_X.M][WW3ZXC]>]^Z]U4CL;Y+?.
MGYI93L+>?POI_BYTG\9MD=B]@]5[([?^2VQNU>]=Y?(7<75VX)]D[WW7L_J[
MJ_=O7]/MK:\&X*')8G&Y/([CR-9D5IGK%QM+3M!YT^W"ZN]BL>9)V1(]T@BO
M+2W )D-E."]K<3S:M,+7EN8[J&%(9BMO+$TLBR.T4:C<#9VF\7'+]OJEEL'\
M"\FJ%CBNU"F6UACTEIS;:O#GF,D*?4!XHEE2/QF-K7_(N'XS]*]>[M^?78G2
M_6N]-P[AKME9O=/7L6^X>G*O<T>/S.ZL6^,JMU0U%;B8)\#AYZZH_C%1X*>=
M)*1:VH8T\E0_?7NUIN5IMMD)?'O8SX4)4RR23PVC7-S##X2 RD>%,+90BS75
M(XXX3<2K 4]E9[E):W=Y/H:*T92TB]@2":ZALX))0['03-<0B8AFC@#-([B"
M.256G-?S OBSMOJ;9_<^X]V=B;?VMV)NK([(ZZVOG/CO\CL1W=V)NK%+/45^
M'Z_^-F0VG'V)G)$IJ:HR ;%;6G1J&-Z]&:B!G]ZF;P+BVLV!::ZBEF2)%:25
M887,<TLT<89[>.%Z+*]PL2QF2'61XT.OT6F:.XG5E$5J\<3RLRI"9)55H4BF
M<K%.TP8>"('D\5@ZQZFC<*I\3\V_BMF.@MP_)^'N;;6.Z1V?79##;RW;N6DS
MVT,ALS=.+RD6#K]A[QV1NNCHL_B=RQU\]/CSMG(XN'*FJFAIA1F>:.-K7I%A
M%:S2'Q%OM M3!_C/U322-$B6OT_B_4NTR/#X<.MQ-')$5$B.H]8 [C<7%I;@
MK)9Z_J%E!@-NJ1+<,]QXWA^!$+=DN/%ET1_3NDX;PF5RR==_/;XK]H;/[BWK
MMOL#<.+H_C_M.??G<FV.QNH>Z>GNU-@;'BPM9N&FWCFNENV]NX3>'\+K:3'U
M\F+R$.#D@KS33QT4E1)%(BL;K=6VR[%-S+N+JME;LZ32(1+X,B*LC13)%KDB
MF$;I)X,BK*8W20(496+^V6MQN^]6W+]@A:[O2@MT8>&LXDD$2O#))IBEC\4B
M-I4=HT?M=U;'28Z]_F5_"WM/L'8/6VQ^W<EE<MVQ-)2=2[LK.I>ZMO=-]MY2
M+"2[BEP'5'R!W+MRCV)N;*+14]5.V*P>XZJL IZE3!KIYUC,DL+M[V;;=&FX
M@220Q,0DKPPT\2>"-R'N;=599?J+<2PF!EN%D,+"0E9W"S%C%N0?5;S-$GB*
M&9(Y9CHCAN&4$6T[2?HF"Y\*59_T&19NSH6/EU\F-J?$#X\=C_(+=^$S6ZZ3
M9%#BJ7 [(VS]O_>;L'?F[L_2;+ZZZ\VV:PK"M=G<[D,?BZ:29A'&\XDD(C1B
M":\GO!-:;;M,(N;_ '*ZM[*TA+B)9+FYD$<8DE(811)4RSRE6\.".1PCE0C'
M-I!;R+<7=_+]/:6-O<WES+I+F*VM('N)W5 09'$<;"*,%3+*4C# N#T7WJE/
MYKN8W'L'>/<&6^!&SM@YS,4E7V)T-M'8G?FY>R=@;4K )9<;@ODI6;LI\+N#
M-4:G1,6ZTQU%-*&$<RQZ96.DAM+2[-K=S?61A) 9X4-N/%$;>&4AE,S20M,$
M4L\D$G@LTOA+(! 25[B[O;);JR@^CD8PD0W#B9A&63QA(\0C6.98R[*B">/Q
M0(C*R$S@4]G_ #T^+'8?;$72.P>P,_O?LE-Y=B[ S>'VCU'W/N/%;&W7U9N7
M+;/W?CNTMXX?;TV$VE'_ !+!9:EQ59N?(T%-EFIV;$S5J/&SI+ ?O.U%_9YM
MS")Q*W9$49%D""232AN/"=)6M=7U2Q21R-"$D1F,]TADV6<VFY4CF7Z8F,$/
M)HO(X9;>7PT+/X$B7$7Z^GP4?Q(G=989DC1^$_F:?"3<79.)ZNQ7<U3+E=Q;
M\EZKVMOBJZM[EQG0F\>T(:^3$-UMLGY.93;T/7&:S[5L,U!'AL5NJHK)*N.2
MD2%JB-XE]M"MOB1/M@+_ %$+7$"M^F]S D9F:>UCET/<P^ K7 EMUD1K=3<*
MQA!?IK<O]U)G%]V_2L$N"OZBVSEE31=-'J6U=9&6-UN#&R2,L;A7(7I^["_F
M$?%7K+M#,=/;@W?V'F=[[8RN!P&]?]&?QW^1W<VS>N<_N>DILC@\!VCV=T_M
M+.[9VM7STM;15GV6X<O1S)35%/4R(L$\4CZVS_=Q.D%AGQ)FMXW?]**2=6"/
M%%-+HAE=)#X3B-VT3 PM2164>W$C:K=KB][?#A^H9%_4E6"CL)F@CU3+&RQN
MZ,8P'1&9-2@GKKL+^81\5>L^S\QT_N#=_8>9WMMC*X' [U_T:?'?Y']S;.ZY
MS^YZ2FR.#P':79O4&TLYMG:U?/2UM%6?9;AR]'.E-44]3)&D$\4C[VP'=YT@
ML<^),UO&[_I123JP1XHIY=$,KI(?"<1NVB8&%J2*RC6X$;7;M<WO:$A^I9%[
MYE@TNPE:!-4RQLL;LC-& ZHS)J4$]'4'//\ 7^HM_O!]ZZ\#45Z][]UOKWOW
M7NO>_=>Z][]U[KWOW7NHU:*QJ.K&.>FBR!IIQ0R5D,M121UAB(IGJH(9(G>,
M/I+HDJ,5N RDW"/<#?"PG.UZ/J?#?P?$!,?BZ3X>L*58IKIJ 925K0@YZ>MC
M;BXC-V&,6I=80A7*5&H*Q# ,1722K &A((QU1UNG^9?\DF_E==??(+K?K+JG
M<WS\[#[6A^*>%Z5KZ+=\75%1\J=H]P9/JWN#$'$T>6.=BPF*IMM[GW#%"V8:
MI6AI4:2>3EGKS!NMI9Q['NNSQO)9[MMT6\F-R&G%A!L<N_;C;HZ*(Q>)':W&
MV02.G@IN3PI,IS&RO:[*$;CO]AOKL@V6\N;+6B:=<DVXQ;;LTS*S.$ANY+[;
M;F<E^RVFD(=2H(,IE?GKF=]X7^5]D?C]B-JYB?\ F![LV_N;+Q[MH,U7MLOX
M_P"&Z*R7=7;.?H:3#UU"T&7HI(,3MZGEK))8*>MKT\]-4%?$PHO]ICLO<>ZY
M16=9;&PLMSOY)T(+36T#6UIMTD#"L>F[OMRV^740XDLQ/X6EB)H@O:WMX>1!
MONYPM:[J]UM^W"U=#^EN$EP[;E;RI74#:65ANYH'JL]O&S%XE<,).4_F:?"/
M#=E5?5V1[FJ8,GCNP8>I<IOQ.K.Y:GX_X?M:?*+@5ZQS?RAI=O/UM1;B7(NF
M+DPE5NN.M2N843PK5$0^R7:_]W1@7;NXWA86VK]/ZLKJK]'XFCZRI1POTOBZ
MV1U3448 WW/_ '3I,^X=@M55[BGZAM495</=K'J-J@C=)&:X$2K$Z2,0C*Q6
M7<OSR^+70>_<KU3V/V!GT[3Q&W-C[NDZPV+U)W-V]V/E-M=B9#/8W;&8VML3
MJ+;V<RN:A\FV<VV1.(I*DXV*G$^2%)!/3237L4;<KF.TLN]Y)WM^("I)%':2
MR/,[42WMXTO[/7=SM':J]Q'$9A*2@?N+:6TMX+JZTQQW(D,)9T7Q3$P5XXP6
MJ\V2RP*#,\:2RHC1PRL@(=1?+Y=N[Z_F?;G^2/;&!VKT7\4OD-L?;>U<_NND
MV_M?#===<Y;XI==]CY#&UF2HJ2FJZV2IS^X,A-!]^]36/-5)1P$J*>G5M+BU
MM>2MOW>_-;FXW#=+6JAG>5HMR:TLX(HHPQDE(T0Q)"C23.1B1VJ7KFU:[YBM
M[':5(AEV>POB&J@5I6W!KB>5IM)A18;='E\4I' D;.PC D/00Y#^9MUUV!\P
MOBKU[U)V3O3$=>YKJ_Y8]C]Z=9=A?'SM7J;L[)[8ZUV1A<YU]OFAZX[NVEAM
M\2XA9WRRX_([?H#29*9):9)*N6'Q(@^K&V7V][CO34VW:MAN+Z72/$>VN(MU
MVJ+5-'"&N(Y/HY[O1;RH#*I:2.)WC5E32H;RRVBUVO-YN>^6=E"3VI<V\NT;
MY<2I!+)2"1%NH-N:6:)R8*Q+))''<%9#J9OYW?$O;FV/BGO/-=S82AVS\WMP
M;'VO\6\LV%W=-#VOF^R-MKNS95-114^/>3&1UU$\++4YM*.&.::"EFDCJIX8
M9!!<[5?VG-S\ASQZ=VCBOIFM]2EO"VU5:]<."8F6!70]KGQ-2^%K)'19'N=E
M)RX>;%8C;UEMX&E*.I26YD:*)'C91*C>(CB36@$ 1VG\-48A%?(WY4]9X?\
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M?[@S1515W..!F,L$@&MW+7F\V,<.;/:;-XXFH 9KS<GM[G<91DN(HX[7;;%
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M)+J)):DAOIII[MK<KHT_67 ?Q-4?AF ]^Z]U[W[KW7O?NO=)C>W_ !YF[O\
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M='Y^97_,J/@Q_P"*QXW_ -Z2J]SM[P?\JMR1_P!*9/\ J\_4(>TO_*S<Y_\
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M.,..H^FN_=\_&'X1XSM?KWY.[^IMM_SE]Q]K[?QWR8@[?[/[?V;\8<'V#O\
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M(@6:-7[.@W^!'26ZMN=#_-S;.1VAFNIMX=Q?.;^8?NJBR^;VOD]JY?.T&_\
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M]^Z]U[W[KW7O?NO=>]^Z]UK_ /37Q<[IQ?\ -[[-P.X.OMR4WP_ZDWWVM_,
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M;/\ Y_L5_P!???NO=>_OKLW_ )ZW;/\ Y_L5_P!???NO=>_OKLW_ )ZW;/\
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M .M/7O\ @O>=O^C98_LN/^MW7O\ AE7H7_GZO;O_ %,V9_\ 6OW[_@-N1?\
MHZ7_ .VW_P"M/7O^"]YV_P"C98_LN/\ K=U[_AE7H7_GZO;O_4S9G_UK]^_X
M#;D7_HZ7_P"VW_ZT]>_X+WG;_HV6/[+C_K=U[_AE7H7_ )^KV[_U,V9_]:_?
MO^ VY%_Z.E_^VW_ZT]>_X+WG;_HV6/[+C_K=U[_AE7H7_GZO;O\ U,V9_P#6
MOW[_ (#;D7_HZ7_[;?\ ZT]>_P""]YV_Z-EC^RX_ZW=>_P"&5>A?^?J]N_\
M4S9G_P!:_?O^ VY%_P"CI?\ [;?_ *T]>_X+WG;_ *-EC^RX_P"MW7O^&5>A
M?^?J]N_]3-F?_6OW[_@-N1?^CI?_ +;?_K3U[_@O>=O^C98_LN/^MW7O^&5>
MA?\ GZO;O_4S9G_UK]^_X#;D7_HZ7_[;?_K3U[_@O>=O^C98_LN/^MW7O^&5
M>A?^?J]N_P#4S9G_ -:_?O\ @-N1?^CI?_MM_P#K3U[_ (+WG;_HV6/[+C_K
M=U[_ (95Z%_Y^KV[_P!3-F?_ %K]^_X#;D7_ *.E_P#MM_\ K3U[_@O>=O\
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M;,_^M?OW_ ;<B_\ 1TO_ -MO_P!:>O?\%[SM_P!&RQ_9<?\ 6[KW_#*O0O\
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MKW_!>\[?]&RQ_9<?];NO?\,J]"_\_5[=_P"IFS/_ *U^_?\  ;<B_P#1TO\
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M?\!MR+_T=+_]MO\ ]:>O?\%[SM_T;+']EQ_UNZ]_PRKT+_S]7MW_ *F;,_\
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M>O?\%[SM_P!&RQ_9<?\ 6[KW_#*O0O\ S]7MW_J9LS_ZU^_?\!MR+_T=+_\
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M7[CZEVEOK<?\#W!WGOZHZOZLQ_\ !\]D_P"]&^J79&7[&GP?W6'I:B"BTX;
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MKMY80"QN[B:2XGN46<3)%++<2O/^DJ+'(VJ%8Z"ECVU]LX#96V=N[-VIBJ3
M[6VE@L1MG;6#Q\?BH,-@,#CX\5AL50Q$G3#3T\4<,2W-E4#V=;A?WFZW\^Z;
MA(9;BYD>65S2KR2,7=C0 59B2: #.!T3;;MUEM&W0;3ML8BM[6-(8D%:)'&H
M1$%23154 5).,GI]]H^EO7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U__]#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW3:V&Q#$LV*QK,Q+,S4-*2Q)N225Y)]^Z]UU_!<-_P ZG&?^
M<%+_ -&>_=>Z!3NKOOXM?&S$XW/_ "*[HZ!Z"P69JGH</FNZNQ>N^K,3E:V-
M0\E'C<COFLH(9Y5!!,<3LP')'MAKJV2X6T:11*X+*A8:RH(!8+6I ) ) H"1
M7CT\MM</"URD;&-2 6"DJ"<@%J4!(!H"?+I7]:[YZ8[FVCCNP.G]X=8=K[#S
M!E&(WMUKN#:F^MHY0P-HG&.W)M>:JHI]!X?Q3-8\'VNGM;FU95NHVC+*& 92
MI*G@PJ!533!&#TCAN;>Y#&WD60*=+:6#48 $J:$T-"#0YH1Z]+S^"X;_ )U.
M,_\ ."E_Z,]L=/=>_@N&_P"=3C/_ #@I?^C/?NO=>_@N&_YU.,_\X*7_ *,]
M^Z]T&VZ.Q.G]F=@]8=5[GR.#Q6_^YI-X0]9[<EPE3/4;JDV!@1N?=ZTU724T
ME-!]E0D5#FKFB#@Z8];^GW6W=;J]EVZ#NFAMGO'7^&VCN+6U>4DXH+B\MH](
M)<F4,%*J[+6X=;2VBN[CMCFN([1&X@W$L%U<QQXJ06@L[EPQHOZ14L&9%82?
MX+AO^=3C/_."E_Z,]VZMTFMX9GK;KS;&:WMO_*['V-LS;=#)D]Q;NWA78';.
MV,!C8B%ER&:S^::"DI8%) :6>55%Q<\^_ AI8H!F2>6*")?Q233R+##"@XO+
M-*Z111K5Y)'5$!9@#NAT/)^&-'D<^2QQ(TDDC'@J1QJSNQHJ(K,Q"@GI1KA\
M(ZJZ8O%.CJ&1UH:1E96%U96"V((Y!'O9!4E6%".(ZHCI(@DC(96 ((-00<@@
MCB#Y'KE_!<-_SJ<9_P"<%+_T9[UU;KW\%PW_ #J<9_YP4O\ T9[]U[KW\%PW
M_.IQG_G!2_\ 1GOW7N@T[8['Z=Z.VO0[T[5R6$VAMC);SV!U[196JP=7D(Y]
MX]H[TH>O-AX408:EJ9@V0S.2HJ)96C$49E$DTD<*O(MK=6NMQM=I@[KB]D,4
M"<#)(L4LY4$T4'PH9'[B =- 2Q -F4I976X/B&RA>XF;R2&.FMR.)I4 *H+$
MD!03T(\V*P-/%+//C<1!!!&\TTTU'1QQ0Q1J7DEED=0%50"68FP')]L3SPVT
M+W-RZQQQJ69F(55515F9C0!0 222  *GK<<<DLBQ1*69B   222:  #)). !
MDGHJ757S;_E_][;Q@Z[Z/^7/P[[D[ J8ZF:FV-U5WYTKV'O&HBHT,E7+!MG:
M.6K*UUB56:1E@(4 EK 'VK@M[BZC>:U1I$C76S*I8*E0-3$ A5J0-1H*D"N>
MFKITL9Q;7I$,A<QA'.AM8J"FEJ'6"""M*BAQUA[-^<?\O?I3?^1ZH[E^8/PU
MZE[2PYQ:Y?K7LWY ]);#W_BFSE!#E<(N1V=NK+TF1@-92U%/4THEIE\L4L<D
M>I'4E-:2QW[%+%A,P<QD1D.0ZFC(0M:.IP5X@X(Z47%M<6D4<]U&T23(9(V=
M2JO&'>,NA( 9 \;H66JZT=:U4@&GQ46TL[C,?FL''MS,X;+4=/D,7EL4F,R.
M,R6/JXA/25V/KZ37%-#*C*\<L;E64@@D'V_-#-;RM!.I1U-&5@0P(\B#0@_(
M])(9X;F)9[=UD1A4,I#*1Z@BH(^SI@W]N?JCJG9VX.Q.T=P]>];=?[3H),KN
MG?._LMMO9VSMM8N)@DN2W!N;<4E-14=.I90TU3.B D7//M)<75K:*KW4BQ*S
M*@+L%!=V"H@)(JSL0JJ,LQ  )/2N"WN+IS%;1M(P#-15+'2BEG:@!-%4%F/!
M5!)H >L>6W9U)@(]ES9W<O7.%A[(S>.VUUW+ELSMG'1[]W'F,7/G,3@-EO62
M(,I6U5%2U-934M"9998(I945HXV8+)8)H-Q.T3(R78\:L+ B;_%U9Y_TSW_H
M(K/-V_IJK,^D GI)%-#/8?O6!U>U B;QE(,6F>2.* ^(.RDTLL441K2222-$
MJSJ"L_X+AO\ G4XS_P X*7_HSVUT[U[^"X;_ )U.,_\ ."E_Z,]^Z]U[^"X;
M_G4XS_S@I?\ HSW[KW7OX+AO^=3C/_."E_Z,]^Z]U[^"X;_G4XS_ ,X*7_HS
MW[KW7OX+AO\ G4XS_P X*7_HSW[KW7OX+AO^=3C/_."E_P"C/?NO=>_@N&_Y
MU.,_\X*7_HSW[KW4/)?PW;N+RN<@Q=&'Q6+KZ]DIH*>FEF2CI6J7@69$NNO1
M:]C_ *Q]IKRX%I:2W9&KPD9Z<*Z5)I7RK3I1:6YN[N*U!T^(ZI7C340*T^5>
MJ2O^'N]K?]X\Y_\ ]&+CO_K1[PK_ .#1VS_IGY?^RM/^M'69'_ =;E_T?HO^
MR5O^M_7O^'N]K?\ >/.?_P#1BX[_ .M'OW_!H[9_TS\O_96G_6CKW_ =;E_T
M?HO^R5O^M_7O^'N]K?\ >/.?_P#1BX[_ .M'OW_!H[9_TS\O_96G_6CKW_ =
M;E_T?HO^R5O^M_7O^'N]K?\ >/.?_P#1BX[_ .M'OW_!H[9_TS\O_96G_6CK
MW_ =;E_T?HO^R5O^M_7O^'N]K?\ >/.?_P#1BX[_ .M'OW_!H[9_TS\O_96G
M_6CKW_ =;E_T?HO^R5O^M_7O^'N]K?\ >/.?_P#1BX[_ .M'OW_!H[9_TS\O
M_96G_6CKW_ =;E_T?HO^R5O^M_7O^'N]K?\ >/.?_P#1BX[_ .M'OW_!H[9_
MTS\O_96G_6CKW_ =;E_T?HO^R5O^M_7O^'N]K?\ >/.?_P#1BX[_ .M'OW_!
MH[9_TS\O_96G_6CKW_ =;E_T?HO^R5O^M_7O^'N]K?\ >/.?_P#1BX[_ .M'
MOW_!H[9_TS\O_96G_6CKW_ =;E_T?HO^R5O^M_7O^'N]K?\ >/.?_P#1BX[_
M .M'OW_!H[9_TS\O_96G_6CKW_ =;E_T?HO^R5O^M_7O^'N]K?\ >/.?_P#1
MBX[_ .M'OW_!H[9_TS\O_96G_6CKW_ =;E_T?HO^R5O^M_7O^'N]K?\ >/.?
M_P#1BX[_ .M'OW_!H[9_TS\O_96G_6CKW_ =;E_T?HO^R5O^M_7O^'N]K?\
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M/=[6_P"\><__ .C%QW_UH]^_X-';/^F?E_[*T_ZT=>_X#K<O^C]%_P!DK?\
M6_KW_#W>UO\ O'G/_P#HQ<=_]:/?O^#1VS_IGY?^RM/^M'7O^ ZW+_H_1?\
M9*W_ %OZ]_P]WM;_ +QYS_\ Z,7'?_6CW[_@T=L_Z9^7_LK3_K1U[_@.MR_Z
M/T7_ &2M_P!;^AUK/YIF I/C?A_D2>FLN]%E^W\AU*NUAO2B6J@J*#:@W2<V
MV5_AI1D93X1!X 0?5K(X]C>;[SMC%[=P^X/[GD*2W[V/@?4+4%8/&\37X-""
M.W3IKYU\N@7%]VN]E]P)>0OWL@>*Q6]\;Z=J$--X/AZ/%K4'NU:OE3SZ K_A
M[O:W_>/.?_\ 1BX[_P"M'L$?\&CMG_3/R_\ 96G_ %HZ&G_ =;E_T?HO^R5O
M^M_7O^'N]K?]X\Y__P!&+CO_ *T>_?\ !H[9_P!,_+_V5I_UHZ]_P'6Y?]'Z
M+_LE;_K?U[_A[O:W_>/.?_\ 1BX[_P"M'OW_  :.V?\ 3/R_]E:?]:.O?\!U
MN7_1^B_[)6_ZW]>_X>[VM_WCSG__ $8N._\ K1[]_P &CMG_ $S\O_96G_6C
MKW_ =;E_T?HO^R5O^M_7O^'N]K?]X\Y__P!&+CO_ *T>_?\ !H[9_P!,_+_V
M5I_UHZ]_P'6Y?]'Z+_LE;_K?U[_A[O:W_>/.?_\ 1BX[_P"M'OW_  :.V?\
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M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NDQO;_CS-W?^&QG_ /W52^RS>O\
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M,@13(S-&D:E55;933[=O=US#8R-%=75_<;B64T\.XN)VN6\+%51)&_3#%F
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MH_C;\9>G_B?UQ_HPZ9P.2QF%K=QY_>VZL]N;<NX=\[^[#[ W95_?[L[#[([
MW?4UF7SN<R4UGJ\CD:N20JL<,>B"&&*,WN;Q[B*WM$1(;>TC$,$,2".*&(,S
MZ(T'#5([RR.Q:26622:5WED=V*(K81W$][,[S7%TP>::0ZI)65%C0L: !4B1
M(HXT"QQ1HL<:(BA0J.]NG]M?(3I'N'H3>E=G<9L_NSJ_?O4NZLEMBIH*+<N/
MVYV+M:JVCFZW;]9E:6MI8JV*FK)7I9*FCGB64*9(95!1B#>-IM][V]MMNV94
M=HV)0@-6.1)%H2&%"R ''"M*'($&P;U=<N;[9\P6*H\UE-%/&K@E"\3AU#A6
M5BI*C4 RFG @YZ*E\ZNC>TNSOAEE/B#T3B*W(#NO$[3^-6]-]Y'<&V\1_HLZ
M#W+3Q[9[A[+R9KY::7(5T.UHLA18NAQ%%/--E:NC,D$-"M544YSO4R\V\X6E
M[S!&HL;C<DW#< H)1HK:;]X-9(FLR?[L)XH[ -4B"&XDG=ZQ .4<M^)R5L+'
MEZ0F^VVR\#;=?Q?5&-;2VN7<*J 6)<;C*!H:5;5H8 )I8P#VX'"8S;.#PVW,
M+3+1X?;^)QV$Q-&A)2DQF*HTH*"F4GFT<4:*+_T]N[A?7.YW\^Y7K:YKB1Y9
M&X:GD8NQH/5B3TAVO;K;:-LM]ILP1#:Q1PI7CHC0(M: "NE16@'V=.WM)TNZ
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z3&]O\ CS-W?^&QG_\ W52^RS>O
M^2/=_P#-&7_CC=&.S_\ )6M?^:T7_'UZT0??#OKM5U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1^?B_
M_P!DI?/_ /\ #!Z:_P#?D2>YV]L_^G6\^?\ /+M__:6>H0]Q_P#IYO(W_/3?
M_P#:(.B#>X)ZF_KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NC\YG_MV7LS_Q<K<7_OHU]SM>?^(W6?\
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MLO\ E.W3_G-:?]L77O\ @NO<C_E"VW_G#=?]MG7O^&7?BY_SWO?O_H4]>?\
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M3_GR'4/_ *+79G_U%[]K;U/7NO?[+YT)_P ^0ZA_]%KLS_ZB]^UMZGKW7O\
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M(3IV6*9+>0Z9'C\55.&:(N\8D4')C\2.2/6!IUHZ5U*P"G_V7SH3_GR'4/\
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M,V?^YC_VX]>_X#;_ ,./_NG_ /;[U[_AT'H3_O7EU#_Z$&S/_L%]^_X-AO\
MIFS_ -S'_MQZ]_P&W_AQ_P#=/_[?>O?\.@]"?]Z\NH?_ $(-F?\ V"^_?\&P
MW_3-G_N8_P#;CU[_ (#;_P ./_NG_P#;[U[_ (=!Z$_[UY=0_P#H0;,_^P7W
M[_@V&_Z9L_\ <Q_[<>O?\!M_X<?_ '3_ /M]Z]_PZ#T)_P!Z\NH?_0@V9_\
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M .Z?_P!OO7O^'0>A/^]>74/_ *$&S/\ [!??O^#8;_IFS_W,?^W'KW_ ;?\
MAQ_]T_\ [?>O?\.@]"?]Z\NH?_0@V9_]@OOW_!L-_P!,V?\ N8_]N/7O^ V_
M\./_ +I__;[U[_AT'H3_ +UY=0_^A!LS_P"P7W[_ (-AO^F;/_<Q_P"W'KW_
M  &W_AQ_]T__ +?>O?\ #H/0G_>O+J'_ -"#9G_V"^_?\&PW_3-G_N8_]N/7
MO^ V_P##C_[I_P#V^]>_X=!Z$_[UY=0_^A!LS_[!??O^#8;_ *9L_P#<Q_[<
M>O?\!M_X<?\ W3_^WWKW_#H/0G_>O+J'_P!"#9G_ -@OOW_!L-_TS9_[F/\
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M:V]3U[KW^R^="?\ /D.H?_1:[,_^HO?M;>IZ]U[_ &7SH3_GR'4/_HM=F?\
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M%K:) SR%3)H,EK#.XD>-%1=)D-*@4336O$@SEKF!]SV:+<-V,<$D\]W%&*Z
MX@O9[9- =B69A$ VDD&350#X0>'L3?\ M7JK8>\>R]\9./#;/V'MO,;LW+E)
M 7%'AL%0OD*Z6.)?5))HC(BB2[.Y5%!9@/8%8R52."-YI972...,:GDEE=8X
MHT&*O)(RHM2!J85(%2!G:6S7EPL"LJ U+.YHD:*"SR2-0Z8XT#22/2B(K,<
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M?W$H]^[@V[\R^Z]W[/HI-MT^Y<O@\_A*ZF:;<NV8)(9IJ:NIL?)7C[NE"S)
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ML=O;B.&V0/)'<*--O&0X*,6E;7JPP>NW1;@=N>ZOR!N=Y*US</0M'XTY>29
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MF&ZB;N8F,Q/#H2.+P[8+-<.8#/*TW5;F$WEO:VMR[.EE<BZMP:?I/]+<VLB
M@ NLZ7(>5I3),7M[<)*D2-$[CE/Y=_2N7^&M#\'JG=':*=3X_>V WY#N&#-;
M37L-LOMWY#P?)>BII<M)A&QIIFSU.E)*@Q(<T!:)9%J+502[;"NUR<LRV]2>
M5$V>.TU9\0;)906%J;FE-9DAMT:X\+P0\A8QB)2$5P(!%OT7ES"-^%SZI_6)
MKYKWP/X?".X3?2^)XF@+%XOCZ7UC?N_XU[&WK\DNFOE)E,ONVF[ Z.ZW[DZO
MVEB<=7XB':%?@.\*[;F0W76[@H*B@EKI:VF?:] ,=)39"GCC$E1YHIRT9BI!
M;BVEW2>!V5]VL8["5@U#'%%<B[62$BA2;Q0!K8NH7@@;NZ>NY#>6%IMTH'AV
M=Y]<A'$R_27%GI>M08_"N';2 K:PIUZ059[^/'2E-\=^H-I=/TG9O<?<5/M(
MYPIV+W]ORH[,[8W"<[N.KW&_]Z=ZU,%,]9]JU6:.B!@40TD4$ N(P28W%R;E
M8%*(G@6]M;U10OB?301P":2F&GF\/Q;B0 >),\CA5#:0W+67<+W<#@WMS<7)
MC&(H?J)6E\"W08BMH=7AP19T1JH+,U6-?W4GP1SC=4_+?X2=NT6XL9\;=P?)
M[)_(3X_=F[&W+M&#,5VT.TNY(OE#G.LZG%95,E4XZLVOOE,K0S-4X@4M7AJN
M@:CJ35_>+1H]MCT[!RO]:U+[E2ZM8X10:;BWV:YBN-EF8J#^D+/Z?;+B+5'.
M9-OFE31%/ Y]N["ZWS?Y;=?\5YFL)UN"!I:"XW+;9-IW1$JQK)(0VYP2A#"C
MWO@M&1;LCGHW;\;-C;R^2G3'RFRF5W9!V#T9UQW'UAM+#T%=AXMG9' =W5^V
M\CNNKW%CZB@EK9JRG?:] ,?)39"GCC62H$T4Y>,Q6V\?NV^W#<(,ON5G#92A
MLJL4-VMXC1@4(D,JA6+%E,=0$#=W5[QS?;=:;9+B.SO#>H1\1E-I<6>EB:@Q
M^%<NU %;Q AUZ058$\]_+J^/6Z\9\L<1NM]_YZC^7W=VR?D1O29MU1X',===
ML]:[+VIL_K[=?2^Y-HTF.R6#JL-)LW"YF@J9:NJJ(\@LLGF-,XI4;A22UVG;
M=LL97@?:+N\OK6X0@3Q7%]<SW,QJP:)XZW$T!ADB:*6UD>WN4GCDD#N33BYW
M:[W6ZC247]C;[=<0.*P2VMM"T"HRUUAG5M;2+(KQS+'-;F&6-&5RZ4^#FVNK
M>W#W[V%WI\@_E-W3CMB9;J_9'8/R(SO6=14=8]=[BRM)F]T;9Z_VETOM39>W
M*1\M58_'297,5&&GRU6M)3PSU[P1+%[?)C&WWMC%&L;[DL:74Z@^--'%XABB
MJ24BAC>5Y1#!'%$\I669)'CB*(9H6N)K9II':&R9W@@K^E'+(HC>8X\268Q#
MPEEN))7CC:18B@FF\3BWP&Z>;X21_ L[D[*_T01[>I]M+N09C:_^DDT--O==
M^I*<Q_!OX7Y36*(RW\'T^'TZ0_[GMI4"ML3#_G7Y-@EM_P"FW+LEA+9";^(2
MMMT NM'AEPTO@F LA3=_"NXP[_#/4#F(;Z+G3@I_6#Z[ZWP*UT^%^\)OI?$\
M71IB\7QM+Z^?=/P>V[V?VOD.]NNN]OD)\5>XMS;-P/7?8N_/CIG>L::H[2V-
MM.MKLAM'!;\VMW1M/>F FFQ$N3R/\,S=%B*;+TT=3+!%D%IR(@S!;?3BZMXY
M'%M>R":>W#%8Y)Q"EN9U==,]O.]O%#!)+:S0/+'!;B0L;> QKYK@7"6QFC1I
MK(2+!,162..5Q(\)SX<L)E'BK%/'*D<C2-$$,\_B9]I_!/JKKC8_QNZXZJWS
MWIU9L_XW=KY'N.GQNRNV,Y35/>6Z]P4^;FWC!\E<SEUK*[>-%G<MGZW<69AK
M:E'JLHL-0\H2/Q,9B[9=UMMR1$6*RL9-N@M H%G%;-;QVT(2#AXEG%$OTLI8
MO'(7E<R2.[$J>S$NW75E-+(\U[>17T]V6_QN2>.X^H<&44 AN#^C/ JB(VRI
M;Q)%%'&J)KXI]*=FX_Y#_,_Y5]T;8&RMV]\[WV3UCUALV7-X'/Y';GQK^.6,
MK\!UKD,U7[8JJZA2LW-FLQNG=OVD-4[TU'DJ*FJEAK8:J&-/M):QY1BVZ9JW
M5]>W>ZW:UJL,MQ%:65M:J=(#&WV[;K,SLA>+ZV:\$,LT(CFD5[L!><S"ZCS:
M[=8P;?;-7^UK+/?7MR%(#();J[^FC5P&,%C!*R1O*Z='Z]UZWU[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW28WM_QYF[O_  V,_P#^ZJ7V6;U_R1[O
M_FC+_P <;HQV?_DK6O\ S6B_X^O6B#[X=]=JNO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z/S\7_ /LE
M+Y__ /A@]-?^_(D]SM[9_P#3K>?/^>7;_P#M+/4(>X__ $\WD;_GIO\ _M$'
M1!O<$]3?U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW6T-_)P_P"R3\Y_XF7=_P#[S6#]],?NA_\ 3K)_
M^EA/_P!6;;KG!]['_IYT/_/!!_U>N.K7_>4W6,?7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]UBF1Y898XYGIY)(I$2HB6)I('=2JS1K.KH64^
MH!T9;CD$<>VIXWE@>**0Q,RD!U"ED)% RAU9"5.0&5E)'<I%1U>-E217=0X!
M!*FH# '()4AJ'@:$'T(.>J[W^&7RH9W9?YN/SEC5F9EC3IW^6$4C!-PBF3X]
MLUA]!J8G^I)]N*"% )K3S-*GYXH/V #K<KK)*TB((PQ)"KJ*J":A06+-0<!J
M9FIQ).>G##?#WY/XS+XK)5_\USYK[AH<?DJ&MK-OY;J+^6I3XO.4E)5+/48?
M)5&"Z#HZZ.GJ44P3/1UD$ZHQ,,T4@5U46TL<%S'--&LR(RLT;EPL@!!*,8V1
MPK#M)1U< ]K*:$)+J*2>VD@AE:!W5E61 A>,D$!U$BO&60]RAT="0-2LM0;!
M?;'3_7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%!VK\(ND]G?-/M+YY8B/<Q[O
M[;ZAVITSN.FJ\CC)=DX_ ;7R$-949_;^&CHDJZ?,9>*@P=#F:N3(2QSTV'QD
M:0Q&G=Y=;.#L>V[MM5B3X.\WMO?SAB3IFMK5K1%B H$C9&:612&+SLTFH$D=
M:W4'>+S:[V\)+;1:SVL"@G1HN+@W+.ZFH,R.TB12+IT12RI0^(Q/NF/A'TKT
M1\F/E3\K=CG=C=F?+R;K27LFAS67H*[:& '6.#J,/0P]>8:GHX)L:F5FJZC*
M9M9JNH^ZKG,X,0]'O>VZ=JY<;E>T5?IGO;J^8E1XC27;&1XF8 !H(I7N9H$8
M%HY+R[;6PEHMMP)W'<X-UG[9(+<0!5[49J1(URZ_BN9+:UL+.22H!M=MLHP@
M:-WD+WF/Y472F7ILYU[_ *9ODSC/BCNC>^3[ W1\'\5OO9%/\:,[F\[NU]^[
MCP\\DVV9-_4NW,EFI)<A7;.QV^J? 2^66E.,%#+)2MK:0-J_=G_$D;(;8[>)
MNX6GT.GZ#3HT?4"P*1?1K>?4K!X-N%%+>$)O<7:_>^FB)M)=T$WUDD!*/<FY
M4I=.2=0@DNE+"XEM!;RRM)+*7\::61SE;?\ CSLG;?R-[#^3F.R&Y?[]]E=/
M]5=)YO"35>(_N90;3Z@W1N?=FV*S"XV"BCK(JZ:HW9D8ZV27(2PM%%3+%!"R
M2O,]:S/:6-Y8(=2WUVM[(S982K;1VH"G T&.-6(8,Q<DZ])"C5P5N(]NBTK&
MFV17,,*H-*Z+J2"1PPR.PVZ"/3H"J6!#5!4$MZ_R]N@>Q,%\L=N[SEW_ )?'
M?+_M;8?=F]YJ?=:;>S/7W9G5^R-J;-Z[W9TYN/:U+0Y'"UF&DV9A,W05,M55
M31Y)))/(:=UI42HDD&V[=86<KP2;5>7%_:W"$">*XN9WN)#5@T3I622'PGB:
M.2W=X9UF1W#+9;YKB_DO;N..9)MOCVR:!U)@GM(S<=DBUU:G^I>KHZ,C)%+"
M8I8UDZ3_ %S_ "\]K;1[YZJ^378GR-^4/R-[LZ9VUV/LC8N[N[-T]5+14&R.
MT*"CH]Q;8?974&SMI8  24-/5+DX,7'E*B1(UKZ^L@@IX855K(+*[NKZU14D
MOK,V=R14B9!=VUY$Y!)$;P26Q2)8!%!X=S<F2&25HI8BB[MOK;:SL[B1S%M]
MV+RW6H[)?H[JR<,Q&N998KK4YG:659(8C%)&C7"3N/5_\N/XX=5;L^:>[,32
M;LW"_P [JW)/W)@-W93#Y7;6%P&=@S4VXMD]=8VDQU,^/P^2RFY=R9^NIJR:
MLDER64K)C*(VCAB))MGMI_;R3VSD9_W=)+?S:M7ZZ&_()1)*46.T TV"A*VP
MK0L<]'<>[7\?.MOSX)";RUCL8XD)/@H;%(HUE5*U$UPEO;+=2!ZRK;6X&D1*
M.DYU]_+'Z&ZX^&_6_P )L3O#N/*]==;]M;%[NCWYN3=&U\OV]O3L/8GR%I/D
MO#F=^[H.$2AK6R6X:..'*-#BH))*)FAADIY0DZ"^[WR[O.8-KYCD5%FVCP_!
M15*Q$I:2VC-(M:EIO'EN9BC)KNI'EP&*$AV^S3;MKW/:8V9X]TMYK61G(+QV
M\L*6T44) 556TM(H;6U#*^B&"(2>*X9V?-^_R^MF[G[B['[BV#WY\F?CW4=Z
M' 2?(C8/1V]MBX38'>U;MS;D6RZ#.[HI]Z[9SV7V_EWP=/38>JSVP<QM[)ST
MU/3&6L:>EIYH@W!8VR6$^RW8-SMT\D\QM)6;P5DN0HN#&T9CN$2=E$DL*SBW
M>4R2&+7-,9#>>]N);FWW*$B&^M8TA2Z15,IBBD:2!)%E$EO-X#/((7E@>1$?
MP@_A)&B,E+_+(Z$P/QV^.GQ[V!O#NGJY_B/45M5\;^[-@;VQ.+[OZLFR4590
M92"BSV1Q57A,M0UN/KI\9D</N+ 9#'5M.(OO*2HGABF57)+>R7MININ'%Y:V
M$.VM-IB+7-I%!9PM'<QM&8'\=K"UN9=,,:I=1)-;+;E(PB"VMK*WM+S;FA66
MVN[VXW#PW:0^#=3W-U<B2"4.L\;0&\N(8G,K2-;2R07#SI+-XAG^A>E=P=+8
M+.8S=/R$[W^1^<S^97+56]>^LEUG-G:*.*C2CI\-@\)T[M?9VW<?1H$,A2CP
M<;R2,SS22-8A]IH_IDMHXE32SNS@NSNSA%.IG=Z*HC71%&$B0EW5 \DC/58G
M%P]P\C-J55"G2$4(7/:%5:LQ<ZG8L[ ("U$4 =_;'3W7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]??X]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]TS[AV_A-V8'-;7W+BZ+-[=W'B<A@L[ALC E3C
M\MA\M2/09+'5M/)P\4\,CQR(>"I(]M30QW$9BE%0:<"000:AE8$,K*0&5E(9
M6 92" >G[6YFL[F.[MFTR1,&4T!HRFHP00<\000>!!'47:&U,)L7:NW-E;:A
MK:;;NT\)C-NX*FR.8S.X:ZFQ&'HTH,=3U6<W%455?5O'%&B&>KJ997M=W9KG
MV8[A?W6Z7TNY7S!YIW9W8*J:G8U9M*!5!)))H!DD]%]G9VVWVJ65HNB*,:46
MI(5?)1J)(5>"KP50%4!0 %%[1]*>O>_=>Z][]U[KWOW7ND-O;K;978[;2.]L
M(N?BV/O'#=@;;I*FORD&.I-W[=$AP&9K<913Q4]<U%+*:FDBKXIHHJE(:J.-
M:B""6-^TN9[&Z^LM6T2B.6(-@T2=#'+IK4*S1LT?B*!((WD16"R.&I<1QW5G
M+M]PH>&;P]:D8;PI4F0'S*B6-'*UTL5 8,!3I<^V.K]>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW2*E[%V5#+)#+GJ9)(I'BD0P5I*O&VEU)$5N"+<>_=>ZQ_Z2MC
M_P#/04W_ %(K?^O7OW7NO?Z2MC_\]!3?]2*W_KU[]U[KW^DK8_\ ST%-_P!2
M*W_KU[]U[KW^DK8__/04W_4BM_Z]>_=>Z]_I*V/_ ,]!3?\ 4BM_Z]>_=>Z]
M_I*V/_ST%-_U(K?^O7OW7NO?Z2MC_P#/04W_ %(K?^O7OW7NO?Z2MC_\]!3?
M]2*W_KU[]U[KW^DK8_\ ST%-_P!2*W_KU[]U[KW^DK8__/04W_4BM_Z]>_=>
MZ]_I*V/_ ,]!3?\ 4BM_Z]>_=>Z]_I*V/_ST%-_U(K?^O7OW7NO?Z2MC_P#/
M04W_ %(K?^O7OW7NO?Z2MC_\]!3?]2*W_KU[]U[KW^DK8_\ ST%-_P!2*W_K
MU[]U[KW^DK8__/04W_4BM_Z]>_=>Z]_I*V/_ ,]!3?\ 4BM_Z]>_=>Z]_I*V
M/_ST%-_U(K?^O7OW7NO?Z2MC_P#/04W_ %(K?^O7OW7NO?Z2MC_\]!3?]2*W
M_KU[]U[KW^DK8_\ ST%-_P!2*W_KU[]U[KW^DK8__/04W_4BM_Z]>_=>Z]_I
M*V/_ ,]!3?\ 4BM_Z]>_=>Z]_I*V/_ST%-_U(K?^O7OW7NO?Z2MC_P#/04W_
M %(K?^O7OW7NO?Z2MC_\]!3?]2*W_KU[]U[KW^DK8_\ ST%-_P!2*W_KU[]U
M[KW^DK8__/04W_4BM_Z]>_=>ZS1[CVEO&&NV[299*PY+'5M+40TZ5,,QI*B
MT]2T<DL8 (5^#_7\>V;B!+JWDMI?AD5E-.-&!!I^1Z>MYWMITN8_BC8,*\*J
M017\QU77_P -!?$/_CGV=_Z&T/\ ]0^\:O\ @2_:;TO/^R@?]:^LC/\ @J?=
M3UL_^R<_];.O?\-!?$/_ (Y]G?\ H;0__4/OW_ E^TWI>?\ 90/^M?7O^"I]
MU/6S_P"R<_\ 6SKW_#07Q#_XY]G?^AM#_P#4/OW_  )?M-Z7G_90/^M?7O\
M@J?=3UL_^R<_];.O?\-!?$/_ (Y]G?\ H;0__4/OW_ E^TWI>?\ 90/^M?7O
M^"I]U/6S_P"R<_\ 6SKW_#07Q#_XY]G?^AM#_P#4/OW_  )?M-Z7G_90/^M?
M7O\ @J?=3UL_^R<_];.O?\-!?$/_ (Y]G?\ H;0__4/OW_ E^TWI>?\ 90/^
MM?7O^"I]U/6S_P"R<_\ 6SKW_#07Q#_XY]G?^AM#_P#4/OW_  )?M-Z7G_90
M/^M?7O\ @J?=3UL_^R<_];.O?\-!?$/_ (Y]G?\ H;0__4/OW_ E^TWI>?\
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M<^SO_0VA_P#J'W[_ ($OVF]+S_LH'_6OKW_!4^ZGK9_]DY_ZV=>_X:"^(?\
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MT,=3DJF*.AI/)&U94P(ZL=V0.X[Y!RW9?J7US%=3QQ#XC#90FXNI2314CAC
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M_P"M?0\_X#S9/^CW/_V3Q_\ 6SKW_#V^_?\ GPNT/_0SS/\ ]1>_?\&?OO\
MT8H/^RB3_K7U[_@/-D_Z/<__ &3Q_P#6SKW_  ]OOW_GPNT/_0SS/_U%[]_P
M9^^_]&*#_LHD_P"M?7O^ \V3_H]S_P#9/'_ULZ]_P]OOW_GPNT/_ $,\S_\
M47OW_!G[[_T8H/\ LHD_ZU]>_P" \V3_ */<_P#V3Q_];.O?\/;[]_Y\+M#_
M -#/,_\ U%[]_P &?OO_ $8H/^RB3_K7U[_@/-D_Z/<__9/'_P!;.O?\/;[]
M_P"?"[0_]#/,_P#U%[]_P9^^_P#1B@_[*)/^M?7O^ \V3_H]S_\ 9/'_ -;.
MO?\ #V^_?^?"[0_]#/,__47OW_!G[[_T8H/^RB3_ *U]>_X#S9/^CW/_ -D\
M?_6SKW_#V^_?^?"[0_\ 0SS/_P!1>_?\&?OO_1B@_P"RB3_K7U[_ (#S9/\
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MZ]_I(V=_SLZG_P \F>_^I??NO=>_TD;._P"=G4_^>3/?_4OOW7NO?Z2-G?\
M.SJ?_/)GO_J7W[KW7O\ 21L[_G9U/_GDSW_U+[]U[KW^DC9W_.SJ?_/)GO\
MZE]^Z]U[_21L[_G9U/\ YY,]_P#4OOW7NO?Z2-G?\[.I_P#/)GO_ *E]^Z]U
M[_21L[_G9U/_ )Y,]_\ 4OOW7NO?Z2-G?\[.I_\ /)GO_J7W[KW7O])&SO\
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M^R:+_-U[_AIOX9?\\AN__P!#[<7_ %\]^_X%?V>_Y1)_^RJ7_/U[_@GO=O\
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M&CQD2(SHHDC(D34A#$_"L'567]+*&%P0;,+BX/(_V/NY!!(/ETU&ZR(LB<&
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MIN/&U:-.N'1XFJ3PV;V9;!MO6:I_>3WB14_";)+1Y?$K2@87D7AZ=52LFH(
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MG]1_''Y'_(W<^7V]U]58NAWEG9\%\=MI[JJJ&DH)LWBHI:C(101EZF-49CJ
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MJ??O^#+YP_Z-%G_O4_\ T'U[_@0.4O\ H[7G^\P_] =>_P"'KNYO^?.]8_\
MG?NK_P"J??O^#+YP_P"C19_[U/\ ]!]>_P"! Y2_Z.UY_O,/_0'7O^'KNYO^
M?.]8_P#G?NK_ .J??O\ @R^</^C19_[U/_T'U[_@0.4O^CM>?[S#_P! =>_X
M>N[F_P"?.]8_^=^ZO_JGW[_@R^</^C19_P"]3_\ 0?7O^! Y2_Z.UY_O,/\
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M4O\ H[7G^\P_] =>_P"'KNYO^?.]8_\ G?NK_P"J??O^#+YP_P"C19_[U/\
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MK.&V/F?;M(\.SWFPN8B*8DW/:FBNTXUR-HLY2 - :1G#&224!'S$@^HY8W$
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MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K:&_DX?\
M9)^<_P#$R[O_ />:P?OIC]T/_IUD_P#TL)_^K-MUS@^]C_T\Z'_G@@_ZO7'5
MK_O*;K&/KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__UM_CW[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5
M>N3_ )6/P@SNZ\MNC<G6>_-UT>>WK7]BYOK#=_R1^3N[OCQE]Y9/-/N2LS62
M^+^Y-Y577$Y;(.U<L,FUC"D]I4C5U5AO:2=D^E.W8:Q$8MF?]9[;P=/@FW>;
MQ&@:#0G@/$4:'2OA%*#K>XLVZO<O=FAO XN/#_1\<25\43>#X?BK+J83*^H2
MAF$@8,:BSWQ\(/C7\D=S8C?'9NS=TTN_,+MY]GTW8/4_</=/Q[[!KMDO6/D3
ML/<._/C_ +AVQE\M@!4R2U*X+*5M10+,\DJTXD=V*46EN)IYM-1=!!<(26AN
M @8)]3 Q,-QH5W53-&Y5'=!178%X7$JVL-DM ELS-!15#P,X0.;>2GB0>((X
MO$$3('\*(L"8TTJ7&?$CXX8+ ?'G:FW.I]N;6VO\4MSG>?Q^VUM.3*[5P'7&
MY7V5F>O9<G0X;;M334U89,3N',P319..IBDEJGJG1JM8YT-6W"\?=3O3/6Y-
MM)9ZJ"BVLJPHT")3PTC"6\*1JBKX,<:I%H3'2*"WAMMJFV2$4MKB5)Y5)):2
M:.Y^K65Y&)D:1KFLTCERTTA8RE]359-R?"?XN[PZR[)Z>W/U-C,WU[VUVKG>
M\MZX6OSV[Y:V;N#<.XHMVUG9&V=R_P 0&5P&7@RD$-?C*W 5M%)CIT22@-,R
M@@G2PMHK+;K" -$FTO))9M&[I+;O+<7-U(\4Z,LRL\UY=:CXE3%/)!_8'PNE
MIN)&O+V^ETR/N*0QW2NB213QP6EK8Q1RPNK0NBVUG:II*:6:%9F!F+2%JZ6^
M"7Q>^/\ V'#V]UML+<"]N+L?.=:UG:^_NV^Y>Y.S\]L7<&=QNY*S;>[>P>XM
MP9[+YFG@K,30OC/XM65#X]%DAH&IH*BICE-H;R:VM;JRMM,45ZUL\ZI&B"62
MT%RL$KZ5&J94NYD>8_JS1^%',\B6]NL1;-907%Q;75QJDDL_&$!9W;PEG$8E
M1 6(6)O"5A$!X:.9)(U5YIF<>NV>J]A=Y]7]A=,]IX'^]'6O:FS=Q=?[]VW_
M !3,X3^/;1W9BI<)N#$_QC;M125]+]Q2S21>>BJH9DOJCD1P&""6&.8QM(*F
M*6&9..)()4FB;''1+&C4-5:FE@5)!-["_N]KNTOK%]$L==+45J5!4X8$'!(R
M/Y],_:?1/4?=O4>=Z([6V-B-\=3;EPE!M_,;-S3USTE1CL1-!5X:2#(4\T=;
M3U=#44U-5T.0IJF.JIJF&*I@FCGC217-QKNMU]?>,WCB87*RHS12QW"OXBS1
M21%'AD5^Y7B9&7@I QTCVFFQVR6>V@)"D#6VA@)$:W>(P/#(LFL2QR0LT<B2
M!A(C$."">@&Z@_EZ_$SH[LS;W=6Q>O\ =5?W+M;;>ZMF8;MSL_NWOCO+M"+9
MF\Y*&;-[.KNP.[=S;ARU;B%DQU-+C\96U<M+CY#424$5,]75M,_#/);23RVV
MF-KJ'P)RBJOC)XT$]9M('BRB2V@TSOJG6.,0K((28RS)!'+%'#+5DAF2>)22
M1%)'#<VZ^"":1(8KN</%'IBD9UED1I8XG185OPO^-.1^/%+\4ZSK;S=!T>Y,
M7NZFV%_?'?T?CW#A>VHN],9D/[T195<T?%NJ&/*>)LB8FM]LZ-1DTY36<:6#
M[+):#0>7EV]-O\_IUVNVBM+ =U?%\"WACCK/XAETZYC(Y9BX% 3=(Q\.]?O3
MZS_AW[Z-T=S_ .:?U)O+G^RT>#XG^+^%HCTB5N#HWJW=/</7G?F>VO\ ?]L]
M5;.[#V#L+=?\;W%3?P':7:U3AZS?V)_@5'5QXRJ^_DP.);SUM'--!X+4TD(E
MF$C0M8!]>0O_ "4[5;*YX_JVR3"X6+CV4E&O7'ID/PEBO;T[/(]S:V]G,:QV
MMQ]7$.&FX\"6V\2HH3^C-*FEB4[M6G6JL(/Q\^/?3OQ7ZCVIT3T'LN#K[JC9
M!S9VOM*FR^X,[#BSN/<-7NO-%<KNJKKJ^8SY"NJJ@F>J?29"J:4554QN+RYN
MU@6Y<N+:"WMHZTJL%K!';0)7BWAPQ(FIJN^G4[,Y9C27]:_O-TE[I]PN9[RX
M?SDN+F5IIY*<%UR,Q"(%C042-50!0"OQ*^-V\?C#N7Y,[2I\OMG*]!]D][;K
M^072N/IJG)Q[TV%FN[*V7>7>.P,_C):-*)L6N[9<AG\%74V0DE:/*ST,U+ N
M/AGK$^W'Z;E3;]AN27EVHSVL#\0^V^*;BQ20FA6:T\>:P50&0V5I92>(97F1
M/;BS7?,MUOD(HNX16TEPII47\,*VDTL85:&.Y@M[6XD+MXAO9+MC5)$(-[G,
M)AMS87+[;W%B\?G-O[@Q=?A,YA,M205^+S&'RM*]#D\7DJ&J5HYJ>HAD>*:*
M12KHQ5@02/:._L+/=+&;;-QB6:WN$:.2-Q571P596'F&4D'I1:75S8W4=]9N
MT4T+JZ.IHR.A#*RD9!5@"".!'1%.L?Y7GPBZBW!UKNC9_5&YZK-=+9VDW#TI
M/O[O?Y"]MTO2E5182IVW%C.FL7VQNO-TFT\2V/JI**?![>@H\=-"E/'-2NM+
M3"$Q2XN$O8MS,C/=Q+.OU#L9+ATN+:6TFCGN'+37$;PS/6.X>1!-HN547,<<
MJ(KB&&YMY;)T5;>9XI&@0".W$L%S'=Q2QP1A8894FC4B2)$?PVE@+&"::*0S
MNU^@NI=F8;M[;^VMI_PW$=\[TWIV'VO2?QW<M9_>K>'8>'I\!O#+_<5]9++0
M_>4E)3Q?;XUZ>"+1J@CC=F8D]WM.WW_+9Y0NX]>W&.]B,6IA^GN-W>7UXOB
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MH;T/7NO?[,'T)_S^_J'_ -&5LS_ZM]^T-Z'KW7O]F#Z$_P"?W]0_^C*V9_\
M5OOVAO0]>Z]_LP?0G_/[^H?_ $96S/\ ZM]^T-Z'KW7O]F#Z$_Y_?U#_ .C*
MV9_]6^_:&]#U[KW^S!]"?\_OZA_]&5LS_P"K??M#>AZ]U[_9@^A/^?W]0_\
MHRMF?_5OOVAO0]>Z]_LP?0G_ #^_J'_T96S/_JWW[0WH>O=>_P!F#Z$_Y_?U
M#_Z,K9G_ -6^_:&]#U[KW^S!]"?\_OZA_P#1E;,_^K??M#>AZ]U[_9@^A/\
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M_!'>\_\ T>?^S2Q_[9NO?[*%_*=_IU#_ .E*[L_^RWW[_@9O97_HQG_LKO\
M_MJZ]_P1WO/_ -'G_LTL?^V;KW^RA?RG?Z=0_P#I2N[/_LM]^_X&;V5_Z,9_
M[*[_ /[:NO?\$=[S_P#1Y_[-+'_MFZ]_LH7\IW^G4/\ Z4KNS_[+??O^!F]E
M?^C&?^RN_P#^VKKW_!'>\_\ T>?^S2Q_[9NO?[*%_*=_IU#_ .E*[L_^RWW[
M_@9O97_HQG_LKO\ _MJZ]_P1WO/_ -'G_LTL?^V;KW^RA?RG?Z=0_P#I2N[/
M_LM]^_X&;V5_Z,9_[*[_ /[:NO?\$=[S_P#1Y_[-+'_MFZ]_LH7\IW^G4/\
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M^RN__P"VKKW_  1WO/\ ]'G_ +-+'_MFZ]_LH7\IW^G4/_I2N[/_ ++??O\
M@9O97_HQG_LKO_\ MJZ]_P $=[S_ /1Y_P"S2Q_[9NO?[*%_*=_IU#_Z4KNS
M_P"RWW[_ (&;V5_Z,9_[*[__ +:NO?\ !'>\_P#T>?\ LTL?^V;KW^RA?RG?
MZ=0_^E*[L_\ LM]^_P"!F]E?^C&?^RN__P"VKKW_  1WO/\ ]'G_ +-+'_MF
MZ]_LH7\IW^G4/_I2N[/_ ++??O\ @9O97_HQG_LKO_\ MJZ]_P $=[S_ /1Y
M_P"S2Q_[9NO?[*%_*=_IU#_Z4KNS_P"RWW[_ (&;V5_Z,9_[*[__ +:NO?\
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M?M#>AZ]U[_9@^A/^?W]0_P#HRMF?_5OOVAO0]>Z]_LP?0G_/[^H?_1E;,_\
MJWW[0WH>O=>_V8/H3_G]_4/_ *,K9G_U;[]H;T/7NO?[,'T)_P _OZA_]&5L
MS_ZM]^T-Z'KW7O\ 9@^A/^?W]0_^C*V9_P#5OOVAO0]>Z]_LP?0G_/[^H?\
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M^$VL 5;PXY*BC-VZ9%&:&H.*4),:2 "2; <DG@ #ZDGV'7=(T,DA"JH)))H
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M<<[O_P">6ZJ_\\>[O_KY[]_R<0]ZO^C7LG_9-?\ _>RZ]_P)GMS_ ,INY?\
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MZ->R?]DU_P#][+KW_ F>W/\ RF[E_P YK7_MCZ]_PXYW?_SRW57_ )X]W?\
MU\]^_P"3B'O5_P!&O9/^R:__ .]EU[_@3/;G_E-W+_G-:_\ ;'U[_AQSN_\
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MA1Y9II75$12S,%!/M->7EIM]I+?W\J000(TDDDC*D<:("SN[L0J(J@LS,0%
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M/;'659D)C24J+'JGFDDEF;3=W=F:[,2:;,Q?8^8%<U _<:@'-%4[R H]  *
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M==(62VV#<(1#-X<@,R0[MNOT6Y6,H"!HMJG3Q'J5-H'6W_;QSX=?^,DNQO\
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M=>]^Z]U[W[KW3)N7_CW,_P#]J3*_^X,GLEYC_P"5>O\ _GFG_P"K3=&.T?\
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MI((C<))%%'MKK @=[@@$;;N%Q%L/*>VTK^\-I;<;F=P'EN9%G2T6 2-J>-(
MAGG,9CEEDO(M4C)'I$_Y25'7F[-[X[XN;)QO\TGY"=C_ !RZCV7_ 'UP?P[^
M4V0Z R.U*'>U'-3=?[Y[G[OWYV9U10[HW+D(,365:4-5N?*NR+)55V,'W,4D
MP8W2]GW0[SS)95M_ =K9YU$<=I:7B6Z7S1PVA/AR,EO?6DTP%K<0QQ/;1U0L
MR.(($@VN&PV:=UD>5&NEA?Q);B>V:9K=9)IPIDBB\>VN(8 +BWDE<7! D6(-
M"9[^5?VQV#WC_+S^)_:7:NXLMN[L+=/5= VZ=T9\X1MP[@R&'RE5@%R^X9MM
M,^.ER$\5)')73T+M!+.9)(F*,"17NS),;*^"QHU[MVUW<@A5TA\:\VVTNIS%
M'(J/'$TTSM'&R(8T(0HFG2"FQC>VN=SVUA*JV&Z[Q91K.ZR3I#9;K>VD$<TB
M,Z231PPQI)(KN)'5G#M740D_FR_\>7\'/_&HOP3_ /?K>R3:?^GF\J?\UN8/
M_))YJZ4[]_T[KF?_ )YMN_\ )BV3HBG\S+NJFW5L/YM=U_&JG_F?[I[ ^)6Q
M^R\0>Y/CS\B\+T9\3^A>ZNDMBR;NR5/N7JKLOLO8>-[#H\=5"E;=T<.S-X1R
MJT^/I4EJ8VHXPZ^ZW&U[6G.>V$"&:[1H9;L":VN$M[U=NN+=+7]206\EQ;74
M E%O&\DKR2P7/AB&2,7[3MEGO',]IR9NJF74L$5Q!:GP;F-;^(7,,OU9,,:W
M?TMU!<1(]V(HHOIFN8T5WUF'WM2;T^3GS^Z Z:WC\B^]NN.J]X?RSZCO+>W5
MG1O<&].D*CL7?]-W'@</2[@CWCUO78[<6'7')E9?/+MO)T%34J]/35=3)1*]
M+,-K[9+2U]P.?;%3+);[._+\-I$97"0&>[YQ22>B%2SM'8P12(Q-O-2)YX99
M;>T>".-LWF_N>3^2;]U"S;I%NSW-QH0B4I:<NR);%&4QAV:XGN(90!-;I%<I
M;M&EQ<:D3UA\BXNI.O/GC\9N[>Z?DYVAM3I_YK[.^(OQGWWL//9?=WRWWU4]
MR],[0[>VYT?B.SZ735UVX,-79O*8D[KSF0IZFFQL:U.6RL,U-+D/9.L[<P\J
M[$\\;ON=]>[M9A;?1;&^BV.ZN)FNF*-!!;Q_16L]K?2(]O&\MC<M&8[F=8P)
M;BVCY>YAW-HI56PAVW;]P?ZC5<"QDW0O8B",,)IIB]VUM/8PND\@DOH8Z26Z
MH &O278O</6_;7\RGI6CQ_SFZ;V%M7^7?M3Y!=>["^9_R5VU\CNV=E=E9FL[
M*VEE>P>L^VML=F]IYC&8C(PX#%R0XK)[KAGI:ZCEJ*;'T4<JR3A;GK<;Q?8_
MGV^AG6.ZV5&^DEA#17-L+K9KV=HWGC5!(T4UHD]M*))98O%<&;3X:1B#EJPM
M3[B<F+)"[1[I/=1W*R%7MKD6=]LXB=8'=FC?1N-Q#< 0PV\T8@ $DD4VESQ.
MS>UNE?CC_+%^87^S6_*W?W??;W9OP$V7WB^_>^=_[DZ8[3VI\DSAMF]@8*N^
M.5;5_P!QL48(<M]SC,M@L#1Y9*JFAJ*K(5<TM8]5,^_V5GL_O7)R=8QCZ"YN
M^8K65' =F-ELV];E#<1,16UD6\VV!A%:>!:+"\MLELL#)&D/;)N=SNWLS'S?
M*[+<PV.T7=NP8AD2XW+;(#!.13ZS5:7<D,TUT)9Y'/CB59@KKL5^P5T.^O>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO__2W^/?NO=>
M]^Z]U[W[KW1=-F_$WX_]?[Q[[W_M'8/\)W;\G7@?O'+?WJWK7_WW:FIJVC@/
MV&3R4U-C=,>1K%_W$0TM_)<W*(56W6XWE[L$7*]R^JQ@:=TBHHTM<G5.=8 D
M.LYH7(7\ 7JJ(L>_1\SH*7T*)&DOHD8A"#1_9G2((LE"3HR3J:J*3X#?$+_9
M<L5\2JGI+;^4^/V!K<ED\%L+.Y?=FX7P>5RV8JL]79?#;NSF0J,Y25C55=5L
ME73Y-)HTE>*-TA.CVNO^8][W/>X^9+NX8WT2JBRH%C8(B*@0B,(I0JB!E8%7
MT@N&(KTDV[;K+:K>XM+*,+%=MJF1JNKMI102LA85 C332FEE#+1L].WQR^$/
MQ4^)>%W/@/C]TQMO8-!O5$AW;*U9N#=F8W'1Q1O%#C<ON+?%9DLA/1H)9=%$
M]48%+N5C!=B=[]S+O?,]J+'?;@SPC5^GI1$[AI8E455)*]NH@FA(!H3U7;=L
ML=HO!N&W)X4XI20,Q=:,&&ABQ*=P5NTBI52<JM$ATG_+E^%/QVS78F>Z?Z#V
MWM:L[7VYD=G]@4E5FMX[LV_N+:>7K%K\EMJ7:N\\ED<73T$TB)KI*2CBB* 1
MZ?'Z?>]SYFW[>=I39-TN6FMHWCD4,%U"2(,(Y#* )2Z:F*N7+!CKKJ (W;[;
M8VF\CF"TC$5V%D4.E4"K*R/(JHI$:*S1IA5  4 46HZ3/4G\K;X%]%=JXCNS
MJCX^XK:'9.WZW(Y' 9RGWMV=DJ#!UN6I)*"OGPVU<WFZG$4NN&62)1!0*$4V
M0+867OSQS7+M[[7+>,T,D?A."J%F3^%I"OB-7S)<DYJ34])Y]BVFXN!=20*&
M5UD 6J('5E96$:%4%"JD +3 QTLZ/^7O\.L=\CS\M\=TGB,?\@VS%=N!]^T&
MY-\T<<F>RF/DQ>3S4FT*;*+@FJZB&:43U#8PR2.[2NQE8O[0[=S/ONU;(_+E
MA<&.R=70Q:48!'.ID5F4NB5.$1E51A0!CI5N6WV>[W<=]N*"26+PM+5*G]#2
M(BVDJ'*!% +!B0HK6G099W^4E_+IW+O+?>_LU\7MGU>Z.R8,_!NRK3<&_P"C
MH)GW.K+FZ_!8"AR\6.P];-K=EK\-2TM3&S,\4J.S,7+/FSF/;]JAV6SNW2V@
M,9C4:25$+K)&@<@R>&I51X18QF,>$RF*J=;NK&SO=P;=+J-7G<.&8C#&2-HW
M9E'8TA#%O$93():3!A, XF=O_P J?X$=]93:.:[9Z';=F2V)U[M3JK:E0>T^
MZ,&N)V%LBF>DVQ@5I]M[CHXIOMHY'4U50DE1+>\TTA (=LN<N9-NN;R[L[G1
M)N%P]U<'PXCXD\BHKO1D(6JQJ-*!4%*A0224[;/MS;=8[48_\7VZ!;:W34_Z
M<*,S*E=6IR"[=[EG(H"Q"J Y[B_E>_!#=O2O7GQZW'\?L3E>I^I\EN++==X&
MHWGV6N8VK6;NRTN=W,,?OJ'-+GS#75<S35%++E'A<K&#'IAB"5?G#F1]];F4
MW)%Z\4<#2!(U#Q1*%C1XP@B?PP.PLA92SD$%W+6M]IV^UV^?:X8Z07,HGD4E
MFK*J",.K,2R'0 IT%01Q!Z677O\ +\^'G5&*[5P?6_26%V7AN[NN<?U-VAB\
M!N#>E#0;IV'C,'4;<I\4],F3T4D[TM74K49*@$%;422-43U,E0?+[2[IS'O>
M]6B6.ZW#3Q1W2WBJP7MN$=71U( 8*K(NF('P0!I$>G'3^VV-IL][;;CMJ"*>
MS1HXG%20KR^.VK542,9>XO('?@NK2 O4_*_!/XJYOJ;IOHW*=6?==6_'_=6%
MWKU'M?\ OOV/#_=+<VWJBHJL/D_XW3YA,C7^%ZNH;PY.KJ8GUV>-@J@/Q\U[
M_#S*.<([BFXK'X0FT1_!2$:?#*>%PMX<Z*]G'N;4G3:-OCV&?EA(Z6-RS-)%
MJ;N9WDD8Z]7B"KRR&BN -5!0!0%CD/B?\?<KWEF_DCE.NJ3)=R;DZWJ>H<]N
MFOSNZJRARO7%8%6KVO6;-J*]L&\4JJ%DE.-\S+=3(5)!+(]SO8MCN^6XWI97
MTBRSQZ5[Y%5$5M9'B)18T ",H[:TJ22OEC6;<++=)*_4;=BW<$@Q]TK8 (#=
MT\IJX8]W]%:%HVW_ "B_Y=&T9GJ=O?&3;F/K/[V[>WO29 [P[.J\EA]Q;6RQ
MSF%FVYDJ[-RSXRE2J(DFQV.DAHZ@*L=1!+&BH!%%[@<X0RVTT=\X>T8-&=,9
M)(4H/$JA\>@8D";Q!JH]-8# JN.7]FNA<I-;J5NXVCD455=#LCL$52%A)**-
M401M T5T$J5AW3_+*^#/R(WKOOL;N;H'"[XWUV2^TWW;NJLW9V'C<S4?W)Q
MP.WDPU7@LQ2G$HE(J0U4>(^V6K"1FK$[1HRE.S<Q[UR_:1V&SW#00Q2S3*@"
MD&2X8O*7U ^(&=BRI)J2,DF-5Z,KZW@W)D:^42&.'P%K^&/Q#+1:4HVLL?$'
MZ@5F37H8J36=4]3=<=&]?[;ZKZDV?A]A]?;1HWH=O;8P<+Q4-!#+4/65,C23
ML\TT\\\DD]34U$CS32N\LKO([,4NZ[MN.]WK;CNLIFF>@+&@PH"JH  5550
MJJ H H .F+#;K+:X/IK",1H26/$EF/%F8DLS' JQ)H .   3[)^,.T-LX;OG
MK[<)P^_^EN[=^;DWX.JMT;7I:S%;9J.P(DK^R=OO55-1-#7XW)YG[G-4T#4,
M+4DU3.HDF4Q&)N2]:7:]NL7!$NVIX44RLRN(8Y3+:+4'4LMKJ,<<RN#X20 *
MKQ%Y%?ZJ[S=;Q&]#>+$94(#!I4A%M+)4\5N8(X1-$X8-()G)*S^''!VG\+OC
M]LRAW3BL/A>QJS#;QV-G^MLS@=U]_?('?FWH=D;GIDH\U@=O;?WSNC(T6'22
M&..&.7$04TL,:A(9(TX]N[CNUYNML;2_\-U9TD9A#"LK/&VI2\R1K,_=W,&<
MAVRX8],V5K#MU[!?V-8GMG$D05F$2. R@K#7P>T,P4>'0 D #KCL?X4_'38.
MZ=K;UQNU=X;HW-L6-(]AY+MGN?N[O(;#,='_  Z*HV-0]T;CS]-AITIR:=*C
M&0P2K&3&KA"1[77/-&]73W$LDB+)=AA/)'#!%+,'.IQ)+%&DCJYRX9B'_$#7
MI*FTV$<,-LJL8;<J8XC)(T2%/@*Q,QC!C_ 0M4QI(IT.^<Z]V?N/>&Q]^YG$
M?>;LZW_O+_<O*_Q#*4_\&_OABTPNX_\ (:2>.FJ/N*9%B_RN&7QVU1:');V2
MP7$UMXO@FGCQ&%\ ZHS+#,5R#3]6")JBC=E*Z68%?-&EPD<<HJ(I5G3RI*L4
M\ ;%*TBN9ETFJ]^HC4J%2Z;F^"GQTW7O[>_9U=0=PXC>O8^1H<MO;*;(^4?R
MCZXI,_7XO&1X;&S5.!Z^WEC,<@IZ6&.G@CAI$2-!I50";F%EO=_M]@FUV_A&
M"-Y757MX):/,YDE8-+$[5=S4YX!5%%50&[NWCO;KZVXU>+X<<6I7=/TX@1&E
M$91I74S4IEW=S5W=F<]U?"SH#>U54U&Y<=VG7T^3PV$V_N#!Q?([Y'XS:6\<
M5M_"0;;H(-^[+Q6[(,1N!WH::&GK9\W154M8JDU;SLSEJP;Q>6^L1K"0\TD]
M&MK9U2621I7:)7B80CQ&9U2((B,>Q5ZHMI&D4,4;RI]/$(4=9IEE\-:TUS*X
MED;)K)([R'S8]#5NKJK8&\^M<CT]G-NQ+UIE-MP[.J]I8*NRFT\?_=2"G2B3
M;=++M2>BGIZ$T\:TKTU/*D;P:H'5H69"BEN9[B_7<[EO&G699]4@$FJ57$H>
M17#+)^H Q$@96/Q ]/6<4>WVRVFWCP(TC,2",F,QH4,=(V0AHV5#V/&5>,@-
M&RNH88,9U!UOA-^P=F83:]+A-Y4^PJ'K$9'#5>3Q-!/L7$U_\3PF K]NX^>/
M&U*8^4R?PV:HHWFHTEGBII(HJB=)'VW*^>&Y@EE9UNYEN)M7<7G567Q=3582
M,K%9&4@RA8Q(7$4>AH6=LJ6D:+I6Q1XH I*B..3P]48 (#1UC0JC:E1@60*S
M,2C.WOC%TIWEF,#N7L+:N2?=^V**LQ> WWLG?/8'5'86,PV1E$]?@:?L'JG*
MX7-?PZ>15EEQ[5YIG<!VB+<^ZV%_=[9)(]FVD3!1(A57CDTUT&2)PT;LE3H9
MT+)5M!&HU>N(TNH5M[@!EC8NE?BC9@%9HW^.,NH ?0RZPJAZA5HC\W\+.@L_
M2;%IZNB[8H:KKC"[OVYM7<6V_DG\D]H;VBP6_LQ2[@WAB\]O[:>[:+-YF&OK
M:*DJ)DS.0JO5#'ITA0/:N+?+^&XGN(_"'U*P)(GT]N866V\004@,1A4Q^-+1
MEC5CK;437ICZ. VL=FVIDBF:="TCM(LKQB)G$I8RBL8\,#7I"=H '2AQ'Q-Z
M V]UAF>H-N[$FV[LO<6:BW/N"3;V\-]8+>^<W5#50UD>[LQVGB<G#NBIRX>G
M@OE9LRU6514,Q0!?;-SNVX7=S;7,\F;.O@*JJD40975E2%%6)482.&0)H;42
M5)SU>WMH;4W#1C4UVNF9G)E>1132'>0NYT4!CS^F0"FDCI.Q?$G8FS]K=IP=
M/9/<.S.T^S]E5&QZCN[L'=W97R"[%PV*DBFCH8J7<G;^X<AEGIJ%JB:JHL<,
MK'2)4E9FADL4:M_N$VZVR[9N 7Z)Y4DGA@CAMEG7M64-X,2KXDD(:%9V1WB5
MR4S@NV"+MM]'NEN"]Q;JP@,SR2I&V&0:&>OA>*D3S11M$9EC"ET.ET'7K/KS
M;/4G7>QNKMF4CT.T^O=J8'9NW:663S3Q8?;N,CQ5":F>P\DK1Q!I9"+NY9CR
M?=]YW6ZWS=;C>+VGBW,C2,%PH+&NE02:*HHJBIHH \ND6U[?'M=A%81LS^&,
MNY+/(Y)9Y'8Y9Y'+.Y/%F)Z7'LMZ7]>]^Z]UTP#*5-[,"#I9E:Q%C9EL0?\
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TR;E_P"/<S__ &I,K_[@R>R7F/\
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M?M#>AZ]U[_9@^A/^?W]0_P#HRMF?_5OOVAO0]>Z]_LP?0G_/[^H?_1E;,_\
MJWW[0WH>O=>_V8/H3_G]_4/_ *,K9G_U;[]H;T/7NO?[,'T)_P _OZA_]&5L
MS_ZM]^T-Z'KW7O\ 9@^A/^?W]0_^C*V9_P#5OOVAO0]>Z]_LP?0G_/[^H?\
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MWS_IE;7_ 'JX_P"MW7O]?'W8_P"CW/\ LB_ZU]>_N=_+X_YW70/_ *-'!_\
MUV]^_P"!0^[Y_P!,K:_[U<?];NO?Z^/NQ_T>Y_V1?]:^O?W._E\?\[KH'_T:
M.#_^NWOW_ H?=\_Z96U_WJX_ZW=>_P!?'W8_Z/<_[(O^M?7O[G?R^/\ G==
M_P#HT<'_ /7;W[_@4/N^?],K:_[U<?\ 6[KW^OC[L?\ 1[G_ &1?]:^O?W._
ME\?\[KH'_P!&C@__ *[>_?\  H?=\_Z96U_WJX_ZW=>_U\?=C_H]S_LB_P"M
M?7O[G?R^/^=UT#_Z-'!__7;W[_@4/N^?],K:_P"]7'_6[KW^OC[L?]'N?]D7
M_6OKW]SOY?'_ #NN@?\ T:.#_P#KM[]_P*'W?/\ IE;7_>KC_K=U[_7Q]V/^
MCW/^R+_K7U[^YW\OC_G== _^C1P?_P!=O?O^!0^[Y_TRMK_O5Q_UNZ]_KX^[
M'_1[G_9%_P!:^O?W._E\?\[KH'_T:.#_ /KM[]_P*'W?/^F5M?\ >KC_ *W=
M>_U\?=C_ */<_P"R+_K7U[^YW\OC_G== _\ HT<'_P#7;W[_ (%#[OG_ $RM
MK_O5Q_UNZ]_KX^['_1[G_9%_UKZ]_<[^7Q_SNN@?_1HX/_Z[>_?\"A]WS_IE
M;7_>KC_K=U[_ %\?=C_H]S_LB_ZU]>_N=_+X_P"=UT#_ .C1P?\ ]=O?O^!0
M^[Y_TRMK_O5Q_P!;NO?Z^/NQ_P!'N?\ 9%_UKZ]_<[^7Q_SNN@?_ $:.#_\
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MC[L?]'N?]D7_ %KZ]_<[^7Q_SNN@?_1HX/\ ^NWOW_ H?=\_Z96U_P!ZN/\
MK=U[_7Q]V/\ H]S_ +(O^M?7O[G?R^/^=UT#_P"C1P?_ -=O?O\ @4/N^?\
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M:&]#U[KW^S!]"?\ /[^H?_1E;,_^K??M#>AZ]U[_ &8/H3_G]_4/_HRMF?\
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MKJ,L\U&9((Y/"228QQO-VEWGUU\9_P"5I-\F/A[E7[0[:[_[$ZSPFY.V._\
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M9CFN$M5D2:&2-;B1D5(99(Y&2%V+J:3,E%.LT0%A6"[CN)_I85<RF)IT3PI
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MTQ0"1-!T#2=7'!J,= ;_ ,.!_(#_ %>RO_0;D_\ JGW"7_!\^_?KMW_9&?\
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M_LC/_6[KW_ N>UWI=_\ 90/^M?7O^' _D!_J]E?^@W)_]4^_?\'S[]^NW?\
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M#8\_T/NDB"2-HR2-0(J#0BHI4$9!]".!Z\,&O59F:_EEX??NG;/=OS+^;WR
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M:/>W4E[<W4HKFKEXPV!W(13S*+F.YAWRR?FN 'P;KF"WM;8D:3]%MYM[:W#
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M'DDTUTJ3;3MXK4#4%3JD0,/1<VNU^Z.Y[EN8$=O<[-:>&[T"S"+;[F.6%"Q
M9F>18@E:.^I/]#DTN7QVR5'\2_F%_+$W]\I,Q0]5[)R_\M./8V%W?V)D$PVW
M=M;OII\GGI]OY3,9LQP8VJ2@K:6%XG=2K5<4!LTFGV.=UN+?<9?<#;-O7QKK
MQ;!]$8UO*(H-L@E>-5J\I\>RNP H+N4+!3J%0-:QO_5OD_<=!6W2]W34Q&E5
M-P;IX96K0*LL5S;J':G:"6I''J!N?Y2W:.VNH?BE\_\ Y6[F>;$]$U_RK[_[
M@V37RQ-0TV<V7C*&F,=7@:%P$_RN9(\;3K&/741^ "Z >P+S]%>[=RARCRZT
M6K=8-LMH#$>/C2LD,,3MQ ,P8D_"JOXE:,3T*]K6UWWW/YEO[-PME-=M^N*:
M%C26ZN)'&0&6*WE20E3I(.D-J# &+_D\=7[LK^J>SOFOVY2/'W/\Y=_5W;.1
M%2H,N$ZPI*F>CZOVW1%QJ6D6EDFK*47L:6:E! ,8]N<]K;\O6.V^W6WN7CVF
M+5.QJ#+>3@23NXK\606!%4G>X6M".BS:+IN9-^W'G.1-$<[_ $UHASX=I:TB
M51DYU)X3-0&5+>%SJJ&)D:6.MR/\PKN,RU<5)GL#\+.L*;J^6OIA+1T4.Z>T
M]VR;ZR5.S!KC[[&;=6M55.I8X PL%N!O$>'VXWRXM9%CG_>2*\CF@B2+:Q)9
MD@@CP_%FOGKI(U*^#PZ%EP+%>8N6VO8S+;+#N+R*I[RQNMM694.*,;=80#44
MU\>XT*?\/]C]M]LY?XR=W5F0^4=#MW";!W?G>Z-\[Z^6&]<[U+\@]]U5%!C-
MM[DZOZ@VUOFOIZ7$_P 4AK\G3T>4VI@J-<?+%"V.D<QI3GW/EW9['LF_+8I%
M;QR;;_B-NUN&O;1Y(XYU>:X>)B)4M6>.207=Q)]0R/&(FC+]!Z.WO[FYCM;U
MFDNK?<YA<SQ,8;9XK9KN%H8X5D0@?5"VTKX.EHX)0\LBR?K!WTYNK.X;XP_
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M3Q3,I_QPR@EF%LBQLV<IEW".!97DM;>*064Q-/WE;M,4.X24H'?]*.$1T"Q
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MZ?=6W(<13[>W-!TKUM#N# P;?IHZ+ P8;,QXP5-*E%#%%%2+!(HA1%6,*J@
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M*D>T<UK:W$D<L\:NT1U(64$HU"-2$@E30D5%#0D<.E,5S<0*ZP2,@D72X5B
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ME^T=>Z]_IOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\
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ME^T=>Z]_IOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\
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ME^T=>Z]_IOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\
M[&O?M)^7[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_]
M)\[[_P#L:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?
M\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z
M]_IOV9_SI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)
M^7[1U[KW^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^_
M_L:]^TGY?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_
M -)\[[_^QKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_
M #I>WO\ TGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO
M?Z;]F?\ .E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?
ME^T=>Z]_IOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>ZQ3=T['J(9:>? ]N2P3Q2
M0S1/\>^^RDD4JE)(V']VN002#[:FMX[B%[><!D<%6!(H584(.>!!H>KQR/%(
MLL9TLI!!'$$&H(^P] ?_ '2^)G_/BMU?^DS=[_\ V-^X4_X&CV%_Z93;?^<*
M_P"?J1_]>'W1_P"C[=_\Y3U[^Z7Q,_Y\5NK_ -)F[W_^QOW[_@:/87_IE-M_
MYPK_ )^O?Z\/NC_T?;O_ )RGKW]TOB9_SXK=7_I,W>__ -C?OW_ T>PO_3*;
M;_SA7_/U[_7A]T?^C[=_\Y3U[^Z7Q,_Y\5NK_P!)F[W_ /L;]^_X&CV%_P"F
M4VW_ )PK_GZ]_KP^Z/\ T?;O_G*>O?W2^)G_ #XK=7_I,W>__P!C?OW_  -'
ML+_TRFV_\X5_S]>_UX?='_H^W?\ SE/7O[I?$S_GQ6ZO_29N]_\ [&_?O^!H
M]A?^F4VW_G"O^?KW^O#[H_\ 1]N_^<IZ]_=+XF?\^*W5_P"DS=[_ /V-^_?\
M#1["_P#3*;;_ ,X5_P _7O\ 7A]T?^C[=_\ .4]>_NE\3/\ GQ6ZO_29N]__
M +&_?O\ @:/87_IE-M_YPK_GZ]_KP^Z/_1]N_P#G*>O?W2^)G_/BMU?^DS=[
M_P#V-^_?\#1["_\ 3*;;_P X5_S]>_UX?='_ */MW_SE/7O[I?$S_GQ6ZO\
MTF;O?_[&_?O^!H]A?^F4VW_G"O\ GZ]_KP^Z/_1]N_\ G*>O?W2^)G_/BMU?
M^DS=[_\ V-^_?\#1["_],IMO_.%?\_7O]>'W1_Z/MW_SE/7O[I?$S_GQ6ZO_
M $F;O?\ ^QOW[_@:/87_ *93;?\ G"O^?KW^O#[H_P#1]N_^<IZ]_=+XF?\
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MXF?\^*W5_P"DS=[_ /V-^_?\#1["_P#3*;;_ ,X5_P _7O\ 7A]T?^C[=_\
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M7L3Z3\OVCHEZ]_IOV9_SI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\
MTGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\
M.E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_
MIOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7
M[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L
M:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TG
MSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_S
MI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)^7[1U[KW
M^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^__L:]^TGY
M?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_ -)\[[_^
MQKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\
MTGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\
M.E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_
MIOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7
M[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L
M:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TG
MSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_S
MI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)^7[1U[KW
M^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^__L:]^TGY
M?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_ -)\[[_^
MQKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\
MTGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\
M.E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_
MIOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7
M[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L
M:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TG
MSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_S
MI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)^7[1U[KW
M^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^__L:]^TGY
M?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_ -)\[[_^
MQKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\
MTGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\
M.E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_
MIOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7
M[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L
M:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TG
MSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_S
MI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)^7[1U[KW
M^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^__L:]^TGY
M?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_ -)\[[_^
MQKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\
MTGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\
M.E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z<L
M/VSM;.9.CQ-%BNS(*JNE\,$N8Z6[CV]C$?27O69K/X&FHZ=+ _N5$Z+>PO<@
M'6DC_BQU[H3/>NO=>]^Z]U__T-_CW[KW7O?NO=>]^Z]T5+KKYO\ Q<[8[\W[
M\8-@]IP9SO3K%,\^]=AR;2WYAI<2NV,I!AL]]OG\]BZ7%5QIZBIA1EH*Z<LK
M&1 T:NZG$7+^[S\N)S;%"6V^0J!*&3\995)35XB@LA%60 &@)!9:H[R_M;#=
M8]DNVT7,H5E2C$$-$)U[P"@)B(< L#2HI52!RSWS<^+VV?DG@/B%FNTH*7Y$
M[GIZ2JPO74.T]]U[U$5?AY\_2"IW3CL7+A*5WHJ:6H$55DHW":25!DC#VVOE
M[>-ZVRZWC;(?%MK(N)GUHH4QJC/0,RL^D.M= ;NJOQ*P&]ROK7:'MX]P?PS=
MA#$*%M0DF:!/A#::RHR]VFE-1HA#%-?(_P#F'_##XDYVCVK\@.^ML;'W76TT
M-8FU*3%[LWMNBEHJE==+6Y7;G7^/RM;10S+ZH):R")) "8RP!]TV78=XYB:1
M=FMVG$1HS"BQAN)3Q'*QZP""4#:P"I( 85=O;B#;H$N+UQ&LGP@GN85(U*@J
MY2H*ZPNG4"M:@CK'D_YB/PWQ'QUH/EE6]STG^R_9/<D6T*+L&CV7V/DXY-R2
MU$E(N*?;6-P\V9CD$L4B.9,<JH5L[+Q[4W/*V_6>\6^P7-N4N[H%HD+)W@+(
MY(?5HIIBD-2PRI7XJ I[3<K*_LKG<+1]<-I3QFHP*5:)152 Q),T6 #AP> )
M$;X[?S(/A)\KMT2;(Z&^0&V-Y;R2GFJH-J9##[QV)N/)T]-&T]7)@L+V'C<3
M4Y 0QJTLXH8Y3&@+OI4$^U&Y\E\T;/:&^O[1EA6FIE9) M30%_#9]()(&IJ"
MI K4@%+#O^SSW"VJ3@.YHH8,NH\=*E@ S4J=()8@$TH#3CW9_,B^$/QT[0H^
MF>Y_D'M39/9-6,:TNW9\5N[,)AERX63'-NK.;<QU9CL,)(W28'+5=-:)EF:T
M3!RDV+EK?.989+C9+<SQQ,4+55%+K\2HSLHD93VL$+%7!0T8$=+]TO+?9HXY
M-R;P_%76@H68K4KJT(&<*2#0E0&H2*@'I;?(KYN?%;XG;=VKNKO[N7;FQ,-O
MD-)LZ2*BW#N_(;GI8X8JB7(X3![&H\G75%(B3PL]9'3&!1)'JD&M;I]NV3=M
MUW.39K&W=[F($R(1I,5"5_5+Z5B)9651(5+%'"@E6I=KB!-M&\,Z_2N5"R @
MJY9=0\.F9.VC'0&HI!- 17K*_.#XFX7X^T'RGR7>FR8.A,H8XL9V#'45]52Y
M#(2S/3_P&AP=)!)E)<HDD4J2XE*$UD9CD$D"F-]-[S8-ZL-YCY>NK9UO)LI$
M!J+K2NM2M5,8'Q2AO#7\3#INPOK3<[.7<+*0-# "9&/9X=*8</I*,2RA48!G
M+H%!+K5V^-GS ^-GR^V]F-S_ !R[7P79>+V[604&X(:.BSV SF#J*M'>B.8V
MMNVDQ^3IHZ@1R_;3S4:QS>.3Q.YC?2[O/+.^\O",[Q;M"LM=#55E8K34 Z,R
MZE!!*UU $$BA'26RWG;-QG>VLY0TD8!92&5M)P& 8 E:BFH56N*UZ'?*[HVS
M@<AM[$YS<6"PV5W=DI\-M3&97+X_'9#<^8I<;/FJG%;>HJR1)*VICHZ:IJY(
M*97=88I)2H1&8$T4,MPSI I<QHTK!025C5D1I& X(K21JSGM#.@)JRU,Y&6&
M+QY3ICUI'J.%\22NA*G&M]+:%^)M)H#0] YMCY8_%C>V[XNOMF?);X_[NW]-
M6U.-AV/MCN3KK/[OER-$[1UE!%MK%9*6M::)D998A!J4@A@"#[7KLN\O9C<4
MM)C;E!()1$YC,9&H.'TZ2A7N#5H1FM.D\UY9VUR;.XE2.8.8RC,JN) =)0J2
M&UAL%:5KBE>F3</S7^&NT<]F-J[K^6WQDVQN?;N3K<)N#;FX>^NJ\+GL%F<;
M4-29'$YC#Y+*Q5%+54\J-%-3SQJZ."K*""/=K+8M[W.WBO-MLY[B&8!HWCBD
MD216RK(RJ58-Y%20?+J]S<V]G*8+R18G 4E78*P#*&4D,0:,I#*?-2",$=&$
MKMP8'%X&KW3D\WB,=MC'XF?/5^XZ[)4=)@:+!4M&<A4YJKR]0ZT\=)'3JT\E
M2\@C6,%RP47]E=PK6CM%=#PV1M#!^TAM6G20:$-J[:'.K%*]/6I%\(S9?K";
M28]'?KU4TZ--=6JHTTK6HITWYC>^S-O;<@WAG]W;8P>T:EL(M-NG,9_%8S;E
M0VYJZ#%[<6#-ULJ4SG(5-534]"%E/GEFBCBU/(@*@V5X-Q7:#$_U;R&%8-+>
M,TJZBT0CIK,@",2@74-+5&#1J.>&:U-[$ZM"(S,9 04$2H9&E+CM\-4!<O72
M$!8FF>D/N'Y"=!;1WUC.KMU]X=0;8[,S4M'#A^NMP]E[+PN^LM-D"%H(L9M'
M)5L60G:<D"%8J=B]_3?VY9;;N.YQ//MUO)<)$2':-&=4*Y8,5!"D>8-*>?6K
MNXM[!5>^D6$/\)D8(&S3M+$5SC'GT+_M%T]U[W[KW05=F=[=(=*QXR7N3N3J
MKJ6+-M*F&D[,[#VCL./+/!83IC'W364@J"FI=8B+6N+_ %'M39V=WN,YM=OB
M>>50&*1JSL%)(!*J"0"00#2A(/IUJ9EM[?ZJX.B*NG6W:FJE::C05IFE:TST
MD]V?+/XK;!CVW-OKY,?'[9<6\L'!N;:$N[.Y>N=N1[JVW53-3TNX=MOF,E"*
MZADD1TCJZ4O$S*P#D@CVJAV7>+BXEM+>TFDEMRHE18G9XRRZE$BA24+*0RA@
M"5-1CI.;RT6U2]:5!#*6"2:ET.4IK"O72Q34NH G345I4=")DNU>K\-L5.T<
MQV1L+$]9R4$&5C[%R6\-O4.Q7Q=4+TV23=U54)CS3R7'CF%1H;\$^T<MK=6]
MV+">-DG+!!&RD2%B*A0A 8L1D"E2,TZ?MW2[A-Q:D2QJ"Q9#J4*IHS%A4  X
M)K0'!Z:-M]Z=([RVKC]];0[CZKW7LC+;BH=H8O>.V^PMI9S:N2W9E*V/&8S:
M^/W#BZR6DFR-14S0T\%%',9I)'2-$+,H*B?:MTM;I+&YMI8YI%9DC:-U=E1'
MD=E0@,RK''([$ A41V- K$)TOK*6&6YCF1HX*>*P=2L>IE5?$8&B:F=%&HBK
M,H&6%14]H.E77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW5;-=_,HP&3WWV!M?IOXD?,[Y)[*ZH[%S'4O8O>'277W5-9U5@.Q-JUW\+
MWQMG$1]B;VV[N?<CX&K#T66J-I;:RE/%4QRTR325$4D:UV-AOD%K?+_BUI?2
M,EM<3]L<RK.]L9U":Y4M?&CD07,L<<+*AE1VATR&^[H=HEGM)/UKJUA2::"*
MK21^+!'<Q1,6"Q&XDMY8I1 DC2JLJ!U1SIZLD4ZE5M++J4'2U@RW%]+ 7Y'Y
MY]W(H2./3,;:T5R"M0#0\17R/'(\\GHLG?OR._T'=C?$S8']S?[T?[-'W[D.
MCOXM_>'^"?W&^QZ2W?W'_>C[#[&K_B>K^ZO\.^R\U);[K[CSGP>"9S;(_P!X
M[X=FKHI8WM[KX_[AM;#PM./[3ZCX]79H^!M7:IN(? V"[WRM?I9K&+1PU?67
M<=KJU?A\/Q/$II.NFFJUU 5.M-T]@;JI=Y3=A=6U/553@^Q]Z;7VG256\=M;
MR.^-@X+*?:;1[0AGVRS)CH\[3?Y6F'K+5E&/VZD!_;%N6DVZUN;@>'<2H[30
MUU> RSS1HAD'9(7@2*X+)VIXWA$EXV):FHE]/;Q'7#'X'AR\!+XEK;S340]R
M>!<R3V9U?VAMC.GZ4L?089/Y%?PWYA[,^)W]S_-_>[XX]A_('^_W]X/'_#_[
MA=D[<Z]_NE_=;[%O+]W_ '@^\^__ (DGB^W\7VTGE\D;FVK^\1O)^#]T#:#Z
M^+^]3O0^7A^!^Z/Z?B_4?Z'X/ZJ?<I_W>^U)37^\WW!.-/"^@CL)*^>OQ?K:
M4[-'A5J^NB!=\ROFYDOAEMS=G8&;^(/RH[NZFZ^ZRS?:O8G;/1U1\6Y=I[(V
M_MJ*MKMQ4&6P_<?9^SMQ5-=1T5$:Z2/%8*KB>*6)89I:CR01H?K L_@S(T8:
M6""-CI*RR7#QQ1!-+,P!ED6,F14 8DUT OT=6>U3[AX,5@ZRSS-(HA&H2*(U
M5@[%U6+2X+!-,C-6)]:H#&9!,^.?R'WMWW!F*W='Q)^2/QGQM%C<%E,#DN^\
MA\9JVFWQ39Q)92NV(_C]V1OV:-Z2..*2J&7BH1:>(0&9A,(CNYL'LUD2Y=5F
MBE:)X>XR K74U0IB*A@5Q(6U?AT]W0>M-PAOHX+FS5I(+B(2I+0!-+!"@(8B
M0,ZOJ4:* *P<JVD,9WV@Z7=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]TV9JJFHL-EJRG(6>DQE?50LRAE6:"E>6,E3P0"!P?9;O-S+9;1
M=WD!H\4,KJ2*C4J,PQYY'#I9MT*7&X06\N5DD13]C, ?Y'JC7_9\_D7_ ,]!
MM_\ ]!7$?]&>^(__  ='WAO^CA:_]D-O_P! ]=(/^!F]I_\ E%G_ .RF7_/U
M[_9\_D7_ ,]!M_\ ]!7$?]&>_?\ !T?>&_Z.%K_V0V__ $#U[_@9O:?_ )19
M_P#LIE_S]>_V?/Y%_P#/0;?_ /05Q'_1GOW_  ='WAO^CA:_]D-O_P! ]>_X
M&;VG_P"46?\ [*9?\_7O]GS^1?\ ST&W_P#T%<1_T9[]_P '1]X;_HX6O_9#
M;_\ 0/7O^!F]I_\ E%G_ .RF7_/U[_9\_D7_ ,]!M_\ ]!7$?]&>_?\ !T?>
M&_Z.%K_V0V__ $#U[_@9O:?_ )19_P#LIE_S]>_V?/Y%_P#/0;?_ /05Q'_1
MGOW_  ='WAO^CA:_]D-O_P! ]>_X&;VG_P"46?\ [*9?\_7O]GS^1?\ ST&W
M_P#T%<1_T9[]_P '1]X;_HX6O_9#;_\ 0/7O^!F]I_\ E%G_ .RF7_/U[_9\
M_D7_ ,]!M_\ ]!7$?]&>_?\ !T?>&_Z.%K_V0V__ $#U[_@9O:?_ )19_P#L
MIE_S]>_V?/Y%_P#/0;?_ /05Q'_1GOW_  ='WAO^CA:_]D-O_P! ]>_X&;VG
M_P"46?\ [*9?\_7O]GS^1?\ ST&W_P#T%<1_T9[]_P '1]X;_HX6O_9#;_\
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M0_T/(Y]SG[;?>N]Y.9?;#GKFC=;RW:\V&VV^6T9;6%51[B[,,I=0*."@H W
MY&>HUYP]C/;W9^=.6=EL;>5;?<YKI)P9Y"66* 2)I8FJT;)(X\.@(_V?/Y%_
M\]!M_P#]!7$?]&>X,_X.C[PW_1PM?^R&W_Z!ZDK_ (&;VG_Y19_^RF7_ #]>
M_P!GS^1?_/0;?_\ 05Q'_1GOW_!T?>&_Z.%K_P!D-O\ ] ]>_P"!F]I_^46?
M_LIE_P _7O\ 9\_D7_ST&W__ $%<1_T9[]_P='WAO^CA:_\ 9#;_ /0/7O\
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M.*WUT%TEM;K=\U\.HJS>FV_DWNW>>[*?'P=U[+?#UE/L"OZQPM-++4RK3I/
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MW$C55!_)8ZT^36P9TJV>JDDR7<_8R];_  JR\\DH&FH7I3&9%@Q)<K7,Q(#
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M9-DWEJ3(S5#R$W]TEW?<9]SCW>>37/#$84JJ&-(3I/A+"5\$1512(_#TAAJ
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MQKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\
MTGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\
M.E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_
MIOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7
M[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L
M:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TG
MSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_S
MI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)^7[1U[KW
M^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^__L:]^TGY
M?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_ -)\[[_^
MQKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\
MTGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\
M.E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_
MIOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7
M[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L
M:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TG
MSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_S
MI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)^7[1U[KW
M^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^__L:]^TGY
M?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_ -)\[[_^
MQKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\
MTGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\
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MOWTNV;M'X4\)560$.=3:=*KX9<.S:E"JA8LQ"@%C3IO:KB+>XUEVLF97+J*
MC,;,CX8 @*4:I( H"U=.>DK\=OE!T3\L-FY?L'X^[]@[$V=@MU9+962SM-@=
MU8"FBW)B*2GKJ^AIX=V4-!-4(L-73R)54\;P2!QXY6LUE6[[!N^Q> -W@,!N
M8Q+&&*DF,LR5*@DH=2,"CA7!&5&.DUKNFWWUU<6=G*))+5@DFFI4,14:7IH<
M$9#1LRD<#T,&5W1MG Y#;V)SFXL%ALKN[)3X;:F,RN7Q^.R&Y\Q2XV?-5.*V
M]15DB25M3'1TU35R04RNZPQ22E0B,P*XH9;AG2!2YC1I6"@DK&K(C2,!P16D
MC5G/:&= 35EJND988O'E.F/6D>HX7Q)*Z$J<:WTMH7XFTF@-#T&.]/DI\<^M
M]V4FP^P^_NE-A;YKQ2M0[,WIVIL7:V[*U:XA:)J3;N<KX*R03$@1%(3K_LW]
MJK#:]SW56?:[>6Y"-I8Q1O(%;^$E :-D8.<]-7=S;[?&)K^18$8%@TC! 5'$
M@L0"!0U/ 4Z:MP?++XL;3WK4]:[J^2_Q_P!M=BT5=28NLV#N#N7KK#;UI,G7
MPQU-#CJG:N1R4=='/-'-%)%"\ =U=&4$,"7+/9MXW&W%WM]I-/$2P#QQ.Z51
MBCC4JD51U9&%>UE*FA!'5;N[M;!]%]*D+!5>DC!#H=!(C48CM=&5U;@R,&!(
M(/0N[JWCM'8FV\IO+>^Z=N;-VAA*3[_-;JW5G,9M[;>(H=03[W*9S+RPTM/%
M=E'DEE5;D<\^T,<4LUQ'9PJ7EE=8T0 EWD8Z51%'<SLV%4 L3@"O2A!XJEX^
MY0I<D9 1069B1^$*"Q;@ "2:=-V^.R.N^L=L5&]NRM^[+Z]V92-3)5;NWQNG
M![3VQ3/6L$HUJ,_GYZ>D0RD@1!I1J/"W][C@FEN5LHD9IG)58P"79@"2JJ.X
MD $D 5 !/D>J0R1W%M]9;L'AT"36I#)X9I1]0JN@U%&KI-1G(Z==K[JVOOC;
M^*W;LK<F W?M7/4B5^#W-M?,8[<&W\S0R$JE9BLSB9)J:HB8@@20R,IL>?=[
MJTNK&=K6]C>&5*:D=2C"HJ*JP!%0014<#7JD%Q;W40FM9%D0DC4K!EJ"014$
MBH((/H00<]/_ +3]/=-&>S^!VKALEN/<^;Q&W-O8:DEK\OG<]DJ/#X;%4, U
M35F2RF0>."")!RTDKJH_)]Z) (!\R /F2: #U))  XDX'5TCDE;1&I8Y- *F
M@%2:#T )/H!7H$L;\N/BEF=J[EWUA_DY\>\KLC9DN,AWAO'&]T=;UVU=J39J
MK^PP\6Y=PTN2:DH6JY_V:9:J9#+)Z$U-Q[-)MDWFVDABN+2:-[ABD2M$ZF5E
M4NRQ@J"[!%+D+4A06(H">DD-W:W#R)!*CM$AD<*P)1 0I=P"=* LH+&@!8 F
MI'2RZR[QZ4[KI<E6]-=P=6]MT6&EA@R]7UEV!M/?E+BIJ@,U/#DJC:M75I T
M@1BBRE2UC:]C[;O=JW3;55]QMI;<-729(W0&G&A8"M/.G#JL-]97,AAMYDD=
M14JKJQ X5(!) ^?4';GR%Z"WCOK(=7[1[PZ?W3V7B16-E>N]N=E[+SF^L8N/
M_P"![9#:6,K9<A"(+_O&2G&C^U;W5=MW%MO_ 'LMO(;4@'Q@C>%0F@/B4T4)
MP,Y..G)KB"VNA8W#K'.V!&Q"N3350(2&/:"W#@*\.A%V]N7;F[L5#G=J9_";
MGP=3/74M/F=O96AS6*GJ<77R8O)T\.1QLDL+/3U4,U-.BN3'+&\;@.K )7BD
MCTF12NM$D6H(U)(H>-UKQ1T971AAE8,I((/3BNC.\:D%HG>-P#E)(V*21L/P
MNC@JZFC*P*L 01T]^Z=6Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>ZK*SW\RFHIM]=][4V!\$/G)W?MOXV]C9'JWLSM'J/#_%;+[23
M=>&VABM\YFGVOM+<_:^(WQEUIL?F:%]%!M&2:9V:*FAF=;%%!?P-LD7,E^&L
M[&9KT++(I<:+"_N]NN)BEN)Y!&+FRN-/9XAC4.8UU4Z>D@(W=]AMF6>ZC6U9
MD5@@!O+:&[A4R3F*,$Q3IJ)<(K5&LTKT=_HSNSK;Y(=/]<=\=/[@_O3UCVOM
M/$[TV5GFH,AB9J_!YFG$].:S$Y>*"KI*B,ZH:FDJ84EAE1XI$5U(!WN.WW&U
MW1M+G23I1U9&#H\<J++%(CJ2K1RQ.DB,#1D8'SZ06MRMTCD*T;Q22PR1R*4D
MBFMY7@GAD4Y62&:.2*0>3H0"1GH5O:'I3U[W[KW13MU_*'^['R@R7QN_N/\
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M/^!F]I_^46?_ +*9?\_7O]GS^1?_ #T&W_\ T%<1_P!&>_?\'1]X;_HX6O\
MV0V__0/7O^!F]I_^46?_ +*9?\_7O]GS^1?_ #T&W_\ T%<1_P!&>_?\'1]X
M;_HX6O\ V0V__0/7O^!F]I_^46?_ +*9?\_7O]GS^1?_ #T&W_\ T%<1_P!&
M>_?\'1]X;_HX6O\ V0V__0/7O^!F]I_^46?_ +*9?\_7O]GS^1?_ #T&W_\
MT%<1_P!&>_?\'1]X;_HX6O\ V0V__0/7O^!F]I_^46?_ +*9?\_7O]GS^1?_
M #T&W_\ T%<1_P!&>_?\'1]X;_HX6O\ V0V__0/7O^!F]I_^46?_ +*9?\_7
MO]GS^1?_ #T&W_\ T%<1_P!&>_?\'1]X;_HX6O\ V0V__0/7O^!F]I_^46?_
M +*9?\_7O]GS^1?_ #T&W_\ T%<1_P!&>_?\'1]X;_HX6O\ V0V__0/7O^!F
M]I_^46?_ +*9?\_7O]GS^1?_ #T&W_\ T%<1_P!&>_?\'1]X;_HX6O\ V0V_
M_0/7O^!F]I_^46?_ +*9?\_7O]GS^1?_ #T&W_\ T%<1_P!&>_?\'1]X;_HX
M6O\ V0V__0/7O^!F]I_^46?_ +*9?\_7O]GS^1?_ #T&W_\ T%<1_P!&>_?\
M'1]X;_HX6O\ V0V__0/7O^!F]I_^46?_ +*9?\_7O]GS^1?_ #T&W_\ T%<1
M_P!&>_?\'1]X;_HX6O\ V0V__0/7O^!F]I_^46?_ +*9?\_7O]GS^1?_ #T&
MW_\ T%<1_P!&>_?\'1]X;_HX6O\ V0V__0/7O^!F]I_^46?_ +*9?\_7O]GS
M^1?_ #T&W_\ T%<1_P!&>_?\'1]X;_HX6O\ V0V__0/7O^!F]I_^46?_ +*9
M?\_0[]9?+;NC<_5G?6ZLMF,/+F-@X'9]?MN6+;^.@AIZG,[B;'5S5$$:Z90T
M0 4/]#R.?<Y^VWWKO>3F7VPYZYHW6\MVO-AMMOEM&6UA54>XNS#*74"C@H*
M-P.1GJ-></8SV]V?G3EG9;&WE6WW.:Z2<&>0EEB@$B:6)JM&R2./#H"/]GS^
M1?\ ST&W_P#T%<1_T9[@S_@Z/O#?]'"U_P"R&W_Z!ZDK_@9O:?\ Y19_^RF7
M_/U[_9\_D7_ST&W_ /T%<1_T9[]_P='WAO\ HX6O_9#;_P#0/7O^!F]I_P#E
M%G_[*9?\_7O]GS^1?_/0;?\ _05Q'_1GOW_!T?>&_P"CA:_]D-O_ - ]>_X&
M;VG_ .46?_LIE_S]>_V?/Y%_\]!M_P#]!7$?]&>_?\'1]X;_ *.%K_V0V_\
MT#U[_@9O:?\ Y19_^RF7_/U[_9\_D7_ST&W_ /T%<1_T9[]_P='WAO\ HX6O
M_9#;_P#0/7O^!F]I_P#E%G_[*9?\_7O]GS^1?_/0;?\ _05Q'_1GOW_!T?>&
M_P"CA:_]D-O_ - ]>_X&;VG_ .46?_LIE_S]>_V?/Y%_\]!M_P#]!7$?]&>_
M?\'1]X;_ *.%K_V0V_\ T#U[_@9O:?\ Y19_^RF7_/U[_9\_D7_ST&W_ /T%
M<1_T9[]_P='WAO\ HX6O_9#;_P#0/7O^!F]I_P#E%G_[*9?\_7O]GS^1?_/0
M;?\ _05Q'_1GOW_!T?>&_P"CA:_]D-O_ - ]>_X&;VG_ .46?_LIE_S]>_V?
M/Y%_\]!M_P#]!7$?]&>_?\'1]X;_ *.%K_V0V_\ T#U[_@9O:?\ Y19_^RF7
M_/U[_9\_D7_ST&W_ /T%<1_T9[]_P='WAO\ HX6O_9#;_P#0/7O^!F]I_P#E
M%G_[*9?\_7O]GS^1?_/0;?\ _05Q'_1GOW_!T?>&_P"CA:_]D-O_ - ]>_X&
M;VG_ .46?_LIE_S]>_V?/Y%_\]!M_P#]!7$?]&>_?\'1]X;_ *.%K_V0V_\
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M&_&[Y&8['4E-08^@^:7=-%0T-'!%2T=%1TN*PD%-24M- %2..-%5(T10JJ
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M_=>Z][]U[KWOW7NO>_=>Z][]U[J[C^7?_P R'R?_ (D7<'_NFQGOM-_=]_\
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M#Y*EO*JL^JPL:-ONXFZM[U/"CEM6D>,QP01=TL+6\FL1QJLH:%WC*RAUTL:
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M^A= J?&C[):I\!\1:/5?PY[?*G3ERQO++]VWA\6V[OTG[H^\ -V-5>X !L9
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MIV1MGN3L_P",_P ?NQ^W]EOCI-G=J[]Z9ZYWAV1M.3$57WN)?;.^=PXVHRE
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M8J6KS=+L3'T"54D:LRQR3JS*"0" ?:@W5RULMFTC&%&+*FHZ%8@ L%KI#$
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ME^T=>Z]_IOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\
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ME^T=>Z]_IOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\
M[&O?M)^7[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_]
M)\[[_P#L:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?
M\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z
M]_IOV9_SI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)
M^7[1U[KW^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^_
M_L:]^TGY?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_
M -)\[[_^QKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_
M #I>WO\ TGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO
M?Z;]F?\ .E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?
ME^T=>Z]_IOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\
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MOW[_ (&CV%_Z93;?^<*_Y^O?Z\/NC_T?;O\ YRGKW]TOB9_SXK=7_I,W>_\
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MQKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\
MTGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\
M.E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_
MIOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7
M[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L
M:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TG
MSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_S
MI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)^7[1U[KW
M^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^__L:]^TGY
M?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_ -)\[[_^
MQKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\
MTGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\
M.E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_
MIOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7
M[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L
M:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TG
MSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_S
MI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)^7[1U[KW
M^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^__L:]^TGY
M?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_ -)\[[_^
MQKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\
MTGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\
M.E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_
MIOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7
M[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L
M:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TG
MSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_S
MI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)^7[1U[KW
M^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^__L:]^TGY
M?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_ -)\[[_^
MQKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\
MTGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\
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M7,5&WNH/D'TAVKGZ2D?(56#ZV[7V'OG,4U!&P22MJ,9MBOJITA4LH:1D"@D
MGGV:76Q[W8P&YO;.>&,4!=XI$4$X +,H&?+/1>FX[?+*((YXV=N"AU+&@)-
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M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_T=_CW[KW7O?NO=>]^Z]UIQ8S+_Z
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M98_3Q@G@D37ETX44&N=V()-0..7CXWNER];M0):06LR+05,M]NUS%<2$G/\
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MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=;0W\G#_LD_.?\
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M"2,+B)8T24,1(B1%FB17KJ58V=VC4$!"[%0"QJ''57Q.^+'1*XQ>D/C3\?\
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M_P!6^_:&]#U[KW^S!]"?\_OZA_\ 1E;,_P#JWW[0WH>O=>_V8/H3_G]_4/\
MZ,K9G_U;[]H;T/7NO?[,'T)_S^_J'_T96S/_ *M]^T-Z'KW7O]F#Z$_Y_?U#
M_P"C*V9_]6^_:&]#U[KW^S!]"?\ /[^H?_1E;,_^K??M#>AZ]U[_ &8/H3_G
M]_4/_HRMF?\ U;[]H;T/7NO?[,'T)_S^_J'_ -&5LS_ZM]^T-Z'KW7O]F#Z$
M_P"?W]0_^C*V9_\ 5OOVAO0]>Z]_LP?0G_/[^H?_ $96S/\ ZM]^T-Z'KW7O
M]F#Z$_Y_?U#_ .C*V9_]6^_:&]#U[KW^S!]"?\_OZA_]&5LS_P"K??M#>AZ]
MU[_9@^A/^?W]0_\ HRMF?_5OOVAO0]>Z]_LP?0G_ #^_J'_T96S/_JWW[0WH
M>O=>_P!F#Z$_Y_?U#_Z,K9G_ -6^_:&]#U[KW^S!]"?\_OZA_P#1E;,_^K??
MM#>AZ]U[_9@^A/\ G]_4/_HRMF?_ %;[]H;T/7NO?[,'T)_S^_J'_P!&5LS_
M .K??M#>AZ]U[_9@^A/^?W]0_P#HRMF?_5OOVAO0]>Z]_LP?0G_/[^H?_1E;
M,_\ JWW[0WH>O=>_V8/H3_G]_4/_ *,K9G_U;[]H;T/7NO?[,'T)_P _OZA_
M]&5LS_ZM]^T-Z'KW7O\ 9@^A/^?W]0_^C*V9_P#5OOVAO0]>Z]_LP?0G_/[^
MH?\ T96S/_JWW[0WH>O=>_V8/H3_ )_?U#_Z,K9G_P!6^_:&]#U[KW^S!]"?
M\_OZA_\ 1E;,_P#JWW[0WH>O=>_V8/H3_G]_4/\ Z,K9G_U;[]H;T/7NO?[,
M'T)_S^_J'_T96S/_ *M]^T-Z'KW7O]F#Z$_Y_?U#_P"C*V9_]6^_:&]#U[KW
M^S!]"?\ /[^H?_1E;,_^K??M#>AZ]U[_ &8/H3_G]_4/_HRMF?\ U;[]H;T/
M7NO?[,'T)_S^_J'_ -&5LS_ZM]^T-Z'KW7O]F#Z$_P"?W]0_^C*V9_\ 5OOV
MAO0]>Z]_LP?0G_/[^H?_ $96S/\ ZM]^T-Z'KW7O]F#Z$_Y_?U#_ .C*V9_]
M6^_:&]#U[KW^S!]"?\_OZA_]&5LS_P"K??M#>AZ]U[_9@^A/^?W]0_\ HRMF
M?_5OOVAO0]>Z]_LP?0G_ #^_J'_T96S/_JWW[0WH>O=>_P!F#Z$_Y_?U#_Z,
MK9G_ -6^_:&]#U[KW^S!]"?\_OZA_P#1E;,_^K??M#>AZ]U[_9@^A/\ G]_4
M/_HRMF?_ %;[]H;T/7NO?[,'T)_S^_J'_P!&5LS_ .K??M#>AZ]U[_9@^A/^
M?W]0_P#HRMF?_5OOVAO0]>Z]_LP?0G_/[^H?_1E;,_\ JWW[0WH>O=>_V8/H
M3_G]_4/_ *,K9G_U;[]H;T/7NO?[,'T)_P _OZA_]&5LS_ZM]^T-Z'KW7O\
M9@^A/^?W]0_^C*V9_P#5OOVAO0]>Z]_LP?0G_/[^H?\ T96S/_JWW[0WH>O=
M>_V8/H3_ )_?U#_Z,K9G_P!6^_:&]#U[KW^S!]"?\_OZA_\ 1E;,_P#JWW[0
MWH>O=>_V8/H3_G]_4/\ Z,K9G_U;[]H;T/7NO?[,'T)_S^_J'_T96S/_ *M]
M^T-Z'KW7O]F#Z$_Y_?U#_P"C*V9_]6^_:&]#U[KW^S!]"?\ /[^H?_1E;,_^
MK??M#>AZ]U[_ &8/H3_G]_4/_HRMF?\ U;[]H;T/7NO?[,'T)_S^_J'_ -&5
MLS_ZM]^T-Z'KW7O]F#Z$_P"?W]0_^C*V9_\ 5OOVAO0]>Z]_LP?0G_/[^H?_
M $96S/\ ZM]^T-Z'KW6"I[Z^/E935%'5=U=/3TM7!+35,$G9.S&CF@GC,4T4
MB_>\JRD@C^GNDD FC:&5=2L""",$$4(/VCJ\<CQ2++&2K*001Q!!J"/L/16O
M]#W\LC_G4?%/_P!"G8W_ -7>XQ_UD?:G_IGK/_G".I)_UY?=3_H_7G_.4]>_
MT/?RR/\ G4?%/_T*=C?_ %=[]_K(^U/_ $SUG_SA'7O]>7W4_P"C]>?\Y3U[
M_0]_+(_YU'Q3_P#0IV-_]7>_?ZR/M3_TSUG_ ,X1U[_7E]U/^C]>?\Y3U[_0
M]_+(_P"=1\4__0IV-_\ 5WOW^LC[4_\ 3/6?_.$=>_UY?=3_ */UY_SE/7O]
M#W\LC_G4?%/_ -"G8W_U=[]_K(^U/_3/6?\ SA'7O]>7W4_Z/UY_SE/7O]#W
M\LC_ )U'Q3_]"G8W_P!7>_?ZR/M3_P!,]9_\X1U[_7E]U/\ H_7G_.4]>_T/
M?RR/^=1\4_\ T*=C?_5WOW^LC[4_],]9_P#.$=>_UY?=3_H_7G_.4]>_T/?R
MR/\ G4?%/_T*=C?_ %=[]_K(^U/_ $SUG_SA'7O]>7W4_P"C]>?\Y3U[_0]_
M+(_YU'Q3_P#0IV-_]7>_?ZR/M3_TSUG_ ,X1U[_7E]U/^C]>?\Y3U[_0]_+(
M_P"=1\4__0IV-_\ 5WOW^LC[4_\ 3/6?_.$=>_UY?=3_ */UY_SE/7O]#W\L
MC_G4?%/_ -"G8W_U=[]_K(^U/_3/6?\ SA'7O]>7W4_Z/UY_SE/7O]#W\LC_
M )U'Q3_]"G8W_P!7>_?ZR/M3_P!,]9_\X1U[_7E]U/\ H_7G_.4]>_T/?RR/
M^=1\4_\ T*=C?_5WOW^LC[4_],]9_P#.$=>_UY?=3_H_7G_.4]>_T/?RR/\
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M3_G]_4/_ *,K9G_U;[]H;T/7NO?[,'T)_P _OZA_]&5LS_ZM]^T-Z'KW7O\
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M_P!6^_:&]#U[KW^S!]"?\_OZA_\ 1E;,_P#JWW[0WH>O=>_V8/H3_G]_4/\
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M++-3V^X7&R;JK*03E-2ZQ$6TW%[7]NV=G>;C.;7;XGGE4!BD:L[!22 2J@D
MD$ TH2#Z=>E(@@^JG.B*NG6V%U4KIU'%:9I6M.EOM?=6U][X#&;KV7N3 [OV
MOFJ?[O#;DVOF,?G\!EJ768_N<9F,5)+3SQZE9=<4C"X(O<>ZW-K<V<S6UY&T
M4BTJKJ585%156 (J""*CATU!<6]U&)K9UD0U&I6#"H-#D$C!P?GT'U'\A.@L
MCV++U!C^\.H*[MJ"2>&?JZC[+V75=BPRTL1GJHI=DP5K9-6CC!>1337502;
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M%E0RH[0Z9#?=T.T2SVDGZUU:PI--!%5I(_%@CN8HF+!8C<26\L4H@21I565
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MEM%W>0&CQ0RNI(J-2HS#'GD<.EFW0I<;A!;RY621%/V,P!_D>J-?]GS^1?\
MST&W_P#T%<1_T9[XC_\ !T?>&_Z.%K_V0V__ $#UT@_X&;VG_P"46?\ [*9?
M\_7O]GS^1?\ ST&W_P#T%<1_T9[]_P '1]X;_HX6O_9#;_\ 0/7O^!F]I_\
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M52: &6=YC($&G6A-6-:#C\+8]XR?(+^:WF=IT/Q^RW\PW'_)&IAV(GRG&5.
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M:F=XW9S!()/N'[^/;Y/:>T?E<S#;(K^57%T!]0\[M=,'5T8Q&%3XX58E4#4
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MUI.M]IU$U+/D(=SS3UD-1M>+'S1BKR,<-%5!J>I=XBW:Q')NT-G/'XR70D@
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M2KDEO(1'[W V&T;^;P_6^'MTC,)>T2@;>&T/]/X)"D=A,1C?3D,&[NG>4/\
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MQKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\
MTGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\
M.E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_
MIOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7
M[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L
M:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TG
MSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_S
MI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)^7[1U[KW
M^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^__L:]^TGY
M?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_ -)\[[_^
MQKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\
MTGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\
M.E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_
MIOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7
M[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L
M:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^__L:]^TGY?M'7NO?Z;]F?\Z7M[_TG
MSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_ -)\[[_^QKW[2?E^T=>Z]_IOV9_S
MI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\ TGSOO_[&O?M)^7[1U[KW
M^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\ .E[>_P#2?.^__L:]^TGY
M?M'7NO?Z;]F?\Z7M[_TGSOO_ .QKW[2?E^T=>Z]_IOV9_P Z7M[_ -)\[[_^
MQKW[2?E^T=>Z]_IOV9_SI>WO_2?.^_\ [&O?M)^7[1U[KW^F_9G_ #I>WO\
MTGSOO_[&O?M)^7[1U[KW^F_9G_.E[>_])\[[_P#L:]^TGY?M'7NO?Z;]F?\
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MC7OVD_+]HZ]U[_3?LS_G2]O?^D^=]_\ V->_:3\OVCKW7O\ 3?LS_G2]O?\
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MC7OVD_+]HZ]U[_3?LS_G2]O?^D^=]_\ V->_:3\OVCKW7O\ 3?LS_G2]O?\
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MC7OVD_+]HZ]U[_3?LS_G2]O?^D^=]_\ V->_:3\OVCKW7O\ 3?LS_G2]O?\
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MC7OVD_+]HZ]U[_3?LS_G2]O?^D^=]_\ V->_:3\OVCKW7O\ 3?LS_G2]O?\
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MC7OVD_+]HZ]U[_3?LS_G2]O?^D^=]_\ V->_:3\OVCKW7O\ 3?LS_G2]O?\
MI/G??_V->_:3\OVCKW7O]-^S/^=+V]_Z3YWW_P#8U[]I/R_:.O=>_P!-^S/^
M=+V]_P"D^=]__8U[]I/R_:.O=>_TW[,_YTO;W_I/G??_ -C7OVD_+]HZ]U[_
M $W[,_YTO;W_ *3YWW_]C7OVD_+]HZ]U[_3?LS_G2]O?^D^=]_\ V->_:3\O
MVCKW7O\ 3?LS_G2]O?\ I/G??_V->_:3\OVCKW7O]-^S/^=+V]_Z3YWW_P#8
MU[]I/R_:.O=>_P!-^S/^=+V]_P"D^=]__8U[]I/R_:.O=>_TW[,_YTO;W_I/
MG??_ -C7OVD_+]HZ]TY8?MG:V<R='B:+%=F055=+X8)<QTMW'M[&(^DO>LS6
M?P--1TZ6!_<J)T6]A>Y .M)'_%CKW0F>]=>Z][]U[K__T-_CW[KW7O?NO=>]
M^Z]T5+KKYO\ Q<[8[\W[\8-@]IP9SO3K%,\^]=AR;2WYAI<2NV,I!AL]]OG\
M]BZ7%5QIZBIA1EH*Z<LK&1 T:NZG$7+^[S\N)S;%"6V^0J!*&3\995)35XB@
MLA%60 &@)!9:H[R_M;#=8]DNVT7,H5E2C$$-$)U[P"@)B(< L#2HI52!RSWS
M<^+VV?DG@/B%FNTH*7Y$[GIZ2JPO74.T]]U[U$5?AY\_2"IW3CL7+A*5WHJ:
M6H$55DHW":25!DC#VVOE[>-ZVRZWC;(?%MK(N)GUHH4QJC/0,RL^D.M= ;NJ
MOQ*P&]ROK7:'MX]P?PS=A#$*%M0DF:!/A#::RHR]VFE-1HA#%-?(_P#F'_##
MXDYVCVK\@.^ML;'W76TT-8FU*3%[LWMNBEHJE==+6Y7;G7^/RM;10S+ZH):R
M")) "8RP!]TV78=XYB:1=FMVG$1HS"BQAN)3Q'*QZP""4#:P"I( 85=O;B#;
MH$N+UQ&LGP@GN85(U*@JY2H*ZPNG4"M:@CH2NO/E?\=>U.D:KY([)[7VU7=&
MT%/EZK(]D9?^([2P&,@P$I@S#Y4[O@H)Z7[>0>-Q40H=7I +$#W3>=DW78+I
M+'=H&BFE"E$%'9];%$"",OK+N"BJM69NT"N.F]LO;7>0YVUO$$9*O@KH*H)&
MU:@ND+&0[,:*J=Q( )Z!7HK^9O\ !CY+=EQ=/=)]_8?>O8U3#E)Z';@VCV-M
MULI%AJ62NR;X?*[LP]!0UGB@BDF(I:F0F-6=;J"?9I>\E\S[=MC[Q>VC1V\2
MAG8LG8I8*"ZABZC4R@EE%"0#3I$V_;0MZFWF=?%D;0H%2K-0G2K@%&) )%&-
M0"14=2=I?S+O@KOKN]OCEM3Y';,R_;YS55MNFV[%0[II\3DMPTDQII<%A=\U
MN/CP%?6-*#%%3464EDED!2-7?CVS;<I\QW>S#?[>T=K4IXH; 8QTU>((R1+H
MT]^K1IT=]=.>GMPW;;MJO?W=N$RQS:Q&0:D+(QTA'8 JCZNPJ[*P<A" ^.A1
M[V^8GQI^-&>Z_P!J]V]L8/9.Z>T\Y0[=V'M@T&X-Q;CS^1R5:N-HY4P6TZ.O
MJJ>C:H=(&R-7%%2)(0CSJQM[1[#L6[<S7YVS8H3<3* 6 *JJZB H>1RL:,Y/
M8K,&<!BH(1B%&Y7EMM&VMNVY.(K=:]QJ2=*ZFT(*N^@4+Z%;1J750NM6WY+?
M-KXM?#^#;TOR+[?PO74^[&J?[N8EL3NC=6X\O#1LJ5=;2;7V10Y/)&FC9E22
MK-*(58A2X;CVWM&T;EOMV]EM,)FDC4.]*!44U"EW8A$U:6TAF!;2^D'2U'KF
M2.SM1>W3!(V;0I)RS8JJ+\3E=2ZM .G6FJFM:BATGWIU'\C>O<1VKTCOO"=B
M;!SCU$-#N#"/4HB5=&P2LQN2QV0CAJZ*KA)7S4=;3Q3IJ4O& RWWNVS;IL5W
M]%NT+0R:0P!H0RFH#*RDJRU!%5)&I64FJD!)8;E8[G$TUC() C%&P058 '2R
ML RG2RL*@55E855@2_[C[/ZUV=)N&+=W8>QMK2[1VH-][KCW'NW 8.3;&QVJ
M9J)=Y;A3)U$1HL49J>HB&1J=%/KBD7R:D8!!'%+,AEA4NHEC@J 2/'EH8H:C
M'BR5'AQ_&]1I!J.C#0Y95 -6260"F3' JM.X]4A5E:5AB-64N0".D/L3Y.?&
MSM*/<$W67R$Z.[&AVGBJC/;IEV)VQL+=T>VL'2H9*K,[@?;^0J!1TD:@M)45
M)2-0+E@/:R^VC==K@^JW.UEMXOXY8WC7@3\3@#@">/ $]);:[M;RY2RM)4EF
MD^&-&#.V0.U5)8Y(&!Q('2<VK\S?A]OO<6'V?LCY7?&O>6[=PUL6-P&U]J]Z
M=7[AW%G,C-?PT&'PF(RDU34SO8Z8H8F8_@>U3\M\Q1QM+)87*HBLS,8)0%50
M69F)6@55!+$X !)P.F&W3;%H&N8AJ95%9$RSL%11G+,Q"J!EF( J2.AZS.Y-
MN[<_A7]X<]A<#_'LU0;;P?\ &<I0XO\ C.XLIJ_AF!Q7WTD?W%;4Z'\%+#JE
MDTMH4V/LHCCDFD$4*EV(8@ $DA$:1S09HD:.['@J*S&BJ2%KLL<;32$*BE 6
M. #)(D2 DX!>61(TK\4CH@JS ''D-U;7Q.<P.V,IN3 XW<FZ8\O-MC;V0S&/
MH\YN.' 4Z5F=EP.)J)%J*Q:**2.6K:GC<0HRM)I5@35%:02M&-0@0224SX<9
M8('>GP(7(0,U 6(4&IIUMB$",YH)'$:DXU2%'D"+ZN4CD<*.XI&[4HK$![M#
MY"]!=@[MR^P-A=X]/[WWWM^*JFSVRMH=E[+W+NW"0T4H@K9<OMO#5LU93+"[
M!)6FA4(Q :Q/M7)MVX0[=^]Y8)%M* ^.480T/ ^(1HH?(ZNFI+BWBO!M\KJM
MP20(BP$A(R1H)U5 R<8Z$;;NY-N[OPN/W)M//87=&W<O":G%9_;N4H<WA<G3
MB1HC48_*XV26"9-:LNN.0BX(O<'VQ-!-;OX=PC(U%:C J=+*&4T-#1E(93P*
MD$8(Z=#*690<HSHP\U>-BCH?1D=61U.592I ((Z>O;76^O>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[JMFN_F48#)[[[ VOTW\2/F=\D]E=4=BYCJ7L7O#I+K[JFLZJP'8FU:[^
M%[XVSB(^Q-[;=W/N1\#5AZ++5&TMM92GBJ8Y:9)I*B*2-:[&PWR"UOE_Q:TO
MI&2VN)^V.95G>V,ZA-<J6OC1R(+F6..%E0RH[0Z9#?=T.T2SVDGZUU:PI--!
M%5I(_%@CN8HF+!8C<26\L4H@21I565 ZHYT]62*=2JVEEU*#I:P9;B^E@+\C
M\\^[D4)''IF-M:*Y!6H!H>(KY'CD>>3T63OWY'?Z#NQOB9L#^YO]Z/\ 9H^_
M<AT=_%O[P_P3^XWV/26[^X_[T?8?8U?\3U?W5_AWV7FI+?=?<><^#P3.;9'^
M\=\.S5T4L;V]U\?]PVMAX6G']I]1\>KLT? VKM4W$/@;!=[Y6OTLUC%HX:OK
M+N.UU:OP^'XGB4TG7335:Z@*G6FZ>P-U4N\INPNK:GJJIP?8^]-K[3I*K>.V
MMY'?&P<%E/M-H]H0S[99DQT>=IO\K3#UEJRC'[=2 _MBW+2;=:W-P/#N)4=I
MH:ZO 99YHT0R#LD+P)%<%D[4\;PB2\;$M342^GMXCKAC\#PY> E\2UMYIJ(>
MY/ N9)[,ZO[0VQG3]*6/H,,G\BOX;\P]F?$[^Y_F_O=\<>P_D#_?[^\'C_A_
M]PNR=N=>_P!TO[K?8MY?N_[P?>??_P 23Q?;^+[:3R^2-S;5_>(WD_!^Z!M!
M]?%_>IWH?+P_ _=']/Q?J/\ 0_!_53[E/^[WVI*:_P!YON"<:>%]!'825\]?
MB_6TIV:/"K5]=$"[YE?-S)?#+;F[.P,W\0?E1W=U-U]UEF^U>Q.V>CJCXMR[
M3V1M_;45;7;BH,MA^X^S]G;BJ:ZCHJ(UTD>*P57$\4L2PS2U'D@C0_6!9_!F
M1HPTL$$;'25EDN'CBB":69@#+(L9,BH Q)KH!?HZL]JGW#P8K!UEGF:11"-0
MD41JK!V+JL6EP6":9&:L3ZU0&,R"9\<_D/O;ON#,5NZ/B3\D?C/C:+&X+*8'
M)=]Y#XS5M-OBFSB2RE=L1_'[LC?LT;TD<<4E4,O%0BT\0@,S"81'=S8/9K(E
MRZK-%*T3P]QD!6NIJA3$5# KB0MJ_#I[N@]:;A#?1P7-FK207$0E26@":6"%
M 0Q$@9U?4HT4 5@Y5M(8SOM!TNZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[I*[ZRM9@MD[QSF.=(\AAMJ[ARM#))&LL:5F.Q$U72N\3\,
M Z*2IX/T/MBY=HK:21.*JQ'V@$CIZW19+B.-N#,H/V$@=: G_00W_,V_Y^1U
MQ_Z*'9?_ %X]XN_ZZW./^_H_^<2?YNLE?];#E+_?3_\ .5_\_7O^@AO^9M_S
M\CKC_P!%#LO_ *\>_?ZZW./^_H_^<2?YNO?ZV'*7^^G_ .<K_P"?KW_00W_,
MV_Y^1UQ_Z*'9?_7CW[_76YQ_W]'_ ,XD_P W7O\ 6PY2_P!]/_SE?_/U[_H(
M;_F;?\_(ZX_]%#LO_KQ[]_KK<X_[^C_YQ)_FZ]_K8<I?[Z?_ )RO_GZ]_P!!
M#?\ ,V_Y^1UQ_P"BAV7_ ->/?O\ 76YQ_P!_1_\ .)/\W7O];#E+_?3_ /.5
M_P#/U[_H(;_F;?\ /R.N/_10[+_Z\>_?ZZW./^_H_P#G$G^;KW^MARE_OI_^
M<K_Y^O?]!#?\S;_GY'7'_HH=E_\ 7CW[_76YQ_W]'_SB3_-U[_6PY2_WT_\
MSE?_ #]>_P"@AO\ F;?\_(ZX_P#10[+_ .O'OW^NMSC_ +^C_P"<2?YNO?ZV
M'*7^^G_YRO\ Y^O?]!#?\S;_ )^1UQ_Z*'9?_7CW[_76YQ_W]'_SB3_-U[_6
MPY2_WT__ #E?_/U[_H(;_F;?\_(ZX_\ 10[+_P"O'OW^NMSC_OZ/_G$G^;KW
M^MARE_OI_P#G*_\ GZ]_T$-_S-O^?D=<?^BAV7_UX]^_UUN<?]_1_P#.)/\
M-U[_ %L.4O\ ?3_\Y7_S]>_Z"&_YFW_/R.N/_10[+_Z\>_?ZZW./^_H_^<2?
MYNO?ZV'*7^^G_P"<K_Y^O?\ 00W_ #-O^?D=<?\ HH=E_P#7CW[_ %UN<?\
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MU4ETGAZ<_P!G]-777NUTTKIJV?L?Y$?Z/_DK\:/CQ_<_^+_[,3@^]<U_>_\
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M*KG4R%6:,%6*7=)2^R;E!)&Z"-ML*N=!21OWWMVE5HY8 LJZV9 520,JNP9
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M&X4JK+-#HEA0FHJ&%M/-;.26U0BW$?A- 6E>=A?$KI#KO>V+['Q6*W]N??.
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MZJZCJ[JFIKGCTU8LVV>'^[3]/X("Q^%^GH4#2 FFFD!>T!: #'#H(NJ/B?\
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MU[W[KW6V'_PE@_X_[YE_^&?TM_[NMQ^YR]E/]R=P_P!+#_ADZA?WB_W&L/\
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M6S5+1O2%3*3(1K)/M,]E9R6UO9O$C0VB0QP(54I#';QK#;QQ+33&D$*)%"J
M+%&JH@55 #T-Q<6TTUS;NT<EP\TDKJQ5I9+AVEN'D8$%WGD=Y)F8DRN[.Y9F
M)/#ISH3HOX[;7EV/\?NE^INB]E3Y";+S;/Z<ZYV?UEM>;*U$:Q5&3EV_LJCH
M:1JB1417F,.M@J@D@#V82W5U/%'!/(SI$"$5F)5 34A 3103D@4J<](X[>WB
MD>:)%5Y*:F"@%J5IJ(%32II7A4]"S[8Z>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[K__T]_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW46NH:3)T59C:^GBJZ#(4M10UM+,NN&II*N$P5-/*A^JNC,K#
M\@^ZLJNI1Q4$4(^1ZVK,C!U-",@_,=$&_P"&IOY<7_>&O1/_ *!M+_T=["_]
M2.4?^C?#_O'0E_KES5_RGS?[UU[_ (:F_EQ?]X:]$_\ H&TO_1WOW]2.4?\
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M)*.%X(5VMV5V+L:G=)'\C-54FR<KCXIWO^F2='<#@,!Q[V"1U[I+?Z$-F?\
M.Z[>_P#2@^^__LE][U'Y?L'7NO?Z$-F?\[KM[_TH/OO_ .R7W[4?E^P=>Z]_
MH0V9_P [KM[_ -*#[[_^R7W[4?E^P=>Z]_H0V9_SNNWO_2@^^_\ [)??M1^7
M[!U[KW^A#9G_ #NNWO\ TH/OO_[)??M1^7[!U[KW^A#9G_.Z[>_]*#[[_P#L
ME]^U'Y?L'7NO?Z$-F?\ .Z[>_P#2@^^__LE]^U'Y?L'7NO?Z$-F?\[KM[_TH
M/OO_ .R7W[4?E^P=>Z]_H0V9_P [KM[_ -*#[[_^R7W[4?E^P=>Z]_H0V9_S
MNNWO_2@^^_\ [)??M1^7[!U[KW^A#9G_ #NNWO\ TH/OO_[)??M1^7[!U[KW
M^A#9G_.Z[>_]*#[[_P#LE]^U'Y?L'7NO?Z$-F?\ .Z[>_P#2@^^__LE]^U'Y
M?L'7NO?Z$-F?\[KM[_TH/OO_ .R7W[4?E^P=>Z]_H0V9_P [KM[_ -*#[[_^
MR7W[4?E^P=>Z]_H0V9_SNNWO_2@^^_\ [)??M1^7[!U[KW^A#9G_ #NNWO\
MTH/OO_[)??M1^7[!U[KW^A#9G_.Z[>_]*#[[_P#LE]^U'Y?L'7NO?Z$-F?\
M.Z[>_P#2@^^__LE]^U'Y?L'7NO?Z$-F?\[KM[_TH/OO_ .R7W[4?E^P=>Z]_
MH0V9_P [KM[_ -*#[[_^R7W[4?E^P=>Z]_H0V9_SNNWO_2@^^_\ [)??M1^7
M[!U[KW^A#9G_ #NNWO\ TH/OO_[)??M1^7[!U[KW^A#9G_.Z[>_]*#[[_P#L
ME]^U'Y?L'7NO?Z$-F?\ .Z[>_P#2@^^__LE]^U'Y?L'7NO?Z$-F?\[KM[_TH
M/OO_ .R7W[4?E^P=>Z]_H0V9_P [KM[_ -*#[[_^R7W[4?E^P=>Z]_H0V9_S
MNNWO_2@^^_\ [)??M1^7[!U[KW^A#9G_ #NNWO\ TH/OO_[)??M1^7[!U[KW
M^A#9G_.Z[>_]*#[[_P#LE]^U'Y?L'7NO?Z$-F?\ .Z[>_P#2@^^__LE]^U'Y
M?L'7NO?Z$-F?\[KM[_TH/OO_ .R7W[4?E^P=>Z]_H0V9_P [KM[_ -*#[[_^
MR7W[4?E^P=>Z]_H0V9_SNNWO_2@^^_\ [)??M1^7[!U[KW^A#9G_ #NNWO\
MTH/OO_[)??M1^7[!U[KW^A#9G_.Z[>_]*#[[_P#LE]^U'Y?L'7NO?Z$-F?\
M.Z[>_P#2@^^__LE]^U'Y?L'7NO?Z$-F?\[KM[_TH/OO_ .R7W[4?E^P=>Z]_
MH0V9_P [KM[_ -*#[[_^R7W[4?E^P=>Z]_H0V9_SNNWO_2@^^_\ [)??M1^7
M[!U[KW^A#9G_ #NNWO\ TH/OO_[)??M1^7[!U[KW^A#9G_.Z[>_]*#[[_P#L
ME]^U'Y?L'7NO?Z$-F?\ .Z[>_P#2@^^__LE]^U'Y?L'7NO?Z$-F?\[KM[_TH
M/OO_ .R7W[4?E^P=>Z]_H0V9_P [KM[_ -*#[[_^R7W[4?E^P=>Z]_H0V9_S
MNNWO_2@^^_\ [)??M1^7[!U[KW^A#9G_ #NNWO\ TH/OO_[)??M1^7[!U[KW
M^A#9G_.Z[>_]*#[[_P#LE]^U'Y?L'7NO?Z$-F?\ .Z[>_P#2@^^__LE]^U'Y
M?L'7NO?Z$-F?\[KM[_TH/OO_ .R7W[4?E^P=>Z]_H0V9_P [KM[_ -*#[[_^
MR7W[4?E^P=>Z]_H0V9_SNNWO_2@^^_\ [)??M1^7[!U[KW^A#9G_ #NNWO\
MTH/OO_[)??M1^7[!U[KW^A#9G_.Z[>_]*#[[_P#LE]^U'Y?L'7NO?Z$-F?\
M.Z[>_P#2@^^__LE]^U'Y?L'7NO?Z$-F?\[KM[_TH/OO_ .R7W[4?E^P=>Z]_
MH0V9_P [KM[_ -*#[[_^R7W[4?E^P=>Z]_H0V9_SNNWO_2@^^_\ [)??M1^7
M[!U[KW^A#9G_ #NNWO\ TH/OO_[)??M1^7[!U[KW^A#9G_.Z[>_]*#[[_P#L
ME]^U'Y?L'7NO?Z$-F?\ .Z[>_P#2@^^__LE]^U'Y?L'7NO?Z$-F?\[KM[_TH
M/OO_ .R7W[4?E^P=>Z]_H0V9_P [KM[_ -*#[[_^R7W[4?E^P=>Z]_H0V9_S
MNNWO_2@^^_\ [)??M1^7[!U[KW^A#9G_ #NNWO\ TH/OO_[)??M1^7[!U[KW
M^A#9G_.Z[>_]*#[[_P#LE]^U'Y?L'7NO?Z$-F?\ .Z[>_P#2@^^__LE]^U'Y
M?L'7NO?Z$-F?\[KM[_TH/OO_ .R7W[4?E^P=>Z]_H0V9_P [KM[_ -*#[[_^
MR7W[4?E^P=>Z]_H0V9_SNNWO_2@^^_\ [)??M1^7[!U[KW^A#9G_ #NNWO\
MTH/OO_[)??M1^7[!U[KW^A#9G_.Z[>_]*#[[_P#LE]^U'Y?L'7NO?Z$-F?\
M.Z[>_P#2@^^__LE]^U'Y?L'7NO?Z$-F?\[KM[_TH/OO_ .R7W[4?E^P=>Z]_
MH0V9_P [KM[_ -*#[[_^R7W[4?E^P=>Z]_H0V9_SNNWO_2@^^_\ [)??M1^7
M[!U[KW^A#9G_ #NNWO\ TH/OO_[)??M1^7[!U[KW^A#9G_.Z[>_]*#[[_P#L
ME]^U'Y?L'7NO?Z$-F?\ .Z[>_P#2@^^__LE]^U'Y?L'7NO?Z$-F?\[KM[_TH
M/OO_ .R7W[4?E^P=>Z]_H0V9_P [KM[_ -*#[[_^R7W[4?E^P=>Z]_H0V9_S
MNNWO_2@^^_\ [)??M1^7[!U[KW^A#9G_ #NNWO\ TH/OO_[)??M1^7[!U[KW
M^A#9G_.Z[>_]*#[[_P#LE]^U'Y?L'7NO?Z$-F?\ .Z[>_P#2@^^__LE]^U'Y
M?L'7NO?Z$-F?\[KM[_TH/OO_ .R7W[4?E^P=>Z]_H0V9_P [KM[_ -*#[[_^
MR7W[4?E^P=>Z]_H0V9_SNNWO_2@^^_\ [)??M1^7[!U[KW^A#9G_ #NNWO\
MTH/OO_[)??M1^7[!U[KW^A#9G_.Z[>_]*#[[_P#LE]^U'Y?L'7NO?Z$-F?\
M.Z[>_P#2@^^__LE]^U'Y?L'7NO?Z$-F?\[KM[_TH/OO_ .R7W[4?E^P=>Z]_
MH0V9_P [KM[_ -*#[[_^R7W[4?E^P=>Z]_H0V9_SNNWO_2@^^_\ [)??M1^7
M[!U[KW^A#9G_ #NNWO\ TH/OO_[)??M1^7[!U[KW^A#9G_.Z[>_]*#[[_P#L
ME]^U'Y?L'7NO?Z$-F?\ .Z[>_P#2@^^__LE]^U'Y?L'7NO?Z$-F?\[KM[_TH
M/OO_ .R7W[4?E^P=>Z]_H0V9_P [KM[_ -*#[[_^R7W[4?E^P=>Z]_H0V9_S
MNNWO_2@^^_\ [)??M1^7[!U[KW^A#9G_ #NNWO\ TH/OO_[)??M1^7[!U[KW
M^A#9G_.Z[>_]*#[[_P#LE]^U'Y?L'7NO?Z$-F?\ .Z[>_P#2@^^__LE]^U'Y
M?L'7NO?Z$-F?\[KM[_TH/OO_ .R7W[4?E^P=>Z]_H0V9_P [KM[_ -*#[[_^
MR7W[4?E^P=>Z]_H0V9_SNNWO_2@^^_\ [)??M1^7[!U[KW^A#9G_ #NNWO\
MTH/OO_[)??M1^7[!U[KW^A#9G_.Z[>_]*#[[_P#LE]^U'Y?L'7NO?Z$-F?\
M.Z[>_P#2@^^__LE]^U'Y?L'7NO?Z$-F?\[KM[_TH/OO_ .R7W[4?E^P=>Z]_
MH0V9_P [KM[_ -*#[[_^R7W[4?E^P=>Z]_H0V9_SNNWO_2@^^_\ [)??M1^7
M[!U[KW^A#9G_ #NNWO\ TH/OO_[)??M1^7[!U[KW^A#9G_.Z[>_]*#[[_P#L
ME]^U'Y?L'7NO?Z$-F?\ .Z[>_P#2@^^__LE]^U'Y?L'7NO?Z$-F?\[KM[_TH
M/OO_ .R7W[4?E^P=>Z]_H0V9_P [KM[_ -*#[[_^R7W[4?E^P=>Z]_H0V9_S
MNNWO_2@^^_\ [)??M1^7[!U[KW^A#9G_ #NNWO\ TH/OO_[)??M1^7[!U[KW
M^A#9G_.Z[>_]*#[[_P#LE]^U'Y?L'7NO?Z$-F?\ .Z[>_P#2@^^__LE]^U'Y
M?L'7NO?Z$-F?\[KM[_TH/OO_ .R7W[4?E^P=>Z]_H0V9_P [KM[_ -*#[[_^
MR7W[4?E^P=>Z]_H0V9_SNNWO_2@^^_\ [)??M1^7[!U[KW^A#9G_ #NNWO\
MTH/OO_[)??M1^7[!U[KW^A#9G_.Z[>_]*#[[_P#LE]^U'Y?L'7NO?Z$-F?\
M.Z[>_P#2@^^__LE]^U'Y?L'7NO?Z$-F?\[KM[_TH/OO_ .R7W[4?E^P=>Z]_
MH0V9_P [KM[_ -*#[[_^R7W[4?E^P=>Z]_H0V9_SNNWO_2@^^_\ [)??M1^7
M[!U[KW^A#9G_ #NNWO\ TH/OO_[)??M1^7[!U[KW^A#9G_.Z[>_]*#[[_P#L
ME]^U'Y?L'7NO?Z$-F?\ .Z[>_P#2@^^__LE]^U'Y?L'7NO?Z$-F?\[KM[_TH
M/OO_ .R7W[4?E^P=>Z]_H0V9_P [KM[_ -*#[[_^R7W[4?E^P=>Z]_H0V9_S
MNNWO_2@^^_\ [)??M1^7[!U[KW^A#9G_ #NNWO\ TH/OO_[)??M1^7[!U[KW
M^A#9G_.Z[>_]*#[[_P#LE]^U'Y?L'7NO?Z$-F?\ .Z[>_P#2@^^__LE]^U'Y
M?L'7NO?Z$-F?\[KM[_TH/OO_ .R7W[4?E^P=>Z]_H0V9_P [KM[_ -*#[[_^
MR7W[4?E^P=>Z]_H0V9_SNNWO_2@^^_\ [)??M1^7[!U[KW^A#9G_ #NNWO\
MTH/OO_[)??M1^7[!U[KW^A#9G_.Z[>_]*#[[_P#LE]^U'Y?L'7NO?Z$-F?\
M.Z[>_P#2@^^__LE]^U'Y?L'7NO?Z$-F?\[KM[_TH/OO_ .R7W[4?E^P=>Z]_
MH0V9_P [KM[_ -*#[[_^R7W[4?E^P=>Z]_H0V9_SNNWO_2@^^_\ [)??M1^7
M[!U[KW^A#9G_ #NNWO\ TH/OO_[)??M1^7[!U[KW^A#9G_.Z[>_]*#[[_P#L
ME]^U'Y?L'7NO?Z$-F?\ .Z[>_P#2@^^__LE]^U'Y?L'7NO?Z$-F?\[KM[_TH
M/OO_ .R7W[4?E^P=>Z]_H0V9_P [KM[_ -*#[[_^R7W[4?E^P=>Z]_H0V9_S
MNNWO_2@^^_\ [)??M1^7[!U[KW^A#9G_ #NNWO\ TH/OO_[)??M1^7[!U[KW
M^A#9G_.Z[>_]*#[[_P#LE]^U'Y?L'7NO?Z$-F?\ .Z[>_P#2@^^__LE]^U'Y
M?L'7NO?Z$-F?\[KM[_TH/OO_ .R7W[4?E^P=>Z]_H0V9_P [KM[_ -*#[[_^
MR7W[4?E^P=>Z]_H0V9_SNNWO_2@^^_\ [)??M1^7[!U[KW^A#9G_ #NNWO\
MTH/OO_[)??M1^7[!U[KW^A#9G_.Z[>_]*#[[_P#LE]^U'Y?L'7NO?Z$-F?\
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M2_WFBJY]M_Z3.RMF;#_O!#0>+[Z;"?WIK:3[M8?/#Y6@UA/(FJVM;UM-OO\
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MBE=62.2955F! )(/M^[V3>=O@^JO[2:"+4%UR1.BZF#$+J90-1"L0*U(5B,
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M"SN0K.0JBI8A%9R "0JLQP">GRI$4DY'Z<0#.WX44LJ!G/!07=$!- 695XL
M4YO3OCH[K?:&W^P>Q.YNJ=A;"W9_#QM;>^].Q-H;6VAN4Y?'-F,4-O[ESE9!
M15GW5(K55/\ ;3/Y(094U("WM0FW;A)N#;3'!(UVFO5"$8RKX;!9-4=-8\-F
M57J.UF :A(Z9BN()[ ;I ZO;$(PF4@Q%9!6,B0'00XRAK1AE:])#8ORX^*/:
M.Y\?LGK/Y.?'KL7>>66K;%;1V+W1UON[<^36@I'KZYL?@-OY*HJYA#!%)/*8
MXCHC1G:RJ2%DW+V_VT#W5Q8W$<48!=VAD55!(4%F*@*"S*H)(%2!Q(Z2_O3;
M Z1FYBU2,%4>(E68UHJBM2QH: 9P>F3.?-WX7;9S.5VYN3Y>?%_;^X<#D:W#
MYS YSOWJG$YG#9;'5#4F0Q>5Q=?EHYZ>I@E1XIH)D5T=2K*""/=+78M[OK:.
M\LK.>:&50Z2)%(Z.K"JLK*I5E8$$,"01D'I3<W-O9SM:WDBQ2H:,CL%93Z%6
M((/R(Z'79&_-C=F;8QF]NM]Y[4[ V9FEJ7PV[MD;BQ&Z]L99:.KDH*ML9G\#
M-44DXBGBEAD,4K:9$9&LRD!'>V5YMLYMMQA>WD #%)%9&"LH9258 @,I# TH
M5((P>JVUW:WB&2SE2558J2C!@&7!4E20&'F.(\^@I'RS^*S;O/7R_)CX_-OY
M:UL8VQQW-UR=WKD4D\38\[:&2^]$X;TF+P:K\6O[4P;-O%U:B^M;2:2$BHD6
M)V0CU#A2I'SKUNYNK6RE,%Y(L,@-"KL%8$\ 0Q!J>H>\OF)\1NNMS9;9?8/R
MF^.6Q-XX&:*GSFT]Y=W]9[8W-AJB>F2M@@RV!S>3@JJ=WAECE19HE)1U8#2P
M)]9[-O&XVXN]OM)IXB6 >.)W0E&*. RJ02CJR,*U5E*FA!'6[FXM[.7P;N18
MGTHVEV"MI=0Z-1B#I=&5T/!E8,*@@]3-A_+/XK=IY]-I]8_)CX_=C;IDHJ[)
M)MK8?<W7.[\^^.QD!JLED$PVW\E45!@IX@9)Y1'IC4:G('/O=YLF\[=:2;AN
M%I-!!"-4DDD3I&BU U.[*%45(%6(%2!Q/3<5]97%Q%9P3(\LS:(T5U+R/0MI
M102S-I5FTJ":*32@/2YZT[DZA[HQF1S?3O:O6_;&&P^1.'RV7ZTWSMC?>,Q>
M76G2K.+R-?M>JJHH*D121R&"5U?0RMIL02U>[7N>W+&^X6TL E!*&2-T#@8)
M74!J )%2*TKU=+FVEF>VCD5I(J:U# LE2P&I0:K4JP%0*E6'D>DQV)\F?C?U
M!F(=O=L_(+I#J_/U$4<]/@^Q.U]A[)S$\,HO%-#C-RU]-,RM_994(/X]ZL=M
MW'<]7[M@DN-!HWA(TFD^C: :'Y'IRXECM$66[81*]=)<A0U.-": T\Z="OM_
M<6W]VX7&[DVKG</N;;N9I8ZW$9_;^3HLSA<K12\Q5>-RF.>2">)O[,D4C*?P
M?;%Q;W%I,UO=1M%(N&5U*L#Z%2 1^8ZK#/#<1B6W=9%/ J0P/YBHZ1FP>Z.G
M>UJ[=&+ZN[8ZT[)R>R*^/%[TQVP=][6WC7;0R<LT]/%CMT4FW:JIDQ\[24U3
M&L-6L;EHI% NC .RV%_!:0[A/!(D%R*Q2,C".4:5:L;D:7&ET:JDC2RG@PKH
MW-NM[)MID47$5=<6H>(E&*G6E=2T8%34"C CB.O)W1T])V5)TQ'VQUI)W##0
M?Q6;JA-][7;LJ+%_9+DOXE)L5:K^*+3_ &S+4>8TNCQD/?20?>H;*]N;*3<K
M>%Y+>(E7E5&:-&#!2K. 54AF52"0=3 <2.MSS0VTL,%RZQR7 )B5B%:0#74Q
M@T+@>')737^S?^%J,78_R1^._3N6HL#VYWWTOU9G,E E3CL+V/VEL?8^6KZ:
M1S''446.W-74LTJ,P*AT0@D6!O[M8[=N&Z%UVR"2X,9 <1(TFDD @-H!TD@@
MBM,$'AU:XDCM(UFNV$2/72SD*&I@Z2: T.#3AY]"E@\]@]SXF@S^VLSB=PX+
M*TZU6,S6#R-'EL3D:5^$J:#)4#R0S1FQL\;D'^OMB>">VE,%RC1NO%6!5A]H
M-".JPS0W$8E@=74\"I!!^PBHZ"OLWY*?'3I7*T&![D[]Z5ZESF5Q_P#%L7AN
MS>U-B[#RN2Q?W#TG\2H,=NFOI)IJ?RQR1>:-"FM66]P0'[';[_=#(NV027!B
M(#^$C2:"PJH?0#I)&0#2HR,=6GDCM8TFN6$:.6"LQ"ABNDL%)H"5#+J R-2U
MXCI]ZU[KZ;[GHJW)=/=M=9=KX[&21PY*OZUWYM7?5%CYI@3#%6U6UZNJ2)F"
ML561@38V^GN]YM>Y[=3]X6TL&KAXD;I7[-0%?RZ8AO;.Y<QV\R2,!4A65B!6
ME2 2:5Q]O7+='<_3VR-X[4Z[WIVQUIM#L#?DD,6QMB[HWWM? ;QWG+45G\/@
MBVIMC+54-;D6>H_81:."0F3T"[<>V[2POK\2FQADF$"ZY?#1G\-*.VN32#H6
MD;G4U!1'-:*:.7-Q;V4<<UXZQ)*XC1G8*'D)11&A8@,Y:2-0HJU9$%*LM>NR
M^ZNF^EZ"ARO<7;76?4^,RD\E-C,EV7OS:VQ*#(U,0#2T]#6;IJZ6.9U#*62-
MB1<7'/MNTMKF_N/I+&-II::M$:EWT\-6E032N*TIT](1%";B7MC4T+'"@G@"
MQP"?2O7'&=V=,YK8.3[6PW;G6.6ZNPM%69+,]DXS?NU:_8.)QV/C\U?7Y/>-
M+5OCH(8$]<TLM2JH.6('MRZL+ZRG2UO89(99&5%1T9&9G8(BJK $L[,JJ *L
MS  $D#IJUGAO@QLG68(K.V@A]*HK.[-IK14169B<*JLQ( )Z!^G^>/P<JYX*
M6E^9OQ1J:JIFBIZ:FI_D3U#-/43S.(X8((8\P6=W8A550220 +^S-.5>9Y&"
M)MMTS,0 !;RDDG@ -&2?(=(YMXVFWB:>>ZA1$!9F:1 JJ!4LQ+   "I)P!D]
M&(WCO79O76VLMO3L'=NV=B[.P,"5.<W9O'/8K;&VL-32SI2Q5&6SN;E@I:=&
MEDCC5YI5!9E4&Y ]D2*TDJ01C4\K!$499W/!5 RS'R45)\AT9JC,&*@G2K,:
M>2HI9F/HJJ"S$X"@DT Z:.N>U.L.X=O-NWJ3L?87:6U%KZG%-N?KG>&WM[[>
M7*4:))68ULUMFHJJ85$2RQM)#Y=:AU+ !A=7>[=N&VNL6XP26[.NI1(C(66I
M74 P!*ZE9:C%5(X@])+>\L[S7])*DOAMI?0RMI;2KZ6TDZ6TLK4-#I93P(Z9
M.S>^NC.E!CF[D[GZGZE7+^0XENS>Q=G[#&4$1TRG''=592>?2>&\6JWY]TLK
M*\W&8VVWQ//(H!*QJSL :T)502 :&A(S0]*)66"'ZF<Z(R=.IL+JXTU'%:$&
ME:YZE/W9TU%UW4]O2=M]8Q]344$=56=H/OW:J==TE++41TD534[U:K_AL<;2
MRQ1*[5(!=U4&[ '<]E>VUVEA<PO'/*P5(V1ED=C6BJA 9F-#0 $FA]#U2VFA
MO$:6T<2J@9F*$,%" LY)6H 102Q.% )- #T%6(^<7PJW!E<9@L#\P/BYF\YF
MLA1XG#8;$?(#J?)97+97(U"T>/QF,QU'EGFGJ)Y72*&&)&=W8*H+$#V9KRMS
M,QHNW71XG%O+P J?P>0R?ETC?=MKB0R27,2JHJ29$  '$DDT 'KT)_9O>O2/
M2L..J.Y.X^J^I:?+M*F)G[-["VCL.'*/!;S)CI=U5E(LY2XU"(M:XO\ 7V56
M=G=[C.;7;XGGE4!BD:L[!22 Q502 2" :4)!].E\I$$'U4_9%73K;"ZJ5TZC
MBM,TK6G2JV9OK9'8V!I=U=>[QVKOO;%<6%%N39FX<1NC UA2Q<4N8PDT]/):
MXOHD-KCWNZL[NQE\"]B>%^.EU9&I]C 'IF"YMKI==M(LBC%58,*^E03TJO:;
MI_KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M_]/?X]^Z]U[W[KW7O?NO=:X/\S_'0_.+^8Q\-OY=J3U<W7^U*3,]W]YKCI70
MPT<^+GJ**BJYX2&@E3%T,D$+@@@Y:,CDK[D+V[M9+7:^9>=PPC>RLWLK1F&K
M1<S(A,@4?&OU$UA4,:#Z>44R0Q3SA?&SVW9]@B&N3=;V*>1.[NMK=G2@(H$)
MB7<22Q)!CA8 8$@K_P B7L+/;:ZV^0_P@W_6,V_/AUW9NC;5'3U+.L\NR-QY
MNL:FEIHI"28DR])E)04]*QU$ X!%S3W!EBYEV+9/<.S32NXVR1S 4.B5%5T5
MV%.X1OX #"O^+-QH0";:[,<L\W;ORB"3")/J;9B!WQ/168%>VC+]/<'"DM=$
MYR% K^1?_P!E?_S:_P#Q.>)_]^?V%[<W_P#Z<GR7_P T$_[0+#I[?/\ I]^\
M_P#-3=?^T^'K/F@&_P"%*FU5/(/0=2"/Z@]&9('VEY7BCG]H>:X)15'N(U8>
MH)V@$8SD>G37.Y(YNY-(\EF_ZM[YT4;^>%\$/B?\:<?\8]P=(=1T>Q<OVKW5
MG<3O^M@W7OS-MN''R04=:]/+%N;*5L<%Y:B9]5*D3>JU[  'WM!S#O&Z\Y6O
M+NX3F2R6V:D950!X<]G$G<JA\)(Z_%FM34@$->Y<,=MR'O/-<(T[@)-8F\]4
MEO?3.=)[.Z2-&IIH--  "0;0/FKT_P!'_P JGX%_*7L_X5]<+TYOKL7&;!V)
M7;AQ&[-[YVNII<ONC^[&.S=)+O#)Y TU3CZ?,9*2DEI?&RS.CMJ,::8_7>-Z
MY[WS9N5>8+@S6DUVY92JKVK;R7$JU15-)EM4A<$D:&:E":]"W;=IVO9UON:;
M>$"?;[1V0Y;NFFMX(^UB4(2>2&8AE(*Q%:$,5("_R]OY,OPH[9^%G5?:'>^Q
M<WV?VQWELU>P\WONIW]OS!U^WVW@CUV*H=OT&!R--1:Z*%XY)*BNI:F2>I,K
MRL\)2%!U[C<W;[LG,,O+O+\PLH;)(HUT1QM5O"1V-'1ETJS%$0*JB-5J-19B
M"^4;*+=+5][WG_&Y)YY^UR]-,<SQ4+*RR,TF@R.Y?5J<A2H Z2/\E?>.^.J>
MT?YA'P%S&Z<IO#K[X]YS>E5US692=YFPJX7=N2V3N*GHHW-H8<EIHJYJ:%%B
M2H6HD50T[EB#W0NH>;O9:QY_GC$5Y<6@632,,MQ9R2A:DEJ0O$XCU%CHDTDT
M11T?<NV*\L^[Z\N63L]I<>'<H&I50);1HV-* 2O#=HLY *LT2E:4.H,/Y,/_
M &ZY_F0?]1O=/_O@H?9S[]?\D;8/R_[2[?ISV^_Z>I??\]%I_P!I-WT7#^1)
MN:L^/'R=Z0H,C7R#8_SHZ/[&Q],U06BHH.T.H.RLW'CL>LD@13)'C<6RH%UW
M?)HH(8Z0//<"+]\[-O6RZ3XNU?0W\ &6>WFMT29J<:>,UX6( (2S!(*@/U'F
MW$V&X[;OZD^#-/<[=+BH5REO.K4XT+RV4:L":-+*&0* X+G_ #?-SU_R3^07
MR;^14,U14=?])=U=9?$'KRICE_W'5E9A-M;BSV^VA)!$ABR=!/-=2!HK(CSQ
M[*?8U!M"[$'%)N89[K<.%/T+=["&W/J/$MY[5\U.H2U K0#SG@-=WMYMV3%L
M-C;Q.*TI>7EP926' M&$O+:115@886=ETJAM$_GV]:-W+W%_+=ZFBJ6HZOL9
M^Q=F8RI4,WBS.X)-LXW"EU17)0U<D(<!?TD\CZ@">WEW)MV^\W;I$OB-9[<M
MR$'%S;_O2?0/F_AZ0?*M:'ATA$D$?M3RL+QA';R7VWQSN?P6\J645Q(,$U2%
MY'6@8U445OA*_P"K?GE6[6_D*[BWI6Y":F[;ZQVQGOB!%32DME:+?GW:[(V@
M3$[&3[BDV_7460?78ZH)."!RJ]P^6UYA]QMML[ >+!S(UM/5.$D=':]R,?XP
M+6X"E*YGC(TD]JKV[NI.6[;<X=Q"Q2\MR7#:3C2VH/9@J#F-+J>.V.@Z"L,E
M&0*V@N7\B#J.NZ(_F%?)[J;+15$&<V?\9MGTNXZ:I8-+2;HR-=M#-;GH^ ++
M#D*FIB1;7"J 22+D7>X&Z1[O[>RW<)#1IO$D",I!#I;2;I;(X(J#K2(/@D=V
M,= G9;=K?GG;784-QLSW.D\5^J79[G0?*J>+I-,5!H2.C(?R#/\ F>G\T#_Q
M.N#_ />PWK["?-'_ $Z/D[_GG_[4MOZ$]S_T^;F#[9_^TZ;K+A_^XE+<G_B!
M1_[Y:B]H^2_^G+[]_P ]DG_:=:=+>=O^5KY2_P":4O\ QS>.JE_DMUOVV?GO
M_,6^5O1&8JZ/LSX6=[;1[A3&4L4DAK-F5&7J:'=669([&6.@>&B>NI6<)+CY
M*W6&"V]C+D'>+39>0MG.YH)++<+V^L)ZXHUS<W?@*30T2?1- 6%6262%AIH3
MTQSGM#<P\UW>T6[LEPFVVUW"4^(M:VNWEM!_#)&DAN(V-:M!X85FD6EA_P#,
M-^2^S/E[AOY,G?VQF6+';W^25#)F,,9DFJ=K;LH-V;4H=T[6KF0G]RBK8YHD
M9@/+%XYE&B1?:+V^Y<FY6]W]TVF0EXQMNN&2E/$A>20H_ #53MD J%E5TJ=/
M1=ON\G>_9V]N9@$G2YACG05 69+2]UZ=7=X;5$D1.6B=&(!) 2?\_3*]6X+Y
MX?!O,]W[3SF^^H,9L[[WLG9FV?)_>#<^SH.QY),YA<-XJ_%M]Q40!HXM.1IC
MJ(_>3]0*/9X2-<<P) 0LK6EN(V/!)2NXB)VX]J2%6;#8![6X$[Y^6=N7MG^G
M8+2_F+U_%$K;8TZ#![I(1(B\.YAW+\0L7_E![S_ER]A9_O/+?!;XT=M]!9G;
M^'V)CNQ*WM&3(Z=R8S/5N4J=OTN$BJ=Y;J0FFEH*EZAM%.P\D8#2 D(USS:\
MZV.QP#F&_ANK:XG;2D="PE@CPS?HQD#1<,%HQ!):JX4]%VTW.P2;XD-E;21W
M'@2D.WP^'XD =?[0]S,8B.W@I[AP85?YX0Q4_P#+B[MQ^2[1Q/5\U?/M(XHY
M:MJJ1-_Y'%;C@SO^C2BAQZ2U%1492&EF\,,4;+JBUU!CI$GE2/\ E<L.=MF:
M. W3)<ES$!5M!AEB,U#VA;9IDF9G( T *?%:,$?Q*'VG<XVD$ >T<>.>$7?&
MU"0-5+@*;0A.YA<$ ."T;Z_W\K[9VP?D7\LNA.[NE>M]C_%/8/P@ZHQ>XODC
MN ]IU^>WEW!FZ+;-329[=,.SZQ_NX*&OE:=*V5(/M8J5Y4FJ7G>EI/>0'-VX
MR\I[-OV[[Y<O<VNY>+%:VRQ$I:JR.:/( U3&"KH" TCVZ"&,N)YEAO:K*3F"
M;8^4MOB!W&&6*::Y9EC^H"SP:=*M1:L4HX0Z(_J6UF*+P1)MT_&SY5]#?+S9
M&2[(^/&]ZC?^R<1N.KVE79Z39^^MG0+N"AH*;)UE!34V_,9BYZ@1PU=.SS4\
M3Q OHUZU95@7>^7-YY<>&+>81"TZ&1!KC<E [)J(C=M(U(P&JA.DTJ.I&L-W
MV[<Y98;&3Q&@*B2BL I8:@I) !;31BH)(5D8@!U)HI_G-_\ ;Q/^4-_XFK#_
M /OZ]F>Q][*?\E3FC_I5Q_\ 5C>.BCW9_P"G:VG_ #6W7_M&VWHKW\Y#XZ[@
M^5'\TS8O3>S<BV/WUEOA_7[DV)&-2KF-V[$_O=O3$[=:9%)B.0-"U)%/=1')
M(CLVE2"W[6[S)RWRCS+S+&C2"PO[>5POQ^&8MKBE9*$$O'%(\J*,NR!!EJ@T
MYVAM[Z;E;9KQE2'</K+=G>FA&<71@+UJ!$;E8$F.EM,+R,!4 B=WS\UZCYB?
MR*^S*/?%5.O?/1F^.ENL>YL=D08<Q5Y#&=A4%/M_>=;2R6D4Y6F@<53.JD5T
M%:@4*BW--VY>MMM]U>7=^VG2=OW2>YFB*4\-9/W;>-+&E"1H[UDBIV^%*B@D
MJU"KE>\N8>4^9>5MT#+=[=:Q)1\.T(W2P5"1QU1%6@DU58M%XC4\5>EY_.>M
M_P -$_ &_P!/+\>[_P"M_LNU;?Z>V]B\+_@A[_QO@KN^KC\/U]I7AGAZ9ZKR
MO7_6*@I_RB[/_P!63T:S^7-2_P DC<'=G7TOPZH<?/\ */;FR,GG89H*#Y2T
M$U%'_=P83>]4)>RTBP#WCK98BA+$Z]4"W4,MN;U]QX[;='G)_=.HANZW(\ W
M,8AP#XOQF'@-8_%C5T4;,G+LT&UP[B =PI&1_:5^I2!GD-5_3P%E/'0:4%:J
M#0UMGL#X%;#^<7SXF^=/Q[[4[]Q&2[V[ BZ[H^K_ +L5&VLE3=F9QMPU.7-+
MNS:IT5,3TJPWDJ.8V],?U8^Y7@WFY]H^7(N7;A+6Y%K:EGD-%:+Z9!I'9)W:
MZ'X1C\7ET=<[M#'[E;C)>J9+>K@HOQ>(?!*-Q7"J) >[BPP>(M=_F)_)+9O4
MO\H_XY[9^#FU=Y=']4_)S=%5M/;^!S5?54N]-L;!JZG*[BW9M^LKJC+9B:&?
M*Y&T<Y7+3#[66:+6J/I4*;9RWN?,OO#;;%S?/'=O% L[D"L<C(EG':HP"(&C
MB6Y5V!3,D*99=6IS;=TVK8^0]PYGV.-[6MP\*DUUQR,]R+BX'=)0E+.1(].0
M)A*GAR(HZ.UUU_(4_E[8WI_9FU=[=89K=/8=)@L)-NCM*/L3?V-SN8W*L,=3
MEZVFQ%)D5PT-+)+Y(H:3^%E%ATAM<P,Q2[M[G\R+S$]YL\PAMH9JQ1-'&RM&
MC=HEUJQ)< &0JRFI(0HM "[8.7[6ZY=B?<U+SW4 9V#%3&\J TBT-0>$32,G
M772"Y>IJ /\ .Z^"'Q.VQ\3N_/E3@>G\=B^^VR/5Z#?M-N7>X:..3=.&V48H
M=M/DSAXT&+1:143'@*H#* _J]D_)G-7,$',^T[''<M]+=WERTR$*Q=IH;V[D
M)=E+U>X_5)# UP*+V]#%]EVN\VR^N;F(,]GMZ+":L-"VRV]M   0#X<**@U
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M.6,@,0$4E:"/Q$K58D4DE">K['#L+O/N>R@ S:$D%7JOAJ2J%'.J,CQ&DTD
MGQ-0["E#Y^P=T(.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[K__4W^/?NO=>]^Z]UCFE6"&69UD988WE988I)YF6-2Y6*"$,
M[L0/2B*23P 3[:GE$$+S%6;0I:B@LQH*T51DL>  R3CJ\:&618E(!8@ DA1D
MTRQ( 'J20 ,DTZU+^@_Y8N6_F9?)GYG_ "0^<>RODKT;A,OV/C8>G<+78&NZ
MHW%FMO?Y90T+-2]F8&JDGHL=AJ/#4J-30*OE>0%[J5]S5:[_  \@^W^T;;LT
MUO<7\IEDN@KI*D<CZ9YJB)J]]Q<2",DT"1$#5Q4*[W%-S#SQ>1O'(NW6D210
MR$,HD"$PQ&(E=/<L,D\Z@"DEPC"I9B15^/OPHWU_+(_FP]=XGH3K[Y ]C_$_
MNWJD;-WKV%4;4R^^L9LW*YRJGDA7>V[MGX>EQ5"M'F<5C:GRU20F&CJG=F*:
MF-[7FZ/GCDO>MLYDD@M;JVE66UJ?"$O@PQR@IK<EW97N[<*E07,8*@D-T7;W
ML";'N.R[YL@>>K-#<J*O(HEE,3@A%JL 5[6YU."K-;RU*^'J5KQNSOFM_*?^
M:ORM[/ZM^'V__F%\?_E1N2;=V-?JF;-5^X\'D)MQ9#=5#3Y:GVQB<]74DV/E
MR^1HIEJL6L%3&T4T-2&5X@7;#N&R<S>WNW\D;S=+8WFT!5CDD%(WCCC$ 8,6
M"'QHDA+H9!)')&0%:,AW.>9K2Z'.,G.]@@F2[63Q8P?U%FN#%+/VU+!?'C9X
MRJO&8G52R2!E09O@;\?_ )9?(S^8MOK^9E\F^ELK\:=NP[-J=G]6]4;JJ*O^
M^,CU.V8]DP+68[)0TE=%3TF/%7-555?CZ,U%54(::G\2N8[7EQR_R?R%<\G[
M=>C<KO<)?$FE2FA1XT<U:@NO:L,,$:"1FT(S.5[0Y7=G<>9^9MLW*2T:UM=I
M1@A<G6[-'<H5H0I)9KN:0L$5$41QCQ&U.%'_ #\.F.X>XMN?#R#J+J?LOM.?
M;'=>7RNY(>N-B;HWQ+M[%RT&/2/)9R/;-+5&DIV*.%FJ B$J0#P?:#V>O[';
M/<."]W*:.WA%O(IDE=8T#&YLF +N0H)5&8"M:*QX T5>Y%O<7WM;N^WV2--<
M2LFB)%+R/2TW!>U%!9NYT7 /<ZCBPK:?\[OB_3_,CXI]N?'PY*EPN7WGA*6H
MVIFJ]97H,3O+;F4@W'M>KR IU:3[8UE+%#5&-&<0O(45F 'N.K.]N=IW6RWV
MS77+8S"4)4+XBE'BECJ< O!+*J$T"N59CI!'0UM9(?#GLKNO@7<3PR4&J@:C
M(^DD:C#,L4RK5=31@:EK446?';YB?S/?@QTG@_B3O7^6+W'WCN;JFCK=I=>=
MI;%_O?EMD5.WQ.[;:BS.0V5M[.X^MAHO($2:#+TC/3+'#+'3S1R3-,7,5CRK
MS_=GF*PW>/;YIT194N% 8/&BQZ@DDD1U:5&NC.C2 NKE6"B/]JAW+E'7MUW
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M=#0B&0@C!!"-0@]&&TJK[K;*PJ#+&"#P(UC!ZTB_]-G<W_/V^SO_ $/=U?\
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M_J?RE_T:[/\ [)H?^@.O?Z;.YO\ G[?9W_H>[J_^J_?OZY\X?]':\_[*I_\
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M_IL[F_Y^WV=_Z'NZO_JOW[^N?.'_ $=KS_LJG_Z#Z]_4_E+_ *-=G_V30_\
M0'7O]-G<W_/V^SO_ $/=U?\ U7[]_7/G#_H[7G_95/\ ]!]>_J?RE_T:[/\
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M8?WKJOYI./\ A')C_P""[K_N\.J:K^8VOQ!DW E)_&ON?[PC;3&N6K-6:/\
MB?[QH#2_Y%[7;!:1[K=<G07!*CF';I[NYTT!22+8=VW15@J#I0W%A"A$GB-X
M+2*&#E9$.N9(UV>/G)[;N/+T,4EMJSK9X]J<B>FG4*WTM/#\,T6.I-&+G+^9
M?R WE\=]H]*9_96,VSE*SL?Y8_&3HC.1[IH\K6TU+M'NCM>@V+NC(XI,36T3
M)DJ>DJI)*":9Y84F"M-3SH#&4.V*+WFS:-AEQ#?G<Q(1\8^BV#>-UBT$U4:K
MC;X4DU*U86E5=#LDB(-WF:PY6W7>X:&6QCM7C#? 3/N=A9/K H2!%=2,M&6D
M@0DE0R,;[W3I3U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U&K16-1U8QSTT
M60--.*&2LAEJ*2.L,1%,]5!#)$[QA])=$E1BMP&4FX1[@;X6$YVO1]3X;^#X
M@)C\72?#UA2K%-=-0#*2M:$'/3UL;<7$9NPQBU+K"$*Y2HU!6(8!B*Z258 T
M)!&.J.MT_P R_P"23?RNNOOD%UOUEU3N;Y^=A]K0_%/"]*U]%N^+JBH^5.T>
MX,GU;W!B#B:/+'.Q83%4VV]S[ABA;,-4K0TJ-)/)RSUY@W6TLX]CW79XWDL]
MVVZ+>3&Y#3BP@V.7?MQMT=%$8O$CM;C;()'3P4W)X4F4YC97M=E"-QW^PWUV
M0;+>7-EK1-.N2;<8MMV:9E9G"0W<E]MMS.2_9;32$.I4$&4ROSUS.^\+_*^R
M/Q^Q&U<Q/_,#W9M_<V7CW;09JO;9?Q_PW162[J[9S]#28>NH6@R]%)!B=O4\
MM9)+!3UM>GGIJ@KXF%%_M,=E[CW7**SK+8V%EN=_).A!::V@:VM-ND@85CTW
M=]N6WRZB'$EF)_"TL1-$%[6]O#R(-]W.%K7=7NMOVX6KH?TMPDN';<K>5*Z@
M;2RL-W- ]5GMXV8O$KAA)RG\S3X1X;LJKZNR/<U3!D\=V##U+E-^)U9W+4_'
M_#]K3Y1<"O6.;^4-+MY^MJ+<2Y%TQ<F$JMUQUJ5S"B>%:HB'V2[7_NZ,"[=W
M&\+"VU?I_5E=5?H_$T?65*.%^E\76R.J:BC &^Y_[ITF?<.P6JJ]Q3]0VJ,J
MN'NUCU&U01NDC-<")5B=)&(1E8K+N7YY?%KH/?N5ZI['[ SZ=IXC;FQ]W2=8
M;%ZD[F[>['RFVNQ,AGL;MC,;6V)U%M[.97-0^3;.;;(G$4E2<;%3B?)"D@GI
MI)KV*-N5S':67>\D[V_$!4DBCM)9'F=J);V\:7]GKNYVCM5>XCB,PE)0/W%M
M+:6\%U=:8X[D2&$LZ+XIB8*\<8+5>;)98%!F>-)941HX960$.HOE\NW=]?S/
MMS_)'MC [5Z+^*7R&V/MO:N?W72;?VOANNNN<M\4NN^Q\AC:S)45)35=;)4Y
M_<&0F@^_>IK'FJDHX"5%/3JVEQ:VO)6W[O?FMS<;ANEK50SO*T6Y-:6<$448
M8R2D:(8DA1I)G(Q([5+US:M=\Q6]CM*D0R[/87Q#50*TK;@UQ/*TVDPHL-NC
MR^*4C@2-G81@2'H(<A_,VZZ[ ^87Q5Z]ZD[)WIB.O<UU?\L>Q^].LNPOCYVK
MU-V=D]L=:[(PN<Z^WS0]<=W;2PV^)<0L[Y9<?D=OT!I,E,DM,DE7+#XD0?5C
M;+[>]QWIJ;;M6PW%]+I'B/;7$6Z[5%JFCA#7$<GT<]WHMY4!E4M)'$[QJRII
M4-Y9;1:[7F\W/?+.RA)[4N;>7:-\N)4@EDI!(BW4&W-+-$Y,%8EDDCCN"LAU
M,W\[OB7MS;'Q3WGFNYL)0[9^;VX-C[7^+>6;"[NFA[7S?9&VUW9LJFHHJ?'O
M)C(ZZB>%EJ<VE'#'--!2S21U4\,,@@N=JO[3FY^0YX].[1Q7TS6^I2WA;:JM
M>N'!,3+ KH>USXFI?"UDCHLCW.RDY</-BL1MZRV\#2E'4I+<R-%$CQLHE1O$
M1Q)K0" ([3^&J,0BOD;\J>L\/_??KC;7R7@Z.[)Z@[4^'N-[/STG2>ZNVJ+%
M4?R([BQ^!V)U;-2BD3'&KW[!'4;?^_HZR:? 1U\.7K(Z>(4[RH]F'[RW6PDM
M@+B%MRGVYX*A#<W,&V+?2VHE)!A,4%W:79N #$2OTVHR&1$,KK_%K.^@D&B<
M;5-N*25U?36RS30"^:,?V@26UNDCMV*O,T3E%=4-5!W!_,"^)O1O9.1ZA[![
M,RM/O[;^"QFY]\T.T.J^X.S\'U%MG-Q25&&W3WOO7K';^8P>P<94PPS54.1W
MKD<73-312U(E^WC>12F6]2XL[U[&15-KJC:9R([>.X\(2+"UQ+IM_'TO&_@&
M3Q=,D1*4ECU/26EQ!]/KC9WN@7ABC4RW$T:R>$9(K:/5</'XH:(2+&4:1)$5
MB\;A2Z_$WY^;/H/Y=?QA^47RQ[>I\EN'N6@;&XS-;=V;5[IW;VWO'*;ERL>W
ML!U=U/TCB*O);AR51CJ(U$.-VO@JB9Z>"6I\1CCEE!G+KM;;9+.YCD^OO-HV
MJYEB6*1IC/+M%G=W\K0HK-&B32R2SG2D-L&HWA1A0$T9CO+[?KJREC;;[+>-
MYMX9O%C6!;2#>KRSL$$[,$?5$D$,)+M+<MIH997)8]70WR,Z;^3.T*_>_2V\
M&W3A\)N+([.W1CLGMS=>Q=Z;'WEB88:K)[-[#ZX[ H<5N';N8@AJ::HEQ6<Q
M=)5+#-#,8O%-&[*)K2:&""[.EX;E2\4D;I)'(JN\3Z)(V9&,<L<D,JAM44T<
MD4@61&4,I<1O<2VA#)-#IUQNCQR*'4/&Q215;1*A#Q/31*A#QLRD'H;?:;I[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO__0W^/?NO=>
M]^Z]UT0&!! (((((N"#P00?;<L44\30S*'1P596 *LI%""#@@C!!P1@];!(-
M1UK$?#(?$KX^?S5?FIU+VCU9L;9':>\^[-C/\.L5-T1)4RX6BK<7EILCD>LL
MYB,)-2;:HIH:JDDDJHZFBAF0\/(48+*T\G-?,'LY >6;MVO(#O2W+^/I98@S
MB%9BS5=%C1E6(AZ1L%$>AQ4(\Q"UL_<8[ANR VEU;;=X1*%UDO'\ /(H -93
M<%C)/Y2I(9'#J>JBY=MQ[=V?W[\<?E#N;XW](_(C<_?F=W=6[X[=^,_RAWO\
MMJS.)G:7)XC<?5';G6='78PX?)2PRK21+2Z95J*B9E*S13@<;/+^\;7EW<>2
MEN'@L((D6"WN;>WC1PLB&"^CGR7C#*7U. ACBRKH2UN8@EOS3S%^^UC,&XS3
M>&]TC31M:O01/;-&>U4/<,%F.I&+P_HI9%\@MP_&OJ_^;=!FOGGMN@[4ZWVO
M\$.NZ3=F:S'6F:[5VI0;\%-2XI-\[FVE28_(3BFJ)FJJ6FJYZ(B"KK*9F,3D
M.H=V5Y;_ )0YJ_JXIM9KG>6%LB2+"^AK6W?Z:"421K'.T:_IE9%[(I0K $GI
M#?)*J<F/<.9XXMM1IW96(9 ^X RRQL"[()"DCHR.PIJ9"5-"D56V-V8+^4C5
M9JIP&>VKU-OO^9WMW>/Q_P !N&FK*.HI^K<A03T^/K,=2UY:1:*:>&58FU,L
MDD<LJLP?6P@LG9/=7D7;]RD6;=;7;Y8[UU(/ZM5.EJ4[]1DDR =$B&E".BS?
MS;7'*/N3N&SKHVR>V<V] 51J7,=6C0TH!";>(D  -$8SW1L!;?OW=/7NR/YT
MGRCW?VU0465ZOVU_*^S&:[#Q.2PT&X\?E=F4&Y</4;CQ=;M^J22*NBJ:198'
MI)49)0QC<%6/N--I;3[0;SI3Q)#S!MZQ+BIG:SA6 *3A6\8QZ7) 1J.6734#
M??H+FXYXY/BLW\.3P9R'J5T:6W=B^H=P"*"Q*U:@P":#HHW\J[MOX!=N_-'<
MG>V0CZKZH^0/8V5S^P/B=\6.LND=P;2P?4^Q\?AJT5NX<]N39VVZ/:]5N?,X
MY:DSUTE>YB@:6(37GCIJ43\]<O<]6GM7?<MV+R[C-<6D\VX7+3@J24JMK;K/
M('6&)ECKI53*51B-1F:0+ON&P[AS1#>S1I:V-J\,-I%X7?-,SJ!=3F-6&LR-
M^DC,PA9N-(89.B@XOY";0V)_*.^5OP-SV [$I_E'C>Y-R9W='6[==[QOL_96
M)[&P6[,MO?<^XTHFQ=%04Z8Z:E<55;',TS1A(FCD21EV[[<_,/,?*'.>V2QO
MMEI'$))_$10))%O88H@K%7:266[A1556(8L'TE2.A-%>Q[-S5SA#>*_C7UQN
M$MLBJ6,\4UHD1D4BM(XHDDN6=J*T*!D+!JBQW>G4W77=7\RS^55L7M7:.#WY
MLF;X!46:R.T-SX^DS.VLW5;>V5F,OB8<]A,@DE/64\55%#4&FJ(VC9XTU*P%
MO:&RNI[&\]R;ZU;1-%>IH<89#)<QPLRGB&\.1P&&5)U*0P! 0!:3D?V_L"2(
M[F259*8)6/:K>X"U]&>! X_$A9>#=%(V-\6/CP_2G\^'*5/4.QZ_(=&]D]L8
M/IJLR&#HZV?JS';?FS>1Q<>P'J%;^$LDE-3(\E#XW>*&.!RT*B/V@DYDWU^0
M^0-P-U()[Z6Q6XD#$/.IFVY&65_BD5EN)M2L2K-(SD%C7H:P[3MLGN/S!9M
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MMQ[K[#Z@K=KX#.;DAB:BI*W)0XS)34%+43)+4)25+0JZP2E5'+K+!<<RM,=
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MKWOW7NDQO;_CS-W?^&QG_P#W52^RS>O^2/=_\T9?^.-T8[/_ ,E:U_YK1?\
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ME"O+UP8MFWK;3%)XYYBN[I%*F,26\W+O*=M'+')+X<+H9[*[B)62B20.KE2
M"YN5E(W,]INVI/IVV&QMM08.5GM]ZYFN)8WCCURHPAO;60!D&M9E*U%:%_[/
MZ,^1O<WQB_G2_+'>/0V_^N^P/F9\3JGIOX]?&2:AI-X=ZQ=6=(]-;JQFP)][
M;7Z\GR\";LW7G=U9JK@VWC:BKJ*2F:AI9W:M,T$*FXADV/E>UVRY83W4_,<&
M\W:P5FCME,NQV201O&I\<PV6T)<W,L8>(33RI$[Q0K(PDY8OK6^]Q]LW?48;
M#;-O^AADG @:6266\O+NX9'(:*%I)X+:W2;1-2U>:2.,W 11,^1?R1[ ^87Q
M-W?\)OBE\7?EW4=G?(+I>LZ%W-VC\@?BIWG\5ND>B=J;^VN-B;_['WENKY,8
M/:D^;?%8VJK:C'X/:=%E*VNJ5AAT00M)4Q&7,^TVW.>_RV]Q*+?:9K]+BZN2
MR>)])'=K<R16UO4S275Q''X$!:-;>&242W$J)&58*\B[O=\A;3MNZ1PF?==L
MMH3;6P#:6OH8 (#-/I,$=M%<*CSMK>1HU9889F8#J)\B?Y9W7/R;^9G5W6W9
M^S^TYNH^J/Y;,FP^LNYMKY+>VUJ?K?NW:G=&'BZ^W?M[=6(D3$'>F#IJ<YS!
M1Y 5,M,\;54<!76Q17$][O'.7.7.MN_[OW.XDY8N;"<*'$4\5WS?=7#01R?I
MS> \MG%=4!;Z2\:TE9;?<98YT>W6D>P;3RARG)&M_MUI:;_;7L3 JD\+0\K6
MT,%RR'Q$BNDCNI8HB^EKFT2[C#7.W0RP8]_YSY@?(WXX8/\ E[]^]1]E'N'=
M'R*V%\9/DYW_ +7ZPWA1="=I?%3$8U^V.Q?D%M;?4=/'B*.D[ V=AI=F9/%+
M7>;$;FS$N,T-&M))4&%M)9\P[]L/,,MLMA;033[GN%D7HD%YLK1S6UE TJE[
MJROMWDVR6UP7N=F-\DS>-8WZQ+6%[RQM6\;=973W=P;:.UVR[!;QWBW9VLC=
M3F ?H;CM-E]=/<&L41OK:SG0I!N%HK'6[ZZZW#E?GI_+USN%V-F\GUULC8/S
M+PF[\WC=M5]?LS:,.YMA;6Q>U\3N;)TT+T5 N1-//3T$%7(GW!BD2(.48 FL
MHOK>;]ZGW9?%AO.7KB!FE&I)I9=\V25H26[9))(8YI#'EFCCE<J51R'KM$LN
M5=JL]K_3:UW^PE5(S1HH(=AYFA\4!>Y(XY9K>+Q,*LDT*:@\B UR==_&[Y ?
M&/\ F:?#KXZ;>ZPW[N_X+=8Y?Y6]T?'7N+$8+*9G9WQ]VEVKT]78+/\ Q0[#
MW#3I)%BZ?![AE2;KZ2M=%J,/7IB82SX4^1=RH;B>ZO&WN0BYV7EVXVJ&XE))
MW*UN-ZY6GVXZV/ZNX65OM5Y:7HJTDMO;6=^^J2XN2B#G*!3-M5[LZ@P[GOT=
M_=01@_XC=0;%S%!>3Z5&E+/<KC<(+F,]JQ7\MY  L;VJ=,F[OC)OWL#^77D>
MEM]?'_>6\:7=_P#.N.\MY=5[GZMSN<7<G0>;_F^_WZW!NW<6R\E0R&JVC5;1
MDES-7D:BF;'R8AFK))#1DR>UW+]OM\]Q[=0[LD;16.TSK<"4*5MYUY9WV.%9
M@V(I5O)+>.,/I<7#PHH\1D!/N:[J8'W#N-LD/BW4%O\ 2-&>Z9UAV('Z<KF1
ME,,H/AZB#%(.*-0>?ES_ "O?A[U?!\7.POB?\ ^@MC=J;.^=GPXW!5[RZ$^-
M>R,)OG:^P<9WABZK?V=J<WL/$1UU%B*;&K-+EZIY$IXJ8.U0ZQ!C[KR]>7-C
MSULLR2M#;D;TERP8K'X<G*^_1PK,:A=$EXUK'&'-'N6@1:RM&"'^9+6.\Y)W
MF 1B6<QV)@72&D+KO.V,YB%"VI;<3LQ05$(E)[ YZO/]H^C+KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NM?\ Z:^+G=.+_F]]FX'<'7VY*;X?]2;[
M[6_F =1;^KL%DZ?8N7^07ROZIVYTAE-D;<S?B6AJ<E@ZJD[5S^4I5E>:G&X*
M&9T45,;>Z\D:+3EW<DO@89]G6[V.RC---UM^];I_66XNT#=Q6SD2/:%"#PTC
M+Q A<-OG$QW>Y6$5CXDB[N-OW*_8-6*&XV*SN-D@MGH2=5U"VV7Z1MI ;;VD
M%2>[C\ OBYW1L/\ F$=^8'L/8>]-O] ?"/;'<FQ?AOO7.X2MQ^R]]8+YY=TC
MY*;OBZ[R<J+3UT>Q\?C,/LVH:G=OMB&ICHL5*78K6Z;VUNTN94M]QGM++EN/
M2I6:.QY>;<$MKL@Z6$=]9W>Q]RL5EN=IF.K7$6.^9=,O,\$=E_N'<75YO\JH
M2T7UFX6EA;,)&/PW*[DO--RUO0F*VW*UGU!;I0P&/ANW-L_RK-^?RC:SXE?(
MS<?RRS77':OQNP^XZ#I+>^0^-6\:_L#=>3@Q/RNRGRLFI*C8=#C9X<@F]\K2
M9//Q[BAK!/2+BGR ACD?9&YEM^5[>Q)VMK!.6DNF:D?[J.RKMZW,EOK""Z\
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MKQ4E220OD9[SF!]PFEEE>*QM+)0R:84A@N=QN42,F-&DE$E],97+2+X9@1&
M0J+3O:'I=U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__
MT=_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=$=Q'PR_A7\P+=/SJ_TD>?^\OQ^I>B
MO]%O]S_%]E]MN&@SW]Z?[[_Q1O)J^Q\7V/\ "%MKU?<'3I816.__ $7*%]RI
MX6KZV^BO/%U4T>%;BW\/1I.K537KUK3X=)^+HMWC;_WMNNT[GK\/]UQNFFFK
MQ=9NS6M1HI]5PH]?#XC5VGB]AWHRZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7ND3V-USLOMK9>=Z][!PB;AVCN.""#*XQJW)8R9FI*R/(T%;
M09;#34U;15=+4PPU-'6T51%44\T<<T,B2(K!VVGEL[VWW&V.B>UE2:)QQ22-
MM2L/(^C*05="R.&1F4[)K%+ P#)/')#(I (:.:-HI$(((HR,R^HK4$$ A911
MK#%'$AD*11I&IEEEGE*HNE3)-,6=VL.6=BQ/))//NCL7<NU*DDX  SZ   #T
M   X =-QQK%&L2U(4 "I+&@%,LQ+,?4L22<DD]9/=>K]>]^Z]TBNQ.N]G=L;
M,SG7O8&'_O!LW<T$-'N'!-D,KC:;,T$-7'6/C,C+AYZ>:6DG:-8ZND:0PU,)
M>GJ$E@DDC9VVFDM+R"_@-);:5)HS0$++&P>-])!5BC@.H8$!U5@-2@C>IO#E
MB!($T<D3T)!,<T;12 ,*,I9'9=2D,M:J0:'I8Q11011P01QPPPQI%##$BQQ1
M11J$CCCC0 *J@   6 X'NCN\CF20EF8DDDU))R22>)/F>FXHHX8UAA4(B *J
MJ  H H  ,  8 & .LGNO5^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z*1#\0-KU_P GJ#Y3[_[2[@[8
MW/LRCW-1](]=;\R77\?4?QY;>^)I\#O3*]5[:V5MS#5T^3R5% U')E]UY7-5
MU/35%72T-12TU740R:VL?NI;J2/]6YO(V@>XDS,+1KE;LV<873%' 9H[8N4B
M$\XL[3ZB:8P@FNXK^\C;Q2G1;V\B3B!*")KF.%H$N9"P:5Y422<HID\"-[B5
MXX5;04$:3H'9TGR3I?E(V2W,.P*/HZOZ!BPXK,7_ '.;9V1W[3=B3Y)\>:/[
MTY,5M+'$DPR @$!933F0B44LHEL)MSFAR=U&V++7@HVH[L;?PZ4IK_?-UXVK
M7J\.#1X>F3Q:7<*WL^WW$M0VVKN"Q4X,-R.V&?Q*UJ4_=5OX6DKIUS:_$U)X
M8X^W.G>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[I-;T1I-G;L1%9W?;6=1$0%F=FQ<H554<DD\ #V6[R"V
MT72J*DPR_P#'&Z,-H(7=;4G $L?_ !]>M&W_ $?;]_YXC=__ *#69_Z\^^*'
M[@WW_E"G_P"<,G_0/79?]^[)_P ID'_.6/\ Z"Z]_H^W[_SQ&[__ $&LS_UY
M]^_<&^_\H4__ #AD_P"@>O?OW9/^4R#_ )RQ_P#077O]'V_?^>(W?_Z#69_Z
M\^_?N#??^4*?_G#)_P! ]>_?NR?\ID'_ #EC_P"@NO?Z/M^_\\1N_P#]!K,_
M]>??OW!OO_*%/_SAD_Z!Z]^_=D_Y3(/^<L?_ $%U[_1]OW_GB-W_ /H-9G_K
MS[]^X-]_Y0I_^<,G_0/7OW[LG_*9!_SEC_Z"Z]_H^W[_ ,\1N_\ ]!K,_P#7
MGW[]P;[_ ,H4_P#SAD_Z!Z]^_=D_Y3(/^<L?_077O]'V_?\ GB-W_P#H-9G_
M *\^_?N#??\ E"G_ .<,G_0/7OW[LG_*9!_SEC_Z"Z]_H^W[_P \1N__ -!K
M,_\ 7GW[]P;[_P H4_\ SAD_Z!Z]^_=D_P"4R#_G+'_T%U[_ $?;]_YXC=__
M *#69_Z\^_?N#??^4*?_ )PR?] ]>_?NR?\ *9!_SEC_ .@NO?Z/M^_\\1N_
M_P!!K,_]>??OW!OO_*%/_P X9/\ H'KW[]V3_E,@_P"<L?\ T%U[_1]OW_GB
M-W_^@UF?^O/OW[@WW_E"G_YPR?\ 0/7OW[LG_*9!_P Y8_\ H+KW^C[?O_/$
M;O\ _0:S/_7GW[]P;[_RA3_\X9/^@>O?OW9/^4R#_G+'_P!!=>_T?;]_YXC=
M_P#Z#69_Z\^_?N#??^4*?_G#)_T#U[]^[)_RF0?\Y8_^@NO?Z/M^_P#/$;O_
M /0:S/\ UY]^_<&^_P#*%/\ \X9/^@>O?OW9/^4R#_G+'_T%T>[XS;.W=2?%
MKYYTE5M;<=-5Y'8G3\>/IJC!Y.&HKI(>Q))9HZ.&2(-*R+ZF" D#D\>YP]M]
MHW:+VQYYBEM9E>2VL JF-P6(NR2%!6IH,FE:#J%?<3=MKE]RN298[F)ECN;X
ML1(A"@VH +$&@J<"O$]$1_T?;]_YXC=__H-9G_KS[@_]P;[_ ,H4_P#SAD_Z
M!ZFK]^[)_P ID'_.6/\ Z"Z]_H^W[_SQ&[__ $&LS_UY]^_<&^_\H4__ #AD
M_P"@>O?OW9/^4R#_ )RQ_P#077O]'V_?^>(W?_Z#69_Z\^_?N#??^4*?_G#)
M_P! ]>_?NR?\ID'_ #EC_P"@NO?Z/M^_\\1N_P#]!K,_]>??OW!OO_*%/_SA
MD_Z!Z]^_=D_Y3(/^<L?_ $%U[_1]OW_GB-W_ /H-9G_KS[]^X-]_Y0I_^<,G
M_0/7OW[LG_*9!_SEC_Z"Z]_H^W[_ ,\1N_\ ]!K,_P#7GW[]P;[_ ,H4_P#S
MAD_Z!Z]^_=D_Y3(/^<L?_077O]'V_?\ GB-W_P#H-9G_ *\^_?N#??\ E"G_
M .<,G_0/7OW[LG_*9!_SEC_Z"Z]_H^W[_P \1N__ -!K,_\ 7GW[]P;[_P H
M4_\ SAD_Z!Z]^_=D_P"4R#_G+'_T%U[_ $?;]_YXC=__ *#69_Z\^_?N#??^
M4*?_ )PR?] ]>_?NR?\ *9!_SEC_ .@NO?Z/M^_\\1N__P!!K,_]>??OW!OO
M_*%/_P X9/\ H'KW[]V3_E,@_P"<L?\ T%U[_1]OW_GB-W_^@UF?^O/OW[@W
MW_E"G_YPR?\ 0/7OW[LG_*9!_P Y8_\ H+KW^C[?O_/$;O\ _0:S/_7GW[]P
M;[_RA3_\X9/^@>O?OW9/^4R#_G+'_P!!=>_T?;]_YXC=_P#Z#69_Z\^_?N#?
M?^4*?_G#)_T#U[]^[)_RF0?\Y8_^@NO?Z/M^_P#/$;O_ /0:S/\ UY]^_<&^
M_P#*%/\ \X9/^@>O?OW9/^4R#_G+'_T%T>[,;.W<W\MK9V+7:VXSDT^8.X*U
M\<,'DS7I1MU0L*U;4@B\@B+^@2%=-^+W]SA=[1NQ^[I:6PM9O$&_2MH\-]6G
MZ$#5ITUI7%:4KCJ%;7=MK'W@[NY-S%X9V*)=7B)IU?6DZ=5:5IFE:TST1'_1
M]OW_ )XC=_\ Z#69_P"O/N#_ -P;[_RA3_\ .&3_ *!ZFK]^[)_RF0?\Y8_^
M@NO?Z/M^_P#/$;O_ /0:S/\ UY]^_<&^_P#*%/\ \X9/^@>O?OW9/^4R#_G+
M'_T%U[_1]OW_ )XC=_\ Z#69_P"O/OW[@WW_ )0I_P#G#)_T#U[]^[)_RF0?
M\Y8_^@NO?Z/M^_\ /$;O_P#0:S/_ %Y]^_<&^_\ *%/_ ,X9/^@>O?OW9/\
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M-_?J#U'\_P#-U[KW^DK>?_>/G;W_ )^NA/\ [-_?J#U'\_\ -U[KW^DK>?\
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MNO?Z2MY_]X^=O?\ GZZ$_P#LW]^H/4?S_P W7NO?Z2MY_P#>/G;W_GZZ$_\
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MX^=O?^?KH3_[-_?J#U'\_P#-U[KW^DK>?_>/G;W_ )^NA/\ [-_?J#U'\_\
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M\W7NO?Z2MY_]X^=O?^?KH3_[-_?J#U'\_P#-U[KW^DK>?_>/G;W_ )^NA/\
M[-_?J#U'\_\ -U[KW^DK>?\ WCYV]_Y^NA/_ +-_?J#U'\_\W7NO?Z2MY_\
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MY_\ >/G;W_GZZ$_^S?WZ@]1_/_-U[KW^DK>?_>/G;W_GZZ$_^S?WZ@]1_/\
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M^H/4?S_S=>Z]_I*WG_WCYV]_Y^NA/_LW]^H/4?S_ ,W7NO?Z2MY_]X^=O?\
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M(Y/B,%4-J'<I!#S%NEQLW-4.U1*K6;&T25R"7CDO+(SPZF4A5669'BC#)W\
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M;Q$>+1XB.HQ?S#._.V/C?\;F[ Z0_P!'<?9F<[J^-74&W:[M7:VY=[;%P_\
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MZ_\ OYO_ /7']P_^C]N/_9;<_P#6WKKU_5'E/_HUVG_9-#_T!U[_ $D]B_\
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M_P#H_;C_ -EMS_UMZ]_5'E/_ *-=I_V30_\ 0'7O])/8O_/?;U_]"G._]?\
MW[_7']P_^C]N/_9;<_\ 6WKW]4>4_P#HUVG_ &30_P#0'7O])/8O_/?;U_\
M0ISO_7_W[_7']P_^C]N/_9;<_P#6WKW]4>4_^C7:?]DT/_0'7O\ 23V+_P ]
M]O7_ -"G._\ 7_W[_7']P_\ H_;C_P!EMS_UMZ]_5'E/_HUVG_9-#_T!U[_2
M3V+_ ,]]O7_T*<[_ -?_ '[_ %Q_</\ Z/VX_P#9;<_];>O?U1Y3_P"C7:?]
MDT/_ $!U[_23V+_SWV]?_0ISO_7_ -^_UQ_</_H_;C_V6W/_ %MZ]_5'E/\
MZ-=I_P!DT/\ T!U[_23V+_SWV]?_ $*<[_U_]^_UQ_</_H_;C_V6W/\ UMZ]
M_5'E/_HUVG_9-#_T!U[_ $D]B_\ /?;U_P#0ISO_ %_]^_UQ_</_ */VX_\
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M<?W#_P"C]N/_ &6W/_6WKW]4>4_^C7:?]DT/_0'7O])/8O\ SWV]?_0ISO\
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M2F:/"U$=**+&"#)R0OYH)(@-:E0([7<MCV_<.8=@L;B,6.W[#8;;9N9%TSM
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MGC"X;PQ+;PS6TD4D+$%9))([1-2@T1I6U%6C".-+V[FV+G.ZYPCC-S!?;;!
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M C$C(%K+9;K=O:F^Y8TF&\DFEGB67],.4FO4T,6 TZH[GQE8_$L>A0S2(.C
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MX_(X&CH<E00TU;519JOH9Z*1IHZF&-8U=Q7OVCG3>I.9MOEAA_>#++-%//%
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MKW7O?NO=:_\ TU\7.Z<7_-[[-P.X.OMR4WP_ZDWWVM_, ZBW]78+)T^Q<O\
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M+5;0@=H9=T]MCR1;0CZ^VDWU6BE(A@NEW+<+S<(+H7+E("#;WD5C,C2BY3Z
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ME+D4LL)<PL4\1#&^DD:HRR.4:GQ(7CC<J:J6C1J552*2QI/&(IE#HKK(%85
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MW7O?NO=>]^Z]U[W[KW7O?NO=,VXD>3;^=CC5GD?#9-$1%+.[M1.JJJKR23P
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M;=B_\\#O7_T%L[_UX]^_UN/</_HP[C_V17/_ %JZ]_6[E/\ Z.EI_P!E,/\
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MC#N/_9%<_P#6KKW];N4_^CI:?]E,/_0?1G>FMD;TH^D_E!15>T=T4M9D]L;
MBQM)4X#*P5.0D@W:\L\=%!+$&E9%]3B,$@<GCWDM[/\ )7.5I[+^YMG=[3>Q
M37-GM8A1[6=7E*WS,PC4QAG*KE@H) R<=0[S_P Q\O3^XG)MQ!?V[QPW%Z9&
M6>(J@:U !<AJ*"< L14X'18O]&W8O_/ [U_]!;._]>/>-/\ K<>X?_1AW'_L
MBN?^M74Q?UNY3_Z.EI_V4P_]!]>_T;=B_P#/ [U_]!;._P#7CW[_ %N/</\
MZ,.X_P#9%<_]:NO?UNY3_P"CI:?]E,/_ $'U[_1MV+_SP.]?_06SO_7CW[_6
MX]P_^C#N/_9%<_\ 6KKW];N4_P#HZ6G_ &4P_P#0?7O]&W8O_/ [U_\ 06SO
M_7CW[_6X]P_^C#N/_9%<_P#6KKW];N4_^CI:?]E,/_0?7O\ 1MV+_P \#O7_
M -!;._\ 7CW[_6X]P_\ HP[C_P!D5S_UJZ]_6[E/_HZ6G_93#_T'U[_1MV+_
M ,\#O7_T%L[_ ->/?O\ 6X]P_P#HP[C_ -D5S_UJZ]_6[E/_ *.EI_V4P_\
M0?7O]&W8O_/ [U_]!;._]>/?O];CW#_Z,.X_]D5S_P!:NO?UNY3_ .CI:?\
M93#_ -!]>_T;=B_\\#O7_P!!;._]>/?O];CW#_Z,.X_]D5S_ -:NO?UNY3_Z
M.EI_V4P_]!]>_P!&W8O_ #P.]?\ T%L[_P!>/?O];CW#_P"C#N/_ &17/_6K
MKW];N4_^CI:?]E,/_0?7O]&W8O\ SP.]?_06SO\ UX]^_P!;CW#_ .C#N/\
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M\W7NO?Z2MY_]X^=O?^?KH3_[-_?J#U'\_P#-U[KW^DK>?_>/G;W_ )^NA/\
M[-_?J#U'\_\ -U[KW^DK>?\ WCYV]_Y^NA/_ +-_?J#U'\_\W7NO?Z2MY_\
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MY_\ >/G;W_GZZ$_^S?WZ@]1_/_-U[KW^DK>?_>/G;W_GZZ$_^S?WZ@]1_/\
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M^H/4?S_S=>Z]_I*WG_WCYV]_Y^NA/_LW]^H/4?S_ ,W7NO?Z2MY_]X^=O?\
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M-_?J#U'\_P#-U[KW^DK>?_>/G;W_ )^NA/\ [-_?J#U'\_\ -U[KW^DK>?\
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MNO?Z2MY_]X^=O?\ GZZ$_P#LW]^H/4?S_P W7NO?Z2MY_P#>/G;W_GZZ$_\
MLW]^H/4?S_S=>Z]_I*WG_P!X^=O?^?KH3_[-_?J#U'\_\W7NO?Z2MY_]X^=O
M?^?KH3_[-_?J#U'\_P#-U[KW^DK>?_>/G;W_ )^NA/\ [-_?J#U'\_\ -U[K
MW^DK>?\ WCYV]_Y^NA/_ +-_?J#U'\_\W7NG+#[\W3D\G1T%;TMV9MZEJ9?'
M/FLQE>G)\9CDTEO/618#=M=6,EP%M3TDK7(]-KD:H/7_  _YNO="9[UU[KWO
MW7NO_]??X]^Z]U[W[KW7O?NO=48?'_\ FC=P[\_F8]G?#?L[:'5N'ZBI-]]S
M=9=3;PVWC-ST&]<EO7JZ"FW'3XS=-=E<Y6T,OW&':I<_;XNF\D^CQ$*DB>Q_
MM'*=CNOMFO-L;R?O 0I</&-/A&(SF"32NG752R.3XC!5#:AW*00\Q;I<;-S5
M#M42JUFQM$E<@EXY+RR,\.IE(55EF1XHPR=_ &J,3WF?YH_<%7_-4VG\+MD[
M,ZSK/C]6;YR?5FX=_P"3P^ZJG?E5O_:O6G]^M[8[;^9H\W#BXUQ\]5CZ.2.;
M$3,O[EV)="CO*/*&W[YR7?\ ,NXR.DT<5S/;I&RA3#!(8$>0,C%A++%,RE&4
M&/0!W*Q-^:]RGV.^M;*R"N2;!;@N"0KWTK,BQD%>%J8V-=6F4G42**%!N'Y\
M_,OY%?(SN?HC^79TST=F]M?'/.G:':O>7R1SF[HMD5>]5EGI:C;6U\'L&II*
M\F.HI*N%*A6JA)XFDD2FB>%ID&S<N[4O+-MS?S3.\5M?U^D@@4&>6,:3XS&3
MM561T<(5!5'2KF1FCC4[Q?26>\MRSM\?BWL,<<EPS&D4 D%5C8#OU@U0U*D2
MI,@C*Q&0O'S!^:GS6^&_P H^_P#L[KSX]T/R1B[5Q&R<OM;%?WWW7U,=NY;+
M5M%09B@6FS-!DEGJ:>FBJHT?(MXA($E3R!D2^U;'R]S#SOM/+FR23_3;@=#F
M;0LL<G@3RZ0RAD(5HXPS:6&7"U&ESN%]S@V7=;_<EC\2R5'A,>KPY%::TB+,
M&[Q0S2BE5-45N!(*<I/GQ\V?C'W!T3L?^87T_P#'ZFZR^2&Z:#86QNY_C-F]
M]_P/9^]LLT:8G$;WP/8D]54NL[31%Y8G@6.+RS(U1X)8E,K/ECECF6YN]FY6
MFN4W*VC>98KE8RMPD9TNL+1THP8J@!J3(\:E L@=0_)OF[6FP6_-US'%)MLQ
MB\0QEUE@69#(CNK5#_II(Y1*]L;]VL(DB*[P_F9_,)^QOF'DOBQTMT;NSX__
M  *K:/&=WY7M#+;X@["W[DZ#SS;TH.KVVO41T%(^-2DK?)_$:>>R1"8>1Y$I
M?97L&Q[ >7MLYAYIGE1-[N3!9K;A*JAD2**>9I :QRM+"XT %5F448+)(HDW
M)[U]\DY8V%0UW:V2WD[2AC'22%KB.*)4HS2-$CJH+=TB,IT#PS(,_P I_P":
M!N[K_P")O6G?'QL^/F[NUMR=N]*5_>-!D<[B<A_HBZBV7@,+3YC=F1[4W7CI
MJ19:JA:<4D&'HZR">LE%HYHRT*34DY1^CYSN.6MTNX[>"SEMT>9L/<"[E$5J
MMK%4EGGU(Q8DK;HZR.)%# )]JW5=SY<CWN.%WFE%RHMT[BDEK'(]P\LE"J01
M"*5E8@-/X91 A+-&<3H?Y14FYOA!UI\N>\:W:^RJ7+]'X?MSL:KPT-=C]KX1
M9\$,OE4P])EJJLJ1$#>.E@DJYI78I&&=V%T//>SVW*_,UWLFVB6=89(XXE.E
MI9'E$81!I5%+/(X1<*,BI J>O<HW5US'813S:(W>2=6.5C1(9I4,CDEBJ)''
MKD8FB@,V%% 4O^6+_,)[:^<^^_E9C>Q>M]M=9;<ZBW%L,=;8*CQF?H=\KM3?
MD.7R>,'8\^5R5932Y'[&DH97%%24B(\DBF-O3I.^9^3;?EOEG;;YY_&O9I;J
MWNM!!@6:U\))4A&D/1)FEC+,S:M ("Y'19;<P_7\V3[59I_B(MHKB!V!\25)
M3^G*<A0DT969%"DJKJ/$DIJ:P'<7=?\ #>_-B=!X#;)W#F,]L3=?:&^<V^8_
MA=%U[L7!U<.W\!724PI*@U];FLQ.**BHO+3@0T]=4M,33+!.!$C!VG=-X=M,
M6V1Q?,RW$_B-';K0]M(()YI9&^ "%0C^/5!%>2FV%G&@URWLTB*N0%A@16N)
MRP5@/#>:UB6,T,K7%0RB)ST'N*^4_P#$_A=FOE]_<3P?P?IG??;O^CS^\_D^
MX_N5AZ_+?W>_O;_#ET?<_8^/[O\ AC>/7J\,FFS*M_LOW'?6MGJ\7ZG]V9II
MT_O%;5N%6KX/U-.(\31^#5VF&TVW[TWA]IU>'HO;FSUTU5^GNY;7Q--1\?A:
M]%>W5IU-344!V9\VJ_K_ !>[,K0]13;GBV7\6]@?*C-4U+O-Z.L_NIN3=L^(
MWAAJ&GCPU299\+BJ2LRT4O'WK1BE\=+K^X4Z?EV"#>K[;;NZ$4-CO5KM#S%!
M2EWXZK=%2X"JDD2!XS)01N\GBUC"2$FWWEQN>T;??V<!>?<;&^NXH PU-+:0
M6DT=JK'2&>Y>[$*/0:75>Q]=%'#L;Y 4&T=T?'/:&U,%'O[+?(O>DF)P1I<V
M,51X?8.'V;5;ZW=V5+4+2U9J*:AHH*:.&F"Q"HJ*NFB,\.O7[*[3:9Y=TO-L
MO#].=OM[B><L*E&BDCMXX=(-2\US-'$,@*HED.KPM#6?<;<['#OEJ?%2ZFM(
M8% 8&4W1,A8=I*B*TBN;IBRT/@B,E/$UJ,YW;M5=R3;-;<VWQN^GP*;JJ-JG
M,XX;D@VQ)6MC4W'-@S)]TM :E'IQ6-$(C(I37J!'LJ.+:6\.(8"%D?\ !&S*
M757;X4)16<!B"54L, GI><21Q'#S:_#7S?PR@?0.+:#)&'TUTF1 ::UJPU':
M?7$/6^3[@BWMMK)=7XG;.8WE6;\PF7HL]M@[8P%)-79?-4F7PSSPU$$$4$S,
MT#/RA4786]^OUFVVJWD;H]$HA4AV,H4Q*JM0EI=:>$/QEUTUU#IVS@?<+I;.
MTH\C2&&E1B17,;HQX*R2*R.&IH96#4(-"U=7=_\ R6[8DV7O+$?%+#;8Z0WQ
M68NLQNXM^=[QX+N2CV/ERLU%O7*],T&U*Z@IQ)3.M6N+DW>*T(RI+%%-JB42
M7FR66TRR;;O%T4OH0XDCBC$T4<JJQ\%YC+&2X<")VCBDC20X=T4OT2Q[DU_"
M+S94$]NS+HDD+0^+&753-$A1R8RI,L?B^$\B*#H0LH(;X/YA_(O-[#W%W5CO
MB=M3<W2^U]X]K8')G8GR(K<WW@VW>H]_Y78F?W+0=4[FV)@\/4SN<345T6*I
M]YO,\96.)Y9RL;,M8;':V=C-NMZ]LU[:6=TS&WUV\"WEM%<KXLJS>-HB$JK+
M(ELVFA?1H!(6G]X76];CLNS0K<26%[<V*JTGA/<26TS0_I@H\:M*1^FLDJ+4
MA6D4=W0R[K[X[CS&W\%OSXX=);)[DZPSG6N'[.QV_=X=ZQ]346Y<5G:!\QC\
M/LG$T.V=SU=17&C$,[-FH\32#SQH*LLLWA1WMG;;#-?Q<U/):-82/&Z11">4
M^$ 9)-)DAC\-3J44E:1C&Q$>DQL^MLN5WZVLIMBI,UZ!3Q"T:1EFT+'(0LD@
MDU8=5A<)P9M89!"ZX^8&W^QLY\:TI]G9;";,^573U?V1U?NK)Y&G-9'NO"8N
MFW-G>L-R8*"$QT]8N'J&R%%64]?4150I*Y0L8ABDJ#/<.6I]NW'=]JEE5I]I
M\*2@#:9[:1_":=&-"K12O;K)"PU*MS&Q-0ZJCCW16L+*^E0I]3=3V4JEE)@N
M8ED9$U*2LJ3?37@61#@P("OZZD'#]AKHUZ][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB@_%;Y ;R[QW=\Q<!NS&;9Q]
M'\>_ECN7HC9DFW:/*TE3D]HX;JC:&^J7([G?)5M6LV2:KW!61R34B4T)A2%1
M3JZO))>Q47/*>U;])B:^.["0#X!]!O\ NVU0Z :L-5O80O)J9JS-(RZ$*QHF
MN)FAYIW'9%IX5I'MKH3\9-YMEI>RZCP(66=UCHJTC"ABS N2@;Y^?_<FV>@/
MEOVK0;:ZSFW#T)_,8Z^^(>SZ.KPVZ9,-DNMMV=[]:]7Y'-[EIX<S'/-G$Q^\
M<G-!4TM13THJ(J5VHWC26*=#R_.^[#DLW "_UCW>\L+G3C1#;\R;YLZ-!6NF
M4VVV02,9/%4SO,P18V2*-6!_NRYNL_P[!MDU[;GS>6/DZRYA"S>31F]N7B(0
M1M]*$0.)09F-'T'\D]\;S^4WS+^+_;&*VEA=Q]$YKJWL'J"LVS1Y?''?/QH[
MFV:3M7=.<CR]=7";+8_=>%WA@<I-2?;P$4E+(M+#Y@9%.V.EWRJ^\W#!+BQO
M[VQO5J!&F@1WMA,M22L<^V74"LSLP>\M;\H45/!AUNBM8;[;V4>;6_L(;NV8
M@ZS)'++:;A Y':6@N(XITTJ*6M]:JQ>02-U[X+_)'??RQV%VMW1FL5M3%=3Y
M#Y"=N[)^-$^W\=F:7+;LZ0ZLW!_HUH^Q-UY+)5]73UTNX<]B\[E,548ZFI*?
M^$RX\"*63R5,SMHCMRQLVZ7JF.\W*T%])&#VQ6]Y-+/MB:2"PE?:FLKBXU,:
M3SR($C":>JWI\'F;==HMR&M]MF2SUY+/=P01#<Q6BKHM]Q-S8J@4D&T=FD8O
MI0[7NG6^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z9MQLR[>SS*2K+ALHRLI(96%#(001]"/9/S$S+R_?,IH1;S$
M$<0?#;HPVD!MUM@<@RQ_\?'6LC_>W=7_ #TVX/\ S\Y'_KY[^:O^M7-'_1RN
MO^RB7_H/KL/^X]E_Y0X/^<4?_0/7O[V[J_YZ;<'_ )^<C_U\]^_K5S1_T<KK
M_LHE_P"@^O?N/9?^4.#_ )Q1_P#0/7O[V[J_YZ;<'_GYR/\ U\]^_K5S1_T<
MKK_LHE_Z#Z]^X]E_Y0X/^<4?_0/7O[V[J_YZ;<'_ )^<C_U\]^_K5S1_T<KK
M_LHE_P"@^O?N/9?^4.#_ )Q1_P#0/7O[V[J_YZ;<'_GYR/\ U\]^_K5S1_T<
MKK_LHE_Z#Z]^X]E_Y0X/^<4?_0/7O[V[J_YZ;<'_ )^<C_U\]^_K5S1_T<KK
M_LHE_P"@^O?N/9?^4.#_ )Q1_P#0/7O[V[J_YZ;<'_GYR/\ U\]^_K5S1_T<
MKK_LHE_Z#Z]^X]E_Y0X/^<4?_0/7O[V[J_YZ;<'_ )^<C_U\]^_K5S1_T<KK
M_LHE_P"@^O?N/9?^4.#_ )Q1_P#0/7O[V[J_YZ;<'_GYR/\ U\]^_K5S1_T<
MKK_LHE_Z#Z]^X]E_Y0X/^<4?_0/7O[V[J_YZ;<'_ )^<C_U\]^_K5S1_T<KK
M_LHE_P"@^O?N/9?^4.#_ )Q1_P#0/7O[V[J_YZ;<'_GYR/\ U\]^_K5S1_T<
MKK_LHE_Z#Z]^X]E_Y0X/^<4?_0/7O[V[J_YZ;<'_ )^<C_U\]^_K5S1_T<KK
M_LHE_P"@^O?N/9?^4.#_ )Q1_P#0/7O[V[J_YZ;<'_GYR/\ U\]^_K5S1_T<
MKK_LHE_Z#Z]^X]E_Y0X/^<4?_0/7O[V[J_YZ;<'_ )^<C_U\]^_K5S1_T<KK
M_LHE_P"@^O?N/9?^4.#_ )Q1_P#0/5E_\N#,9;*9KM=<GE,CD5AQ>TC"M=6U
M-6(B]77AS&*AFTWL+V^MA[Z1_P!W7NVZ[GO/-2[E<RW 2&QT^+(\FFKW5::B
M:5H*TXTZQ!^]K86-GMVR&SACB+27-="*M:+#2ND"M.K6/?4GK";KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[JGG^7[_,BW_P#(OO3O_P"/OR)V;L;KW=F*[;^2;_%//[(BW%1[=[MZ
M'^/O?F9^/^\*6O&YJNM/]]MK9/$TM7N:DHZA:>2@S&*KJ6GA1JJ*G?V6)=UY
M0L]V) W!;2RN[R%35#;[C$);6]M@0'%MXOC;=<*YD:"^M"6D,-[9%W.9(FV'
MF^?:!WV#R""VE/QK=QV=M=W-I<'X?$,-S'=6K*$$\'U"*I>PN'/5;_,&[FI_
MCUG.V4VSUB=QXS^;-CO@?!1/AMU'"/U%5_S Z'XI2;CFIAFA.=R#;M3)6K6+
M4BB_B(68X\TP-(?<HQ+O\?)C7G;_ %BM-TN+G1C0]E8\PW,0@U:M*M)M-L)!
M)XI*/.%9"T;1N\T0KLD7-CVM6.PV.W75OKSKDO-NV*\E$U-.I%EW.X5 GAL$
M2$,S,KM(O/YE/SU[ ^&Z=0XWI_8.VNS=TY&7>7>G>>%SXSDU1LKX1_'VGH<G
M\ENR]M4FWYH9)L_2QY?#T&W::<O#-5U1,D4R0NGM!874$O,L-IN+"#:[=8&W
M&Z-%%L-PO(=KV\F1RL48%S<2;C<&2NK:]HW01A9O"=;3V-Y)L4LNUQ-<;I=R
M-;;7;+H_QJ]CMKB_>(JSHS*\%HUFC1GLW"_VX2D12-4?ODO\E<[U6OP\R/6J
M;0W-M_Y(?*3JGIW+9;*PY')TQZ[[#V9GMTON':-3B*VD1:UOX;2-25-0*BG\
M3OJIW+(R/F*[M^>;#E*_C,7CKNXG!!$L<FW;3?WR**X7_&+5$E#*Q,9=5*.0
MZE:WMI=<EWO->W.)5B3:9(#_ *')'N&][3MS,PPQ'TU_+)'0K241LVI T;E9
MQO<7\QCO3Y$_-?8WQ^[*^%/7?7OQ:[FV;U)M?;O<?QG[T['WEO27._'O9W<U
M=D\_V5LKM_;-#0*]5N::AA^WVA.88H4D9:ARRFE@EY+RS!S#*$E>XN=RA2(%
MH0%LKM[9-4I%P:R*H9F$1 -:)2@!ONT5I9;Q!M,1=0^WV=X\ATR=]U)=H56,
M>%VI]," 9*G6:L*9,K\-?EMF_D%MGNG =R;#Q/2W?_Q;[0RG3_R)V'BMUR;P
MV3B<]1[6H-_;=WUL/>E=18R>OVUN';N5QV:QE16X^FJ(5EEI:J)9Z:0EZ]N]
MGCY:AYSMI63;Y%NO%\8*)+2>PE>&]MI]!96:!D$J2IVSVLMO<*J>+X:EL,&Y
MQ[]+RQ=QB2[5;:6%H0Q2[MKQ2;6>%3WJ7=);>2%JO%<P31!I%5)7K5[6_FI?
M+/:7QQ^'7R9Z[Z,ZV[&P7RH^4/;]3A^KZ##[^'8^X_@AU_USOCNC;&Y>N?#D
MS'4=CYO9.T8]S8^GJJ3["J:J3%I213O'4^_6\<FU[EM]KSF#:11;&^Z[V0C+
M)MLDMYM-NJF,^(2FSQ[S#^^(S665K&^:U,1,4'3]W!/>6V[/RPR320[U;[3M
MYD9/!NV5+F"8O*L@15W'<;&:';+E6\*""[LY;I)42:4V%=F_,^G7(_RYMP=#
MY/8G874?S?[RIMF2;SFARF36JZPRWQFWOWA@MQ[&J\;6TD<%;-5[<QL3O705
M*+3R5,34ZSE)83*+:;JWYRGY5W5?#,&W[C=-I(),MFUH(M+C4CP2+<,VI:B1
M?#>.0*:LEMKRTO\ DFYYKLM6J.;;HT1U*E?J[Z*TG2:,@.DT(=U*$JT4RE9%
M.EDZ ;>_S[[BVU\;OG!W#0[;ZTEW-\:?F_%\:MBT-7A]TR8++;%?L78>T3EM
MVTT.9CJ)\M]MNC(/YZ.JI:?RQTY^UTI(DH;VF[DO[+DZYF #<P[T^W7%*T2!
M><-TY?#0U)TR_1V44I:0R)]4TCZ/"*PIZ[E:"[YP@3(Y?VN:]MZ\7ECY-L^8
M56;^*,WMP\1">&WTH5 XE!G8VOSM^06\_C#\=:_MW8.,VQE]R4O;OQHV#'1;
MOHLK7X,X?N7Y)[2Z<W/4O386MQ\_W,&,SU9/0.*D(E4D+RQSQ*\$BRU8S\U<
MO[&_]ENVZ6EC,1\:Q3E@[1GX1(-(TEE=1YH>C**!)-LW>]).K;]IW>_C'DTU
MAMEU>PJ_F8VE@190I5FC+!'1B'!PO;G23KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NHU:*QJ.K&.>FBR!IIQ0R5D,M121UAB(IGJH(9(G>,/I+HDJ
M,5N RDW"/<#?"PG.UZ/J?#?P?$!,?BZ3X>L*58IKIJ 925K0@YZ>MC;BXC-V
M&,6I=80A7*5&H*Q# ,1722K &A((QU1UNG^9?\DF_E==??(+K?K+JG<WS\[#
M[6A^*>%Z5KZ+=\75%1\J=H]P9/JWN#$'$T>6.=BPF*IMM[GW#%"V8:I6AI4:
M2>3EGKS!NMI9Q['NNSQO)9[MMT6\F-R&G%A!L<N_;C;HZ*(Q>)':W&V02.G@
MIN3PI,IS&RO:[*$;CO\ 8;Z[(-EO+FRUHFG7)-N,6V[-,RLSA(;N2^VVYG)?
MLMII"'4J"#*97YZYG?>%_E?9'X_8C:N8G_F![LV_N;+Q[MH,U7MLOX_X;HK)
M=U=LY^AI,/74+09>BD@Q.WJ>6LDE@IZVO3STU05\3"B_VF.R]Q[KE%9UEL;"
MRW._DG0@M-;0-;6FW20,*QZ;N^W+;Y=1#B2S$_A:6(FB"]K>WAY$&^[G"UKN
MKW6W[<+5T/Z6X27#MN5O*E=0-I96&[F@>JSV\;,7B5PPDY3^9I\(\-V55]79
M'N:I@R>.[!AZERF_$ZL[EJ?C_A^UI\HN!7K'-_*&EV\_6U%N)<BZ8N3"56ZX
MZU*YA1/"M41#[)=K_P!W1@7;NXWA86VK]/ZLKJK]'XFCZRI1POTOBZV1U344
M8 WW/_=.DS[AV"U57N*?J&U1E5P]VL>HVJ"-TD9K@1*L3I(Q",K%9=R_/+XM
M=![]RO5/8_8&?3M/$;<V/NZ3K#8O4G<W;W8^4VUV)D,]C=L9C:VQ.HMO9S*Y
MJ'R;9S;9$XBDJ3C8J<3Y(4D$]-)->Q1MRN8[2R[WDG>WX@*DD4=I+(\SM1+>
MWC2_L]=W.T=JKW$<1F$I*!^XMI;2W@NKK3''<B0PEG1?%,3!7CC!:KS9++ H
M,SQI+*B-'#*R AU%\OEV[OK^9]N?Y(]L8':O1?Q2^0VQ]M[5S^ZZ3;^U\-UU
MUSEOBEUWV/D,;69*BI*:KK9*G/[@R$T'W[U-8\U4E' 2HIZ=6TN+6UY*V_=[
M\UN;C<-TM:J&=Y6BW)K2S@BBC#&24C1#$D*-),Y&)':I>N;5KOF*WL=I4B&7
M9["^(:J!6E;<&N)Y6FTF%%AMT>7Q2D<"1L[","0]!#D/YFW778'S"^*O7O4G
M9.],1U[FNK_ECV/WIUEV%\?.U>INSLGMCK79&%SG7V^:'KCN[:6&WQ+B%G?+
M+C\CM^@-)DIDEIDDJY8?$B#ZL;9?;WN.]-3;=JV&XOI=(\1[:XBW7:HM4T<(
M:XCD^CGN]%O*@,JEI(XG>-65-*AO++:+7:\WFY[Y9V4)/:ES;R[1OEQ*D$LE
M()$6Z@VYI9HG)@K$LDD<=P5D.IF_G=\2]N;8^*>\\UW-A*';/S>W!L?:_P 6
M\LV%W=-#VOF^R-MKNS95-114^/>3&1UU$\++4YM*.&.::"EFDCJIX89!!<[5
M?VG-S\ASQZ=VCBOIFM]2EO"VU5:]<."8F6!70]KGQ-2^%K)'19'N=E)RX>;%
M8C;UEMX&E*.I26YD:*)'C91*C>(CB36@$ 1VG\-48A%?(WY4]9X?^^_7&VOD
MO!T=V3U!VI\/<;V?GI.D]U=M46*H_D1W%C\#L3JV:E%(F.-7OV".HV_]_1UD
MT^ CKX<O61T\0IWE1[,/WENMA); 7$+;E/MSP5"&YN8-L6^EM1*2#"8H+NTN
MS< &(E?IM1D,B(977^+6=]!(-$XVJ;<4DKJ^FMEFF@%\T8_M DMK=)';L5>9
MHG**ZH:J#N#^8%\3>C>R<CU#V#V9E:??VW\%C-S[YH=H=5]P=GX/J+;.;BDJ
M,-NGO?>O6.W\Q@]@XRIAAFJH<CO7(XNF:FBEJ1+]O&\BE,MZEQ9WKV,BJ;75
M&TSD1V\=QX0D6%KB73;^/I>-_ ,GBZ9(B4I+'J>DM+B#Z?7&SO= O#%&IEN)
MHUD\(R16T>JX>/Q0T0D6,HTB2(K%XW"EU^)OS\V?0?RZ_C#\HOECV]3Y+</<
MM V-QF:V[LVKW3NWMO>.4W+E8]O8#J[J?I'$5>2W#DJC'41J(<;M?!5$ST\$
MM3XC''+*#.77:VVR6=S')]?>;1M5S+$L4C3&>7:+.[OY6A16:-$FEDEG.E(;
M8-1O"C"@)HS'>7V_75E+&VWV6\;S;PS>+&L"VD&]7EG8()V8(^J)((827:6Y
M;30RRN2QZNAOD9TW\F=H5^]^EMX-NG#X3<61V=NC'9/;FZ]B[TV/O+$PPU63
MV;V'UQV!0XK<.W<Q!#4TU1+BLYBZ2J6&:&8Q>*:-V436DT,$%V=+PW*EXI(W
M22.15=XGT21LR,8Y8Y(95#:HIHY(I LB,H92XC>XEM"&2:'3KC='CD4.H>-B
MDBJVB5"'B>FB5"'C9E(/0V^TW3W7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=?_]#?X]^Z]U[W[KW7O?NO=:I'8'QI^2.$W'\[?DGU]T=V
MG7=L=&_S(]@_([HO#KL'=\5?W%LJGJJW ;TQ^PX$H7ES6.K*.LCDJ9<6DRF.
M'@GZ&2>6-ZMMLY;Y0LY9E436V[[?>*2";>*]BAT2RI4-&1+#&J,]% 9R00"0
M2[_MO[ZWWF.VKI5[#8KBTFR%^LVZ.5R$<=KR1H\J^#5@TK1QNM6'2YZ1^)O>
MNQNZ_P"4GV-NKJOL:KWCNO?WRJ^0WRAW)'L?<LM%U_OGO#"PY7'T/9&12F:/
M"U$=**+&"#)R0OYH)(@-:E0([7<MCV_<.8=@L;B,6.W[#8;;9N9%TSM ;QI1
M$Q(69_%E8_I5JAC85#!B5;C]=O/+R[[<PLMYN/,/U<D.EB\%NLEO%""K#6L*
M0PAQJ5$34X %"2T[FZ.WO\4]_P#SB^/_ 'W\(?D9\P?A_P#+KN&/O79VY?C!
MAL]NK<>/R[9]]S_W>W;2;2JZ*NHOMYVIHG>2JIPSTI:-:B&I/B#FU7D>^\E;
M%MEG?1;;O/+0DCA>YHD$FJW2T296970ZHHPQC/B%2[*R@HKN=[P;RTYNW/F2
MV3Q[/?H5%RB9E27Q'FE4)A@CS2R%2#01^%IDUB5%+MDOB5\E,1_)&W5U13?&
M[NJE[!S/S57L#;W4M-U_NG.]DP=?ST%)!09:LVCBH*K(QQ1"%HY9)X@5*W<V
M96887',6VI[H\H[K<7D4Z[?"!=3(RB(2JFXLW<=*#49$TY"UD5<$TZ(MEL?"
MVOG(6MO);PWUR'LXI*^(T.K:50 $LS,@AD#98_INU2HU$]?;:_)#^:9VM\1]
MBXOXB=^?&/H/X]]M[8[E[3[*^2VUTZVW+EZW:L2PT>VMD;/JWEGJC/$M1"E1
M$9E\LT;SK3Q0EIB7EY=KY$Y@N^=KS<+:ZG6":*TM[9S*7DFDBFU3,  BK)#%
M48'AB6CL[(@0SK?WW(%O[?6UM*'D^E%Q/(FB*);>WFMV9*FLA*W$C*O:VM8U
M(TL\D81=N;'^4OQEW5_-.Z)VQ\2N\N]<;\_]Q9?=/1_:'5>TWW/L#"5?9-/D
M*'<M'VAG::6-,(N.&4=8C4J"SP$O:GD6H!'L4&V<P\E\M;!/>Q6,_+MTGC"X
M;PQ+;PS6TD4D+$%9))([1-2@T1I6U%6C".-+V[FV+G.ZYPCC-S!?;;! BQ*7
MDCN;:TEMU$L8.KPVDF+$CC&JZ"S,XBLKWY\<NP^K_P"35NOXSTV%RF]NTMM?
M#K*[%DVYLS&UNY<IFMZR[2<UV#VWC</'+45SBLEDIZ9:>)GF"J56[6]EO.6]
MVF_^X,6\V7^XPW'; K&H_0M;FTC\9ZTT Q0^*^J@05U4"GIOD"SFVC8Y;;<=
M,<KV>[,5U TDNK6]=(@>#/KE6(!:ZWH$U5%2U;E^'_S([Q_ES?R^^F.K8>IM
MF'KW;/6>Y^^^H_E!'VGM"AWA4;'Q='6[8Z_WA@]F8R;*FACR"2S9?%SR43N\
M5.#)Z&7V*]XW[9;'WAO>:9V^I@A0_226YCE*7+Q)&;A=3")FBCU+$:L%=WUH
MV*!W9+*\D]O9MB77;7%U/*LA8%";0W-R\L1)!91<'P*LJAC%J"R(&.IJ_E<=
M7?/+8WSC^=FZ>_.NNL=G[+[ W;@\CV%N+"[1[DV_@-[;RH*?(Q[7K_C-E]YT
M\-)DMMPB6J&7EKI))T+T@A(U/=K>KWD^7VYL;*PEN&>*>^>WCD: SI)+=1M.
MUXBFJPR)K:T9 &?!<D5ZHUINR<^?5/%& +.TBD>)7^F\".W58HX&I_N2C")9
MT8Z% E"@$+U9%CV3;'\QC?*9J-8V[?\ B+L =?UTQE45<_379VX3V#@*%F_;
M:6./=>$K9(E.O0=>G2K'W&^F2Y]N=^VZW4F6&^2Y=5&HO#=[>+6%R!W#PY[*
M:/A2LZ#BZ@B_=G'[RV&Y-1&(=QMB:'3XQEL[E06X!Y81(4!H66VE(J$.DB^*
M^#9J_P"6ONZ:MF^8%%W!5?'#MN6GZDI/D/\ *C$8VHWA/M_,/B-I0="4>X8L
M8T57,88AM]<-X*@2>$TSI*480\S[_-#?[?%8+;7$:#8PS/;6UPR@)8"XK*\3
MN#;TD[BVJV,>"GA#2KV:UMKCFJ>XO7>&.3=;]M:320+X3;C<%)5:-T"AXRL@
ME6FL-XNHEM1.5U7UOG:KO_'_ -[-E9U=F9/^7YU!USFZK,8#)4^!J,Y'N_,#
M<6RZVMJHEA^^BI9U:JH&?S)&X9T"L";\T/8[D.=+99E*7V]QO$4=:R0&WW!&
MFA.0Z*9$'B*&0,RU.0"'>7&O-NVKE.:-3'/96EWK!7,4FG93&)%8=K,T,FE7
M U>%(*'0U >^!_4'<&.[8SLG=6U]R8K#_#WKVL^)'0>;W+C:ZFI]_P"V*C>]
M3N*O[3V[6UZ**V&KVM0;%Q35T!*_<TV0@+%DD'MW=-VBN]BDWLNHW#F![:2]
MC4J&B-C;*DJNBU(%SN<]_<K4T>);:11HT'KTE@MKO<>PV*$;9M9N;FV8:A&Q
MW*37!"JY2NV62"TIK?0TTH 0&G2K^?G4O9G?^Y=B[!Z2V?F,7OW:.T][;MW-
MW%63[CV9M?(=99S'/@,]\9J/?&+6/[BKW_*D5-6BGDD.$IZ9<PRI61XU9B/E
MN\L]KN+K>=U07%A$((Y[*@+W["9+B,+&V'2S6-YM; ))*ZV&HQ7=Z$/+\32V
M%OM]M,8;F>9WM[D5;]VND31M>M3)9Q,+>. $-(KR70&JRB),/NW8M-\COA'N
MOK#:>TLSTPG:?Q_W!U]M[9&\-MUFU,GUK697:$VVL=MO,[>JHHWABQDX2G/A
M0Q20H):9WA>*1DW,$EW:[Z=R@G7<)K>Z@O4D!Q<F*>.[2M2#&T^D*ZO1X'8K
M(H9&7JO)D]OMJ6L<UL;.*$-;R1 AO"4!K>7PW%5E51J:&52R3+HD4LKBJ9Z)
M^3]56XGK;JKL7H/Y(]=]N4V-P&SMV8NJZ*[)SG66%S^+HH\9E,I1][8"@JMF
MU.%9XWJ*6O7.!W@*>2*.<M IYOMC;[KNEWO>T7$3VEP\TZ>)+'#,JMKE\-X)
M62;Q1_9T1&5Y*>&S(0W1!M"S[)M5ML^Y(3-;+%!JA5YHY NF)94=%(6-Q20B
M7PWB74)%5ER6+I?NW=/57Q\WETS@OCO\E]Z=ZU/9_P HH=N;2;X^=N[.V'4U
M.^.]-T9W9V9R_=V_<1BMFPX:HI,A1UTM?!G9C]NQ,4<LNF(E^[[(W,>R[9:Q
M7-O!%)M&UVLTDL\2F!DVVW@N-=N&:Y9X65QX2PEG=0O:#K!Y9W\.Q\Y[WNMX
MDLD?[[O[N)88VD-Q$UX\L7A2*/!'BJ!I>21$ .HMP!E9_KGJCKGXX=0?$3NW
M;/S(W9D^J.EMK;8&;^-^QOE97;#W[F)=N4]!F\?59'HR&;;62@%7"\<>+W\A
MHXXS>6(Q2RLYES!N%YS'S#NG,G+H@5WDT0I>-:?#&JF!_#O3X))&GQ)8AK#A
MU##2!T7[+'<;5MMO!O#:'N7DN96@\?\ 2DGFG:2'Q+0FZ14,C#M*B1/#DIJ
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MQA8HU "JB*H   Z">Q;=-M6TP65U*;B=5U3S-\4UQ(3)<3M_2FF:25L :G-
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M .4>^_[+7_Z!Z]_P3WNI_OVV_P"R=?\ /U[_ &03X\_\Z[=?_H3U/_1GOW_
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M?M;>IZ]U[_9?.A/^?(=0_P#HM=F?_47OVMO4]>Z]_LOG0G_/D.H?_1:[,_\
MJ+W[6WJ>O=>_V7SH3_GR'4/_ *+79G_U%[]K;U/7NO?[+YT)_P ^0ZA_]%KL
MS_ZB]^UMZGKW7O\ 9?.A/^?(=0_^BUV9_P#47OVMO4]>Z]_LOG0G_/D.H?\
MT6NS/_J+W[6WJ>O=>_V7SH3_ )\AU#_Z+79G_P!1>_:V]3U[KW^R^="?\^0Z
MA_\ 1:[,_P#J+W[6WJ>O=>_V7SH3_GR'4/\ Z+79G_U%[]K;U/7NO?[+YT)_
MSY#J'_T6NS/_ *B]^UMZGKW7O]E\Z$_Y\AU#_P"BUV9_]1>_:V]3U[KW^R^=
M"?\ /D.H?_1:[,_^HO?M;>IZ]U[_ &7SH3_GR'4/_HM=F?\ U%[]K;U/7NO?
M[+YT)_SY#J'_ -%KLS_ZB]^UMZGKW7O]E\Z$_P"?(=0_^BUV9_\ 47OVMO4]
M>Z]_LOG0G_/D.H?_ $6NS/\ ZB]^UMZGKW7O]E\Z$_Y\AU#_ .BUV9_]1>_:
MV]3U[KW^R^="?\^0ZA_]%KLS_P"HO?M;>IZ]U[_9?.A/^?(=0_\ HM=F?_47
MOVMO4]>Z]_LOG0G_ #Y#J'_T6NS/_J+W[6WJ>O=>_P!E\Z$_Y\AU#_Z+79G_
M -1>_:V]3U[KW^R^="?\^0ZA_P#1:[,_^HO?M;>IZ]U[_9?.A/\ GR'4/_HM
M=F?_ %%[]K;U/7NO?[+YT)_SY#J'_P!%KLS_ .HO?M;>IZ]U[_9?.A/^?(=0
M_P#HM=F?_47OVMO4]>Z]_LOG0G_/D.H?_1:[,_\ J+W[6WJ>O=>_V7SH3_GR
M'4/_ *+79G_U%[]K;U/7NO?[+YT)_P ^0ZA_]%KLS_ZB]^UMZGKW7O\ 9?.A
M/^?(=0_^BUV9_P#47OVMO4]>Z]_LOG0G_/D.H?\ T6NS/_J+W[6WJ>O=>_V7
MSH3_ )\AU#_Z+79G_P!1>_:V]3U[KW^R^="?\^0ZA_\ 1:[,_P#J+W[6WJ>O
M=>_V7SH3_GR'4/\ Z+79G_U%[]K;U/7NO?[+YT)_SY#J'_T6NS/_ *B]^UMZ
MGKW7O]E\Z$_Y\AU#_P"BUV9_]1>_:V]3U[KW^R^="?\ /D.H?_1:[,_^HO?M
M;>IZ]U[_ &7SH3_GR'4/_HM=F?\ U%[]K;U/7NO?[+YT)_SY#J'_ -%KLS_Z
MB]^UMZGKW7O]E\Z$_P"?(=0_^BUV9_\ 47OVMO4]>Z]_LOG0G_/D.H?_ $6N
MS/\ ZB]^UMZGKW7O]E\Z$_Y\AU#_ .BUV9_]1>_:V]3U[KW^R^="?\^0ZA_]
M%KLS_P"HO?M;>IZ]U[_9?.A/^?(=0_\ HM=F?_47OVMO4]>Z]_LOG0G_ #Y#
MJ'_T6NS/_J+W[6WJ>O=>_P!E\Z$_Y\AU#_Z+79G_ -1>_:V]3U[KW^R^="?\
M^0ZA_P#1:[,_^HO?M;>IZ]U[_9?.A/\ GR'4/_HM=F?_ %%[]K;U/7NO?[+Y
MT)_SY#J'_P!%KLS_ .HO?M;>IZ]U[_9?.A/^?(=0_P#HM=F?_47OVMO4]>Z]
M_LOG0G_/D.H?_1:[,_\ J+W[6WJ>O=>_V7SH3_GR'4/_ *+79G_U%[]K;U/7
MNO?[+YT)_P ^0ZA_]%KLS_ZB]^UMZGKW7O\ 9?.A/^?(=0_^BUV9_P#47OVM
MO4]>Z]_LOG0G_/D.H?\ T6NS/_J+W[6WJ>O=>_V7SH3_ )\AU#_Z+79G_P!1
M>_:V]3U[KW^R^="?\^0ZA_\ 1:[,_P#J+W[6WJ>O=>_V7SH3_GR'4/\ Z+79
MG_U%[]K;U/7NO?[+YT)_SY#J'_T6NS/_ *B]^UMZGKW7O]E\Z$_Y\AU#_P"B
MUV9_]1>_:V]3U[KW^R^="?\ /D.H?_1:[,_^HO?M;>IZ]U[_ &7SH3_GR'4/
M_HM=F?\ U%[]K;U/7NO?[+YT)_SY#J'_ -%KLS_ZB]^UMZGKW7O]E\Z$_P"?
M(=0_^BUV9_\ 47OVMO4]>Z]_LOG0G_/D.H?_ $6NS/\ ZB]^UMZGKW7O]E\Z
M$_Y\AU#_ .BUV9_]1>_:V]3U[KW^R^="?\^0ZA_]%KLS_P"HO?M;>IZ]U[_9
M?.A/^?(=0_\ HM=F?_47OVMO4]>Z]_LOG0G_ #Y#J'_T6NS/_J+W[6WJ>O=>
M_P!E\Z$_Y\AU#_Z+79G_ -1>_:V]3U[KW^R^="?\^0ZA_P#1:[,_^HO?M;>I
MZ]U[_9?.A/\ GR'4/_HM=F?_ %%[]K;U/7NO?[+YT)_SY#J'_P!%KLS_ .HO
M?M;>IZ]U[_9?.A/^?(=0_P#HM=F?_47OVMO4]>Z]_LOG0G_/D.H?_1:[,_\
MJ+W[6WJ>O=>_V7SH3_GR'4/_ *+79G_U%[]K;U/7NO?[+YT)_P ^0ZA_]%KL
MS_ZB]^UMZGKW7O\ 9?.A/^?(=0_^BUV9_P#47OVMO4]>Z]_LOG0G_/D.H?\
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M_:!!UR)]RO\ IXV__P#2ROO^TJ7HK?\ - _[(9[P_P#*:?\ OW]O^PU]Y?\
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MCD17+QNJAUWS\]_BA\:-Y4FP.X^T:G [JDQ>%W!G*#;W7?:79%+UWM7<>7?
M;?WMW+FNLL)F*'8V K:R*>GI<_O&IQF.E:"HT5+"GG,;.W']Z[DNTV'?,T\-
MJ*]L?U5R4%O:F9],(NK@R1^#;&03R^)'X<;:UJY>C]W[>VY7?;$L4T]!W2&"
MV4O<3I"M9G@@4$S3)&T<1P[*2!TI-[_,KXV=<4_>,^]NRX< _P <JS8&.[8H
M*C:V]I\UB\CVOCZ6OZOQVU,#18V6MW14;C>L@H,%!M6GR+UV1\F*I5ER4,U)
M'2WD6[2%[6LAGOVVQ%4$R&^5;>1K?PZ>(K+#=V]P691&+:47)?Z<-('#'24Q
M%T%+']Y,QD0(MCKNHOJ7D+>&D8DLKE3K96!CRHUQZVG?GS@^-W7?:F'Z1S6Z
M=[YSM7*4FU<CD-F=9]&][]R9+8.,WO5_9;0RW<DO46VLY3[%I,BX<TE7O.;%
MPR)'-('\<,K([9*=QW"7;;(B1X9A;NX(%NMP55Q ;HD6WC>&\<GA^-K$<D4A
M&B6-F3W$JVFW1[I<@I'+$TZ(5;QV@0D-*MK3ZDQJRM&7\+2)4>*OB(Z@E^VO
MYEW6VR/E+\X=M=]=NY+#=5]2=T=+=$]<X?#]3[LWEM[K>LJNI\)N+?'8_;.^
M^L-O9([6PF9W-N;^ 09W?F4HL.M1B)X*2HCEBK5%.6U?=MEM69DDN]UW;<(;
M0UT((89K;:+6P,K%;?ZR;=;+<I(+=F^LG^JA2-9(S;H'-_5-JW&2<24M+#:;
M6>\4 ,4N6:^W"YF"C5,\4&SS;3+</&O@6JL7FT-(78Z7=?SC^+OQYWUBNM.U
MNS9</O;([=7>N1PFWMB]D=B'8?7SUSXQ>SNX,AUOA\O2;(VI]Q%/$=U;PGQF
M)#0U%ZS_ ">;0W!/#<7$MO&P'@%%ED<^'!%)*"8H9;A],$<\P%88'D6:8?V2
M/4=7FBDM[2.\<$K/K\)5[Y9A$ 96A@35-,D09?&>*-TBU+XC+J6J8SG\Q3X=
M8##=1YRJ[=ER4/?W6&?[CZ/Q6UNN>U]Z[L[<Z^VU78B@R64ZYV/L[!5^9S%6
M[9W&S4.'H:"3(UM,\M714E12TM7- ZXEB:2*2*1984LI)(3%(+B)-PBN)K;Q
M;?3X\1\.TN6N$DC5[/P9%O%@92.KM"41I)'C1%N;FSUM+&J&XLY#%.BN7".J
MRZ(DE4F*:6:WCA>1[FW65XK/GK\5*7I+K_Y!0=DY+.]=]K9^KVCUK1;0ZR[:
MWMVKOG>V+J*^ES^P-L=!;/P5=ORKW%B9,3EES>WH=MG(XS["N-?2TPHZDQ6N
MD>TN;>T8&5[J!+N+P1]0LEI)%%.EVKP>(AM#%-"_U6KP )H@9 94#,6Y%Q#<
MS@^$ME*8)_&_0,4XD,7@.LWAL)V<:8X:>)+@QJX(/2*VG_,T^&N\^ELQ\@L7
MO_L'&=6XGL"?J>DR6]?C?\FNN-T;T[1I<Q5;<JNN.J>M.PMGXO<V\\[%DJ&N
MQDN*VGA\C4I6TM32-$*FGFB2L];>*QE8%SN:A[5(P9I9XC MT)XX8M<IMC:L
M+H7.CP#;!YQ)X4<CKN']:YO;7X&VT#ZII/THX"TGA".6:71$LQE*1>"7\7Q9
M8(]&N>%9#)]%=^=4_)3KJB[5Z;W)6;EV;69?<FW9)<KM7>&Q=R87<VS<[4;9
MW;M;=>P^P,?BL]A<KC,A2U%'78O+XVFJH)4*R0J;7=NH7M+:*\<J\,\0GB>)
MEF26)J@-&T)=9*,K(RH2RRH\3*)$9 U',LD\UK1DEMW$<B2(\;HQ1)5U+(JL
M \4D<L;4TR12)(A9'5C55U3\^L;V_P#)_P"8/9V\?D'WE\>?B5\(L_3[!DV?
MO/XN9SJKI3LZ;"[%QL_9^\.U>\>^>MER29JDW/N*GPV!V;M7=N)R3)C(ZZ6@
MR-%E8&9+L]Q G*IYKW!UN#N5Y+:VD'<&B07)V^V%M!&$NKV_GO[._CF6,7,5
MNTEMMTMO#N$<@=9O$)_K''RCMI'B6EHEQ=S)WA;@%[N>*:X+/:06<6UR;?<I
M*ZPM-'/<W4-Q+:1I)&?_ *S^=/Q@[9VAV]O7:V_L[B<=T)MYMW]QX/LWJCN'
MI3L/K[9[8*JW-0[PS_5'<F P.Z$Q%=0T%=48O*)AVI:\4U0M%+.\,BK3=[JW
MV+8)^:-S<)8VQF69U_4:*2"..66"2*+7,ERD4L,GTK1BX9)H66)A+&6UMUO/
MNV]6_+VWJ9+N[\/P$^%9UED,*202-IBFB,H,9FC=HE<,K."" M>A_E+TE\FH
MMQUO2.X]P[TP>V4P3U>[WZT[0VQL',_W@IYIZ:+8_86\,-C\'N.2E:GFILO%
MM_(5KXNJ1J/)+258\/LVNMMO;)"]VGATEDAHQ4,S1:"9$2NI[>175K>[0-:W
M2'7;32H"P++7<;.]$36KZQ+$DP(5J*KY"2&E(9QPDMI=%Q$:B6)"".D%T3\@
MMW]P_)/YI=;''[8BZM^,N\>GNJ-MYC'T653=&7[,W'U'1=P=H09[)SULE'+2
MT-%N/;$%##34,$D4AJS/+.'B$2';%EN^6SO=TAC,^Y7\%K0]LMC91V4'CE2"
M?$.ZC=K<L&"&.UB 02+(S+=S26QW^':D*E#MEI>2YK(EQ=7FY(L1 H$065K9
MW"@AF?ZK5J"Z5/OA/\@MY?)SJC>O;6Z,3MS$X*;Y#?)#8752[<HLK2G+=2]/
M=S9GJ79VYLV^3K*S[BORPPD^2DGI1!3M'/$(8%5=<E+<L.5=EWJZ(>XW+;;?
M<I%B!9%COP][8K$,L6_=DUD9:DEKDS%0B%8D]=M"G,>[;59OXD&WW2V:N10F
M>WM;:/<58_"PAW47T$;*J_HQ1JX,BN[%A^'OR)^;GS'I=O\ R3VQE_B5L7XJ
M[A[7[(VC2]*Y;K[MS<_R.H-B=:[_ ,IUO79K<O<M#N^@V_C=SU-7BIJN?:S;
M!FBH%D6EERL\J-*7-G&O9]IW?=J2+O&V6NY*("%6W&X62WEI"';Q5O/#$L,-
MW*OTJB3ZCPE<0IXS>ZLR[KN>T;6/#?:MPGL':?N\=K.Z-O<RB-/#-LDNB26S
M#-<>-";>9RBSTBM>]ZZ<Z(AE_P"9E\(L%OO+]=Y+NP)F<-V'C>GY<Y2]<=M9
M+K/*]R93<=-M*'I?:?<F-P,VT<WO.'(524]=M+#9RJR]'HJ)*NCACI*IX?;9
MJW@6YVU6E^K=%MP%(-PKRB SVX8 SVD4A_QB]B#V=JBO+<SQ11NZWOXWVPSK
M>#2;6&2><#O-O'%;O=D7 348)7MT,D,$VB>X!18(Y'EC5\O8_P#,K^%?4^Z.
MP]F[W[CJ://]0;TQFQ>WX,)U?W%O/']0Y/,;:Q.[J'/]L9W9>W\A0;9VT:'-
MX]Y-X9RII<#%*9Z:7))4T=9#3VV]3NDMG#8T?Z^4P0-4+&\_ULVW+ 9&TQQW
M$M[!+;6\$C)+<R)_BZ2 J3N]B?;UE^J'=% +EHU(DE\#PO':188]4KB. I-,
M$1C!%+!),$2X@,@B]W?-'XW?'C=>V=B]H[]R5+O/=6#J=VT6UMD]==H=MY[#
M;$HJU<=D.S=]8OJ/"YR;;6TZ:=A#5;LW$M%AX7#++6H4?2S!+'<7LM@C /;B
M,S.Y\.&W\8N(1<7$FF"W:8Q2^$LTD;2"*0H&$;D:$<C6,.X0J98[EF6W6(>+
M+<LBHSK:P1ZIKHHLL1<6\<I3QH0U#-&&0G\O;N'L3Y!?'.3O'L/<<.XH.R^Z
M/D7G>KY:;&83&46,Z&QW>FX-L=&T-&^%IJ85<;[7Q^,K?OJH25$[5#/)-("K
M>W8A'!RQL5W<NQGNMIV^_NI)!X;>+N5JFY&-DHJQ?217<=G32I(M@\M9FD8I
MGO+6^WW=SM7^X-O?36=OD,&_=ZQ[?<S*PJ62ZO[6[NXZLX"3JL9\$1JH#[,^
M0_S@^8[[O['^&K_&#IWXV;<WEN_8_6_8OR0Z][5[IW;\EZK8.>FVINC>VT=J
M]9[OV+3;1VG)E:.NHL%F:S(9RJRD,1R*XVEI9*;[EFP2\DVNSWV^TJFXPPW5
MO:BHF%G<+XMM/<3DLL4EU;M%<Q6RP2F*WEB::99VDMH%MZ;.#=+G8[;4\EA(
M]O<W&/"2\B.BXM88<-/]'*&M[B9IH%^KBG@C1TB%Q(-79O\ ,?\ A_T+N/<V
MP>[.Z\9M_=_6&V\9E^ZLW@>O^V-R=5]39#(8$9RAQ'9O:FVL-DMM[3R66B*2
M[?P&Y<W2Y3)+/21T--52U5.LMWNK&X>YN-K$LEO')-'%5&9YGB[FM;<(M+V^
M1*>)9V0FN0QIX-2!UJUV_="UE872H;R[6$Z$(P)7$2SNC,7M[-YM2I=7/AV_
M:U9NQR'OM+^87\2>G-R9G96]^Q]PMOO ==[)[:RG7NRNF^[^T^Q8NMNP)LM#
MM_>=-U_U=MO,YFIH8OX)D7S$M-0R?PB-89<L**.KI'GW>M'MS7(O'1%LKB>U
MN9-:F*WEMHK:>8SS F*&".*[MF-U(ZVI\9568M50U9#]X6MC=V?>NY1":U6H
M$DZ,Q5!'"U)6ED*R>% $\:407#1QLMM.8U+V3\W_ (O=5[#ZF['W'V>,YMWO
MNBH,IT=0]6;,[![PWSW#B<A@8MTQYCK#K#I?$Y_<V=HX<9-%D:VKQF(FAI*9
MUGJGAB(;V[N$,^U[Y)RW?QM'?0>*9HM+$P) XCEEG904@@CD9(VGF9(1(\:>
M)J= S5C+%N.T?OZU=3:511(Q"!I)-6B%0Y5FN&$<A%NH,](I3X=(I-+'_P .
M#?#R3INO[^H>Z\3F^JJ3?]-U10;@VUMK?.Z<EO#M"LIJ:II>N>L]G;<Q=5F]
MUYV0U24ZXK;..KZHU,=52>+[JCJX8&97$0LM-9CN1N!:B$&=IQ:374%Q)$L(
MD9H8GLKIS,!X)MXC=JYM629KVS?4RW\-#"VUF,7GC@V_TS2Q6TR1SFX$8CE(
MO+:(Q,1(MU*+-E%V&@4N/5?S\VCO_O[Y<=EY'M^@V=\)/C1\?N@CFJ[L3:55
MU;-M7NW>.X=Y9_M-^P*/L?$XK=6%RF*PM)M/'2[<RL<$L$]0R24*5<BZJV\M
MI:;#N.[[C-XKMO$>VVJQ:9EI%MNVW)%N;?6;N:^NMYBMA&OBR)/9"WB59FGC
M-IG^KWG;]@VV*1)X["XO[XRJ8J1W%R\-EK68*84MX-JW"\:8^'&]K>Q7#L\'
MT\H-)T;\X_C/\C-XGKKJO>^Y*OL6':>4WYD.N]\=1=S=0;_P>S,7D\;B%W/N
M79/;^W\%E,715\V6HCA)\C20KE8C-/C#5P4M5)"MCM)I;>YN8M++9M;QW%'0
MM!+<BY,,,R!M<<[+:3.T#JLT48BDE1([BW:5&]]:QW,%H[4>Z65X!1J3Q0>$
M)9X6IIFMU::./ZB,M 9285D,J.BOG=/S!^//Q^W=@^ONT-[Y+'=A;JV9N3?V
MT>OMJ]?=E]F[]WGMS:61I,9GO[E[*ZPP^9R>8KXI*V.2/#XREGR$\$=7504L
ME-0ULM.7"YA;ZH1DN;$6K3JJL[1)>&[$$K*H+>"38W7B3 &*W$=;AXA)&7,/
M!<& .507 N#&6954_2_3":K,0JD->6J(&*F66>.*$/(=/2.S'\P3X>8'J?I;
MO#*]V8:GZP^1&4K\#TUN--N[VJYMZ[DQ>ULON^NVI3[>H\9)DZ3+I38+*4O\
M)R%%3UC9*)<.L!RT]/12K+N*2SNC9./$E^E6]182+@S6KO9I'-;>!X@NEE;<
M+/P1;>*TRW"/$'34P:MBMU:3WH8116MPUK.TQ%OX-PDDT4L4PG,9B:%K>X-Q
MX@46\<$TLQCBBD=6;L/^8U\2.JL5LG);[WMV#AJS?FQ/]*5!LZ#XZ?)/-]H[
M6ZP2H>CJ.R>VNH=O[1JMU;&V_!-%-#59K>F'Q5'!)'(DTT;1N%8DD@ANI;::
M2-!;I"\\ID06ULMPFN$75V6^EM6D0,0EQ-&X\.74H,4@5R"&>YM8[J")V$\L
MT$,81_'N);=@LR6MMI^HNBA>.IMXI 1- RDK/"7+3\[_ )RC;VYOAIT)T-V-
MW#MG+?,7>4.>;O\ ^/?QFW[\FJK:_P =\)L:NWCEM]=7U>+V+OK9U;6Y'(';
M>(:HR..R,&+Q^5;,UE(M'$M2KMOMUW><[ORA=R/8R;?!<3W,;HL;O*DUO96]
MLTLZ^%;P?57B2W=VX\&)+9K-YK:XO+9^D\VYV%IR4_-UL$O%NI+>"T*%I5K)
MKN9Y?"@D6:65-OM;QK6VC#33S:9$@GAMKE U;J_F9X#XW8/'TF^\UO/Y3Q[I
M^7]#\.NHLOTM\;OD5NKL+)9+J[%8S ?)+,=TGJ+8V0P]?NW!9#';XST>+V/M
MVEH\I34(HL12WI,E4T>[/<;#?+G;/IX6@_>\>ZWJM#',UM'96;[@MNT"3,]R
MX,MI%9RM)([*TZWQIMX%PRF\VZ[VJ#<9&+RKM<>VQRK*T(G-WN*VLT1<KX,"
M6KP[C9R+(JED&NW_ %]Q>&R>RGLSY =3=-=13]Z=I[FJ=C=;T]!MRM:OW!M?
M=]'N62JWA64V+VIMFEZZ^P.XYL_DJZMI,;0[;AQ+96:NECH8Z-JMA#[I?G]V
MWJ[=-^I.\WT\:0?XR99:D:8/I_%\<45GUPZT\)6FU>$K.&MNKN=I]?;@I"(3
M<.TP-L(H536SS_4>$;<(OQB<1LC=CA7[>J_/ES_,#P%!\7MB]I]$[]W3U+6;
M^^6GQWZ'FW?W5TEOSI7/;0P&8[+Q.YN[:VOZW^4&VL-7Q^'KZEW#4P5-5ABA
M!62F?RJCI>!$3FWEO;+YR8-RGN9&CATSRW$5CM^XWIM D/B3(][<6,>WJJ*M
MR9+J)8!XLL.JKS)_5[?[Z&-WFL++3&2K1I%<WT]MM]I<M)(%B\&TGOHKR9W+
M6ZQPL;C]$2#HWG7_ ,VOC%V/L#N#L[%=EOM39WQ]KJ^@[QJNX]D]B= 9KJ=\
M?MNGWE)6[^VAWIB-N9C&44V(JJ;)T60JJ!*6KI9$J*6::)@WMFYEBM-JBWN9
MU^FF=HE96#GQTD6)K9HT+2)=B1XT^D=%N:RP_I?K1:WK>*:ZW,[- C-<!$E"
MZ2 \,AE"3Q.0(Y;=C#,!<1,\.J&9==8I J4ZL_F'_$3N3<3[/V3V9G(-XQ;
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MRLK)YJJKJZJ62>IJJFHD,L]143RDL[NY+.[$DDDDW]@2&&*WB6"!0B( JJH
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MVLD^21%S%<,;SGYW@$DM[;265HD1U)-:7]M:\JV,Z3)59)H-L"[C>1*?'M!
M[74<:#6PE[FSG</1^]/YI?6=#\8N^.T_D/\ ,;L^7)_&;=FW.I][;EZ+WOU[
MG_C7M;ISKRB["^1&.HIMI;)Q>S<G0YM\UBMT9/'U2P">IQ=)DIJ^(5!#>;,_
M-WMH/;>%ULKFZFWJ+<)YET1(FY[E=.NZ!S1;TQ;+)8VZP0M)=M)MZV9A55A=
MSFWW"'EWGR'GB\#7-A:6FU?20VP#3UV^-WEVQ8A0P//N37-PEQ,$L@-Q$[W
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MHW45\*2MAOP,V7NVGW/\Z.Z=][0W5LS/]^?-KLO)83';RP.5VYF*KK+I3:6
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M1@YN4\V[6:37-L\;\P<Q;COMQ&SJWTD-G'(FVVER(RT;2D;Q"P))22ZVF6>
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MM/\ MBZ]_P %U[D?\H6V_P#.&Z_[;.O?\,N_%S_GO>_?_0IZ\_\ L6]^_P"
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MW_T*>O/_ +%O?O\ @.O;+_E.W3_G-:?]L77O^"Z]R/\ E"VW_G#=?]MG7O\
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M -@'L._ZS7+'^_[K_>XO^M'1_P#Z[G,G^^+;_>)?^MW7O^@8?X$_\_<^7O\
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M<^7O_H>],_\ V >_?ZS7+'^_[K_>XO\ K1U[_7<YD_WQ;?[Q+_UNZ]_T##_
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I>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>mgnx-123116_chartx18988.jpg
<TEXT>
begin 644 mgnx-123116_chartx18988.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %N J$# 2(  A$! Q$!_\0
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MR9_P21_Z1T?L@_\ AD?!_P#\A4?\.3/^"2/_ $CH_9!_\,CX/_\ D*OU&HH
M_+G_ (<F?\$D?^D='[(/_AD?!_\ \A4?\.3/^"2/_2.C]D'_ ,,CX/\ _D*O
MU&HH _+G_AR9_P $D?\ I'1^R#_X9'P?_P#(5'_#DS_@DC_TCH_9!_\ #(^#
M_P#Y"K]1J* /RY_X<F?\$D?^D='[(/\ X9'P?_\ (5'_  Y,_P""2/\ TCH_
M9!_\,CX/_P#D*OU&HH _+G_AR9_P21_Z1T?L@_\ AD?!_P#\A4?\.3/^"2/_
M $CH_9!_\,CX/_\ D*OU&HH _+G_ (<F?\$D?^D='[(/_AD?!_\ \A4?\.3/
M^"2/_2.C]D'_ ,,CX/\ _D*OU&HH _+G_AR9_P $D?\ I'1^R#_X9'P?_P#(
M5'_#DS_@DC_TCH_9!_\ #(^#_P#Y"K]1J* /RY_X<F?\$D?^D='[(/\ X9'P
M?_\ (5'_  Y,_P""2/\ TCH_9!_\,CX/_P#D*OU&HH _+G_AR9_P21_Z1T?L
M@_\ AD?!_P#\A4?\.3/^"2/_ $CH_9!_\,CX/_\ D*OU&HH _+G_ (<F?\$D
M?^D='[(/_AD?!_\ \A4?\.3/^"2/_2.C]D'_ ,,CX/\ _D*OU&HH _+G_AR9
M_P $D?\ I'1^R#_X9'P?_P#(5'_#DS_@DC_TCH_9!_\ #(^#_P#Y"K]1J* /
MRY_X<F?\$D?^D='[(/\ X9'P?_\ (5'_  Y,_P""2/\ TCH_9!_\,CX/_P#D
M*OU&HH _+G_AR9_P21_Z1T?L@_\ AD?!_P#\A4?\.3/^"2/_ $CH_9!_\,CX
M/_\ D*OU&HH _+G_ (<F?\$D?^D='[(/_AD?!_\ \A4?\.3/^"2/_2.C]D'_
M ,,CX/\ _D*OU&HH _+G_AR9_P $D?\ I'1^R#_X9'P?_P#(5'_#DS_@DC_T
MCH_9!_\ #(^#_P#Y"K]1J* /RY_X<F?\$D?^D='[(/\ X9'P?_\ (5'_  Y,
M_P""2/\ TCH_9!_\,CX/_P#D*OU&HH _+G_AR9_P21_Z1T?L@_\ AD?!_P#\
MA4?\.3/^"2/_ $CH_9!_\,CX/_\ D*OU&HH _+G_ (<F?\$D?^D='[(/_AD?
M!_\ \A4?\.3/^"2/_2.C]D'_ ,,CX/\ _D*OU&HH _+G_AR9_P $D?\ I'1^
MR#_X9'P?_P#(5'_#DS_@DC_TCH_9!_\ #(^#_P#Y"K]1J* /RY_X<F?\$D?^
MD='[(/\ X9'P?_\ (5'_  Y,_P""2/\ TCH_9!_\,CX/_P#D*OU&HH _+G_A
MR9_P21_Z1T?L@_\ AD?!_P#\A4?\.3/^"2/_ $CH_9!_\,CX/_\ D*OU&HH
M_+G_ (<F?\$D?^D='[(/_AD?!_\ \A4?\.3/^"2/_2.C]D'_ ,,CX/\ _D*O
MU&HH _+G_AR9_P $D?\ I'1^R#_X9'P?_P#(5'_#DS_@DC_TCH_9!_\ #(^#
M_P#Y"K]1J* /RY_X<F?\$D?^D='[(/\ X9'P?_\ (5'_  Y,_P""2/\ TCH_
M9!_\,CX/_P#D*OU&HH _+G_AR9_P21_Z1T?L@_\ AD?!_P#\A4?\.3/^"2/_
M $CH_9!_\,CX/_\ D*OU&HH _+G_ (<F?\$D?^D='[(/_AD?!_\ \A4?\.3/
M^"2/_2.C]D'_ ,,CX/\ _D*OU&HH _+G_AR9_P $D?\ I'1^R#_X9'P?_P#(
M5'_#DS_@DC_TCH_9!_\ #(^#_P#Y"K]1J* /RY_X<F?\$D?^D='[(/\ X9'P
M?_\ (5'_  Y,_P""2/\ TCH_9!_\,CX/_P#D*OU&HH _+G_AR9_P21_Z1T?L
M@_\ AD?!_P#\A4?\.3/^"2/_ $CH_9!_\,CX/_\ D*OU&HH _+G_ (<F?\$D
M?^D='[(/_AD?!_\ \A4?\.3/^"2/_2.C]D'_ ,,CX/\ _D*OU&HH _+G_AR9
M_P $D?\ I'1^R#_X9'P?_P#(5'_#DS_@DC_TCH_9!_\ #(^#_P#Y"K]1J* /
MRY_X<F?\$D?^D='[(/\ X9'P?_\ (5'_  Y,_P""2/\ TCH_9!_\,CX/_P#D
M*OU&HH _+G_AR9_P21_Z1T?L@_\ AD?!_P#\A4?\.3/^"2/_ $CH_9!_\,CX
M/_\ D*OU&HH _+G_ (<F?\$D?^D='[(/_AD?!_\ \A4?\.3/^"2/_2.C]D'_
M ,,CX/\ _D*OU&HH _+G_AR9_P $D?\ I'1^R#_X9'P?_P#(5'_#DS_@DC_T
MCH_9!_\ #(^#_P#Y"K]1J* /RY_X<F?\$D?^D='[(/\ X9'P?_\ (5'_  Y,
M_P""2/\ TCH_9!_\,CX/_P#D*OU&HH _+G_AR9_P21_Z1T?L@_\ AD?!_P#\
MA4?\.3/^"2/_ $CH_9!_\,CX/_\ D*OU&HH _+G_ (<F?\$D?^D='[(/_AD?
M!_\ \A4?\.3/^"2/_2.C]D'_ ,,CX/\ _D*OU&HH _+G_AR9_P $D?\ I'1^
MR#_X9'P?_P#(5'_#DS_@DC_TCH_9!_\ #(^#_P#Y"K]1J* /RY_X<F?\$D?^
MD='[(/\ X9'P?_\ (5<+\3_^"+O_  2>TCX;?$#5--_X)X_LC66H:?X&\87E
MC>6_P4\'I<6EY;>&M4GM;J"3["3'/;SI'/#*F)(I8TDC9)%5E_8"O./C#_R2
MCXF?]D^\;?\ J+:M0!_@G4444 ?[67_!$S_E$C_P3H_[-!^"/_J'V5?J-7Y<
M_P#!$S_E$C_P3H_[-!^"/_J'V5?J-0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5PWQ,^)?@#X-?#_QC\5?BGXOT
M'P%\.?A]X=U7Q9XT\9>*-0@TK0/#?AW1;62\U/5M4O[AA'!:VMO&S' >6:0Q
MV]O%-<310OW-?E'_ ,%M_P!C/XM_M]_\$S?VE_V8?@7K,&F_%7QIH_@_7O!V
MFWVK0:'I/C+4_AWX^\,_$ > M5U:Z>&RT^#QC#X<DT:RO=2N;32+769M*GUF
M[MM(COIT /J3X:_ME_#?XGVWP3U72O!OQJT'PU^T9?7=K\%O%/C'X1^*?#6C
M>+[6#P1K_P 1K+5=42\B?6/AM8Z_X-\-ZIK/AB+XM:1X"U7Q$([>QTK2[G4K
MRVLY/K;>I!/S<?[+9^H&,D>X!%?!OAKXB?%GXJ_LH0Z-\-OA/\2/@Q^T+=_
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MG3=+USP[XR\#? [7?B)_PE6I:?\ "[4(=*U:WLKZ74-.\)6NGZGH\%J ?U'
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MU;PC\0+K4=/MK'1O&/A[X4^%'[+_ .W7\(O%W[?WQ=^/7P6_:J^*/[3GQ/\
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M&.2" <^A( ;\"<'@\U_+1^W-X'_;O_;/TK]A'X@6?P(_:5^&VHZI_P $^/\
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M^&5M>S^(KO1? L4CS77BGQ-_PC^BZ_XW71+#P9_PD&D1ZAXCLP#]]_#?Q_\
MA!XM^-?Q1_9V\/>,])U+XP?!OPC\-_''Q(\%P,PU'PWX;^+4GBQ?!%]=%E6*
M4ZLO@[5YYK:!Y)]/MIM(N=0CMX=<TI[KYS\=_P#!1C]FKP3K'[1NG07OC?Q]
MI?['>GV6J_M5>+/AC\/]<\>>%O@3%=Z3-XBN[/Q1?Z.AN_$7B3P[X7M[CQ3X
MT\(_#+3?'OB[P-X?C&I>+]$T5)84D_(3Q)^SO^UW\!/^"H7[&G_!2#P'\,?$
M/Q,TG]I;P%XM^ /[>W@SX;?#+Q-X=\3>#_AWXJU*U\<_"WXA_$.QU_QSX@L]
M=U_X+^*+_1_!5^-%L;+7E\#?#^WL]!T:[LKM+6R\]\(_#/Q3_P $OO '_!6'
M]GGXQV.L>+_$'_!2W]KC]H'Q?^P7XPM;_3H_#W[0'Q*_:R^$&H:3X9^ WB3Q
MUK=Y9^&/@[\2?"?B+1[BRUC5/C1K'@CPIXITR;^V/A_K'BJX@O\ 2+4 _IM\
M/?%?X8>*/A;I7QL\.>/?!^J_"#6_!%O\2]*^)=EK^F/X%O?A_=Z(/$D'C2+Q
M,;A-('AE] /]L-K,MS'91:<KW4\T<<<A7YA^&_[?/P1^+'@OX>_%3P-H'Q?U
M?X,?&#X@>&/AS\*_B\/A)XI@\$^/=2\8Z^_AGPSXDTZ&6%?&&C_#?7=97[/H
MWQ.\8^$O#/@/6H;G3;_1M>U#3]<T*YU/X*\%?\$O_B]X=_X(&/\ \$O#\2](
M_P"%X7O['OC'X33>-K34+Z;PC'\1O&,FN>++GPPFL26B:E/\.;;7=:D^'C:K
M_945Y+X)22^31X9'73D^K/\ @F]KGC[PO^Q;^R/\!_BG^S]\4OA=\7O@O\&O
MA-\%/BCX/\3>&[8>'/#&O?"+PGIG@W4O%&C_ !&L[FZ^'/CKPMK%UX8BU[PS
MJ'@#Q'XEU"]M=9TS[1IVF7T6I1Z: ?I.KH0-N<8!'R,,C'&T;1G [ $CTI 4
M! 52,84 1L, _-Q\H^7U/W0W!(/%?R=:/^SU_P %1X_A?XOTK5[7XN3_ !H?
M]B;_ (+'^%_VK/$=MJ6NQZ?\;OC_ /%'XN:GJ'_!/>7X0ZLNJPZ=KGB;1?"[
M6]_\+O$?@PP0_!?X=A_A]K6J^#KRZM_#D7S7X>_9&_X*0>&-*N=9L_!/[83>
M+=!3_@@E\3?"\EW\2/BEK./C-\/] MO#W_!17Q!/:ZCX]O=/U+4X=!MX]"^*
M5MJ<-WHOB6Q$UII-GJL<CRN ?VLXC4_< )^4D1G&&Y.6"XVG^(D[0?O$4;8L
M[=BYP!]SC"\JN[;MX[+GCL*_D8_;4T+]I3XT_MO?\%F/A-^S?JOQEUCX]^%/
MA=_P2E\3_L?VG@WQCXVTSP_\(OC3K?B3Q1/K?Q#@FL];L_!W@'3)_#>D7][\
M0]?UR*RT/Q#X.TO7O#VL_P!LR:NF@:U]AZ+\(?\ @H9IG[:B>+=1C^(%WJ]I
M_P %3OBO\4-;^(%O-JDGPOU;_@EM+^QE'X>\"?""PD;51X8N)IOC&EAI&A_"
MI4N?$^B?&BWOOB[?Z7;:3)=>-;\ _<[XN_%[PW\&]#\.^(/$GA_Q_P"(;7Q-
M\0O 'PVLK;X=_#OQ7\1=6M-8^(?B6S\,:1JVL:7X3TS4K[2/".EWM['>>)_%
ME]%%HOAO2TEU#4KB-!&DO:Z7XL\*Z[K/BKP[I&MZ3JFN>"K_ $S3/%^E6-U!
M=7WAW4]7T2Q\2:58:S;PEWL;Z^\/ZIINM6MK<!;B32]1L;X1BVO+>27^2^S_
M &=/^"D'AG]F/Q?X(T/2/CQ\0M6T[]I__@FMXW^&7QL32OB#\(?VDO'?PITS
MXJ^(O%G[0/@O]I/X<S^+Y_#M_P#$_P""?@V]D\+?%[XT_#Z>3P3^TEI6MZ4]
MXWB+Q%HFJN)/$O[+W[=/P<UG_@IQXP^$7P2^-$WB+QU_P63^"'[3'CC^P(;G
MQ5)^TC_P3Q=O 6O>,_ ?PFT_4O'_ (?TCQ]J<>IZ-J<'CSX6:;K/A/6=>\#6
MFH?"F_U5=)U?3= C /ZL_B?\0?#WPD^&_CGXI^*8=1?PO\.O"GB#QQXD_L?3
M_P"TM4@\/^%]+NM;UZ\LM-$MO-?3V.DV-Y>_8K=S>W2V[064-S>206TOF_[+
M'[37PK_;#^ _@#]I#X)W6MZG\*/BCIUUKG@76=>\/7OAF_US1K74[W2#JPT'
M4<:MIUO/J&G7T-M'JMM8WTR6YN1:"VFMYIOCCPG\'_'WA7_@EI\6/A.NK_';
MXL>*_$/P1_:4L/ EE\7?"2Z5\8YH/BA9?$.Z^'OP[G\)6.K^(]2TBP\,KXIT
MGP5X+T;Q#JTNN>&O!FG:%IGBN73IM(O1:_S_ /@W]B7]N&U_8N_X(Z_!!_A!
M^T?X4C^#O['G_!4'P!^U3X%\*:]XS\#0Z7\0_%GP/\1C]F/0?'*^#O%.A1^*
M&U+XK3Z==^!Y;6YUK2K/5YQ<WEUIUN]\P /[ OC)\5/!WP+^$WQ-^-OQ!FOK
M3P)\(/A]XQ^)_C:^TS2[G6-1T_P?X#T"_P#%'B:_L]*LU:]U&XL=%TR]NX["
MS1[R[,)@M8I;AXXVL_"GXF^#OC7\+/AI\8O 5[/JO@/XM^ /!OQ-\$ZC>:=>
M:9<ZAX1\>>'=.\5>&KZ[TR_BBO=,N+O1M5LYYK&_BAN[.61K>XC2:-U'\MOQ
M5^!'_!07X@?LX_ _P?\ ''X9?M ?%?3O%/\ P;\_&K]G>3P;I\FIZWXC\,?\
M%/=;\">%M+N_$/Q@AL?$%E+;>)_%G@_2]0\)>%?BEXBFO=&AU%_&NC2>(+2X
M\?.GB#>^%'[.7[?6E?$_]COX5?%"S_::^&WPP\-_L*_\$P-$^#7C3X*>#_#_
M (OT[X"_'?\ 9F5-2_:@^%WQ,O+GXC:+H/PTNOBC/#IOACXA>*]?\+>*_"/Q
M2^$%K)\.K+6IKG3+'1KX _JS&P@+MXYP#&P XYZJ ,@D>^2!GF@B//*@DC:3
MLS\O7#$ @+QT8@5^%?['/PS^+_P:_P""D_[1MI>_"S]H+Q#^R+\;[?Q1\9/V
M</B#\1;CQ?=V?[.'Q8?6!X)^/GPCU'3_ !-JDEYI'PX^,:>#= ^*_P"S];FV
MNM$\"^'+W5?#6G6WA"]\9WVB-X;_ ,%0?"?[:WBW]IC5]7_9R^$7[5MTGPT\
M2?\ !-WQUX8\?^%/$O\ :_P]U?1/#'[2_C"Y_: TKX0^'-,UGPXO@;7+;X=>
M)(].^/UMJ]QXOU+XV^#9="TF_P##/AKP1\/Y-8\4@'](N(\XV#.1_P LSC*C
MY23MQP.%)..RG/%?/'Q2_:B^#WP@^-/[-_P#\=ZIJEC\1?VK-?\ B+X8^#-C
M:^'=3U33-;UOX6^!KCXC^+[/4]9LX9;+P]]D\)VESJ%I<:LT%MJ,L+V5I,]Y
MMA;^>74?V=_VZ[#_ (*"7?QDT+PI^TJOARU_X+9>#/$>EZN/%_CB;X?6G[!W
MB/\ 9(U3PC\6+ZQ\+3^*7\'P_#;6/BZVGIK%I'H(U&XU6VLM7M+86MLMRN+\
M$_V9/VT]6_;%_P"":7C_ ..GP<^,.O\ Q4_9Z_;Y_P""I7C#]J?XU:O'<7'@
M"\^'OQF\$_$31?V:?&/A/7[WQ'<:3KWP[N_ >N?#OP3X'TCPU;RW/PXL='O?
M!FI:)X9N-.OK.[ /ZD]9\9^$]!UO0/#6J:SI=KXG\7P:]-X6\.RW=K'KGB6/
MPQIT6J:\-'T^62.:^72;&:VFOY$Q!9K=6@N98C=0"3R7]E;]IWX/_ME_ 3X?
M?M)_ C5]1\0?"CXE6_B"Z\):MK/AW5?"^HW">&/%FO>"=9%SH>MV]MJ.GR6O
MB+PWJ]H$N(D,T4$=W"7MKB&1_P U_P!IS]G?QUKO_!9K_@GU^TO/\*?B%XU^
M$?@?]FG]IKX;:CXX\(SZO?>'_AG\4]3\1>!?%/@F^\::7INO6$6C:3K6@6?B
MFVCU6[TJ_P!/\1:A:6&@7T&I:E;>';6#\??^"5/[&O\ P4B_9IT7X2>%_#_P
M^^,'P9UW4_\ @D;^VA\.M:C\=ZOJ,WPQ\+?MJ77[9'Q%\;?LO2:_H&HZYK7A
M+1M<TWX?^(%UO3]3T/2H;"/P]K%_9:G>27VHW=DX!_98!'RP51C.24V]>IR0
M,@]VZ'J37YY_#'_@I[^R5\7=2_:X\(^"?$GBB[^)7[#]SK<?[1'PAU+P3JVA
M?$WPK9^'EU)]3U[1?"VKFT/C3PW&-(U%8/$'A*]U;2[J:&WM[>XDN-4T>+4?
MF/\ X(U_#/X^>%OAIJ/C'X_/^TWX2^(>N?"+]G?X>_%?X2?'?PG8>'O"^D?'
MKX/>#-2\)_%;XI^ M:;X@>/M3^)&O?&'5)H?$'Q$^+EG<V/AKXG36GAKQ#;V
M\/B&/7K#3_CK]N__ ()M?&#XX>"-3_;<_8ST7Q!\*?V__@Y\1?VK/!LVE^(O
M#TOA6W_:O_9.^+/QE^(VH^)O@KXZT[6ELH/$EMJW@'Q>_BWX.ZMJS%=.\0-%
MH#S:)J,FD:OX- /WW^*'[27P?^"&E?![5?BUXG@^'J_'CXJ?#SX)_#>R\00F
M"_UWXK?%)+QO!W@HPVCW4<.L:@=/O4E#3O;6K6LOG7(0*[,^*/[1_P ._A7\
M0OA9\(=2_MSQ%\6?C-9>.]9^'GPX\)Z;!J/B;7/#/PNLM$OOB-XJ;^T;_1M'
MT_0/!\?B?PS;ZC<ZAJ]M=7FI^(='T?0[+5M5OH[,?D%_P6$_9$^,?_!0/X _
MM%^ OAAI%_X3\7?LQZ)X0\=?LO:OXA^&'BVX\6^)/VC? 3:9\4]%\8_ [QEI
MWBC3M-LUUM['3_@;=ZQJGA+7&TJYN?%VI@0:%<V>HW.%\>/@CJW_  4<^"G[
M&'B;]JGX _M??LH_M.^!O@YXF^)F@_M-_L]P:SI7QE_9!_:BL7\(^$_''@FR
MTWP/-K6K^(O!7Q>ECN_$.C6=CH7B#PQK_A3PTL6MZOX(U:?3+^, _07QG_P4
M]_9F\#^)?V4/!NKP_%QO%?[:X\81?L[^&X/A#XO@UWQ=JOP_59_&WA_6=(U6
M#2]1\"^(?#5G)#>:GI'C>VT&Z2.400+/?Q7-G!]*_ #]J#X%?M0?#&;XO_!+
MX@Z9XO\  NGZ[XG\*>(;Z:TU7PSJW@SQ=X(O)-/\9^#_ !]X6\66&A^*/ ?B
MWPI=Q,GB#PWXNT?1]7TR)H+R>U%A=6EU/_.3\1/@?_P4&\5?&S_@W<^,/[1W
MPF\:?$WXG?LI7O[1WB7]M+QW\-O!%C>Z?X6D^(O@[0?"W@36]>TKPDW]E7/C
M/Q):Z7:7GCG1/ ,&LV&C>*#KL\"QZ.;&XN/>OV#/V0/VF_@%X7_;*OOB#X$U
M+P5XI_X*A_\ !1+XP?'*U^'.J:)_PM3PE^SU\!]<>]UA+?X\3?#CQ78:/8>(
MOBUX;TH^!=>T_P +^,-0M='?QAX;M[W57.A>*!I8!^W/PM_:D^ OQC_9UT7]
MK#P+\2_#=_\ L]Z[X'U;XD6WQ1U"\70_"]GX)\/KJ;^(/$.LWVK_ &1-%T_0
M4T756UN;4S;#2QI]W]L\KR7QX#X%_P""E?[+_CEOV<-176/&GA'P1^V)J=QH
MG[*?Q,^(/@+7_!G@'X[:T+&XUC1=&\*ZOJ\::AX=UCQQH-I=:_\ #+2OB7H_
M@._^)^D0-=> +?Q"SPQ2_AC^SS_P3L_:KTW]D3_@K[_P1JU/PYXA\#_!;Q9J
MWQ/\5_L _M$'POJWAGX*7'A;XS+:^-=<^"D,)UKQ%XE\->%O!'Q)":+<17T.
MK2ZYX>\0^--3T:^U^"TMXKY?BU\*_&G[<7P8_P""3O\ P2WTK3-1^#?[4G["
M?Q$_8A_:$_;9T3Q5JNFZ9<_ ?X9_L[_#/7_ UMX@\":_%.NE?'%OB_XOM#I?
MPI\0?!.\\9^']'G"W7Q/U+X?W5L=,D /Z!/VMOVY_@7^Q5-\$(/C=-XSM9?V
MBOB[X>^ OPDC\)>#=1\8/XE^+OBX2MX6\%2)I4N_1[S7EM[DV6I:PMEH*?9Y
MA>ZM:%0#RW@3_@HW^S5\3].N+GX?7?Q/\7:UH'[46D?L>?$CP3HGP8^)EWX]
M^#GQOU6:>%]/^+WA >'5U;P'X'TM(/MFJ?%?4XG^&46G2P:C:^*KRSF68?G3
M_P %XOV>?C9^T(W_  3(@^#7PQ^)_P 18/@M_P %+/@1\?\ XLW_ ,,M*N+O
M5_ 7PA\"V_B"+Q7XP@NXWB8ZEI3:K;2:7IFE&^\07DZF;3=*NC PKX/\%_LJ
M?\%$? ?AG63X9^"_Q+\'> _$W_!?3]GO]HWPMKNE:Q:6O[6'Q0_8Y7XB>(=2
M^-WQ#_:R\1>#O%$VI^+/#EUX;DTO3-(T+XAW\WCJ;PFK^'/$GA:.UM-%M% /
MZ] ZGN1SC)! )SC 8C:3GC@FN<\)>,?"OCSP]IOBWP9K^E>*/#.LQS3:3KVA
M7D.IZ5J4%O=W%C+<6-]:M);W=NMW:W$(N('>!VB8QR.A5C_-?X;_ &;?^"CG
MB'XXVVD^(8_B.+S6OB1_P6)MOVI?&5YXEU71/ ?Q0^ 7QD\,S:-_P3\\->#?
M$TNL)IE[%H%[=^!)OAUH7AF\37_@=I?A;XAVVN1^#KS7M0?Q5\D_#3]EK]M7
MP+^QK_P2U^"4'PJ_:S^%/P8L?V5_VD/@'^T]X<^&'A&_\5?&'X*_M<^--%\&
M^&_AW^T3_P (->?%'P_?+IWA:]TOQI<?!CXF:)/J_ACX6>*;R#Q\WAO3M!U;
M3=8A /[([FY6V@FF\N:;R899O*@3S)9/*B:7RXP62,RR!=L:O(@9V4%@#D>!
M_LK_ +3_ ,(?VR_@'\//VEO@1K.J>(?A1\4+'6=0\(ZOK'A[5_#&I7=OH'B?
M6_!^J"ZT+6K>VU.PEM]>\/:K:B*YA5Y8X4N8@\$\,C_DM\%?A3^T-:?\%!/B
MG;?M3>%?VMO&%MX6\:_!;XK?LA?M'>"M>6+X2ZC\*?#_ .RO9?"OXI?!CXT6
MOA'Q.?#FBW-_\47\7?$?X@_#*XTA],^)?Q'UG1O%_@E=6M=!T:.'\B?^"='[
M%7_!0;]G?X3>'O UY\(OVB/ -AK?_!$;]M;X7>.?"TVN:_\ V/;?MC7'[57Q
M1\5?L^:/I>D1^*+O1O#_ ,2!\,/$DM[X2UOPE#IL5M9ZXT,^KQ:K=RQ( ?VP
MA@<]1C&<JR]?3(&?0@9P>#@\5\]?M(?M0_"/]E+PCX/\<?&/5=7T?P[XW^+?
MPQ^">B7>D^']3\02GQY\7_$T'A#P-9WMIID4ES9Z=J/B"ZM;&YU:2,VFG>>D
M]VT=N))4_F(^!_[,7_!53P7^SI^VMX/^%UM^T-X*^,_Q2_X(^_L&:;X*USXF
M?$/Q9J5WJ'[='A/X6^(_#_[3EOX3\5^./%VJQ^$_C#>P7EOX93Q3IFHZ%I*Z
M\GA;5;;5!:^&K;4+#T_]H?\ 9A_;#^(/AOXVV7@SX5?%;5?V:+G_ (*A_P#!
M+/XL?LQ_![4=*UBT\8>!_A=\&_#7P8O_ -KCQO:^$?%%XOB/P=X&N?B+X?\
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M<[P9^R!^W!H7@_\ ;]LM ^#'[17@;4?CC_P<#_#3]I_PK=^$G\3>!O$/BO\
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MIU?SII\#/VA/@S^W+^QWX_TWPY^UG^T/\&+[X8_"3]GG]LRZ\?2ZM-=M\8O
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M]U*PB?5/#]_?V$VE7][H&KQ>3JNAW>H:5<W.EW]QI5[9RWVF7-QI]VTUG/+
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MUQ2!$7!5%4@$#"@8!.2!@< GDCUIU% "*JKG:JKDY.T 9/J<=Z J@$!0 <Y
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M_P"R?>-O_46U:O1Z\X^,/_)*/B9_V3[QM_ZBVK4 ?X)U%%% '^UE_P $3/\
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MO_DNC9XH_P">V@_]^-2_^2Z .@HKG]GBC_GMH/\ WXU+_P"2Z-GBC_GMH/\
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MY1(_\$Z/^S0?@C_ZA]E7ZC4 %<=XM^'O@3Q[_8W_  FW@WPMXN/AW6-.\0:
M?$N@:3KC:+KND7L&HZ7K&E-J=I=-I^I:??6MM=VEY:&*>"Y@AFC</&I'8T4
M>=3?"'X57'B8^-)_AMX F\8'4;;6#XJF\%^&)?$C:M9I EIJ;:])I3ZNVHVR
M6UND%\;TW<*P0K%,@BCV]?#H.B6^KWFOP:1I<.NZC:VMCJ&LQ:?9QZK?65DT
MCV=G>:DD*WMU:6CRRM:VUQ/)!;M([0QH6).M10!E:;H6BZ-+J4^DZ3IFF3:S
M?RZKJ\NGV%I92:IJDZ)'-J6I/:PQ/?ZA,D4:2WMV9KJ1$17E95 &K110!F:U
M_P @C5/^P=?_ /I)-7XJ_P#!N!_RA0_8)_[)QXX_]79\4:_:K6O^01JG_8.O
M_P#TDFK\5?\ @W _Y0H?L$_]DX\<?^KL^*- '[>T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YQ\8?^24
M?$S_ +)]XV_]1;5J]'KSCXP_\DH^)G_9/O&W_J+:M0!_@G4444 ?[67_  1,
M_P"42/\ P3H_[-!^"/\ ZA]E7ZC5^7/_  1,_P"42/\ P3H_[-!^"/\ ZA]E
M7ZC4 %%%% !1110 4444 9FM?\@C5/\ L'7_ /Z235^*O_!N!_RA0_8)_P"R
M<>./_5V?%&OVJUK_ )!&J?\ 8.O_ /TDFK\5?^#<#_E"A^P3_P!DX\<?^KL^
M*- '[>T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !10"#R** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O./C#_ ,DH^)G_ &3[QM_ZBVK5Z/7G'QA_Y)1\
M3/\ LGWC;_U%M6H _P $ZBBB@#_:R_X(F?\ *)'_ ()T?]F@_!'_ -0^RK]1
MJ_+G_@B9_P HD?\ @G1_V:#\$?\ U#[*OU&H **** "BBB@ HHHH S-:_P"0
M1JG_ &#K_P#]))J_%7_@W _Y0H?L$_\ 9./''_J[/BC7[5:U_P @C5/^P=?_
M /I)-7XJ_P#!N!_RA0_8)_[)QXX_]79\4: /V]HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BD!!S@@XZX.<?6J&HZKIFCVLM]JVH66F64
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M8*I.GPA1SNIQ9##T<3@J\*V*KY+2PU.*IU95?95J4Y_3)('4@?4@4I.!GG\
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MX_\  3C_ !W'?$7#?A=QEP-Q-Q!FU//,@67\8Y)BN%,%B,9'*Z><99F'#O\
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M1117:?-!1110 4444 %%%% !1110 4444 %%%% !7G'QA_Y)1\3/^R?>-O\
MU%M6KT>O./C#_P DH^)G_9/O&W_J+:M0!_@G4444 ?[67_!$S_E$C_P3H_[-
M!^"/_J'V5?J-7Y<_\$3/^42/_!.C_LT'X(_^H?95^HU !7G'Q$^,/PH^$<.C
MW'Q2^)/@7X=0>(+T:=H<WC?Q7H?A>/5[TS6ENUMISZU>V8O)(9;ZS6X,&^.U
M^U6[73P)-&S>CU_/=_P5Y\)7WAWXY?"+]IS]GWX\^'OA9^V#\$_#'P[TJS^%
M'QPL[R3]FW]IGX+^)_CSIWBJ'X?^(M1@M1XAT+Q1X:^)_P /=*\1?\)#\([Z
MX\<:=#+H&E^*_#6L^&/$>DSV8!^\9\?^!A>^#M-;QGX474/B';7-YX!L3XCT
M87GC>ULM(;7[RY\(VOV[S_$MO:Z$CZU<SZ)'?0P:2CZC+(EFIFKS8_M2?LSC
MXW?\,T']H;X'?\-&^2+G_A07_"U_ I^-7V9O#Q\6BY/PM&NGQN+<^%0?$HG.
MB"+^P/\ B<;_ .SB+@_@=XDUS0/$7_!3;_@W2\<)\&;/]G'5]<_8Z_;4F\3?
M!+4+?3+#7_@E#XP_9W^"^H^"?@OXC-O9Z=/I:^%]8U/Q)X9\+:)J-CHQ-_;Z
MS:Z=H>GZ@-4TVWXK0_@-\4;K]KOXG_'G]BK]H'X>?M82?';Q#^W3\&?C.WQ*
M_96^%'PY_:5_8N^,'_"HOBMJO@3Q%X5^.VE?#SX=?&^U^'VF_$GP_P##GX)Z
M?X0^*&HZEI.N^#-;\':SX-US6=$:TUO1P#^F7PA\3/AU\0;G7;+P+X[\'^,K
MOPO=K8>)+;PMXET;7Y]!O7GO;9+75XM)O;M].F>YTW4;:-+M8C)<Z?J%NFZ:
MQNXX>XK^4;_@CE\,_C3I_P"U3^PSKD6@>)- ^'WP:_X()?"O]GO]HVWU32]0
MT^W\,?M*6/[2%UJ6C?"?Q?8W45L^D_%KPG;Z+\0M;U31-3C77O#VC:A=7%_:
MVEKXPT^ZU#^KF@#,UK_D$:I_V#K_ /\ 22:OQ5_X-P/^4*'[!/\ V3CQQ_ZN
MSXHU^GWQ$\,_'N_O?$5[X.^+?P^\-^%Y=/F_L_0=;^"NI^*M5LPFD>7=BX\1
MVWQB\,17QN+U;BY@*^'[(6T4T=HXN?(:YF_*W_@W+@U=_P#@BK^P2UGJ%G;P
M_P#"MO&X$<VER73[O^%V_%(DF4:I; \%1@1#&,Y.<  _=&BL+[+XA_Z#&G?^
M".7_ .7='V7Q#_T&-._\$<O_ ,NZ -VBL+[+XA_Z#&G?^".7_P"7='V7Q#_T
M&-._\$<O_P NZ -VBL+[+XA_Z#&G?^".7_Y=T?9?$/\ T&-._P#!'+_\NZ -
MVBL+[+XA_P"@QIW_ ((Y?_EW1]E\0_\ 08T[_P $<O\ \NZ -VBL+[+XA_Z#
M&G?^".7_ .7='V7Q#_T&-._\$<O_ ,NZ -VBL+[+XA_Z#&G?^".7_P"7='V7
MQ#_T&-._\$<O_P NZ -VBL+[+XA_Z#&G?^".7_Y=T?9?$/\ T&-._P#!'+_\
MNZ -VBL+[+XA_P"@QIW_ ((Y?_EW1]E\0_\ 08T[_P $<O\ \NZ -VBL+[+X
MA_Z#&G?^".7_ .7='V7Q#_T&-._\$<O_ ,NZ -VBL+[+XA_Z#&G?^".7_P"7
M='V7Q#_T&-._\$<O_P NZ -VBL+[+XA_Z#&G?^".7_Y=T?9?$/\ T&-._P#!
M'+_\NZ -VBL+[+XA_P"@QIW_ ((Y?_EW1]E\0_\ 08T[_P $<O\ \NZ -VBL
M+[+XA_Z#&G?^".7_ .7='V7Q#_T&-._\$<O_ ,NZ -VBL+[+XA_Z#&G?^".7
M_P"7='V7Q#_T&-._\$<O_P NZ -VBL+[+XA_Z#&G?^".7_Y=T?9?$/\ T&-.
M_P#!'+_\NZ -VBL+[+XA_P"@QIW_ ((Y?_EW5#5+R^T2PN]5UGQ1H.DZ780/
M<WVI:EIJ6&GV=O'S)/=WMWK\-K;0H#EI)Y8T4<EA2;23;:22;;;LDEJVV]$D
MM6WL73ISJSA3IPE4J5)1A3IPBY3G.348PA&*;E*3:48I-MM)*YUE%><>%_%M
MMX\\,6OC+X?^.?"'COPUJ2:@='UWPHMCK.B:S+IEY=Z;=PZ=K5CXCN-,N##J
MEC=:;--'</#!=P31RL#$X'Y4_#;]K7_@II\>OBIX7/A#]BS3?@O\ =,\;:?#
MX\\2_&S4I=-\?:KX/L-3DL_$L?A73I=4TF*76)[2.>719=-\-ZUH]W>0VL0\
M0PV%V^HIY&89Y@LNE@83AC<74S*7^R0RW 8O,/:4XNC[3$3J86E4HT</2C7I
MU)5:U6G&5-MT_:--'Z'PEX7<3<7T^*,1A\1PUD&$X-I*7$.)XSXJX?X1>$Q5
M2..^JY7A\%GV88+,\RS;&ULNQ>$H8#+,#BZU/%4XT\6L*IPF_P!:8?B)X(G\
M?ZC\+(?$VE2_$/2?"6E^.M1\(I< ZU:>$-:U?4M!TO7YK;;\NG7FKZ1J-A'+
MO)6:V)E1(Y8'EZ*QUC2=3DO8=.U/3[^73IEM[^*RO;6[DLIWB$R07:6\LKVT
MSQ,LBQ3B.1HR'52A#'^1[XG_ +"7_!1+]HW]L+7OCC\:/@)\0=.^'WQ#\?Z;
MI_BW3O OQG^%WA[Q)HGP6M;ZWT?3/#^C3VOCZZB:?P[X8@M-5ETR=+ZSU36H
M-0W+)<:@+E?Z*/V5?V(?A%^QEHOBS0_@3#JFDP>.=1TK5O%=WXGU37?%M]K&
MI:+97&G6%Z7U+7DM;&46ES*DXT^SM1<YC-QYGD0B/Y_AWB3/L\Q^,IU^&ZN5
M99A<7B*4<9F4\?@<;B<-^\>!K8;+L1ED85?:J--8A_7H>Q;D^2_)"?ZOXP^#
M?A3X7\,<.XK+/&?!<=\;9]PYDV/J\.<&8?A;B?AO)L\_V"/%&6YSQCE'&M3$
MX!8&5?%3R>"X5Q']I*G1BL2HO%5\+S?Q\_X*7?L5_LT>+=>^'_Q<^->F:'\0
M/#26+ZOX)TWP[XO\1^(K0:GIEKK&G"6VT/0;VUB:\TR]M;R#S;U%>&=#N!R!
M])7/Q<L-3^!<WQS^'>A:S\1M+O\ X6/\4_!GAO0X3;>(O&MA<^%?^$JT+1-)
MM;J.1X-;UZV>WL;.SN(6ECU&X2UEB,H*51U#X%_#_5O%MYX_U3P#\)M2\=:@
MMDE]XTU#X5^';_Q7>1Z=:Q6.GQW/B"\N)]5DCLK.""UM$-T%@MX8XHPJHH'I
M4-AKEO%%;P:GI4,$,:0PPQ: T<444:A(XXXTUI4CC1 %1$4*J@*H  %?0X>E
MGCQ&/>-QN7+"5/:PRV&"P->GBL-%SG[*KBJ^)QF(HXBK&FX<T*>$HTO:*3]Z
M#Y3\DSC'^&$,IX3CPUPWQB\_PCP>(XTQ/$W$^58O(LYK0P^&^NX#(<JR7AS*
M<RR? 5<9#$^QQ.+S[,\:L)5IP:I8BFZTOS;^ 7[9_P"V+\:_BYX*\/\ B+_@
MG?\ $KX)?!W5YM27Q7\2?B/XWTRWUGP_;IH6L7FDW<?A&ZT?0+RX6[UFVTO3
M+J" WDUO%>27*(ZK&U?0/[77A#]M+QCIG@2R_8Z^+'PM^$FH1:IK1^(>L_$G
MPJWBJ2?1YK"T_L/_ (1NU.AZ];IJ%IJ,=V;J*YMH8;F"XC)N%\@H_P!3?9/$
M&=W]K:;GU_L*3/Y_VWFE^R^(?^@QIW_@CE_^7=84<FQ+R[$X#,,]S;'U,35C
M4>.A/#97C*$8NBU1PM3*</@G0I\U%MN\ZTE6JQE5<)1C'T<Q\1<DAQEDW%?"
M'A=P%PGA,EP4\)2X5Q.'SKCKAW,Z]2.80EF6>X+Q S?B6.9XU4\?&-.%L/EM
M*> P%>EE\,12JU:WS+^R/\*_VF_A=X5\6V?[4/[1%C^T+XK\0>([;6-%U73?
M!%EX*L_">EC1;+3[OP]90V/D17]G+J%M)J<$[Z?92PRW,X<2F7]W\U_%W_@D
M-^RG\>?BUXZ^+OQ:U+XT>,=0\>:U+K5]X/N/BIJ^F^!=)DGTRQTV:UT'2-*M
M+34-.LY?L7VQK=-8:-+JYG,2QPB*)/TN^R^(?^@QIW_@CE_^7='V7Q#_ -!C
M3O\ P1R__+NG6X;R;%X#"Y9F&#6:X3!U'5HPS:K7S*;JOVB=2K6QM2O5KRM5
MFE[:=1*+44E&,4EEOC/XD9!Q7GO&G"7$4^!<_P"(L+' YC7X#P.6\%X6.!@\
M&X83+\NX:PF6X'*:*E@,+4:RS#X24ZL)U:DI5*U>52G+X*\+7?@Q_A]J>BV6
MM^#9O#B^$KW0-?B&NV&J>'?[-72)=*UB+5OM?]KVUWIR_9;Y=1-P;Z-Y#=&5
MI'+9?@[X5_#+X>(L7@'X=^!?!$2JR+%X1\(^'O#2*C@!U"Z+IMEPX WCHW\6
M>*Z#[+XA_P"@QIW_ ((Y?_EW1]E\0_\ 08T[_P $<O\ \NZ]?ZO0YX5/84?:
M4H*G3J>SASTX+:$)\O-&*Z1BTO(_/?[6S58?$X-9ECUA,;7>)QF%6,Q"PV*Q
M,E:6(Q-!5/95JS6CJU(2FUIS6T-P@'J >,<C/%   P  /0# _(5A_9?$/_08
MT[_P1R__ "[H^R^(?^@QIW_@CE_^7=;'GF[16%]E\0_]!C3O_!'+_P#+NC[+
MXA_Z#&G?^".7_P"7= &[16%]E\0_]!C3O_!'+_\ +NC[+XA_Z#&G?^".7_Y=
MT ;M%87V7Q#_ -!C3O\ P1R__+NC[+XA_P"@QIW_ ((Y?_EW0!NT5A?9?$/_
M $&-._\ !'+_ /+NC[+XA_Z#&G?^".7_ .7= &[00",'H:POLOB'_H,:=_X(
MY?\ Y=T?9?$/_08T[_P1R_\ R[H \XTW]GGX&:-\3D^,^B_"7X?:-\54TK5M
M$?Q]H_A72-)\3W.F:W):R:I;7NI:;;6LM^;MK.W62XOA<W8C1H8[A(I9DD^8
M/VR?V?OVQ_BCXF\"^/?V3_VLO^%%:IX(T?5-/N?A]KGAA=9\!^-[_4[^&\.K
M>)K@QZS%+-:6]G:Z;86]]X1UF*PA>^N+.:WFOKD/]S?9?$/_ $&-._\ !'+_
M /+NC[+XA_Z#&G?^".7_ .7=>7C,GP.-P=?!.%7"4L16CB*D\LQ%?+,1]9A.
M%2.(6(P-2A6]JITJ;E)S:J*$8U%.*Y3[GASQ%XIX;XBROB>&)P/$&/RC+ZV4
M83#<:Y3EG&V4+)Z]#$X:ME,\GXIPN:Y>\ Z&,Q4*5&%"F\++$5:V#GAZ\O:K
MQ']EM/VDK7X,Z(O[6M]\/;SXRPZAK\>N77PVMI;3PR^C6NJW%MX?NG>6;R)]
M2O=)@BU34Y[.STFSBDO!:1Z59R6DH?YR^"W_  59_8?^-_BB7P/H?QAL_!_C
M3_A([KPQ8^&?B=IM[X$O-9U"'4Y-)LAHNI:JK>'=2;6KI8FT:QBUI-8NDN[6
M)],ANY?LR_??V7Q#_P!!C3O_  1R_P#R[KPGQK^RO\&OB+XS\,?$;QM\,/A3
MXA\?^#?$6E>*_#7C>\^'EG%XLTS7M#N8[W2KY=?LM7M-2O5LKR&*YCL]3N+Z
MP,T4;O:L44CEQ.$SS#4,LHY-CL'4AA(QH8U9Y3Q6*Q&.HQ5*"K+'8>O2G2Q<
M8PJSE*>'Q%/$5*BYE24;OW,FX@\,<XS+C7,/$?A;/\'7S^K6S'AJ7A?C,DR#
M*>%<PJ3Q]>>7_P"J^;Y7C\/C\@K5:^!P]&AALXRK%95A,'-TJN/J5^6'TED#
MDD 9QG(ZYQCZYXQZ\4M?('[6GPE_:=^*WPWTO1OV<OVAM-^!'Q!T7Q;IOB9?
M$;^#9-3M?$%CIMG?PKX3U1VU/4X['1;^]N[>^U2630=>6[2PAM'L?*>5FY[]
MCZ+]O&+PWXTTC]LR^^#<NOZ#K]EIW@;Q1\--.FN#XTT$:<;C4_$.NV\.H:38
M:?(VHRQV%A90>'O#]TOV2^GNK PS64K=,LSJPS:&63RK,_95:7M*6;0I4*N6
M.4:<JE2C5JT\1+$8:K'EY(_6,-3IU9R4:4Y75_'I<$X'$< U^-J''?!3Q^"Q
MZP>.X"Q&.S/!<;0HU<50PN%S# 8+%Y32RG.<'5]L\17_ +*SC%8K X:G4JXS
M#45"?+]P45^=OB#_ (*4_LG^#?CIXV_9X\>?'WPQX!^(/@34=-TG59?&7A/5
M]$\(7&HZAI5AJ[VUGXUEU.3PY$^G1:C!:ZC_ &O>Z2L%\EQ;QM.(7DK[KLI=
M4U.RM-2TWQ)H>H:=?VMO?6.H66EB[LKVRNX4N+6\M+J#7I(+FUN8)(Y[>XAD
M>*:&1)8W9&5CO@\TRW,)XFG@<?@\94P=:IA\73PV)HUJF&KTIRIU*6(A3G*=
M&<9PG%QJ*+;B[76IY?$7 _&7"-#)\5Q3PKQ#P]A.(<NPN;9!B\YR?,,MPN=9
M9C<+0QF&QV58G%X>E0S##5<-B</557"5*L(QJP4W&3L=/16%]F\0_P#08T[_
M ,$<O_R[H^R^(?\ H,:=_P"".7_Y=UW'RQNT5A?9?$/_ $&-._\ !'+_ /+N
MC[+XA_Z#&G?^".7_ .7= &[16%]E\0_]!C3O_!'+_P#+NGQ0:VDL37&JV$D(
M<&2--(>!Y$!^94E;5Y1&Q' <Q2;>NPT ;5%'7I10 5YQ\8?^24?$S_LGWC;_
M -1;5J]'KSCXP_\ )*/B9_V3[QM_ZBVK4 ?X)U%%% '^UE_P1,_Y1(_\$Z/^
MS0?@C_ZA]E7ZC5^7/_!$S_E$C_P3H_[-!^"/_J'V5?J-0 53O=.L-16%+^SM
M;U+>ZM;ZW2[@BN4@O;&=+FRO(4F1UAO+.X1)[6ZC"W%M,B2PR)(JL+E% $1@
MA)+&*,DF,DE%))B.8B3C),1YC)R4/*X-2;1[GJ>23UZ]2?H/0$@8!Q2T4 -5
M%7) QGKUY]^>YXR>I  /"C#J** ,S6O^01JG_8.O_P#TDFK\5?\ @W _Y0H?
ML$_]DX\<?^KL^*-?M5K7_((U3_L'7_\ Z235^*O_  ;@?\H4/V"?^R<>./\
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M8:)X<\->-=%U_4M2N[;3;C5YH+:/2;F\B9ET^UN+@%IE1Q"\<;-,/*KECF&
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MRVE5]O1IU:LL,WBH2I59.4*M-MR/$R;Q*^D*\XX2I8KA+A&APQPEQ#A<UR_
M<3^(F8\68# T5C\!7S*K@>#:W V*X=K5,=0P%#ZWEF,Q$,OS18>C@\RJ5,.G
MR<'^R')_P4UT#XF:UX#_ &P[?X%^-?A=IWA2[U'1?C1\/9&T_P 1:[XG2_TR
MTT[0;C0+;^PXHQ+82ZGJ>HW5SX*TB"+[+!%:7]U+.T2>N?'3]OK]E_\ 9O\
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MB,7B<DIXSB3C3*,=FWU3#83VO#E?BF&.GB\31PN25,[J2J27Z'_M >-/BKX
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M%#]@G_LG'CC_ -79\4: /V]HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN$N#)9[GN$E!./+ALYRNAAX2Y959Q;DUSY3XQX_@CBGB?/O"/)L+P5A<^H+
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M]7\>^+]/GDE>29UTG5-/MQ)(QC@C 55^TUAB15144(@543'R(J@*JHGW$50
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MZUH>B^)=*O\ 0?$6D:7K^AZK:R66J:-K6GVFJZ5J5G, )K2_TZ^AN+.\MI0
M)(+F&2)P '0BN-TWX/\ PGT5H7T?X9?#W26MH3;V[:9X)\,6#6]N5V&" VNE
M1&*$H AB0JA4;2N.*,9#-IU(_4,3E]"ER6G];P>(Q57VG,[N#HX["04.2UHR
M4GS7?-9I(XJPOB3B<7AX\%9WP5D^ ^KVQ<^).&L[S_'/%NK*\\*LMXIX>PT*
M$:#A:G6C5J2JJ;=2,'%+Q#]FO]L[X"_M<W?CFQ^#.L:_K\7@2+0FUZZUGPKK
M7AW3[B#Q,=6BT]M/&M10O?H[:-?QW*&VC: HHE3;,I/6>/?V1/V5/BE-/=?$
MK]FSX"^/;RX+-)?^+_A#\/\ 7]1WNYD>1-2U'P]/J$<K.2QECNED+$DMDMGW
MRQTW3],@6VTZQL["W0;4@LK6"TA5=S/A8K>.*-1N=FP% W,S=6)-VO9R;,L\
MR?DKX;-\3A,P2:GC,IJXK*VUSMP4%2Q52M!0CRQ=Z\N9Q<ERWY5[^0X3.Z&4
M83#\4YCEF=YU#V[QN/RO)ZN2Y=6Y\15J4(8?*\5FF=UL/&AAI4</.53,L3*O
M4I2Q#]E[7V-/^=3X@:-\%?A_X^\=>!O@!_P3R_;XT*_\)^*=:\(V_B_]G7XP
M_M#? WP/K%_HU_<VLVI:!;^ _'8\(RZ%>11KJ>EW5UX?GM[Z*6%9K1(Y&WZ/
MPGC_ ."AOB3Q[X0\,>"K/_@H!\#? VN:Y!;:_P",/CK\1OV>OCEI/A;P[('0
MZK<:'\4_V>(O'MY<VLL<8ET__A/9K^:*7SQ(Y1I)/Z&<#GODYY)/\\X'L.!1
MM7.=JY]<#/YUZ:XS\1:M;VF9<=YIGE%5HU%@^(LNR+B?"\D)J4:/LN)\MSM*
M'*O9R<.2;C[RE&?O'P,. ^.)9HL9B/%S/(8"./CBO['RKA3@G+L/4PD,3&M'
M+:V,K9)F&8RI2HQ^JUL11Q6'Q4Z?OTZM*JW,^"1\/_\ @HUX2M0- _:._9>^
M*ZJ0?LOQ._9H\>?#[69E!8^7+XI^%WQWU'1XW8!4,\/PY*!F:06I"+%+X1\:
MOB-_P69T1-&L_A1^S9^QAXE0:=>2:_K.E?'[QKJ-U=:A%=0O8II6A?$3P!\+
MH-*6>T$T$MI=ZSK\33LL_P#;5DJ".7];J*].OQ93Q].5/..%>$LSYI7]I0RO
M$\+U(VM91EP-C^%DEI;52NG9W/T'-LFAFV K9?+,<XR^G75-2Q.4YGB<!CX*
M%2-3]SCJ4OK-!SY>6;I5(.4)2@])-'\X6K?M/?\ !:[3-2EM?B)^SW?_  KL
MIGCMSK'@7X'Z1^T'I-G#E(I=3LX_@Y\0/BIXFN''[VX6VN?#4S2>6H%HBS11
M5^B'PN_X*-_L[^&? W@GP[^T9\<X?!7Q6M= TRT\<:W\6/@S\9OV;] U/Q*L
M.-1OM/B^,7PR^'VG6-C/)B2*+?!%#&5.U$92WZ5E$)R44GU*@G\R*:\4<@97
M7>CJR.C,S1NK#:RM&Q*,K#(964@@D$$$UQX.KP/"K/$8SAGB*-6<'#V.4<<X
MFCE\+RC+FAAN(\FXKQ":M:ZQRG:ZY[-GS7#' G^JV-Q>-H\6\:9]+%T?8/#\
M5\18_/<)AHNK&MSX3"5*M##4*UXJ"KJC*LJ+=)5.1M/Y*\2_%KX._M1_#3Q9
MX#_9]_:[^'.G>*/$VFQ6>C?$+X-_$GP+XW\1>%[E+VSO3?:;9Z%XJ$LEQ);P
M26CQFYMF^SWDA+@_*?D=O^"9/Q(U9HT\6?\ !1#]LK6[==UQ)#8^,[C14^W.
MN#<V[OJ6I1P6XWS!;0I+LC=8UG7R]S?=/CW]D7]E;XISS77Q+_9M^ WCZ\G+
M&2^\7_"'X?\ B#42SL7:1=2U+P]<:A'*6)8RQW229));).?%(?\ @FS^REHI
MFF^'GAWXF_!:ZD#>5+\"OVAOV@O@Y:6K$,0T&@^ _B=H_A8JKD.(9]!FMV8
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MX(F?\HD?^"='_9H/P1_]0^RK]1J "BBB@ HHHH **** ,S6O^01JG_8.O_\
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MFO;,VVMZUXKT^XEE@6%X;Q!I0$-PDD2M)L5I,BV_X+)_L7_\*KTSQGX@\?\
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MTL96P6$JXNA!TZ.*JX>C/$T:;ESN%*O*#JTX.7O.,)J+EJU<0 #GG\23^A)
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M@IX#UN^CEM[?[-'*M_K^C:K>^9Y1)D<SEIY6>XG,EP[RM]B?V5J?_0R:A_X
MZ)_\K*/[*U/_ *&34/\ P!T3_P"5E=4N/^.Y0E3EQIQ8Z<_BI_ZQ9NJ<M$K.
M"QBC:R2M:UC&EE664*U3$4<MP%&O6J.K6KTL'AZ=:K5>]2I4A34YU'UG*3D^
MYY_X2_9^^!/@$1+X%^#'PG\%K;FT:!/"?PV\%>'%@.G[_L'DC1M"LO+^Q;W%
MH4P;;>WDE-QSZPD$42+'$@BC082.(F)%&<X5(RJ*.>@4#VK'_LK4_P#H9-0_
M\ =$_P#E91_96I_]#)J'_@#HG_RLKYO%X[&X^HZV.QF*QE9N[JXK$5<14;22
MNYU9SDW9)7;N=RC&.D8J*[))?D>*_M$?LF?LX_M9:)X0\.?M&_"#P9\7M%\!
M>-M%^(?A&P\9:>]_%HOBO09UFL[ZW>.:":2SNE7[%KNAW,LV@^)]*:31_$>F
M:IIDCVI^@X88;:*.""..&&&-(HHHD6..*.-0D<<<:!4CCC152.-%5$151%55
M &-_96I_]#)J'_@#HG_RLH_LK4_^ADU#_P  =$_^5E:U\TS/%8# Y7B<QQ^(
MRS*YXNKEF75\7B*N!RZICY4IXZI@<)4J2P^$GC9T*,\7+#TZ<L1.C2E6<W3B
MTE""E*:C%3FDI244I24;\JE)*[4;NUV[7=C>HK!_LK4_^ADU#_P!T3_Y64?V
M5J?_ $,FH?\ @#HG_P K*X"C>HK!_LK4_P#H9-0_\ =$_P#E91_96I_]#)J'
M_@#HG_RLH WJ*P?[*U/_ *&34/\ P!T3_P"5E']E:G_T,FH?^ .B?_*R@#>H
MK!_LK4_^ADU#_P  =$_^5E']E:G_ -#)J'_@#HG_ ,K* -ZBL'^RM3_Z&34/
M_ '1/_E91_96I_\ 0R:A_P" .B?_ "LH WJ*P?[*U/\ Z&34/_ '1/\ Y64?
MV5J?_0R:A_X Z)_\K* -ZBL'^RM3_P"ADU#_ , =$_\ E91_96I_]#)J'_@#
MHG_RLH WJ*P?[*U/_H9-0_\  '1/_E91_96I_P#0R:A_X Z)_P#*R@#>HK!_
MLK4_^ADU#_P!T3_Y64?V5J?_ $,FH?\ @#HG_P K* -ZBL'^RM3_ .ADU#_P
M!T3_ .5E']E:G_T,FH?^ .B?_*R@#>HK!_LK4_\ H9-0_P# '1/_ )64?V5J
M?_0R:A_X Z)_\K* -ZBL'^RM3_Z&34/_  !T3_Y64?V5J?\ T,FH?^ .B?\
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M''4,* -FBBB@ KSCXP_\DH^)G_9/O&W_ *BVK5Z/7G'QA_Y)1\3/^R?>-O\
MU%M6H _P3J*** /]K+_@B9_RB1_X)T?]F@_!'_U#[*OU&K\N?^")G_*)'_@G
M1_V:#\$?_4/LJ_4:@ IK*K8W '!!'U!R#]0>1Z'D<TZB@!NT9'48Z ,P'';:
M"%Q[8I=HSG'/]3U('0$]R.3WI:* $  Z#_\ 5Z#T'L./:EHHH S-:_Y!&I^V
MG7^/_ 2<?RK\5?\ @W  _P"'*/[!)QS_ ,*X\;C/?'_"[/BCQ7[5:U_R"-4_
M[!U__P"DDU?BK_P;@?\ *%#]@G_LG'CC_P!79\4: /V]HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *R=:T'1/$FDZAH/B#2-,US0]7M9K'5=
M&UBPM-4TG4[*X79<6FHZ9?0W%C?6TR?)+!=V\T4BDJR$'%:U%5"<Z<X5*<Y0
MJ4Y1G"<).,X3BU*,XR33C*,DG&2:::33N&^Y^<FI?\$VOAGX(O[_ ,2_L?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7G'QA_Y)1\3/\ LGWC;_U%M6KT>O./C#_R2CXF?]D^\;?^HMJU
M '^"=1110!_M9?\ !$S_ )1(_P#!.C_LT'X(_P#J'V5?J-7Y<_\ !$S_ )1(
M_P#!.C_LT'X(_P#J'V5?J-0 444C=#QG@\>O'3\>E 'R[XW_ &S_ -FSX=>/
MM6^&OBSXEV=AXH\-7%A9^,S:Z%XKUKP]\/K[5+;P=?Z;8?$GQAH>@ZEX2^'E
M]?:7\0?!&L06GC+6M%F71/%?A_6KE;;2=8TZ\N?/4_X*3?L42_M<ZM^PG#\;
M[*?]J;0=-U+6-=^&MOX)^)4UEH>EZ/X+@^(6L7VL_$:/P:WPLTN'2/"5U:ZE
MJOVWQM VG3W5KI%XL.M7$6G/^2G[7GPC^-'@?_@H#I7[2G[!W@[XO^$_V@?&
MOC.3P5^T3\!_B+X"\2>)OV2OVQ_A[97?[-'@76/B/'KTT4O@+X2^*;/X.ZW)
M-J'QJT+Q#I>M*GP0@\!>+_!>O75_#%KN/XT_8D^.GQ(\4_'K5/V+?BU^WG\+
M="_:"'[?OP1_:T^ '[9^J>,[CX-2:C\3/A%\;(/AU\>_V=H/'J:GH/AA]8^/
M6L_#W4?"VM_!WQ!JWAO4_ACXAODUK1O#5WX9UO0;D _>KX,_M1? 7]H*YNK+
MX0_$?1?&-Y;>#_!OQ&CM+6#5=-NM4^&WQ%;6D^'WQ-\/6VMZ=I<_B7X:>.W\
M.:^G@WX@Z!'J7A#Q,^BZFFCZQ=O9S*OOU?S@_P#!*[]DK]H3P-^U7^SU\:O'
MW@?Q9\./!/P0_P""%G[%7[ _CO1/%VEW>@3WO[37PY^(.O\ B;X@^']&M-2M
MU?Q+I'PQTS2H8/\ A.= EN_!FM2^-K2/PSKVOHFI&P_H^H S-:_Y!&J?]@Z_
M_P#22:OQ4_X-P6 _X(H_L$YS_P DX\;]%8_\UL^*/< BOU/\9_";Q3XIUG4]
M4LOC]\9?!NF:F+> >%?"T/P:;0-/A-K!87*6$GB?X.^)O$0-YMENYWO/$-Y(
MEW<2M9O:0+;V\'X)?\$^/^",/[/VK?L8?L\W^E_M&?\ !1#P+8W?@(747A3X
M9?M\_M$_#GP)I$MWXAUZZO$\.>"?"'BG3/#'AVTN[V:XU">QT/3+"Q:_N[RZ
M6V6:XF>0 _I:W#T;_OA__B:-P]&_[X?_ .)K\;O^'*'P-_Z.Y_X*E_\ BR[]
MJS_YMJ/^'*'P-_Z.Y_X*E_\ BR[]JS_YMJ /V1W#T;_OA_\ XFC</1O^^'_^
M)K\;O^'*'P-_Z.Y_X*E_^++OVK/_ )MJ/^'*'P-_Z.Y_X*E_^++OVK/_ )MJ
M /V1W#T;_OA__B:-P]&_[X?_ .)K\;O^'*'P-_Z.Y_X*E_\ BR[]JS_YMJ/^
M'*'P-_Z.Y_X*E_\ BR[]JS_YMJ /V1W#T;_OA_\ XFC</1O^^'_^)K\;O^'*
M'P-_Z.Y_X*E_^++OVK/_ )MJ/^'*'P-_Z.Y_X*E_^++OVK/_ )MJ /V1W#T;
M_OA__B:-P]&_[X?_ .)K\;O^'*'P-_Z.Y_X*E_\ BR[]JS_YMJ/^'*'P-_Z.
MY_X*E_\ BR[]JS_YMJ /V1W#T;_OA_\ XFC</1O^^'_^)K\;O^'*'P-_Z.Y_
MX*E_^++OVK/_ )MJ/^'*'P-_Z.Y_X*E_^++OVK/_ )MJ /V1W#T;_OA__B:-
MP]&_[X?_ .)K\;O^'*'P-_Z.Y_X*E_\ BR[]JS_YMJ/^'*'P-_Z.Y_X*E_\
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M7XW?\.4/@;_T=S_P5+_\67?M6?\ S;4?\.4/@;_T=S_P5+_\67?M6?\ S;4
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M8^"?CE\2_ V@@6L'CIX5EA\.^&M)M[B6/8;FXAENI4\^:5F^F?\ ARA\#?\
MH[G_ (*E_P#BR[]JS_YMJ /V1W#T;_OA_P#XFC</1O\ OA__ (FOQN_X<H?
MW_H[G_@J7_XLN_:L_P#FVH_X<H? W_H[G_@J7_XLN_:L_P#FVH _9'</1O\
MOA__ (FC</1O^^'_ /B:_&[_ (<H? W_ *.Y_P""I?\ XLN_:L_^;:C_ (<H
M? W_ *.Y_P""I?\ XLN_:L_^;:@#]D=P]&_[X?\ ^)HW#T;_ +X?_P")K\;O
M^'*'P-_Z.Y_X*E_^++OVK/\ YMJ/^'*'P-_Z.Y_X*E_^++OVK/\ YMJ /V1W
M#T;_ +X?_P")HW#T;_OA_P#XFOQN_P"'*'P-_P"CN?\ @J7_ .++OVK/_FVH
M_P"'*'P-_P"CN?\ @J7_ .++OVK/_FVH _9'</1O^^'_ /B:-P]&_P"^'_\
MB:_&[_ARA\#?^CN?^"I?_BR[]JS_ .;:C_ARA\#?^CN?^"I?_BR[]JS_ .;:
M@#]D=P]&_P"^'_\ B:-P]&_[X?\ ^)K\;O\ ARA\#?\ H[G_ (*E_P#BR[]J
MS_YMJ/\ ARA\#?\ H[G_ (*E_P#BR[]JS_YMJ /V1W#T;_OA_P#XFC</1O\
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M\+Z-86W@C[!J<=AK&JVGB*Z;6-,CM]$D26XFM0#[$HKXVT_]N#X43_M6Z/\
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MQ,US\4_B3>?\)!IJZ;'XCF'[B8'''3I[=N/PXI-JXQM&!T&!@?A0!_,CK?[
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MWO+S1=,TUG_=X@$@D D="0,CZ4N!UQR>I]<=* $4$*H8Y( !/J0.3^)I:**
M"BBB@ HHHH **** "BBB@#\;_A5\*_C;\/O^"K/_  4,_:>U;X*>/]0^#OQ#
M_90_9@\'_"_7]'E\$S7GQ)\<? IOBGJ/C/P=X;TF_P#&6GW^G:M=MXKT:Q\,
MZCXR@\+>%]9O9YF7Q!!96LUX/E3X=>$?VTOVAM,_;)C^+W_!.?XB?LF_$+]M
M;Q5^S[\+/BK\5?$?Q[^!_P 4;W4?V?!XIF\"^)O!?A?2/A9K-ZWAGP;\&OV;
ME^)MU+JFO:F^N>*OB[\8+B[TRUEL=3:V\/?T=;5Y.!D\$X'(]#ZT!5'10._
M Y]?U/YT ?A+\;_@-^UG^TU^V=^S!X[\/? ;XG_LB:K^Q?\ M=S-:?M :/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YQ\8?^24?$S_ +)]
MXV_]1;5J]'KSCXP_\DH^)G_9/O&W_J+:M0!_@G4444 ?[67_  1,_P"42/\
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M"?$_@;7-$E\!#29?'^MZSJ.FZQ:>&I=1O_!M_P"'Y+JVU;Q7;WD/V&Z^:O\
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MIY^''CGQ;X2^$7Q$^(_@+XF>/OA9K_BCPS<^(-"\,:1:ZC:ZWH.JVUA\[?\
M!1S_ ()6_M3?M:?&W]NKQQ\,=4^$6C>&_P!I+]BK]EG]FOX=W'BOQQXFT?6-
M/\:_ S]JBT^/7B?7/%5EHO@76%T;PQJ7AF:^T7P[>Z-J>NZW+XAM(5O]'TK3
M;O\ M.T /WQ^)?Q7\#_";X7^/?C#XQU<6_@3X;>#?&/CSQ3J>F02ZU/;^'/
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M<?Y_S]!Z444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M(0",$ @]01D'\#2T44 %%%% "8YSSG&.IQ^6<9]\9I:** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@        P .  .@ [ 444
M4 %%%% !1110 4$9]?P)'\L444 ( !T_^M^ Z#\*6BB@ HHHH **** "BBB@
M KSCXP_\DH^)G_9/O&W_ *BVK5Z/7G'QA_Y)1\3/^R?>-O\ U%M6H _P3J**
M* /]K+_@B9_RB1_X)T?]F@_!'_U#[*OU&K_/\_8 _P"#MO\ 8Q_9%_8F_98_
M9C\9?LW?M0^)O%OP(^!OP_\ A=XDU_PO%\)O^$<U?6?"&BQ:7>:AHC:MX_L=
M3?3+EX1+:M?V-E=;&VS6R,I9OK__ (C9OV#/^C4OVOO^_?P6_P#GD4 ?VB45
M_%W_ ,1LW[!G_1J7[7W_ '[^"W_SR*/^(V;]@S_HU+]K[_OW\%O_ )Y% ']H
ME%?Q=_\ $;-^P9_T:E^U]_W[^"W_ ,\BC_B-F_8,_P"C4OVOO^_?P6_^>10!
M_:)17\7?_$;-^P9_T:E^U]_W[^"W_P \BC_B-F_8,_Z-2_:^_P"_?P6_^>10
M!_:)17\7?_$;-^P9_P!&I?M??]^_@M_\\BC_ (C9OV#/^C4OVOO^_?P6_P#G
MD4 ?VB45_%W_ ,1LW[!G_1J7[7W_ '[^"W_SR*/^(V;]@S_HU+]K[_OW\%O_
M )Y% ']HE%?Q=_\ $;-^P9_T:E^U]_W[^"W_ ,\BC_B-F_8,_P"C4OVOO^_?
MP6_^>10!_:)17\7?_$;-^P9_T:E^U]_W[^"W_P \BC_B-F_8,_Z-2_:^_P"_
M?P6_^>10!_:)17\7?_$;-^P9_P!&I?M??]^_@M_\\BC_ (C9OV#/^C4OVOO^
M_?P6_P#GD4 ?VB45_%W_ ,1LW[!G_1J7[7W_ '[^"W_SR*/^(V;]@S_HU+]K
M[_OW\%O_ )Y% ']HE%?Q=_\ $;-^P9_T:E^U]_W[^"W_ ,\BC_B-F_8,_P"C
M4OVOO^_?P6_^>10!_:)17\7?_$;-^P9_T:E^U]_W[^"W_P \BC_B-F_8,_Z-
M2_:^_P"_?P6_^>10!_:)17\7?_$;-^P9_P!&I?M??]^_@M_\\BC_ (C9OV#/
M^C4OVOO^_?P6_P#GD4 ?VB45_%W_ ,1LW[!G_1J7[7W_ '[^"W_SR*/^(V;]
M@S_HU+]K[_OW\%O_ )Y% ']HE%?Q=_\ $;-^P9_T:E^U]_W[^"W_ ,\BC_B-
MF_8,_P"C4OVOO^_?P6_^>10!_:)17\7?_$;-^P9_T:E^U]_W[^"W_P \BC_B
M-F_8,_Z-2_:^_P"_?P6_^>10!_:)17\7?_$;-^P9_P!&I?M??]^_@M_\\BC_
M (C9OV#/^C4OVOO^_?P6_P#GD4 ?VB45_%W_ ,1LW[!G_1J7[7W_ '[^"W_S
MR*/^(V;]@S_HU+]K[_OW\%O_ )Y% ']HE%?Q=_\ $;-^P9_T:E^U]_W[^"W_
M ,\BC_B-F_8,_P"C4OVOO^_?P6_^>10!_:)17\7?_$;-^P9_T:E^U]_W[^"W
M_P \BC_B-F_8,_Z-2_:^_P"_?P6_^>10!_:)17\7?_$;-^P9_P!&I?M??]^_
M@M_\\BC_ (C9OV#/^C4OVOO^_?P6_P#GD4 ?VB45_%W_ ,1LW[!G_1J7[7W_
M '[^"W_SR*/^(V;]@S_HU+]K[_OW\%O_ )Y% ']HE%?Q=_\ $;-^P9_T:E^U
M]_W[^"W_ ,\BC_B-F_8,_P"C4OVOO^_?P6_^>10!_:)17\7?_$;-^P9_T:E^
MU]_W[^"W_P \BC_B-F_8,_Z-2_:^_P"_?P6_^>10!_:)17\7?_$;-^P9_P!&
MI?M??]^_@M_\\BC_ (C9OV#/^C4OVOO^_?P6_P#GD4 ?VB45_%W_ ,1LW[!G
M_1J7[7W_ '[^"W_SR*/^(V;]@S_HU+]K[_OW\%O_ )Y% ']HE%?Q=_\ $;-^
MP9_T:E^U]_W[^"W_ ,\BC_B-F_8,_P"C4OVOO^_?P6_^>10!_:)17\7?_$;-
M^P9_T:E^U]_W[^"W_P \BC_B-F_8,_Z-2_:^_P"_?P6_^>10!_:)17\7?_$;
M-^P9_P!&I?M??]^_@M_\\BC_ (C9OV#/^C4OVOO^_?P6_P#GD4 ?VB45_%W_
M ,1LW[!G_1J7[7W_ '[^"W_SR*/^(V;]@S_HU+]K[_OW\%O_ )Y% ']HE%?Q
M=_\ $;-^P9_T:E^U]_W[^"W_ ,\BC_B-F_8,_P"C4OVOO^_?P6_^>10!_:)1
M7\7?_$;-^P9_T:E^U]_W[^"W_P \BC_B-F_8,_Z-2_:^_P"_?P6_^>10!_:)
M17\7?_$;-^P9_P!&I?M??]^_@M_\\BC_ (C9OV#/^C4OVOO^_?P6_P#GD4 ?
MVB45_%W_ ,1LW[!G_1J7[7W_ '[^"W_SR*/^(V;]@S_HU+]K[_OW\%O_ )Y%
M ']HE%?Q=_\ $;-^P9_T:E^U]_W[^"W_ ,\BC_B-F_8,_P"C4OVOO^_?P6_^
M>10!_:)17\7?_$;-^P9_T:E^U]_W[^"W_P \BC_B-F_8,_Z-2_:^_P"_?P6_
M^>10!_:)17\7?_$;-^P9_P!&I?M??]^_@M_\\BC_ (C9OV#/^C4OVOO^_?P6
M_P#GD4 ?VB45_%W_ ,1LW[!G_1J7[7W_ '[^"W_SR*/^(V;]@S_HU+]K[_OW
M\%O_ )Y% ']HE%?Q=_\ $;-^P9_T:E^U]_W[^"W_ ,\BC_B-F_8,_P"C4OVO
MO^_?P6_^>10!_:)17\7?_$;-^P9_T:E^U]_W[^"W_P \BC_B-F_8,_Z-2_:^
M_P"_?P6_^>10!_:)17\7?_$;-^P9_P!&I?M??]^_@M_\\BC_ (C9OV#/^C4O
MVOO^_?P6_P#GD4 ?VB5YQ\8?^24?$S_LGWC;_P!1;5J_D"_XC9OV#/\ HU+]
MK[_OW\%O_GD5R_C?_@](_83\5>#/%OAJV_98_:YMKGQ!X7\1Z':W%Q%\&6MX
I;K5]%O\ 3K:6<1?$@R"".XNHWF:-9)%B5V2*5@(G /\ -SHHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6831515568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Feb. 24, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MACROGENICS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001125345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,974,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 936<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and entity information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6831882528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 84,098<span></span>
</td>
<td class="nump">$ 196,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">192,898<span></span>
</td>
<td class="nump">142,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">2,764<span></span>
</td>
<td class="nump">1,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">3,483<span></span>
</td>
<td class="nump">1,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other current assets</a></td>
<td class="nump">704<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">283,947<span></span>
</td>
<td class="nump">342,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">17,961<span></span>
</td>
<td class="nump">14,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">7,986<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,369<span></span>
</td>
<td class="nump">2,044<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">311,263<span></span>
</td>
<td class="nump">359,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,995<span></span>
</td>
<td class="nump">2,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">16,134<span></span>
</td>
<td class="nump">11,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">4,261<span></span>
</td>
<td class="nump">5,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="nump">1,319<span></span>
</td>
<td class="nump">914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Lease exit liability</a></td>
<td class="nump">1,593<span></span>
</td>
<td class="nump">2,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">727<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">27,302<span></span>
</td>
<td class="nump">24,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">10,045<span></span>
</td>
<td class="nump">12,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="nump">4,867<span></span>
</td>
<td class="nump">6,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveNoncurrent', window );">Lease exit liability, net of current portion</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">2,693<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">42,512<span></span>
</td>
<td class="nump">45,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value &#8211; 125,000,000 shares authorized, 34,870,607 and 34,345,754 shares outstanding at December 31, 2016 and 2015, respectively</a></td>
<td class="nump">349<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">561,198<span></span>
</td>
<td class="nump">547,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(82)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(292,714)<span></span>
</td>
<td class="num">(234,186)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">268,751<span></span>
</td>
<td class="nump">313,337<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 311,263<span></span>
</td>
<td class="nump">$ 359,269<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3-4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3<br> -Subparagraph a(1)<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 4<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated appreciation or loss, net of tax, in value of the total of available-for-sale securities at the end of an accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 12<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Available-for-Sale Securities<br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.32)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 25<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate carrying amounts, as of the balance sheet date, of assets not separately disclosed in the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 10<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=51662447&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section P<br> -Subsection 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid after one year or beyond the next operating cycle, if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section P<br> -Paragraph Question 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819055184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">34,870,607<span></span>
</td>
<td class="nump">34,345,754<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6831661808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Revenue from collaborative agreements</a></td>
<td class="nump">$ 86,582<span></span>
</td>
<td class="nump">$ 99,368<span></span>
</td>
<td class="nump">$ 47,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Revenue from government agreements</a></td>
<td class="nump">5,298<span></span>
</td>
<td class="nump">1,486<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">91,880<span></span>
</td>
<td class="nump">100,854<span></span>
</td>
<td class="nump">47,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">122,091<span></span>
</td>
<td class="nump">98,271<span></span>
</td>
<td class="nump">70,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">29,831<span></span>
</td>
<td class="nump">22,765<span></span>
</td>
<td class="nump">15,926<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">151,922<span></span>
</td>
<td class="nump">121,036<span></span>
</td>
<td class="nump">86,112<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(60,042)<span></span>
</td>
<td class="num">(20,182)<span></span>
</td>
<td class="num">(38,315)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">1,514<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(58,528)<span></span>
</td>
<td class="num">(20,140)<span></span>
</td>
<td class="num">(38,313)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on investments</a></td>
<td class="num">(77)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Comprehensive loss</a></td>
<td class="num">$ (58,605)<span></span>
</td>
<td class="num">$ (20,145)<span></span>
</td>
<td class="num">$ (38,313)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Basic and diluted net loss per common share (in dollars per share)</a></td>
<td class="num">$ (1.69)<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="num">$ (1.40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted average number of common shares (in shares)</a></td>
<td class="nump">34,685,274<span></span>
</td>
<td class="nump">31,801,645<span></span>
</td>
<td class="nump">27,384,990<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseAndServicesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6832588848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2013</a></td>
<td class="nump">$ 78,914,000<span></span>
</td>
<td class="nump">$ 252,000<span></span>
</td>
<td class="num">$ (58,000)<span></span>
</td>
<td class="nump">$ 254,453,000<span></span>
</td>
<td class="num">$ (175,733,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,177,597<span></span>
</td>
<td class="nump">14,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">3,244,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,244,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">76,716,000<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,694,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">725,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="num">$ (19,000)<span></span>
</td>
<td class="nump">738,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">568,041<span></span>
</td>
<td class="nump">865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredParValueMethodAmount', window );">Retirement of treasury stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,000<span></span>
</td>
<td class="num">(58,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,381)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(38,313,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,313,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2014</a></td>
<td class="nump">121,286,000<span></span>
</td>
<td class="nump">$ 280,000<span></span>
</td>
<td class="num">$ (19,000)<span></span>
</td>
<td class="nump">335,071,000<span></span>
</td>
<td class="num">(214,046,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,995,638<span></span>
</td>
<td class="nump">865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">7,847,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,847,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">203,467,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,407,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,976,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">882,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="num">$ (29,000)<span></span>
</td>
<td class="nump">908,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">373,289<span></span>
</td>
<td class="nump">925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredParValueMethodAmount', window );">Retirement of treasury stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000<span></span>
</td>
<td class="num">(48,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on investments</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,140,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,140,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2015</a></td>
<td class="nump">313,337,000<span></span>
</td>
<td class="nump">$ 343,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">547,185,000<span></span>
</td>
<td class="num">(234,186,000)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,345,754<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">12,165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">1,854,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="num">$ (39,000)<span></span>
</td>
<td class="nump">1,887,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524,853<span></span>
</td>
<td class="nump">1,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredParValueMethodAmount', window );">Retirement of treasury stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,000<span></span>
</td>
<td class="num">(39,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,862)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on investments</a></td>
<td class="num">(77,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(58,528,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,528,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2016</a></td>
<td class="nump">$ 268,751,000<span></span>
</td>
<td class="nump">$ 349,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 561,198,000<span></span>
</td>
<td class="num">$ (292,714,000)<span></span>
</td>
<td class="num">$ (82,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,870,607<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued due to stock plan related activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodSharesStockPlanActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued due to stock plan related activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodValueStockPlanActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredParValueMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the par value method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredParValueMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6831658560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (58,528)<span></span>
</td>
<td class="num">$ (20,140)<span></span>
</td>
<td class="num">$ (38,313)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">7,608<span></span>
</td>
<td class="nump">2,863<span></span>
</td>
<td class="nump">1,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">12,165<span></span>
</td>
<td class="nump">7,847<span></span>
</td>
<td class="nump">3,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,540)<span></span>
</td>
<td class="nump">1,711<span></span>
</td>
<td class="num">(931)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(1,677)<span></span>
</td>
<td class="nump">2,405<span></span>
</td>
<td class="num">(3,239)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">276<span></span>
</td>
<td class="num">(285)<span></span>
</td>
<td class="num">(1,179)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,232<span></span>
</td>
<td class="num">(163)<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">4,659<span></span>
</td>
<td class="nump">3,545<span></span>
</td>
<td class="nump">4,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestructuringReserve', window );">Lease exit liability</a></td>
<td class="num">(2,822)<span></span>
</td>
<td class="num">(3,293)<span></span>
</td>
<td class="num">(1,439)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(4,191)<span></span>
</td>
<td class="num">(12,223)<span></span>
</td>
<td class="nump">3,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
<td class="num">(1,134)<span></span>
</td>
<td class="nump">4,650<span></span>
</td>
<td class="num">(234)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="num">(727)<span></span>
</td>
<td class="num">(878)<span></span>
</td>
<td class="nump">1,242<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(43,679)<span></span>
</td>
<td class="num">(13,661)<span></span>
</td>
<td class="num">(32,759)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(347,762)<span></span>
</td>
<td class="num">(142,910)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">288,894<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(11,381)<span></span>
</td>
<td class="num">(9,197)<span></span>
</td>
<td class="num">(3,572)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(70,249)<span></span>
</td>
<td class="num">(152,107)<span></span>
</td>
<td class="num">(3,572)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">203,467<span></span>
</td>
<td class="nump">76,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">1,893<span></span>
</td>
<td class="nump">911<span></span>
</td>
<td class="nump">744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Purchase of treasury stock</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,854<span></span>
</td>
<td class="nump">204,349<span></span>
</td>
<td class="nump">77,441<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(112,074)<span></span>
</td>
<td class="nump">38,581<span></span>
</td>
<td class="nump">41,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">196,172<span></span>
</td>
<td class="nump">157,591<span></span>
</td>
<td class="nump">116,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 84,098<span></span>
</td>
<td class="nump">$ 196,172<span></span>
</td>
<td class="nump">$ 157,591<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other current operating liabilities not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as operating activities. This may include cash restricted for regulatory purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying amount (including both current and noncurrent portions of the accrual) of the liability pertaining to the exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt securities classified as available-for-sale securities, because they are not classified as either held-to-maturity securities or trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6822017008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Nature of Operations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Nature of Operations</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MacroGenics, Inc. (the Company) was incorporated in Delaware on August 14, 2000. The Company is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. These product candidates, which the Company has identified through its understanding of disease biology and immune-mediated mechanisms, may address disease-specific challenges which are not currently being met by existing therapies.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6822092624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation and Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited.&#160; All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment, which is developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, stock-based compensation, income taxes, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Marketable Securities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income (expense).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. The Company considers factors including: the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not that it will be required to sell a security prior to recovery of its fair value.&#160; An impairment loss is recognized at the time the Company determines that a decline in the fair value below its cost basis is other-than-temporary. There were </font><font style="font-family:inherit;font-size:10pt;color:#252525;">no</font><font style="font-family:inherit;font-size:10pt;color:#252525;"> unrealized losses at </font><font style="font-family:inherit;font-size:10pt;color:#252525;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;color:#252525;"> or </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;color:#252525;"> that the Company determined to be other-than-temporary.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> allowance was recorded as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, as the Company has a history of collecting on all outstanding accounts.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#252525;">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</font><font style="font-family:inherit;font-size:10pt;"> The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements and Disclosures</font><font style="font-family:inherit;font-size:10pt;"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 &#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 &#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 &#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.34146341463415%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurement at December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices in</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Active Markets for</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Identical Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Observable Inputs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inputs</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,781</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,781</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S Treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government-sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,759</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,759</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,300</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,300</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets measured at fair value </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">251,666</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,781</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204,885</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Total assets measured at fair value at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> includes approximately </font><font style="font-family:inherit;font-size:10pt;">$50.8 million</font><font style="font-family:inherit;font-size:10pt;"> reported in cash and cash equivalents on the balance sheet.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.24390243902438%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurement at December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices in</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Active Markets for</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Identical Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Observable Inputs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inputs</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,353</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,353</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S Treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government-sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,202</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,202</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,928</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,928</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets measured at fair value </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250,831</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,353</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188,478</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Total assets measured at fair value at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> includes approximately </font><font style="font-family:inherit;font-size:10pt;">$108.0 million</font><font style="font-family:inherit;font-size:10pt;"> reported in cash and cash equivalents on the balance sheet.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of Level 2 securities is determined from </font><font style="font-family:inherit;font-size:10pt;color:#252525;">market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data.  There were no transfers between Level 1 and Level 2 investments during the periods presented.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </font><font style="font-family:inherit;font-size:10pt;color:#252525;">We maintain our cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, we have not experienced any losses on related accounts to date.&#160;</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#252525;">Our investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</font><font style="font-family:inherit;font-size:10pt;"> The counterparties are various corporations, financial institutions and government agencies of high credit standing.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's revenue relates to agreements with various collaborators and&#160;contracts and research grants received from U.S. government agencies.&#160;The following table includes those collaborators that represent more than 10% of total revenue earned in the periods indicated:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen Biotech, Inc. (Janssen)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Les Laboratoires Servier and Institut de Reserches Servier (collectively, Servier) </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Boehringer Ingelheim GmbH (Boehringer)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Takeda Pharmaceutical Company Limited (Takeda)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gilead Sciences, Inc. (Gilead)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes those collaborators that represent more than 10% of accounts receivable at the date indicated:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Servier</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Takeda</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Eli Lilly</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">* Balance is less than 10%</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred. Depreciation is computed using the straight-line method over the following estimated useful lives:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:50%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory and office equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shorter of lease term or useful life</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property, Plant and Equipment</font><font style="font-family:inherit;font-size:10pt;">. ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company determined that there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> impaired assets and had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> assets held-for-sale.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company's policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenues</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company enters into collaboration and license agreements with collaborators for the development of monoclonal antibody-based therapeutics to treat cancer and other complex diseases. The terms of these agreements contain multiple deliverables which may include (i) licenses, or options to obtain licenses, to the Company's technological platforms, such as its Fc Optimization and Dual-Affinity Re-Targeting (DART) technologies, (ii) rights to future technological improvements, (iii) research and development activities to be performed on behalf of the collaborator or as part of the collaboration, and (iv) the manufacture of preclinical or clinical materials for the collaborator. Payments to the Company under these agreements may include nonrefundable license fees, option fees, exercise fees, payments for research and development activities, payments for the manufacture of preclinical or clinical materials, license maintenance payments, payments based upon the achievement of certain milestones and royalties on product sales. Other benefits to the Company of these agreements include the right to sell products resulting from the collaborative efforts of the parties in specific geographic territories. The Company follows the provisions of FASB ASC Topic 605-25, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition &#8211; Multiple-Element Arrangements</font><font style="font-family:inherit;font-size:10pt;">, and FASB ASC Topic 605-28, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition&#8211;Milestone Method</font><font style="font-family:inherit;font-size:10pt;">, in accounting for these agreements. In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the periods presented, the Company had the following two types of agreements: 1) exclusive development and commercialization licenses to use the Company's technology and/or certain other intellectual property to develop compounds against specified targets (referred to herein as exclusive licenses); and 2) option/research agreements to secure on established terms, development and commercialization licenses to therapeutic product candidates to collaborator-selected targets developed by the Company during an option period (referred to herein as right-to-develop agreements).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are no performance, cancellation, termination or refund provisions in any of the arrangements that contain material financial consequences to the Company.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exclusive Licenses</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The deliverables under an exclusive license agreement generally include the exclusive license to the Company's DART technology with respect to a specified antigen target, and may also include deliverables related to rights to future technological improvements, research and preclinical development activities to be performed on behalf of the collaborator. In some cases the Company may have an option to participate in the co-development of product candidates that result from such agreements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Generally, exclusive license agreements contain nonrefundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i) at the collaborator's request, provide research and preclinical development services at negotiated prices which are generally consistent with what other third parties would charge, (ii) earn payments upon the achievement of certain milestones, (iii) earn royalty payments, and (iv) in some cases grant the Company an option to participate in the development and commercialization of products that result from such agreements. Royalty rates may vary over the royalty term depending on the Company's intellectual property rights and whether the Company exercises any co-development and co-commercialization rights.The Company does not directly control when any collaborator will achieve milestones or become liable for royalty payments.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When entering into a new collaboration arrangement or materially modifying an existing arrangement, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator.&#160;&#160;The selling prices of deliverables under an arrangement may be derived using third-party evidence (TPE), or a best estimate of selling price (BESP), if vendor specific objective evidence (VSOE) is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the license agreement was sold on a standalone basis. Establishing BESP involves management's judgment and considers multiple factors, including market conditions, company-specific factors, and factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i) the delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the Company's control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of accounting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In determining the separate units of accounting, the Company evaluates whether the exclusive license has standalone value to the collaborator based on consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research and development capabilities of the collaborator and the availability of relevant research expertise in the marketplace. In addition, the Company considers whether or not (i) the collaborator could use the license for its intended purpose without the receipt of the remaining deliverables, (ii) the value of the license was dependent on the undelivered items and (iii) the collaborator or other vendors could provide the undelivered items. If the Company concludes that the license has stand-alone value and therefore will be accounted for as a separate unit of accounting, the Company then determines the estimated selling prices of the license and all other units of accounting based on market conditions, similar arrangements entered into by third parties, and entity-specific factors such as the terms of the Company's previous collaboration agreements, recent preclinical and clinical testing results of therapeutic product candidates that use the Company's technology platforms, the Company's pricing practices and pricing objectives, the likelihood that technological improvements will be made, the likelihood that technological improvements made will be used by the Company's collaborators and the nature of the research services to be performed on behalf of its collaborators and market rates for similar services. Total arrangement consideration is then allocated to each of the units of accounting using the relative-selling-price method.&#160;&#160;If facts and circumstances dictate that the exclusive license does not have stand-alone value, then the related payments are deferred and revenue is recognized throughout the period of performance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management reassesses the period of performance over which the Company recognizes deferred upfront license fees and makes adjustments as appropriate in the period in which a change in the estimated period of performance is identified. In the event a collaborator elects to discontinue development of a specific product candidate under a single target license, but retains its right to use the Company's technology to develop an alternative product candidate to the same target or a target substitute, the Company would cease amortization of any remaining portion of the upfront fee until there is substantial preclinical activity on another product candidate and its remaining period of substantial involvement can be estimated. In the event that a single target license were to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination or through the remaining substantial involvement in the wind down of the agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront payments on exclusive licenses may be recognized upon delivery of the license if facts and circumstances dictate that the license has stand-alone value from the undelivered elements, which generally include rights to future technological improvements, research services and the manufacture of preclinical and clinical materials.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue related to research and preclinical development services that represent separate units of accounting as they are performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection is reasonably assured. The Company recognizes revenue related to the rights to future technological improvements over the estimated term of the applicable license.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company typically performs research activities and preclinical development services, including generating and engineering product candidates, on behalf of its licensees during the early evaluation and preclinical testing stages of drug development under its exclusive licenses. The Company records amounts received for research materials produced or services performed as revenue from collaborative agreements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's license agreements have milestone payments which for reporting purposes are aggregated into three categories: (i) development milestones, (ii) regulatory milestones, and (iii) sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the U.S. Food and Drug Administration (FDA) or other countries' regulatory authorities or on receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of each agreement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (i) the consideration is commensurate with either (a) the entity's performance to achieve the milestone, or (b) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity's performance to achieve the milestone, (ii) the consideration relates solely to past performance and (iii) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-refundable development and regulatory milestones that are expected to be achieved as a result of the Company's efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute effort to their achievement are generally recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligations, assuming all other revenue recognition criteria are met.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Right-to-Develop Agreements</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's right-to-develop agreements provide collaborators with an exclusive option to obtain licenses to develop and commercialize in specified geographic territories product candidates developed by the Company under agreed upon research and preclinical development product programs. The product candidates resulting from each program are all directed to a specific target selected by the collaborator. Under these agreements, fees may be due to the Company (i) at the inception of the arrangement (referred to as "upfront" fees or payments), (ii) the selection of a target for a program, (iii) upon the exercise of an option to acquire a development and commercialization license (referred to as exercise fees or payments earned) for a program, or (iv) some combination of all of these fees.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accounting for right-to-develop agreements is dependent on the nature of the options granted to the collaborator. Options are considered substantive if, at the inception of a right-to-develop agreement, the Company is at risk as to whether the collaborator will choose to exercise the options to secure development and commercialization licenses. Factors that are considered in evaluating whether options are substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the total upfront consideration, and the additional financial commitments imposed on the collaborator as a result of exercising the options.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For right-to-develop agreements where the options to secure development and commercialization licenses to a product program are considered substantive, the Company does not consider the development and commercialization licenses to be a deliverable at the inception of the agreement, and therefore defers any upfront payments received and recognizes this revenue over the period during which the collaborator could elect to exercise options for development and commercialization licenses. These periods are specific to each collaboration agreement. If a collaborator selects a target for a product program, any substantive option fee is deferred and recognized over the life of the option. For right-to-develop agreements that include multiple deliverables, the Company determines the selling prices of deliverables under the arrangement using TPE or a BESP, if VSOE is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the right-to-develop agreement was sold on a standalone basis. Establishing BESP involves management's judgment and considers multiple factors, including market conditions and company-specific factors, including those factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the right-to-develop agreement. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i) the delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the Company's control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of accounting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a collaborator exercises an option and acquires a development and commercialization license to a product program, the Company attributes the exercise fee to the development and commercialization license. The Company determines the selling price of the option license, upon exercise, through management's best estimate using the process for an exclusive license as described above.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon exercise of an option to acquire a development and commercialization license, the Company would also attribute any remaining deferred option fee, in addition to the consideration received for the license upon exercise of the option, to the development and commercialization license.&#160;&#160;The Company then applies the multiple-element revenue recognition criteria to the development and commercialization license and other deliverables, if any, to determine the appropriate revenue recognition method. This model is consistent with the Company's accounting policy for upfront payments on exclusive licenses (discussed above).&#160;&#160;In the event a right-to-develop agreement were to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination. The Company's right-to-develop agreements have been determined to contain substantive options.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For right-to-develop agreements where the options to secure development and commercialization licenses to product programs are not considered substantive, the Company considers the development and commercialization licenses to be a deliverable at the inception of the agreement and applies the multiple-element revenue recognition criteria to determine the appropriate revenue recognition. The Company does not directly control when any collaborator will exercise its options for development and commercialization licenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Costs</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities.&#160; Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive Loss</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale securities.</font><font style="font-family:inherit;font-size:10pt;"> Comprehensive loss equals net loss for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> as there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> unrealized gains or losses in that period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based payments are accounted for in accordance with the provisions of ASC 718, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation &#8211; Stock Compensation</font><font style="font-family:inherit;font-size:10pt;">. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per common share is computed as follows (in thousands except share and per share data):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.97560975609755%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss used for calculation of basic and diluted EPS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,528</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,140</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,313</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, basic</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,685,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,801,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,384,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options and restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,685,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,801,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,384,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.69</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.63</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.40</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following common stock equivalents were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,394,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,955,398</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,094,904</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Standards</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers </font><font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;">(Topic 606)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">(ASU 2014-09).  ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract.  ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017 and interim periods therein, with early adoption permitted for interim and annual reporting periods beginning after December 15, 2016.  ASU 2014-09 may be adopted either retrospectively or on a modified retrospective basis&#160;whereby ASU 2014-09 would be applied to new contracts and existing contracts with remaining performance obligations&#160;as of the effective date, with a cumulative catch-up adjustment recorded to beginning retained&#160;earnings at the effective date for existing contracts with remaining performance obligations.  </font><font style="font-family:inherit;font-size:10pt;color:#252525;">In 2016, the FASB issued ASU 2016-08, </font><font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;">Revenue from Contracts with Customers: Principal versus Agent Considerations</font><font style="font-family:inherit;font-size:10pt;color:#252525;">, ASU 2016-10,&#160; </font><font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;">Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing</font><font style="font-family:inherit;font-size:10pt;color:#252525;">, and ASU 2016-12, </font><font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;">Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients</font><font style="font-family:inherit;font-size:10pt;color:#252525;"> &#160;to provide supplemental adoption guidance and clarification to ASU 2014-09.  The effective date for these new standards is the same as the effective date and transition requirements for ASU 2014-09.  </font><font style="font-family:inherit;font-size:10pt;">Management has begun an initial review of each of the Company's collaboration and license agreements and is performing an assessment of the potential effects of the standard on the Company's consolidated financial statements, accounting policies, and internal controls over financial reporting. The Company anticipates that the adoption of the new revenue recognition standard will have primarily two impacts on its contract revenues generated by its collaborative research and license agreements: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i) Changes in the model for distinct licenses of functional intellectual property which may result in a timing difference of revenue recognition.&#160;&#160;Whereas revenue from these arrangements was previously recognized over a period of time pursuant to revenue recognition guidance that was in place for the arrangements at the time such arrangements commenced, revenue from these arrangements may now be recognized at point in time under the new guidance. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii) Assessments of milestone payments, which are linked to events that are in the Company&#8217;s control, will result in variable consideration that may be recognized at an earlier point in time under the new guidance, when it is probable that the milestone will be achieved without a significant future reversal of cumulative revenue expected. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has not yet completed its final review of the impact of this guidance. The Company has also not concluded on the implementation approach to be used.&#160;&#160;Management plans to adopt the new standard effective January 1, 2018. The Company continues to monitor additional changes, modifications, clarifications or interpretations being undertaken by the FASB, which may impact the implementation approach management decides to use. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">In August 2014, the FASB issued ASU 2014-15, </font><font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;">Presentation of Financial Statements - Going Concern, </font><font style="font-family:inherit;font-size:10pt;color:#252525;">which requires management of an entity to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued or available to be issued.  ASU 2014-15 is effective for annual periods ending after December&#160;15, 2016, and interim periods within </font><font style="font-family:inherit;font-size:10pt;">annual periods beginning after December 15, 2016</font><font style="font-family:inherit;font-size:10pt;color:#252525;">. The Company&#8217;s adoption of this new standard for the year ended December&#160;31, 2016 had no impact on the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes, Balance Sheet Classification of Deferred Taxes</font><font style="font-family:inherit;font-size:10pt;"> (ASU 2015-17).&#160; ASU 2015-17 requires entities to present deferred tax assets and deferred tax liabilities as noncurrent on a classified balance sheet. ASU 2015-17 is effective for annual and interim reporting periods after December 15, 2016 and companies are permitted to apply ASU 2015-17 either prospectively or retrospectively. Early adoption of ASU 2015-17 is permitted. The Company adopted ASU 2015-17 on a prospective basis in the first quarter of 2016.&#160; The prior reporting period was not retrospectively adjusted. The adoption of this guidance had no impact on the Company's results of operations or cash flows.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;"> (ASU 2016-02) that provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors.&#160; ASU 2016-02 requires a lessee to recognize assets and liabilities on the balance sheet for operating leases and changes many key definitions, including the definition of a lease. ASU 2016-02 includes a short-term lease exception for leases with a term of 12 months or less, in which a lessee can make an accounting policy election not to recognize lease assets and lease liabilities. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous guidance. ASU 2016-02 is effective for fiscal years beginning after December&#160;15, 2018, and interim periods within those fiscal years, with earlier application permitted. The Company is currently evaluating the effect of the standard on its consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March&#160;2016, the FASB issued ASU 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Improvements</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">to Employee Share-Based Payment Accounting </font><font style="font-family:inherit;font-size:10pt;">(ASU 2016-09). This amendment addresses several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within that year. Early adoption is permitted. The Company is evaluating the impact&#160;of the standard on its consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6822026768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;font-weight:bold;">Marketable Securities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">Available-for-sale marketable securities as of </font><font style="font-family:inherit;font-size:10pt;color:#252525;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;color:#252525;"> and </font><font style="font-family:inherit;font-size:10pt;color:#252525;">2015</font><font style="font-family:inherit;font-size:10pt;color:#252525;"> were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government-sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,764</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,759</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,376</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(127</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,300</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(138</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,884</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,354</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,349</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government-sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,055</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,047</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,473</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,481</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,882</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,877</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">The contractual maturities of the available-for-sale marketable securities as of </font><font style="font-family:inherit;font-size:10pt;color:#252525;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;color:#252525;"> were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mature in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,985</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mature between one and five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,981</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,986</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,884</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the Company's available-for-sale securities held at December 31, 2015 had maturity dates of less than one year.  All available-for-sale securities in an unrealized loss position as of </font><font style="font-family:inherit;font-size:10pt;color:#252525;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> were in a loss position for less than twelve months.&#160; There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> unrealized losses at </font><font style="font-family:inherit;font-size:10pt;color:#252525;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> that the Company determined to be other-than-temporary.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -Glossary Debt Security<br> -URI http://asc.fasb.org/extlink&amp;oid=6509901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6379141&amp;loc=d3e15032-111544<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -Glossary Equity Security<br> -URI http://asc.fasb.org/extlink&amp;oid=6511694<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27405-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6822092624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment consists of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,352</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,801</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and office equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">919</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,208</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,306</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,807</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,936</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,784</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,031</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,823</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,190</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,961</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,841</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment balance at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> includes approximately </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> in assets that were purchased in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> but were not paid for by year end.&#160; Depreciation expense for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$6.8 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51719941&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821994288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stockholders' Equity</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;The Company's amended and restated certificate of incorporation authorizes </font><font style="font-family:inherit;font-size:10pt;">125,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, and </font><font style="font-family:inherit;font-size:10pt;">5,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of undesignated preferred stock, both with a par value of </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share.&#160;&#160;There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> shares of undesignated preferred stock issued or outstanding as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2014, the Company completed an equity offering, in which the Company sold </font><font style="font-family:inherit;font-size:10pt;">1,800,000</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$36.50</font><font style="font-family:inherit;font-size:10pt;"> per share.&#160;&#160;Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional </font><font style="font-family:inherit;font-size:10pt;">450,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$36.50</font><font style="font-family:inherit;font-size:10pt;"> per share.&#160;&#160;The Company received proceeds of </font><font style="font-family:inherit;font-size:10pt;">$76.7 million</font><font style="font-family:inherit;font-size:10pt;"> from this offering, net of underwriting discounts and commissions and other offering expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2015, the Company's stock purchase agreement and investor agreement, each with Johnson &amp; Johnson Innovation &#8211; JJDC, Inc. (JJDC) became effective (See Note 9 for additional information).&#160; Under these agreements, JJDC purchased </font><font style="font-family:inherit;font-size:10pt;">1,923,077</font><font style="font-family:inherit;font-size:10pt;"> new shares of the Company's common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$39.00</font><font style="font-family:inherit;font-size:10pt;"> per share, representing proceeds of </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the Company completed an equity offering, in which the Company sold </font><font style="font-family:inherit;font-size:10pt;">3,525,000</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$37.00</font><font style="font-family:inherit;font-size:10pt;"> per share.&#160; Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional </font><font style="font-family:inherit;font-size:10pt;">528,750</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$37.00</font><font style="font-family:inherit;font-size:10pt;"> per share.&#160; The Company received net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$141.0 million</font><font style="font-family:inherit;font-size:10pt;"> from this offering, net of underwriting discounts and commissions and other estimated offering expenses.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section C<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6822092624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. The 2003 Plan originally allowed for the grant of awards in respect of an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,051,644</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock. Between 2006 and 2012, the maximum number of shares of common stock authorized to be issued by the Company under the 2003 Plan was increased to </font><font style="font-family:inherit;font-size:10pt;">4,336,730</font><font style="font-family:inherit;font-size:10pt;">. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan. Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Plan, up to a specified number of shares.&#160; As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, under the 2003 Plan, there were options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,193,941</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock outstanding at a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.81</font><font style="font-family:inherit;font-size:10pt;"> per share.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2013, the Company implemented the 2013 Stock Incentive Plan (2013 Plan).&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards. The aggregate number of shares of common stock initially available for issuance pursuant to awards under the 2013 Plan was </font><font style="font-family:inherit;font-size:10pt;">1,960,168</font><font style="font-family:inherit;font-size:10pt;"> shares.&#160;&#160;The number of shares of common stock reserved for issuance will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) </font><font style="font-family:inherit;font-size:10pt;">1,960,168</font><font style="font-family:inherit;font-size:10pt;"> shares, (b) </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;"> of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Board of Directors. During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to </font><font style="font-family:inherit;font-size:10pt;">5,375,064</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, under the 2013 Plan, there were options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,644,119</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock outstanding at a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$26.66</font><font style="font-family:inherit;font-size:10pt;"> per share.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following stock-based compensation amounts were recognized for the periods indicated (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,778</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,623</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,562</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,387</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,224</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,682</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,165</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,847</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,244</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employee Stock Options</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64% - 69%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73% - 75%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2% - 2.4%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.6% - 2.1%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.8% - 2.3%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25 years</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expected Dividend Yield</font><font style="font-family:inherit;font-size:10pt;"> &#8211; The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expected Volatility</font><font style="font-family:inherit;font-size:10pt;"> &#8211; Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period.&#160;&#160;As the Company does not yet have sufficient history of its own volatility, the Company has identified several public entities of similar size, complexity and stage of development and estimates volatility based on the volatility of these companies.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk-Free Interest Rate</font><font style="font-family:inherit;font-size:10pt;"> &#8211; This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expected Term</font><font style="font-family:inherit;font-size:10pt;"> &#8211; This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;">. The Company uses a simplified method to calculate the average expected term.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the assumptions above, the Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.&#160;&#160;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option and restricted stock unit (RSU) activity for </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate Intrinsic Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,146,064</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">399,949</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised or RSUs vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(526,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited or expired</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(181,238</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.53</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,838,060</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,862</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,292,923</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.71</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,458</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,651,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,496</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> the Company issued </font><font style="font-family:inherit;font-size:10pt;">526,715</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">374,214</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">568,906</font><font style="font-family:inherit;font-size:10pt;"> net shares of common stock, respectively, in conjunction with stock option exercises and RSU lapses.&#160;&#160;The Company received cash proceeds from the exercise of stock options of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> during </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted-average grant-date fair value of options granted during </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$15.17</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$20.90</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$17.41</font><font style="font-family:inherit;font-size:10pt;"> per share, respectively. The total intrinsic value of options exercised during </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> was approximately </font><font style="font-family:inherit;font-size:10pt;">$10.8 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$10.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$14.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;The total fair value of stock options which vested during </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$11.6 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$7.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the total unrecognized compensation expense related to non-vested stock options and RSUs, net of related forfeiture estimates, was </font><font style="font-family:inherit;font-size:10pt;">$22.2 million</font><font style="font-family:inherit;font-size:10pt;">, which the Company expects to recognize over a weighted-average period of approximately </font><font style="font-family:inherit;font-size:10pt;">2.5 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6822027568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> there was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> provision for income taxes due to taxable losses generated, fully offset by a valuation allowance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal U.S. net operating loss carryforward</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,377</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,949</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State net operating loss carryforward</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,907</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development credit, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,829</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,278</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Orphan drug credit, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,855</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,497</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,947</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,632</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,926</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,597</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,085</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,532</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross deferred income tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,126</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(128,844</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(104,399</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred income tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,406</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">727</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenditures</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,406</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(727</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross deferred income tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,406</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(727</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred income tax asset/(liability)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i) future reversals of existing taxable temporary differences; (ii) future taxable income exclusive of reversing temporary difference and carryforwards; (iii) taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv) tax planning strategies. The Company's net deferred income tax asset is not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. The net increase in the valuation allowance in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> is due to the fact the Company generated research and development and orphan drug credits and NOL carryforwards which increased the net deferred tax asset.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company has U.S. federal and state NOL carryforwards of approximately </font><font style="font-family:inherit;font-size:10pt;">$215.4 million</font><font style="font-family:inherit;font-size:10pt;"> that will expire in various years beginning in </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;"> through </font><font style="font-family:inherit;font-size:10pt;">2036</font><font style="font-family:inherit;font-size:10pt;">. In addition, the Company has U.S. federal tax credits of </font><font style="font-family:inherit;font-size:10pt;">$32.5 million</font><font style="font-family:inherit;font-size:10pt;"> which will expire in various years beginning in </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;"> through </font><font style="font-family:inherit;font-size:10pt;">2036</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The use of the Company's U.S. federal NOL and tax credit carryforwards in future years are restricted due to changes in the Company's ownership and tax attributes acquired through the Company's acquisitions. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$13.5 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company's US Federal NOLs are limited for use over the years </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> &#8211; </font><font style="font-family:inherit;font-size:10pt;">2029</font><font style="font-family:inherit;font-size:10pt;"> in which a range of such amounts could be utilized on an annual basis of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">. The remaining </font><font style="font-family:inherit;font-size:10pt;">$201.9 million</font><font style="font-family:inherit;font-size:10pt;"> of NOLs is not limited and can be offset against future taxable income.&#160;&#160;Additionally, approximately </font><font style="font-family:inherit;font-size:10pt;">$18.6 million</font><font style="font-family:inherit;font-size:10pt;"> of NOLs will be recognized as a benefit through additional-paid-in-capital when realized.&#160;&#160;Further, despite the NOL and credit carryforwards, the Company may have a future tax liability due to an alternative minimum tax or state tax requirements in which net operating losses do not exist.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States federal tax at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,489</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,049</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,410</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State taxes (net of federal benefit)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">661</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred state blended rate adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(493</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,034</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research credit, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,551</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,296</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,228</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transaction cost deduction</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transaction cost deduction - prior year adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(564</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Orphan drug credit, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(571</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(139</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other permanent items</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(382</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,997</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">756</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,444</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,103</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,920</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense/(benefit)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,708</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases/(decreases) for current year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">308</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">357</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases/(decreases) for prior year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(268</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,465</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,425</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,047</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, of the total gross unrecognized tax benefits, approximately </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;"> would favorably impact the Company's effective income tax rate, respectively. Although, due to the Company's determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance would be recorded, therefore, zero net impact would result within the Company's effective income tax rate. The Company's uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute carryforward amounts.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, the Company has </font><font style="font-family:inherit;font-size:10pt;">not</font><font style="font-family:inherit;font-size:10pt;"> recognized any interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within the next twelve months.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's U.S. Federal and state income tax returns from </font><font style="font-family:inherit;font-size:10pt;">2001</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#252525;">forward remain open to examination due to the carryover of unused net operating losses and tax credits.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6814730544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Exit Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Lease Exit Liability</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lease Exit Liability</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2008, the Company acquired Raven Biotechnologies, Inc. (Raven), a private South San Francisco-based company focused on the development of monoclonal antibody therapeutics for treating cancer. The Company undertook restructuring activities related to the acquisition of Raven. In connection with these restructuring activities, as part of the cost of acquisition, the Company established a restructuring liability attributed to an existing operating lease.&#160; During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into an agreement to sublease a portion of the space subject to this operating lease.&#160; The Company will receive approximately </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> in sublease payments over its term, which ends at the same time as the original lease in February 2018.&#160; No sublease income was contemplated when the restructuring liability was recorded in 2008; therefore, the Company adjusted the liability to reflect the future sublease income during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and recorded an offset to research and development expenses of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> in the same period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the lease exit liability are as follows (in thousands): </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrual balance at December&#160;31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal payments and other adjustments </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,293</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrual balance at December&#160;31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,713</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal payments and other adjustments (net of sublease receipts)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,822</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrual balance at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,891</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During 2015, the Company corrected an immaterial error attributed to the estimated lease term that resulted in a reduction of research and development expense of </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future principal payments to be made under the lease agreement as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, net of the sublease amounts, are as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,593</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">298</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,891</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section P<br> -Subsection 3, 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821994832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock', window );">Collaboration and Other Agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaboration and Other Agreements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Janssen</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">December 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a collaboration and license agreement with Janssen for the development and commercialization of MGD011 (also known as JNJ-64052781 or duvortuxizumab), a product candidate that incorporates the Company's proprietary DART technology to simultaneously target CD19 and CD3 for the potential treatment of B-cell hematological malignancies (MGD011 Agreement). The Company contemporaneously entered into an agreement with JJDC under which JJDC agreed to purchase </font><font style="font-family:inherit;font-size:10pt;">1,923,077</font><font style="font-family:inherit;font-size:10pt;"> new shares of the Company's common stock for proceeds of </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Upon closing the transaction in January 2015, the Company received a </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment from Janssen as well as the </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> investment in the Company's common stock.&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the MGD011 Agreement, the Company granted an exclusive license to Janssen to develop and commercialize duvortuxizumab. Following the Company's submission of the Investigational New Drug (IND) application, Janssen became fully responsible for the development and commercialization of duvortuxizumab.&#160;&#160; Assuming successful development and commercialization, the agreement entitles the Company to receive up to </font><font style="font-family:inherit;font-size:10pt;">$205.0 million</font><font style="font-family:inherit;font-size:10pt;"> in development milestone payments, </font><font style="font-family:inherit;font-size:10pt;">$220.0 million</font><font style="font-family:inherit;font-size:10pt;"> in regulatory milestone payments and </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> in sales milestone payments. The Company determined that each potential future clinical and regulatory milestone is substantive.&#160; Although the sales milestones are not considered substantive, they will be recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time.&#160; The Company may elect to fund a portion of late-stage clinical development in exchange for a profit share with Janssen in the U.S. and Canada. If commercialized, the Company would be eligible to receive low double-digit royalties on any global net sales and has the option to co-promote the molecule with Janssen in the United States.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the MGD011 Agreement with Janssen and determined that it is a revenue arrangement with multiple deliverables, or performance obligations.&#160; The Company's substantive performance obligations under the collaboration and license agreement include the delivery of an exclusive license and research and development services during the preclinical research period (through the filing of the IND for duvortuxizumab). &#160; The Company evaluated the MGD011 Agreement and determined that the license and preclinical research and development activities each represented separate deliverables and were accounted for as separate units of accounting.&#160; The Company concluded that the license had standalone value to Janssen and was separable from the research and development services because the license was sublicensable, there were no restrictions as to Janssen's use of the license and Janssen or other third parties have significant research capabilities in this field.&#160; Thus, the total arrangement consideration for these two deliverables was allocated using the relative best estimate of selling price method to each deliverable.&#160; The best estimate of selling price for the exclusive license was determined using a discounted cash flow model that includes Level 3 fair value measurements. The best estimate of selling price for the research and development services was determined using third party evidence of other similar research and development arrangements, which are Level 2 fair value measurements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the stock purchase agreement and the collaboration and license agreement as one arrangement and determined that the stock purchase price of </font><font style="font-family:inherit;font-size:10pt;">$39.00</font><font style="font-family:inherit;font-size:10pt;"> per share exceeded the fair value of the common stock by </font><font style="font-family:inherit;font-size:10pt;">$12.3 million</font><font style="font-family:inherit;font-size:10pt;">. This excess was recognized in the same manner as the upfront payment allocated to the license and preclinical research and development activities.&#160; Of the total arrangement consideration of </font><font style="font-family:inherit;font-size:10pt;">$125.0 million</font><font style="font-family:inherit;font-size:10pt;">, the Company allocated </font><font style="font-family:inherit;font-size:10pt;">$62.7 million</font><font style="font-family:inherit;font-size:10pt;"> to equity (representing the fair value of common stock purchased), </font><font style="font-family:inherit;font-size:10pt;">$62.3 million</font><font style="font-family:inherit;font-size:10pt;"> to the license and preclinical research and development activities, and a de minimis amount to the ongoing research and development activities.&#160; The Company submitted the IND application and therefore met its performance obligation during the year ended December&#160;31, 2015.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, Janssen dosed the first patient in an open-label Phase 1 study of duvortuxizumab which triggered a </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> milestone to the Company.&#160; During the years ended December&#160;31, 2016 and 2015, the Company recognized revenue of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$72.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, under the MGD011 agreement. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2016, the Company entered into a separate collaboration and license agreement with Janssen, a related party through ownership of the Company's common stock, for the development and commercialization of MGD015, a product candidate that incorporates the Company's proprietary DART technology to simultaneously target CD3 and an undisclosed tumor target for the potential treatment of various hematological malignancies and solid tumors (MGD015 Agreement). The transaction closed in June 2016, and the Company received the </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment from Janssen in July 2016.&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the MGD015 Agreement, the Company granted an exclusive license to Janssen to develop and commercialize MGD015. Janssen will complete the IND-enabling activities and will be fully responsible for the future clinical development and commercialization of MGD015.&#160;&#160; Assuming successful development and commercialization, the agreement entitles the Company to receive up to </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;"> in development milestone payments, </font><font style="font-family:inherit;font-size:10pt;">$265.0 million</font><font style="font-family:inherit;font-size:10pt;"> in regulatory milestone payments and </font><font style="font-family:inherit;font-size:10pt;">$300.0 million</font><font style="font-family:inherit;font-size:10pt;"> in sales milestone payments. The Company determined that each potential future clinical and regulatory milestone is substantive.&#160; Although the sales milestones are not considered substantive, they will be recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time.&#160; The Company may elect to fund a portion of late-stage clinical development in exchange for a profit share with Janssen in the U.S. and Canada. If commercialized, the Company would be eligible to receive low double-digit royalties on any global net sales and has the option to co-promote the molecule with Janssen in the United States.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the MGD015 Agreement with Janssen and determined that it is a revenue arrangement with multiple deliverables, or performance obligations.&#160; The Company's substantive performance obligations under the MGD015 Agreement include the delivery of an exclusive license and research and development services during the preclinical research period. &#160; The Company evaluated the MGD015 Agreement with Janssen and determined that the license and preclinical research and development activities each represented separate deliverables and were accounted for as two separate units of accounting.&#160; The Company concluded that the license had standalone value to Janssen and was separable from the research and development services because the license was sublicensable, there were no restrictions as to Janssen's use of the license and Janssen or other third parties have significant research capabilities in this field.&#160; Thus, the total arrangement consideration for these two deliverables was allocated using the best estimate of relative selling price method to each deliverable.&#160; The best estimate of selling price for the exclusive license was determined using information from the previous collaboration and license agreement with Janssen as well as other third party collaboration and license agreements, which are Level 2 fair value measurements. The best estimate of selling price for the research and development services was determined using other similar research and development arrangements, which are also Level 2 fair value measurements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized revenue of </font><font style="font-family:inherit;font-size:10pt;">$75.8 million</font><font style="font-family:inherit;font-size:10pt;">, including the </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront fee for the exclusive license under the MGD015 Agreement.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Takeda</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">May 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a license and option agreement with Takeda for the development and commercialization of MGD010, a product candidate that incorporates the Company's proprietary DART technology to simultaneously engage CD32B and CD79B, which are two B-cell surface proteins.&#160;&#160;MGD010 is being developed for the treatment of autoimmune disorders.&#160; Upon execution of the agreement, Takeda made a non-refundable payment of </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> to the Company.&#160;&#160;Takeda had an option to obtain an exclusive worldwide license for MGD010 following the completion of a pre-defined Phase 1a study.&#160; Following the announcement of its therapeutic area re-prioritization, Takeda gave formal notification in September 2016 that it did not intend to exercise this option.&#160; As a result of Takeda not exercising the option, the Company regained worldwide development and commercialization rights to MGD010. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of the license and option agreement with Takeda, the Company evaluated it and determined that it was a revenue arrangement with multiple deliverables, or performance obligations. The Company's substantive performance obligations under the license and option agreement included exclusivity, research and development services through the Phase 1a study and delivery of a future license for an initial research compound.&#160;&#160;The Company concluded that the MGD010 option was substantive and that the license fee payable upon exercise of the option was not a deliverable at the inception of the arrangement as there was considerable uncertainty that the option would be exercised. The Company determined that each potential future clinical and regulatory milestone was substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time.&#160;&#160;&#160;The Company determined that these performance obligations represent a single unit of accounting, because the exclusivity clause does not have stand-alone value to Takeda without the Company's technical expertise and development through the pre-defined Phase 1a study.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After identifying the deliverables included within the arrangement, the Company determined its best estimate of selling price.&#160;&#160;The Company allocated </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> to the exclusivity clause to its technology and the research and development services and </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> to the exclusive license for the initial research compound.&#160;&#160;The Company's determination of best estimate of selling price for the research and development services relied upon other similar transactions.&#160;&#160;The Company relied upon the income approach (e.g., discounted future cash flows) to determine the value of the license of the to-be-delivered compound along with other similar license transactions with differing indications but similar stage of development. The portion of the up-front fee allocated to the MGD010 option was being recognized over an initial </font><font style="font-family:inherit;font-size:10pt;">24</font><font style="font-family:inherit;font-size:10pt;">-month period, which represented the expected period of development through the completion of a pre-defined Phase 1a study.&#160;&#160;During the first quarter of 2016, the Company determined that the development period would be extended by eight months, and prospectively adjusted the MGD010 option fee recognition period.&#160; The portion of the up-front fee allocated to the license for the initial research compound was deferred until the research collaboration and license option agreement was executed and the license delivered in September 2014.&#160; Upon the notification that Takeda would not exercise the option to obtain an exclusive worldwide license for MGD010 during the three months ended September 30, 2016, the Company's performance obligation to Takeda ceased, and the remaining deferred revenue under the MGD010 agreement was recognized in full.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized revenue of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$8.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> under the MGD010 agreement during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160; Revenue recognized during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> included a </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> milestone payment received upon initiation of a Phase 1a trial of MGD010.&#160;&#160;&#160;At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> revenue was deferred under this agreement.&#160; At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;"> of revenue was deferred under this agreement, all of which was current.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">September 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company and Takeda executed a research collaboration and license option agreement, which formalized the license for the initial research compound contemplated in the May 2014 arrangement. Under the terms of the agreement, Takeda may nominate up to three additional compounds on or before September 25, 2017, which will be subject to separate research and development plans.&#160;&#160;The Company determined that it could recognize the entire license fee allocated to this agreement as (1) the executed contract constituted persuasive evidence of an arrangement, (2) the delivery of the license occurred and the Company had no current or future performance obligations, (3) the total consideration for the license was fixed and known at the time of its execution and there were not any extended payment terms or rights of return, and (4) the cash was received. &#160;The Company is also entitled to receive reimbursements for research and development services provided to Takeda with respect to the initial research compound under a separate research plan.&#160; The Company recognized revenue of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> under this agreement during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160; Revenue during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> includes the </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> license fee.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;text-indent:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Takeda terminated its option to license the first program under this research collaboration agreement in 2015 and retains an option for three others.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Servier</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">September 2012</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a right-to-develop collaboration agreement with Servier and granted it options to obtain three separate exclusive licenses to develop and commercialize DART molecules, consisting of those designated by the Company as MGD006 (or flotetuzumab) (also known as S80880) and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India.  During 2014, Servier exercised its exclusive option to develop and commercialize flotetuzumab, and during 2016 Servier notified the Company that it did not intend to exercise the option for the third DART molecule.  Servier retains the option to obtain a license for MGD007.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon execution of the agreement, Servier made a nonrefundable payment of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> to the Company. In addition, the Company will be eligible to receive up to </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> in license fees, </font><font style="font-family:inherit;font-size:10pt;">$63.0 million</font><font style="font-family:inherit;font-size:10pt;"> in clinical milestone payments, </font><font style="font-family:inherit;font-size:10pt;">$188.0 million</font><font style="font-family:inherit;font-size:10pt;"> in regulatory milestone payments and </font><font style="font-family:inherit;font-size:10pt;">$420.0 million</font><font style="font-family:inherit;font-size:10pt;"> in sales milestone payments if Servier exercises the remaining available options and successfully develops, obtains regulatory approval for, and commercializes a product under each license. In addition to these milestones, the Company and Servier will share Phase 2 and Phase 3 development costs. The Company has determined that each potential future clinical and regulatory milestone is substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. Under this agreement, Servier would be obligated to pay the Company from low double-digit to mid-teen royalties on net product sales in its territories.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the research collaboration agreement with Servier and determined that it is a revenue arrangement with multiple deliverables, or performance obligations. The Company concluded that each option is substantive and that the license fees for each option are not deliverables at the inception of the arrangement and were not issued with a substantial discount. The Company's substantive performance obligations under this research collaboration include an exclusivity clause to its technology, technical, scientific and intellectual property support to the research plan and participation on an executive committee and a research and development committee. The Company determined that the performance obligations with respect to the preclinical development represent a single unit of accounting, since the license does not have stand-alone value to Servier without the Company's technical expertise and committee participation. As such, the initial upfront license payment was deferred and initially recognized ratably over a </font><font style="font-family:inherit;font-size:10pt;">29</font><font style="font-family:inherit;font-size:10pt;">-month period, which represented the expected development period. During 2014, the Company and Servier further refined the research plan related to the three DART molecules and as such, the development period was extended.&#160;&#160;Based on this revised development period, the Company prospectively adjusted its period of recognition of the upfront payment to a </font><font style="font-family:inherit;font-size:10pt;">75</font><font style="font-family:inherit;font-size:10pt;">-month period. The impact of this change in accounting estimate reduced revenue that would have been recognized in 2014 by </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of Servier exercising its option in 2014, the Company received a </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> payment from Servier for its license to develop and commercialize flotetuzumab in its territories.&#160;&#160;Upon exercise of the option, the Company evaluated its performance obligations with respect to the license for flotetuzumab. The Company's substantive performance obligations under this research collaboration include an exclusive license to its technology, technical, scientific and intellectual property support to the research plan and participation on an executive committee and a research and development committee. The Company determined that the performance obligations with respect to the clinical development represent a single unit of accounting, since the license does not have stand-alone value to Servier without the Company's technical expertise and committee participation. As such, the </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> license fee was deferred and is being recognized ratably over a period of </font><font style="font-family:inherit;font-size:10pt;">82 months</font><font style="font-family:inherit;font-size:10pt;">, which represents the expected development period for flotetuzumab.&#160;&#160;In accordance with the agreement, the Company and Servier will share costs incurred to develop flotetuzumab.&#160;&#160;Reimbursement of research and development expenses received in connection with this collaborative cost-sharing agreement is recorded as a reduction to research and development expense.&#160;&#160;During the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> the Company recorded approximately </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> as an offset to research and development costs under this collaboration arrangement, respectively.&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> the Company recognized revenue of </font><font style="font-family:inherit;font-size:10pt;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$16.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, under this agreement.&#160;&#160;Revenue during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> includes </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> milestone payments from Servier upon the achievement of clinical milestones related to the IND applications for flotetuzumab and MGD007 clearing the </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">-day review period by the U.S. FDA.&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> milestones were recognized under this agreement during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$11.1 million</font><font style="font-family:inherit;font-size:10pt;"> of revenue was deferred under this agreement, </font><font style="font-family:inherit;font-size:10pt;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;"> of which was current and </font><font style="font-family:inherit;font-size:10pt;">$7.8 million</font><font style="font-family:inherit;font-size:10pt;"> of which was non-current. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$14.4 million</font><font style="font-family:inherit;font-size:10pt;"> of revenue was deferred under this agreement, </font><font style="font-family:inherit;font-size:10pt;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;"> of which was current and </font><font style="font-family:inherit;font-size:10pt;">$11.1 million</font><font style="font-family:inherit;font-size:10pt;"> of which was non-current.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Boehringer</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">October 2010</font><font style="font-family:inherit;font-size:10pt;"> the Company entered into a collaboration and license agreement with Boehringer to discover, develop and commercialize multiple DART molecules that were to be evaluated during a five-year period that ended in </font><font style="font-family:inherit;font-size:10pt;">October 2015</font><font style="font-family:inherit;font-size:10pt;">. Under the terms of the agreement, the Company granted Boehringer an exclusive, worldwide, royalty-bearing, license under its intellectual property to research, develop, and market DART molecules generated under the agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon execution of the agreement, the Company received an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;">. The Company subsequently received </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> annual maintenance payments. These maintenance payments were being recognized over the estimated period of development. The Company has the potential to earn additional milestone payments of approximately </font><font style="font-family:inherit;font-size:10pt;">$34.0 million</font><font style="font-family:inherit;font-size:10pt;"> related to preclinical and clinical development, </font><font style="font-family:inherit;font-size:10pt;">$88.5 million</font><font style="font-family:inherit;font-size:10pt;"> related to regulatory milestones and </font><font style="font-family:inherit;font-size:10pt;">$82.5 million</font><font style="font-family:inherit;font-size:10pt;"> related to sales milestones for each of the two ongoing programs under this agreement. The Company determined that each potential future preclinical, clinical and regulatory milestone is substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. Boehringer would be required to pay the Company mid-single digit royalties on product sales.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the deliverables under the Boehringer agreement include the license, the research and development services to be performed by the Company, and the co-promotion/manufacturing services. The Company concluded that the co-promotional activities were optional and were subject to further negotiation upon reaching regulatory approval. As such, the co-promotional period is not included in the expected obligation period to perform services.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company concluded that the undelivered element of research and development services had fair value. The Company concluded that the license did not have value on a standalone basis (e.g. absent the provision of the research and development services) and therefore did not represent a separate unit of accounting. The Company concluded that because the drug candidate had not yet been developed, the license was of no value to Boehringer without the ensuing research and development activities using the DART technology, which is proprietary to the Company. Likewise, Boehringer could not sell the license to another party (without the Company agreeing to provide the research and development activities for the other party). Therefore, the upfront license fee and research and development services were treated as a combined unit of accounting and recognized over the expected obligation period associated with the research and development services through October 2015, which represented the estimated period of development.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company and Boehringer also agreed to establish a joint research committee to facilitate the governance and oversight of the parties' activities under the agreements. Management considered whether participation on the joint committee may be a deliverable and determined that it was not a deliverable. However, had management considered participation on the joint committee as a deliverable, it would not have had a material impact on the accounting for the arrangement as the period of participation in this committee matched the obligation period for the research and development services.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> revenue under this agreement during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.  The Company recognized revenue of approximately </font><font style="font-family:inherit;font-size:10pt;">$12.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$13.7 million</font><font style="font-family:inherit;font-size:10pt;"> during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, under this agreement. Revenue recognized during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> included milestone payments of </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, for the achievement of clinical milestones.  </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> revenue was deferred under this agreement at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Green Cross</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">June 2010</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a collaboration agreement with Green Cross Corp. (Green Cross) for the development of the Company's anti-HER2 antibody margetuximab. This arrangement grants Green Cross an exclusive license to conduct specified Phase 1 and Phase 2 clinical trials and commercialize margetuximab in South Korea. In March 2014, the Company and Green Cross entered into an amendment to the original agreement, causing the terms of the original agreement to be materially modified.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon execution of the amendment, the Company became eligible to receive reimbursement for costs incurred for Phase 2 and Phase 3 clinical trials up to </font><font style="font-family:inherit;font-size:10pt;">$5.5 million</font><font style="font-family:inherit;font-size:10pt;"> as well as clinical development and commercial milestone payments of up to </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">. The Company determined that each potential clinical development and commercial milestone is substantive. The Company is also entitled to receive royalties on net sales of margetuximab in South Korea. The Company and Green Cross have formed a joint steering committee to coordinate and oversee activities on which the companies collaborate under the agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the collaboration agreement with Green Cross and determined that it is a revenue arrangement with multiple deliverables or performance obligations. As a result of the material modification to the arrangement in March 2014, the Company reassessed the entire arrangement in accordance with the guidance provided by ASC 605-25, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Multiple Element Arrangements (Revenue Recognition)</font><font style="font-family:inherit;font-size:10pt;"> as the original agreement was accounted for prior to adopting ASU 2009-13</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;"> The Company's substantive performance obligations under this agreement include an exclusive license to its technologies, research and development services, and participation in a joint steering committee. The Company concluded that the license and the reimbursements for research and development services do not have value on a standalone basis and therefore do not represent separate units of accounting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The initial </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment received by the Company upon execution of the original agreement is non-refundable; as such, there is no right of return for the license. Therefore, the upfront license fee and participation on the joint steering committee were treated as a combined unit of accounting and will be recognized over the term of the agreement through </font><font style="font-family:inherit;font-size:10pt;">June 2020</font><font style="font-family:inherit;font-size:10pt;">. Further, due to the fact the research and development services are not deemed to have stand-alone value, revenue for those services will be recognized over the entire term of the agreement (through June 2020). As a result of reassessing the arrangement in accordance with ASC 605-25, the Company was required to record an adjustment on the date of the material modification to reflect the revenue that would have resulted had the entity applied the requirements of ASC 605-25 from the inception of the agreement.&#160;&#160;As a result, the Company recorded an additional </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> of revenue during 2014.  The Company has received a total of </font><font style="font-family:inherit;font-size:10pt;">$5.5 million</font><font style="font-family:inherit;font-size:10pt;"> through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> for reimbursement of research and development services, which is also being recognized over the remaining term of the agreement.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized revenues of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;"> under this agreement during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> milestones were achieved under this agreement during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;"> of revenue was deferred under this agreement, </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> of which was current and </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;"> of which was non-current.&#160; At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> of revenue was deferred under this agreement, </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> of which was current and </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;"> of which was non-current.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">NIAID Contract</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;15, 2015</font><font style="font-family:inherit;font-size:10pt;">,&#160;to perform product development and to advance up to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> DART molecules, including MGD014. Under this contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. This contract includes a base period of </font><font style="font-family:inherit;font-size:10pt;">$7.5 million</font><font style="font-family:inherit;font-size:10pt;"> to support development of MGD014 through IND application submission with the FDA, as well as up to </font><font style="font-family:inherit;font-size:10pt;">$17.0 million</font><font style="font-family:inherit;font-size:10pt;"> in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to </font><font style="font-family:inherit;font-size:10pt;">$24.5 million</font><font style="font-family:inherit;font-size:10pt;">. The total potential period of performance under the award is from September 15, 2015 through </font><font style="font-family:inherit;font-size:10pt;">September&#160;14, 2022</font><font style="font-family:inherit;font-size:10pt;">. The Company recognized </font><font style="font-family:inherit;font-size:10pt;">$5.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> in revenue under this contract during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6822026768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company leases manufacturing, office and laboratory space in Rockville, Maryland under </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> leases that have terms that expire between </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2022</font><font style="font-family:inherit;font-size:10pt;"> unless renewed.&#160;&#160;&#160;This includes a </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;">-year lease executed in </font><font style="font-family:inherit;font-size:10pt;">July 2015</font><font style="font-family:inherit;font-size:10pt;"> for additional space that the Company intends to use as mixed-use office, laboratory and manufacturing space.&#160;&#160; Under the terms of the lease, which commenced on </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company received an assignment fee from the former tenant and a tenant improvement allowance from the landlord totaling </font><font style="font-family:inherit;font-size:10pt;">$5.1 million</font><font style="font-family:inherit;font-size:10pt;">, which has been recorded as deferred rent and will be recognized over the lease term.&#160;&#160; The Company also leases office and laboratory space in South San Francisco under a lease that expires on </font><font style="font-family:inherit;font-size:10pt;">February&#160;28, 2018</font><font style="font-family:inherit;font-size:10pt;">.  During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a sublease agreement for a portion of the South San Francisco space (see Note 8). Future payments to be received by the Company under this sublease total approximately </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the leases contain rent escalation clauses and certain leases contain rent abatements.&#160;&#160;For financial reporting purposes, rent expense is charged to operations on a straight-line basis over the term of the lease.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company had recorded a deferred rent liability of </font><font style="font-family:inherit;font-size:10pt;">$6.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$7.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Rent expense for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future minimum lease payments under noncancelable operating leases as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,210</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,142</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,636</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,679</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company does not believe it is currently subject to any material matters where there is at least a reasonable possibility that a material loss may be incurred.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6650619904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation and Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employee Benefit Plan</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section 401(k) of the IRC. Under this Plan, all employees at least </font><font style="font-family:inherit;font-size:10pt;">21</font><font style="font-family:inherit;font-size:10pt;"> years of age are eligible to participate in the Plan, starting on the first day of each month. Employees may contribute up to </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of their salary, subject to government maximums.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees are </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> vested in their contributions to the Plan. The Company's contribution to the Plan, as determined by the Board of Directors, is discretionary. The Company's contributions to the Plan totaled </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=49170332&amp;loc=SL14450702-114947<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=58740216&amp;loc=d3e2410-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39675-114964<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6414199&amp;loc=d3e39622-114963<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6822026768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Information (Unaudited)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarterly Financial Information (unaudited)</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1st Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2nd Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3rd Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4th Quarter</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in thousands, except per share data)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,846</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,673</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,255</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,106</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,464</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.88</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.97</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.97</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,279</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,716</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,681</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,178</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,129</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,376</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,442</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,451</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.53</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.71</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.46</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.83</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the quarterly financial data in the annual financial statements.  The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=51655806&amp;loc=d3e765-108305<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=51825399&amp;loc=d3e1280-108306<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=51655806&amp;loc=d3e725-108305<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section G<br> -Subsection 1<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 302<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6832518560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation and Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited.&#160; All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment, which is developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, stock-based compensation, income taxes, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Marketable Securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Marketable Securities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income (expense).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. The Company considers factors including: the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not that it will be required to sell a security prior to recovery of its fair value.&#160; An impairment loss is recognized at the time the Company determines that a decline in the fair value below its cost basis is other-than-temporary. There were </font><font style="font-family:inherit;font-size:10pt;color:#252525;">no</font><font style="font-family:inherit;font-size:10pt;color:#252525;"> unrealized losses at </font><font style="font-family:inherit;font-size:10pt;color:#252525;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;color:#252525;"> or </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;color:#252525;"> that the Company determined to be other-than-temporary.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> allowance was recorded as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, as the Company has a history of collecting on all outstanding accounts.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#252525;">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</font><font style="font-family:inherit;font-size:10pt;"> The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements and Disclosures</font><font style="font-family:inherit;font-size:10pt;"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 &#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 &#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 &#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of Level 2 securities is determined from </font><font style="font-family:inherit;font-size:10pt;color:#252525;">market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data.  There were no transfers between Level 1 and Level 2 investments during the periods presented.  </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </font><font style="font-family:inherit;font-size:10pt;color:#252525;">We maintain our cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, we have not experienced any losses on related accounts to date.&#160;</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#252525;">Our investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</font><font style="font-family:inherit;font-size:10pt;"> The counterparties are various corporations, financial institutions and government agencies of high credit standing.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property, Plant and Equipment</font><font style="font-family:inherit;font-size:10pt;">. ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company determined that there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> impaired assets and had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> assets held-for-sale.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company's policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenues</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenues</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company enters into collaboration and license agreements with collaborators for the development of monoclonal antibody-based therapeutics to treat cancer and other complex diseases. The terms of these agreements contain multiple deliverables which may include (i) licenses, or options to obtain licenses, to the Company's technological platforms, such as its Fc Optimization and Dual-Affinity Re-Targeting (DART) technologies, (ii) rights to future technological improvements, (iii) research and development activities to be performed on behalf of the collaborator or as part of the collaboration, and (iv) the manufacture of preclinical or clinical materials for the collaborator. Payments to the Company under these agreements may include nonrefundable license fees, option fees, exercise fees, payments for research and development activities, payments for the manufacture of preclinical or clinical materials, license maintenance payments, payments based upon the achievement of certain milestones and royalties on product sales. Other benefits to the Company of these agreements include the right to sell products resulting from the collaborative efforts of the parties in specific geographic territories. The Company follows the provisions of FASB ASC Topic 605-25, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition &#8211; Multiple-Element Arrangements</font><font style="font-family:inherit;font-size:10pt;">, and FASB ASC Topic 605-28, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition&#8211;Milestone Method</font><font style="font-family:inherit;font-size:10pt;">, in accounting for these agreements. In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the periods presented, the Company had the following two types of agreements: 1) exclusive development and commercialization licenses to use the Company's technology and/or certain other intellectual property to develop compounds against specified targets (referred to herein as exclusive licenses); and 2) option/research agreements to secure on established terms, development and commercialization licenses to therapeutic product candidates to collaborator-selected targets developed by the Company during an option period (referred to herein as right-to-develop agreements).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are no performance, cancellation, termination or refund provisions in any of the arrangements that contain material financial consequences to the Company.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exclusive Licenses</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The deliverables under an exclusive license agreement generally include the exclusive license to the Company's DART technology with respect to a specified antigen target, and may also include deliverables related to rights to future technological improvements, research and preclinical development activities to be performed on behalf of the collaborator. In some cases the Company may have an option to participate in the co-development of product candidates that result from such agreements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Generally, exclusive license agreements contain nonrefundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i) at the collaborator's request, provide research and preclinical development services at negotiated prices which are generally consistent with what other third parties would charge, (ii) earn payments upon the achievement of certain milestones, (iii) earn royalty payments, and (iv) in some cases grant the Company an option to participate in the development and commercialization of products that result from such agreements. Royalty rates may vary over the royalty term depending on the Company's intellectual property rights and whether the Company exercises any co-development and co-commercialization rights.The Company does not directly control when any collaborator will achieve milestones or become liable for royalty payments.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When entering into a new collaboration arrangement or materially modifying an existing arrangement, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator.&#160;&#160;The selling prices of deliverables under an arrangement may be derived using third-party evidence (TPE), or a best estimate of selling price (BESP), if vendor specific objective evidence (VSOE) is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the license agreement was sold on a standalone basis. Establishing BESP involves management's judgment and considers multiple factors, including market conditions, company-specific factors, and factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i) the delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the Company's control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of accounting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In determining the separate units of accounting, the Company evaluates whether the exclusive license has standalone value to the collaborator based on consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research and development capabilities of the collaborator and the availability of relevant research expertise in the marketplace. In addition, the Company considers whether or not (i) the collaborator could use the license for its intended purpose without the receipt of the remaining deliverables, (ii) the value of the license was dependent on the undelivered items and (iii) the collaborator or other vendors could provide the undelivered items. If the Company concludes that the license has stand-alone value and therefore will be accounted for as a separate unit of accounting, the Company then determines the estimated selling prices of the license and all other units of accounting based on market conditions, similar arrangements entered into by third parties, and entity-specific factors such as the terms of the Company's previous collaboration agreements, recent preclinical and clinical testing results of therapeutic product candidates that use the Company's technology platforms, the Company's pricing practices and pricing objectives, the likelihood that technological improvements will be made, the likelihood that technological improvements made will be used by the Company's collaborators and the nature of the research services to be performed on behalf of its collaborators and market rates for similar services. Total arrangement consideration is then allocated to each of the units of accounting using the relative-selling-price method.&#160;&#160;If facts and circumstances dictate that the exclusive license does not have stand-alone value, then the related payments are deferred and revenue is recognized throughout the period of performance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management reassesses the period of performance over which the Company recognizes deferred upfront license fees and makes adjustments as appropriate in the period in which a change in the estimated period of performance is identified. In the event a collaborator elects to discontinue development of a specific product candidate under a single target license, but retains its right to use the Company's technology to develop an alternative product candidate to the same target or a target substitute, the Company would cease amortization of any remaining portion of the upfront fee until there is substantial preclinical activity on another product candidate and its remaining period of substantial involvement can be estimated. In the event that a single target license were to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination or through the remaining substantial involvement in the wind down of the agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront payments on exclusive licenses may be recognized upon delivery of the license if facts and circumstances dictate that the license has stand-alone value from the undelivered elements, which generally include rights to future technological improvements, research services and the manufacture of preclinical and clinical materials.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue related to research and preclinical development services that represent separate units of accounting as they are performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection is reasonably assured. The Company recognizes revenue related to the rights to future technological improvements over the estimated term of the applicable license.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company typically performs research activities and preclinical development services, including generating and engineering product candidates, on behalf of its licensees during the early evaluation and preclinical testing stages of drug development under its exclusive licenses. The Company records amounts received for research materials produced or services performed as revenue from collaborative agreements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's license agreements have milestone payments which for reporting purposes are aggregated into three categories: (i) development milestones, (ii) regulatory milestones, and (iii) sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the U.S. Food and Drug Administration (FDA) or other countries' regulatory authorities or on receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of each agreement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (i) the consideration is commensurate with either (a) the entity's performance to achieve the milestone, or (b) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity's performance to achieve the milestone, (ii) the consideration relates solely to past performance and (iii) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-refundable development and regulatory milestones that are expected to be achieved as a result of the Company's efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute effort to their achievement are generally recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligations, assuming all other revenue recognition criteria are met.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Right-to-Develop Agreements</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's right-to-develop agreements provide collaborators with an exclusive option to obtain licenses to develop and commercialize in specified geographic territories product candidates developed by the Company under agreed upon research and preclinical development product programs. The product candidates resulting from each program are all directed to a specific target selected by the collaborator. Under these agreements, fees may be due to the Company (i) at the inception of the arrangement (referred to as "upfront" fees or payments), (ii) the selection of a target for a program, (iii) upon the exercise of an option to acquire a development and commercialization license (referred to as exercise fees or payments earned) for a program, or (iv) some combination of all of these fees.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accounting for right-to-develop agreements is dependent on the nature of the options granted to the collaborator. Options are considered substantive if, at the inception of a right-to-develop agreement, the Company is at risk as to whether the collaborator will choose to exercise the options to secure development and commercialization licenses. Factors that are considered in evaluating whether options are substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the total upfront consideration, and the additional financial commitments imposed on the collaborator as a result of exercising the options.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For right-to-develop agreements where the options to secure development and commercialization licenses to a product program are considered substantive, the Company does not consider the development and commercialization licenses to be a deliverable at the inception of the agreement, and therefore defers any upfront payments received and recognizes this revenue over the period during which the collaborator could elect to exercise options for development and commercialization licenses. These periods are specific to each collaboration agreement. If a collaborator selects a target for a product program, any substantive option fee is deferred and recognized over the life of the option. For right-to-develop agreements that include multiple deliverables, the Company determines the selling prices of deliverables under the arrangement using TPE or a BESP, if VSOE is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the right-to-develop agreement was sold on a standalone basis. Establishing BESP involves management's judgment and considers multiple factors, including market conditions and company-specific factors, including those factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the right-to-develop agreement. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i) the delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the Company's control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of accounting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a collaborator exercises an option and acquires a development and commercialization license to a product program, the Company attributes the exercise fee to the development and commercialization license. The Company determines the selling price of the option license, upon exercise, through management's best estimate using the process for an exclusive license as described above.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon exercise of an option to acquire a development and commercialization license, the Company would also attribute any remaining deferred option fee, in addition to the consideration received for the license upon exercise of the option, to the development and commercialization license.&#160;&#160;The Company then applies the multiple-element revenue recognition criteria to the development and commercialization license and other deliverables, if any, to determine the appropriate revenue recognition method. This model is consistent with the Company's accounting policy for upfront payments on exclusive licenses (discussed above).&#160;&#160;In the event a right-to-develop agreement were to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination. The Company's right-to-develop agreements have been determined to contain substantive options.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For right-to-develop agreements where the options to secure development and commercialization licenses to product programs are not considered substantive, the Company considers the development and commercialization licenses to be a deliverable at the inception of the agreement and applies the multiple-element revenue recognition criteria to determine the appropriate revenue recognition. The Company does not directly control when any collaborator will exercise its options for development and commercialization licenses.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Costs</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities.&#160; Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive Loss</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale securities.</font><font style="font-family:inherit;font-size:10pt;"> Comprehensive loss equals net loss for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> as there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> unrealized gains or losses in that period.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based payments are accounted for in accordance with the provisions of ASC 718, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation &#8211; Stock Compensation</font><font style="font-family:inherit;font-size:10pt;">. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants.  </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Standards</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers </font><font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;">(Topic 606)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">(ASU 2014-09).  ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract.  ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017 and interim periods therein, with early adoption permitted for interim and annual reporting periods beginning after December 15, 2016.  ASU 2014-09 may be adopted either retrospectively or on a modified retrospective basis&#160;whereby ASU 2014-09 would be applied to new contracts and existing contracts with remaining performance obligations&#160;as of the effective date, with a cumulative catch-up adjustment recorded to beginning retained&#160;earnings at the effective date for existing contracts with remaining performance obligations.  </font><font style="font-family:inherit;font-size:10pt;color:#252525;">In 2016, the FASB issued ASU 2016-08, </font><font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;">Revenue from Contracts with Customers: Principal versus Agent Considerations</font><font style="font-family:inherit;font-size:10pt;color:#252525;">, ASU 2016-10,&#160; </font><font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;">Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing</font><font style="font-family:inherit;font-size:10pt;color:#252525;">, and ASU 2016-12, </font><font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;">Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients</font><font style="font-family:inherit;font-size:10pt;color:#252525;"> &#160;to provide supplemental adoption guidance and clarification to ASU 2014-09.  The effective date for these new standards is the same as the effective date and transition requirements for ASU 2014-09.  </font><font style="font-family:inherit;font-size:10pt;">Management has begun an initial review of each of the Company's collaboration and license agreements and is performing an assessment of the potential effects of the standard on the Company's consolidated financial statements, accounting policies, and internal controls over financial reporting. The Company anticipates that the adoption of the new revenue recognition standard will have primarily two impacts on its contract revenues generated by its collaborative research and license agreements: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i) Changes in the model for distinct licenses of functional intellectual property which may result in a timing difference of revenue recognition.&#160;&#160;Whereas revenue from these arrangements was previously recognized over a period of time pursuant to revenue recognition guidance that was in place for the arrangements at the time such arrangements commenced, revenue from these arrangements may now be recognized at point in time under the new guidance. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii) Assessments of milestone payments, which are linked to events that are in the Company&#8217;s control, will result in variable consideration that may be recognized at an earlier point in time under the new guidance, when it is probable that the milestone will be achieved without a significant future reversal of cumulative revenue expected. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has not yet completed its final review of the impact of this guidance. The Company has also not concluded on the implementation approach to be used.&#160;&#160;Management plans to adopt the new standard effective January 1, 2018. The Company continues to monitor additional changes, modifications, clarifications or interpretations being undertaken by the FASB, which may impact the implementation approach management decides to use. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">In August 2014, the FASB issued ASU 2014-15, </font><font style="font-family:inherit;font-size:10pt;color:#252525;font-style:italic;">Presentation of Financial Statements - Going Concern, </font><font style="font-family:inherit;font-size:10pt;color:#252525;">which requires management of an entity to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued or available to be issued.  ASU 2014-15 is effective for annual periods ending after December&#160;15, 2016, and interim periods within </font><font style="font-family:inherit;font-size:10pt;">annual periods beginning after December 15, 2016</font><font style="font-family:inherit;font-size:10pt;color:#252525;">. The Company&#8217;s adoption of this new standard for the year ended December&#160;31, 2016 had no impact on the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes, Balance Sheet Classification of Deferred Taxes</font><font style="font-family:inherit;font-size:10pt;"> (ASU 2015-17).&#160; ASU 2015-17 requires entities to present deferred tax assets and deferred tax liabilities as noncurrent on a classified balance sheet. ASU 2015-17 is effective for annual and interim reporting periods after December 15, 2016 and companies are permitted to apply ASU 2015-17 either prospectively or retrospectively. Early adoption of ASU 2015-17 is permitted. The Company adopted ASU 2015-17 on a prospective basis in the first quarter of 2016.&#160; The prior reporting period was not retrospectively adjusted. The adoption of this guidance had no impact on the Company's results of operations or cash flows.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;"> (ASU 2016-02) that provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors.&#160; ASU 2016-02 requires a lessee to recognize assets and liabilities on the balance sheet for operating leases and changes many key definitions, including the definition of a lease. ASU 2016-02 includes a short-term lease exception for leases with a term of 12 months or less, in which a lessee can make an accounting policy election not to recognize lease assets and lease liabilities. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous guidance. ASU 2016-02 is effective for fiscal years beginning after December&#160;15, 2018, and interim periods within those fiscal years, with earlier application permitted. The Company is currently evaluating the effect of the standard on its consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March&#160;2016, the FASB issued ASU 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Improvements</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">to Employee Share-Based Payment Accounting </font><font style="font-family:inherit;font-size:10pt;">(ASU 2016-09). This amendment addresses several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within that year. Early adoption is permitted. The Company is evaluating the impact&#160;of the standard on its consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 203<br> -Paragraph 02-03<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51676700&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51676700&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51717228&amp;loc=d3e202-110218<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section CC<br> -Subsection 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section B<br> -Paragraph Question 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6378556&amp;loc=d3e10133-111534<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e5212-111524<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3, 4<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819750064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurement Financial Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.34146341463415%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurement at December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices in</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Active Markets for</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Identical Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Observable Inputs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inputs</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,781</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,781</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S Treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government-sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,759</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,759</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,300</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,300</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets measured at fair value </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">251,666</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,781</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204,885</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Total assets measured at fair value at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> includes approximately </font><font style="font-family:inherit;font-size:10pt;">$50.8 million</font><font style="font-family:inherit;font-size:10pt;"> reported in cash and cash equivalents on the balance sheet.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.24390243902438%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurement at December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices in</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Active Markets for</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Identical Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Observable Inputs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inputs</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,353</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,353</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S Treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government-sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,202</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,202</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,928</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,928</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets measured at fair value </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250,831</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,353</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188,478</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Total assets measured at fair value at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> includes approximately </font><font style="font-family:inherit;font-size:10pt;">$108.0 million</font><font style="font-family:inherit;font-size:10pt;"> reported in cash and cash equivalents on the balance sheet.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Estimated Useful Lives</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation is computed using the straight-line method over the following estimated useful lives:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:50%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory and office equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shorter of lease term or useful life</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Loss Per Common Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per common share is computed as follows (in thousands except share and per share data):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.97560975609755%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss used for calculation of basic and diluted EPS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,528</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,140</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,313</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, basic</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,685,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,801,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,384,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options and restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,685,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,801,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,384,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.69</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.63</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.40</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following common stock equivalents were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,394,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,955,398</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,094,904</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of Percentage of Customer Concentration</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes those collaborators that represent more than 10% of total revenue earned in the periods indicated:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen Biotech, Inc. (Janssen)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Les Laboratoires Servier and Institut de Reserches Servier (collectively, Servier) </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Boehringer Ingelheim GmbH (Boehringer)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Takeda Pharmaceutical Company Limited (Takeda)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gilead Sciences, Inc. (Gilead)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes those collaborators that represent more than 10% of accounts receivable at the date indicated:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Servier</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Takeda</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Eli Lilly</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">* Balance is less than 10%</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment estimated useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a,b,bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=SL7498348-110258<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6442-108592<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6327-108592<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821966736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Available-for-sale Securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">Available-for-sale marketable securities as of </font><font style="font-family:inherit;font-size:10pt;color:#252525;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;color:#252525;"> and </font><font style="font-family:inherit;font-size:10pt;color:#252525;">2015</font><font style="font-family:inherit;font-size:10pt;color:#252525;"> were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government-sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,764</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,759</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,376</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(127</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,300</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(138</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,884</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,354</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,349</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government-sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,055</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,047</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,473</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,481</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,882</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,877</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">The contractual maturities of the available-for-sale marketable securities as of </font><font style="font-family:inherit;font-size:10pt;color:#252525;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;color:#252525;"> were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mature in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,985</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mature between one and five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,981</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,986</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,884</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6607386640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment consists of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,352</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,801</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and office equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">919</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,208</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,306</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,807</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,936</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,784</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,031</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,823</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,190</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,961</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,841</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821975296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following stock-based compensation amounts were recognized for the periods indicated (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,778</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,623</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,562</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,387</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,224</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,682</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,165</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,847</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,244</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Employee Stock Options Award Valuation Assumptions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64% - 69%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73% - 75%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2% - 2.4%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.6% - 2.1%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.8% - 2.3%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25 years</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Stock Option and Restricted Stock Unit Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option and restricted stock unit (RSU) activity for </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate Intrinsic Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,146,064</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">399,949</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised or RSUs vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(526,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited or expired</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(181,238</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.53</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,838,060</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,862</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,292,923</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.71</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,458</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,651,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,496</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Share Based Compensation Stock Options And Restricted Stock Units Activity Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6814684832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of the Company's Deferred Income Tax Assets (Liabilities)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal U.S. net operating loss carryforward</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,377</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,949</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State net operating loss carryforward</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,907</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development credit, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,829</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,278</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Orphan drug credit, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,855</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,497</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,947</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,632</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,926</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,597</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,085</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,532</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross deferred income tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,126</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(128,844</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(104,399</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred income tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,406</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">727</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenditures</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,406</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(727</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross deferred income tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,406</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(727</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred income tax asset/(liability)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Reported Estimated Income Tax Benefit</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States federal tax at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,489</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,049</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,410</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State taxes (net of federal benefit)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">661</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred state blended rate adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(493</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,034</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research credit, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,551</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,296</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,228</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transaction cost deduction</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transaction cost deduction - prior year adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(564</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Orphan drug credit, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(571</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(139</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other permanent items</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(382</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,997</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">756</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,444</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,103</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,920</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense/(benefit)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,708</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases/(decreases) for current year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">308</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">357</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases/(decreases) for prior year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(268</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,465</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,425</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,047</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=51663037&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6773087728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Exit Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Changes in Lease Exit Liability</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the lease exit liability are as follows (in thousands): </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrual balance at December&#160;31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal payments and other adjustments </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,293</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrual balance at December&#160;31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,713</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal payments and other adjustments (net of sublease receipts)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,822</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrual balance at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,891</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Future Principal Payments Under Lease Agreement</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future principal payments to be made under the lease agreement as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, net of the sublease amounts, are as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,593</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">298</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,891</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6822146960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Schedule of Minimum Future Lease Payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future minimum lease payments under noncancelable operating leases as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,210</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,142</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,636</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,679</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a lessee's leasing arrangements including: (1) the basis on which contingent rental payments are determined, (2) the existence and terms of renewal or purchase options and escalation clauses, (3) restrictions imposed by lease arrangements, such as those concerning dividends, additional debt, and further leasing, (4) rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.  Disclosure may also include the specific period used to amortize material leasehold improvements made at the inception of the lease or during the lease term. Additionally, for operating leases having initial or remaining noncancelable lease terms in excess of one year: (a) future minimum rental payments required as of the date of the latest balance sheet presented, in the aggregate and for each of the five succeeding fiscal years, (b) the total of minimum rentals to be received in the future under noncancelable subleases as of the date of the latest balance sheet presented, and (c) for all operating leases, rental expense for each period for which an income statement is presented, with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 1,3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6452660&amp;loc=d3e36991-112694<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6851643&amp;loc=d3e12069-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6832618688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Company's Consolidated Quarterly Results of Operations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1st Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2nd Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3rd Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4th Quarter</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in thousands, except per share data)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,846</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,673</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,255</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,106</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,464</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.88</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.97</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.97</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,279</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,716</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,681</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,178</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,129</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,376</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,442</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,451</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.53</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.71</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.46</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.83</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the quarterly financial data in the annual financial statements. The disclosure includes financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income (loss) before extraordinary items and cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=51825399&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819370048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities', window );">Available-for-sale securities, other than temporary impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance recorded</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset', window );">Impaired assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup', window );">Assets held-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on investments</a></td>
<td class="num">$ (77,000)<span></span>
</td>
<td class="num">$ (5,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6390208&amp;loc=d3e400-110220<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount on the books of the entity of the impaired asset to be disposed of by a method other than sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51719941&amp;loc=d3e2921-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=51824106&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6833004000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 50,800<span></span>
</td>
<td class="nump">$ 108,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">251,666<span></span>
</td>
<td class="nump">250,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">46,781<span></span>
</td>
<td class="nump">62,353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">8,826<span></span>
</td>
<td class="nump">9,348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">29,759<span></span>
</td>
<td class="nump">41,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">166,300<span></span>
</td>
<td class="nump">137,928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">46,781<span></span>
</td>
<td class="nump">62,353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">46,781<span></span>
</td>
<td class="nump">62,353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">204,885<span></span>
</td>
<td class="nump">188,478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">8,826<span></span>
</td>
<td class="nump">9,348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">29,759<span></span>
</td>
<td class="nump">41,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">166,300<span></span>
</td>
<td class="nump">137,928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs, Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs, Level 3 | U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs, Level 3 | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs, Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6833073120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned (Details) - Sales revenue, net - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. (Janssen)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=mgnx_ServierMGA271Member', window );">Les Laboratoires Servier and Institut de Reserches Servier (collectively, Servier)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=mgnx_BoehringerIngelheimMember', window );">Boehringer Ingelheim GmbH (Boehringer)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=mgnx_TakedaMember', window );">Takeda Pharmaceutical Company Limited (Takeda)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=mgnx_GileadSciencesIncMember', window );">Gilead Sciences, Inc. (Gilead)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=mgnx_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=mgnx_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=mgnx_ServierMGA271Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=mgnx_ServierMGA271Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=mgnx_BoehringerIngelheimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=mgnx_BoehringerIngelheimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=mgnx_TakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=mgnx_TakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=mgnx_GileadSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=mgnx_GileadSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818987024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Accounts Receivable (Details) - Customer Concentration Risk - Accounts receivable<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Janssen Biotech, Inc. (Janssen)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Les Laboratoires Servier and Institut de Reserches Servier (collectively, Servier)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Eli Lilly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=mgnx_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=mgnx_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=mgnx_USGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=mgnx_USGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=mgnx_ServierMGA271Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=mgnx_ServierMGA271Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=mgnx_TakedaPharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=mgnx_TakedaPharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=mgnx_EliLillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=mgnx_EliLillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819923296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember', window );">Laboratory and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Leasehold improvements</a></td>
<td class="text">Shorter of lease term or useful life<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51661791&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6829683488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Computation of Basic and Diluted Income (Loss) Per Common Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss used for calculation of basic and diluted EPS</a></td>
<td class="num">$ (34,783)<span></span>
</td>
<td class="num">$ (33,846)<span></span>
</td>
<td class="nump">$ 40,464<span></span>
</td>
<td class="num">$ (30,363)<span></span>
</td>
<td class="num">$ (28,451)<span></span>
</td>
<td class="num">$ (15,442)<span></span>
</td>
<td class="num">$ (21,376)<span></span>
</td>
<td class="nump">$ 45,129<span></span>
</td>
<td class="num">$ (58,528)<span></span>
</td>
<td class="num">$ (20,140)<span></span>
</td>
<td class="num">$ (38,313)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,685,274<span></span>
</td>
<td class="nump">31,801,645<span></span>
</td>
<td class="nump">27,384,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,685,274<span></span>
</td>
<td class="nump">31,801,645<span></span>
</td>
<td class="nump">27,384,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.69)<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="num">$ (1.40)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1500-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6765050496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, (in shares)</a></td>
<td class="nump">1,394,608<span></span>
</td>
<td class="nump">1,955,398<span></span>
</td>
<td class="nump">2,094,904<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6832007856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 200,966,000<span></span>
</td>
<td class="nump">$ 142,882,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">56,000<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(138,000)<span></span>
</td>
<td class="num">(49,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">200,884,000<span></span>
</td>
<td class="nump">142,877,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Available-for-sale securities, mature in one year or less, amortized cost basis</a></td>
<td class="nump">192,985,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Available-for-sale securities, mature in one year or less, fair value</a></td>
<td class="nump">192,898,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Available-for-sale securities, maturing between one and five years, amortized cost basis</a></td>
<td class="nump">7,981,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Available-for-sale securities, maturing between one and five years, fair value</a></td>
<td class="nump">7,986,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities', window );">Available-for-sale securities, other than temporary impairment losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">4,826,000<span></span>
</td>
<td class="nump">9,354,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">4,825,000<span></span>
</td>
<td class="nump">9,349,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">29,764,000<span></span>
</td>
<td class="nump">22,055,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="num">(9,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">29,759,000<span></span>
</td>
<td class="nump">22,047,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">166,376,000<span></span>
</td>
<td class="nump">111,473,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">51,000<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(127,000)<span></span>
</td>
<td class="num">(34,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 166,300,000<span></span>
</td>
<td class="nump">$ 111,481,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after adjustments of available-for-sale debt securities at cost, maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after adjustments of available-for-sale debt securities at cost, maturing in the next fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26610-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)-(g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6833068544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 43,784<span></span>
</td>
<td class="nump">$ 35,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(25,823)<span></span>
</td>
<td class="num">(20,190)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">17,961<span></span>
</td>
<td class="nump">14,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PropertyPlantAndEquipmentNonCashAdditions', window );">Property and equipment purchased but not yet paid</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">6,800<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">2,520<span></span>
</td>
<td class="nump">3,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">2,352<span></span>
</td>
<td class="nump">1,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember', window );">Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">897<span></span>
</td>
<td class="nump">919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">20,208<span></span>
</td>
<td class="nump">17,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 17,807<span></span>
</td>
<td class="nump">$ 11,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PropertyPlantAndEquipmentNonCashAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PropertyPlantAndEquipmentNonCashAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819554624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2015</div></th>
<th class="th"><div>Jan. 31, 2015</div></th>
<th class="th"><div>Feb. 28, 2014</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold (in shares)</a></td>
<td class="nump">3,525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share (in dollars per share)</a></td>
<td class="nump">$ 37.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption', window );">Additional shares sold under over-allotments option to underwriter (in shares)</a></td>
<td class="nump">528,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of shares</a></td>
<td class="nump">$ 141.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_JohnsonAndJohnsonDevelopmentCorporationMember', window );">Johnson &amp; Johnson Innovation JJDC, Inc,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,923,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember', window );">Undesignated Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Undesignated preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Undesignated preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Undesignated preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Undesignated preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, shares to underwriters for exercise of over allotment option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgnx_JohnsonAndJohnsonDevelopmentCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgnx_JohnsonAndJohnsonDevelopmentCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6832230816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock- based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">84 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
<th class="th"><div>Oct. 31, 2013</div></th>
<th class="th"><div>Feb. 28, 2003</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</a></td>
<td class="nump">3,838,060<span></span>
</td>
<td class="nump">4,146,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 18.93<span></span>
</td>
<td class="nump">$ 16.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 12,165<span></span>
</td>
<td class="nump">$ 7,847<span></span>
</td>
<td class="nump">$ 3,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member', window );">Equity Incentive Plan 2003</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,051,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease', window );">Increased number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,336,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</a></td>
<td class="nump">1,193,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,960,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease', window );">Increased number of shares authorized (in shares)</a></td>
<td class="nump">5,375,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</a></td>
<td class="nump">2,644,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 26.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance', window );">Stock reserved for future issuance (in shares)</a></td>
<td class="nump">1,960,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan', window );">Percentage of common stock share outstanding</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 5,778<span></span>
</td>
<td class="nump">3,623<span></span>
</td>
<td class="nump">1,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 6,387<span></span>
</td>
<td class="nump">$ 4,224<span></span>
</td>
<td class="nump">$ 1,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Capital Shares Minimum Increase In Shares Reserved For Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares of company's common stock outstanding for increase in shares reserved for issuance under stock plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares authorized after increase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6832216224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock- based Compensation - Option Pricing Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">64.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">69.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options granted, maximum term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section D<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6820306976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock- based Compensation - Stock Option and Restricted Stock Unit Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Beginning balance (in shares)</a></td>
<td class="nump">4,146,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares, Granted (in shares)</a></td>
<td class="nump">399,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised or RSUs vested (in shares)</a></td>
<td class="num">(526,715)<span></span>
</td>
<td class="num">(374,214)<span></span>
</td>
<td class="num">(568,906)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Forfeited or expired (in shares)</a></td>
<td class="num">(181,238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Ending balance (in shares)</a></td>
<td class="nump">3,838,060<span></span>
</td>
<td class="nump">4,146,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Exercisable (in shares)</a></td>
<td class="nump">2,292,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Shares, Vested and expected to vest (in shares)</a></td>
<td class="nump">3,651,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, Outstanding, Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 16.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, Granted (in dollars per share)</a></td>
<td class="nump">23.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, Exercised or RSUs vested(in dollars per share)</a></td>
<td class="nump">3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, Forfeited or expired (in dollars per share)</a></td>
<td class="nump">26.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, Outstanding, Ending balance (in dollars per share)</a></td>
<td class="nump">18.93<span></span>
</td>
<td class="nump">$ 16.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, Exercisable (in dollars per share)</a></td>
<td class="nump">13.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 18.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual term, Outstanding</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term, Exercisable</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term, Vested and expected to vest</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding, Ending balance</a></td>
<td class="nump">$ 24,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable</a></td>
<td class="nump">22,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, Vested and expected to vest</a></td>
<td class="nump">$ 24,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">526,715<span></span>
</td>
<td class="nump">374,214<span></span>
</td>
<td class="nump">568,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of stock options</a></td>
<td class="nump">$ 1,893<span></span>
</td>
<td class="nump">$ 911<span></span>
</td>
<td class="nump">$ 744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 15.17<span></span>
</td>
<td class="nump">$ 20.90<span></span>
</td>
<td class="nump">$ 17.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value</a></td>
<td class="nump">$ 10,800<span></span>
</td>
<td class="nump">$ 10,900<span></span>
</td>
<td class="nump">$ 14,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="nump">11,600<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to non-vested stock-based compensation arrangements</a></td>
<td class="nump">$ 22,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6832001440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Provision for federal or state income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal U.S. net operating loss carryforward</a></td>
<td class="nump">75,377,000<span></span>
</td>
<td class="nump">57,949,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforward</a></td>
<td class="nump">6,583,000<span></span>
</td>
<td class="nump">3,907,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit, net</a></td>
<td class="nump">12,829,000<span></span>
</td>
<td class="nump">10,278,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther', window );">Orphan drug credit, net</a></td>
<td class="nump">19,855,000<span></span>
</td>
<td class="nump">19,284,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Deferred rent</a></td>
<td class="nump">2,497,000<span></span>
</td>
<td class="nump">2,947,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">5,098,000<span></span>
</td>
<td class="nump">6,632,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">2,926,000<span></span>
</td>
<td class="nump">1,597,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">5,085,000<span></span>
</td>
<td class="nump">2,532,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred income tax assets</a></td>
<td class="nump">130,250,000<span></span>
</td>
<td class="nump">105,126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(128,844,000)<span></span>
</td>
<td class="num">(104,399,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td>
<td class="nump">1,406,000<span></span>
</td>
<td class="nump">727,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred income tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenditures</a></td>
<td class="num">(1,406,000)<span></span>
</td>
<td class="num">(727,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred income tax liabilities</a></td>
<td class="num">(1,406,000)<span></span>
</td>
<td class="num">(727,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred income tax asset/(liability)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation', window );">Remaining portion of net operating losses</a></td>
<td class="nump">201,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward', window );">Net operating losses, recognized as a benefit through additional-paid-in-capital</a></td>
<td class="nump">18,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember', window );">U.S. Federal and State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">215,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">US Federal tax credits carry forward</a></td>
<td class="nump">32,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount', window );">Net operating loss for limited use</a></td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal Government | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount', window );">Net operating losses limited for use utilized on an annual basis</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal Government | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount', window );">Net operating losses limited for use utilized on an annual basis</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net operating loss which are limited for use, utilized on a annual basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OperatingLossCarryforwardsAnnualLimitationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net operating loss carryforward, which are limited for use over the range of years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards not subject to limitation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OperatingLossCarryforwardsNotSubjectToLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits resulting in net operating losses carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section I<br> -Subsection 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Liability<br> -URI http://asc.fasb.org/extlink&amp;oid=6510232<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 15<br> -Subparagraph b(2)<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, before jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to other deductible tax credit carryforwards not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Carryforwards<br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6829642496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">United States federal tax at statutory rate</a></td>
<td class="num">$ (20,489)<span></span>
</td>
<td class="num">$ (7,049)<span></span>
</td>
<td class="num">$ (13,410)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes (net of federal benefit)</a></td>
<td class="num">(3,116)<span></span>
</td>
<td class="num">(897)<span></span>
</td>
<td class="num">(1,608)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount', window );">Deferred income tax adjustments</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">661<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount', window );">Deferred state blended rate adjustments</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(493)<span></span>
</td>
<td class="nump">3,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credit, net</a></td>
<td class="num">(2,551)<span></span>
</td>
<td class="num">(3,296)<span></span>
</td>
<td class="num">(2,228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationDeductions', window );">Transaction cost deduction</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(379)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncomeTaxRateReconciliationDeductionPriorYearAdjustment', window );">Transaction cost deduction - prior year adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(564)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsOther', window );">Orphan drug credit, net</a></td>
<td class="num">(571)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other permanent items</a></td>
<td class="nump">145<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(382)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Equity-based compensation</a></td>
<td class="nump">1,997<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
<td class="nump">756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">24,444<span></span>
</td>
<td class="nump">10,103<span></span>
</td>
<td class="nump">14,920<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense/(benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred state blended rate adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncomeTaxRateReconciliationDeductionPriorYearAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deductions. Including, but not limited to, extraterritorial income exclusion deduction, qualified production activity deduction, dividend deduction, deduction for dividend paid to employee stock ownership plan, Medicare prescription drug benefit subsidy deduction, and other deductions related to prior year adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_IncomeTaxRateReconciliationDeductionPriorYearAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deductions. Including, but not limited to, extraterritorial income exclusion deduction, qualified production activity deduction, dividend deduction, deduction for dividend paid to employee stock ownership plan, Medicare prescription drug benefit subsidy deduction, and other deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph h<br> -Subparagraph 2<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph h<br> -Subparagraph 1<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6814724400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 2,425,000<span></span>
</td>
<td class="nump">$ 2,047,000<span></span>
</td>
<td class="nump">$ 1,708,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases/(decreases) for current year tax positions</a></td>
<td class="nump">308,000<span></span>
</td>
<td class="nump">357,000<span></span>
</td>
<td class="nump">242,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases/(decreases) for prior year tax positions</a></td>
<td class="num">(268,000)<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="nump">97,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">2,465,000<span></span>
</td>
<td class="nump">2,425,000<span></span>
</td>
<td class="nump">2,047,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Gross unrecognized tax benefits</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized interest or penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Unrecognized Tax Benefit<br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819688112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Exit Liability Lease Exit Liability - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>May 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals', window );">Future sublease payments to be received</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ReductionInResearchAndDevelopmentExpense', window );">Reduction in research and development expense</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mgnx_RavenBiotechnologiesIncMember', window );">Raven Biotechnologies Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals', window );">Future sublease payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ReductionInResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction In Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ReductionInResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractually required future rental payments receivable on noncancelable subleasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mgnx_RavenBiotechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mgnx_RavenBiotechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819802032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Exit Liability - Changes in Lease Exit Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AmountOfImmaterialErrorCorrection', window );">Reduction of research and development expense</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember', window );">Contract termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrual beginning balance</a></td>
<td class="nump">4,713<span></span>
</td>
<td class="nump">$ 8,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Principal payments and other adjustments (net of sublease receipts)</a></td>
<td class="num">(2,822)<span></span>
</td>
<td class="num">(3,293)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrual ending balance</a></td>
<td class="nump">$ 1,891<span></span>
</td>
<td class="nump">$ 4,713<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AmountOfImmaterialErrorCorrection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of immaterial error correction made during period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AmountOfImmaterialErrorCorrection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section P<br> -Subsection 3, 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6832573760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Exit Liability - Future Principal Payments Under Lease Agreement (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2017</a></td>
<td class="nump">$ 6,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2018</a></td>
<td class="nump">4,210<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">21,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mgnx_RavenBiotechnologiesIncMember', window );">Raven Biotechnologies Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2017</a></td>
<td class="nump">1,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2018</a></td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 1,891<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mgnx_RavenBiotechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mgnx_RavenBiotechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6832851152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements, Janssen Biotech, Inc. (Details) - Janssen Biotech Inc. - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2016</div></th>
<th class="th"><div>Jan. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenMGD011AgreementMember', window );">Janssen MGD011 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,923,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Nonrefundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PremiumReceivedOnStockPurchase', window );">Premium received on stock purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_TotalConsideration', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AmountAllocatedToEquity', window );">Amount allocated to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AmountAllocatedToLicenseAndRD', window );">Amount allocated to license and R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ClinicalMilestoneEarnedDuringPeriod', window );">Clinical milestone earned during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 72,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenMGD011AgreementMember', window );">Janssen MGD011 Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement', window );">Potential clinical milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement', window );">Potential regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialSalesMilestonePaymentsUnderAgreement', window );">Potential sales milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenMGD015AgreementMember', window );">Janssen MGD015 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Nonrefundable upfront payment</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement', window );">Potential clinical milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement', window );">Potential regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialSalesMilestonePaymentsUnderAgreement', window );">Potential sales milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AmountAllocatedToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of consideration allocated to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AmountAllocatedToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AmountAllocatedToLicenseAndRD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of consideration allocated to license and pre-clinical research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AmountAllocatedToLicenseAndRD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ClinicalMilestoneEarnedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical milestone earned during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ClinicalMilestoneEarnedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total potential clinical milestone payments company could earn under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialClinicalMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total potential regulatory milestones company could earn under agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialSalesMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total potential sales milestones company could earn under agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialSalesMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PremiumReceivedOnStockPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which purchase price exceeds fair value for common stock purchased by collaborator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PremiumReceivedOnStockPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TotalConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total consideration received under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TotalConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenMGD011AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenMGD011AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenMGD015AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenMGD015AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6829684768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements, Takeda (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue included in current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,261,000<span></span>
</td>
<td class="nump">$ 5,866,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_TakedaMember', window );">Takeda Pharmaceutical Company Limited (Takeda) | Takeda MGD010 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Nonrefundable upfront payment</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontFeeAllocatedToAgreement', window );">Amount allocated to agreement</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue included in current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontPaymentRecognitionPeriod', window );">Expected period of development</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestone received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_TakedaMember', window );">Takeda Pharmaceutical Company Limited (Takeda) | Research Collaboration and License Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontFeeAllocatedToAgreement', window );">Amount allocated to agreement</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontFeeAllocatedToAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of upfront fee allocated to agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_UpfrontFeeAllocatedToAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontPaymentRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to upfront payment recognition period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_UpfrontPaymentRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=51671726&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgnx_TakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgnx_TakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_TakedaMGD010AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_TakedaMGD010AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_ResearchCollaborationAndLicenseOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_ResearchCollaborationAndLicenseOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6829615760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements, Servier (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>Milestone</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue included in current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,261,000<span></span>
</td>
<td class="nump">$ 5,866,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue included in long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,045,000<span></span>
</td>
<td class="nump">12,631,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_ServierMember', window );">Servier | Servier DART</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Nonrefundable upfront payment</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OriginalPeriodOfDevelopment', window );">Original period of development</a></td>
<td class="text">29 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontPaymentRecognitionPeriod', window );">Expected period of development</a></td>
<td class="text">75 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ChangeInAccountingEstimateCurrentYearImpact', window );">Change in accounting estimate, current year impact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OptionExerciseFee', window );">Option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OptionExerciseFeeRecognitionPeriod', window );">Option exercise fee recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">82 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts', window );">Offset to research and development costs under collaboration arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">$ 16,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfMilestonesAchieved', window );">Number of milestones achieved | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ReviewPeriodByRegulatoryAuthority', window );">Review period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,100,000<span></span>
</td>
<td class="nump">14,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue included in current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue included in long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800,000<span></span>
</td>
<td class="nump">$ 11,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_ServierMember', window );">Servier | Maximum | Servier DART</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialLicenseFee', window );">Potential License Fee</a></td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement', window );">Potential clinical milestone payments under agreement</a></td>
<td class="nump">63,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement', window );">Potential regulatory milestone payments under agreement</a></td>
<td class="nump">188,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialSalesMilestonePaymentsUnderAgreement', window );">Potential sales milestone payments under agreement</a></td>
<td class="nump">$ 420,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ChangeInAccountingEstimateCurrentYearImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the effect of a change in accounting estimate on current year operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ChangeInAccountingEstimateCurrentYearImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to collaboration arrangement offset to research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of clinical milestones achieved during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment from collaborator upon exercise of option to develop and commercialize product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OptionExerciseFeeRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to option exercise fee recognition period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OptionExerciseFeeRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OriginalPeriodOfDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Original recognition period for development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OriginalPeriodOfDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total potential clinical milestone payments company could earn under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialClinicalMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential license fee company could earn under agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total potential regulatory milestones company could earn under agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialSalesMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total potential sales milestones company could earn under agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialSalesMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ReviewPeriodByRegulatoryAuthority">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to review period by regulatory authority.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ReviewPeriodByRegulatoryAuthority</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontPaymentRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to upfront payment recognition period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_UpfrontPaymentRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=51671726&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgnx_ServierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgnx_ServierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_ServierDARTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_ServierDARTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6820966864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements, Boehringer (Details) - Boehringer Ingelheim GmbH (Boehringer)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2010 </div>
<div>USD ($) </div>
<div>Payment</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Nonrefundable upfront payment</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfAnnualMaintenancePaymentReceived', window );">Number of annual maintenance payments received | Payment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement', window );">Clinical milestone payments</a></td>
<td class="nump">$ 34,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement', window );">Additional potential regulatory milestone payments under agreement</a></td>
<td class="nump">88,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement', window );">Additional potential sales milestone payments under agreement</a></td>
<td class="nump">$ 82,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="nump">$ 13,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential clinical milestone payments available to be earned under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential regulatory milestone payments available to be earned under a collaboration arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential sales milestone payments available to be earned under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfAnnualMaintenancePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of annual maintenance payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfAnnualMaintenancePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=51671726&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgnx_BoehringerIngelheimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgnx_BoehringerIngelheimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6831394096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements, Green Cross (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2010</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue included in current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,261,000<span></span>
</td>
<td class="nump">$ 5,866,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue included in long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,045,000<span></span>
</td>
<td class="nump">12,631,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember', window );">Green Cross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Nonrefundable upfront payment</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification', window );">Adjustment to revenue from contract material modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsFromResearchAndDevelopmentServices', window );">Proceeds from research and development services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue included in current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue included in long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember', window );">Green Cross | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AggregatePotentialFutureCostReimbursement', window );">Aggregate potential future cost reimbursement</a></td>
<td class="nump">5,500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement', window );">Clinical and commercial milestone payments</a></td>
<td class="nump">$ 2,500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential clinical and commercial milestone payments available to be earned under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the adjustment to revenue under the accounting standards codification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AggregatePotentialFutureCostReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential future cost reimbursement from collaborator</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AggregatePotentialFutureCostReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsFromResearchAndDevelopmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Research And Development Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsFromResearchAndDevelopmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=51671726&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821268592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements, NIAID Contract (Details) - NIAID<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 15, 2015 </div>
<div>USD ($) </div>
<div>Molecule</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement', window );">Commercialization of molecules | Molecule</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_FundedValueOfBasePeriod', window );">Base period value</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement', window );">Additional development funding options</a></td>
<td class="nump">17,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_TotalPotentialValueUnderAgreement', window );">Total potential value</a></td>
<td class="nump">$ 24,500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional funding available under agreement at counterparty's option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_FundedValueOfBasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funded value of base period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_FundedValueOfBasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of molecules to be developed and commercialized as per collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TotalPotentialValueUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to total potential value under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TotalPotentialValueUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6820165168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>Lease</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfLease', window );">Number of leases | Lease</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Lease incentives</a></td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals', window );">Future sublease payments to be received</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred rent liability</a></td>
<td class="nump">6,200<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Future minimum rental payments required under all non-cancelable operating leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2017</a></td>
<td class="nump">6,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2018</a></td>
<td class="nump">4,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2019</a></td>
<td class="nump">3,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2019</a></td>
<td class="nump">2,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2020</a></td>
<td class="nump">2,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">2,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 21,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=mgnx_MixedUseOfficeLaboratoryAndManufacturingSpaceMember', window );">Office, laboratory and manufacturing space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Lessee leasing arrangements, term of operating leases</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of lease during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property by the lessor or lessee, respectively.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractually required future rental payments receivable on noncancelable subleasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=mgnx_MixedUseOfficeLaboratoryAndManufacturingSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=mgnx_MixedUseOfficeLaboratoryAndManufacturingSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819659552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation and Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan', window );">Eligible age to participate in plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percentage of employee contribution to salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage', window );">Percentage of employee vested contribution</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan, employer discretionary contribution amount</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage vested of employee's contributions to defined contribution plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to minimum eligible age of employee to participate in benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6820962880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 5,106<span></span>
</td>
<td class="nump">$ 3,255<span></span>
</td>
<td class="nump">$ 80,673<span></span>
</td>
<td class="nump">$ 2,846<span></span>
</td>
<td class="nump">$ 8,178<span></span>
</td>
<td class="nump">$ 14,681<span></span>
</td>
<td class="nump">$ 6,716<span></span>
</td>
<td class="nump">$ 71,279<span></span>
</td>
<td class="nump">$ 91,880<span></span>
</td>
<td class="nump">$ 100,854<span></span>
</td>
<td class="nump">$ 47,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (34,783)<span></span>
</td>
<td class="num">$ (33,846)<span></span>
</td>
<td class="nump">$ 40,464<span></span>
</td>
<td class="num">$ (30,363)<span></span>
</td>
<td class="num">$ (28,451)<span></span>
</td>
<td class="num">$ (15,442)<span></span>
</td>
<td class="num">$ (21,376)<span></span>
</td>
<td class="nump">$ 45,129<span></span>
</td>
<td class="num">$ (58,528)<span></span>
</td>
<td class="num">$ (20,140)<span></span>
</td>
<td class="num">$ (38,313)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic (in dollars per share)</a></td>
<td class="num">$ (1.00)<span></span>
</td>
<td class="num">$ (0.97)<span></span>
</td>
<td class="nump">$ 1.17<span></span>
</td>
<td class="num">$ (0.88)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (0.46)<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted (in dollars per share)</a></td>
<td class="num">$ (1.00)<span></span>
</td>
<td class="num">$ (0.97)<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="num">$ (0.88)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (0.46)<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
<td class="nump">$ 1.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>77
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M77_X785=;^S._F/CBZ!JX-==J"]02P,$%     @ V8!<2IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MB57"/+W374A6#U'45&KRUK_+QKR[_DN2#C28@ <"'@DX_I00#81H)*#/"?%
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M^#IK'L%&SXN2R-TM]4<S,HN1L]A2%B.GK$$+;.D(LF'GQ9:.3&.T[.MB(Y!
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M5#XZUUDOE#UXB6=_W;H/2GOL^M?$OS?CG6,<=.XRW:>B^Z5N\S]02P,$%
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M9 D\))$JY:QF'32N[XP\'C&Y0!\;DP#.Q$Z]W"?\H2:U9'I28:<0P"IB$Q3
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MQ*FD"7UU/(FN=\'!JF+@'7P!]W6X&&^QE:41"K05J(F!MJ0/R>F<A_@8\$W
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M>'S9V/_&& ^82G*#(]3A!UL-"8T/Q_=XMO.8S88WP_*#V/J-RS]02P,$%
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MMA@*:A>.[_W93&,V&0[[^0>QY1L7OP%02P,$%     @ V8!<2BW L$BT 0
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M[<+QQI_-.&:CX;";?A";OW'Q&U!+ P04    " #9@%Q*M1!3H[0!  #2 P
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M9S.,V6 X;,<?Q*9OG/\&4$L#!!0    ( -F 7$I@OYJ&LP$  -(#   9
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M;"7-,%S7.%I2$#?10-!*IF&X_#%0V\3--1"TDFP8/@$P4-[$33<0M)9O\"&
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MWFQP*(W;'NU>C:T_&D9VTU2C\VC-_@)02P,$%     @ V8!<2L0@.\2V 0
MT@,  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL;5/;;IPP$/T5RQ\0
M@V'3: 5(V515(K72*E7;9R\,8,478ILE_?O:AE":\F)[QN><N7A<3-J\V![
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MH''AN/=G,XW99#C=SS^(+-^X_ =02P,$%     @ V8!<2JC9T933 0  G 0
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M?2J6@$-EW/;>[M4T,%-@9#^_!61YD/(_4$L#!!0    ( -F 7$H]ZD08Q0$
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MYQ.:7"MEP:6RN7&YM&Z*%T- ;?WVSNWU])8GPZI^'E.R_"N*OU!+ P04
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M+QO[7QGC 5-);G"$&OQ@LZ&@\N'X"<]V'+/1\*:;?A";OW'^%U!+ P04
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M/S/;QEQ]WU+.UM%[5VC0/%XT]%8S5CS9"A9?)9$Q<'5!H0O:CV<C%QP78+
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M85/"4>IEI-:\FY?=1K*F_Q=PAA^2]"]02P,$%     @ V8!<2CM=AIHX @
MPP<  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&ULE55A;]HP$/TK47Y
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M3%&"*9+!]$.-,,P,#S)#@\P0@@0G2%""Y':9<Y1@?H-,##,B<X$&62 $<YR
M1OB-C6X72D<N/;U!*@I:C,1!;_Z:LBN*.(I&*/#;3^-/J,7O/YW<HO8:%$<C
M;4[Q-J'7/1!'(ZU.\2:@LT^HQ=N )O_-HE>+@3X^*N3B#:U '?WTT$$N3[4?
M71?684*MF7^#_\&[\?:#JV-9ZV GC7W)_7M[D-* S26ZLV4K[$0=#@(.QFT3
MNU?=6.D.1C;]R"3#W,[^ E!+ P04    " #9@%Q*X>OP'QT#  !A#   &0
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M+\U1".6]E475+/RC4J>[(&BV1U%FS4R>1*7_LY=UF2G]6A^"YE2+;-<9E44
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M&[QV<1&)6#B548P&%",!6>5?]1@^<$2266H5=XV@V"S%8V%H+ RI;H(3<)2
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MOCZ!V3[&W(D-0;'AE&!A1A3"S.0U C>)  (CLSF$\8V(/('9/L;<B8U!L3%
M$, $"Y!@\?P!2D""Y/\YR2%,:(0+PD2P$.3"_[P+4$Q^>@AD'/@-"#)/,P1*
MW!G%,U4* 10SAQ6!56B-O.<3B. :@OPG4@B!$K/@@:"9\XS@>H2 (C%-(@!*
M E,,! K-)$*@N6,'%R4$5)QDHG@*\A*S]CDWMUM-V%EW#MPZT$LCU"5QLSIV
M)VM/W8[&>JZZ%GUK_J/I6YYOF)W+AEM[*N3=JV_($Z6"2(WNB]18R"YKG%3D
M)-0PEF/6MQK]1-!V:*.<L9?+_@)02P,$%     @ V8!<2E^<><,"!   TQ$
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MW#,S^,Q!T&Z8Z=[XQU+^!5!+ P04    " #9@%Q*0R&#KP$"  #A!0  &0
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M>.54M"L5?6N?16V?)Z=_IL&$V!'BCJ!MCQ$21T@NA&R4D#I">B&DHP3B"&1
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M>WO+N6+:3W2C-VFOF\5N4+*M,J\3_2[:CJD=*-ZX;C#J6M+%/U!+ P04
M" #9@%Q*Z!Z0.8,#  #"#P  &0   'AL+W=O<FMS:&5E=',O<VAE970T.2YX
M;6R55^UNFS 4?17$ Q1\C0VIDDA-FFF3-JGJM.TW39P$%7 &3M*]_<Q'&=@7
MFO5' ^;<>XZO[0-W?I7%:WD40CEO69J7"_>HU.G>\\KM461Q>2=/(M=/]K+(
M8J5OBX-7G@H1[^J@+/7 ][F7Q4GN+N?UV%.QG,NS2I-</!5.><ZRN/BS$JF\
M+ESBO@\\)X>CJ@:\Y?P4'\1WH7Z<G@I]YW59=DDF\C*1N5.(_<)](/<;"*N
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MW9!19G)AH#&3PJV0V#X76+MG9K]A"$&W#X(,@HG9 VZ=@%FG^8)L01]OZAN
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MYGHL^@:JGRC>#<UA-':HJ_]02P,$%     @ V8!<2AI<(LDE @  7 8  !D
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MFW+-AI^[;6M_E8Z^O[Y^?PP["QH!.B@LJX.MQ^/*2C<KG/]?MK,[]UY8X*;
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M,$,0A@70;I<,0K'$NEJ9I$E[K4F\;:,(T%KCI,"/W++ATI0T*7Q-_$0E/'\
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ML/*'DEP"\75@;MU%>L!*,<+!<TG.<R8J0/JE#I+TP<&ZL@34B\>/%&I\'0I
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M*1;LW:U-CACOB)^.YI[5C5LAH>=:<51( M@=YO\KR2L'Z02\'6#B8^B!$'^
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M;%C,$<(/Y (" .B"8](G[\&TK-8;O_WH(^<2<)Z7BCV$/PBP!OJF!ZI,@_8
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M&]I]N'9!9ZP:I3[CAIIH-X[1Z72<L22%\K8HMVR9<I#=J.$,T'O+8#]Q-GE
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MX/' 4 3DZ8DHO$B2"R6'3G>9!*MLFTKE<"Y57! 3#@[-/2'[3B:E8,JC[/G
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M3R_/$,,&/V70[([3&DU@PF<@P(=G^0@&^G.B2_?1:'R97YXBF/5H-#S-0?6
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M=]AB9!!A:D[EO$,*4F;]GF8UW<*?2^(-: 1](@M7Z]4$ZVX#6T#E3>"Z8<8
MLDVGA746/I&,=AP&&2I;L5K--OD& @7ZT]7^(1I=3P;@]++D"LBWV,XB6+6\
MDZ,35.+ 4IE23WPW7N'=_[-R;.N%=JI1]$CV>;GXED+:_^<WA#1O/I6_.62<
M*#Z05L.,OC;MT_?SM!Z:I^C1?*@M]>@>BS:LS@.F451S'_VE["'Q X<DQN =
M+";'5(W(M7-U?E)Y634F8!$8UYJ:[L-&]\!R!A0:7Z&5%;<ATSDRC!==B(I?
M9S"^?M+3S[8OV\0?K?$2WU!F FK%'"DZ>G5]\^PX_8OG%HY]='WS_#B[' _S
MS%#0&SL/G+$/IK3T"#Z!>B#_);Y-*RYS$W+$BV(6Z=1Z:<F=<@?I3LQ"TT5=
M3.($@Y,N* XU,]-C!^K.7L<Z;3^3AJQ0W-Z_;@OEKMCQS##;:K7>;KAJL7%1
MY(A=<G*GT[+-FEUVZCW+9CLO6K4:Y,;*6[DU\[O)%2VN1]/M%2L H0/WCBIH
M?IO]R_^^'(_/OQ-+;$3_'HV^XZ/G=U6Q<<AFQG;EZJ#^=5M33GQ3>1\BPA2<
M+YH(E^X/LXG8LNSS (:S&S]A=GPTMF>!KK!GLC,*HZ(_OZ&&</JO6^2FG*O^
MFL><%KY.9SC8W%C(/<?9W0EXICO*OJVA:JBK<"0T)+53D)LH:<D^VH+^0Z5.
MUB2(*K75.\Z 7>NS<H&*/()3B]9Y*++&^4X?L;$[AD$^Z2[BZY HZZ:I.:V0
MSL/OH&KW&.:,SW9RT-G*PMRA;5=F=.:CF\X$@K?^Z/@UXI]XN&H%E@@NP[:U
MQ]$D_(][[%W%FI8+^PF#%P9E)0DINA#I?B@+8$[/OAW89DK7],DR; !*@7!1
M;)@0%NS3(R,IJF]1H/<9]$@U6OHT12_6>XC)EMGI$3VB0ZJ$8BNDT[O1KFY!
MYUIHY K5<V97Y*I;LKO 0-1<+>0J[G.Y,\21/*/"H1MBTUV.7.^ /9V(,3,N
MB&Z /+2H2NL;ZL@,WG\SC/%P!2Y+2]7D>!82U>OGG>K=RR-SF:>=<=RG0H=5
M_9UZE0RX:@Q> TU+;5S%-QFUK#9<@TOS%??RMR0_\_%4> >!)VDZ?9P@M%DI
M,CM';XPBDI5SX[;H?EJWL@&+,Q5AX1TIVW*2=4%60 H(,U>!_!R4BFJ3?:C:
MGY[R6Z-V66V9>).#WEO\64B\4SLT!Z!X[ ;'5IU;XGTTD.C?^:'*MZK L;)\
MDOV[E/C#<%>];;Q:W^>=3SOB/1^>ES/1J>%[5-+@'??5PGF%D>+)>>?T(J(Y
M,U0]WY241(SE<5[Q<&!\T4-HL6P;NL'/Q06/QX&A>ES\0\D$QPTOU;2;$=K/
M.U(U:N8V!)D7>:G?;1M#3G!VBVKZ**,'=(:G)D'"S>.:?7,4"3@T'I$'P0@)
M09M-H+WV;QS<-2AEE"XH?,]/K1<%-^T%NJNF#K,KH1T=.R QFA+,FM^*LVS$
MPJ*T\48*!]%Q*M^8^MV&?>XA AS/AEQT=; Y&)72Z:O=VS%WWVNM31P(PV*<
M3A-\7+J/P[ *>L2D&D;CH9(U ?A*K?G&IJOP*Y"Q:U*1"6:A6:..-+;+K02K
MD05.*ZV%3*F1M>-D 6R%KAE%(3"N2/@)NEB-\PCR%N!+FS3@&E4W]",J(L*7
MW^1Z' 2'9"-VQOI8#\STM7='HO"I5W>#'X@!7]/RG_CST'I5SSUO&7E%K2V$
M A('6'"FA!$/78O5E9AS6;J3<[ W]<QS B5N(HHXT1]:A0 1I)VWDBF/OB6I
MAF"<M.AXPUPV]1CQB:SN6*4.P1#2%]KDJ:2\$2MQ<G-CS8WF7K@*5Q\Z6T5^
MOVC2Y+16"Y?T2HXG5*V'D"3>3H382JEO<75A'IKKN(T!'=]N.W"0W9:F7*TP
M+![+.>X)" 2&S]R_FS4;9M1,"V#X4CJ:?:U_91C^V=R7J]#['2M,',5QX9)@
M'M<8JO)GZ1(T7)N+< ]I0;Q5\"]3 F77/M*K@O7YHF_=F8;38^KC:06,QOJC
MM2I%_5 VO2?;!"X.\D,S)Y!0Q9.S+1(51HW.Q9OJ+Q .(LU*Y9-[L/9<I*[+
M=C@>^!$1)# GR>38%)_[+(XH<'FK75D8C5'2]5/U+_0U>XN!V#>\XE9QBGWO
M0O[<E)XT?)BT1!-:9NI-VT7Q8'2;Z,H E^ <8>_#MY..G^#$67$$RH.XS@/V
M"%=D^L#X.48QIE;#L1HX-*6VR7S1)QVGHTGRTGEBQM3CUW;GQV^EMC,4+EB5
MV">/$)C$KKPWP?O3J_G><%R+$W<)6XUV;6;/66<.%+ES3)8C6R=&$7?A>HN(
MXA7A(#Y^#)8CO2XZ7/Z<@JRT:5ST)')#**T6M*P!+XMC8KPLD$P8X^=UD#4@
MK^7""RT8_62D$6.E^*"=VY)"4I0RX8;BNWPK21T[^9X$)1:H9;0;92@<^NP[
MB-KN)X=^4).A5D.P[9M%M_H#-G5G19G] %("Q#F*2$L%&N.R6 :RMETY'=JL
M.H7/\+ TUV8CYCL"%^_H-?IYEBBDU"TGT')&X0$E]!U8:>%R(]N^TG@'PE/1
M3X$I]8)1#0!UR_6B_.RAJ9S;;1):PZEI5F"Z?!:+/U12U!MX5!V[3K7DP^YV
MN/5?A]5KM?<-E75"+R6V*$= @/49PI1>3;-W,.BR^IO?U!?;8C&XGL^QT-$C
M',S@(]5(PYMQA 42CJ.*44<5S%,Z3WLE)WR]R;#E)_"1 RK>QL6OZ8[>%XNY
M$\SFI%DMHE2D[M<$I,0W'56?C@7*H(G)C*4SL$I4.EV-2 &)>CJR[SS)WIMT
M5"O0'<HQ) )[P&&+V+!;JW:SI7^X8@3\3]_:9%=I++^-T1-?LGC?D2'5>\"\
MP$2GV0@+*V\*:XEJ]N\JP_Z.[IJPULXNI^Z9S5W@^EB*'Y&A6V,*.G,Q[$($
MF@#(/)>8KL8WMK15Y-9=B2T"UG!M^]MV:A9HUZ;":!_92Q_K-8R@59Q2_%#]
MU5J3;I"L2<?4G1KV,CFLC/K&%5=\P]"S7&W"L-ANL,4$_<8H/)>PFXI7//'+
M*/D4)*LBWAZ%)QL6Z!#=QHEK:JZBGT%\YL(M@Z</*^+FU8,=Y*G]#"RVVZ+8
MNI7B$5N0;%#691@?[V,HNN^0U;H$#D+T*UAPQWI\ P"IGL)(EAT]&BCRIS6Y
MZJ #1O@B3E=/>FV[F>)1'/.A]BXX3PW?9J-C4XBPO^:GRB/;J%V+S"=$'#FA
MOD'&)0>H*,B>EC&^S3RH,^1%+0A+:8O7;DCJM=E1X]3<.D.CK*+2J=UF\L??
ML6UW++S[&\^9/6\B3C0EKKL*4WQ+$LY/VQ*CJ*2J# 4Z$YJ&Y4*4:5F;J\<?
M%T_0!D$KE4-BL_1L!G'9P:8>N"9%;L5:H%Z[?QA@8LXJU6(ATCF(PU/GT2TJ
MJ9YM$NC4>6@*R_TXP*D*EF9^!P@H;K@S+6,9<I*]=&?Y@V[NQY@W20V-5!U-
MSZ(\=,7*H&3ES9"2HPX%G=Z*A2%,5%;OT+*E0]1F1X]A)#GBC#XAY2EZ6J!:
M]/7G_5)MC60(69?30KV6MD@!A0P\ :9SS*>.Y)2%IZX!TH;46"1QSQJPD6;?
MZ[GENX[7:_"AXL8:/U5U52T(7HYW&8RBF<E][^N:Y?M 1/!.,J?1#'#]6?S^
M?<TE'BDM00<XZ,!\.<R-:];B0XB2X=#%8;4$Z"3"?,!Y*G*C:F9./>)JD.Q!
M%\. FD;YRAH'ZX5J)=#STA[,Z)M.DZ\"(J)RY<$6[J.@_0S7$]4AI/1!ILJ>
M("3D3Y0M["HXRO<$0NM0B.<(:=DEUU?"WTX?<=:RV EMQK#Y07=U@^X">= 3
MJ[>ZHAT.9T-P^'K!3C4>W5A>1*ARIE:YKU%S)R\!.LXDZ34^38Q%EI)1R] @
MXGBK\J&_Y26.'%=>?Q2157X&8J6_;8O,7_70A!Z*5I&DK4XU7IH2>G;GI9**
M(@?46>L1#"7R(C0/CSZ^?WG,Z+LPNY.3)LRKLZ-G+V_>'Y/C$E37&48(U<ZJ
M'7[$#_SGFW<OC[4QE(.Q\9K\[^$M.&R60L+P:SWZQ7)=XF*:@(ZR%Y-?*F;;
MNM&&-!*-'/$4R,.8JD%]@LG(K/CA!O 4%>+DL?3 !!0PH]%BR8)Q#B0!6%OR
M$&R 0WS#EY)?/W [ZAZC'#Z3[X*%7S2WWO7QTE+$QJ8S-1C)H;BB2^BU28:G
MB5-32Y";'%&CD,A\:ZH1B??D,<]ZXE0^SM-IDTLB\-:$\( O3\O6E?OF#(]5
M6<[XK6''B:*K-6!J9;LM?+,(5U#[-0'SJ.: [ P>8)#6[$]*+ZL)8?Y4/@9[
M04BG#GD241!793TH@+[Y,,5&L@2F02J[O:VAI6E#-DDWY$GV(MW6+NBUT^RV
M2?&NH-82LBA@94OB3R%/DLR#'>7:28^HNDLS50Y%5^F40W?Y4/*V<#:Y_ONQ
MT[S QSF#Z5=MT/B(:$Z0C:Y&/]T%PQZB\CZUI$GU'Y+& N986I'+/XAI=,N)
MH3AJMTJVW1GK1U"@W:'"B/#TLFVA?)")&PQARM% EY^F$#D9E'4RJIH?K%K!
M'V#*W&,4-@N>HB"/'$:0O>Z5'GM''.N,0(1Z(\.>6%60$IKJ@/<Z'&:_6R;0
MRSI9<&F[T$GO/<+;GU=(.;7V US &P6G*E"C #CA.I\:HCG)7GE)H!2N;;-"
MO&?@8.UM7UZL@U!I9PW.;\7BNS(8?IZ]&YI 8YNJ=4H["PT"6='):.'2N#YO
MS(;KAA0&Y4W!=+C:@#J9G#.^]MV'*6]!*C4&70G)?[?>^.W7(NV6LXH]A#\(
M$ JV"2+; Z4OSA\S(,<04RMP*''6H+2 @NTRV!G/A3CC_ARMMT8[U!GHEG*,
MTE!#4S?#;B?%GNNU'X/B97]790UT,,02N%ZU.UE=0E-RV%GK6BIM55/RDQF3
MEW4H!I9W%"P7:NL8_R9(BT HQO(E6_:0&V9*N,>^CLF;DLT=K9O![]CI&,2C
MW>E/-?'">+X,@5YC<;9*ZPOIIT[WUHQGGSW)Y-3K;7*4@\#])S],:'\=@32J
MT*'Y=9N%,6%E/IP&YF^N<)S>[KN!2XMS?N-AA:X:5^C=P\!=RT"N0]NK 1"T
MH%R%0MPZZE.$[5$S*KX'<E<&;.QP;0&Z\7V"859--P&@KBNCG&N@KW?*1F$W
MJN5[KUAC0".1%F DOQ0S5^Z:+(X>: "N#52G!Z15Z= #TS7VW'MM!X5NDQP]
MVI_P+Y<6PJ@(HP^%")]*^WH%,*'[=)M2.U=,()>Z$(1"D:<^D?84,GURZ;-]
MBU83DL*V W4HO#7=M72T.K14+6"WLN]2?;O%#=Y0J0DD.A=1W<D_3)"%DIS(
M2.3*!)T)J():+-W;R64@?Y-B38TBHDX+[&SD"M-<OL5I07RR*H:C>M-ZO%@>
M'._.@N57T%V.G&Z&W[*3^Y&L%&WRVUF(5K,Q;W;':T<68U_4)$K*<A01G;94
M'TB>C;1A8F"4J&=Q:.Y!>Q0PD5.P1MNZP=<[=D9*T7/*EDJIQ6.WQ+F,QY1"
M#46"VC:F;K3\+BIBQ!"X,/:C_0Q"=:IO#^56/52H@M8/J<9!/X8-N@AHT WA
MJ6_+,"/R6'LS,=0VJB=PTMU:E(,A)-J0N_Y W?#2EX5S? 3 5?7H18,$FH:#
M@_0TE6B-06AJH#TE*"$>]H-<J*Q9/9)<<2*:O%.(WM8V*G2QUU@#I6@#+Z*
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M;<B70'EM^KZ$,9$YHF+W=.IB)<D/;3.%OY,! [8%P:]9"7*<,97&EN',*7R
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M5. T%BV_X;I!F6R%3O!L@)#/OY8Y)/CA[.675NJK%\B/DU>32?AP?G6(G[G
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MSI_S355J4<B V3OE=]CQ,FS Z2"'Z31+)^.GP7STQ-X/)H/I<,2R#Z/1/ .
M$0(8G0V07<P$@(P1R/@?0F9SO_DXFGK ])FEL]%G ,D12'XVR&R>#@%D@D F
M9X,<#K(/ /(*@;RBA4SM6FCUH]W1_KNGPM56,K-BZ59: 'F-0%[30F9U60J[
M:Z RM=;*GR9\,!KDN:E], *0-PCD#2WD1V%?I!/^FBR3>6V54[(":+<(VBTM
MVLSZLZV/V6WX_EJK;7,"C-I]+&SWB>^N,_G+QA1+::O_6CRW@VRH4HB=TK)=
M+D0EEVQH2M]3]8?Q,*.$Q$H9Z]R4DLW%Z]&S%F(""8D-,I%^N-CH53DV46*A
MBM_N)^:-D%H<IBC$PMBW>)>ZC;1LL+92EA)B8N8(J=5ARE*YYJ"JA1P:'^;T
M6NK\.*:$F#E"8G6,RFUA=E*R]U++E;_;LT(<_3$P8X3$ROA4"^ND+7;L66GA
MQTT4IS)6S!DAL310LX6W$!/S1T@L$!0SZL/T&C-)1&R23@6SBWG34KV#E)A3
M(F*G=-NX$Q,M5HC5<DI]OT A)F:;B-@VT("=8XCI)B+639<*.R$QV43GE V[
M@)B8;B)BW: 1/;J&F)AXHG/6*M$-Q,3$$YU3/!$43X2))SJG>&(HGA@33TQ=
MPJ"8(<3$S!-35S,H9@0Q,?/$U.9!,6.(B4Z4$9L'Q^00$W-03.R@$TG1DV]3
MQ9&%8LQ",;&%3F5%OS@A)F:AF-A"79,5W8.)22BFEE";N[&.Y.V2^7T0$Y-0
M3"TA!#/=P@FJ&)-03"TA;#0YE!#'),2))724"5^VH$:W69V/4&X#,3$)<6()
M_8;Y6>;&)W.%VH\H?#8Y)B'^#V?6_L#D4$(<DQ _PV0;>VN$F.C[FG,40OX9
MW0A?:%0,8F(2XL02.H'Y7+?O1&80$Y,0)Y80.HO)82G$,0MQ8@OAF+ 4XIB%
M.+&%<$Q8"G',0IS80BAF BV48!9*B"V$8\)2*,$LE% O%D Q82F48!9*J)<,
M8',S";10@EDH(;90YZN SK0XP2R4$%L(G4)*$HB)KAMH+=0[++M9^E^LY7+J
M+U'Y]EP4^<RR9K-_/<B39NY^51?%T+>E>F)$NU"FZ>.PQN?Q)U!+ P04
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M%BBR%BBR%BBR%BBR%BBR%B>4=3CFG6[,7TG>K%ULY[/AWQ*WGU!+ 0(4 Q0
M   ( -F 7$H?(\\#P    !,"   +              "  0    !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( -F 7$IF\PM@@@   +$    0              "
M >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ V8!<2@-WOYSO
M*P(  !$              ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ V8!<2IE<G",0!@  G"<  !,              ( !MP(  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " #9@%Q*G\:%Q)D"  "<"0  &
M            @ 'X"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ V8!<2OJ\*N8!!   PQ(  !@              ( !QPL  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( -F 7$H_$)OVYP$  /4$
M   8              "  ?X/  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " #9@%Q*W!NU:'0#  #@#0  &               @ $;$@
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ V8!<2K(./R$6
M!0  61H  !@              ( !Q14  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( -F 7$J4.,ECS00  .\6   8              "
M 1$;  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #9@%Q*
M*>+*++$!  #2 P  &               @ $4(   >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ V8!<2N%];/JR 0  T@,  !@
M     ( !^R$  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M -F 7$KPP])TM $  -(#   8              "  >,C  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " #9@%Q*[:Q 6+0!  #2 P  &0
M            @ '-)0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( -F 7$JUT^F#LP$  -(#   9              "  ;@G  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ V8!<2D YV$:T 0
MT@,  !D              ( !HBD  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " #9@%Q*W-C2QK0!  #2 P  &0              @ &-
M*P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( -F 7$H9
M:^#SM0$  -(#   9              "  7@M  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ V8!<2L#_!PRT 0  T@,  !D
M     ( !9"\  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M" #9@%Q*+<"P2+0!  #2 P  &0              @ %/,0  >&PO=V]R:W-H
M965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( -F 7$JU$%.CM $  -(#   9
M              "  3HS  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L!
M A0#%     @ V8!<2F"_FH:S 0  T@,  !D              ( !)34  'AL
M+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #9@%Q***<6(7@"
M  !T"0  &0              @ $/-P  >&PO=V]R:W-H965T<R]S:&5E=#$Y
M+GAM;%!+ 0(4 Q0    ( -F 7$J>*&S6Y@$  &8%   9              "
M ;XY  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ V8!<
M2L0@.\2V 0  T@,  !D              ( !VSL  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    " #9@%Q*W57 *;<!  #2 P  &0
M        @ '(/0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( -F 7$JHV=&4TP$  )P$   9              "  ;8_  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ V8!<2C[;:PO. 0  G 0
M !D              ( !P$$  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    " #9@%Q*/>I$&,4!   W!   &0              @ '%0P
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( -F 7$K@@Y#:
MN $  -(#   9              "  <%%  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ V8!<2DFB7<ZW 0  T@,  !D
M ( !L$<  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #9
M@%Q*?&SQLD8"  !7!P  &0              @ &>20  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( -F 7$H$2'S]-00  +<8   9
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M970S,RYX;6Q02P$"% ,4    " #9@%Q*<>G1(0 "   G!0  &0
M    @ %U6P  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M -F 7$HDZ*B$K ,  -<0   9              "  :Q=  !X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ V8!<2OQA87$. P  5 P  !D
M             ( !CV$  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    " #9@%Q*A"TR<QH#  !9#   &0              @ '49   >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( -F 7$JYQ. _AP,
M  L/   9              "  25H  !X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ V8!<2GKXA5^+ @  UPD  !D              ( !
MXVL  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #9@%Q*
M7YQYPP($  #3$0  &0              @ &E;@  >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( -F 7$J@O9Y&] ,  ,<2   9
M      "  =YR  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ V8!<2H$341P< P  >PP  !D              ( !"7<  'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " #9@%Q*E4!Y-W,"  !""
M&0              @ %<>@  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    ( -F 7$H5;]2.^ $  ',%   9              "  09]  !X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ V8!<2I)#//LQ
M @  9 8  !D              ( !-7\  'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    " #9@%Q*0R&#KP$"  #A!0  &0
M@ &=@0  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( -F
M7$K*E%M < ,  "(/   9              "  =6#  !X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ V8!<2AU-Y?#) @  G@H  !D
M         ( !?(<  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
M    " #9@%Q*Z!Z0.8,#  #"#P  &0              @ %\B@  >&PO=V]R
M:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( -F 7$KL>6[LA0(  (@(
M   9              "  3:.  !X;"]W;W)K<VAE971S+W-H965T-3 N>&UL
M4$L! A0#%     @ V8!<2L8*K= ! P  #0P  !D              ( !\I
M 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " #9@%Q*>(<)
M71<"  !1!@  &0              @ $JE   >&PO=V]R:W-H965T<R]S:&5E
M=#4R+GAM;%!+ 0(4 Q0    ( -F 7$IY[N/:UP(  *T*   9
M  "  7B6  !X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @
MV8!<2AI<(LDE @  7 8  !D              ( !AID  'AL+W=O<FMS:&5E
M=',O<VAE970U-"YX;6Q02P$"% ,4    " #9@%Q*[<*Y75@#  "[#0  &0
M            @ 'BFP  >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4
M Q0    ( -F 7$K ?O8LY)D  %!\ @ 4              "  7&?  !X;"]S
M:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    ( -F 7$H!K/'+.P(  'P*   -
M              "  8<Y 0!X;"]S='EL97,N>&UL4$L! A0#%     @ V8!<
M2H36P18D!   4B0   \              ( ![3L! 'AL+W=O<FMB;V]K+GAM
M;%!+ 0(4 Q0    ( -F 7$HMGDXW^0$  'HA   :              "  3Y
M 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( -F 7$IW
MOQ-;U@$  #4A   3              "  6]" 0!;0V]N=&5N=%]4>7!E<UTN
9>&UL4$L%!@    !  $  <A$  '9$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.6.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>214</ContextCount>
  <ElementCount>298</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>58</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/OrganizationAndNatureOfOperations</Role>
      <ShortName>Organization and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Lease Exit Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/LeaseExitLiability</Role>
      <ShortName>Lease Exit Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Collaboration and Other Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationAndOtherAgreements</Role>
      <ShortName>Collaboration and Other Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - Quarterly Financial Information (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited</Role>
      <ShortName>Quarterly Financial Information (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecurities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/PropertyAndEquipment</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/IncomeTaxes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Lease Exit Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/LeaseExitLiabilityTables</Role>
      <ShortName>Lease Exit Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/LeaseExitLiability</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2315301 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables</Role>
      <ShortName>Quarterly Financial Information (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilitiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarnedDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2402406 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivableDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2402407 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2402408 - Disclosure - Summary of Significant Accounting Policies - Computation of Basic and Diluted Income (Loss) Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Computation of Basic and Diluted Income (Loss) Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2402409 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedLossPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockholdersEquity</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Stock- based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock- based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Stock- based Compensation - Option Pricing Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails</Role>
      <ShortName>Stock- based Compensation - Option Pricing Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2406404 - Disclosure - Stock- based Compensation - Stock Option and Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock- based Compensation - Stock Option and Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesComponentsOfCompanysDeferredTaxAssetsLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Lease Exit Liability Lease Exit Liability - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/LeaseExitLiabilityLeaseExitLiabilityNarrativeDetails</Role>
      <ShortName>Lease Exit Liability Lease Exit Liability - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Lease Exit Liability - Changes in Lease Exit Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/LeaseExitLiabilityChangesInLeaseExitLiabilityDetails</Role>
      <ShortName>Lease Exit Liability - Changes in Lease Exit Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Lease Exit Liability - Future Principal Payments Under Lease Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/LeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreementDetails</Role>
      <ShortName>Lease Exit Liability - Future Principal Payments Under Lease Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2412401 - Disclosure - Collaboration and Other Agreements, Janssen Biotech, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationAndOtherAgreementsJanssenBiotechIncDetails</Role>
      <ShortName>Collaboration and Other Agreements, Janssen Biotech, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Collaboration and Other Agreements, Takeda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationAndOtherAgreementsTakedaDetails</Role>
      <ShortName>Collaboration and Other Agreements, Takeda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/CollaborationAndOtherAgreements</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Collaboration and Other Agreements, Servier (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationAndOtherAgreementsServierDetails</Role>
      <ShortName>Collaboration and Other Agreements, Servier (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Collaboration and Other Agreements, Boehringer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationAndOtherAgreementsBoehringerDetails</Role>
      <ShortName>Collaboration and Other Agreements, Boehringer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Collaboration and Other Agreements, Green Cross (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationAndOtherAgreementsGreenCrossDetails</Role>
      <ShortName>Collaboration and Other Agreements, Green Cross (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Collaboration and Other Agreements, NIAID Contract (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationAndOtherAgreementsNiaidContractDetails</Role>
      <ShortName>Collaboration and Other Agreements, NIAID Contract (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2414401 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="mgnx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2415402 - Disclosure - Quarterly Financial Information (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails</Role>
      <ShortName>Quarterly Financial Information (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mgnx-20161231.xml</File>
    <File>mgnx-20161231.xsd</File>
    <File>mgnx-20161231_cal.xml</File>
    <File>mgnx-20161231_def.xml</File>
    <File>mgnx-20161231_lab.xml</File>
    <File>mgnx-20161231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>83
<FILENAME>0001125345-17-000041-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001125345-17-000041-xbrl.zip
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MM=).0G#OZUX:1I*ER8T&TW3$E7I&!LDK")9U-)XZ&CD*402<#)+4!N ^SA:
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M$MS6L9EG!E"1]XYHHY&3\/>R^CZUU8/?&RIZU]S6/*QT5EE*9H.ARM 444>
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ME1XID8XTYW/B\R1L1]Z:<V0J4=E1!S&!F0D ZV,E2 R&A#3,^\&(BCW2M^9
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M"/)(\G9J\2%%"&!AC? QIEHI2XT01#CFE0?Y9@6+&K,U1#8TQMB"UI4]'6R
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M <PDFR\M?1S!AV1]74\J'0FC2OF8)A*F$GA5=UVA*/@\88\876A><;J\KTD
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MP ](-[E".+5)OWIY">BVN6B4X IE%PP%AV&M*):YZY$G(>VZ:(Q;EN@7GT-
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M<[_'GK>D<>QL\'3A[C*&X7**>1.;6AQ3#^5<-4&M#E8H,^G02.DT'FZSVV4
M_P->L$D<:1,K@#/I0WM@JG9W5!,N^8XJJ=5UN-^9-ZFCT ?%&=B<.DSZW/4
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M%2-;# G&#(>ZCB#@$0E)33 K=%LRG-OL<0(LZYF/_NR7&1@^B!&!^#!M8L@
M:P@*0]&5X#H/C))Q>C/'#W^.?G?C>3Q-VJC85G]E>0'UN"2F(,Q'E]^JUA-2
M*Q0=PY98ANP<N.<4CSKHIBJ(T  W!,Y'F<%\S-UQ79CMAJ"B>L81&KR+V:$.
MNBD5*8S0<8W0L@/&N<&I;96.4X .<[?.E-,N0P]UT$T) 4(\.W0YJ ]/2A[(
MT"]'[00&#]Q.U0OE8JB#5N&V7V*PTQ=)G#OS2;E:#COCY_E.&RI:M?L&AD%#
MCIE/DQF$D+!(47N&*WHR:-M!V>6<!P-W6ZN""\:) )D"#@O6'D@C""P-+@>.
M[ACI1P[NMJ8%.Z T$(9E!%CA"MP=V%H ,)]3UJEL?4YPT0!$HR]?PF/F-V&6
MWGG++ .)K?<'P3O27+FE^[<U4-^EOB%#S_5#"T2*ZY2;30-BB; 3G0*!L@N;
M[GGLYT#$%M.14IO95##+,82P<<&157:!FX9M=[,_YDX:X @1L<7N$B;S MLS
MX;,!IFFIK06=:U.[,VH3IVSLI+.?"Q&_P).R 1@C]#W+)!(;?5W+<8/ <S4:
MPI" B&BCP7X".:PY\^%QL(4GA&LPYO@2E($%YA%GPF6EM1$2WN$)2DX0!UO8
M07)/1>E"8H22 A8,I\Q6<0=<XF[*5#R!'QZ/A<^WT>)_T^5L\N'N'LX=3*?Q
M& >>PT>ZFX3[S,QZDC'P@I"+$*X_,'T.ECKQ=%4# XN@"S3EK1SCXPYY"##;
M1JK9S#/9'HI]WS)<*:EEENNFU?*#KO)KIU*?#F9K(%.Y5-9/9DOX;1'OJ<UO
MVD6,&8VMD:$'2MV$_V,+DP0V-<*R \8,>5_#,+68Y'8][K;G&0<%KRNAZN"%
M#C$819U-J7 <!KJKW.88V [KZ_]G1 )1</,XP.L*'Z-ADTCXC 4?(X11'G!>
M[8YF#EBHO<,FP#VA%C\D>.H[M:^X49Z,P;K5C]R71J7G.(;OAE9@2$\0:IN>
MKC(- H>[?1N%=J;1+4<]!+";*1:$*3,L$\>@!.!#$FF5UA6N:.[=R+PSQ;X
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MWXIL?G(3%46*RJ3SL^7-Z/V'G_QO1M']/9Q%_?&B.LIU/([NXM%T.9LA5^7
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M< X^P@:_S]%O\20Z*$0GT=^G<Q3/T-I7M\NT1]HR!8H[>416PGB.K$0\O\$
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M.')P:UCZHF<HC!KUO$[F[9QP76T+?<1ZE4FZ6[*VE6=-6VG61I(U;V593UO
M#KH]>?BQ .T:SJH<LC4/?MEK7?;(@Z2HR5]-X/Z^,9,NBXM/%$/S5_N"VBN+
M=L[?;DA6]1@"^^=RRYG;?3E=U'N=>MDJ,3ND$TN'<6*O1F%11W,QFA0%!7AT
M+.79,>F\&D\:WQ7&7?_(IHM*^Q?WBLL&5@GU#2C5.K@?L^]+U%98^:9C&Y0Z
MO70%MVCSNM*NTWNQK&I5I%;,1U'.J!IN6'CI!;6IHHYM9@G0\BRN\-P_#+"
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M%V6 P;)%P!8)/@UV88J! 5#Z!%&@WK9CZI[^H"14/T:3A%QKZ9#Y0;#3P Q
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MXT*V]2KJ%MDLLNT)V78N0G1HQ4&,Q=INENP7V#.:OB% ZP;$R@#.8J+%Q&H
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M4%]/0!^E6.SCRW<^##DA0]K8SXI)Q;ABTP!O8A0[D3X,&L0*QE*G'_<*K6W
MR8U;X+O-9 P#8?R<G]@/PCGW"CREA<^D Q.",5=XGGGFKQ^:'^@S4(^;?-YP
M++=R+A3[73RPK\&<KTFS!SF)9O G[-M0-!"DQQ=*?$S^6-M\MJB\MR<CY/9&
M'][N#B.]IG[[ST^SBHT,R^SIE:\WWW=ZN_DCV7Q-KM<KIQ5GRVU5^YK"!88O
MPK( 1A\?M-08!]Y$#_0OK#=T36UPKH0KYF,1LD[+>8$J8W'P)3C8>0<47(?E
M[IZ$]\?8=K.\'N1O#3V+IL>$IJ6G95DTM6A:/IKN'%QGK^NWX^U%ZI 8<^^9
MP9VETW[E/6CE>6$/P<G:=KKEI?!6_NQ?ZSVM$<.IG*"TG.;8.4VS:_,N+:>Q
MG,9RFGTGH0Z:I75AJOS9OY;3O-Z-VJJ]!?7)=T/!E5 _GTR$^?.430, :QR&
M6 *+:N/C/>XB4!)O@VT]+'RO4QZA5047]BVYK8 ^9'KHE:;B6GJP]%![>FAW
M2ZL&<BCTL$=/]B$K8KD617M7PYZZJCF<DB(G[7YYEM)KH7;8I>RL1^<-!.3Q
M4&Z[O!X7+X5954C0^EHM95:(,DNL+GGLE%F3$,^]5GG5^24E1W;L)0&O*B![
MNSR[.MV*M)UNO[Q(CZ<@4Q5<L-ZK][UNM8SF&!E-B2%EEM%81F,9C64T&QE-
MF1%EQ\)H; 6 W2L *$SH7UO_2X9*$APSQM=I.6QC/ME+AJ=2!*6,M#%WZ"4#
M.4F]A"B(N/=4602'\<4B#'[(.8^$MRQG+W]J-WH,GO(V-45Y7S##TKKE+NTA
MB+T)F_+[( 2J7C(Y7W WHA.X#.!O?_F38F(Z%6XD[[$L>%KC,020.RP4:J%_
M\Y8-=NYA58J[F<,F,1[ARC@3$8EP+GU=&".:<3W11$Q%&,+1YD;G2HG(K,X/
M(C8/0L$\^1U/.<+NUOCE6,#\0-: %H )FPJ6FQ'H01=Y-3R(;0K%%,9SV']%
M&&!K[&3;^FG84^S!!QG-J,[&3J!HL-O"@S','D8<!L@]F-P_PD[X6'HR6K(9
M5[ \X:<+1+!M@(A0^$,PG2)<B$ 02E$4RG$<">;R,%S"IAYX.#%E152COCST
M)@AIDWASJ[!:BBB)@O;,49V*L=-2.?QZVMW+0)2C*$+_4H8%?E .Q'*B!A<H
M,:-1J(AA-('PN1=)(,50>$#SDX3%/4KL*L\,I\AF5.S.,EX@B\-M)6O%'F82
M7IQQX#[(_I8BTJPCCB0QP0(/ DT4%HK/835>%_NQKDC238P)5J" Q.44=%T_
M F:;!%3DV:$/I,^B!^'!0N8 PUF=64V1;?_1^-9@-P*4>M ^D'A4!"=38/8B
MBD,XU&D8S,LBK>;ZM>R+</>UHYC[H'8/_Z_'3&1**.:(WP'0 "*)^,%309Y#
M;\)7= &@&A?[,3:90_D*KX&0Q"L)#Q0ZP$L$+4(3D&LBGQ)5R=]_^3E69W><
M+S[J6M.W_,>55"X,&8?B%I#DP@O<[W_[W__YR]IS7P)/NLOT&;#$?,2JKV+Z
MUP\W5\C__]']U^W5!R8G\ 40Z5FW,VAU!^WK]OGUZ.9J,!Q>#?K7[<%P<-$<
M7=P,^A_^MH+:>?@^48IJD_57:G&N9YZ[_HB/?Y2@=DM7?[.6>VU*?-^B.E(*
MQN[HT:DT [E*E+54;]7HG>AX*"]X*%+M%Y[4W1>1="3HDZ$ \8%:(+!4H3GL
M%&C+=R7PH% L@I H)R$9>%F2B;EM+OB,\\V!;<>XKECAZS@LR"\W,BM%I=6\
MS!^4UL;Q-2TMM# :4R,@K?."]#&+RR]Z]8U0 /$KHPV;%W&?.\ (=\3<M/U0
MMD82D)E05@DW-M((6(L,)GH#)%F3-\U@9I%ZZWIA!C1SH8OO\0WKT[-.8A=-
M!CD%+@;;53Q<.FR\W&)LP&.27MQHK>@%XL+I1+$T8(@O)Q;OAC4\@*FW:NF
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M;_;7,S?*V6PY#/$$S\:<RRDJ)=E'@!MH*,*3P-2P^AM TU< 4!"+9R3" 9<
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M;!4CTN1_!8MHCCN?.$]N!*'G!P^H6N8V <,O @ ZG13.H0V]A#Z2U39JCY.
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M<T>-5D3QJL\-0M!F(GW?)>=) !@388AA787[<'P/H]3F=.6H52&\\-21::'
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MYJNH<B\8J$9!&"5T3#@E=;Z,6@A73J7+[D1P!VP"R!9I'IA9@*4;BJFKR74
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MG4@OQC/^AGA$D6A4K@V(_R8,Y@B(.*+%?9Y>\Q#%FOHBPF\SGBN0OT/-^]$
MOKSICVY&-[W^Q46GW;QJFIKW(_CAJA(U[_=^2Y)5T<2SQY##",&'<3%@5&HB
M%Z%)AD/^FU4NYIX;>ZF53*<&OV.[0B]0%.[$%!Y*/O@ +"%C:FLYD;%3I.NS
MY.AMY\)G="X<C1JC9KO;2?[5*Z^/X:B4/H;]7JT:$=:[C6*]5U^37FQX/X!>
MU8\S.0&64&Y+FMWB:K9T9!M6NR.;2T4&2HU\6FO<\B_!0W9-12R2YKRLTW)V
MA:9%P5>BX'LT!5R'I9G%O/-8;[WWQ]B-W:+?L+WK:Z!GT?28T+1GT=2B:?71
MM+M787\DS4F_D2? N(O*HOM285>AKIJ=4=?I-\MK#GSHC3-K1&.5DPU'26"C
M7@^(S!)8)?'$$EC=":SM-$&"C9H[:TY'3V EM'XN_]YK\ZW:E;D1O^4_SI42
MD3KW)[_*M&KM+:[^.5=GE^?MZ^N;3KMSV;N^;K<O!M>CMKXZZ_3ZHYO!<5R=
MY6/CJ.R%KR,Q5A./TW@$Z>OD=?Z#DKBQW9N7G<*IOFCC*FW?>4+ACD'\_V_O
M6Y\;1XX\/^_^%8@^3UA] 6GXDD3UV(Z0NJ6YWIM'NZ59AS]=E,"B6&X0H%&
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M:C6%-K6E4]N4%#WTCX]KNV&H*2N)[W%Y_-NI=$:!EJ% WS_JU;:)IBDKR2C
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MW<%YMW?4/3L[&0[ZQYWC3O_TO+L#9R!<+5_.YJDH"+,1S"V=Q%IZM.,>I$?
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M6H,6P>>@&QH/*(/JTMTJ>:>)N^Q0D 7P77A6W$CSTW4&C: ^:MRJVH7S[3H
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M<QQS7"L(UQAB,<?M L?QF<]\M>^&=R^T:7/"4<_O'S[:+=J58QDYW, PP##
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M/%YYM4=^OIRBNS3P,BM/*^A&).YPX^M4E".]%8F*,PVKII+1_DPDZ=P;B51
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M#]@ZPA@J(>9_=9H;$32.M0L1N_3T,DQT8XX9#1VP,-(T))H:5K&*\L\:1@S
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M8&DP2)4%=7*AT=C1WEY2.-6QAZ%-E&OMS"(?XWL3JNV]MRK[QU(AERJ)%%!
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MO@QC2OH\'C2N2+'DF_L)" J3P!;]K"D-H]J]A1(*;6LHEM6PN\(^4<L%G/*
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M^/./^. [^WPZG\'S@%I4-O(.F_YQJ>V__>=??L1VU ?\]V__'U!+ P04
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MC9@$Q@N8_["Q4@EQ\*M%/7@8/6.T?^/Q0UWY#O;C77'H810&PYA@ODL!29T
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M7-2_B=,=_07 S:&$_[GY=?9@H%\+554Q-%OG)OY>ANW7\__\,?RTR"=K5UD
MIGBU+*ZW0H06Q>SO/X<!9WV\)K.>8664IE1"PH%1G&(..<"6(4.$>@SF+![P
M**N-5OM%\]X"[D#@]6JS!]/N7Y9ARPD1C$CF+'$$(0'8!EEHF9%-D+W_8E0U
M^:FL+HKJ[S_#NN5F.CEJ-8R'>L9 IW)D^ >HPB_6L^N_3F;EHKCX^\_+:E7<
M_[*<+\-<XF;KUX6)M?AR%]0;X%,PT78JJIN\BED!UX7Z-MT_07S_>.:U( Q
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M]7_DLU6P<'2P.??'^W8\GF&)O40N?%:&$N#C-6/WLZ650U;K.!M^=(-E>@K
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M9E?O#!O*ZGA:Z FIH=BRV_GVK!_@Z<.9CZYL2(S$EDK@':5(W2^!.%W_O1F
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MHMC[&@,E27I-W=X21_ID2E^X)1_,]:LJ(+M:C^CMY>5T4AR>')HUS 1A!CD
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ML$^Y7,5:'S=YM;QM<+3QN<<SX8WD$D)G"'6&,N0PKR53&J:;?<?[54Z^EG<
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MURY_5(>OR)A77BF(1;S'%G*/[;HF\!H5)T'Z/<]RW 0Y,9##&1GEI"@N%C[
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M%3I":1SIP^O0Q.F2@#\L@ZT7-Q2O&V3R?O]PIB%#B')LH)"">N&5 7<9VTI
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MXKNJ#/N$Y>V[671 S"^B;_4F2NT6R^EU0.#BTZ*X7,U>3R^+@_-4RQXS@@4
M!@%"""+4$LHIKV6&QJ8OA+TYLCH@R;"@#3WCO+V,%X:$R7+QKJ@^7.55$6?-
M21#13F>K(%?CQ2^QQVQ=/=-"3A@F&#GA+*WM!JF52'?9]!;W[6'FZ1>TX4FE
MYLOI11SY].L#;[_[-IFM+HH+'R UY?7-:KF99I\*?QS?NGI9!CRU#AF%I!>&
M4(\E1C6J#J!T8ZNWXK2]4/%$>!YTZ6]^'?_XG"^*?_^7_P]02P,$%     @
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M@PT'09$F+_9DS8V^ R/6[ 6YX6OX^F@1:_H=#N.W%LG$C?\5"Q>:OQQ;RQ
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MAU7*G>4;4>GA6*2T1]8<!&*[Q)C9+/^:YNLLK4ZL286VZ?JNXT1!')D6B*+
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MBH#?6S4]&(@HWUA;FA5O#Z^9U36*W,CVZ,2T;S2M?)HW):-B6G= )H/6W3_
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ML;T<V>*B\(*:J0W!,D1.L4_'9] T,,8KB;=ELDFI\6:%XNU"=0MB%=@!B:S
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M1:AQ/"Y#@<8Z<;SPI((37I6A7;TRI;90VOY]T+F#R5-6)]NA9V=&'L118 &
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M =!N%M@C@H&E9HP['H=F<7XE$%F'S6 CVQZSJJ&L@I",'<%.&PV5 ]=^%]F
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M6T&8X-55OF2'O[*LC1;\UNLM+Z+%P\:LBPQ-SM8;2.;WL]FXPL&SN%*"SB#
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M*N.N ZK!2VLG%Y\VO=E7O9'@660:V=F$G+="4F\N:.SM/H1;_ /V%IGRO^N
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M#M9U=JC;P@9NB#S,YJE68B70(5'@>#BR'2^T41 GKMQ;+3H:-*P:/49^R'-
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M2/PX#CSHXX @$B1AY"6QT%$%@\T;UN,/[^ [+'/AT S'EY5W)?3*:6Z/%PR
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MS:GQ+&L'=U4R>")17OX4'+!JV5.Q1TSNE)D2RD)=3(AU#7^L\K)Y!_TT2=U
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M7I2W=8R/*0:\?7A>C@NEP_.>0RF-81C:R/8=:&'<GT)B0\[UH?1(D/GP^<:
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MI1Z/MLT$!P)S+S3"2%,F,;K;[=%(I=S],<(TF[Z)<L"T;4,=@WAB<9QO/F\
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MI338$V EH,QK4N%'/4[)F!AG6:SV)ZW>M3 &%K=TE7MK5X5CY*V(%[/&>P2
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M'G9?3NTM ]@XH;1$ E&$(27(J J7>+I_69-;RUQYZJUTC/\(>;G)I0[^W^M
MC7D[Y'S092:QADXC29C!QBJ"'$$50L#RE$",$<Z0HV%HBA(&HVGXP82_SU8/
M1'D7E!^&=',*.P_WE%'@D!(4&2.EYH08ZV#]VFJ1<@'=2#<I>R1EJ]B/C(N;
M<^QT(FZZR9RQ.KQ^&$JN,890(> J)(RW*74U1[KA.#@+SP%^2 I6G^U<KO@2
ME5_R99C8U71:KB?S>OOBW=&#QL3.,Q@6#6BPQ- #83 WCI@[6X>EQ.*.*$%U
M.+IVJH[!2%Q]L/4=3V'HPY:9"O\0A2C53 8;VSG,6"4O!"S%U1E1]NM ]$O"
M>C!NO2V+8 "OOL5#I4U<Z[_6L\^W)TZ$>SO)*&%$6FDLYB#N83!C?;U,2)G"
MN!$EU [$N+9@'\ZG/M44W-H>!D,'I".042P91E0I7DG')$E)IAQ1_NU0_O 9
M$ ]&H+^7ATN$/M\@\T(01(+]"I!7 % AE:RDP\+U4YRX(E"QFLPOB4#G0#P8
M@6)Y[JT*Y_/BS\EB>I)Y];1U1JW7CA,6WA\.$#,.*U!O$R&3XI">D++;8PGU
MGMF5#/E@5/LM/\FF"H]GA@)L@<9.$@U1L!^QL95DCB2%I9Z1UWMI$]7I" ]\
M\'HOJN+\T]=G.LDP]M R!22 4$%L-##5?B+QT*<<,(QP+[?'(]ATL >8KNX-
M^FV9?Y[,JNV4AI;6_O89=0:%?Z7B-+RJ!GCOJW>7"(Z35L<7M#@FT6+_M-8:
M\'V3KGXC[TG0@&O/-<N"P6D8"^:GEY0S9XPSE35 )$[*6F]^6/KHXI&A5LXN
M>-8"Z(.98/>&?*(U]K!EQBQ5ECA!.376<RFLKV(62/!U^KW[])+8U0[@?1%L
M?^S YG;T P0[TC(C0%,<[Z_C"#'J*37.UCBR2[O&M N+K%V$^V)4C81:KVZ*
M<K;ZIK[.#JV%SS?(* 2:0.61#6^'DTQY5J%&B%*]7CO?/7]:T_6^*/T4<(>C
MCBUN)[/G$KN/-<F<@18S"@AQ4&CKE$-5L!/!UEY83&2JFH^RYBQ4S\]GW456
MWA_!9'&]"6>;[,+9_G-=SI;7LVE4SJ_Y[8>\W/[Y#%F2^\QB)KK F$I#@)#!
M[W!0AC\LE# LY>[BV72J^HMA@._-+-^)9&*&8OEM+_$./I]Y@,-LK@26&""$
M*):R.J&*MPU=UL4R?7#@L47> NI],>K=9/$I/V(HU<]D''+O8K4U"CQ12%!
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M._-KA5G[=O 'T$?O9T</97QP==(S-_XV9^^^GC+'28ST\Y00#+TWUG!0X8%
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M+-;S"'+$*JJTD[OLQ-;SUN-!>".YA- 90IVA##G,BY$I#>NH*@,TJ+6QZS0
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MK0O%B92%Y5X0I(U[KU B_A-W90&E(ZQ '^IRR59'8<.H2L-6<.[,5+&9,?%
M$*?+:OEUH5.FU/M%/(]^O-$/?V>KV\7U?IXECQXSR?.'"-\FE/'CS:;=,6M%
M$^\/U+%4/MTH#Q0B1G+ P18[30BA=6Y4!QB,V@)'^Q!#9POE9DS_D<U2R9G4
M]P^+U:=)ODK'VC3&R>RO?+&^/[92EGM#B&.$E%MCD$$*$X*)I,7XM65U:G-<
MUNFP\E+9"M!=$>W;/,\FLY0;X*_)=)XTC(_S)QK&$8*=:!F(Y,9!@E!4. C
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M.'8/"P0HKQ40,,"MIPDJ+#K N3./CY0FM%BBCCIX/'LP"((=E<QRP!A  %$
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ML3DD6<J0Q )BYZ13")O(O:T@)5,EL[(-VR&)8*U$Y*C1RG(FC.34[$>H2:V
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MJD#8:C!6?:\ZTXY;7_H23&>1:HMY]O#W)/\G6_GU_'IY<N]^NT$@FCLLX[B
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M     &UG;G@M,C Q-C$R,S$N>&UL4$L! A0#%     @ V8!<2EY_F\*J$@
M!\(  !$              ( !R8<! &UG;G@M,C Q-C$R,S$N>'-D4$L! A0#
M%     @ V8!<2NV2;&(W'P  JT(! !4              ( !HIH! &UG;G@M
M,C Q-C$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( -F 7$ITDIJGW4H  (B> P 5
M              "  0RZ 0!M9VYX+3(P,38Q,C,Q7V1E9BYX;6Q02P$"% ,4
M    " #9@%Q*MQ)3D,O$  #=)@H %0              @ $<!0( ;6=N>"TR
M,#$V,3(S,5]L86(N>&UL4$L! A0#%     @ V8!<2CV1_>39>   K1\& !4
M             ( !&LH" &UG;G@M,C Q-C$R,S%?<')E+GAM;%!+!08
..!@ & (H!   F0P,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
